Clustering O 0 1.0268115602229955e-06
of O 0 1.1885741457717813e-07
missense O 0 3.690831533731398e-07
mutations O 0 1.207420030624462e-08
in O 0 8.407858409498203e-09
the O 0 1.336925947725831e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 2.869035370167694e-06
in O 0 3.7491496129860025e-08
a O 0 1.2931877790833823e-08
sporadic B-Disease 0 4.625628662324743e-06
T I-Disease 0 0.00048356709885410964
- I-Disease 0 0.0005705870571546257
cell I-Disease 0 0.008865294978022575
leukaemia I-Disease 1 0.9999996423721313
. O 0 4.620836079993751e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 2.560345092206262e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.4788871238735624e-09
is O 0 5.7355696581051774e-11
a O 0 1.0010330064869066e-10
recessive B-Disease 0 1.6711576567018938e-09
multi I-Disease 0 1.8686785097088432e-06
- I-Disease 1 0.986748456954956
system I-Disease 0 0.00242748879827559
disorder I-Disease 0 0.0584268681704998
caused O 0 3.773235890403015e-10
by O 0 7.146115838831124e-13
mutations O 0 1.4769906218209394e-12
in O 0 2.2547044092879887e-11
the O 0 3.9181899391671493e-10
ATM O 0 1.9051007029702305e-06
gene O 0 1.0790654592085502e-08
at O 0 1.23166913112982e-07
11q22 O 0 1.1883731531270314e-05
- O 0 1.108904143620748e-05
q23 O 0 1.903772135847248e-05
( O 0 2.6631827854117773e-09
ref O 0 2.993722034716484e-07
. O 0 2.332832593765488e-09
3 O 0 2.6983105527733642e-08
) O 0 6.603092295165425e-09
. O 0 6.187082135511446e-08

The O 0 1.5424362231897248e-07
risk O 0 5.199314614401374e-07
of O 0 4.159693745009463e-08
cancer B-Disease 0 1.1813929177151294e-06
, O 0 2.3098800649989926e-09
especially O 0 9.940873013647433e-09
lymphoid B-Disease 0 4.52119229521486e-06
neoplasias I-Disease 0 0.00019263116701040417
, O 0 1.3626277883815874e-09
is O 0 1.3483473886022335e-11
substantially O 0 1.9563793640653415e-10
elevated O 0 4.495760652645231e-09
in O 0 4.7969805905268e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 8.606068149674684e-06
and O 0 3.184653207810584e-09
has O 0 2.6801608155047063e-10
long O 0 5.887351717248634e-11
been O 0 1.2022917383891496e-10
associated O 0 5.917210055272903e-10
with O 0 9.027642522418944e-10
chromosomal O 1 1.0
instability O 1 1.0
. O 0 8.359556886716746e-06

By O 0 2.213237060288975e-08
analysing O 0 8.614325111011567e-07
tumour B-Disease 1 1.0
DNA O 0 1.29964320194631e-07
from O 0 1.7120709294715653e-09
patients O 0 4.950213572385564e-10
with O 0 4.471415425422176e-12
sporadic B-Disease 0 9.347981233531755e-08
T I-Disease 0 7.570249181299005e-06
- I-Disease 0 0.0033124350011348724
cell I-Disease 1 0.9999692440032959
prolymphocytic I-Disease 1 0.9999995231628418
leukaemia I-Disease 1 1.0
( O 0 1.2260996662405432e-08
T B-Disease 0 3.4538598470135184e-07
- I-Disease 0 3.8418602343881503e-07
PLL I-Disease 0 3.3748722216841998e-06
) O 0 6.073915259641183e-10
, O 0 2.380095009968386e-10
a O 0 3.8330139062736635e-10
rare O 0 2.1946977568632065e-09
clonal B-Disease 0 1.3091708694901172e-07
malignancy I-Disease 0 5.65736058888433e-07
with O 0 3.2605078359448925e-11
similarities O 0 3.5650765672912144e-10
to O 0 6.457477885746243e-10
a O 0 2.9082949382086554e-09
mature B-Disease 0 2.816168453989576e-08
T I-Disease 0 5.107979177410016e-07
- I-Disease 0 5.594757226390357e-07
cell I-Disease 0 1.1037091098842211e-06
leukaemia I-Disease 0 7.231390191009268e-05
seen O 0 3.6191760699466613e-09
in O 0 1.0760353719163618e-09
A B-Disease 1 1.0
- I-Disease 1 0.9999381303787231
T I-Disease 1 1.0
, O 0 1.862203724556366e-09
we O 0 2.5908969414345506e-10
demonstrate O 0 6.02457916887289e-10
a O 0 1.066850843778333e-10
high O 0 2.620537675745993e-10
frequency O 0 2.5069015752166024e-09
of O 0 2.055798198341563e-09
ATM O 0 1.4135309356788639e-05
mutations O 0 2.0069060724381416e-07
in O 0 1.995018692468875e-06
T B-Disease 0 0.023845480754971504
- I-Disease 0 0.0010308854980394244
PLL I-Disease 0 0.0009529953822493553
. O 0 5.1784900279017165e-06

In O 0 3.560615269293521e-08
marked O 0 1.0824790841468257e-08
contrast O 0 1.0501212122093762e-09
to O 0 2.0774293396641497e-10
the O 0 1.2014847450281252e-10
ATM O 0 2.6252661200487637e-07
mutation O 0 6.312295686150549e-10
pattern O 0 5.759931975823918e-10
in O 0 1.120540549237603e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
, O 0 9.97766758104035e-09
the O 0 9.309575332849818e-10
most O 0 5.06285846579857e-11
frequent O 0 4.696725647290734e-11
nucleotide O 0 3.3095565177276853e-10
changes O 0 2.5794671953960346e-10
in O 0 1.184126685593867e-09
this O 0 1.8809660495833214e-09
leukaemia B-Disease 0 4.070824070367962e-05
were O 0 6.896451765214806e-08
missense O 0 8.222010592362494e-07
mutations O 0 7.4600002619718e-08
. O 0 3.866372537686402e-07

These O 0 1.0978073561318524e-08
clustered O 0 2.466896686925679e-09
in O 0 4.6350728810651276e-10
the O 0 3.723434061075892e-10
region O 0 2.507307916843615e-09
corresponding O 0 2.628583573027754e-09
to O 0 2.837869939043003e-09
the O 0 3.90644672165763e-09
kinase O 0 2.530722120752671e-08
domain O 0 6.493706905530416e-09
, O 0 1.7654132322686422e-10
which O 0 2.5002519152272917e-11
is O 0 8.107536343671118e-12
highly O 0 4.57224536010159e-11
conserved O 0 3.6137115522194563e-10
in O 0 1.5685036602874902e-09
ATM O 0 1.4220447610568954e-06
- O 0 3.1478265327677946e-07
related O 0 1.5430533295557325e-08
proteins O 0 2.4352828087437217e-10
in O 0 1.2454428599539824e-09
mouse O 0 4.0982669702316343e-08
, O 0 1.103264368751411e-09
yeast O 0 6.6909255913572e-09
and O 0 5.5007616239777235e-09
Drosophila O 0 7.861674475861946e-07
. O 0 2.3204928822906368e-07

The O 0 2.3229641499256104e-07
resulting O 0 2.1765481861280023e-08
amino O 0 1.0903366209902288e-08
- O 0 1.0847385567558376e-07
acid O 0 1.4835381811906245e-08
substitutions O 0 3.092566558393628e-08
are O 0 6.117001349892348e-10
predicted O 0 2.5903412748107257e-08
to O 0 7.600156948228687e-09
interfere O 0 5.805035812045389e-07
with O 0 7.106034427550867e-09
ATP O 0 3.0986397177912295e-05
binding O 0 2.2101113827943664e-08
or O 0 8.060520251262915e-09
substrate O 0 1.5929858321328538e-08
recognition O 0 8.73477574714343e-08
. O 0 2.934861242920306e-07

Two O 0 7.510698907253754e-08
of O 0 3.5217048832691944e-08
seventeen O 0 2.2942809607684467e-07
mutated O 0 7.318195116567949e-08
T B-Disease 0 5.196425263420679e-07
- I-Disease 0 7.53192921365553e-07
PLL I-Disease 0 7.388021003862377e-06
samples O 0 1.938233928910904e-08
had O 0 1.8105573706961309e-09
a O 0 2.0874464656817082e-10
previously O 0 1.5210869230841695e-09
reported O 0 8.565026021756239e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
allele O 0 4.590839580487227e-06
. O 0 6.26617179477762e-07

In O 0 4.589665891785444e-08
contrast O 0 6.6522800601376275e-09
, O 0 1.0677797535052491e-09
no O 0 2.2911263997116293e-09
mutations O 0 1.724015263881995e-09
were O 0 6.100087102112184e-09
detected O 0 3.207148324690934e-08
in O 0 4.937617426037377e-09
the O 0 8.241022086963312e-09
p53 O 0 2.378726904339601e-08
gene O 0 1.4098223033442991e-08
, O 0 9.32893673422086e-09
suggesting O 0 3.426948325113699e-08
that O 0 3.3836616841753653e-10
this O 0 9.601759387578568e-10
tumour B-Disease 1 1.0
suppressor O 0 3.1594034226145595e-05
is O 0 1.1816900791217222e-09
not O 0 4.75194661397893e-10
frequently O 0 7.844638827414485e-10
altered O 0 5.848888928738916e-09
in O 0 3.412876425912259e-09
this O 0 4.693533117716697e-09
leukaemia B-Disease 0 0.00010127797577297315
. O 0 4.599472447353037e-07

Occasional O 0 2.7144112664245768e-06
missense O 0 2.9493351121345768e-06
mutations O 0 3.64043941658565e-08
in O 0 8.02499222629649e-09
ATM O 0 2.7181155019206926e-05
were O 0 5.9553734388373414e-08
also O 0 1.1435760116640381e-09
found O 0 8.398441664336787e-11
in O 0 2.313269159559539e-10
tumour B-Disease 1 1.0
DNA O 0 7.323040307483097e-08
from O 0 1.804455362908186e-09
patients O 0 6.529759510875977e-10
with O 0 3.754948088574572e-11
B B-Disease 0 5.039723873778712e-07
- I-Disease 0 2.401929179995932e-07
cell I-Disease 0 7.03348487149924e-05
non I-Disease 1 1.0
- I-Disease 1 1.0
Hodgkins I-Disease 1 1.0
lymphomas I-Disease 1 0.9999977350234985
( O 0 7.982640659598417e-10
B B-Disease 0 2.1256662208202215e-08
- I-Disease 0 3.957262073583934e-09
NHL I-Disease 0 4.105793394160173e-08
) O 0 1.108190483822824e-10
and O 0 2.8021063247507527e-10
a O 0 5.676284331457282e-09
B B-Disease 0 2.6033139874925837e-06
- I-Disease 0 8.064335474955442e-07
NHL I-Disease 0 6.341084826999577e-06
cell O 0 1.6318117559421808e-05
line O 0 3.1655351904191775e-06
. O 0 6.848501357126224e-07

The O 0 8.836710208015575e-08
evidence O 0 9.542882928315066e-09
of O 0 1.330384802322726e-09
a O 0 2.966407119942005e-10
significant O 0 9.913710824482891e-11
proportion O 0 1.3404936882732699e-10
of O 0 2.039332924752557e-09
loss O 0 3.562637962417625e-09
- O 0 9.343810347672843e-08
of O 0 4.005783011962194e-07
- O 0 1.1035747604637436e-07
function O 0 1.5277744624953016e-09
mutations O 0 7.378888472464595e-11
and O 0 4.6261768721356233e-11
a O 0 2.988543856830006e-10
complete O 0 7.684921143891188e-09
absence O 0 5.7130868924559763e-08
of O 0 2.956112021834656e-09
the O 0 2.1917724579711972e-10
normal O 0 7.499282861367362e-10
copy O 0 1.4959695704419573e-08
of O 0 5.713781003890972e-09
ATM O 0 1.2722401834253105e-06
in O 0 8.016073138605861e-09
the O 0 9.63131352449409e-09
majority O 0 2.464017323511314e-10
of O 0 1.180843511860985e-08
mutated O 0 1.961014390872151e-07
tumours B-Disease 1 0.9999998807907104
establishes O 0 3.1113394527437777e-08
somatic O 0 4.2323540583311114e-07
inactivation O 0 6.129597522885888e-07
of O 0 2.4802782050414862e-08
this O 0 1.1826770118794627e-10
gene O 0 5.8169424138609926e-11
in O 0 1.6600695817992062e-10
the O 0 6.521046480578718e-10
pathogenesis O 0 6.634238616243238e-07
of O 0 2.041349844716933e-08
sporadic B-Disease 0 9.241581210517325e-06
T I-Disease 0 0.1984190046787262
- I-Disease 1 0.8054599165916443
PLL I-Disease 1 0.9692195653915405
and O 0 2.6583627743548277e-08
suggests O 0 1.4179772911404598e-08
that O 0 5.783708234563534e-11
ATM O 0 3.202337950369838e-07
acts O 0 1.3484112493244993e-08
as O 0 2.8511259131391853e-08
a O 0 1.6313185824401444e-07
tumour B-Disease 1 1.0
suppressor O 0 0.00940977968275547
. O 0 5.834067906107521e-06

As O 0 2.0366253750125907e-07
constitutional O 0 9.46757552355848e-08
DNA O 0 3.60315013381296e-08
was O 0 8.585912425473907e-09
not O 0 1.2620160472209818e-10
available O 0 1.2127046034038358e-09
, O 0 1.8647192123744105e-10
a O 0 1.0007396022970738e-09
putative O 0 1.94213453141856e-06
hereditary O 1 0.9999971389770508
predisposition O 1 0.9999996423721313
to O 0 0.00019094947492703795
T B-Disease 1 0.9999748468399048
- I-Disease 1 0.94060218334198
PLL I-Disease 0 0.00020444512483663857
will O 0 5.312600137585832e-09
require O 0 4.3722181430894125e-09
further O 0 1.5870984526600296e-09
investigation O 0 1.943982752550255e-09
. O 0 4.235783723771647e-09
. O 0 1.0808434325326743e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 2.2984070824350056e-07
kinase O 0 6.080087189275218e-08
is O 0 8.860241706987182e-11
involved O 0 1.0516058857046318e-10
in O 0 1.2991395459405197e-10
the O 0 7.584238237434704e-10
modulation O 0 2.875099447408047e-08
of O 0 7.869955354067315e-09
the O 0 9.379607313064753e-09
Ca2 O 0 1.566763444316166e-06
+ O 0 1.934184638230363e-06
homeostasis O 0 5.997817424940877e-06
in O 0 1.2105265057016368e-07
skeletal O 0 4.866012022830546e-05
muscle O 0 2.034962562902365e-06
cells O 0 1.2418259984769975e-06
. O 0 9.645616501074983e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 5.0464750529499725e-06
DM B-Disease 1 1.0
) O 0 1.0641834968794228e-08
, O 0 7.246406252825466e-10
the O 0 5.843845962694161e-10
most O 0 1.9814727636457974e-10
prevalent O 0 2.1831719720921683e-07
muscular B-Disease 0 1.3595750942840823e-06
disorder I-Disease 0 8.732893519436402e-08
in O 0 1.8800541679020455e-10
adults O 0 5.79699448166604e-11
, O 0 1.4860251917880873e-11
is O 0 7.127090150688131e-12
caused O 0 7.919487288177152e-11
by O 0 7.510959909584614e-11
( O 0 2.346312311107823e-10
CTG O 0 3.6659699276242463e-08
) O 0 1.4634896072784898e-10
n O 0 6.402302021868422e-10
- O 0 3.5095792938477643e-09
repeat O 0 9.564216085777844e-10
expansion O 0 1.2101859514501712e-09
in O 0 3.049197005999815e-10
a O 0 1.669293175909914e-10
gene O 0 4.135969344787327e-11
encoding O 0 1.0325181820647344e-09
a O 0 4.525398722421414e-09
protein O 0 9.678085888253918e-09
kinase O 0 5.778787226518034e-07
( O 0 2.0381053289497686e-08
DM B-Disease 1 1.0
protein O 0 9.922123922478931e-08
kinase O 0 1.1683583522881236e-07
; O 0 2.103984098056344e-09
DMPK O 0 3.3285377867287025e-06
) O 0 4.254923913205033e-10
and O 0 1.4893289379536157e-10
involves O 0 4.1122708016594345e-10
changes O 0 9.65571622657535e-10
in O 0 3.284842620132622e-09
cytoarchitecture O 0 1.2297975899855373e-06
and O 0 3.274647752959936e-08
ion O 0 8.999230885819998e-06
homeostasis O 0 0.0005453312187455595
. O 0 1.5619294572388753e-05

To O 0 7.79535085371208e-08
obtain O 0 1.4571008932762197e-07
clues O 0 2.81568560467349e-07
to O 0 1.5929547680926248e-09
the O 0 5.374769518340372e-10
normal O 0 2.903666862508203e-09
biological O 0 1.3247490215917423e-08
role O 0 1.7822536335643235e-08
of O 0 4.6307832235470414e-08
DMPK O 0 0.00015660379722248763
in O 0 6.900293669787061e-08
cellular O 0 5.966680305391492e-07
ion O 0 5.303136845213885e-07
homeostasis O 0 6.668773494311608e-06
, O 0 1.2717626063363241e-08
we O 0 2.5221431609878664e-09
have O 0 2.832034329269817e-10
compared O 0 6.794292906064925e-10
the O 0 1.2466739862659892e-09
resting O 0 6.123520535084026e-08
[ O 0 4.936706687885817e-08
Ca2 O 0 1.1036379277129527e-07
+ O 0 6.069242175499312e-08
] O 0 3.452219132782375e-08
i O 0 5.539687375488711e-09
, O 0 2.620327843594339e-10
the O 0 1.1780301734098941e-10
amplitude O 0 4.742728432205467e-10
and O 0 3.335068610166303e-10
shape O 0 1.149068928896213e-08
of O 0 2.7784897937976893e-08
depolarization O 0 1.2246498215517931e-07
- O 0 1.7794012308058882e-07
induced O 0 7.104979715677473e-08
Ca2 O 0 4.297364242233925e-08
+ O 0 3.000970849598161e-08
transients O 0 1.044729547317047e-08
, O 0 1.2856264663962946e-10
and O 0 1.0726292076768118e-10
the O 0 2.2256001208642573e-10
content O 0 6.291753229525909e-10
of O 0 6.678452790787048e-10
ATP O 0 1.1963527413172415e-07
- O 0 3.42873960335055e-08
driven O 0 5.0354575620303876e-08
ion O 0 9.723848393150547e-08
pumps O 0 2.8624495485018997e-07
in O 0 1.6684925441268206e-08
cultured O 0 5.646356657962315e-05
skeletal O 0 0.001446814858354628
muscle O 0 1.3478666005539708e-07
cells O 0 2.3001385685006426e-08
of O 0 3.923486868728787e-09
wild O 0 1.0557765772745142e-09
- O 0 4.313901680319532e-09
type O 0 1.0667664973595947e-08
and O 0 4.9175237215592915e-09
DMPK O 0 5.313285510055721e-05
[ O 0 8.251246867985174e-07
- O 0 7.00112013873877e-06
/ O 0 7.436557643814012e-05
- O 0 7.182586705312133e-05
] O 0 4.8047299969766755e-06
knockout O 0 3.564673170330934e-05
mice O 0 1.005115973384818e-05
. O 0 7.942580850794911e-07

In O 0 2.121996516279978e-07
vitro O 0 4.859317641603411e-07
- O 0 4.692434742992191e-07
differentiated O 0 2.704876180814608e-07
DMPK O 0 3.167775139445439e-05
[ O 0 2.2979685354584944e-07
- O 0 7.670586228414322e-07
/ O 0 1.6566066278755898e-06
- O 0 1.5655028846595087e-06
] O 0 1.2918718539367546e-07
myotubes O 0 2.644663368300826e-07
exhibit O 0 7.565748028071084e-09
a O 0 6.180153611090589e-10
higher O 0 5.163693916898637e-09
resting O 0 2.907748353209172e-07
[ O 0 2.5344544951622083e-07
Ca2 O 0 1.5459131645911839e-06
+ O 0 1.1460197129053995e-06
] O 0 2.2503949992369598e-07
i O 0 4.862627278612308e-08
than O 0 1.1483189954475392e-09
do O 0 1.1791886356249393e-09
wild O 0 4.674495013290425e-09
- O 0 1.5720235779781433e-08
type O 0 1.3244282115465467e-08
myotubes O 0 2.2969783231019392e-07
because O 0 2.321765141255483e-10
of O 0 5.489188548146728e-10
an O 0 1.317422039515126e-11
altered O 0 2.7808941260865083e-10
open O 0 1.955335671155467e-09
probability O 0 6.950030551067243e-10
of O 0 3.512591051357816e-10
voltage O 0 1.1982705494517631e-08
- O 0 7.169123961148216e-08
dependent O 0 6.371365657287242e-08
l O 0 8.50554329190345e-08
- O 0 1.062654675365593e-07
type O 0 3.477782328786816e-08
Ca2 O 0 2.8724966227855475e-07
+ O 0 1.3749766480941616e-07
and O 0 1.1523149545666911e-08
Na O 0 5.366003733797697e-06
+ O 0 1.5625852256562212e-06
channels O 0 4.3609435351754655e-07
. O 0 2.3633513990262145e-07

The O 0 2.042292180703953e-06
mutant O 0 1.6855515241331887e-06
myotubes O 0 5.29836233909009e-06
exhibit O 0 8.349244495775565e-08
smaller O 0 1.5986679757773459e-09
and O 0 5.134123792771561e-09
slower O 0 1.912572002993329e-07
Ca2 O 0 5.760255703535222e-07
+ O 0 9.663371258739062e-08
responses O 0 2.363070183974969e-09
upon O 0 2.32394148369508e-09
triggering O 0 8.692657260667147e-09
by O 0 2.1006829609149236e-10
acetylcholine O 0 9.519341759300914e-09
or O 0 9.240709530899949e-09
high O 0 5.277093961808532e-08
external O 0 6.21226945440867e-07
K O 0 2.933547875727527e-06
+ O 0 1.9949579836975317e-06
. O 0 2.435313888327073e-07

In O 0 1.5114045481823268e-07
addition O 0 3.2877153444133e-08
, O 0 1.5153013288582429e-09
we O 0 9.595277905560806e-10
observed O 0 6.629135573810174e-10
that O 0 2.0241362405637453e-11
these O 0 1.0486474882887009e-10
Ca2 O 0 2.151109015358088e-07
+ O 0 5.408298306974757e-07
transients O 0 7.768455390078088e-08
partially O 0 1.0721435295124593e-08
result O 0 2.7063484786538083e-10
from O 0 9.61825133427574e-11
an O 0 2.164439981411359e-11
influx O 0 2.769481588504874e-10
of O 0 3.723924224541264e-10
extracellular O 0 1.3788030717165611e-09
Ca2 O 0 3.956056104925665e-08
+ O 0 9.940209544367917e-09
through O 0 3.665903414162841e-10
the O 0 1.3106937757356718e-09
l O 0 1.4393104486032371e-08
- O 0 3.8454299300383354e-08
type O 0 3.4603143461708896e-08
Ca2 O 0 6.493103228422115e-07
+ O 0 4.4962561673855816e-07
channel O 0 2.584368132829695e-07
. O 0 1.5410952869387984e-07

Neither O 0 7.799498007443617e-07
the O 0 9.636917930322397e-09
content O 0 1.3095492468195857e-09
nor O 0 3.7162699584314396e-09
the O 0 2.2348776995695374e-10
activity O 0 3.07490644058106e-10
of O 0 1.1433295421525713e-09
Na O 0 1.6432131815236062e-06
+ O 0 7.877284815549501e-07
/ O 0 1.4943346968721016e-06
K O 0 7.787606364217936e-07
+ O 0 5.632521151710534e-07
ATPase O 0 3.7985387280059513e-06
and O 0 5.481765086301493e-08
sarcoplasmic O 0 4.194580469629727e-05
reticulum O 0 4.431833986018319e-06
Ca2 O 0 3.2497459869773593e-06
+ O 0 1.5386281120299827e-06
- O 0 7.274676363522303e-07
ATPase O 0 1.3726161114391289e-06
are O 0 4.809694309493295e-10
affected O 0 2.4968851430884342e-09
by O 0 1.4809279358374283e-09
DMPK O 0 9.770542965270579e-05
absence O 0 6.272399332374334e-06
. O 0 1.2960863386979327e-06

In O 0 1.3957891553673107e-07
conclusion O 0 6.037524968860453e-08
, O 0 6.899277149585714e-09
our O 0 4.88906470863526e-09
data O 0 8.29138002700347e-09
suggest O 0 1.5321370838705661e-09
that O 0 1.180979619652689e-10
DMPK O 0 5.610573339254188e-07
is O 0 5.991503820856892e-11
involved O 0 6.289205961573785e-11
in O 0 3.859342845302649e-10
modulating O 0 9.634972997218938e-08
the O 0 1.991029208170403e-08
initial O 0 1.2490237288886874e-08
events O 0 1.3615469862671148e-09
of O 0 3.4355327471757846e-09
excitation O 0 6.186456857903977e-07
- O 0 4.621280822902918e-06
contraction O 0 5.5817970689986396e-08
coupling O 0 2.0062243422103165e-08
in O 0 1.2891981704399313e-08
skeletal O 0 4.681841801357223e-06
muscle O 0 3.1665271649217175e-07
. O 0 4.5016147254273164e-08
. O 0 2.0495433261658036e-07

Constitutional O 0 8.984393207356334e-05
RB1 O 0 0.002100424375385046
- O 0 2.7551872335607186e-05
gene O 0 4.969005473753896e-08
mutations O 0 1.4912121315546756e-08
in O 0 3.5400480324909722e-09
patients O 0 1.4518999336132765e-08
with O 0 2.39836900339796e-10
isolated O 0 5.463248342607585e-08
unilateral B-Disease 0 2.3532695649919333e-06
retinoblastoma I-Disease 1 0.9460378289222717
. O 0 0.0002377299970248714

In O 0 1.9177299748207588e-07
most O 0 3.4620684097319554e-09
patients O 0 3.4008291738274465e-09
with O 0 6.271932279089398e-11
isolated O 0 1.773393165649395e-08
unilateral B-Disease 0 1.417692828908912e-06
retinoblastoma I-Disease 1 0.9972277283668518
, O 0 1.3902639750540402e-07
tumor B-Disease 0 1.5749754311400466e-05
development O 0 4.693974275937762e-08
is O 0 7.509326493959634e-11
initiated O 0 6.396687068921381e-10
by O 0 2.884608524267307e-11
somatic O 0 1.4168742623610342e-08
inactivation O 0 1.8085259512190532e-07
of O 0 4.41857253008493e-08
both O 0 2.4302495571504323e-09
alleles O 0 1.2992243947351767e-09
of O 0 7.973437909924996e-09
the O 0 4.572818923520572e-08
RB1 O 0 2.4655097149661742e-05
gene O 0 1.0283800122579123e-07
. O 0 9.46892726005899e-07

However O 0 2.3778203228630446e-07
, O 0 7.174250526986725e-09
some O 0 2.892157624501124e-10
of O 0 5.388072210621431e-10
these O 0 1.0244513570789593e-10
patients O 0 4.61883475910696e-10
can O 0 4.439586198667911e-10
transmit O 0 1.8009770030857908e-07
retinoblastoma B-Disease 0 2.0286581275286153e-05
predisposition O 0 4.910122152068652e-05
to O 0 7.474990297851036e-07
their O 0 5.131253715262574e-07
offspring O 0 2.3003988189884694e-06
. O 0 1.7384611510351533e-06

To O 0 8.097982728827446e-09
determine O 0 1.3211701732629422e-09
the O 0 7.015504843721487e-10
frequency O 0 2.5327938857344634e-08
and O 0 5.084285770173835e-10
nature O 0 2.7868796159680187e-09
of O 0 8.72641248150785e-09
constitutional O 0 2.0651218335387966e-07
RB1 O 0 2.3492679247283377e-05
- O 0 9.161386742562172e-07
gene O 0 8.083985036932972e-09
mutations O 0 4.531764741244615e-09
in O 0 1.7626249348978718e-09
patients O 0 4.7960382332234985e-09
with O 0 1.4883860810499527e-10
isolated O 0 1.4527891778470803e-08
unilateral B-Disease 0 1.7403061747245374e-07
retinoblastoma I-Disease 0 0.008117117919027805
, O 0 5.727554253098788e-08
we O 0 1.8172563898133376e-08
analyzed O 0 2.7301071625629447e-08
DNA O 0 6.454011014511707e-08
from O 0 2.3981014507512555e-08
peripheral O 0 1.1478198757686187e-05
blood O 0 2.6207510472886497e-07
and O 0 3.3225511231194105e-08
from O 0 1.2994213705042057e-07
tumor B-Disease 0 2.166088597732596e-05
tissue O 0 5.521837465494173e-06
. O 0 3.0580235943489242e-06

The O 0 6.492669513136207e-08
analysis O 0 2.2424462287062852e-08
of O 0 2.9348715457899743e-08
tumors B-Disease 1 1.0
from O 0 2.564042844710457e-08
54 O 0 6.529466389793015e-08
( O 0 7.221597209117192e-10
71 O 0 2.295878331892709e-08
% O 0 3.6009825676863727e-10
) O 0 4.570579678619957e-11
of O 0 2.705811963377158e-10
76 O 0 1.1405770550254601e-08
informative O 0 2.248364872059483e-08
patients O 0 1.0098208491626792e-08
showed O 0 4.132409081591959e-09
loss O 0 2.8705606780476955e-09
of O 0 1.2121526005159922e-08
constitutional O 0 1.1649343605313334e-06
heterozygosity O 0 0.143794447183609
( O 0 3.355475655553164e-06
LOH O 1 1.0
) O 0 2.875976790051027e-08
at O 0 1.1222649476394508e-07
intragenic O 0 3.5366122119739885e-06
loci O 0 5.787126724499103e-07
. O 0 4.3879182953787677e-07

Three O 0 1.3766180018137675e-07
of O 0 3.687210892167059e-08
13 O 0 2.7970637006546895e-07
uninformative O 0 0.0002115256356773898
patients O 0 6.084402457418037e-07
had O 0 1.6186513107641076e-07
constitutional O 0 3.98927795686177e-06
deletions O 0 4.520071161095984e-05
. O 0 7.0635574047628324e-06

For O 0 2.3131620707772527e-07
39 O 0 2.992925658418244e-07
randomly O 0 2.0396841549086275e-08
selected O 0 3.8567864635297155e-07
tumors B-Disease 1 1.0
, O 0 2.7542350267140137e-07
SSCP O 0 0.00024495317484252155
, O 0 2.3055761744217307e-08
hetero O 0 5.458164764604589e-07
- O 0 5.53351249266143e-08
duplex O 0 1.190254081961939e-07
analysis O 0 7.546089975107861e-09
, O 0 1.5146012222189142e-10
sequencing O 0 8.574222998269931e-10
, O 0 2.7718174977486854e-10
and O 0 3.177280383237502e-10
Southern O 0 5.955009640956632e-08
blot O 0 1.455757825397086e-07
analysis O 0 1.1748938488764793e-09
were O 0 7.76726294393626e-10
used O 0 2.8090372250488826e-09
to O 0 4.692253252613909e-09
identify O 0 6.066625957146243e-08
mutations O 0 1.2405008931182238e-07
. O 0 2.0623795080609852e-06

Mutations O 0 3.3835368640211527e-07
were O 0 1.810078309461005e-08
detected O 0 1.6740807851078898e-08
in O 0 1.2443838182107925e-09
21 O 0 5.1364089870276075e-08
( O 0 8.103632764822066e-10
91 O 0 3.7293084176326374e-08
% O 0 4.918496721018073e-10
) O 0 1.175272101860969e-10
of O 0 3.2002476224590737e-09
23 O 0 2.361941596973338e-06
tumors B-Disease 1 1.0
with O 0 1.9948434783145785e-05
LOH O 1 1.0
. O 0 0.0003391942591406405

In O 0 9.862707628371936e-08
6 O 0 2.943382355624635e-07
( O 0 1.3065180048954517e-09
38 O 0 8.011350693948316e-09
% O 0 1.9333176726199497e-10
) O 0 5.851751028185248e-11
of O 0 4.742475301355853e-10
16 O 0 1.2122478665332892e-07
tumors B-Disease 1 1.0
without O 1 0.5883216261863708
LOH O 1 1.0
, O 0 1.5425177579686533e-08
one O 0 6.029567956034043e-10
mutation O 0 3.1553756829616475e-10
was O 0 1.4480798782301463e-09
detected O 0 3.030436346307397e-09
, O 0 6.511535755038267e-11
and O 0 1.2343132071990226e-10
in O 0 8.797937378623999e-10
9 O 0 1.286302762082414e-07
( O 0 9.841502057739149e-10
56 O 0 7.599924245482725e-09
% O 0 3.2537253447095793e-10
) O 0 1.8335767626442845e-10
of O 0 1.2295603424306023e-09
the O 0 1.9083300273337045e-08
tumors B-Disease 1 1.0
without O 1 0.9991324543952942
LOH O 1 1.0
, O 0 4.9207347530000334e-08
both O 0 4.522370034010237e-09
mutations O 0 5.035128758379415e-09
were O 0 1.525227588672351e-08
found O 0 1.6149639847640174e-08
. O 0 1.1944671030050813e-07

Thus O 0 8.23761538981671e-08
, O 0 9.207875018013567e-10
a O 0 2.7764154864051704e-10
total O 0 3.023102879140538e-10
of O 0 8.467125334199466e-10
45 O 0 4.288412291941768e-09
mutations O 0 3.6823155635801186e-10
were O 0 5.404336533842979e-09
identified O 0 3.4832655870786766e-08
in O 0 1.0277681639081493e-07
tumors B-Disease 1 1.0
of O 0 1.0737502634583507e-05
36 O 0 8.121874088828918e-07
patients O 0 1.1374881125902903e-07
. O 0 1.8764454523534368e-07

Thirty O 0 2.160116309823934e-06
- O 0 9.131189244726556e-07
nine O 0 8.333759460299461e-09
of O 0 1.98031013809441e-09
the O 0 5.300107575045843e-10
mutations O 0 7.555218117794027e-10
- O 0 3.7094874727472416e-08
including O 0 6.915825245812357e-09
34 O 0 1.9926598326946987e-07
small O 0 1.1751852824204434e-09
mutations O 0 5.165299743481455e-09
, O 0 2.3745190258495086e-09
2 O 0 4.3428232743281114e-07
large O 0 6.349044667786075e-08
structural O 0 0.008183960802853107
alterations O 0 0.010308966040611267
, O 0 2.2065773208623796e-08
and O 0 3.364100553682192e-09
hypermethylation O 0 6.089707312639803e-06
in O 0 4.7614413745122874e-08
3 O 0 3.434805421420606e-06
tumors O 1 1.0
- O 0 3.040070851056953e-06
were O 0 1.7290643583578458e-08
not O 0 2.1111272729967823e-09
detected O 0 5.504435129921603e-09
in O 0 7.935034851414002e-10
the O 0 1.9575525644910385e-09
corresponding O 0 6.014202913462441e-09
peripheral O 0 5.668691187565855e-07
blood O 0 6.697121079923818e-08
DNA O 0 2.887272501084226e-07
. O 0 9.88013880487415e-07

In O 0 1.0225025448562519e-07
6 O 0 8.157218900350927e-08
( O 0 4.751465887409267e-10
17 O 0 2.905339968606313e-09
% O 0 4.842942019633867e-11
) O 0 1.326709228588463e-11
of O 0 4.5981406182615814e-11
the O 0 1.0023284285898271e-10
36 O 0 3.0056090949415193e-09
patients O 0 5.916792611415644e-10
, O 0 7.522214101607361e-11
a O 0 6.695595189398773e-10
mutation O 0 1.3772601947792396e-09
was O 0 4.358961636086178e-09
detected O 0 8.432848197514886e-09
in O 0 9.461591510273593e-10
constitutional O 0 1.3183163893870642e-08
DNA O 0 6.534048413442406e-09
, O 0 4.3254338999432207e-10
and O 0 4.595442637533864e-10
1 O 0 2.2252159226354706e-08
of O 0 2.451039371464958e-09
these O 0 8.878545815216299e-11
mutations O 0 6.988686851450154e-10
is O 0 3.872894366319102e-11
known O 0 2.939053167505534e-10
to O 0 4.0766670594827303e-10
be O 0 4.5233944367950585e-10
associated O 0 5.512462042389643e-09
with O 0 2.0606179262916413e-10
reduced O 0 1.8062610251945443e-07
expressivity O 0 1.2112037438782863e-05
. O 0 1.5154168977460358e-06

The O 0 1.575220807126243e-07
presence O 0 1.803802440747404e-08
of O 0 8.056155742508508e-09
a O 0 1.763960089107286e-09
constitutional O 0 2.5814928861223052e-08
mutation O 0 1.0032966679673905e-09
was O 0 1.7274978114656392e-09
not O 0 1.7535399521317885e-10
associated O 0 6.692760234905393e-10
with O 0 1.1674184188792402e-11
an O 0 2.7220644141512373e-11
early O 0 3.83305254203492e-09
age O 0 2.000758669851166e-09
at O 0 6.629265580926358e-09
treatment O 0 4.2906645347784433e-08
. O 0 3.0692086738781654e-07

In O 0 8.26331287839821e-08
1 O 0 2.6759602178572095e-07
patient O 0 2.2858291970351274e-07
, O 0 7.2397918771116565e-09
somatic O 0 8.475440154143143e-06
mosaicism O 0 0.00033023772994056344
was O 0 2.2865005178118736e-07
demonstrated O 0 9.865732231162383e-09
by O 0 1.3265126497241653e-10
molecular O 0 1.568716045952101e-09
analysis O 0 2.3784885172517534e-10
of O 0 4.682488286000819e-10
DNA O 0 1.4796941449901624e-09
and O 0 9.187296479140628e-10
RNA O 0 5.3018421652950565e-08
from O 0 4.166196632127139e-08
peripheral O 0 1.2755343050230294e-05
blood O 0 1.8593423192214686e-06
. O 0 1.2188072560093133e-06

In O 0 5.16413045659192e-08
2 O 0 2.194590393855833e-07
patients O 0 1.161496765433867e-08
without O 0 4.2501078212353605e-09
a O 0 2.369695994985932e-09
detectable O 0 6.065828301871079e-07
mutation O 0 3.161268802287509e-09
in O 0 3.0806728279486606e-09
peripheral O 0 3.675341577036306e-05
blood O 0 3.0319929464894813e-06
, O 0 1.3354906513995957e-08
mosaicism O 0 1.1251341675233562e-05
was O 0 3.61235059642695e-08
suggested O 0 1.7904812077418342e-09
because O 0 3.635465886664413e-11
1 O 0 4.391700336725535e-09
of O 0 1.8896935127798997e-09
the O 0 2.46280662530296e-09
patients O 0 9.646664800300186e-09
showed O 0 8.068368373415069e-08
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 7.245624260576733e-07
the O 0 1.7978777577809524e-07
other O 0 1.6596176655170325e-09
later O 0 3.645365964644043e-08
developed O 0 4.411700516016026e-08
bilateral B-Disease 0 8.979137419373728e-06
retinoblastoma I-Disease 0 0.00867275521159172
. O 0 6.802241387049435e-06

In O 0 3.379795288083187e-08
conclusion O 0 2.313320202063096e-08
, O 0 2.0930330801860464e-09
our O 0 2.614502836451038e-09
results O 0 4.100092210190809e-10
emphasize O 0 8.429487330374741e-09
that O 0 9.245760407283754e-11
the O 0 4.497868466568633e-10
manifestation O 0 1.7694636866849578e-08
and O 0 1.1046835668437893e-09
transmissibility O 0 7.799944228281674e-07
of O 0 9.851047089171061e-09
retinoblastoma B-Disease 0 1.1369957064744085e-07
depend O 0 3.568269013598524e-09
on O 0 8.825152164604333e-09
the O 0 3.804802861662182e-10
nature O 0 1.1020692691765532e-10
of O 0 3.793817204833516e-10
the O 0 1.3648875085703338e-10
first O 0 5.755231846649167e-10
mutation O 0 1.33565991600193e-10
, O 0 4.5026728873187594e-11
its O 0 3.734840908764525e-11
time O 0 2.0432565361883093e-10
in O 0 8.102422899280981e-11
development O 0 1.045670106059049e-09
, O 0 2.9949293045561376e-10
and O 0 4.1509556902852296e-10
the O 0 2.550652133948006e-09
number O 0 2.391021158842932e-09
and O 0 9.661519362325066e-10
types O 0 4.4082518968480144e-08
of O 0 8.995487910112843e-09
cells O 0 5.490154109111245e-09
that O 0 1.1814595135550832e-10
are O 0 3.947939544723944e-11
affected O 0 8.716526944674285e-10
. O 0 6.29682261887865e-09
. O 0 4.004377274213766e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 0.9999994039535522
of I-Disease 0 0.00020580321142915636
the I-Disease 0 8.912387556847534e-07
fifth I-Disease 0 6.138723733783991e-07
component I-Disease 0 3.2575474762097656e-08
of I-Disease 0 2.7637787614054332e-09
complement I-Disease 0 1.0545454287580469e-08
in O 0 5.174946693387028e-08
man O 0 2.879621888496331e-06
. O 0 3.3130763767985627e-06

I O 0 0.0017426718259230256
. O 0 2.43113208853174e-05

Clinical O 0 3.8210448110476136e-05
, O 0 6.085110726417042e-08
immunochemical O 0 4.700950285041472e-06
, O 0 6.918820627532796e-09
and O 0 2.1249233483899843e-09
family O 0 3.3459464088281266e-09
studies O 0 3.135401271947558e-08
. O 0 1.7591973744401912e-07

The O 0 4.027279487672786e-07
first O 0 5.1338233220121765e-08
recognized O 0 1.1376113384642395e-08
human O 0 3.3634590668185638e-09
kindred O 0 1.7175851780848461e-06
with O 0 1.2076847966113746e-08
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 1.0
the I-Disease 0 0.0013144841650500894
fifth I-Disease 0 7.966788871272001e-06
component I-Disease 0 3.341452270433365e-07
of I-Disease 0 1.0292335872463809e-07
complement I-Disease 0 1.3572457646660041e-06
( O 0 1.0851130838318568e-07
C5 O 1 0.9752554297447205
) O 0 7.3839498959671346e-09
is O 0 1.4112151447420729e-09
described O 0 3.0143194607035184e-08
. O 0 1.7316742173534294e-07

The O 0 2.946825929939223e-07
proband O 0 4.6485624807246495e-06
, O 0 4.129785402540165e-09
a O 0 1.0891763047027325e-09
20 O 0 1.8024739478761376e-09
- O 0 3.819361271695243e-09
year O 0 9.482730156662456e-10
- O 0 7.376380040113872e-08
old O 0 2.7467532248692805e-08
black O 0 2.6061883762196203e-09
female O 0 2.6654123352898296e-10
with O 0 3.522130920252664e-10
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 1 1.0
age O 0 0.4280886948108673
11 O 0 2.083182607748313e-06
, O 0 1.3891117589537316e-08
lacked O 0 5.847837769579201e-07
serum O 0 1.1021044343806352e-07
hemolytic O 0 5.8374240552439005e-08
complement O 0 7.069735907805352e-09
activity O 0 1.5988669943567402e-08
, O 0 9.399429012901805e-10
even O 0 1.353866241338153e-09
during O 0 2.5442203011039055e-08
remission O 0 8.141121270455187e-07
. O 0 1.459522280811143e-07

C5 O 0 0.005418605636805296
was O 0 4.413217538967729e-06
undetectable O 0 3.438128715060884e-06
in O 0 5.8401044000788715e-09
her O 0 1.863361909215655e-09
serum O 0 1.332643329021721e-08
by O 0 9.305758386091156e-10
both O 0 1.131860649650207e-08
immunodiffusion O 0 1.7173630112665705e-05
and O 0 2.6701428623709944e-07
hemolytic O 0 3.1980925996322185e-05
assays O 0 3.425186514505185e-05
. O 0 1.1896499927388504e-05

Other O 0 1.6865833174506406e-08
complement O 0 5.562334148834225e-09
components O 0 5.574466044322435e-08
were O 0 3.094488443267096e-09
normal O 0 6.842205468871043e-09
during O 0 1.0547888784628867e-08
remission O 0 2.186084486766049e-07
of O 0 1.2111565084182985e-08
lupus O 0 9.08776030428271e-07
, O 0 3.1860871718691897e-09
but O 0 1.862864529300623e-09
C1 O 0 0.00039232333074323833
, O 0 2.7385246070821267e-08
C4 O 1 0.9971312284469604
, O 0 4.802466690989604e-08
C2 O 0 2.6488018193049356e-05
, O 0 6.748936076661494e-09
and O 0 3.0733307010422095e-09
C3 O 0 0.00010339414438931271
levels O 0 4.332004209572915e-06
fell O 0 1.929998234118102e-06
during O 0 2.4231928819062887e-07
exacerbations O 0 0.0004088992136530578
. O 0 1.0936065564237651e-06

A O 0 6.514627330034273e-06
younger O 0 1.7793063022963906e-07
half O 0 1.0971166197748516e-08
- O 0 7.285174774551706e-08
sister O 0 4.2359555862958587e-08
, O 0 5.026511651351484e-09
who O 0 4.6541663856203286e-09
had O 0 2.4485689920084042e-08
no O 0 5.072434916542079e-08
underlying O 0 0.23917360603809357
disease O 0 2.7734689865610562e-05
, O 0 6.006244390732718e-10
was O 0 1.1783105691165474e-07
also O 0 9.079175633530667e-09
found O 0 5.851254591959787e-09
to O 0 4.729742997255926e-08
lack O 0 1.3777761523670051e-05
immunochemically O 0 0.0006756992661394179
detectable O 0 4.692462971433997e-05
C5 O 0 7.314719550777227e-05
. O 0 3.9366850614896975e-06

By O 0 2.6650369022718223e-07
hemolytic O 0 6.44335614197189e-06
assay O 0 4.1355346525051573e-07
, O 0 9.02096886079562e-09
she O 0 1.0753583579159454e-09
exhibited O 0 5.318023799105731e-09
1 O 0 2.2674344180018124e-08
- O 0 1.2050139730490628e-07
2 O 0 3.6536423664301765e-08
% O 0 7.928529499601211e-10
of O 0 6.007883079917065e-10
the O 0 2.805592980159588e-10
normal O 0 1.8359372688792064e-08
serum O 0 1.0842835251878569e-07
C5 O 0 2.3529889858764363e-06
level O 0 1.9185091559847933e-07
and O 0 6.012207176553375e-09
normal O 0 3.7743987491012376e-08
concentrations O 0 7.990203698682308e-08
of O 0 4.731274483305015e-09
other O 0 4.3834383345320305e-10
complement O 0 7.889839892527561e-09
components O 0 7.642022978870955e-07
. O 0 8.955002499533293e-07

C5 O 0 0.0001172639022115618
levels O 0 2.547846236211626e-07
of O 0 7.12628533960924e-09
other O 0 1.9768524317509417e-10
family O 0 5.43623514259739e-11
members O 0 8.114528146641042e-12
were O 0 1.5417221665980918e-10
either O 0 3.3691333056751205e-10
normal O 0 4.207450743365371e-08
or O 0 1.3097816164986398e-09
approximately O 0 1.2897255485810888e-10
half O 0 9.331473094231768e-11
- O 0 5.835283367616739e-09
normal O 0 6.782552741668724e-09
, O 0 9.980061221881442e-10
consistent O 0 3.802848169698336e-08
with O 0 8.779263427349804e-10
autosomal O 0 2.757383583684714e-07
codominant O 0 7.273698656717897e-07
inheritance O 0 7.707673610468646e-09
of O 0 5.298200100867234e-09
the O 0 2.355950545762653e-09
gene O 0 1.9294478903475465e-08
determining O 0 7.784140507283155e-06
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 3.053174077649601e-05

Normal O 0 1.8315449779038318e-05
hemolytic O 0 4.150940367253497e-05
titers O 0 8.476135008095298e-06
were O 0 2.807388987946524e-08
restored O 0 3.68508466408457e-07
to O 0 9.166646108837995e-09
both O 0 1.1704568869674858e-08
homozygous O 0 0.000579026760533452
C5 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
( O 0 1.7081206351576839e-06
C5D B-Disease 1 1.0
) O 0 9.546360146828192e-09
sera O 0 5.8506660849388936e-08
by O 0 4.1365688652206245e-11
addition O 0 3.3014108113960106e-10
of O 0 8.70904848238041e-10
highly O 0 6.498192206549902e-09
purified O 0 5.435579808477087e-08
human O 0 5.0176154786640836e-08
C5 O 0 0.00016874798166099936
. O 0 1.662991962803062e-06

In O 0 7.83994721587078e-07
specific O 0 3.5325700764587964e-07
C5 O 0 0.00011990620259894058
titrations O 0 9.63070215220796e-06
, O 0 3.871996945292722e-09
however O 0 1.0499509039973987e-09
, O 0 1.342369132517618e-10
it O 0 1.3281879068793856e-11
was O 0 6.214823100592071e-10
noted O 0 8.7922341629465e-10
that O 0 1.2763998191722692e-11
when O 0 7.252941996993556e-11
limited O 0 9.145510460051298e-10
amounts O 0 1.1462860660671481e-09
of O 0 4.2191090621201965e-09
C5 O 0 9.208960136675159e-07
were O 0 1.9026275666078618e-08
assayed O 0 1.4979345053234283e-07
in O 0 2.72244116139575e-09
the O 0 1.6470038666227538e-09
presence O 0 7.332733309439732e-10
of O 0 1.0743742562269176e-09
low O 0 1.4596607478267742e-08
dilutions O 0 2.919942119206098e-07
of O 0 6.6895222694540735e-09
either O 0 1.7758404524670368e-08
C5D B-Disease 1 1.0
serum O 0 3.2382973813582794e-07
, O 0 1.695070750429295e-09
curving O 0 8.987427690954064e-09
rather O 0 8.127331585505715e-10
than O 0 3.816714305715507e-11
linear O 0 2.855395087042467e-10
dose O 0 1.0085874180276733e-07
- O 0 9.612377027679031e-08
response O 0 5.470909947291602e-09
plots O 0 6.607022928761808e-09
were O 0 7.169886462321529e-09
consistently O 0 6.457493650913193e-09
obtained O 0 5.000768688034896e-09
, O 0 1.2831871121221639e-09
suggesting O 0 1.6977789174532631e-09
some O 0 4.693698554825154e-11
inhibitory O 0 2.199165649585666e-08
effect O 0 1.0940076577981017e-07
. O 0 7.384446121250221e-07

Further O 0 2.67991111968513e-07
studies O 0 4.019627652951385e-08
suggested O 0 8.512307303476518e-09
that O 0 2.964732626065114e-10
low O 0 3.386053748499762e-08
dilutions O 0 2.3611826236447087e-06
of O 0 1.244223568619418e-07
C5D B-Disease 1 1.0
serum O 0 3.4740901355689857e-07
contain O 0 2.4924979857843255e-09
a O 0 5.176738482326471e-10
factor O 0 1.6855501439039244e-09
( O 0 4.065638450900799e-11
or O 0 8.375087429124406e-11
factors O 0 3.780994961566364e-10
) O 0 8.542942048217483e-11
interfering O 0 8.40567793147784e-09
at O 0 1.4766753153594436e-08
some O 0 5.506721745263121e-10
step O 0 7.254084444241471e-09
in O 0 1.956298234517817e-09
the O 0 3.966685646616952e-09
hemolytic O 0 2.2264096344315476e-07
assay O 0 1.5445279188952554e-07
of O 0 8.844093599691405e-07
C5 O 0 8.299537148559466e-05
, O 0 4.011866394648678e-09
rather O 0 1.3209232596622655e-09
than O 0 2.715563052202441e-10
a O 0 1.82325143871509e-09
true O 0 2.412171085097725e-08
C5 O 0 9.71218105405569e-06
inhibitor O 0 5.053175300417934e-07
or O 0 5.6505026435615946e-08
inactivator O 0 1.557948417030275e-05
. O 0 1.0112435120390728e-06

Of O 0 2.6439672637934564e-06
clinical O 0 5.386460998124676e-06
interest O 0 2.202213664759256e-07
are O 0 4.256571761729333e-10
( O 0 1.9964881137202184e-10
a O 0 1.4156147365440575e-09
) O 0 1.472623550879959e-10
the O 0 7.445778438253114e-10
documentation O 0 2.472118012519786e-06
of O 0 2.9688447966691456e-07
membranous O 1 0.9999213218688965
glomerulonephritis B-Disease 1 1.0
, O 0 5.560996214626357e-06
vasculitis B-Disease 1 1.0
, O 0 4.6689279997735866e-08
and O 0 3.7121203888546006e-08
arthritis B-Disease 1 1.0
in O 0 2.7255493861844116e-08
an O 0 2.7550142722709836e-10
individual O 0 1.436503277441048e-10
lacking O 0 1.0096727010022732e-06
C5 O 0 0.00036610409733839333
( O 0 1.4362545597279563e-09
and O 0 5.009004322431565e-10
its O 0 1.310298258783149e-10
biologic O 0 2.1978573627734477e-08
functions O 0 7.713376048990028e-10
) O 0 3.831484435279364e-11
, O 0 4.396213254542758e-11
and O 0 6.202658525689131e-11
( O 0 7.797629208994294e-11
b O 0 4.909229911476132e-09
) O 0 4.228433922448538e-11
a O 0 2.594492121144043e-10
remarkable O 0 2.3530404291705054e-09
propensity O 0 1.7578858546585252e-07
to O 0 7.2838788334195215e-09
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 8.004091833768712e-10
the O 0 5.884806530964681e-10
proband O 0 3.4915203173113696e-08
, O 0 1.8805490498152722e-10
even O 0 1.0094289293327563e-10
during O 0 5.477474585013908e-10
periods O 0 3.5092446726281423e-09
of O 0 3.800545711474257e-10
low O 0 1.8135227763949047e-09
- O 0 9.987716209636233e-10
dose O 0 3.984406138357599e-09
or O 0 3.4658195757764076e-10
alternate O 0 2.77550249450087e-08
- O 0 7.774931418680353e-07
day O 0 1.5110254025785252e-07
corticosteroid O 0 4.929691203869879e-05
therapy O 0 2.2540800273418427e-05
. O 0 2.074470302204645e-07

Other O 0 9.559374092305006e-08
observations O 0 6.781740324868224e-08
indicate O 0 1.541955896300351e-08
that O 0 2.1711309139416102e-10
the O 0 5.016053350459515e-09
C5D B-Disease 1 1.0
state O 0 3.1681621770474067e-09
is O 0 1.2593638631930304e-10
compatible O 0 1.4010324456137369e-08
with O 0 4.6142270559990095e-11
normal O 0 1.188118048389697e-08
coagulation O 0 4.769901806866983e-09
function O 0 5.070824316000255e-10
and O 0 2.4695365197224817e-10
the O 0 1.4964968153563518e-09
capacity O 0 4.0235836884505716e-09
to O 0 3.753899413538875e-09
mount O 0 5.975767635391094e-06
a O 0 2.499116931176104e-07
neutrophilic O 0 0.0008466157014481723
leukocytosis O 0 6.819389818701893e-05
during O 0 5.314626378094545e-06
pyogenic B-Disease 0 0.00030062778387218714
infection I-Disease 0 3.73955884924726e-07
. O 0 7.531825829687477e-09
. O 0 5.388776003201201e-08

Susceptibility O 0 0.000639290374238044
to O 0 1.131443877966376e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 1.923883246490732e-05
twins O 0 3.4431843687343644e-07
: O 0 4.755736360273488e-10
the O 0 2.7670635227572404e-10
role O 0 1.9631234415840026e-09
of O 0 5.381767920198399e-09
genes O 0 5.365123456613219e-09
, O 0 4.537143993843529e-09
HLA O 0 4.493827509577386e-05
, O 0 2.3958705241966527e-08
and O 0 1.5729954228049792e-08
the O 0 7.544827695937784e-08
environment O 0 4.427988073985034e-07
. O 0 6.177555178510374e-07

OBJECTIVE O 0 1.6662985217408277e-05
To O 0 1.4465457276457983e-08
determine O 0 1.585111042423648e-09
the O 0 6.849057432312122e-10
relative O 0 3.2497283086740936e-08
effects O 0 2.281686732885646e-07
of O 0 2.1647363013244103e-08
genetic O 0 9.701095926573089e-09
and O 0 4.3007788996796137e-10
environmental O 0 2.55957055550482e-09
factors O 0 5.562776905776445e-10
in O 0 1.9829964059692173e-10
susceptibility O 0 6.897122517557364e-08
to O 0 1.8598140059111756e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 1.8688853060666588e-06
AS B-Disease 1 1.0
) O 0 5.9362159632314615e-09
. O 0 2.187969627698294e-08

METHODS O 0 7.896548595454078e-06
Twins O 0 1.2978402992303018e-06
with O 0 1.2266604398902814e-09
AS B-Disease 1 0.9999992847442627
were O 0 1.4530101566379017e-09
identified O 0 5.389674817557477e-10
from O 0 1.2551552852624326e-10
the O 0 8.27773960487832e-10
Royal O 0 1.601131043571513e-05
National O 0 5.12108817929402e-06
Hospital O 1 0.9005792140960693
for O 0 1.7101372407068993e-07
Rheumatic B-Disease 1 0.9999920129776001
Diseases I-Disease 1 0.9999943971633911
database O 0 5.643501026497688e-07
. O 0 4.829997237720818e-07

Clinical O 0 1.9852988771162927e-05
and O 0 2.8587821887526843e-08
radiographic O 0 2.5504575660306728e-06
examinations O 0 3.052819238291704e-06
were O 0 2.166309975848435e-08
performed O 0 1.4036966256014693e-08
to O 0 2.911275220895959e-09
establish O 0 3.533034487190889e-08
diagnoses O 0 3.590367668948602e-06
, O 0 2.189604941804646e-09
and O 0 4.10201872469429e-09
disease O 0 2.780033128146897e-07
severity O 0 1.7568730754646822e-06
was O 0 2.8383208672266846e-08
assessed O 0 3.139135174023977e-08
using O 0 1.3355925254643353e-08
a O 0 8.474335011499079e-09
combination O 0 2.145404920383953e-08
of O 0 1.4628659172899461e-08
validated O 0 4.164806099993257e-08
scoring O 0 3.8000930402404265e-08
systems O 0 5.047453441875405e-07
. O 0 4.965235120835132e-07

HLA O 0 0.0008491064654663205
typing O 0 1.4951023331377655e-05
for O 0 2.985277092193428e-08
HLA O 0 2.7138987661601277e-06
- O 0 3.2585346616542665e-06
B27 O 0 1.2489671462390106e-05
, O 0 2.017389588715446e-09
HLA O 0 1.0551333673447516e-07
- O 0 1.3244236640730378e-07
B60 O 0 1.1586312211875338e-06
, O 0 1.1137916144932092e-09
and O 0 5.509190326158375e-10
HLA O 0 1.636855631659273e-05
- O 0 0.000979044707491994
DR1 O 1 0.9999943971633911
was O 0 6.257506584006478e-07
performed O 0 3.3595174642186976e-08
by O 0 1.024211493394489e-09
polymerase O 0 3.125000702652869e-08
chain O 0 9.594844030402783e-09
reaction O 0 5.850280815344888e-10
with O 0 3.319746214036634e-11
sequence O 0 2.090402989596285e-10
- O 0 7.025042325636832e-09
specific O 0 1.2819371120187384e-09
primers O 0 3.82798361897585e-08
, O 0 2.2299522228763635e-09
and O 0 1.661895066007446e-09
zygosity O 0 1.2221512406540569e-06
was O 0 4.6586890789512836e-08
assessed O 0 3.130799797190775e-08
using O 0 1.901107715696071e-08
microsatellite O 0 2.7584353574638953e-06
markers O 0 1.0818257578648627e-06
. O 0 1.1184969253008603e-06

Genetic O 0 2.4101782400975935e-05
and O 0 2.2018769030296426e-08
environmental O 0 8.452510691370207e-09
variance O 0 7.168228233211948e-10
components O 0 1.2620029465892912e-08
were O 0 4.823320853830637e-09
assessed O 0 2.1608089539881803e-08
with O 0 1.0801598504528442e-10
the O 0 2.025474676869976e-09
program O 0 4.351626614607085e-09
Mx O 0 6.394046181412705e-08
, O 0 1.4439008322320035e-10
using O 0 4.439357215169082e-10
data O 0 4.516376994612159e-10
from O 0 2.552776566522308e-11
this O 0 5.4597997130312326e-12
and O 0 4.197721337195759e-11
previous O 0 2.729406700652248e-10
studies O 0 6.96526503141115e-10
of O 0 4.795413510727542e-10
twins O 0 1.3207198890086147e-08
with O 0 8.214072755308166e-10
AS B-Disease 1 1.0
. O 0 2.266912588311243e-06

RESULTS O 0 1.5097492678251e-06
Six O 0 1.2298335150262574e-07
of O 0 1.2910880364813693e-08
8 O 0 5.040569703851361e-07
monozygotic O 0 1.819150747905951e-05
( O 0 6.477949199279465e-08
MZ O 0 0.00020688767835963517
) O 0 1.3394804376787306e-08
twin O 0 1.7319086964562302e-07
pairs O 0 8.088179903609216e-09
were O 0 9.381557752874414e-09
disease O 0 3.2521775494842586e-08
concordant O 0 2.156292566724005e-08
, O 0 3.3031868906796547e-10
compared O 0 1.741945893085628e-10
with O 0 9.875752993160347e-12
4 O 0 2.170214052910069e-08
of O 0 1.200015731228632e-08
15 O 0 3.4861237452332716e-08
B27 O 0 8.540638987142302e-07
- O 0 1.392453555126849e-06
positive O 0 3.822159921895718e-09
dizygotic O 0 2.015580776060233e-06
( O 0 1.401366489517386e-08
DZ O 0 0.0002048419846687466
) O 0 3.149040139760473e-09
twin O 0 1.3386764408096496e-07
pairs O 0 1.9784867077987656e-09
( O 0 1.7627416193377599e-10
27 O 0 9.134950573752576e-09
% O 0 1.0769404118482484e-10
) O 0 1.2349695918678627e-11
and O 0 3.4402834747648825e-11
4 O 0 1.4014654325933407e-08
of O 0 4.99015726518337e-08
32 O 0 5.684802886207763e-07
DZ O 0 0.000353125185938552
twin O 0 1.0170753057536785e-06
pairs O 0 5.508194789172194e-09
overall O 0 4.0780633980830316e-08
( O 0 6.770399796351967e-10
12 O 0 4.960045263402435e-09
. O 0 4.203019043913514e-10
5 O 0 8.1558155784478e-09
% O 0 1.094518031763414e-09
) O 0 1.8419059610863542e-09
. O 0 2.9427527081793414e-08

Nonsignificant O 0 4.769574661622755e-05
increases O 0 3.7450263334903866e-08
in O 0 9.784342225316323e-10
similarity O 0 3.000183435020176e-10
with O 0 9.076788799744495e-12
regard O 0 3.9369800752808715e-09
to O 0 5.037297245991113e-10
age O 0 2.2685753275908382e-09
at O 0 4.15980228041235e-09
disease O 0 1.5185359636404883e-09
onset O 0 4.393595887108859e-08
and O 0 2.775975838087419e-10
all O 0 2.736819382231914e-10
of O 0 1.9642885096260443e-09
the O 0 1.2139682592504641e-09
disease O 0 3.033142625952223e-09
severity O 0 3.891484023910152e-09
scores O 0 4.221392957415304e-10
assessed O 0 2.429151324534473e-09
were O 0 2.413246713572903e-09
noted O 0 5.911798162117066e-09
in O 0 5.5988009783902726e-09
disease O 0 1.152354940359146e-07
- O 0 3.439836575580557e-07
concordant O 0 2.4066805508482503e-06
MZ O 0 0.00019768820493482053
twins O 0 5.414129304881499e-07
compared O 0 3.968904849216415e-08
with O 0 8.853420774279641e-10
concordant O 0 1.598520793777425e-05
DZ O 1 0.9999860525131226
twins O 0 0.00012279466318432242
. O 0 8.07331525720656e-06

HLA O 0 0.0002831981109920889
- O 0 3.309487146907486e-05
B27 O 0 1.3168410077923909e-05
and O 0 2.226760331680566e-09
B60 O 0 2.1196281352331425e-07
were O 0 1.7275768593449925e-09
associated O 0 1.9954347063588784e-09
with O 0 3.896292663507772e-11
the O 0 2.911675123229429e-09
disease O 0 1.258783921542772e-08
in O 0 7.611888896974506e-10
probands O 0 7.607525844832708e-07
, O 0 5.600175878583968e-10
and O 0 4.646739937275157e-10
the O 0 3.765688649792764e-09
rate O 0 1.1627661677948709e-07
of O 0 1.6292414084517759e-09
disease O 0 1.9085255598128015e-09
concordance O 0 1.066229504687044e-08
was O 0 5.73315839247357e-09
significantly O 0 1.848081909727739e-09
increased O 0 1.1307925262826757e-08
among O 0 2.784971808722503e-09
DZ O 0 0.00015598293975926936
twin O 0 2.4411878030150547e-07
pairs O 0 6.457194778874964e-10
in O 0 3.7726313739661066e-10
which O 0 3.933838671477119e-11
the O 0 2.425613043754993e-10
co O 0 4.697088495930757e-09
- O 0 1.3560305944793072e-07
twin O 0 2.457117034282419e-07
was O 0 3.1216885076901235e-08
positive O 0 6.154556864146343e-10
for O 0 4.3529777005169024e-10
both O 0 1.883680322833925e-09
B27 O 0 7.659894436073955e-06
and O 0 2.0134680767114332e-07
DR1 O 1 0.9917795062065125
. O 0 5.81808808419737e-06

Additive O 0 2.0877566839772044e-06
genetic O 0 2.1553967144427588e-07
effects O 0 5.2982230158704624e-08
were O 0 3.839535356320312e-09
estimated O 0 2.484124850266056e-10
to O 0 1.2905844448685144e-10
contribute O 0 1.0265897021355386e-09
97 O 0 1.2369025625957875e-07
% O 0 4.795761565645762e-10
of O 0 4.096434025324669e-10
the O 0 1.9822363195309833e-10
population O 0 4.853268828486357e-12
variance O 0 4.4944895027931864e-10
. O 0 2.8376604177537956e-08

CONCLUSION O 0 2.956502157758223e-06
Susceptibility O 0 1.936235639732331e-05
to O 0 7.035651350406624e-08
AS B-Disease 1 1.0
is O 0 8.188575373324625e-10
largely O 0 6.395894369681798e-10
genetically O 0 1.7788319428557742e-10
determined O 0 2.6473953584904564e-10
, O 0 1.7192068602067678e-10
and O 0 3.6543146286760475e-10
the O 0 9.070585393899933e-10
environmental O 0 3.6306326833823732e-09
trigger O 0 7.044135053035916e-09
for O 0 4.2687592349821557e-10
the O 0 2.5573063666683993e-09
disease O 0 2.0599166816737124e-08
is O 0 1.8567938853131238e-10
probably O 0 8.425468323025598e-09
ubiquitous O 0 2.7331194019097893e-07
. O 0 2.3204488286410196e-07

HLA O 0 4.429867840372026e-05
- O 0 1.8909295249613933e-06
B27 O 0 1.590662350281491e-06
accounts O 0 2.762050144156092e-09
for O 0 1.570682195417561e-10
a O 0 1.685015738051021e-10
minority O 0 2.3439672078295892e-11
of O 0 5.714311801519045e-10
the O 0 7.989281458620212e-10
overall O 0 5.50420686806774e-08
genetic O 0 5.984294659810985e-08
susceptibility O 0 4.808479729945248e-07
to O 0 4.1238217818317935e-07
AS B-Disease 1 1.0
. O 0 0.0003557192685548216

Cell O 0 1.5193354556686245e-06
cycle O 0 5.5635258178199365e-08
- O 0 1.9170423115610902e-07
dependent O 0 3.1357600960291165e-08
colocalization O 0 9.053193821273453e-07
of O 0 3.3502328022905203e-08
BARD1 O 0 4.4353972043609247e-05
and O 0 2.948944555214439e-08
BRCA1 O 0 2.1941881200859825e-08
proteins O 0 2.1536310235159561e-10
in O 0 1.546989758516304e-09
discrete O 0 1.4619232047152764e-08
nuclear O 0 7.261880909936735e-07
domains O 0 1.3002338619116927e-06
. O 0 1.0235108902634238e-06

Germ O 0 0.00017060920072253793
- O 0 2.6533534764894284e-06
line O 0 4.474888726235804e-08
mutations O 0 2.6452866563886346e-09
of O 0 1.999686638498588e-09
the O 0 3.381321667106363e-09
BRCA1 O 0 1.2110368174944597e-07
gene O 0 9.729633099198054e-09
predispose O 0 6.961047915865493e-08
women O 0 7.064677176593648e-10
to O 0 3.435118300920692e-10
early O 0 3.7526700680245995e-07
- O 0 2.800368019961752e-05
onset O 1 0.9999991655349731
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 1.8212752195267967e-07
compromising O 0 1.045108092512237e-06
the O 0 4.1472876688430915e-08
genes O 0 3.8164631455117615e-09
presumptive O 0 9.516912058415983e-08
function O 0 5.728753027511857e-09
as O 0 6.2204481565686365e-09
a O 0 1.146859673895051e-08
tumor B-Disease 0 7.732694484730018e-07
suppressor O 0 4.681155405705795e-05
. O 0 3.502073468553135e-06

Although O 0 1.6683007970641484e-06
the O 0 7.924364098244041e-08
biochemical O 0 7.686953722441103e-07
properties O 0 3.9708967847218446e-07
of O 0 1.2738364318920503e-07
BRCA1 O 0 1.1908399244475731e-07
polypeptides O 0 8.799402095860387e-09
are O 0 6.007971203869644e-11
not O 0 1.3162096412777657e-10
understood O 0 1.4527524738738862e-09
, O 0 1.150006131989123e-10
their O 0 2.230763768151789e-10
expression O 0 2.0447079585039774e-09
pattern O 0 4.499644545852277e-10
and O 0 2.1249667303546715e-10
subcellular O 0 1.4299935457984247e-07
localization O 0 1.1501660992507823e-06
suggest O 0 1.08904183448999e-08
a O 0 1.2746736999247332e-09
role O 0 2.24041851737411e-09
in O 0 4.25404955706199e-09
cell O 0 2.6893354743151576e-07
- O 0 3.501628498270293e-07
cycle O 0 1.303248780004651e-07
regulation O 0 2.188029611716047e-06
. O 0 8.00738746420393e-07

When O 0 5.256651434137893e-07
resting O 0 4.6006482534721727e-07
cells O 0 1.9948304341710354e-08
are O 0 1.204054217440742e-10
induced O 0 4.2165266833649184e-09
to O 0 1.257647597174838e-10
proliferate O 0 3.2705389507725613e-09
, O 0 2.550524236255569e-10
the O 0 4.824624588728454e-10
steady O 0 1.0967545982509819e-08
- O 0 3.0000935069551815e-09
state O 0 4.740889972265627e-11
levels O 0 1.2210602529094672e-09
of O 0 2.4948415555670067e-10
BRCA1 O 0 6.85601075911535e-10
increase O 0 4.922107166294154e-11
in O 0 5.765471988716797e-10
late O 0 3.2873333566385554e-07
G1 O 0 3.8547266711930206e-08
and O 0 4.5796746950266254e-10
reach O 0 1.0806920913708495e-09
a O 0 8.092122111280631e-11
maximum O 0 3.1736417938077466e-09
during O 0 1.6520921519713738e-08
S O 0 7.298442028513819e-07
phase O 0 5.202281272431719e-07
. O 0 1.725544620967412e-06

Moreover O 0 1.034553065437649e-06
, O 0 8.633568526761337e-09
in O 0 2.1467627675519907e-09
S O 0 1.4096251277351257e-07
phase O 0 4.807516518212651e-08
cells O 0 9.882234763836095e-08
, O 0 2.23030642843014e-08
BRCA1 O 0 7.049836625583339e-08
polypeptides O 0 3.244396040713582e-08
are O 0 1.5394192587336875e-09
hyperphosphorylated O 0 1.0825826990412679e-07
and O 0 3.3626124107399846e-09
accumulate O 0 2.467632143066112e-08
into O 0 6.818989373158502e-09
discrete O 0 1.812071559470496e-08
subnuclear O 0 1.3688121498489636e-06
foci O 0 5.984146014270664e-07
termed O 0 2.403858729849162e-07
" O 0 2.651532327035966e-07
BRCA1 O 0 3.1697840086053475e-07
nuclear O 0 2.2828669443697436e-06
dots O 0 2.6868178792938124e-06
. O 0 1.3508176834875485e-06

" O 0 2.5639126761234365e-05
BRCA1 O 0 2.450294778100215e-05
associates O 0 7.599477385156206e-07
in O 0 2.5107405932089932e-08
vivo O 0 1.7087430705942097e-06
with O 0 9.227090203012267e-10
a O 0 6.681093456251119e-09
structurally O 0 6.144568232002712e-08
related O 0 6.723678325215587e-08
protein O 0 9.433291836558055e-08
termed O 0 1.4274144177761627e-06
BARD1 O 0 0.0011627509957179427
. O 0 3.089830443059327e-06

Here O 0 2.82521313010875e-07
we O 0 8.37670821596248e-09
show O 0 1.5584540324908858e-09
that O 0 1.5855386448215825e-11
the O 0 1.4986269170069733e-10
steady O 0 1.9877168355719732e-08
- O 0 1.5466984137901818e-08
state O 0 2.6477434134086764e-10
levels O 0 6.495280313600915e-09
of O 0 1.4466223774434184e-09
BARD1 O 0 1.0626237099131686e-06
, O 0 4.3972553376292467e-10
unlike O 0 5.501997191181829e-10
those O 0 1.3125343867326222e-10
of O 0 8.440584342572777e-10
BRCA1 O 0 5.518700607609617e-09
, O 0 3.662646574920103e-10
remain O 0 3.2961648965823542e-09
relatively O 0 9.090884156570667e-10
constant O 0 2.1019503915198356e-09
during O 0 1.997586096535997e-09
cell O 0 1.888836997920862e-08
cycle O 0 2.079131888876873e-08
progression O 0 3.277935434198298e-07
. O 0 4.806590823136503e-07

However O 0 3.4659956327232067e-07
, O 0 3.987510055480925e-08
immunostaining O 0 5.139773747941945e-06
revealed O 0 6.493746695923619e-08
that O 0 5.66155455850037e-10
BARD1 O 0 2.3702589260210516e-06
resides O 0 2.25531007203017e-08
within O 0 1.2096529333760486e-09
BRCA1 O 0 5.293280924689725e-09
nuclear O 0 3.7905589778119975e-08
dots O 0 9.609386175668533e-09
during O 0 7.007312774476304e-08
S O 0 2.158123635354059e-08
phase O 0 4.273600584525639e-09
of O 0 1.1585401527014483e-09
the O 0 1.265149235374352e-10
cell O 0 4.793795360669151e-10
cycle O 0 8.224007586044024e-11
, O 0 2.2554399320418028e-11
but O 0 8.821453116591993e-12
not O 0 1.6977425021380554e-10
during O 0 6.188944468021873e-09
the O 0 1.2424846929093292e-08
G1 O 0 3.388606728549348e-07
phase O 0 3.0040951060072985e-07
. O 0 5.142192662788148e-07

Nevertheless O 0 1.6996489648590796e-05
, O 0 7.142045177488399e-08
BARD1 O 0 7.071018444548827e-06
polypeptides O 0 3.6675714909506496e-08
are O 0 1.4015040517012523e-10
found O 0 6.077191527786852e-11
exclusively O 0 1.4835961625880856e-10
in O 0 1.1200031180269576e-10
the O 0 1.6059070739871117e-10
nuclear O 0 9.252931754133442e-09
fractions O 0 5.405099479105502e-09
of O 0 6.793052342857209e-09
both O 0 1.05290898222421e-09
G1 O 0 9.71741442867824e-08
- O 0 1.327086209812478e-07
and O 0 5.109223266686058e-09
S O 0 2.317726170986134e-07
- O 0 5.240543288209665e-08
phase O 0 1.0806331829371629e-07
cells O 0 2.543442292335385e-07
. O 0 2.680920658804098e-07

Therefore O 0 1.203688526629776e-07
, O 0 4.235807704588979e-09
progression O 0 3.5291147781890686e-08
to O 0 1.8903929532854136e-09
S O 0 5.902044364347603e-08
phase O 0 2.775724716741479e-08
is O 0 3.476372800736982e-10
accompanied O 0 1.354001266662408e-08
by O 0 4.4035752821969254e-10
the O 0 1.3952475841350065e-09
aggregation O 0 8.142506668917804e-10
of O 0 3.019704708506765e-09
nuclear O 0 4.7317735152319074e-07
BARD1 O 0 1.84451255336171e-05
polypeptides O 0 1.4731735120676603e-07
into O 0 5.7864092184445326e-08
BRCA1 O 0 5.399670612860064e-07
nuclear O 0 2.022111630139989e-06
dots O 0 2.3370080270979088e-06
. O 0 2.160602662115707e-06

This O 0 1.9543263007903988e-08
cell O 0 2.2394798904201707e-08
cycle O 0 4.910447160000331e-09
- O 0 3.888910882210439e-08
dependent O 0 8.934546436023538e-09
colocalization O 0 4.307211440846004e-07
of O 0 9.07676778183486e-09
BARD1 O 0 9.217816113959998e-06
and O 0 9.532167943859804e-09
BRCA1 O 0 2.3185238617884352e-08
indicates O 0 4.120155328024566e-09
a O 0 2.366781215457081e-10
role O 0 1.510920388803072e-09
for O 0 1.0967770025516188e-09
BARD1 O 0 4.705996616394259e-05
in O 0 1.730912941866336e-07
BRCA1 O 0 2.2608890049014008e-06
- O 0 5.638107268168824e-06
mediated O 0 2.8606368687178474e-06
tumor B-Disease 0 6.0464124544523656e-05
suppression O 0 0.00010037746687885374
. O 0 1.2496848285081796e-06

Ethnic O 0 4.688480359504865e-08
differences O 0 6.227024673677306e-09
in O 0 5.0839488174858616e-09
the O 0 1.2753748279692445e-08
HFE O 0 4.149095911998302e-05
codon O 0 1.6334013253072044e-06
282 O 0 1.7700328953651479e-06
( O 0 1.86459701012609e-07
Cys O 0 0.28474581241607666
/ O 0 0.0007730296929366887
Tyr O 0 0.0003579392796382308
) O 0 2.6092438432101517e-08
polymorphism O 0 1.5963933037710376e-06
. O 0 6.873810889373999e-07

Recent O 0 1.3266054565974628e-07
studies O 0 6.945118258272487e-09
have O 0 8.598818185268087e-11
shown O 0 9.613505547179102e-10
that O 0 7.563901505136528e-09
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 1.0443031897011679e-06
HH B-Disease 0 0.44240787625312805
) O 0 7.250443023743003e-10
is O 0 1.4190276557968229e-11
likely O 0 1.1651678233359775e-10
to O 0 5.4398860416249306e-11
be O 0 2.2150423162337063e-10
caused O 0 1.1115992570864819e-09
by O 0 1.624471251959747e-10
homozygosity O 0 1.323264626762466e-07
for O 0 3.798743097860324e-09
a O 0 7.457265915888911e-09
Cys282Tyr O 0 4.964581421518233e-07
mutation O 0 1.751154443674352e-09
in O 0 1.3909590146354844e-09
the O 0 7.428659909436419e-09
HFE O 0 1.464926936023403e-05
gene O 0 2.4786180219393827e-08
located O 0 2.4979962987004e-08
4 O 0 5.308804702508496e-07
. O 0 7.217403208414908e-07

5 O 0 2.97466049232753e-05
Mb O 0 0.0014764770166948438
telomeric O 0 0.00010239950643153861
to O 0 6.060982400413195e-07
HLA O 0 6.111931725172326e-05
- O 0 5.695862273569219e-05
A O 0 1.0885083611356094e-05
. O 0 8.21161904696055e-07

Population O 0 1.1403508359819625e-08
studies O 0 6.698587462494743e-09
of O 0 9.408900325524883e-10
this O 0 3.5589194785634604e-11
polymorphism O 0 4.815140286495989e-09
are O 0 1.0247381068695383e-11
facilitated O 0 6.126401053130337e-10
by O 0 4.382608512210062e-11
the O 0 1.1123586496353255e-09
fact O 0 3.437235218672896e-10
that O 0 3.267168827147948e-11
the O 0 8.449378974262345e-10
Cys282Tyr O 0 1.2064781458320795e-06
mutation O 0 4.1504986114659914e-09
creates O 0 1.7116594808186392e-09
a O 0 1.656051473730713e-08
Rsal O 0 1.120995784731349e-05
restriction O 0 5.482182814375847e-07
site O 0 1.5646833162463736e-07
. O 0 1.0834648378477141e-07

We O 0 1.3202645732235396e-07
have O 0 1.3738625792569792e-09
studied O 0 1.352277134714086e-08
the O 0 5.233947497629288e-09
codon O 0 8.99973073842375e-08
282 O 0 8.053055466916703e-08
( O 0 3.552915828208825e-08
Cys O 0 0.003076522145420313
/ O 0 7.636221562279388e-05
Tyr O 0 1.9011833501281217e-05
) O 0 7.853965811044361e-10
polymorphism O 0 5.6296514117093466e-09
in O 0 1.4443608808978325e-10
different O 0 1.8225230352664212e-11
ethnic O 0 8.49193076968291e-11
groups O 0 1.0721300930383038e-10
. O 0 9.815225077147716e-09

In O 0 4.006095721820202e-08
agreement O 0 2.9274694668401935e-08
with O 0 3.4487140920802517e-10
previous O 0 1.9000456319417935e-08
observations O 0 2.3757433353921442e-08
the O 0 4.94824270447225e-09
Tyr O 0 9.120465620071627e-06
allele O 0 6.636086880007497e-08
appeared O 0 2.7530420609878092e-08
to O 0 9.238942388911653e-10
be O 0 9.116704613454374e-10
rare O 0 7.719179073717441e-09
or O 0 3.077407439988633e-09
absent O 0 2.1545371708953098e-08
in O 0 1.9592558686554185e-09
Asiatic O 0 1.0490065278645488e-06
( O 0 5.487827414718538e-10
Indian O 0 9.903057263116466e-10
, O 0 1.0891196972062644e-10
Chinese O 0 1.2678529337506461e-09
) O 0 3.196945486116931e-10
populations O 0 7.472553686937999e-10
. O 0 1.2563541318399984e-08

The O 0 8.095668846408444e-08
highest O 0 8.953433905389829e-08
allele O 0 1.7817541220210842e-08
frequency O 0 2.48343070552437e-08
( O 0 1.5507083117594078e-10
7 O 0 3.222463629271033e-09
. O 0 2.368176765799035e-10
5 O 0 4.140061626856095e-09
% O 0 1.904233992711113e-10
) O 0 5.4257102283239433e-11
was O 0 1.2614149724754498e-09
found O 0 4.5622033928438555e-10
in O 0 1.6961378968005647e-09
Swedes O 0 3.0775286177231465e-06
. O 0 1.1637029047051328e-06

Saamis O 0 0.0004544536059256643
( O 0 9.308905646321364e-09
2 O 0 3.303656725961446e-08
% O 0 1.0760456969904908e-09
) O 0 1.1262711596682351e-10
and O 0 1.806544774884955e-10
Mordvinians O 0 4.367673795968585e-07
( O 0 1.7970938626099553e-10
1 O 0 3.1768636610252088e-09
. O 0 3.0116847904437805e-10
8 O 0 6.755478842990215e-09
% O 0 4.181365809152737e-10
) O 0 1.5659977481430332e-10
had O 0 9.525874533622414e-10
significantly O 0 7.567794169105468e-10
lower O 0 1.174082941979293e-09
frequencies O 0 9.258403821377215e-09
of O 0 7.769014764846816e-09
the O 0 3.692165506663514e-08
Tyr O 0 2.984936145367101e-05
allele O 0 1.4764098068553722e-06
. O 0 6.901938149894704e-07

Comparisons O 0 6.957955065445276e-07
with O 0 4.7242227907418055e-09
allele O 0 4.776832440711587e-08
frequencies O 0 1.79754131579557e-08
based O 0 1.1508362041112719e-09
on O 0 1.1038206793045902e-08
prevalence O 0 5.566986160943088e-08
estimates O 0 1.2494567602772122e-09
of O 0 4.6637187445242034e-09
HH B-Disease 1 0.9997560381889343
showed O 0 1.5730184941276093e-06
some O 0 3.97329591450557e-09
disagreements O 0 1.4795142000423311e-08
with O 0 2.8869218127169916e-10
the O 0 1.4540256110251448e-08
RFLP O 0 1.6339934063580586e-06
data O 0 1.0822190255055375e-08
, O 0 2.6866966984506746e-10
particularly O 0 2.19741203011381e-09
in O 0 8.816133600930698e-09
Finns O 0 2.8192375793878455e-06
. O 0 4.3931061100010993e-07

The O 0 8.514647902302386e-07
newly O 0 2.0085481082787737e-06
described O 0 3.7498367078114825e-07
HFE O 0 0.00038430618587881327
marker O 0 1.4544605164701352e-06
provides O 0 1.291698836780597e-08
a O 0 4.996199565177051e-10
new O 0 2.6776006412099207e-10
approach O 0 5.539106062713017e-09
to O 0 4.767797823213016e-10
the O 0 3.7515854311998e-10
screening O 0 9.059160532842725e-09
of O 0 1.4195306263786733e-08
HH B-Disease 0 5.841212623636238e-05
as O 0 6.805035202006593e-09
well O 0 1.0178879961131315e-09
as O 0 1.265511306858258e-10
studies O 0 3.745372068042485e-10
of O 0 2.5094692990279555e-10
the O 0 1.267550092665104e-10
relationship O 0 8.076532498346722e-11
between O 0 3.088684308316658e-10
the O 0 1.615456923786951e-08
HFE O 0 0.0306589026004076
Tyr O 0 0.00032362554338760674
allele O 0 1.0361372915212996e-07
and O 0 7.461320450374842e-09
different O 0 2.1499026559013146e-08
disorders O 1 0.9998905658721924
including O 0 4.7195967454172205e-06
cancer B-Disease 1 0.9909947514533997

Autosomal B-Disease 1 0.9999990463256836
dominant I-Disease 0 0.021575795486569405
neurohypophyseal I-Disease 1 0.9999998807907104
diabetes I-Disease 1 1.0
insipidus I-Disease 0 0.004476016853004694
associated O 0 2.4102947193682667e-08
with O 0 1.0340352879500969e-10
a O 0 3.45493122999585e-09
missense O 0 8.718297550558418e-08
mutation O 0 3.073688192856139e-09
encoding O 0 1.3257650977038793e-08
Gly23 O 0 3.112327976850793e-05
- O 0 0.00018181327322963625
- O 0 4.962941602570936e-05
> O 0 1.874062763818074e-05
Val O 0 3.399084562261123e-06
in O 0 4.8256332263463264e-08
neurophysin O 0 1.8058897694572806e-05
II O 1 0.9999548196792603
. O 0 4.938242000207538e-06

Autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999998807907104
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 1.006907091039011e-08
ADNDI B-Disease 0 0.00036070882924832404
) O 0 1.3568806078723128e-09
is O 0 1.0681458495476193e-10
an O 0 6.575991418067417e-10
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.7510203123092651
by O 0 1.8928427714115514e-09
progressive O 1 0.6738165616989136
degeneration O 1 0.9999996423721313
of O 0 7.191782174231776e-07
the O 0 1.563713070140693e-08
magnocellular O 0 2.690843814434629e-07
neurons O 0 1.8173674121158e-08
of O 0 3.029305162272067e-08
the O 0 2.9845939053529946e-08
hypothalamus O 0 6.259822384890867e-07
leading O 0 3.4288181183228517e-08
to O 0 2.153389910830583e-09
decreased O 0 1.1134714483773678e-08
ability O 0 1.47117840132438e-09
to O 0 3.2267628569115914e-09
produce O 0 1.4433791051260414e-08
the O 0 2.0064544514752924e-07
hormone O 0 1.1754501656469074e-06
arginine O 0 8.069305863500631e-07
vasopressin O 0 6.383800609910395e-06
( O 0 3.408018756090314e-08
AVP O 0 4.4120642996858805e-05
) O 0 2.507945318086513e-08
. O 0 2.2942548127957707e-07

Affected O 0 8.409094789385563e-07
individuals O 0 2.704398094355298e-10
are O 0 1.6894204785122824e-11
not O 0 2.0375280629369996e-10
symptomatic O 0 1.600090371312035e-08
at O 0 1.144324413004938e-09
birth O 0 9.03932928508766e-09
, O 0 1.7482801317747487e-10
but O 0 4.106805173709205e-11
usually O 0 4.954776033905262e-10
develop O 0 5.145692316688155e-09
diabetes B-Disease 0 0.0001765803899616003
insipidus I-Disease 0 2.5602469122532057e-06
at O 0 1.735494059573739e-08
1 O 0 1.858183367176025e-07
- O 0 1.2370514923532028e-05
6 O 0 6.736464001733111e-06
yr O 0 4.801221803063527e-05
of O 0 1.020832556264395e-07
age O 0 1.009561287901306e-07
. O 0 1.131893512251736e-07

The O 0 1.6071672348516586e-07
genetic O 0 3.285189009716305e-08
locus O 0 2.0760765551131044e-08
of O 0 3.820818772481971e-09
the O 0 2.4375705898194155e-09
disease O 0 1.848777486657127e-08
is O 0 5.292407484480677e-11
the O 0 1.3353141925520617e-09
AVP O 0 0.1279820054769516
- O 0 0.0043226927518844604
neurophysin O 1 0.9983891248703003
II O 1 1.0
( O 0 3.5576082524357844e-08
NPII O 0 2.075656630040612e-05
) O 0 8.063161249793893e-10
gene O 0 9.96860816115941e-10
, O 0 2.439797253117604e-10
and O 0 5.763536869984875e-10
mutations O 0 3.6596037311653618e-09
that O 0 2.9134736290181706e-10
cause O 0 2.5143730653098828e-08
ADNDI B-Disease 0 4.184089630143717e-05
have O 0 1.6707305539043205e-09
been O 0 3.3416969191790713e-10
found O 0 1.4243831808480323e-11
in O 0 3.1409090606171475e-11
both O 0 5.7122060553860265e-11
the O 0 3.4626151945715833e-10
signal O 0 9.410501711215602e-09
peptide O 0 2.8327056256216565e-09
of O 0 1.4698861683370978e-08
the O 0 3.996807151906978e-08
prepro O 0 0.00045799624058417976
- O 0 0.0004004180955234915
AVP O 0 0.0022267531603574753
- O 0 1.0510430911381263e-05
NPII O 0 3.17659396387171e-05
precursor O 0 1.0286275937687606e-06
and O 0 5.27084464962968e-09
within O 0 7.1354793185207654e-09
NPII O 0 1.0883246432058513e-05
itself O 0 1.5643573547663436e-08
. O 0 6.491752913007076e-08

An O 0 1.4459499375618634e-08
affected O 0 4.784051377271226e-09
girl O 0 2.155297629258257e-08
who O 0 5.455474405557936e-10
presented O 0 2.3898676371203464e-09
at O 0 7.792433365239049e-09
9 O 0 2.3253440062376285e-08
months O 0 6.330634350071307e-10
of O 0 1.0240019943097423e-10
age O 0 1.940902993879945e-10
and O 0 1.960129281108891e-10
her O 0 6.237541039233463e-10
similarly O 0 2.5902409106492996e-09
affected O 0 5.921206303050042e-10
younger O 0 5.160078475618946e-10
brother O 0 1.4981083040765952e-08
and O 0 2.8579083544144623e-09
father O 0 4.0420772506877256e-08
were O 0 7.312917382762407e-09
all O 0 3.329932718454387e-10
found O 0 1.3674854304479567e-10
to O 0 1.0002963041211288e-10
have O 0 3.018762670392583e-11
a O 0 1.0032062680576104e-10
novel O 0 6.75784650461253e-10
missense O 0 2.9709285698231724e-08
mutation O 0 9.869981498766833e-10
( O 0 6.518867390337135e-11
G1758 O 0 2.7501029009613376e-08
- O 0 2.9686797020644917e-08
- O 0 4.570839706730112e-08
> O 0 1.5177961643075832e-07
T O 0 4.6284167609655924e-08
) O 0 3.2289820123265756e-11
encoding O 0 2.5084306853884186e-10
the O 0 3.5867728231941953e-10
amino O 0 2.7072882824441535e-10
acid O 0 4.891757554581488e-10
substitution O 0 1.4802086667486947e-08
Gly23 O 0 7.488035862479592e-06
- O 0 3.228327477700077e-05
- O 0 2.975730058096815e-05
> O 0 2.2238884412217885e-05
Val O 0 5.82120674152975e-06
within O 0 1.5932327812606673e-07
NPII O 0 0.0003040457668248564
. O 0 7.409955173898197e-07

The O 0 5.753014420406544e-07
mutation O 0 4.0739351447882655e-08
was O 0 7.079805186549493e-08
confirmed O 0 1.2198109189398565e-08
by O 0 9.812561874156245e-10
restriction O 0 8.445632460052366e-08
endonuclease O 0 5.8184878071188e-07
analysis O 0 8.446099997172496e-08
. O 0 1.207381217227521e-07

A O 0 1.7556791135575622e-05
T1 O 0 7.016060408204794e-05
- O 0 3.913379714504117e-06
weighted O 0 4.346821924627875e-07
magnetic O 0 5.266385869617807e-07
resonance O 0 1.3510417602446978e-06
imaging O 0 0.007216361351311207
of O 0 1.0481121535121929e-05
the O 0 8.426085514656734e-06
fathers O 0 0.04628754407167435
pituitary O 0 0.0020324981305748224
gland O 0 8.238404006988276e-06
demonstrates O 0 2.2582375436286384e-07
an O 0 3.854665475699903e-09
attenuated O 0 1.9018081331978465e-07
posterior O 0 1.646452716386193e-07
pituitary O 0 0.001652398845180869
bright O 0 0.0002926317392848432
spot O 0 0.0002570834185462445
. O 0 2.6926172722596675e-06

This O 0 1.2376365532418276e-07
mutation O 0 5.597436825155455e-08
may O 0 8.473381107876321e-09
be O 0 1.2741682153816214e-09
valuable O 0 6.123707407823531e-08
for O 0 1.192772214331228e-09
developing O 0 8.717744748309997e-09
models O 0 1.6930295387851402e-08
of O 0 1.4616359678143453e-08
dominantly B-Disease 0 6.647514510405017e-06
inherited I-Disease 0 9.44542080105748e-06
neurodegeneration I-Disease 1 1.0
, O 0 1.003118699216543e-09
as O 0 4.575516701632587e-11
the O 0 1.8267373724789593e-11
early O 0 7.926306833105912e-10
age O 0 2.498541651352326e-10
of O 0 2.307998236972253e-10
onset O 0 4.313296813052148e-06
of O 0 1.2545275751563167e-07
symptoms O 0 1.479871389165055e-05
suggests O 0 2.2069308158734202e-08
that O 0 1.1871338634339423e-10
this O 0 2.2853029191249874e-10
mutation O 0 1.6153420823172837e-09
may O 0 4.400487974010048e-09
be O 0 5.252849266668136e-09
particularly O 0 8.904399884102077e-09
deleterious O 0 1.944792700214748e-07
to O 0 5.898026955719615e-08
the O 0 1.3001354659536446e-07
magnocellular O 0 4.738230927614495e-06
neuron O 0 5.283288260216068e-07
. O 0 6.938593344330002e-08
. O 0 4.3504800828486623e-07

Frequent O 0 9.030317187352921e-07
inactivation O 0 1.595243338670116e-05
of O 0 2.1603453205898404e-05
PTEN O 1 0.9999912977218628
/ O 0 0.42983588576316833
MMAC1 O 0 0.01604308933019638
in O 0 3.107105897015572e-07
primary O 1 0.7898296117782593
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.33329465118004e-05

Sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 4.6042123358347453e-07
the O 0 3.890534117090283e-09
most O 0 2.2532567478528165e-10
common O 0 3.102335055515937e-10
male B-Disease 0 1.780566527553873e-10
cancer I-Disease 0 9.780493082089947e-11
in O 0 4.462676408967248e-11
the O 0 6.957670550811201e-10
Western O 0 7.293071035974208e-08
world O 0 3.5517755403446927e-09
, O 0 1.8307844129594741e-10
yet O 0 1.5017544152673423e-10
many O 0 1.475284998331272e-11
of O 0 8.746232904588425e-11
the O 0 9.5614752226858e-11
major O 0 9.14517961358996e-10
genetic O 0 6.61251664535456e-10
events O 0 1.2215466138609798e-10
involved O 0 1.1585594289487133e-10
in O 0 1.9673883355775246e-10
the O 0 7.184324801734476e-10
progression O 0 4.262222219608702e-08
of O 0 1.005496019779173e-09
this O 0 1.5039214318335326e-10
often O 0 1.9983787957755794e-09
fatal O 0 2.5964507699427486e-07
cancer B-Disease 0 3.7696183881053003e-06
remain O 0 3.0414346952056803e-07
to O 0 1.9971222897652297e-08
be O 0 1.00211181575105e-07
elucidated O 0 1.835643888625782e-05
. O 0 6.138142907730071e-06

Numerous O 0 7.192626299001859e-07
cytogenetic O 0 3.069797458010726e-05
and O 0 4.0716667371043513e-08
allelotype O 0 1.6226665593421785e-06
studies O 0 1.500330171211317e-08
have O 0 2.196698378753581e-10
reported O 0 3.010295068772706e-10
frequent O 0 4.856773871964037e-10
loss O 0 1.6881691600190152e-09
of O 0 3.958833971751119e-08
heterozygosity O 0 0.0004491523141041398
on O 0 8.239260750997346e-06
chromosomal O 0 1.3151316125004087e-05
arm O 0 1.1986785466433503e-05
10q O 0 0.00011363699013600126
in O 0 3.0495323244394967e-07
sporadic B-Disease 1 0.9999996423721313
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.653865031898022e-05

Deletion O 0 1.7249756638193503e-05
mapping O 0 1.2609679060915369e-06
studies O 0 7.64205267955731e-08
have O 0 1.2485610323409446e-09
unambiguously O 0 5.418487436514852e-09
identified O 0 3.0877671530760153e-09
a O 0 1.0023404328762808e-09
region O 0 1.4196984920999967e-08
of O 0 3.151144767343794e-08
chromosome O 0 3.2279191941597674e-07
10q23 O 0 2.6302434434910538e-06
to O 0 1.6928025647899858e-09
be O 0 5.715729001209979e-10
the O 0 8.359370973209934e-10
minimal O 0 1.5048159696107177e-07
area O 0 1.7669714580392792e-08
of O 0 4.710977830058027e-09
loss O 0 5.209946962736467e-08
. O 0 3.5581078350332973e-07

A O 0 1.5053942661324982e-06
new O 0 5.1982638638037315e-08
tumor B-Disease 0 7.385635854006978e-07
suppressor O 0 6.059108272893354e-06
gene O 0 1.059796517210998e-07
, O 0 2.8476693003653963e-08
PTEN O 0 0.00014800405187997967
/ O 0 4.043524313601665e-05
MMAC1 O 0 0.00011446002463344485
, O 0 6.787379991379794e-09
was O 0 4.685110255309155e-08
isolated O 0 1.748345290764064e-08
recently O 0 3.257601965955814e-09
at O 0 5.877727748959671e-10
this O 0 2.324630939132266e-11
region O 0 2.797685860755905e-09
of O 0 3.828354522283917e-09
chromosome O 0 2.232098061938359e-08
10q23 O 0 3.08574414020768e-07
and O 0 1.523682846560348e-09
found O 0 5.299127248115099e-10
to O 0 1.4667143888313916e-10
be O 0 5.1678567675184084e-11
inactivated O 0 2.0063302130779448e-09
by O 0 2.1796742188939788e-10
mutation O 0 1.1892079543329714e-09
in O 0 4.7281711879065824e-09
three O 0 3.093616953719902e-07
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 7.929184903332498e-06
lines O 0 1.2113093816878973e-07
. O 0 4.967512836628885e-07

We O 0 5.296748213368119e-07
screened O 0 3.791134076891467e-06
80 O 0 1.3745764590566978e-05
prostate B-Disease 1 0.996198832988739
tumors I-Disease 1 1.0
by O 0 4.052350011107819e-09
microsatellite O 0 3.3262413268175806e-08
analysis O 0 7.019868020208264e-10
and O 0 1.3942519361265227e-10
found O 0 3.1027019842255754e-10
chromosome O 0 4.9577186800320305e-09
10q23 O 0 8.432980536099421e-08
to O 0 1.0456739918396352e-09
be O 0 1.952827455298234e-09
deleted O 0 2.6850290879565364e-08
in O 0 4.477378912071117e-09
23 O 0 3.982220064813191e-08
cases O 0 2.089965311924402e-09
. O 0 4.627357341746574e-08

We O 0 5.3098773378223996e-08
then O 0 1.4441163820322345e-09
proceeded O 0 9.761804697916432e-10
with O 0 1.4834983285208492e-12
sequence O 0 2.8054188746379216e-12
analysis O 0 3.1207789824572174e-11
of O 0 1.5035141187613732e-10
the O 0 7.552177772041091e-10
entire O 0 1.867226728791138e-08
PTEN O 0 0.00010996690980391577
/ O 0 0.0002408680593362078
MMAC1 O 0 0.00026703308685682714
coding O 0 1.1841919331345707e-05
region O 0 8.581774579852208e-08
and O 0 2.821629596638786e-09
tested O 0 1.7199663915334895e-08
for O 0 5.711620620907354e-10
homozygous O 0 7.311271588150703e-09
deletion O 0 9.463870576098543e-09
with O 0 1.3259307540813836e-10
new O 0 1.4497498312948665e-08
intragenic O 0 1.8662032061911304e-06
markers O 0 1.3087210426476759e-08
in O 0 7.013939429256766e-10
these O 0 1.0719256732238946e-10
23 O 0 2.891706651908521e-09
cases O 0 6.009198000311855e-11
with O 0 2.454152506214946e-11
10q23 O 0 3.375206915734452e-06
loss O 0 1.2044716868331307e-07
of O 0 2.690876954147825e-06
heterozygosity O 0 0.4047797918319702
. O 0 1.913988307933323e-05

The O 0 2.728160275466962e-08
identification O 0 6.966480725623114e-08
of O 0 1.2696879103657466e-08
the O 0 2.9800300005433655e-09
second O 0 1.2040485053432803e-08
mutational O 0 1.2042595471939421e-06
event O 0 5.970473893057715e-09
in O 0 1.2543421856747727e-09
10 O 0 1.4972540540725277e-08
( O 0 8.532003437089486e-10
43 O 0 1.9202328616074738e-08
% O 0 4.984323176415728e-09
) O 0 2.1284980888935934e-08
tumors B-Disease 1 1.0
establishes O 0 6.368016329361126e-06
PTEN O 0 0.04612469673156738
/ O 0 0.0004707833577413112
MMAC1 O 0 6.966299406485632e-05
as O 0 1.637966562384463e-08
a O 0 1.912632496825495e-09
main O 0 1.6854184714532039e-09
inactivation O 0 3.917655888585614e-08
target O 0 7.2254446870090305e-09
of O 0 2.6016440113352246e-09
10q O 0 1.164740979220369e-06
loss O 0 2.6129290731091714e-08
in O 0 2.2388050524568825e-08
sporadic B-Disease 1 0.999983549118042
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.215315124791232e-07
. O 0 8.45103670599201e-07

Risk O 0 2.08895744435722e-05
reversals O 0 9.748712272994453e-07
in O 0 9.282310031721863e-09
predictive O 0 9.013783142108878e-08
testing O 0 2.3776971502798006e-08
for O 0 1.4750312971045787e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.1110646482848097e-06

The O 0 2.1063667077214632e-07
first O 0 8.05401967340913e-09
predictive O 0 1.478033517798849e-08
testing O 0 1.0141541828545542e-08
for O 0 8.14302225649044e-09
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 6.067812363674818e-10
HD B-Disease 0 7.442248488587211e-07
) O 0 1.0533603850282347e-10
was O 0 1.0004552741804673e-09
based O 0 1.9891596703125458e-10
on O 0 4.1631840197453585e-09
analysis O 0 1.3324266134873142e-09
of O 0 1.0396402627677048e-09
linked O 0 3.0789575333756147e-09
polymorphic O 0 3.875114895635079e-09
DNA O 0 9.771664366553523e-09
markers O 0 2.196058446202187e-09
to O 0 5.501241684413571e-10
estimate O 0 9.757710195401614e-10
the O 0 4.022730204500391e-10
likelihood O 0 3.870512799153403e-09
of O 0 4.8323265389171866e-09
inheriting O 0 7.594146467226892e-08
the O 0 1.7141434938139355e-08
mutation O 0 1.9120827587926215e-08
for O 0 2.4806423581935633e-08
HD B-Disease 0 0.00018555806309450418
. O 0 1.8949859850181383e-06

Limits O 0 1.3095633448756416e-06
to O 0 8.720039801346502e-09
accuracy O 0 1.0569905128932078e-07
included O 0 7.270249291480013e-09
recombination O 0 1.1760596940746382e-09
between O 0 3.45238032606332e-10
the O 0 1.0823505425250346e-09
DNA O 0 4.945949871881794e-09
markers O 0 5.279910286759559e-09
and O 0 2.9927211819824606e-09
the O 0 1.0584204623853566e-08
mutation O 0 9.632580955099002e-09
, O 0 1.1719126780107558e-09
pedigree O 0 1.5803360398081168e-08
structure O 0 1.6405640179684156e-09
, O 0 6.556029052973145e-10
and O 0 1.5915145590295054e-10
whether O 0 1.372536528876367e-10
DNA O 0 5.089605625840932e-09
samples O 0 6.859022239069645e-09
were O 0 6.286427489676782e-10
available O 0 6.702907118238954e-09
from O 0 1.2479562938594313e-09
family O 0 1.180252895416345e-09
members O 0 2.759022565967939e-09
. O 0 1.1221108309200645e-07

With O 0 5.27567234342996e-09
direct O 0 1.117036685371886e-08
tests O 0 1.0371031811118314e-09
for O 0 1.6324944174250788e-10
the O 0 1.3656642483539372e-09
HD B-Disease 0 7.472812285413966e-06
mutation O 0 4.129116160100921e-09
, O 0 8.864251554996372e-10
we O 0 9.279508828008431e-10
have O 0 1.8386688005467278e-10
assessed O 0 4.5674561910402645e-09
the O 0 5.300835326238484e-10
accuracy O 0 7.458378803448795e-08
of O 0 6.519856210474018e-09
results O 0 1.2590449793847824e-09
obtained O 0 4.9699599991015475e-09
by O 0 1.251796166723551e-10
linkage O 0 4.09182865368507e-09
approaches O 0 4.451254920212477e-09
when O 0 4.262453723313797e-10
requested O 0 1.7259145224102213e-08
to O 0 2.0642378917301585e-09
do O 0 1.6820720372123787e-09
so O 0 3.487583555283891e-10
by O 0 1.3445242141862934e-10
the O 0 4.653036844715075e-10
test O 0 1.9716417387627416e-09
individuals O 0 2.6228327842936494e-10
. O 0 5.5021391887066784e-08

For O 0 2.7000979230251687e-07
six O 0 6.80371181616124e-09
such O 0 2.0478684026326022e-10
individuals O 0 3.99322727662188e-11
, O 0 8.376109528196451e-11
there O 0 5.5462471421074966e-11
was O 0 5.598950192364782e-09
significant O 0 4.708399448105638e-09
disparity O 0 4.385246832327994e-09
between O 0 1.0868769217964314e-09
the O 0 9.697581404566336e-09
tests O 0 2.0953308421667316e-08
. O 0 9.774371534376769e-08

Three O 0 5.5190721326425773e-08
went O 0 2.8740466007093346e-08
from O 0 9.052523730623818e-10
a O 0 6.651210693320309e-10
decreased O 0 2.953851829801124e-09
risk O 0 7.674078039698884e-10
to O 0 2.824913081234115e-10
an O 0 6.336780405957754e-11
increased O 0 1.1205506522671271e-09
risk O 0 1.7445935807103297e-09
, O 0 1.4769920009261028e-10
while O 0 2.848655200615724e-10
in O 0 4.720401292068743e-10
another O 0 9.275757384408223e-10
three O 0 2.854044778288767e-10
the O 0 9.11524411506548e-10
risk O 0 9.389470534415523e-09
was O 0 2.5840099837637354e-08
decreased O 0 1.8466070628164744e-07
. O 0 2.2928441012481926e-07

Knowledge O 0 8.630642696516588e-06
of O 0 5.651558865338302e-08
the O 0 1.7641753613517608e-09
potential O 0 1.7126129403521873e-09
reasons O 0 3.2321771925580833e-09
for O 0 1.5434845068718062e-10
these O 0 2.6491567620134937e-11
changes O 0 2.478421912144313e-10
in O 0 3.379972413064536e-10
results O 0 5.215499143673696e-10
and O 0 4.0825187674897734e-10
impact O 0 1.4814513171756971e-08
of O 0 3.01089353449413e-09
these O 0 8.854227073751275e-11
risk O 0 1.0247449555578214e-09
reversals O 0 2.778488328303297e-09
on O 0 5.6950342219863614e-09
both O 0 4.0489098185325645e-10
patients O 0 1.0370576619678218e-09
and O 0 3.3776006991281804e-10
the O 0 3.050763641709864e-09
counseling O 0 8.726932065883375e-08
team O 0 2.410066868296923e-10
can O 0 5.7643254752770545e-11
assist O 0 1.058981879964449e-08
in O 0 1.2269060212233285e-09
the O 0 1.7691219600379782e-09
development O 0 6.628000814856705e-09
of O 0 1.7549194319954609e-09
strategies O 0 5.838088679155362e-09
for O 0 2.693721357083234e-10
the O 0 3.6379230183847255e-10
prevention O 0 5.546615255980214e-08
and O 0 1.933819215871324e-10
, O 0 1.1098700430922648e-10
where O 0 9.190569832950857e-11
necessary O 0 3.54600815377637e-09
, O 0 4.784697082982348e-10
management O 0 6.301484223314446e-09
of O 0 2.039757029947964e-09
a O 0 1.6097596589048635e-09
risk O 0 4.786844254311973e-09
reversal O 0 2.206685500993899e-09
in O 0 1.566165863664537e-09
any O 0 8.316257682494665e-10
predictive O 0 1.1199594140975933e-08
testing O 0 1.564475993198755e-09
program O 0 3.174695173413511e-09
. O 0 4.088146265956993e-09
. O 0 8.636998671818219e-08

A O 0 2.648393433446472e-07
novel O 0 2.3915788460726617e-08
common O 0 1.58366120217579e-08
missense O 0 3.7312230460884166e-07
mutation O 0 1.9494343916903745e-08
G301C O 0 3.5135403209096694e-07
in O 0 7.02694480381183e-09
the O 0 6.811709862830639e-09
N O 0 5.922906964883623e-08
- O 0 1.2806698634904023e-07
acetylgalactosamine O 0 1.429598341928795e-06
- O 0 7.372616437351098e-07
6 O 0 8.714795853848045e-07
- O 0 2.904194616348832e-06
sulfate O 0 6.012645599184907e-07
sulfatase O 0 7.237451427499764e-06
gene O 0 3.5305959045217605e-08
in O 0 2.130252596543869e-08
mucopolysaccharidosis B-Disease 0 0.00012296935892663896
IVA I-Disease 1 0.7537803053855896
. O 0 1.5904190149740316e-05

Mucopolysaccharidosis B-Disease 0 0.008229055441915989
IVA I-Disease 1 0.9999994039535522
( O 0 7.3315331974299625e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 5.996931662366478e-08
is O 0 1.7628433157668155e-09
an O 0 1.4456927877048997e-09
autosomal B-Disease 0 0.19316506385803223
recessive I-Disease 1 0.9998506307601929
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 7.12903371891116e-08
by O 0 2.6155891341694826e-10
a O 0 6.476170142377669e-07
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 2.5136523618130013e-06
N O 0 1.5449153067947918e-07
- O 0 1.4502094813906297e-07
acetylgalactosamine O 0 8.574957064411137e-07
- O 0 2.1866444512852468e-06
6 O 0 5.254623829387128e-06
- O 0 2.968013177451212e-05
sulfate O 0 3.7384502320492174e-06
sulfatase O 0 3.164656300214119e-05
( O 0 7.610964303239598e-09
GALNS O 0 1.1739506589947268e-05
) O 0 1.1233653118836173e-08
. O 0 1.0991716692387854e-07

In O 0 1.6337473596195196e-07
previous O 0 1.2511076619148298e-08
studies O 0 2.2094495122360058e-08
, O 0 1.1702397939572506e-09
we O 0 1.1132182953232928e-09
have O 0 1.7531052998176477e-10
found O 0 2.3720189701315064e-10
two O 0 1.426678775118262e-10
common O 0 3.815144034025053e-10
mutations O 0 9.383772647808541e-10
in O 0 1.5112633366953787e-09
Caucasians O 0 6.395899987410303e-08
and O 0 3.444456053713907e-09
Japanese O 0 2.861984739865875e-06
, O 0 8.266950679569618e-09
respectively O 0 3.936035852802888e-08
. O 0 9.262170408419479e-08

To O 0 5.886024041501514e-07
characterize O 0 6.764093427591433e-07
the O 0 8.558171060712993e-08
mutational O 0 2.00453469005879e-05
spectrum O 0 1.2981506358755723e-07
in O 0 1.0595470056884437e-09
various O 0 4.5927087133357247e-10
ethnic O 0 2.4353095928741908e-11
groups O 0 4.72279203592163e-12
, O 0 2.4144505839096553e-11
mutations O 0 4.657429303334126e-11
in O 0 3.7769803951093195e-10
the O 0 3.9335947832341844e-09
GALNS O 0 2.709171667447663e-06
gene O 0 7.758619524622645e-09
in O 0 2.376504859569195e-08
Colombian O 0 0.00011463194095995277
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 3.401866933927522e-06
were O 0 1.4807027604035738e-08
investigated O 0 1.2832146900620955e-08
, O 0 7.639203714049358e-10
and O 0 3.37005257033951e-10
genetic O 0 2.428298895296166e-09
backgrounds O 0 2.079483918393521e-09
were O 0 3.97960597808833e-09
extensively O 0 8.032066567409402e-09
analyzed O 0 7.2296360009715954e-09
to O 0 1.5533347941243392e-09
identify O 0 8.721253941246232e-09
racial O 0 1.2131001758675097e-09
origin O 0 6.521830853145616e-10
, O 0 1.1323583737343768e-10
based O 0 1.1807926858509177e-10
on O 0 2.7748869868560178e-09
mitochondrial O 0 5.529089186495639e-09
DNA O 0 3.67601771245063e-08
( O 0 3.981823315513111e-09
mtDNA O 0 5.964454885543091e-08
) O 0 5.215661236235292e-09
lineages O 0 6.8695520383244e-08
. O 0 1.0588044574433297e-07

Three O 0 1.9095101322363917e-07
novel O 0 1.372229689877713e-07
missense O 0 7.230159553728299e-06
mutations O 0 2.5392230895704415e-07
never O 0 2.109792518467657e-07
identified O 0 7.598927709295822e-08
previously O 0 1.5870661229655525e-08
in O 0 2.0265361611038202e-10
other O 0 1.5299745845243073e-11
populations O 0 1.395890434491287e-11
and O 0 9.307027371008303e-12
found O 0 2.6026191618511163e-11
in O 0 1.614980787989495e-10
16 O 0 7.294375770072747e-09
out O 0 3.138880544373279e-10
of O 0 3.0496871694651873e-09
19 O 0 2.5646059498285467e-07
Colombian O 0 1.4522840501740575e-05
MPS B-Disease 1 0.8623437881469727
IVA I-Disease 1 0.9999972581863403
unrelated O 0 4.119886796161154e-07
alleles O 0 3.4841012297448515e-09
account O 0 3.613561672111132e-09
for O 0 3.5842373513617076e-09
84 O 0 5.765685955338995e-07
. O 0 4.1979038201134244e-07

2 O 0 6.061895874154288e-07
% O 0 7.540594815225177e-09
of O 0 2.2145956179997484e-09
the O 0 4.787901186631416e-10
alleles O 0 2.414101973879923e-10
in O 0 6.604751745520332e-10
this O 0 4.320667990054261e-10
study O 0 1.1379476916317799e-08
. O 0 6.154714782269366e-08

The O 0 1.0162502803723328e-06
G301C O 0 1.9521006834111176e-05
and O 0 1.2314056441198318e-08
S162F O 0 1.5369078028015792e-06
mutations O 0 2.0958614843635814e-09
account O 0 2.9327884565333306e-09
for O 0 2.971510815186207e-09
68 O 0 1.3866414292351692e-06
. O 0 1.125797666645667e-06

4 O 0 2.3278946628124686e-06
% O 0 1.4503775958019105e-08
and O 0 2.763320239296263e-09
10 O 0 6.323073620251307e-08
. O 0 9.242369714002052e-08

5 O 0 8.018108133001078e-07
% O 0 7.0458954226637616e-09
of O 0 1.505316871153184e-09
mutations O 0 1.0290657215250576e-09
, O 0 3.2926947279854346e-10
respectively O 0 4.354748561752331e-09
, O 0 3.376106338937035e-10
whereas O 0 2.052655823092664e-09
the O 0 2.0584978166482415e-09
remaining O 0 4.283280929939792e-08
F69V O 0 5.452252025861526e-06
is O 0 2.715687397181199e-10
limited O 0 1.2483728495382707e-09
to O 0 8.880141622036319e-10
a O 0 3.7737417635241854e-09
single O 0 4.28004689467798e-08
allele O 0 1.5423245258716634e-07
. O 0 3.7778238493046956e-07

The O 0 3.2614900646876777e-07
skewed O 0 2.7225107146477967e-07
prevalence O 0 2.78169608236567e-07
of O 0 2.256281383949954e-09
G301C O 0 2.2908200492111064e-07
in O 0 1.4039770457330292e-09
only O 0 7.70602415212096e-10
Colombian O 0 3.8115260281301744e-08
patients O 0 1.83390636010472e-09
and O 0 3.567620643352143e-10
haplotype O 0 1.5889014548520208e-08
analysis O 0 2.6798041563580455e-09
by O 0 1.6514069278716903e-10
restriction O 0 3.3472355998043213e-09
fragment O 0 1.1822692824736691e-09
length O 0 2.886184069517128e-10
polymorphisms O 0 3.861966302309838e-09
in O 0 9.384094612485683e-10
the O 0 4.696326882935864e-09
GALNS O 0 1.325065841228934e-05
gene O 0 1.904199642410731e-08
suggest O 0 6.752232550866211e-09
that O 0 1.6871157249020996e-10
G301C O 0 1.482277269815313e-07
originated O 0 1.0176517406534913e-08
from O 0 6.956755171927398e-10
a O 0 1.3362747575129674e-09
common O 0 3.0073237233807504e-09
ancestor O 0 1.7729881562900118e-07
. O 0 1.773847344566093e-07

Investigation O 0 9.547680974719697e-07
of O 0 9.161669112245363e-08
the O 0 1.2826543382971067e-08
genetic O 0 7.812151814334811e-09
background O 0 7.178096339544027e-09
by O 0 3.080342092509625e-10
means O 0 5.629254395955741e-09
of O 0 8.554708053054583e-09
mtDNA O 0 7.499333065652536e-08
lineages O 0 9.623545516035392e-09
indicate O 0 2.347544381109401e-09
that O 0 4.0743797224962464e-11
all O 0 1.3316688030062807e-10
our O 0 3.3703049240330074e-09
patients O 0 1.2702783269702422e-09
are O 0 2.020352288245597e-11
probably O 0 1.3066002724215764e-09
of O 0 1.9743437995600743e-09
native O 0 1.227501300604672e-08
American O 0 2.376721340624499e-06
descent O 0 5.693608181900345e-05

Low O 0 5.526845825443161e-07
frequency O 0 6.956496179100213e-08
of O 0 4.5237182888513416e-08
BRCA1 O 0 2.759177561983961e-07
germline O 0 2.4652811134728836e-06
mutations O 0 3.3743055016799417e-09
in O 0 2.2374635477717675e-09
45 O 0 5.9608268543343e-08
German O 1 0.9999995231628418
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.8982466321613174e-07
. O 0 4.7486804533036775e-07

In O 0 4.442504319968066e-08
this O 0 4.671907305464629e-10
study O 0 4.7637349620544e-10
we O 0 1.4487919197669896e-10
investigated O 0 1.02461594764236e-09
45 O 0 7.774470844879033e-09
German O 1 0.9999728202819824
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.707205292220351e-09
for O 0 2.1763850721612243e-09
germline O 0 1.2144232641730923e-07
mutations O 0 1.6697780935714945e-09
in O 0 4.7823545124003886e-09
the O 0 2.483383276796758e-08
BRCA1 O 0 1.1459242443834228e-07
gene O 0 9.812571022393968e-08
. O 0 1.1202262157894438e-06

We O 0 4.577016099460707e-08
identified O 0 9.707481929410733e-09
four O 0 1.6353404186375542e-09
germline O 0 9.21221896987845e-07
mutations O 0 5.799422275742927e-09
in O 0 3.587766750356991e-09
three O 0 1.1520556064681386e-08
breast B-Disease 1 0.8600404262542725
cancer I-Disease 0 7.246680979733355e-07
families O 0 8.214695590424981e-11
and O 0 7.106189942041041e-11
in O 0 8.778597404557331e-09
one O 0 2.6458932552486658e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 9.788229817786487e-07
. O 0 2.2553088285803824e-09
among O 0 3.7310533135270774e-11
these O 0 2.0443821982518706e-11
were O 0 6.096664284527264e-10
one O 0 4.0155243019590614e-10
frameshift O 0 9.463296635203733e-08
mutation O 0 6.388789941524919e-09
, O 0 2.300966750468092e-09
one O 0 5.286288740080636e-09
nonsense O 0 3.7908165495537105e-07
mutation O 0 1.7639340654795888e-08
, O 0 8.996410283401701e-10
one O 0 1.987453257523697e-10
novel O 0 1.3158111267230765e-09
splice O 0 6.615386638486598e-08
site O 0 1.4271810400146023e-08
mutation O 0 1.058795495723075e-09
, O 0 3.272359605510644e-10
and O 0 1.3070140525428542e-09
one O 0 8.27938517744542e-09
missense O 0 4.356389581516851e-06
mutation O 0 6.991892291807744e-07
. O 0 4.264298240741482e-06

The O 0 1.3393728295341134e-06
missense O 0 4.2320734792156145e-06
mutation O 0 1.2774226831879787e-07
was O 0 6.734806135000326e-08
also O 0 1.9473487267163136e-09
found O 0 3.712223028973227e-10
in O 0 2.3136896842856913e-09
2 O 0 7.165855322455172e-07
. O 0 5.385055601436761e-07

8 O 0 9.20220941225125e-07
% O 0 6.248606965186809e-09
of O 0 2.266810739115499e-09
the O 0 2.0993451421702503e-10
general O 0 8.490202429989324e-10
population O 0 3.755800531690667e-11
, O 0 8.763165193492739e-11
suggesting O 0 1.5087230353927339e-09
that O 0 3.368347961663076e-11
it O 0 2.9415810065547277e-11
is O 0 5.946056841343861e-11
not O 0 1.0021032892382209e-09
disease O 0 1.4429551775663185e-08
associated O 0 9.275341028569528e-08
. O 0 9.701143426354975e-07

The O 0 1.2430552942532813e-07
average O 0 7.048556405209183e-09
age O 0 1.3583072444589561e-09
of O 0 1.4655491265003207e-09
disease O 0 1.343149147459144e-08
onset O 0 1.278589479625225e-06
in O 0 4.1156078545157015e-09
those O 0 1.965551499338858e-09
families O 0 1.2889171951968592e-09
harbouring O 0 1.8894428421845078e-07
causative O 0 3.7887737391884e-08
mutations O 0 1.797733339969909e-08
was O 0 4.8800860241726696e-08
between O 0 1.6869750041337284e-09
32 O 0 2.385542927640927e-07
. O 0 2.820095801325806e-07

3 O 0 3.4328470519540133e-06
and O 0 1.376363343297271e-07
37 O 0 2.6507736947678495e-06
. O 0 6.152719720375899e-07

4 O 0 4.904917432213551e-07
years O 0 1.0260030158804057e-08
, O 0 2.4684299049226865e-10
whereas O 0 7.217315078911213e-10
the O 0 4.931224872883888e-10
family O 0 1.4109836632414385e-09
harbouring O 0 7.300976108126633e-07
the O 0 1.1902820062914543e-08
missense O 0 3.2373927183471096e-07
mutation O 0 6.826211151889083e-09
had O 0 3.838700912695003e-09
an O 0 5.5014173772072184e-11
average O 0 7.957461772845065e-11
age O 0 1.2014252093184297e-10
of O 0 3.8470474028606816e-10
onset O 0 5.564013463299489e-07
of O 0 1.6780775524694036e-07
51 O 0 8.709420171726379e-07
. O 0 1.0084371524499147e-06

2 O 0 5.328948645910714e-06
years O 0 9.538953236187808e-07
. O 0 8.579995665058959e-07

These O 0 3.0765171743496467e-08
findings O 0 2.457552383816619e-08
show O 0 9.149772495220532e-09
that O 0 6.311898226307733e-10
BRCA1 O 0 3.6032052008749815e-08
is O 0 5.032917416158966e-10
implicated O 0 2.4420192534790885e-09
in O 0 5.61644619700985e-10
a O 0 6.870266022751537e-10
small O 0 1.8376310195744594e-10
fraction O 0 9.954168600501134e-10
of O 0 1.3620470440400823e-07
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.585573141317582e-08
suggesting O 0 2.7606388286471883e-09
the O 0 1.8805383639186601e-10
involvement O 0 1.174463637454437e-09
of O 0 4.3741257838014747e-10
another O 0 3.4647357205486173e-10
susceptibility O 0 8.322847300235026e-09
gene O 0 1.2059815368559157e-08
( O 0 2.797905906959386e-08
s O 0 8.134601557685528e-06
) O 0 1.0369840310886502e-06

Paternal O 0 7.327461207751185e-05
transmission O 0 0.0009665926336310804
of O 0 0.0013908962719142437
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9999351501464844

We O 0 1.6693911675247364e-07
report O 0 6.340256319958826e-09
a O 0 1.3261741704795327e-09
rare O 0 2.443827362696993e-09
case O 0 1.180698649960732e-09
of O 0 1.2018023021198587e-08
paternally O 1 0.9999692440032959
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.2287659956200514e-06
DM B-Disease 1 1.0
) O 0 5.067368036293374e-08
. O 0 2.564256362802553e-07

The O 0 2.3674795102124335e-07
proband O 0 6.048710474715335e-06
is O 0 5.866393482101273e-10
a O 0 3.8838440796773455e-10
23 O 0 3.626819067292786e-09
year O 0 2.9166205561814706e-10
old O 0 2.995475156808425e-08
, O 0 7.798217183108136e-09
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 2.7919943477172637e-06
who O 0 1.5846983103529055e-07
suffers O 0 3.1073980153450975e-06
severe O 1 0.6019321084022522
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 0 0.03564091771841049

He O 0 3.4932196513182134e-07
presented O 0 6.98950586297542e-08
with O 0 5.2226192259752224e-09
respiratory O 0 0.0018447554903104901
and O 0 1.961013929019373e-08
feeding O 0 8.668454398730319e-08
difficulties O 0 7.040873128971725e-08
at O 0 8.14077480981723e-08
birth O 0 1.2931035371366306e-06
. O 0 2.539777824495104e-06

His O 0 5.903614237467991e-06
two O 0 2.8244480176908837e-07
sibs O 0 0.0025132272858172655
suffer O 0 8.130468813760672e-07
from O 0 7.151341918643084e-08
childhood O 0 1.1732713574019726e-05
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 0.000689237960614264

Their O 0 5.59600650262837e-08
late O 0 3.8094583487691125e-06
father O 0 1.0075510203932936e-07
had O 0 1.3562472922501456e-08
the O 0 4.369473116661027e-10
adult O 0 8.792250816291869e-10
type O 0 1.350315081971587e-09
of O 0 1.8800417223019394e-08
DM B-Disease 1 1.0
, O 0 2.9586686878246837e-08
with O 0 1.251154735371074e-09
onset O 1 0.9221394062042236
around O 0 7.111132127590736e-09
30 O 0 1.9826543962153664e-08
years O 0 4.77847050817104e-09
. O 0 8.977511356533796e-08

Only O 0 8.363700487734604e-08
six O 0 5.652752488316537e-09
other O 0 3.3578279046153625e-11
cases O 0 9.962972287447247e-12
of O 0 6.793447054898039e-11
paternal O 0 1.1993610087301931e-06
transmission O 1 0.9999982118606567
of O 1 0.9999996423721313
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.00011081555567216128
been O 0 1.1831299673303874e-07
reported O 0 1.2251412329078448e-08
recently O 0 1.499483381905975e-08
. O 0 8.128858297595798e-08

We O 0 6.909697702894846e-08
review O 0 9.753806651247032e-09
the O 0 1.7207529845464364e-09
sex O 0 2.221926947987285e-10
related O 0 6.418511555583706e-11
effects O 0 6.525040507909807e-10
on O 0 3.91823684608994e-09
transmission O 0 1.928478695845115e-06
of O 0 3.876546543324366e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.985595703125

Decreased O 0 7.481218744942453e-06
fertility O 0 7.268505441970774e-08
of O 0 9.252326682585021e-10
males O 0 3.74080801057719e-11
with O 0 3.514256160380702e-12
adult O 0 5.230754496210466e-09
onset O 0 1.0792590728669893e-05
DM B-Disease 1 1.0
and O 0 7.753903474849722e-08
contraction O 0 2.3225737777465838e-08
of O 0 1.3933779685615377e-09
the O 0 1.0937765276830547e-10
repeat O 0 2.2236948393761224e-10
upon O 0 1.9277832108421933e-10
male O 0 1.037791380609221e-10
transmission O 0 2.2118759601674753e-10
contribute O 0 7.121223749573247e-11
to O 0 1.710382668829169e-10
the O 0 7.829257242519816e-10
almost O 0 1.5534088460000817e-09
absent O 0 1.0408014894380813e-08
occurrence O 0 3.0353304314445495e-09
of O 0 8.010735408348069e-10
paternal O 0 6.112505275268632e-07
transmission O 0 3.799997648457065e-05
of O 0 1.0787272003653925e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.8255085945129395

Also O 0 1.0987692178332509e-07
the O 0 1.8680734736875593e-09
fathers O 0 1.5057253222039435e-08
of O 0 2.4685864463691587e-09
the O 0 1.087586132264562e-09
reported O 0 3.6144784942848673e-09
congenitally O 0 3.383108833077131e-06
affected O 0 3.7633336447129295e-09
children O 0 1.3801396692159074e-09
showed O 0 3.207189402942845e-09
, O 0 3.576232088242648e-10
on O 0 1.995583964742309e-08
average O 0 6.505831873226953e-09
, O 0 7.830392445562495e-10
shorter O 0 2.4762042016845953e-07
CTG O 0 3.451743395999074e-06
repeat O 0 1.5660179997212254e-07
lengths O 0 1.4220270827536297e-07
and O 0 1.8973032034352855e-09
hence O 0 3.401899428823185e-09
less O 0 1.2233984936216302e-09
severe O 0 7.254817635526933e-09
clinical O 0 1.7206094327093524e-08
symptoms O 0 4.49164661020518e-09
than O 0 1.7632855245364176e-11
the O 0 7.880536501136959e-11
mothers O 0 3.4332187093255584e-10
of O 0 2.7836213889465e-10
children O 0 5.139196845860283e-10
with O 0 4.2221359741745346e-09
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9999836683273315

We O 0 3.807421080637141e-07
conclude O 0 3.7582216805276403e-07
that O 0 8.761364411746797e-10
paternal O 0 1.4077485275265644e-06
transmission O 0 0.0011415139306336641
of O 0 0.00010689764894777909
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 2.4605500925645174e-07
rare O 0 5.578930650784741e-09
and O 0 4.784858967377126e-11
preferentially O 0 1.6295039970137815e-11
occurs O 0 5.10524088281894e-12
with O 0 2.4154348226418376e-12
onset O 0 8.42963345348835e-07
of O 0 5.529977329388203e-07
DM B-Disease 1 1.0
past O 0 1.0199509148378638e-07
30 O 0 1.2746938615748604e-08
years O 0 3.535970405366129e-10
in O 0 1.2459934473074696e-10
the O 0 2.5135168946199826e-10
father O 0 5.18921616787793e-09
. O 0 3.8050953499180196e-09
. O 0 7.016728886810597e-08

The O 0 2.1428752461361e-06
RB1 O 0 6.960322934901342e-05
gene O 0 2.8277566954670874e-08
mutation O 0 4.47346115706182e-09
in O 0 3.758247935081727e-09
a O 0 4.129992348111955e-08
child O 0 9.859619467533776e-07
with O 0 6.068037805562199e-08
ectopic B-Disease 1 0.9999996423721313
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 0.0042638410814106464

The O 0 1.7961450566872372e-06
RB1 O 0 7.600681419717148e-05
gene O 0 4.5754976696343874e-08
mutation O 0 8.831078979198992e-09
was O 0 2.3186034425748403e-08
investigated O 0 8.874440737827172e-09
in O 0 4.532620501151996e-09
a O 0 2.9194509920671408e-08
child O 0 1.586452356150403e-07
with O 0 4.555049670784683e-09
ectopic B-Disease 0 0.06960775703191757
intracranial I-Disease 1 0.9999992847442627
retinoblastoma I-Disease 0 0.00018272270972374827
using O 0 9.862463201670835e-08
DNA O 0 4.1135848505291506e-08
obtained O 0 6.255238815811026e-08
from O 0 2.8359006254419228e-09
both O 0 1.9214041468984533e-09
the O 0 7.169175475496559e-09
pineal B-Disease 0 6.531866529257968e-05
and I-Disease 0 2.7526439794200996e-07
retinal I-Disease 1 0.9999998807907104
tumours I-Disease 1 1.0
of O 0 9.29396537685534e-06
the O 0 1.6524489865332725e-07
patient O 0 7.257843890329241e-07
. O 0 2.242125987095278e-07

A O 0 3.936463599529816e-06
nonsense O 0 8.408380836044671e-07
mutation O 0 1.3010751587216873e-08
in O 0 4.20701518066835e-09
exon O 0 2.612964635773096e-07
17 O 0 2.6492119786780677e-07
( O 0 1.0889353863063889e-09
codon O 0 2.734182302788213e-08
556 O 0 9.561229141752392e-09
) O 0 3.642567913964001e-10
of O 0 1.7877069824479008e-09
the O 0 6.073292091457461e-09
RB1 O 0 7.4904642133333255e-06
gene O 0 7.556805847741543e-09
was O 0 3.078629973174429e-08
found O 0 4.723192947864163e-10
to O 0 3.1007613143785306e-10
be O 0 4.9607334906554e-10
present O 0 4.881151594027244e-10
homozygously O 0 4.982415475751623e-07
in O 0 3.6766050204306566e-09
both O 0 2.07145967046074e-09
the O 0 1.2580758657065871e-08
retinal B-Disease 0 3.174044877596316e-06
and I-Disease 0 4.0621574726174003e-07
the I-Disease 0 6.578006832569372e-06
pineal I-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 2.0354485968709923e-05

The O 0 3.3178650937770726e-08
same O 0 2.405590393550483e-09
mutation O 0 1.449204423131789e-09
was O 0 3.2753835199628156e-09
present O 0 1.4669075676376764e-10
heterozygously O 0 3.01466442920173e-08
in O 0 5.904425837144345e-10
the O 0 2.1994150944948387e-10
DNA O 0 1.5608813130896237e-09
from O 0 3.0137820017372974e-10
the O 0 4.948089715739457e-10
constitutional O 0 5.394758417764933e-09
cells O 0 1.9807255835502247e-09
of O 0 9.16192233191282e-10
the O 0 3.602116105394515e-10
patient O 0 5.552815540710299e-09
, O 0 4.71990613259976e-10
proving O 0 2.2004915223305943e-08
it O 0 8.654697097876252e-11
to O 0 3.9495687276236424e-10
be O 0 1.7567345356184205e-09
of O 0 1.7056084544719852e-08
germline O 0 4.42566351921414e-06
origin O 0 1.850520732205041e-07
. O 0 3.942588477912068e-07

The O 0 5.1209333662427525e-08
initial O 0 1.3268731891002972e-08
mutation O 0 2.5838016171064737e-09
was O 0 1.12479101588292e-08
shown O 0 1.291001194836383e-09
to O 0 1.0912828418696563e-09
have O 0 3.3864253068394135e-10
occurred O 0 4.0840082426996105e-09
in O 0 6.708800737165177e-10
the O 0 3.9115612970874736e-09
paternally O 0 3.7034507727184973e-07
derived O 0 3.5191473557460995e-07
RB1 O 0 0.00010834524437086657
allele O 0 1.8384447457719943e-06
. O 0 4.736261018933874e-07

The O 0 1.4644230361682276e-07
mutation O 0 1.4212102605881682e-08
is O 0 5.0848845967177425e-11
in O 0 3.925234443036274e-11
an O 0 1.7261884630026536e-11
area O 0 2.3869278775734415e-10
of O 0 1.149037642811379e-09
the O 0 1.57550172907861e-09
gene O 0 1.875589017430457e-09
that O 0 3.768474421406154e-10
encodes O 0 1.509865898974283e-09
the O 0 2.0057526750605348e-09
protein O 0 7.503975774092453e-10
- O 0 8.620964386807373e-09
binding O 0 2.0286952118198087e-09
region O 0 7.340741348116353e-09
known O 0 2.8886746328282698e-09
as O 0 4.179588064534556e-10
the O 0 7.613951136242747e-10
pocket O 0 0.009986698627471924
region O 0 5.332856289896881e-08
and O 0 3.434536877122696e-09
has O 0 3.5068875581245607e-10
been O 0 4.661564467767221e-10
detected O 0 2.4352841965225025e-09
in O 0 5.250673229539871e-10
other O 0 4.3081679890200064e-10
cases O 0 4.988039425946056e-10
of O 0 4.507420658939054e-09
retinoblastoma B-Disease 0 6.565645094269712e-07
. O 0 6.770160609903542e-08
. O 0 5.624147547678149e-07

Low O 0 3.708851409101044e-06
levels O 0 1.2590168019244175e-08
of O 0 8.538873497165866e-10
beta O 0 1.9018148833538362e-08
hexosaminidase O 0 4.0902241948970186e-07
A O 0 4.1662524097318965e-08
in O 0 2.1588884013823417e-09
healthy O 0 5.0104307369736034e-09
individuals O 0 1.5365897790275973e-11
with O 0 1.266812904576753e-10
apparent O 0 1.4103944749876973e-06
deficiency O 0 2.693013084353879e-05
of O 0 4.300485670682974e-06
this O 0 2.5407580039882305e-08
enzyme O 0 6.463066171136234e-08
. O 0 3.4663395354073145e-07

Appreciable O 0 5.9102899285790045e-06
beta O 0 1.5836392321944004e-06
hexosaminidase O 0 1.3555973055190407e-05
A O 0 1.8515389683670946e-06
( O 0 7.582029226682607e-09
hex O 0 3.8148249359437614e-07
A O 0 5.773972588940524e-07
) O 0 1.3924825736921775e-09
activity O 0 9.380806353931348e-09
has O 0 1.2087321421550001e-10
been O 0 4.2768927288605596e-10
detected O 0 8.934801343229992e-09
in O 0 2.4420392819024528e-08
cultured O 1 1.0
skin O 1 1.0
fibroblasts O 1 1.0
and O 0 3.0549394978152122e-06
melanoma B-Disease 1 0.9999997615814209
tissue O 0 2.0273848804208683e-06
from O 0 2.3420254624539893e-09
healthy O 0 2.381694841346871e-09
individuals O 0 9.080286869633802e-12
previously O 0 3.2566310759207795e-10
reported O 0 3.160380845912414e-10
as O 0 1.8493407916153615e-09
having O 0 9.612175944084811e-08
deficiency B-Disease 0 1.2930603361382964e-06
of I-Disease 0 2.4882297111616936e-07
hex I-Disease 0 3.582271119739744e-07
A I-Disease 0 4.293644551012221e-08
activity O 0 3.215562482949963e-09
indistinguishable O 0 9.539765644106524e-10
from O 0 6.420936699003121e-11
that O 0 3.5990631048338217e-12
of O 0 9.582178106537498e-11
patients O 0 5.429284799518541e-10
with O 0 3.5245655283233646e-09
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 5.98192073653081e-08
TSD B-Disease 0 7.551310409326106e-05
) O 0 1.103172397876051e-08
. O 0 1.4141829751679325e-07

Identification O 0 3.821732207143214e-06
and O 0 3.7130270413854305e-08
quantitation O 0 9.998807945521548e-05
of O 0 1.0988411531798192e-06
hex O 0 1.5870818970142864e-06
A O 0 3.063772169298318e-07
, O 0 1.8334727069913015e-09
amounting O 0 6.136309238513604e-09
to O 0 2.215956307338729e-09
3 O 0 1.991861751093893e-07
. O 0 6.185052825458115e-07

5 O 0 1.1818922303064028e-06
% O 0 5.2413231088621615e-08
- O 0 4.55033273283334e-07
6 O 0 8.006142593330878e-07
. O 0 5.241242888587294e-07

9 O 0 1.5518763802901958e-06
% O 0 1.2113114067346942e-08
of O 0 2.3979676022634067e-09
total O 0 1.057899212675295e-09
beta O 0 2.696720891037785e-08
hexosaminidase O 0 3.8893716691745794e-07
activity O 0 3.685607907755184e-08
, O 0 1.3149857869265702e-09
has O 0 1.8192730655286482e-10
been O 0 1.914452901763397e-10
obtained O 0 2.9029694204041334e-09
by O 0 9.540876977354174e-10
cellulose O 0 3.2597174026705034e-07
acetate O 0 1.3858323200111045e-06
gel O 0 1.6903341020224616e-06
electrophoresis O 0 7.29118028175435e-08
, O 0 2.6559592303243562e-09
DEAE O 0 9.75215243670391e-07
- O 0 3.1854689552801574e-08
cellulose O 0 6.47021920485713e-08
ion O 0 2.2766222684822424e-07
- O 0 1.3657830777447089e-06
exchange O 0 1.311196683673188e-06
chromatography O 0 8.524364147888264e-07
, O 0 5.7632094652149135e-09
radial O 0 6.984522116226799e-08
immunodiffusion O 0 1.5611791468472802e-06
, O 0 5.570297112456046e-09
and O 0 7.072635366256463e-09
radioimmunoassay O 0 3.959329114877619e-05
. O 0 9.119527817347262e-07

Previous O 0 4.8476067604497075e-06
family O 0 9.408796408649778e-09
studies O 0 1.701562979405935e-08
suggested O 0 7.3964669944359684e-09
that O 0 1.9101296933055067e-11
these O 0 1.890401724047308e-11
individuals O 0 6.140702096119055e-12
may O 0 1.3845290192104898e-10
be O 0 2.1675641836971238e-10
compound O 0 1.5538423880911978e-08
heterozygotes O 0 6.759231752084816e-08
for O 0 8.687662811368568e-10
the O 0 1.157049456246284e-09
common O 0 2.7013062897651707e-09
mutant O 0 1.930014725814999e-08
TSD B-Disease 0 5.832482088408142e-07
gene O 0 2.3328547982259806e-09
and O 0 8.973959908509244e-10
a O 0 7.721800088233977e-09
rare O 0 4.28745750014059e-08
( O 0 1.613423727953034e-09
allelic O 0 1.2119033954149927e-07
) O 0 2.134147747412385e-09
mutant O 0 4.8986628087277495e-08
gene O 0 2.0751343754454865e-08
. O 0 3.3539868127263617e-07

Thus O 0 4.001800562036806e-07
, O 0 9.655610533343406e-09
the O 0 2.035547952417005e-09
postulated O 0 3.7000187802505025e-08
rate O 0 1.2676262706179386e-08
mutant O 0 2.6137552122662555e-09
gene O 0 5.112798517892259e-10
appears O 0 6.423254705900661e-10
to O 0 2.2798478382934917e-10
code O 0 1.290741957760133e-10
for O 0 9.218923541221002e-11
the O 0 1.8548683422547896e-10
expression O 0 5.083684584406001e-10
of O 0 6.517639761227656e-10
low O 0 2.4674235987731663e-09
amounts O 0 5.763184929286069e-10
of O 0 2.1369295222228857e-09
hex O 0 2.7474246167003e-07
A O 0 1.114879182750883e-06
. O 0 1.8685894929149072e-06

Heterozygotes O 0 0.00012752122711390257
for O 0 7.828442960544635e-08
the O 0 1.138225602659304e-08
rare O 0 1.275287253577062e-08
mutant O 0 2.23363549878286e-08
may O 0 1.2325870324403354e-09
be O 0 1.545219507903539e-10
indistinguishable O 0 3.1479834294856346e-09
from O 0 3.757579247753995e-10
heterozygotes O 0 5.247064294167103e-08
for O 0 1.5386882878942743e-09
the O 0 8.94049545507869e-09
common O 0 5.508156064593095e-08
TSD B-Disease 0 4.1312458051834255e-05
mutant O 0 8.553827797186386e-07
. O 0 3.828510273251595e-07

However O 0 1.87868721468476e-07
, O 0 3.6515992452024193e-09
direct O 0 5.777451406174805e-09
visualization O 0 1.4433631179144868e-07
and O 0 4.5149755045770235e-09
quantitation O 0 6.31571892881766e-05
of O 0 1.1315853498672368e-06
hex O 0 6.420773956961057e-07
A O 0 6.454269652067524e-08
by O 0 3.3240818431146124e-10
the O 0 7.034920423976132e-10
methods O 0 2.177088020971496e-08
described O 0 1.6927154122825527e-09
may O 0 5.674614667050548e-10
prevent O 0 7.25547844027119e-10
false O 0 9.127705702383082e-09
- O 0 7.945295266154062e-08
positive O 0 1.3618923766500757e-09
prenatal O 0 3.928146838916291e-07
diagnosis O 0 3.7731143720520777e-07
of O 0 1.811117833483422e-08
TSD B-Disease 0 1.7250446035177447e-05
in O 0 1.2703492480170553e-08
fetuses O 0 1.2021880024803977e-07
having O 0 2.036433244256841e-09
the O 0 8.996272615746648e-10
incomplete O 0 4.065342196213351e-08
hex B-Disease 0 1.0317398846382275e-05
A I-Disease 0 6.716951611451805e-05
deficiency I-Disease 0 0.0006615013116970658
of O 0 3.7486465771507937e-06
the O 0 8.692726538583884e-08
type O 0 1.546497060189722e-06
described O 0 1.8646215238504737e-08
in O 0 3.3594969028882815e-09
the O 0 6.487816506250965e-08
four O 0 1.4517898705435073e-07
healthy O 0 6.017504574629129e-07
individuals O 0 2.185437786295097e-08

The O 0 2.1246200958557893e-06
tumor B-Disease 0 1.294680896535283e-05
suppressor O 0 9.299576777266338e-05
gene O 0 2.207542820542585e-06
Smad4 O 0 0.02239484339952469
/ O 0 0.00018310380983166397
Dpc4 O 0 8.405260450672358e-05
is O 0 9.490112029553188e-10
required O 0 7.824539904888184e-10
for O 0 4.697543465326248e-10
gastrulation O 0 3.083543447246484e-07
and O 0 2.0037833614594547e-09
later O 0 3.608425203083243e-08
for O 0 1.5261493180318553e-09
anterior O 0 2.8988527134288233e-09
development O 0 1.8058539552612274e-08
of O 0 1.1421705359282441e-08
the O 0 5.914076783852806e-09
mouse O 0 3.244872459617909e-08
embryo O 0 3.2936906535496746e-08
. O 0 2.0556194613163825e-07

Mutations O 0 4.3328080323590257e-07
in O 0 3.770131939972998e-08
the O 0 8.2572782389434e-08
SMAD4 O 1 0.999297022819519
/ O 0 0.0006339033716358244
DPC4 O 0 0.00020087849406991154
tumor B-Disease 0 9.880742481982452e-07
suppressor O 0 2.4686070787538483e-07
gene O 0 6.972951993589049e-09
, O 0 1.1490945972525424e-09
a O 0 6.853098533099455e-09
key O 0 1.994543026739848e-06
signal O 0 1.8571467080619186e-05
transducer O 0 2.0803672668989748e-06
in O 0 6.547412567670108e-08
most O 0 1.2903568880062721e-08
TGFbeta O 0 7.95993946667295e-06
- O 0 3.026799220151588e-07
related O 0 7.739759944058733e-09
pathways O 0 3.815305849030892e-09
, O 0 3.3437610319486666e-11
are O 0 9.746590470469108e-13
involved O 0 8.772692641767499e-12
in O 0 1.7125534323980673e-10
50 O 0 1.0641332437444362e-07
% O 0 1.6219775744730214e-08
of O 0 3.0606122436438454e-07
pancreatic B-Disease 1 0.9999988079071045
cancers I-Disease 1 1.0
. O 1 0.9873492121696472

Homozygous O 0 9.022263839142397e-05
Smad4 O 0 6.900683365529403e-05
mutant O 0 1.485941879764141e-06
mice O 0 4.129606523406437e-08
die O 0 1.9300662401633417e-08
before O 0 7.423320624866392e-09
day O 0 1.0288547258596736e-07
7 O 0 1.547751253383467e-06
. O 0 9.086634236155078e-07

5 O 0 3.3633632483542897e-06
of O 0 4.2900836660919595e-07
embryogenesis O 0 3.223177918698639e-05
. O 0 1.8548366824688856e-06

Mutant O 0 1.3044492561675725e-06
embryos O 0 3.938746928611181e-08
have O 0 6.313535250157543e-10
reduced O 0 1.0177055864701856e-09
size O 0 1.8793810951933665e-09
, O 0 1.9211183754919148e-09
fail O 0 1.069284820687244e-07
to O 0 1.0760524027375595e-08
gastrulate O 0 3.6023163829668192e-06
or O 0 1.6068277375325124e-08
express O 0 6.2997775884809926e-09
a O 0 1.8178378802247153e-09
mesodermal O 0 3.553736576122901e-07
marker O 0 1.3949747312835825e-07
, O 0 3.137828441523993e-09
and O 0 5.520121693081137e-09
show O 0 1.5176571821484686e-07
abnormal O 0 2.0403267342317122e-07
visceral O 0 9.450973834645993e-07
endoderm O 0 8.217023423640057e-05
development O 0 1.6312374100380111e-06
. O 0 1.2090064274161705e-06

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 0 1.030067778629018e-06
the O 0 5.655796542214375e-08
Smad4 O 0 7.499740604544058e-05
- O 0 1.811173547139333e-06
deficient O 0 7.89723557659272e-08
embryos O 0 2.5604654396715887e-08
results O 0 4.209688153622437e-09
from O 0 1.2950975847303425e-09
reduced O 0 4.019717891878827e-09
cell O 0 4.267403852509233e-08
proliferation O 0 3.833998221125512e-07
rather O 0 1.1699584634428106e-09
than O 0 2.5674171122425093e-10
increased O 0 2.071321336671872e-09
apoptosis O 0 2.9517875077544886e-07
. O 0 3.4617076494214416e-07

Aggregation O 0 2.5639556042733602e-06
of O 0 4.190172546714166e-07
mutant O 0 9.682481731942971e-07
Smad4 O 0 2.1982988982927054e-05
ES O 0 6.637669866904616e-05
cells O 0 6.267528362968733e-08
with O 0 3.697207262565172e-10
wild O 0 2.0848581527843635e-08
- O 0 6.627181647900215e-08
type O 0 8.742709667330928e-08
tetraploid O 0 1.5604721284034895e-06
morulae O 0 5.085472821519943e-06
rescues O 0 7.854510499782918e-07
the O 0 5.189338025957113e-08
gastrulation B-Disease 0 8.928724128054455e-05
defect I-Disease 0 1.6459531252621673e-05
. O 0 8.504341053594544e-07

These O 0 4.4068062976521105e-08
results O 0 1.2847526598136483e-08
indicate O 0 2.09381276761178e-08
that O 0 4.367415040729128e-10
Smad4 O 0 4.5126918735149957e-07
is O 0 1.4245606083651552e-10
initially O 0 3.183079078095119e-10
required O 0 2.1643707659446676e-10
for O 0 2.224398998329491e-10
the O 0 5.038353623199043e-10
differentiation O 0 7.662994683244051e-09
of O 0 1.0387924298527196e-08
the O 0 5.1514077448189255e-09
visceral O 0 6.401392482757728e-08
endoderm O 0 5.135615310791763e-07
and O 0 7.294163051341229e-10
that O 0 5.917963341595112e-11
the O 0 6.594254031710989e-10
gastrulation B-Disease 0 1.610315280231589e-06
defect I-Disease 0 1.1650960374254282e-07
in O 0 2.522576370012075e-09
the O 0 7.720327488414114e-09
epiblast O 0 4.7086905397009104e-05
is O 0 2.1648580150746e-10
secondary O 0 3.2187534859673406e-09
and O 0 4.290929833672408e-10
non O 0 9.522565278530237e-07
- O 0 9.532096783004818e-07
cell O 0 6.151783964014612e-06
autonomous O 0 2.1573721369350096e-06
. O 0 1.1613303740887204e-06

Rescued O 0 5.5428474297514185e-05
embryos O 0 9.97761162579991e-07
show O 0 2.2683997258354793e-07
severe O 0 2.2129505339307798e-07
anterior O 0 2.870037576485629e-07
truncations O 0 0.0010079304920509458
, O 0 1.395818429728024e-07
indicating O 0 2.591374936855573e-07
a O 0 6.805411345567336e-09
second O 0 3.6642902045969095e-09
important O 0 1.674511085347774e-09
role O 0 4.1758130286950745e-09
for O 0 1.7093757520569852e-09
Smad4 O 0 3.4837557905120775e-06
in O 0 1.1625028939477033e-08
anterior O 0 2.730884034463088e-07
patterning O 0 0.00024189539544750005
during O 1 0.9908915162086487
embryogenesis O 0 0.0023393321316689253
. O 0 1.657997472648276e-06

Prevalence O 0 2.5922450731741264e-05
of O 0 1.1703166080678784e-07
p16 O 0 1.720280124573037e-06
and O 0 5.3947101008589016e-08
CDK4 O 0 0.13068269193172455
germline O 0 0.0005865316488780081
mutations O 0 6.862413926000954e-08
in O 0 2.652032549121941e-08
48 O 0 1.4605235492126667e-06
melanoma B-Disease 1 0.9112064242362976
- O 0 0.00014681856555398554
prone O 0 5.198511985327059e-07
families O 0 2.8759356007768133e-10
in O 0 2.2348958239604144e-09
France O 0 2.9566641046585573e-07
. O 0 2.999903756517597e-07

The O 0 4.113218892598525e-06
French O 0 0.0001396611041855067
Familial B-Disease 1 0.6997649073600769
Melanoma I-Disease 1 1.0
Study O 0 5.123527557771013e-07
Group O 0 1.3868693748975147e-08
. O 0 2.6524876517441953e-08

Germline O 0 0.00023274072736967355
mutations O 0 2.1736322253218532e-07
in O 0 2.177511504442009e-08
the O 0 2.3828684803106626e-08
p16 O 0 7.714382945778198e-07
and O 0 1.1298891600119987e-08
CDK4 O 0 1.8644650481292047e-05
genes O 0 2.9953994840070663e-09
have O 0 2.2085709650010443e-10
been O 0 1.8036354354489248e-10
reported O 0 1.0084628965234543e-10
in O 0 1.79934719901631e-10
a O 0 1.7114375472360166e-09
subset O 0 8.476747836994036e-08
of O 0 2.0438900349972755e-08
melanoma B-Disease 0 3.023437238880433e-05
pedigrees O 0 5.832148417539429e-07
, O 0 4.001061260083816e-09
but O 0 6.774842908896517e-10
their O 0 3.0207529810866163e-09
prevalence O 0 1.504762821014083e-07
is O 0 2.531833596941535e-11
not O 0 7.780173033600235e-11
well O 0 2.1557733376198485e-09
known O 0 5.450051432376313e-08
. O 0 4.131647699523455e-07

We O 0 2.8800178597521153e-07
searched O 0 2.4646269025652146e-07
for O 0 1.461704979277556e-09
such O 0 1.4369396783564525e-09
germline O 0 1.2300613889237866e-05
mutations O 0 4.5011169902409165e-08
in O 0 2.6028416755252692e-08
48 O 0 3.581134478736203e-06
French O 0 4.698812699643895e-05
melanoma B-Disease 1 0.9999547004699707
- O 0 0.00017771513375919312
prone O 0 1.1956136347635038e-07
families O 0 8.468122036919823e-11
selected O 0 1.9067017409390985e-10
according O 0 6.294402499218421e-11
to O 0 7.072790270123974e-11
two O 0 2.0210191159497626e-11
major O 0 1.9087721681021463e-10
criteria O 0 3.9914399563301117e-10
families O 0 1.0954024146081487e-11
with O 0 6.8996878523075456e-12
at O 0 2.1383608217462324e-09
least O 0 5.077879783321748e-10
three O 0 4.040331402777042e-10
affected O 0 1.7477143066102485e-09
members O 0 9.262320355141185e-10
( O 0 1.1305095748426197e-09
n O 0 1.0593333321651244e-08
= O 0 2.9657538647143156e-08
20 O 0 4.851702595232155e-09
) O 0 1.1706655089760432e-10
or O 0 6.755845188832765e-11
families O 0 8.179013889775266e-12
with O 0 2.0116380349682883e-12
two O 0 2.574462344695494e-11
affected O 0 1.3953213584549928e-10
members O 0 2.3416435457335183e-11
, O 0 3.3586734088375536e-11
one O 0 4.4691670503249625e-11
of O 0 7.227960591160709e-11
them O 0 1.7638841776079772e-11
affected O 0 4.075319942620226e-11
before O 0 1.699615170824842e-10
the O 0 3.560306216510156e-10
age O 0 1.6778936018368995e-09
of O 0 1.7229928594986177e-09
50 O 0 7.35923233463609e-09
( O 0 1.915987091205551e-10
n O 0 3.398384462727222e-09
= O 0 2.0273423828598425e-08
28 O 0 1.0618053103428338e-08
) O 0 3.2004107697325423e-10
, O 0 2.4511645491109846e-10
and O 0 1.4803228087778564e-10
one O 0 1.1564708218836373e-10
additional O 0 1.963370799273889e-09
minor O 0 3.3405022747956536e-08
criterion O 0 1.605282159289345e-05
. O 0 2.6752406938612694e-06

Sixteen O 0 3.438227167862351e-06
different O 0 2.3611249844179838e-08
p16 O 0 1.080853280654992e-06
germline O 0 2.192700321757002e-06
mutations O 0 5.2737907374478254e-09
were O 0 8.677826235370389e-10
found O 0 9.310138771034815e-11
in O 0 4.314168466912349e-11
21 O 0 3.989394592451845e-09
families O 0 4.576651557730571e-11
, O 0 7.601728968520405e-11
while O 0 2.1440364761371455e-10
one O 0 4.740123848989697e-10
germline O 0 5.016084969611256e-07
mutation O 0 8.491226388684936e-09
, O 0 6.548458664212831e-09
Arg24His O 0 1.7784894225769676e-05
, O 0 1.1069663408136421e-08
was O 0 3.821914162926987e-08
detected O 0 1.1219049689259464e-08
in O 0 1.8235851717562923e-09
the O 0 1.1741058791869818e-08
CDK4 O 0 3.7672787584597245e-05
gene O 0 1.679518533137525e-07
. O 0 1.0607627700665034e-06

The O 0 7.053710504578703e-08
frequency O 0 2.5021836336236447e-07
of O 0 1.0412899875689163e-08
p16 O 0 7.53591109514673e-08
gene O 0 8.586797051179929e-09
mutation O 0 1.357841061810916e-09
in O 0 1.7047783185120124e-09
our O 0 1.6089041210420874e-08
sample O 0 6.28266683122547e-09
( O 0 4.4937353838037097e-10
44 O 0 2.6200042135826607e-09
% O 0 3.060454112358002e-10
) O 0 6.392366497243174e-11
is O 0 1.2213037005326388e-11
among O 0 3.810398611220345e-12
the O 0 2.8890905293121882e-11
highest O 0 5.26787669041795e-10
rates O 0 5.690460325169511e-10
yet O 0 1.6923239198884943e-10
reported O 0 7.695243331440338e-10
and O 0 5.328519292469025e-10
the O 0 9.301522219118397e-09
CDK4 O 0 6.655875495198416e-06
mutation O 0 2.44559905659969e-09
is O 0 6.252415946095269e-11
the O 0 2.956239975038244e-10
second O 0 1.2445245722858544e-08
mutation O 0 3.020701022649064e-09
detected O 0 9.41619315852904e-09
in O 0 4.3213685407827995e-10
this O 0 2.3497473411460135e-10
gene O 0 6.608207758773688e-09
worldwide O 0 1.9270279594252315e-08
. O 0 2.1282713191794755e-07

In O 0 3.655392077916986e-08
summary O 0 2.395462104232138e-07
, O 0 6.19934992229787e-10
our O 0 1.0012684015237028e-09
results O 0 4.346266124777287e-10
show O 0 1.745858457802285e-09
frequent O 0 1.0791061377801725e-09
involvement O 0 4.904101569280783e-09
of O 0 6.32739061146026e-09
the O 0 1.7283785069821533e-08
p16 O 0 7.845945333428972e-07
gene O 0 3.7939585695312417e-08
in O 0 1.4186968932961008e-08
familial B-Disease 0 1.4981103504396742e-06
melanoma I-Disease 1 0.999077558517456
and O 0 2.1467966959676232e-08
confirm O 0 3.536284154392888e-08
the O 0 5.97739058250113e-09
role O 0 6.570117250248586e-08
of O 0 1.2945751848292275e-07
the O 0 3.271563642215369e-08
CDK4 O 0 7.04214908182621e-05
gene O 0 2.611105820449211e-08
as O 0 8.954762265034333e-09
a O 0 3.5284283939063243e-08
melanoma B-Disease 0 0.004216100554913282
- O 0 1.8106562492903322e-05
predisposing O 0 7.84151052357629e-06
gene O 0 2.944779708968781e-08
. O 0 1.9716088317522917e-08
. O 0 1.3049103131379525e-07

Progression O 0 6.44217652734369e-06
of O 0 5.11175073825143e-07
somatic O 0 1.1000460290233605e-05
CTG O 0 1.2553031410789117e-05
repeat O 0 1.4034105788596207e-07
length O 0 6.476167602187388e-09
heterogeneity O 0 2.529993459177149e-08
in O 0 2.2403416899408057e-09
the O 0 1.6623770138224359e-09
blood O 0 1.9836368103653967e-09
cells O 0 1.3003457866034296e-08
of O 0 1.061186125639324e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.199001282453537
. O 0 3.621575388024212e-06

The O 0 4.9684558689477853e-08
genetic O 0 6.37098684919124e-09
basis O 0 2.2974464997105315e-08
of O 0 2.7476866648612486e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 2.6801383228303166e-06
DM B-Disease 1 1.0
) O 0 2.141119725962426e-09
is O 0 5.522274998392973e-11
the O 0 2.4366661466324047e-11
expansion O 0 8.727373823624873e-10
of O 0 8.807776730179739e-10
an O 0 6.683904124615836e-11
unstable O 0 4.8469668278983136e-09
CTG O 0 1.475727060551435e-07
repeat O 0 4.797986896676321e-09
in O 0 2.7195345975172813e-09
the O 0 3.5752656390997117e-09
34 O 0 2.964843304198439e-08
UTR O 0 3.1395804853673326e-06
of O 0 4.5439623619358827e-08
the O 0 2.6150230425514565e-08
DM B-Disease 1 0.9999998807907104
protein O 0 2.3944222604654897e-08
kinase O 0 3.6026484906415135e-08
gene O 0 6.389179407761958e-09
on O 0 4.2125336108256306e-08
chromosome O 0 2.1357494972562563e-07
19 O 0 2.2333217657433124e-06
. O 0 9.72997668213793e-07

One O 0 4.468150649472591e-08
of O 0 1.3832290868265318e-08
the O 0 1.62967350725296e-09
principal O 0 1.778908398364365e-08
features O 0 5.101297162468654e-09
of O 0 1.8301404836051915e-08
the O 0 1.69612334843805e-07
DM B-Disease 1 1.0
mutation O 0 9.555323003951344e-07
is O 0 7.48660577976068e-10
an O 0 3.0006300222318316e-10
extraordinarily O 0 3.2357689860873506e-08
high O 0 1.415656640801899e-07
level O 0 3.486416915166046e-07
of O 0 3.1381592435764105e-08
somatic O 0 2.6703617095336085e-06
mosaicism O 0 6.098814537836006e-06
, O 0 9.52207868110122e-10
due O 0 2.4652879737629974e-09
to O 0 6.877738933930289e-10
an O 0 1.0869426886328526e-10
extremely O 0 4.559402300152726e-10
high O 0 1.6009961134599848e-09
degree O 0 5.30151815780755e-08
of O 0 2.833533585544501e-08
somatic O 0 2.7732707167160697e-05
instability O 0 1.2382733984850347e-06
both O 0 5.697530225390324e-10
within O 0 3.94074189946636e-10
and O 0 1.4960935268426567e-10
between O 0 3.657771655007913e-11
different O 0 3.195141096146159e-10
tissues O 0 8.951743524221456e-08
. O 0 2.1259445759369555e-07

This O 0 6.142798980590669e-08
instability O 0 1.3587481362264953e-06
appears O 0 6.148071385325693e-09
to O 0 1.920128361865281e-10
be O 0 7.195744694543649e-11
biased O 0 1.6116398215970662e-09
towards O 0 1.5546004483724118e-09
further O 0 2.543669441745777e-10
expansion O 0 4.120742636004593e-10
and O 0 1.0620108265024797e-10
continuous O 0 3.659345271245229e-09
throughout O 0 3.0465463485285227e-10
the O 0 9.771449621664985e-11
life O 0 3.053957919885164e-10
of O 0 1.4360483635567078e-10
an O 0 1.494806362023482e-11
individual O 0 2.728525738682208e-11
, O 0 5.340543632326167e-11
features O 0 4.266349773462963e-10
that O 0 7.863641161842683e-12
could O 0 4.864790861813795e-11
be O 0 4.895965230455879e-11
associated O 0 7.915610389375161e-10
with O 0 7.491016140726003e-11
the O 0 5.856189311259641e-09
progressive O 0 3.7286829979166214e-07
nature O 0 3.189029929018261e-09
of O 0 3.0395828076734688e-09
the O 0 3.131479076046162e-09
disease O 0 3.062734776904108e-08
. O 0 5.6638931766883616e-08

Although O 0 4.253695067291119e-07
increasing O 0 3.742134424555843e-08
measured O 0 3.396921499643213e-08
allele O 0 2.6110360096254226e-08
size O 0 2.2906587737736572e-09
between O 0 3.6416095139379934e-10
patients O 0 8.795290717955595e-09
clearly O 0 7.119569933600189e-10
correlates O 0 1.0006250272809325e-09
with O 0 1.2426866827230931e-11
an O 0 3.962748879038358e-11
increased O 0 3.5587990887542276e-10
severity O 0 2.2635369134604844e-08
of O 0 2.1311699072157353e-09
symptoms O 0 8.357892156141133e-09
and O 0 1.482204498026718e-10
an O 0 5.017177298616282e-11
earlier O 0 3.444283469544729e-10
age O 0 7.1530820155985e-10
of O 0 5.806060077162556e-10
onset O 0 4.814729237523352e-08
, O 0 1.36453612298304e-10
this O 0 2.387960662542099e-11
correlation O 0 2.1743301603649456e-10
is O 0 2.225896203467137e-11
not O 0 1.4653470103986876e-10
precise O 0 4.557606914090684e-08
and O 0 2.131878495958972e-08
measured O 0 2.429320034025295e-07
allele O 0 1.6369172683994293e-08
length O 0 4.895649996505824e-10
cannot O 0 7.814368041536568e-10
be O 0 2.2071684757651866e-10
used O 0 8.621617864079667e-10
as O 0 2.5050933549763954e-10
an O 0 3.3764265688907e-11
accurate O 0 5.131901570365471e-09
predictor O 0 7.23308701822134e-08
of O 0 3.6235416889240923e-09
age O 0 1.1591530402199623e-08
of O 0 1.5076622617016255e-08
onset O 0 7.896699571574572e-06
. O 0 2.664582154920936e-07

In O 0 3.379556545723972e-08
order O 0 3.779706325701682e-09
to O 0 3.758202637982322e-10
further O 0 5.419383830584934e-10
characterize O 0 2.535063936548454e-09
the O 0 1.5201762071370695e-09
dynamics O 0 1.568686869291014e-08
of O 0 2.443465518808807e-07
DM B-Disease 1 1.0
CTG O 0 4.0855480619939044e-05
repeat O 0 3.658412879303796e-07
somatic O 0 2.6818081551027717e-06
instability O 0 3.7371344774328463e-07
, O 0 2.810048582713165e-10
we O 0 9.00380395241207e-11
have O 0 1.3158073589036867e-11
studied O 0 4.2770473274167387e-10
repeat O 0 4.5857148633920986e-10
length O 0 3.0949767748644774e-10
changes O 0 2.2693272261342656e-10
over O 0 1.388736764473819e-10
time O 0 6.275668873456652e-10
in O 0 2.302924961838926e-09
111 O 0 6.971411949052708e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 8.279010188516622e-08
with O 0 4.031145903193867e-11
varying O 0 5.345774378717749e-10
clinical O 0 1.3030023282567527e-08
severity O 0 4.6942343345790505e-08
and O 0 1.805791183251415e-09
CTG O 0 3.9941178897606733e-07
repeat O 0 9.070434181523979e-09
size O 0 1.4042875751130168e-09
over O 0 1.5535207842365395e-10
time O 0 1.9084300806326837e-10
intervals O 0 1.600006377389107e-10
of O 0 1.3989856495477682e-10
1 O 0 2.980359736781679e-09
- O 0 5.991946494532385e-08
7 O 0 1.1061943183676703e-07
years O 0 6.195289614652211e-08
. O 0 1.7369917770793109e-07

We O 0 2.0647910048410267e-07
have O 0 1.926519610506716e-09
found O 0 3.3514438446680117e-10
a O 0 9.882465679122987e-11
direct O 0 9.148057866781301e-10
progression O 0 4.467296310650681e-09
of O 0 1.0615051060369751e-09
the O 0 5.711533468399921e-10
size O 0 8.316527466689649e-10
heterogeneity O 0 4.694025612650421e-09
over O 0 3.364561129703958e-10
time O 0 8.612955904041542e-10
related O 0 4.691564026160222e-09
to O 0 3.0409337270498327e-09
initial O 0 1.724233200661729e-08
CTG O 0 4.828486908081686e-07
repeat O 0 1.7271986507694237e-08
size O 0 4.880976955945471e-09
and O 0 1.2226846202167962e-09
the O 0 1.7017893760851166e-09
time O 0 2.8702706877936635e-09
interval O 0 5.166521432897753e-09
and O 0 8.731785849924734e-10
always O 0 7.329758577867551e-09
biased O 0 9.170056713969643e-09
towards O 0 4.84232787201222e-09
further O 0 3.5841278833714796e-09
expansion O 0 8.489967484592853e-08
. O 0 2.7795454116130713e-07

Attempts O 0 6.445762892326456e-07
to O 0 3.5203531201233318e-09
mathematically O 0 8.2981035376406e-09
model O 0 3.018784511255035e-08
the O 0 4.192444613693169e-09
dynamics O 0 5.302823069541773e-08
have O 0 4.536503617202925e-09
proved O 0 4.5294942907503355e-08
only O 0 5.96965088472956e-10
partially O 0 1.626785994801594e-08
successful O 0 1.0648028236914797e-08
suggesting O 0 7.240427368770952e-09
that O 0 1.9607603735094514e-11
individual O 0 6.5593745712799745e-12
specific O 0 8.886812813413414e-11
genetic O 0 1.9945480822514128e-09
and O 0 3.1918898635296955e-09
/ O 0 0.3899460732936859
or O 0 1.1934305099714493e-08
environmental O 0 1.0569074504473974e-08
factors O 0 1.0102326752914337e-09
also O 0 1.1668803423514618e-10
play O 0 1.0018396112698724e-09
a O 0 2.3213633237872955e-09
role O 0 1.934363424993535e-08
in O 0 2.808144294874637e-08
somatic O 0 7.950257895572577e-06
mosaicism O 0 3.423733141971752e-05
. O 0 1.017382302848091e-07
. O 0 5.589157581198378e-07

Aspartylglucosaminuria B-Disease 1 1.0
among O 0 1.1447074399484336e-07
Palestinian O 0 2.3567304197058547e-06
Arabs O 0 1.7450772702432005e-06
. O 0 2.1208313683018787e-07

Aspartylglucosaminuria B-Disease 1 1.0
( O 0 2.230847348982934e-05
AGU B-Disease 1 1.0
) O 0 2.254424025238677e-08
is O 0 4.1217723678599327e-10
a O 0 3.6420144677862254e-09
rare O 0 8.001349556252535e-07
disorder B-Disease 1 0.9999860525131226
of I-Disease 0 2.221643808297813e-05
glycoprotein I-Disease 0 5.602399596682517e-06
metabolism I-Disease 0 4.1560883801139425e-06
caused O 0 3.0552288876606326e-07
by O 0 1.4024219563424367e-09
the O 0 2.469735136401141e-07
deficiency B-Disease 0 8.64639241626719e-06
of I-Disease 0 2.908710030169459e-06
the I-Disease 0 1.1245083442190662e-07
lysosomal I-Disease 0 3.4276915812370135e-06
enzyme I-Disease 0 2.205702109847607e-08
aspartylglucosaminidase I-Disease 0 7.843738103474607e-07
( O 0 3.892003608285677e-09
AGA O 0 1.1054144124500453e-05
) O 0 4.530392772039704e-08
. O 0 1.90514114706275e-07

AGU B-Disease 1 1.0
is O 0 1.279183123870098e-07
inherited O 0 3.4241949720126286e-07
as O 0 4.330019720555356e-08
an O 0 1.1488694440231484e-08
autosomal O 1 0.8156282305717468
recessive O 0 0.00038875226164236665
trait O 0 2.365967333162189e-07
and O 0 6.208899505644183e-10
occurs O 0 6.651219852660262e-11
with O 0 1.2281240477710065e-12
a O 0 7.106353006047783e-11
high O 0 2.863959958077089e-09
frequency O 0 9.741594908518891e-08
in O 0 9.52847845070437e-09
Finland O 0 7.595347710775968e-07
because O 0 2.274970878346494e-09
of O 0 2.0839159731167456e-08
a O 0 1.0896090252288104e-08
founder O 0 2.1192057886310067e-07
effect O 0 5.7798903441153016e-08
. O 0 3.0668212502860115e-07

While O 0 1.0368648162284444e-07
very O 0 1.7618013714582048e-09
few O 0 2.9116085098479516e-09
patients O 0 3.321510400056127e-09
with O 0 4.047365775861067e-10
AGU B-Disease 1 1.0
have O 0 1.8391441258813757e-08
been O 0 8.426043751619261e-10
reported O 0 1.8409428148569162e-10
from O 0 1.9230303113793035e-11
non O 0 5.692091242792685e-09
- O 0 1.4003138204543575e-08
Finnish O 0 1.297942731071089e-07
origin O 0 9.139198287044792e-10
, O 0 8.722642746983311e-11
we O 0 5.516140322292529e-10
diagnosed O 0 7.07962968249376e-08
the O 0 5.481710196875156e-09
disorder O 0 2.8428341920516687e-06
in O 0 1.8865100592790895e-09
8 O 0 1.5819381360415719e-07
patients O 0 1.230085699965855e-09
originating O 0 4.5687867378241265e-10
from O 0 8.002026818942909e-11
3 O 0 1.7266148510941548e-09
unrelated O 0 8.046783794846135e-10
families O 0 2.958980283018775e-11
, O 0 3.802407000375041e-11
all O 0 5.370718453301393e-11
Palestinian O 0 6.85274841316641e-08
Arabs O 0 5.869183361539854e-09
from O 0 3.739875631403322e-10
the O 0 2.024017620172458e-10
region O 0 1.2756271594582813e-09
of O 0 1.911144797972497e-09
Jerusalem O 0 7.678369001951069e-06
. O 0 2.496558408893179e-07

The O 0 1.4471066833721125e-07
clinical O 0 5.651515380122873e-07
diagnosis O 1 0.9983793497085571
of O 0 8.377517951885238e-05
AGU B-Disease 1 1.0
is O 0 4.870301051340675e-09
often O 0 6.973104732521662e-11
difficult O 0 3.8459374573918126e-11
, O 0 1.0577185828586355e-11
in O 0 1.2867149186412963e-11
particular O 0 6.596703738814824e-11
early O 0 5.173877770658919e-09
in O 0 2.004042209957646e-10
the O 0 6.828722032281576e-10
course O 0 8.499442039067162e-09
of O 0 9.791920607682414e-10
the O 0 5.918485146416685e-10
disease O 0 7.729916151610894e-10
, O 0 1.8643342078461522e-11
and O 0 2.0602670611213902e-11
most O 0 7.326229206627843e-11
of O 0 3.6219643950730074e-10
the O 0 2.3639884494386365e-10
patients O 0 1.4136067316705692e-10
are O 0 9.433939740510766e-12
diagnosed O 0 1.1987111303568554e-09
after O 0 4.352371518745457e-10
the O 0 7.956600933667346e-10
age O 0 3.913919410791777e-09
of O 0 4.053718249963367e-09
5 O 0 2.9535717871453926e-08
years O 0 1.4742943754697535e-08
. O 0 1.629280319548343e-07

However O 0 1.9373511861431325e-07
, O 0 6.045854483716084e-09
since O 0 4.04343269977403e-09
these O 0 2.3675986171589614e-10
patients O 0 5.078625853194296e-10
excrete O 0 1.3997797587705918e-08
early O 0 4.138895093319661e-08
large O 0 1.9290862240950446e-09
amounts O 0 7.2695285346924265e-09
of O 0 1.8812684743352293e-08
aspartylglucosamine O 0 2.941652610388701e-06
in O 0 4.2206966810454105e-08
urine O 0 1.741100597030254e-08
, O 0 6.146708142473756e-10
biochemical O 0 6.453824141772202e-09
screening O 0 4.9444999206116336e-08
is O 0 3.0330846723103377e-09
easy O 0 3.692813521638527e-08
by O 0 4.129367958682906e-09
urine O 0 1.8934466439191056e-08
chromatography O 0 4.8013401254820565e-08
. O 0 2.9193564898832847e-08
. O 0 2.651759700711409e-07

Detection O 0 1.8034046661341563e-05
of O 0 6.852395983969473e-08
heterozygous O 0 3.0805433759439893e-09
carriers O 0 1.1458576310019453e-09
of O 0 2.1134398675570765e-09
the O 0 5.6849550844617625e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 1.6391017254591134e-07
ATM O 0 3.091420148848556e-05
) O 0 1.6051667772742917e-09
gene O 0 3.822741290182563e-10
by O 0 5.486602838722376e-10
G2 O 0 5.727236498387356e-07
phase O 0 7.347117048084328e-07
chromosomal O 0 2.530191977712093e-06
radiosensitivity O 0 2.2541358703165315e-05
of O 0 2.3495843493037682e-07
peripheral O 0 2.2765167159377597e-05
blood O 0 7.733151505817659e-07
lymphocytes O 0 4.762395349189319e-07
. O 0 1.3033930201800104e-07

In O 0 2.687560936465161e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.6926686763763428
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 6.549832676228107e-09
patients O 0 1.0189840971008834e-08
, O 0 9.847204995860892e-11
mutations O 0 1.2160975004782415e-10
in O 0 3.3674887878198945e-10
a O 0 8.412923135914241e-10
single O 0 6.924071316305458e-10
gene O 0 2.770596529977354e-10
, O 0 2.22405968641759e-10
ATM O 0 1.3350734207051573e-07
, O 0 1.7196202795055626e-10
result O 0 8.844251719875018e-11
in O 0 4.65080085554348e-10
an O 0 8.019472375053738e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 2.490503447916126e-08
embraces O 0 2.265466481077283e-09
a O 0 1.601508370363547e-10
variety O 0 7.76925884737878e-11
of O 0 3.7287073428871054e-10
clinical O 0 3.4628346856635517e-09
features O 0 4.288846167099791e-09
and O 0 8.772534920709063e-10
manifests O 0 3.61328567066721e-09
extreme O 0 2.1490171420168735e-08
radiosensitivity O 0 2.4313132485076494e-07
and O 0 3.3581641911695215e-09
a O 0 4.0727385908212455e-08
strong O 0 6.164101051808757e-08
pre O 0 0.00016311810759361833
- O 0 1.922394039866049e-05
disposition O 0 1.6203613995458e-05
to O 0 6.686883580186986e-07
malignancy B-Disease 0 0.0011373882880434394
. O 0 1.2171936987215304e-06

Heterozygotes O 0 2.5002469556056894e-05
for O 0 4.064683167825933e-08
the O 0 8.010738739017143e-09
ATM O 0 8.508116479788441e-06
gene O 0 3.4162713546948e-08
have O 0 1.6453648443714997e-09
no O 0 9.707940007430693e-10
clinical O 0 5.51019141425968e-09
expression O 0 1.1969610858031388e-09
of O 0 4.1292027574968415e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 1.3806082943546016e-09
may O 0 1.31594157792847e-09
be O 0 1.3264424003622821e-09
cancer B-Disease 0 2.2073392003107983e-08
prone O 0 2.4932111930553447e-09
with O 0 1.522751542915035e-11
a O 0 2.7138864489018033e-09
moderate O 0 2.619905536960232e-08
increase O 0 2.271671295517308e-09
in O 0 5.05759345514889e-09
in O 0 5.020439530767362e-08
vitro O 0 6.311124707281124e-06
radiosensitivity O 0 1.9738417904591188e-05
. O 0 2.4209900857385946e-06

We O 0 7.107257005145584e-08
performed O 0 1.081769553934464e-07
a O 0 2.4931029685149042e-08
blind O 0 1.7286183151554724e-07
chromosomal O 0 8.30935178441905e-08
analysis O 0 2.5961480076830412e-08
on O 0 2.6645357920074275e-08
G2 O 0 6.32567918046334e-08
- O 0 1.8008424973459114e-08
phase O 0 3.9365467330299e-08
lymphocytes O 0 6.910023664374876e-09
from O 0 1.1443303943314831e-10
7 O 0 2.0763368802079185e-09
unrelated O 0 2.0957864776960378e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.1640370303211967e-06
, O 0 2.586931779902102e-10
13 O 0 1.4253955793464002e-09
obligate O 0 5.769195965399376e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 7.938103954074904e-05
( O 0 4.711433465587334e-10
parents O 0 1.4021189764790165e-10
of O 0 2.7540881034071596e-11
the O 0 2.4529029848952e-11
patients O 0 4.884138579686059e-11
) O 0 4.474939516163623e-12
, O 0 1.2504377741584527e-11
and O 0 1.230451296407864e-10
14 O 0 1.9167236686712386e-08
normal O 0 3.9120031658512744e-08
controls O 0 1.0700212982328594e-07
following O 0 6.308170430457949e-09
X O 0 1.3049751146354538e-07
- O 0 2.565901979778573e-08
irradiation O 0 2.4197376546908345e-08
with O 0 3.875970377986704e-10
1 O 0 9.238016929202786e-08
Gy O 0 7.107606961653801e-06
in O 0 5.922572987593355e-10
order O 0 9.224028763021863e-10
to O 0 7.035255711329569e-10
evaluate O 0 1.08903552842321e-08
this O 0 6.152091613920163e-10
cytogenetic O 0 2.1711358044740336e-07
method O 0 2.140447108445187e-08
as O 0 1.2797383153184683e-09
a O 0 4.96990060216973e-10
tool O 0 2.205794480403256e-08
for O 0 2.9706648252414425e-10
detection O 0 2.2778861819006124e-07
of O 0 5.5431780054959745e-08
ATM O 0 0.000100799894426018
carriers O 0 2.07152606890304e-06
. O 0 1.9161373074894072e-06

Both O 0 3.247950530749222e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 0 0.00016467776731587946
and O 0 9.141385959310355e-08
heterozygotes O 0 7.3316173256898765e-06
showed O 0 3.624905176025095e-08
significantly O 0 5.701870975372003e-09
increased O 0 1.638606361709094e-09
levels O 0 1.1168550528850574e-09
of O 0 9.410909829199454e-10
radiation O 0 1.4251036191126332e-05
- O 0 6.720519195368979e-06
induced O 0 2.5322585770481965e-06
chromatid O 0 9.519914101474569e-07
damage O 0 3.444648939421313e-07
relative O 0 8.86405757682951e-08
to O 0 1.1930338938981322e-09
that O 0 8.987693228545979e-11
of O 0 1.1404459598907124e-09
normal O 0 3.014078231444728e-08
controls O 0 8.951212180363655e-07
. O 0 4.6933030262152897e-07

These O 0 6.306221767005127e-09
results O 0 1.8206277596632958e-09
show O 0 3.0074269741220405e-09
that O 0 5.5758193201471684e-11
the O 0 1.0557624774421015e-09
G2 O 0 4.997705786990991e-07
- O 0 6.52033179449063e-07
phase O 0 6.673695907011279e-07
chromosomal O 0 2.026288939305232e-06
radiosensitivity O 0 1.5509693866988528e-06
assay O 0 1.0101270930817918e-08
can O 0 9.257370564563772e-11
be O 0 3.431246606289129e-11
used O 0 5.690153209725324e-11
for O 0 1.6846067943387943e-11
the O 0 1.7737965610220563e-11
detection O 0 1.9627089287155286e-08
of O 0 8.814977547899616e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 8.04563460405916e-05
. O 0 1.2920988865516847e-06

In O 0 2.530727840621694e-07
combination O 0 1.9457054634131055e-07
with O 0 5.378994472060583e-10
molecular O 0 3.328881703623665e-08
genetic O 0 9.964734815071097e-09
analyses O 0 3.363292311320265e-09
, O 0 1.1312724368384153e-10
this O 0 3.617074695316802e-11
test O 0 1.9440669907222485e-10
may O 0 8.170785575911665e-11
be O 0 4.373056083917248e-11
of O 0 4.783736601288169e-11
value O 0 1.5700622746361859e-10
in O 0 4.751889506882101e-11
studies O 0 5.717233908519859e-10
of O 0 6.197375390648574e-10
familial B-Disease 0 4.3726098297725e-09
and I-Disease 0 5.6914504220628714e-09
sporadic I-Disease 0 5.92069341109891e-07
cancers I-Disease 0 7.67103244925238e-07
aimed O 0 9.548691650707042e-07
at O 0 3.115918190133016e-08
determination O 0 1.8196844919771138e-08
of O 0 7.97754893255842e-08
the O 0 8.411259244667235e-09
potential O 0 5.213015796812215e-09
involvement O 0 1.9000600204321927e-08
of O 0 2.3111150326826646e-08
ATM O 1 0.6335203647613525
mutations O 0 1.6655268098020315e-07
in O 0 2.9205036611301693e-08
tumor B-Disease 0 0.06594184786081314
risk O 0 4.0667390521775815e-07
or O 0 1.2132251869800825e-09
development O 0 3.645190371770468e-09
. O 0 1.0221004487220853e-08
. O 0 7.622269748708277e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 1.850506663458873e-07
identification O 0 1.0375869408107974e-07
and O 0 2.953512434622496e-10
detection O 0 3.8773353594478976e-07
of O 0 1.108136693517281e-08
founder O 0 8.389439898337514e-08
- O 0 2.5074383458445482e-08
effect O 0 9.758887031807717e-09
mutations O 0 1.4988533747484212e-09
in O 0 2.0614130402663022e-09
the O 0 3.9085108483050135e-09
ATM O 0 2.105456132994732e-06
gene O 0 3.115298685685275e-09
in O 0 3.4263842874082684e-09
ethnic O 0 9.139128898105753e-10
populations O 0 1.946405481234592e-09
. O 0 3.039642137991905e-08

To O 0 5.1261814348890766e-08
facilitate O 0 1.6727665297366912e-07
the O 0 3.9965688536369726e-09
evaluation O 0 3.079129484717669e-08
of O 0 4.1477463241790247e-08
ATM O 0 0.16193580627441406
heterozygotes O 0 8.199534931918606e-06
for O 0 5.402780001162455e-09
susceptibility O 0 1.0874807685468113e-06
to O 0 8.882365953866156e-09
other O 0 2.827933220928003e-09
diseases O 0 8.050595852182596e-07
, O 0 2.0954366020120574e-10
such O 0 4.4747219818397355e-10
as O 0 3.8432887095041224e-08
breast B-Disease 0 2.307281829416752e-05
cancer I-Disease 0 5.953459094598657e-07
, O 0 2.3742110499824776e-09
we O 0 2.020632106081166e-09
have O 0 6.971352939366682e-10
attempted O 0 7.4296098162562885e-09
to O 0 5.632720401216318e-10
define O 0 2.936986875923253e-09
the O 0 1.6026582283501511e-09
most O 0 1.9942807127915074e-10
common O 0 2.266839771447593e-10
mutations O 0 4.0534665901592604e-11
and O 0 1.7730488952039103e-11
their O 0 3.354166597246966e-11
frequencies O 0 2.5983857288025547e-09
in O 0 6.042419009588684e-09
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.0002522021241020411
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.0625637581493947e-09
homozygotes O 0 3.627416447216092e-07
from O 0 7.400344226304867e-10
10 O 0 1.2546246264122374e-09
ethnic O 0 7.870247509256245e-11
populations O 0 6.875772173842165e-10
. O 0 1.526726656209121e-08

Both O 0 1.5109188211681612e-07
genomic O 0 1.1471816918628974e-07
mutations O 0 3.315351770893926e-09
and O 0 3.337295717553701e-10
their O 0 2.5655860769191463e-10
effects O 0 2.1747222689327828e-08
on O 0 3.7738299596412617e-08
cDNA O 0 1.1843412295320377e-07
were O 0 3.197857267878135e-08
characterized O 0 2.482038574669332e-08
. O 0 1.3699531109523377e-07

Protein O 0 5.69863374266788e-08
- O 0 6.90409791559432e-08
truncation O 0 9.817662061095689e-08
testing O 0 1.2915140956692994e-08
of O 0 1.5818673038126008e-09
the O 0 7.010902969284416e-10
entire O 0 2.5936321979003196e-09
ATM O 0 3.138043211947661e-07
cDNA O 0 1.1077440831286367e-07
detected O 0 8.22634191877114e-08
92 O 0 9.625825470038762e-08
( O 0 9.98009896946428e-10
66 O 0 1.9402460083028927e-08
% O 0 8.765660419740584e-10
) O 0 2.973947477169503e-10
truncating O 0 4.8766061411242845e-08
mutations O 0 4.3072501121343976e-09
in O 0 5.267768887762259e-09
140 O 0 9.385874477629841e-08
mutant O 0 6.614465064558317e-08
alleles O 0 3.3506530883187224e-09
screened O 0 1.3400610043845518e-07
. O 0 1.246191800419183e-06

The O 0 6.287416454142658e-07
haplotyping O 0 3.6618166632251814e-05
of O 0 1.428845735063078e-07
patients O 0 3.505326162667188e-08
with O 0 8.497569314869224e-11
identical O 0 3.097814627039952e-08
mutations O 0 5.089180632467105e-08
indicates O 0 5.543220282788752e-08
that O 0 5.447904904976042e-10
almost O 0 1.1773950703286573e-09
all O 0 4.40032621451536e-10
of O 0 8.413195695666786e-10
these O 0 4.143107038001581e-11
represent O 0 9.475348977661113e-11
common O 0 9.016749569212834e-10
ancestry O 0 5.886872100901996e-10
and O 0 2.4117177699345405e-10
that O 0 1.2721156072981188e-10
very O 0 4.3435974261818444e-10
few O 0 3.6465463981727453e-09
spontaneously O 0 5.4643605196247336e-09
recurring O 0 6.969963095571075e-08
ATM O 0 2.0027689970447682e-05
mutations O 0 2.1348128598219773e-07
exist O 0 5.731433248001849e-07
. O 0 1.2811282203983865e-06

Assays O 0 1.312399126618402e-05
requiring O 0 6.90149079218827e-07
minimal O 0 2.2498636553791584e-06
amounts O 0 6.027008936371203e-08
of O 0 1.0603703692879662e-08
genomic O 0 3.0847665755118214e-08
DNA O 0 2.0825330793172725e-08
were O 0 3.2767579760673016e-09
designed O 0 9.26214838159467e-09
to O 0 6.864058210709345e-10
allow O 0 5.847681783244241e-10
rapid O 0 1.4128902492416273e-09
screening O 0 8.946342555660181e-10
for O 0 5.807976322103059e-10
common O 0 1.3452251534928905e-09
ethnic O 0 5.203664721342705e-10
mutations O 0 6.8961987231830335e-09
. O 0 7.206372032442232e-08

These O 0 4.406259535016943e-08
rapid O 0 1.735895409638033e-07
assays O 0 2.397205776105693e-07
detected O 0 8.471462820125453e-08
mutations O 0 8.367426196365102e-10
in O 0 5.583580264811872e-10
76 O 0 7.09828853473482e-08
% O 0 1.2067287169514884e-09
of O 0 2.442121838086564e-09
Costa O 0 3.8900907384231687e-08
Rican O 0 2.175963516037882e-07
patients O 0 7.319671535555017e-09
( O 0 8.48202341696691e-11
3 O 0 2.0439046011233586e-09
) O 0 1.1193773685747033e-10
, O 0 6.73825370500758e-11
50 O 0 1.3793344244561467e-09
% O 0 4.902150907426517e-11
of O 0 1.5429695021662582e-10
Norwegian O 0 6.042951383733453e-08
patients O 0 9.924106869618754e-09
( O 0 6.08683173308755e-11
1 O 0 2.5699169459159066e-09
) O 0 1.80226666923744e-10
, O 0 1.9369901516075316e-10
25 O 0 1.4200416398324478e-09
% O 0 1.1194328797259345e-10
of O 0 3.6242309153777796e-10
Polish O 0 1.0816003737090796e-07
patients O 0 6.160161269974651e-09
( O 0 3.8027844762034135e-11
4 O 0 9.733192030125792e-10
) O 0 6.857642231850036e-11
, O 0 2.768128434804673e-11
and O 0 7.055974554637245e-11
14 O 0 1.7668290164252198e-09
% O 0 1.1246118619689938e-10
of O 0 3.111733926086657e-10
Italian O 0 1.4552407279211366e-08
patients O 0 3.6426532901145947e-09
( O 0 5.378519851717556e-11
1 O 0 2.930652387433952e-09
) O 0 4.1280032170298853e-10
, O 0 1.5187959223617042e-10
as O 0 2.414543842643724e-10
well O 0 2.1488263945990127e-10
as O 0 1.6994011753368454e-10
in O 0 1.8901721854369669e-10
patients O 0 3.5881478344101936e-10
of O 0 1.1613188188874801e-09
Amish O 0 1.3332429489310016e-06
/ O 0 6.382802439475199e-06
Mennonite O 0 4.276458639651537e-06
and O 0 2.7331500618288374e-08
Irish O 0 1.285539923401302e-07
English O 0 5.816928805302268e-08
backgrounds O 0 5.736201913464356e-08
. O 0 1.413473853517644e-07

Additional O 0 1.3597669976661564e-06
mutations O 0 6.056313139879421e-08
were O 0 8.704635234835223e-09
observed O 0 1.5691470345302605e-09
in O 0 5.564920746436997e-10
Japanese O 0 1.146702643950448e-07
, O 0 7.449443284457402e-10
Utah O 0 9.750775298300596e-09
Mormon O 0 9.71984004394244e-09
, O 0 1.5005575948467964e-10
and O 0 1.5192276603404054e-10
African O 0 9.220322283454152e-09
American O 0 1.1887301809565542e-08
patients O 0 1.1343590955448235e-08
. O 0 7.06797251837088e-08

These O 0 2.454816261376891e-08
assays O 0 1.6122033485999054e-08
should O 0 5.344693576603277e-10
facilitate O 0 1.1941516664393248e-09
screening O 0 1.7922100470357805e-09
for O 0 1.3957966338296046e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 1.0564791637079907e-06
in O 0 1.4086415367486893e-09
the O 0 2.646345087509161e-10
populations O 0 3.950274829467304e-11
studied O 0 1.8058324835479311e-09
. O 0 3.3613365424400854e-09
. O 0 9.755930818755587e-08

The O 0 8.899341992218979e-06
von B-Disease 1 0.9997004270553589
Hippel I-Disease 1 0.9999973773956299
- I-Disease 1 0.9979912042617798
Lindau I-Disease 0 0.06714625656604767
tumor I-Disease 0 0.0001108872311306186
suppressor O 0 8.371779586013872e-06
gene O 0 9.241167830964514e-09
is O 0 1.3366513451629203e-10
required O 0 2.2540262711867598e-10
for O 0 2.0178272941429043e-10
cell O 0 4.63929428207166e-09
cycle O 0 1.8469613616289848e-09
exit O 0 6.227618420950876e-09
upon O 0 1.1950409550820495e-08
serum O 0 5.772916367163816e-08
withdrawal O 0 6.919798920534959e-07
. O 0 6.762235784663062e-07

The O 0 2.901355173889897e-07
inactivation O 0 4.333285232860362e-06
of O 0 7.179495469245012e-07
the O 0 1.6343471997970482e-07
von B-Disease 1 0.9999974966049194
Hippel I-Disease 1 1.0
- I-Disease 1 1.0
Lindau I-Disease 1 1.0
( I-Disease 0 4.615766044935299e-07
VHL I-Disease 0 0.0021034148521721363
) I-Disease 0 4.128448338747148e-08
tumor I-Disease 0 9.326871804660186e-06
suppressor O 0 0.0015802220441401005
gene O 0 1.58088687385316e-06
predisposes O 0 5.926296466896019e-07
affected O 0 1.939560512198568e-09
individuals O 0 1.386063399472226e-11
to O 0 1.334292537569226e-10
the O 0 1.4376386747727565e-09
human O 0 2.32696848456726e-07
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 3.191526332102512e-08
is O 0 1.8173308691249446e-10
associated O 0 3.202977438832022e-09
with O 0 2.3995222475647893e-10
sporadic B-Disease 0 0.0005623796605505049
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 2.958696768473601e-06
RCC B-Disease 1 0.9882853031158447
) O 0 3.4869682252747225e-08
and O 0 8.02346562522871e-08
brain B-Disease 0 0.0372559130191803
hemangioblastomas I-Disease 0 0.0016446169465780258
. O 0 2.6509153485676507e-06

VHL O 0 0.0008608947973698378
- O 0 3.7141053326195106e-05
negative O 0 1.6997312002331455e-07
786 O 0 3.394743998796912e-06
- O 0 2.616400524857454e-05
0 O 0 8.745258810449741e-07
RCC B-Disease 0 8.893170888768509e-05
cells O 0 2.1392916096374393e-06
are O 0 4.467688441422979e-09
tumorigenic O 0 3.850869234156562e-06
in O 0 1.23098104154451e-07
nude O 0 2.6394945962238126e-05
mice O 0 1.293775397925856e-07
which O 0 1.0674675726685123e-10
is O 0 1.645068109512593e-11
suppressed O 0 2.692724654362877e-10
by O 0 9.01660759944356e-11
the O 0 1.4375647339193165e-09
reintroduction O 0 1.1890843865103307e-07
of O 0 2.7679213587816776e-08
VHL B-Disease 0 4.609823372447863e-05
. O 0 2.8584822757693473e-06

Remarkably O 0 7.572964022983797e-06
, O 0 2.1831576546560427e-09
this O 0 3.443125992652618e-11
occurs O 0 4.104737730270536e-11
without O 0 2.4205476512051405e-10
affecting O 0 5.299784500145677e-10
the O 0 1.2462429699322541e-10
growth O 0 1.0325498234209363e-09
rate O 0 5.983869844072842e-09
and O 0 3.6424568916615385e-10
cell O 0 2.999694714844736e-08
cycle O 0 8.960623354425934e-09
profile O 0 5.3846842540394846e-09
of O 0 1.3392958964075774e-09
these O 0 8.898635300846891e-11
cells O 0 9.020345026478083e-10
in O 0 2.416166600127667e-09
culture O 0 1.6030082861107076e-07
. O 0 3.06025924601272e-07

The O 0 2.551296347519383e-07
786 O 0 6.792627118556993e-07
- O 0 1.4679160358355148e-06
0 O 0 8.99653826991198e-08
cell O 0 3.828868102573324e-07
line O 0 8.994221900593402e-08
, O 0 1.660421911076071e-09
like O 0 1.3920126162858537e-09
many O 0 1.4862017172490027e-10
cancer B-Disease 0 1.0071371514541738e-09
cells O 0 7.517484412744579e-10
, O 0 7.822599790152651e-10
fails O 0 6.719804268584539e-09
to O 0 4.6421799737572655e-09
exit O 0 5.406411318631399e-08
the O 0 1.210198252721284e-08
cell O 0 4.064814973503417e-08
cycle O 0 2.7105033773011655e-09
upon O 0 6.6722427582988075e-09
serum O 0 8.149817176672514e-08
withdrawal O 0 6.561150485140388e-07
. O 0 9.512426686342224e-07

Here O 0 3.7634436012012884e-07
, O 0 3.1579121539948574e-09
it O 0 6.010848069282204e-11
is O 0 1.0504065499350457e-11
shown O 0 5.276602765835747e-11
that O 0 5.481586972527763e-12
reintroduction O 0 6.687506548530564e-09
of O 0 2.0100956454882635e-09
the O 0 2.903367990469974e-09
wild O 0 1.5426326882561625e-08
- O 0 3.142759652519089e-08
type O 0 1.4925268132515157e-08
VHL B-Disease 0 3.1022163966554217e-06
gene O 0 1.2579462804751529e-08
restores O 0 4.3714450725929055e-07
the O 0 1.549722306037893e-08
ability O 0 1.2322421305555054e-08
of O 0 7.030902082760804e-08
VHL O 0 0.30848923325538635
- O 0 0.04213685169816017
negative O 0 1.1565806090629849e-07
RCC B-Disease 0 0.00017054380441550165
cancer I-Disease 0 4.313196200200764e-07
cells O 0 3.165347539635377e-09
to O 0 9.944338685841103e-10
exit O 0 3.300587803067856e-09
the O 0 1.9325665512326395e-09
cell O 0 1.529664750421489e-08
cycle O 0 3.4561440376279506e-09
and O 0 2.364183737668668e-09
enter O 0 3.234239045468712e-07
G0 O 0 8.751868881518021e-05
/ O 0 6.899209984112531e-05
quiescence O 0 8.424526640737895e-06
in O 0 1.0317002363535721e-07
low O 0 9.687007604952669e-07
serum O 0 1.519325394383486e-07
. O 0 1.6769769217717112e-07

Both O 0 1.3413183523880434e-06
VHL O 0 0.001218045363202691
- O 0 0.00011673242261167616
positive O 0 6.557560539022234e-08
and O 0 1.3844167590093548e-08
VHL O 0 0.00014083311543799937
- O 0 3.3096890547312796e-05
negative O 0 3.037567353203485e-08
RCC B-Disease 0 8.531833373126574e-06
cells O 0 1.9151383412463474e-07
exit O 0 8.006679763639113e-08
the O 0 4.5845101048769266e-09
cell O 0 1.6192913676604803e-08
cycle O 0 1.3230312401191213e-09
by O 0 6.016506182149328e-10
contact O 0 6.485466030881071e-08
inhibition O 0 4.337980499258265e-07
. O 0 6.679630359940347e-07

The O 0 1.2944932677783072e-05
cyclin O 0 3.279370503150858e-05
- O 0 9.067995961231645e-06
dependent O 0 1.5963977375577088e-06
kinase O 0 1.0795820344355889e-06
inhibitor O 0 4.332936214268557e-07
, O 0 8.797371719992952e-09
p27 O 0 7.213506705738837e-06
, O 0 3.387538027865844e-09
accumulates O 0 6.072990998973182e-09
upon O 0 1.1674083921775491e-09
serum O 0 5.972193850567464e-09
withdrawal O 0 3.0971765596632395e-08
, O 0 5.027928628997813e-10
only O 0 1.890438916518633e-10
in O 0 1.4022821792636364e-10
the O 0 3.454593278107154e-10
presence O 0 1.061075893815655e-09
of O 0 3.7467891011999654e-09
VHL B-Disease 0 1.672056441748282e-06
, O 0 6.058133439346136e-10
as O 0 3.2831312668513135e-10
a O 0 1.3234267848272196e-10
result O 0 2.6020137433580004e-11
of O 0 2.2276344657790048e-10
the O 0 9.540507273086973e-11
stabilization O 0 6.736161708431609e-07
of O 0 8.381778826560549e-08
the O 0 3.075889054571235e-08
protein O 0 1.3036312473957423e-08
. O 0 1.3514964791738748e-07

We O 0 3.9582225497269974e-08
propose O 0 2.3963776740743015e-08
that O 0 1.543761368738572e-10
the O 0 5.63326829627897e-10
loss O 0 2.5547468585074284e-09
of O 0 6.261826168696416e-09
wild O 0 6.9806169733510615e-09
- O 0 3.199840392653641e-08
type O 0 5.8071069730658564e-08
VHL B-Disease 0 3.658800414996222e-05
gene O 0 4.061784864006768e-08
results O 0 9.034072157021455e-09
in O 0 6.405652008822926e-09
a O 0 1.2619596034824099e-08
specific O 0 8.303743470605696e-08
cellular O 0 1.4914879102434497e-05
defect O 0 4.723748077140044e-07
in O 0 3.8494492038410044e-09
serum O 0 8.351840818932033e-08
- O 0 4.73598078087889e-07
dependent O 0 9.283731117193383e-08
growth O 0 1.669320326413981e-08
control O 0 3.095103906503027e-08
, O 0 4.712268908413364e-10
which O 0 4.090427649372508e-11
may O 0 8.607191626097688e-10
initiate O 0 5.0270319462697444e-08
tumor B-Disease 0 1.1556206800378277e-06
formation O 0 3.3556310086169105e-07
. O 0 2.096027856168803e-06

This O 0 4.455079860576916e-08
is O 0 1.2585696929079404e-09
corrected O 0 5.564650251699277e-08
by O 0 4.0218095520572206e-10
the O 0 5.581908268936786e-10
reintroduction O 0 7.203129115396223e-08
of O 0 6.67427979550439e-09
wild O 0 4.5441790774702895e-08
- O 0 1.8644973920345365e-07
type O 0 4.178986614533642e-07
VHL B-Disease 0 0.24652883410453796
, O 0 1.586860918223465e-07
implicating O 0 1.6250905900960788e-05
VHL B-Disease 0 0.0792723223567009
as O 0 3.3431856394372517e-08
the O 0 4.884525228732173e-09
first O 0 6.843641653375698e-09
tumor B-Disease 0 3.097619583058986e-08
suppressor O 0 3.8162946225384076e-07
involved O 0 2.241286267690157e-09
in O 0 2.9632927223133265e-09
the O 0 2.2511112973688796e-08
regulation O 0 8.114867341646459e-06
of O 0 6.42187600874422e-08
cell O 0 2.3562122919429385e-08
cycle O 0 2.7442330630123024e-09
exit O 0 1.4414065496737294e-08
, O 0 1.1455845161378875e-09
which O 0 8.417798402771126e-11
is O 0 2.4671200846149155e-11
consistent O 0 7.997285611516247e-10
with O 0 1.18886202965518e-11
its O 0 1.7289042419932343e-10
gatekeeper O 0 2.155774581069636e-08
function O 0 1.2980008179397373e-09
in O 0 8.999533895881484e-10
the O 0 4.041165624357745e-09
kidney O 0 7.510396358156868e-07
. O 0 5.556939797202176e-08
. O 0 3.928742273728858e-07

Piebaldism B-Disease 1 1.0
with O 0 5.037464143242687e-05
deafness B-Disease 1 1.0
: O 0 5.375400391471885e-08
molecular O 0 2.415601230154607e-08
evidence O 0 1.085223910735067e-09
for O 0 2.0076537654567517e-10
an O 0 4.98591834485751e-10
expanded O 0 2.4568901153543266e-06
syndrome O 1 0.9999972581863403
. O 0 7.329779236897593e-06

In O 0 3.04927567640334e-08
a O 0 4.645138051984077e-09
South O 0 1.9453858968176974e-08
African O 0 1.800983362443276e-08
girl O 0 7.195326556796999e-09
of O 0 9.321586835753237e-10
Xhosa O 0 4.972779379386338e-07
stock O 0 4.883602855443314e-09
with O 0 2.5065546860325583e-11
severe O 0 2.6464334723641514e-08
piebaldism B-Disease 0 1.1998872651020065e-06
and O 0 1.9686364538529233e-08
profound O 1 0.9956114888191223
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 2.4488448957527e-07
identified O 0 1.0794977356454183e-08
a O 0 4.1799386174545816e-10
novel O 0 5.206831632520448e-10
missense O 0 5.289163329535995e-09
substitution O 0 1.0098863079122111e-08
at O 0 2.5286377436373186e-08
a O 0 3.0653219962317735e-09
highly O 0 4.34192681808554e-09
conserved O 0 7.504838528404889e-09
residue O 0 1.394985389424619e-07
in O 0 9.868424299952494e-09
the O 0 1.6954079029574132e-08
intracellular O 0 1.409457155432392e-07
kinase O 0 1.0753182522194038e-07
domain O 0 1.257744752791723e-08
of O 0 7.55595586099389e-09
the O 0 2.9905770304594625e-08
KIT O 0 0.027255147695541382
proto O 0 0.00363930338062346
- O 0 2.2558779164683074e-05
oncogene O 0 0.0001951777230715379
, O 0 2.2037340841052355e-08
R796G O 0 8.252385669038631e-06
. O 0 2.225866069238691e-07

Though O 0 4.0035411075223237e-07
auditory B-Disease 0 1.9497823814162984e-05
anomalies I-Disease 0 8.577896551287267e-06
have O 0 2.7319289053195916e-09
been O 0 4.6191339642120965e-10
observed O 0 3.5708272450030165e-10
in O 0 4.556993948856558e-10
mice O 0 1.1997501658811416e-08
with O 0 1.8920874589323233e-10
dominant O 0 2.8733623480547976e-07
white O 0 4.8008363506824026e-08
spotting O 0 0.0006596262101083994
( O 0 5.088967114375009e-08
W O 0 0.17847372591495514
) O 0 1.401205484974355e-09
due O 0 1.8125589917872276e-08
to O 0 4.287578292405669e-09
KIT O 0 0.002745320787653327
mutations O 0 5.715761517421925e-07
, O 0 2.76532603038504e-07
deafness B-Disease 1 1.0
is O 0 4.210009230121159e-09
not O 0 2.0644062848074185e-10
typical O 0 1.6434766880735197e-09
in O 0 6.35635766244036e-10
human O 0 2.3352455524872084e-09
piebaldism B-Disease 0 9.612099347577896e-07
. O 0 2.674222798759729e-07

Thus O 0 8.333922352221634e-08
, O 0 1.3153218514361242e-09
the O 0 2.3090331036090816e-10
occurrence O 0 7.3782766563113e-09
of O 0 1.0836507868816625e-07
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 1 0.9648864269256592
this O 0 1.607109822998609e-08
patient O 0 3.3410628930141684e-08
extends O 0 1.1936182597871436e-10
considerably O 0 4.6051823465731445e-10
the O 0 2.650436814466417e-10
phenotypic O 0 3.3571458946113353e-09
range O 0 1.1204465799607988e-08
of O 0 4.88142415377979e-09
piebaldism B-Disease 0 5.798899564979365e-07
due O 0 4.056868263546676e-08
to O 0 1.6964493809723535e-08
KIT O 0 4.272929436410777e-05
gene O 0 1.275611225537432e-07
mutation O 0 4.880939652451843e-09
in O 0 1.3650288677169442e-09
humans O 0 4.078006821117697e-09
and O 0 1.3916356955689935e-09
tightens O 0 1.8904269438735355e-07
the O 0 4.347014304073582e-09
clinical O 0 4.856454438595392e-08
similarity O 0 6.638751770537965e-10
between O 0 1.8205224827649857e-10
piebaldism B-Disease 0 9.209849594071784e-08
and O 0 6.175404632102754e-10
the O 0 6.017045750539296e-10
various O 0 3.8101261035095035e-10
forms O 0 1.4880262577676717e-09
of O 0 4.419836940883215e-08
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 0.99988853931427
. O 0 8.21306258558252e-08
. O 0 2.9561257974819455e-07

Cycloheximide O 0 9.652108019508887e-06
facilitates O 0 3.2308349773302325e-08
the O 0 1.0867691191407403e-09
identification O 0 1.3105870166896239e-08
of O 0 2.9739789297877905e-08
aberrant O 0 9.665048850138191e-08
transcripts O 0 1.3950943866802845e-07
resulting O 0 5.213602438658427e-09
from O 0 1.0756743273887537e-09
a O 0 8.386680239169664e-10
novel O 0 2.2221569029312604e-09
splice O 0 8.685086783088991e-08
- O 0 1.037806711678968e-07
site O 0 1.2528484027996e-08
mutation O 0 1.3111238761354116e-09
in O 0 3.544113336140242e-10
COL17A1 O 0 1.9688673091877718e-06
in O 0 7.705424742709965e-09
a O 0 1.1777438579940736e-08
patient O 0 9.36888326918961e-08
with O 0 2.1240318393012103e-09
generalized O 0 0.00043667785939760506
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999576807022095
. O 0 9.415750355401542e-06

Patients O 0 1.6278732800856233e-05
with O 0 1.3493503203676482e-08
generalized O 0 6.28729958407348e-06
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999966621398926
often O 0 1.5492286564722235e-08
show O 0 1.6137807756777534e-09
decreased O 0 1.4400071135511894e-09
expression O 0 7.052667894136277e-10
of O 0 3.4649358937599573e-09
type O 0 2.34876893046021e-07
XVII O 0 0.002095333533361554
collagen O 0 2.9354089292610297e-06
, O 0 6.973633048801275e-08
a O 0 3.716867169600846e-08
transmembrane O 0 2.8837879639809216e-08
hemidesmosomal O 0 1.2465775967029913e-07
protein O 0 6.02130512117327e-10
encoded O 0 6.128691443230139e-10
by O 0 1.873032617893955e-09
COL17A1 O 0 0.00011198042921023443
. O 0 1.7292328493567766e-06

This O 0 2.7582876427345582e-08
report O 0 8.568571630007682e-09
documents O 0 3.11122683172016e-08
a O 0 2.7894480059131865e-09
novel O 0 2.672892351895939e-09
splice O 0 1.8735987339368876e-07
- O 0 9.944442780351892e-08
site O 0 1.1843984459858348e-08
mutation O 0 5.743323039375525e-10
in O 0 4.607958736801976e-10
COL17A1 O 0 9.638604751671664e-06
in O 0 6.56599352666376e-09
a O 0 8.09089506503824e-09
patient O 0 5.087220245059143e-08
with O 0 1.6828389792777898e-09
generalized O 0 9.305075218435377e-05
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9997153878211975
, O 0 1.086858780752209e-08
and O 0 7.398156531834843e-10
applies O 0 8.004569451713905e-09
a O 0 2.4814966748110123e-10
new O 0 3.3599947824036747e-10
methodology O 0 9.090801889044542e-09
to O 0 5.855504969787262e-10
define O 0 5.779402734162886e-09
and O 0 2.221720363237978e-09
characterize O 0 9.050857130432632e-08
the O 0 1.2230818136060861e-08
resulting O 0 5.117991364045338e-09
mRNA O 0 1.7340845204216748e-08
splice O 0 7.147114047256764e-07
variants O 0 7.443540539497917e-07
. O 0 5.861969611942186e-07

Mutational O 0 2.1789797756355256e-05
analysis O 0 8.579597476909839e-08
of O 0 2.9257222422529594e-08
COL17A1 O 0 2.1450552594615147e-05
identified O 0 2.0146379142715887e-07
a O 0 2.687396261080721e-08
maternally O 0 9.030764545059355e-07
inherited O 0 3.5476614357321523e-07
G O 0 1.6740796127123758e-06
- O 0 1.1564674196051783e-06
to O 0 4.165385902865637e-08
- O 0 1.1808065210061613e-05
T O 0 8.234997608269623e-07
transversion O 0 1.8605683749228774e-07
at O 0 1.1806896571542325e-09
the O 0 1.0425867114083331e-10
- O 0 2.97782554170567e-09
1 O 0 9.990083427169338e-09
position O 0 1.948902728088342e-08
of O 0 8.921518634963377e-09
exon O 0 6.236904255274567e-07
32 O 0 4.2168952063548204e-07
. O 0 3.6204556863594917e-07

This O 0 1.205788269231789e-08
acceptor O 0 4.514510099085101e-09
splice O 0 5.531570081984682e-07
- O 0 2.3131487125738204e-07
site O 0 2.6184018508956797e-08
mutation O 0 2.7549420522632317e-09
led O 0 8.242526661206284e-10
to O 0 1.9188761690713818e-10
the O 0 4.390885710581216e-10
formation O 0 9.768310604840735e-09
of O 0 4.517716689633744e-08
aberrant O 0 1.1170050839837131e-07
transcripts O 0 3.646347010999307e-07
present O 0 9.358004149362387e-09
at O 0 2.730529615746491e-07
extremely O 0 8.654198069280028e-08
low O 0 4.2045547843372333e-07
levels O 0 1.1411149358764305e-07
. O 0 1.0760896884676185e-07

Based O 0 1.0213954482196641e-07
on O 0 6.047194034408676e-08
our O 0 1.249273928749517e-08
recent O 0 1.0117522375452381e-09
finding O 0 9.904965736495797e-10
that O 0 4.4240052593513823e-11
cycloheximide O 0 1.395294049189033e-07
stabilized O 0 3.4919941072075744e-07
mutant O 0 1.0331140742891876e-07
COL17A1 O 0 3.126067440462066e-06
transcripts O 0 1.9040076892906654e-07
in O 0 6.532216989540984e-09
keratinocytes O 0 7.724107717876905e-07
homozygous O 0 1.004881156063675e-08
for O 0 1.1350749229421808e-09
a O 0 3.4698428574841955e-09
frameshift O 0 1.3445055913052784e-07
mutation O 0 2.368819140841083e-09
, O 0 2.8658328488084805e-10
the O 0 3.2317132303560925e-10
effects O 0 3.567862449926906e-08
of O 0 3.621650535023946e-08
the O 0 3.9205092505767425e-09
splice O 0 3.8413539016346476e-08
- O 0 3.9846742794225065e-08
site O 0 5.653205459310584e-09
mutation O 0 1.4867573838728276e-10
on O 0 4.690855481825906e-10
splicing O 0 1.6716175110786935e-08
of O 0 3.8065493868089106e-08
COL17A1 O 0 1.2637304280360695e-05
transcripts O 0 2.6617018988872587e-07
were O 0 3.3174898383947493e-09
determined O 0 1.1896957863299917e-09
using O 0 2.1271171490866436e-09
reverse O 0 8.836049225635634e-09
transcriptase O 0 1.8526602474366882e-08
polymerase O 0 8.251921812529872e-09
chain O 0 7.965032189360954e-09
reaction O 0 1.1363942009623429e-09
of O 0 3.155582017910774e-09
total O 0 6.219210701985389e-10
RNA O 0 2.2937760579821997e-09
from O 0 1.5803925945689912e-09
keratinocytes O 0 9.673827605638508e-08
incubated O 0 7.88439358245796e-09
for O 0 1.0489040747074796e-09
2 O 0 4.3318038933648495e-08
. O 0 1.596959720018276e-07

5 O 0 8.42194367578486e-07
h O 0 1.8644583121840697e-07
in O 0 1.3633063566942383e-09
the O 0 9.158759861627175e-10
presence O 0 2.0768202713128403e-09
or O 0 2.2418291667491985e-09
absence O 0 5.5966683731867306e-08
of O 0 1.562395368637226e-08
10 O 0 4.102443185161064e-08
microg O 0 1.6879483837328735e-06
cycloheximide O 0 7.903306027401413e-07
per O 0 2.6996704605153354e-07
ml O 0 5.121317371958867e-06
. O 0 3.7401756003418996e-07

Using O 0 1.2338253441157576e-07
this O 0 3.2997110599453094e-10
approach O 0 8.166291642908163e-09
, O 0 1.0217238166632114e-09
an O 0 1.9780743709674198e-10
abnormally O 0 1.4839088180451654e-08
spliced O 0 2.83081131868812e-08
transcript O 0 4.131111666083598e-07
was O 0 5.091997081763111e-07
identified O 0 2.798877396514854e-08
that O 0 1.1062982474552285e-10
contains O 0 6.62630089687255e-11
an O 0 1.171763987922736e-11
extra O 0 1.5027120658928084e-09
264 O 0 3.704267559356822e-09
bases O 0 6.545936237500882e-09
upstream O 0 2.6934758867724895e-09
from O 0 3.279282401180694e-10
exon O 0 1.2389941517199077e-08
32 O 0 4.8942614405689255e-09
, O 0 1.2670570148642923e-10
resulting O 0 1.1470815963754433e-10
in O 0 2.7248292511217187e-10
a O 0 1.1266476640514611e-09
premature O 0 1.6198011820733882e-08
termination O 0 3.2887566447925565e-08
codon O 0 2.5577134010745795e-07
27 O 0 1.3195789279052406e-06
bp O 0 7.211527872641454e-07
downstream O 0 2.0957225288498194e-08
from O 0 8.696039444089365e-09
the O 0 3.5495965278187214e-08
cryptic O 0 9.881119922283688e-07
splice O 0 3.6562887544278055e-06
site O 0 1.0914435506492737e-06
. O 0 1.9997892763967684e-07

Three O 0 4.741087309412251e-07
other O 0 2.3593815789979544e-09
splice O 0 1.3186789260544174e-07
variants O 0 2.7164929861100973e-08
, O 0 6.39107711197795e-10
including O 0 1.4004673809520085e-10
one O 0 1.1335398765466298e-11
derived O 0 9.90635767861292e-11
from O 0 6.456057910497748e-11
the O 0 2.7017069137436067e-10
skipping O 0 2.7243020284117847e-08
of O 0 1.0332338540308683e-08
exon O 0 2.0393112265537638e-07
32 O 0 1.3883573046769015e-07
, O 0 2.8101840854333204e-09
were O 0 8.185300437446585e-09
also O 0 3.87798371193071e-09
identified O 0 2.0178445581109372e-08
. O 0 1.3524349640192668e-07

These O 0 4.160455446822198e-08
results O 0 1.4616583499105218e-08
indicate O 0 6.6722427582988075e-09
the O 0 1.3855123714989759e-09
usefulness O 0 6.895925963590344e-08
of O 0 3.34476579766374e-09
cycloheximide O 0 1.753907099555363e-07
treatment O 0 2.8521740524922734e-09
in O 0 2.902563467355179e-10
evaluating O 0 3.556738015220162e-09
the O 0 2.242286800679949e-09
abnormal O 0 7.93862664494327e-09
processing O 0 6.486579451348007e-08
of O 0 5.105631473156791e-08
mRNA O 0 2.0415679813368115e-08
due O 0 2.769279205949715e-07
to O 0 6.306582367443525e-09
splice O 0 9.066251749345611e-08
- O 0 1.5640478068235097e-07
site O 0 1.2678705196833562e-08
mutations O 0 6.953398967723956e-10
, O 0 1.1551767875594976e-10
because O 0 6.440671607155224e-11
( O 0 2.8164340304392965e-10
i O 0 1.052060305539726e-08
) O 0 3.6988509477531295e-10
aberrant O 0 3.4253124781002953e-09
splicing O 0 1.721502229656835e-08
often O 0 4.98252439307123e-10
generates O 0 2.2669131849450963e-10
a O 0 2.315741487457501e-10
premature O 0 2.182466651845516e-09
termination O 0 5.375510259142402e-09
codon O 0 2.8447812994158994e-08
, O 0 2.0277282075653602e-09
( O 0 2.5243657164608635e-10
ii O 0 3.2994569210131885e-07
) O 0 6.823200893180115e-10
transcripts O 0 2.0572191061773992e-08
with O 0 1.0924171983672792e-10
premature O 0 3.821651617386124e-08
termination O 0 2.373854357529126e-08
codons O 0 1.5038914114029467e-08
can O 0 1.5263347530325433e-10
occur O 0 2.0440751868910922e-10
at O 0 6.646686756539566e-09
low O 0 5.720425022559539e-08
or O 0 8.252610261827442e-10
undetectable O 0 1.5137075592974725e-08
levels O 0 1.0024014951426352e-09
due O 0 2.4927593322843222e-09
to O 0 1.6449255291206555e-09
nonsense O 0 1.4915135793103218e-08
- O 0 5.863085128510193e-09
mediated O 0 2.355132755482714e-09
mRNA O 0 6.086172676944557e-10
decay O 0 3.2437756924963423e-09
, O 0 2.1544321882061013e-10
and O 0 1.555246209594685e-10
( O 0 1.299454294168001e-10
iii O 0 3.086438482569065e-07
) O 0 2.2219279749435827e-09
the O 0 3.1366376163077803e-09
levels O 0 1.6970448157849205e-08
of O 0 9.070637019270578e-10
these O 0 1.7872593682799476e-10
transcripts O 0 1.6058566032484123e-08
can O 0 3.19592741160335e-10
be O 0 3.7222411264359323e-10
increased O 0 1.5001861974894837e-09
by O 0 1.542308281088367e-09
cycloheximide O 0 4.2502097130636685e-06
. O 0 4.3943589389527915e-07

A O 0 3.1478191431233427e-06
deletion O 0 7.042981451377273e-07
mutation O 0 4.2559751278758995e-08
in O 0 6.684050202210301e-09
COL17A1 O 0 2.8941891287104227e-05
in O 0 1.2313305042255251e-08
five O 0 2.110221553053293e-09
Austrian O 0 1.1151914236506855e-07
families O 0 1.0402373407103482e-09
with O 0 4.1834480324354217e-10
generalized O 0 3.7764402804896235e-06
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9985944628715515
represents O 0 1.1144169143051386e-08
propagation O 0 5.886293763524009e-08
of O 0 6.619043535494029e-09
an O 0 1.8072314755812613e-09
ancestral O 0 7.722494501649635e-07
allele O 0 8.142883984874061e-07
. O 0 3.387792446574167e-07

Patients O 0 1.6944699382293038e-05
with O 0 1.9571501752579934e-08
generalized O 0 2.457249502185732e-05
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999915361404419
, O 0 4.7599339580983724e-08
a O 0 2.214283201240619e-09
usually O 0 3.1062666328018906e-10
nonlethal O 0 5.054288862993417e-07
form O 0 3.660580949471637e-09
of O 0 4.934588559990516e-07
junctional B-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999992847442627
, O 0 1.3851040137069504e-07
have O 0 3.6487723953371187e-09
generalized O 0 8.284254704449268e-08
blistering B-Disease 0 1.8088277329297853e-06
, O 0 5.768139743622669e-08
nail B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 2.1875619495403953e-05
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 4.0911680798672023e-07
and O 0 1.6795087276477716e-06
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 0 0.0009635730530135334

Skin B-Disease 1 1.0
fragility I-Disease 1 0.995025098323822
in O 0 2.1089309854005478e-08
most O 0 1.7756862646933769e-10
cases O 0 1.591131219835784e-11
is O 0 1.973742133273837e-12
due O 0 1.027441395851092e-10
to O 0 4.672148223860972e-10
mutations O 0 2.7019336767963864e-10
in O 0 3.164882800277269e-09
the O 0 1.8154375780454757e-08
gene O 0 7.64827579047278e-09
encoding O 0 6.296416898976531e-08
type O 0 1.2762997357640415e-05
XVII O 1 0.9997133612632751
collagen O 0 1.942227390827611e-05
( O 0 3.655308233874166e-08
COL17A1 O 0 2.547286385379266e-05
) O 0 1.734253274321418e-08
. O 0 1.1198616078900159e-07

Recently O 0 2.195761908296845e-06
, O 0 1.404749117028814e-08
we O 0 2.7816910996847355e-09
reported O 0 3.4893816724945736e-09
five O 0 1.6067411845455126e-09
Austrian O 0 1.3137209009528306e-07
families O 0 1.4196841480185185e-09
with O 0 6.311898226307733e-10
generalized O 0 1.7217032564076362e-06
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999998807907104
who O 0 2.565007264365704e-07
share O 0 9.212218543552808e-09
the O 0 6.419766940268801e-09
same O 0 2.0094411468107864e-08
COL17A1 O 0 7.888886466389522e-05
mutation O 0 2.031201944419081e-07
. O 0 4.372337230051926e-07

Affected O 0 1.8109784605258028e-07
individuals O 0 1.196011067960967e-10
in O 0 2.6113769480140547e-10
three O 0 1.0432271713156638e-10
families O 0 2.4617190230724617e-11
are O 0 1.2223733310279261e-11
homozygous O 0 6.315197809136919e-10
for O 0 3.854634389455214e-10
4003delTC O 0 5.291557414466297e-08
, O 0 1.616423772610176e-09
whereas O 0 2.0799835187546023e-09
those O 0 3.4810704319099273e-10
in O 0 1.3802343712399079e-09
two O 0 1.0236627101534168e-09
others O 0 3.3435858526331685e-09
are O 0 2.653097186389175e-10
compound O 0 2.3350200706317992e-07
heterozygotes O 0 1.96700170818076e-06
. O 0 5.422795084086829e-07

To O 0 4.3026624041431205e-08
determine O 0 6.973563948520223e-09
if O 0 4.6441703260846623e-10
the O 0 8.635342996221596e-10
occurrence O 0 8.358562730848007e-09
of O 0 2.0318706717148416e-09
4003delTC O 0 3.0083693758342633e-08
in O 0 3.8650299627462914e-10
these O 0 5.422886098505053e-11
unrelated O 0 1.7576394784057925e-09
families O 0 8.101449372466263e-11
signifies O 0 1.3147399835489182e-09
propagation O 0 1.9187831767908392e-08
of O 0 2.677045474186457e-09
an O 0 2.1458813892483164e-10
ancestral O 0 1.0266494854249686e-07
allele O 0 7.641484245368702e-08
or O 0 3.692508521169202e-09
a O 0 3.2777411007600676e-08
mutational O 0 7.534823816968128e-05
hot O 0 0.000577104976400733
spot O 0 1.3159243508198415e-06
, O 0 5.579867679017525e-09
haplotypes O 0 3.664676384573795e-08
were O 0 4.70282568443281e-09
determined O 0 3.7032859001584484e-09
for O 0 2.09706518816688e-09
polymorphisms O 0 1.7166668442314403e-07
both O 0 4.865092773087554e-09
within O 0 1.6124246826620947e-08
and O 0 3.8914265587663976e-08
flanking O 0 9.336438779428136e-06
COL17A1 O 0 0.0019644296262413263
. O 0 5.705453531845706e-06

Five O 0 8.142604883687454e-07
intragenic O 0 3.196204033883987e-06
polymorphisms O 0 3.8420577652686916e-07
were O 0 1.1604803340503622e-08
chosen O 0 2.4824065025796926e-09
based O 0 1.140258887311063e-09
on O 0 3.6021127414187504e-08
their O 0 1.381241165887559e-08
informativeness O 0 2.8935710361110978e-05
. O 0 1.4919281738912105e-06

One O 0 5.011436599033914e-08
of O 0 3.084729804925246e-09
these O 0 4.761542896081217e-11
, O 0 6.002599112209239e-11
not O 0 5.204128794566998e-11
previously O 0 2.939664067724834e-10
reported O 0 2.6740179515094553e-10
, O 0 8.532389378368421e-11
was O 0 7.090383391528121e-09
2988 O 0 9.913419489748776e-07
A O 0 3.325265254261467e-07
or O 0 1.874255772804645e-08
C O 0 1.8433289596941904e-06
that O 0 8.733097578428328e-11
introduces O 0 1.655400261313389e-09
a O 0 4.691105837117959e-10
new O 0 1.465568666425554e-09
restriction O 0 3.8063095786355916e-08
site O 0 4.5588133268381625e-09
for O 0 1.5825885046893973e-09
Eco0109 O 0 2.4676849079696694e-06
I O 0 4.786874796991469e-06
. O 0 1.026916265800537e-06

All O 0 4.7904638478257766e-08
the O 0 2.9583737681804223e-09
4003delTC O 0 1.0646001413761041e-07
alleles O 0 7.063118090400167e-09
showed O 0 3.3450846537164125e-09
the O 0 8.569057130536351e-10
same O 0 1.6870748131836422e-09
haplotype O 0 5.679373771272367e-08
for O 0 1.2627149326149834e-09
these O 0 3.875970377986704e-10
five O 0 2.017116251806783e-09
polymorphic O 0 2.016213329625316e-08
markers O 0 1.8445406624323368e-07
. O 0 7.592074098283774e-07

Fourteen O 0 5.353572760213865e-06
microsatellite O 0 2.299464540556073e-06
polymorphisms O 0 4.226021417252923e-07
were O 0 6.255237217089871e-09
selected O 0 1.1148905132429832e-09
based O 0 2.494912887396339e-10
on O 0 2.53424681240233e-09
their O 0 8.282824981442616e-10
high O 0 3.2631071178457205e-08
heterozygosity O 0 2.795426325974404e-07
and O 0 2.7479569730815e-09
their O 0 1.1864552673657158e-09
location O 0 2.426240008901459e-08
within O 0 3.260511194369542e-09
10q23 O 0 1.0820455145221786e-06
- O 0 4.180569135314727e-07
q25 O 0 6.117863449617289e-06
near O 0 8.847063099892694e-07
COL17A1 O 0 0.00013903687067795545
. O 0 1.2985149169253418e-06

Three O 0 4.336085979161908e-08
families O 0 1.3626095807239835e-09
shared O 0 9.968612602051508e-09
microsatellite O 0 1.0449915635035723e-06
polymorphisms O 0 2.1559983451879816e-06
covering O 0 3.728893034349312e-07
at O 0 2.163209167349578e-08
most O 0 5.280673120999779e-10
19 O 0 3.4431181461513916e-08
cM O 0 2.330801329719634e-08
, O 0 3.6545866333170807e-10
whereas O 0 8.686751873376863e-10
the O 0 1.400703109055712e-09
others O 0 2.9771896059571645e-09
shared O 0 8.614187696487363e-10
smaller O 0 1.7542892138955324e-10
regions O 0 2.4807725318432006e-10
consistent O 0 1.5361751870557327e-09
with O 0 8.420170810596872e-12
cross O 0 3.01415137293759e-09
- O 0 1.726705392002259e-07
over O 0 8.101901927126676e-10
events O 0 2.1031926200620887e-10
during O 0 4.311143664281758e-10
passage O 0 1.2402774363096114e-09
of O 0 6.534926766388338e-11
this O 0 8.842999249525363e-12
mutation O 0 2.6079161399850115e-11
through O 0 7.410821262210376e-11
several O 0 3.1786562271207686e-10
generations O 0 1.5378734730120414e-08
. O 0 1.5453633750439622e-07

These O 0 5.2660340088550583e-08
results O 0 1.2512222369309711e-08
indicate O 0 8.117064353996284e-09
that O 0 5.617878731656312e-11
4003delTC O 0 1.1157419876894892e-08
occurs O 0 1.169654512134244e-10
on O 0 1.1789726972466497e-09
a O 0 9.504984577191067e-10
single O 0 8.768791914803842e-09
ancestral O 0 1.3833984269240318e-07
allele O 0 7.720066008687354e-08
. O 0 1.437516061741917e-08
. O 0 1.7542701868933364e-07

The O 0 9.320640970145178e-07
haptoglobin O 0 2.2325668396661058e-05
- O 0 1.7134542531493935e-06
gene O 0 1.3834481116248298e-08
deletion O 0 6.609395342138669e-08
responsible O 0 5.974793992891136e-08
for O 0 1.8056610429084685e-08
anhaptoglobinemia B-Disease 0 0.00012120288738515228
. O 0 2.0918103018630063e-06

We O 0 4.1146176954498515e-07
have O 0 2.5409745418869534e-09
found O 0 3.224232547616168e-10
an O 0 1.3638465357068696e-10
allelic O 0 1.0148995954750717e-07
deletion O 0 2.6870588953897823e-07
of O 0 9.515638907942048e-07
the O 0 6.225192237252486e-07
haptoglobin O 0 0.008844202384352684
( O 0 6.900738647175331e-09
Hp O 0 5.3675826450216846e-08
) O 0 2.2499843654877338e-10
gene O 0 5.67712599153225e-10
from O 0 4.4715395275396475e-10
an O 0 7.978282617893129e-11
individual O 0 6.897336868316728e-11
with O 0 3.9448555533283525e-10
anhaptoglobinemia B-Disease 0 1.404889644618379e-05
. O 0 1.156079179054359e-06

The O 0 8.407739642279921e-07
Hp O 0 4.327980320795177e-07
gene O 0 7.134364210514832e-09
cluster O 0 2.01995375981312e-09
consists O 0 5.354294785320235e-10
of O 0 1.1873200200795964e-09
coding O 0 2.4897823891478765e-07
regions O 0 1.108823788342761e-08
of O 0 9.949014412313772e-08
the O 0 9.480547014106833e-09
alpha O 0 7.300614868199773e-08
chain O 0 3.5175073964666126e-09
and O 0 2.6444277323456333e-10
beta O 0 1.2192107767816651e-08
chain O 0 1.1301285240961079e-08
of O 0 4.7218087217970606e-09
the O 0 3.6190519470125082e-09
haptoglobin O 0 5.410248036241683e-07
gene O 0 9.094444308743732e-09
( O 0 5.749811737842947e-10
Hp O 0 1.4992545871450602e-08
) O 0 1.1970655022786048e-10
and O 0 2.1073848222030733e-10
of O 0 1.5756490556739777e-09
the O 0 6.384668349568301e-10
alpha O 0 1.2804592053328179e-08
chain O 0 1.8118702094227501e-09
and O 0 7.953410846583964e-11
beta O 0 1.11835198879362e-08
chain O 0 7.447173988595068e-09
of O 0 2.9303506288158587e-09
the O 0 3.034890339037588e-09
haptoglobin O 0 1.3636498579217005e-06
- O 0 3.114391802228056e-07
related O 0 7.026049786418298e-08
gene O 0 2.219785777413108e-08
( O 0 5.503571487430747e-10
Hpr O 0 5.899365973505155e-08
) O 0 1.502696994615249e-10
, O 0 9.516280818910872e-11
in O 0 1.8431492443404807e-10
tandem O 0 6.2425313807068505e-09
from O 0 6.750104364350307e-10
the O 0 1.2731187215564432e-09
5 O 0 1.0779056935916742e-07
side O 0 5.1956369873096264e-08
. O 0 4.820977892450173e-07

Southern O 0 2.1933254174655303e-05
blot O 0 1.9276221792097203e-05
and O 0 3.1434073122227346e-08
PCR O 0 4.874643764196662e-07
analyses O 0 3.8176445116278046e-08
have O 0 9.65376445449806e-10
indicated O 0 2.04098271616715e-09
that O 0 2.265745056850843e-11
the O 0 1.2979951835578873e-10
individual O 0 3.353040414766362e-11
with O 0 2.6298747901609687e-11
anhaptoglobinemia B-Disease 0 2.066830120384111e-07
was O 0 3.1461119931464054e-08
homozygous O 0 4.692915389625796e-09
for O 0 7.302822235821793e-10
the O 0 3.685071803261053e-09
gene O 0 5.14475972934747e-09
deletion O 0 1.0371967285038863e-08
and O 0 1.099881741239983e-09
that O 0 7.138140772910972e-11
the O 0 2.3441831809023483e-10
gene O 0 1.7385171080519513e-10
deletion O 0 3.023958194958709e-09
was O 0 5.903144639773927e-09
included O 0 2.6350088777604697e-09
at O 0 2.9323408146098018e-09
least O 0 1.5282661247617568e-10
from O 0 4.161798336510536e-11
the O 0 1.602492305519121e-10
promoter O 0 4.396362029979173e-08
region O 0 4.81038746613649e-08
of O 0 1.2299226170853217e-07
Hp O 0 6.17375064848602e-07
to O 0 2.0214924845163296e-08
Hpr O 0 5.592293064182741e-07
alpha O 0 1.3896595874030027e-07
but O 0 1.5216382598381983e-09
not O 0 1.414945383082511e-09
to O 0 6.4681313638459415e-09
Hpr O 0 3.6911237089043425e-07
beta O 0 2.0821367741064023e-07
( O 0 6.864742108092514e-09
Hpdel O 0 4.863554750045296e-06
) O 0 1.7907280991380503e-08
. O 0 9.607794737576114e-08

In O 0 2.396633824730543e-08
addition O 0 2.9635920384407655e-09
, O 0 3.244751412001534e-10
we O 0 2.346119964968807e-10
found O 0 1.583411873840035e-10
seven O 0 1.4391360325660685e-10
individuals O 0 8.65089683915743e-12
with O 0 1.2772740330679877e-11
hypohaptoglobinemia B-Disease 0 4.1865413891173375e-07
in O 0 1.6365574451171483e-09
three O 0 4.3772138691444695e-10
families O 0 2.5904261374831705e-11
, O 0 2.1563058630325038e-11
and O 0 4.957893123824775e-11
the O 0 7.811864488616038e-10
genotypes O 0 6.7032650541420935e-09
of O 0 8.623266545271235e-09
six O 0 4.727738200926979e-09
of O 0 3.2720866016688888e-09
the O 0 9.56976276000887e-10
seven O 0 2.4715629542981787e-10
individuals O 0 4.3179782666102895e-12
were O 0 4.689074684094408e-10
found O 0 4.600459180270633e-10
to O 0 2.550569533354974e-09
be O 0 6.09450765409747e-08
Hp2 O 1 0.9696637988090515
/ O 1 0.9999470710754395
Hpdel O 0 0.188813254237175
. O 0 5.9360081650083885e-06

The O 0 3.135775443752209e-07
phenotypes O 0 2.3887983502390853e-07
and O 0 1.8416285163525004e-09
genotypes O 0 7.796596257492183e-09
in O 0 6.720646816837927e-10
one O 0 1.2931593296183763e-10
of O 0 1.367248120276443e-10
these O 0 4.3719112531592774e-12
three O 0 6.134052901035636e-12
families O 0 5.976389522155401e-12
showed O 0 2.537955678949544e-10
the O 0 3.9615796754155497e-10
father O 0 1.7515461081529793e-08
to O 0 7.811705060589702e-09
be O 0 1.4292512950930814e-08
hypohaptoglobinemic B-Disease 0 1.1807164810306858e-05
( O 0 5.326317165099681e-09
Hp2 O 0 6.383313575497596e-06
) O 0 1.7446533107090545e-09
and O 0 1.4595598063493753e-09
Hp2 O 0 6.558419045177288e-06
/ O 0 9.57635165832471e-07
Hpdel O 0 2.00186445908912e-06
, O 0 1.019302420246504e-09
the O 0 1.0881296974574184e-09
mother O 0 8.412826546511099e-10
to O 0 2.863892734072948e-10
be O 0 1.0852109488812545e-10
Hp2 O 0 8.092704462114853e-08
- O 0 1.0071245526432904e-07
1 O 0 4.990718949215989e-08
and O 0 1.0297005026416173e-08
Hp1 O 0 1.699927815934643e-05
/ O 0 1.5129994608287234e-06
Hp2 O 0 2.0333932297944557e-06
, O 0 2.850818470179206e-10
one O 0 3.299633830056159e-11
of O 0 7.599772200439503e-11
the O 0 8.40395392165405e-11
two O 0 2.691583067537806e-11
children O 0 6.799293766901471e-11
to O 0 1.0174566050791256e-10
be O 0 2.5136477344034347e-09
hypohaptoglobinemic B-Disease 0 3.0275603421614505e-05
( O 0 2.218444095092309e-08
Hp2 O 0 4.237593020661734e-05
) O 0 3.2989952991613336e-09
and O 0 7.99152566344219e-09
Hp2 O 0 0.00016632907500024885
/ O 0 7.869484761613421e-06
Hpdel O 0 9.895048606267665e-06
, O 0 1.2291921924756366e-09
and O 0 4.048739954409797e-10
the O 0 4.843914713781317e-10
other O 0 7.832031551080476e-11
child O 0 6.846458400211475e-10
to O 0 2.7387203616058287e-10
be O 0 1.4265678638381019e-09
Hp1 O 0 3.259896402596496e-06
and O 0 2.9910218302120484e-08
Hp1 O 0 0.00037281887489371
/ O 0 3.364450458320789e-05
Hpdel O 0 1.8092425307258964e-05
, O 0 6.782526984494552e-09
showing O 0 1.4819741878113746e-08
an O 0 2.5434851447236895e-10
anomalous O 0 3.8178342265382526e-08
inheritance O 0 2.620006114284479e-07
of O 0 5.235306161921471e-06
Hp O 0 6.480161687250074e-07
phenotypes O 0 1.5459079349966487e-08
in O 0 6.581236666747259e-10
the O 0 1.3129081155582867e-09
child O 0 8.826043895737712e-09
with O 0 5.918925904957462e-10
Hp1 O 0 0.00013602622493635863
. O 0 1.4269190842242097e-06

The O 0 3.802366109084687e-06
Hp2 O 0 0.00949037354439497
/ O 0 0.000104827486211434
Hpdel O 0 3.4548487747088075e-05
individuals O 0 1.4253793700902406e-09
had O 0 2.378181429563142e-09
an O 0 4.736000480676239e-11
extremely O 0 2.981916380484506e-10
low O 0 1.489469525495224e-08
level O 0 2.4377019514076892e-08
of O 0 1.7054945899985796e-08
Hp O 0 5.582148077110105e-08
( O 0 2.482751226828839e-10
mean O 0 7.648782718305824e-10
+ O 0 2.110145169709199e-09
/ O 0 1.3337011495195839e-08
- O 0 5.1162473369004147e-08
SD O 0 3.525643990087701e-07
= O 0 3.3042617531009455e-08
0 O 0 3.6077079101914933e-09
. O 0 3.779163926243001e-10
049 O 0 1.3122634356932394e-07
+ O 0 1.6528865387499536e-08
/ O 0 2.9791507927257044e-08
- O 0 6.663177742893822e-08
0 O 0 8.558216357812398e-09
. O 0 1.4511767343350357e-09
043 O 0 1.9462452200968983e-06
mg O 0 9.44858584261965e-07
/ O 0 1.8384854172381893e-07
ml O 0 9.610140239146858e-08
; O 0 2.075005722801393e-10
n O 0 1.0131734340390608e-09
= O 0 1.9324448707891406e-09
6 O 0 8.656219629976647e-10
) O 0 2.044331544326372e-11
, O 0 1.04618770244147e-11
compared O 0 1.7427127449454183e-11
with O 0 2.1335583039877593e-12
the O 0 1.5118276075476444e-10
level O 0 3.68422137242419e-09
( O 0 2.7721439727068642e-11
1 O 0 1.5081160764651713e-09
. O 0 3.820131988518938e-10
64 O 0 2.2708870339727127e-09
+ O 0 1.6406828118320504e-09
/ O 0 9.078031659726093e-09
- O 0 3.35033512044447e-08
1 O 0 9.231865938374995e-09
. O 0 2.4528774567045275e-09
07 O 0 3.887495267917984e-07
mg O 0 3.553373915110569e-07
/ O 0 1.846644011038734e-07
ml O 0 1.3200858006712224e-07
) O 0 1.1471800592799397e-10
obtained O 0 6.033217925249801e-09
from O 0 1.052208320473369e-09
52 O 0 4.1945821038780196e-08
healthy O 0 7.315334471513779e-08
volunteers O 0 9.524375599312407e-08
having O 0 2.729232484455224e-08
phenotype O 0 8.527521799805982e-08
Hp2 O 0 5.679216883436311e-06
, O 0 5.2491242463759136e-09
whereas O 0 1.1976924341183803e-08
the O 0 2.9805304890828666e-09
serum O 0 9.384457655414735e-09
Hp O 0 2.437850810110831e-08
level O 0 1.0265863714664647e-08
of O 0 1.2248226877176194e-09
an O 0 6.753075182386326e-11
individual O 0 4.2429920688036304e-11
with O 0 1.948202155155343e-10
Hp1 O 0 7.486035610781983e-05
/ O 0 9.40282698138617e-05
Hpdel O 0 3.917904177797027e-05
was O 0 4.137096425438358e-07
0 O 0 3.1315289561462123e-07
. O 0 2.3440831853349664e-07

50 O 0 6.276079147937708e-06
mg O 0 1.044670534611214e-05
/ O 0 3.2363482205255423e-06
ml O 0 1.7480405176684144e-06
, O 0 1.3874190685214671e-09
which O 0 2.7899136126330326e-11
was O 0 2.0016736879124863e-10
approximately O 0 6.830824968162563e-12
half O 0 1.911576626156819e-11
the O 0 8.735513007396278e-11
level O 0 3.437702567055112e-09
of O 0 9.369787168367338e-10
Hp O 0 8.167054588170686e-09
in O 0 7.321678263672027e-10
control O 0 2.2684552902774158e-08
sera O 0 1.0382581194789964e-07
from O 0 1.165297192073922e-09
the O 0 8.470646961633577e-10
Hp1 O 0 2.7540957603378047e-07
phenotype O 0 9.814714596600993e-10
( O 0 1.1993456575098982e-11
1 O 0 3.210198773473394e-10
. O 0 7.575141208748803e-11
26 O 0 8.234010140384385e-10
+ O 0 1.230803903240485e-09
/ O 0 6.333729540841659e-09
- O 0 2.2928936971311487e-08
0 O 0 2.4159914069343813e-09
. O 0 3.880896992658478e-10
33 O 0 6.7352794452801845e-09
mg O 0 5.068015340725651e-08
/ O 0 4.815206722241783e-08
ml O 0 4.705466238874578e-08
; O 0 1.1940691491130195e-10
n O 0 9.264617961690647e-10
= O 0 2.8002908880608857e-09
9 O 0 2.112807262477645e-09
) O 0 1.7390709705633611e-10
, O 0 2.9585922600716685e-10
showing O 0 4.725196234289797e-09
a O 0 3.673576776108689e-09
gene O 0 7.094604015378536e-09
- O 0 5.487999601427873e-07
dosage O 0 3.78394611288968e-06
effect O 0 4.5536884840657876e-07
. O 0 1.0926287359325215e-06

The O 0 5.912872325097851e-07
other O 0 1.3686584310335093e-08
allele O 0 1.2180166208963783e-07
( O 0 1.090294521333135e-09
Hp2 O 0 1.242268922396761e-06
) O 0 3.290095695884787e-10
of O 0 6.095884907963978e-10
individuals O 0 3.349065122448813e-11
with O 0 1.0623917717778042e-10
Hp2 O 1 0.9967138767242432
/ O 1 0.8705314993858337
Hpdel O 0 0.0005151014775037766
was O 0 2.1302004427070642e-07
found O 0 1.3980713253758381e-09
to O 0 5.366021516017838e-10
have O 0 1.2122138015602246e-10
, O 0 1.0802093247663791e-10
in O 0 5.839956851438899e-10
all O 0 1.0747308598624272e-09
exons O 0 1.8126453227296224e-08
, O 0 1.069855093405181e-09
no O 0 3.436869899786643e-09
mutation O 0 3.281847849034847e-10
, O 0 1.6163366478583185e-10
by O 0 1.2681884709042635e-10
DNA O 0 7.596287154854053e-09
sequencing O 0 1.2761307743858197e-07
. O 0 8.291215181088774e-07

On O 0 3.643107220341335e-07
the O 0 2.0366779374114685e-09
basis O 0 4.1983261311884235e-09
of O 0 8.990475031112055e-10
the O 0 1.3875718629652312e-10
present O 0 3.356540739796188e-11
study O 0 3.2594585364087436e-10
, O 0 1.0020492768880729e-10
the O 0 3.048894747781361e-10
mechanism O 0 5.809810232904056e-08
of O 0 1.72920611163363e-08
anhaptoglobinemia B-Disease 0 7.928141485535889e-07
and O 0 3.801011949633448e-09
the O 0 4.345173998387963e-09
mechanism O 0 3.2893498769226426e-07
of O 0 1.6915413070250906e-08
anomalous O 0 5.418922910394031e-07
inheritance O 0 5.05775062720204e-07
of O 0 1.6350221585526015e-06
Hp O 0 7.62961406053364e-07
phenotypes O 0 5.20944034576587e-08
were O 0 5.05972552744538e-09
well O 0 6.03490946105012e-09
explained O 0 7.158411108321161e-08
. O 0 2.0920128918078262e-07

However O 0 8.451482358395879e-08
, O 0 2.813262511836001e-09
the O 0 5.921341750259046e-10
mechanism O 0 3.653356728250401e-08
of O 0 2.3168704288423214e-08
hypohaptoglobinemia B-Disease 0 1.0176080650126096e-05
remains O 0 5.202559236749948e-07
unknown O 0 8.655814781377558e-06

ATM O 0 0.0004402306512929499
mutations O 0 7.710779073022422e-07
and O 0 1.4488874100493376e-08
phenotypes O 0 3.7472344160960347e-07
in O 0 2.704845201151329e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 4.100581918464741e-07
in O 0 3.5746110516043927e-09
the O 0 1.909213676043464e-09
British O 0 5.550753101601913e-08
Isles O 0 8.382160103792557e-07
: O 0 1.2009195859974398e-09
expression O 0 8.297403319978969e-10
of O 0 4.804770470379083e-10
mutant O 0 1.6637694555399207e-09
ATM O 0 4.250913150372071e-07
and O 0 1.982570108083337e-09
the O 0 4.952303012117909e-09
risk O 0 8.58621191923703e-08
of O 0 1.7131759122435142e-08
leukemia B-Disease 1 0.9999995231628418
, O 0 6.529939469146484e-07
lymphoma B-Disease 1 1.0
, O 0 0.0005206387722864747
and O 0 0.0010138611542060971
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 0.11281254142522812

We O 0 2.6899963145865513e-08
report O 0 2.17302109639661e-09
the O 0 2.971979884414111e-10
spectrum O 0 3.742089749181332e-09
of O 0 1.8002338508793514e-09
59 O 0 9.689594016037972e-09
ATM O 0 7.49356217966124e-07
mutations O 0 2.7629512011628776e-09
observed O 0 5.821731985378165e-09
in O 0 4.025151767450552e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.7887188196182251
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.4957919347580173e-09
patients O 0 7.839583426871854e-10
in O 0 2.7389032708491357e-10
the O 0 2.6818187670585303e-09
British O 0 4.886000510850863e-07
Isles O 0 2.248973942187149e-05
. O 0 1.3207195479481015e-06

Of O 0 5.3871390264248475e-06
51 O 0 1.2517398317868356e-06
ATM O 0 2.6007877750089392e-05
mutations O 0 1.7848458711000603e-08
identified O 0 5.87535442519993e-09
in O 0 3.949116589296864e-10
families O 0 1.0292949825796427e-10
native O 0 1.2612316746540841e-10
to O 0 1.3237172469260372e-10
the O 0 1.085114220700234e-09
British O 0 1.599038483846016e-07
Isles O 0 1.0728737152021495e-06
, O 0 4.0362664321946795e-09
11 O 0 1.193064047555481e-08
were O 0 4.694992838949474e-09
founder O 0 4.292768096547661e-08
mutations O 0 7.403661572702447e-10
, O 0 1.2238997315616729e-10
and O 0 1.847562935974878e-10
2 O 0 1.148900086178628e-08
of O 0 7.802785084720654e-09
these O 0 3.7029943000810306e-10
11 O 0 1.1566948288077583e-08
conferred O 0 1.0164784924882042e-07
a O 0 1.3455697889241947e-08
milder O 0 6.724127388224588e-08
clinical O 0 1.7919205674843397e-08
phenotype O 0 2.7174813510555396e-09
with O 0 1.0639491371255971e-10
respect O 0 5.798305391380154e-09
to O 0 5.57280488422407e-09
both O 0 2.7473451069681687e-08
cerebellar B-Disease 1 0.8585449457168579
degeneration I-Disease 1 1.0
and O 0 5.402854412750457e-07
cellular O 0 7.410346825054148e-06
features O 0 2.3268928828201751e-07
. O 0 2.6509709982747154e-07

We O 0 5.049210471952392e-08
report O 0 3.193266095991021e-09
, O 0 6.117254619519841e-11
in O 0 4.079262969081121e-11
two O 0 1.091871523750676e-10
A B-Disease 1 0.9999988079071045
- I-Disease 1 0.9999909400939941
T I-Disease 1 1.0
families O 0 1.7087107284652348e-09
, O 0 7.931127282700956e-11
an O 0 3.3476856703407165e-11
ATM O 0 1.674917439231649e-05
mutation O 0 5.580625739298739e-08
( O 0 6.346617675845323e-10
7271T O 0 8.460528420073388e-07
- O 0 7.513996024499647e-06
- O 0 1.2842994692618959e-05
> O 0 3.893527264153818e-06
G O 0 5.761255579272984e-07
) O 0 1.1671429100967856e-10
that O 0 5.879650499113209e-12
may O 0 2.5637847747561615e-11
be O 0 1.737183834282785e-11
associated O 0 1.877989846965633e-10
with O 0 4.8002591485074575e-12
an O 0 1.497925915250331e-11
increased O 0 2.4095475614771544e-10
risk O 0 7.76908937183407e-09
of O 0 2.046097691277282e-08
breast B-Disease 0 0.029899606481194496
cancer I-Disease 0 3.84332224712125e-06
in O 0 1.0848212639302801e-07
both O 0 5.9348035819084544e-08
homozygotes O 0 2.1655700948031154e-06
and O 0 2.585888481121401e-08
heterozygotes O 0 3.6508598100226664e-07
( O 0 2.1282645090714425e-10
relative O 0 1.8845141003254184e-09
risk O 0 6.434204280481026e-10
12 O 0 2.678617327944721e-10
. O 0 3.6331989500260065e-11
7 O 0 2.813149935221304e-09
; O 0 2.6096641514428143e-10
P O 0 8.2000077838984e-08
= O 0 2.8073783298054877e-08
. O 0 6.462775870019755e-10
0025 O 0 3.9363709447570727e-07
) O 0 2.394666409610835e-10
, O 0 4.257892996517576e-11
although O 0 4.4622163603014187e-11
there O 0 7.759466680301585e-12
is O 0 2.364022389303444e-12
a O 0 1.003556005657602e-11
less O 0 1.5427575883464328e-10
severe O 0 1.0992446277668932e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 1.1696890567236551e-08
in O 0 1.4532755554519383e-10
terms O 0 3.1890526330791147e-10
of O 0 7.777725685720327e-11
the O 0 2.941738172501651e-11
degree O 0 1.5204523862166752e-08
of O 0 1.2842455099359995e-08
cerebellar B-Disease 0 9.116557339439169e-05
degeneration I-Disease 1 0.9999986886978149
. O 0 2.7593300728767645e-06

This O 0 2.5019872396114806e-08
mutation O 0 1.2065520138548891e-08
( O 0 3.661382308450811e-10
7271T O 0 1.707334291722873e-07
- O 0 2.587603944448347e-07
- O 0 3.826451688837551e-07
> O 0 3.4576626717353065e-07
G O 0 2.9327350148378173e-07
) O 0 2.1253397652909456e-10
also O 0 8.776045168357172e-11
allows O 0 8.441964488570264e-11
expression O 0 1.8943588364628283e-10
of O 0 3.666910386446176e-10
full O 0 4.427369137971482e-09
- O 0 1.9738362055932157e-08
length O 0 1.4183146879176434e-09
ATM O 0 9.402446039530332e-07
protein O 0 3.528009218101147e-09
at O 0 2.8262079343477353e-09
a O 0 9.350362706328497e-10
level O 0 1.9534793782582938e-09
comparable O 0 3.177736296322564e-09
with O 0 3.335645648583352e-11
that O 0 2.15927831170859e-10
in O 0 2.0228609898254035e-09
unaffected O 0 5.221237486807695e-08
individuals O 0 1.927850323824032e-09
. O 0 9.967096303853396e-08

In O 0 2.1084884949118532e-08
addition O 0 4.5667154502382346e-09
, O 0 1.7582689471051793e-10
we O 0 6.68343227983037e-11
have O 0 1.3073742609337469e-11
studied O 0 1.7845351862888492e-09
18 O 0 6.589029766246313e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.946796857055233e-07
, O 0 9.657830091214237e-11
in O 0 6.363535393072439e-11
15 O 0 8.837730547384126e-10
families O 0 2.2538058225274327e-11
, O 0 6.462735901990868e-11
who O 0 1.4979867346553988e-10
developed O 0 1.0652456694515422e-08
leukemia B-Disease 1 1.0
, O 0 2.296523462064215e-06
lymphoma B-Disease 1 1.0
, O 0 0.002439679577946663
preleukemic O 1 0.9999995231628418
T O 0 0.023505840450525284
- O 0 1.422182049282128e-05
cell O 0 6.125189884187421e-06
proliferation O 1 0.9947870969772339
, O 0 1.9398944672843754e-08
or O 0 5.726635663449997e-07
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 4.5721563424194755e-08
mostly O 0 2.6735245128861607e-09
in O 0 7.334174378925695e-10
childhood O 0 9.868541184232527e-08
. O 0 8.061277867454919e-08

A O 0 9.09338632482104e-06
wide O 0 2.940184060662432e-07
variety O 0 1.4774641066139793e-08
of O 0 9.273001921883406e-09
ATM O 0 1.355182484985562e-05
mutation O 0 7.562545256689646e-09
types O 0 9.679600232459507e-09
, O 0 2.1035346797759757e-09
including O 0 7.728887752023184e-09
missense O 0 2.3822578043564135e-07
mutations O 0 5.090780241800985e-09
and O 0 1.7158893195201586e-09
in O 0 1.647488545586384e-08
- O 0 1.195713366541895e-06
frame O 0 9.487068268754228e-07
deletions O 0 2.960679523766885e-07
, O 0 2.4704704948419476e-09
were O 0 3.952615124092063e-09
seen O 0 1.4529464298362882e-09
in O 0 2.975927837489678e-10
these O 0 7.01114388768076e-10
patients O 0 3.6228919864100817e-09
. O 0 4.055034708017047e-08

We O 0 4.808121545352151e-08
also O 0 8.56703097351641e-10
show O 0 8.263884021530998e-11
that O 0 1.5932381282335317e-12
25 O 0 1.5785631135578626e-10
% O 0 2.7766311819221734e-11
of O 0 6.758616583057986e-11
all O 0 1.880333805326373e-10
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.938940812351575e-07
carried O 0 2.8445410471533705e-09
in O 0 1.015777906232529e-09
- O 0 1.9512168591973023e-07
frame O 0 9.250073844668805e-07
deletions O 0 1.936044782269164e-06
or O 0 5.173003003733356e-08
missense O 0 4.861950628765044e-07
mutations O 0 4.333677416923365e-09
, O 0 2.988441161200228e-10
many O 0 2.5652912086226998e-11
of O 0 1.030172891436365e-10
which O 0 8.947783486368266e-12
were O 0 1.831339940805421e-10
also O 0 5.5229914391885515e-11
associated O 0 6.045021150313801e-10
with O 0 2.0946415435485477e-10
expression O 0 6.872605240459961e-08
of O 0 2.3529975123892655e-07
mutant O 0 1.2494317047639925e-07
ATM O 0 6.446300176321529e-06
protein O 0 1.4065969367038633e-07
. O 0 5.648583965012222e-07

The O 0 7.454338515344716e-07
DMPK O 0 0.00014874794578645378
gene O 0 1.3482805627518246e-07
of O 0 4.329127634150609e-08
severely O 0 0.06800095736980438
affected O 0 4.997382711735554e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9755553007125854
is O 0 1.1195081528470041e-09
hypermethylated O 0 6.459774937184193e-08
proximal O 0 2.457561620872184e-08
to O 0 5.2810587014562316e-09
the O 0 8.605554491225575e-09
largely O 0 2.2354766926468983e-08
expanded O 0 6.576085098686235e-08
CTG O 0 6.5777239797171205e-06
repeat O 0 6.96794245413912e-07
. O 0 7.360434892689227e-07

Using O 0 2.218800773334806e-06
methylation O 0 1.9557306586648338e-05
- O 0 3.264054612373002e-05
sensitive O 0 4.601333330356283e-06
restriction O 0 1.43153812359742e-07
enzymes O 0 1.1986700521049443e-09
, O 0 1.1993989135206107e-10
we O 0 1.178535879997611e-10
characterized O 0 5.219029375336248e-11
the O 0 4.31538658973718e-11
methylation O 0 2.4894240002737433e-09
pattern O 0 1.3063461423712397e-09
on O 0 4.1527550287412396e-09
the O 0 1.1644551989320462e-09
5 O 0 5.925005819307216e-09
side O 0 9.439762305163413e-10
of O 0 2.2759170104080795e-09
the O 0 2.6709150446890817e-09
CTG O 0 7.371878609774285e-07
repeat O 0 2.926665487734681e-08
in O 0 7.177535454871986e-09
the O 0 6.257289353328588e-09
DMPK O 0 2.8403085252648452e-06
gene O 0 3.2917923942221705e-09
of O 0 1.0969654073988977e-09
normal O 0 7.843281579766881e-09
individuals O 0 1.6938183494685788e-11
and O 0 3.4457339759264016e-11
of O 0 6.950587883025605e-10
patients O 0 9.039980430891603e-10
affected O 0 6.444189626364505e-10
with O 0 4.71316141670286e-09
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 6.490403734460415e-07
showing O 0 2.709284885327179e-08
expansions O 0 1.2371404345401515e-08
of O 0 9.987683569079309e-09
the O 0 2.730985881882475e-09
repetitive O 0 2.5134667680504208e-08
sequence O 0 1.148562756014826e-08
. O 0 4.232595927078364e-07

The O 0 4.1981039089478145e-07
gene O 0 1.6634784216762455e-08
segment O 0 1.5220773974533586e-08
analyzed O 0 1.3079748839572858e-08
corresponds O 0 2.354131334314502e-09
to O 0 1.963895268630722e-09
the O 0 4.941018261206409e-09
genomic O 0 1.3601129467133433e-07
SacI O 0 3.852573172480334e-06
- O 0 1.7410184227628633e-07
HindIII O 0 3.181662293627596e-07
fragment O 0 9.724828053947476e-09
carrying O 0 9.440578097041907e-09
exons O 0 1.2846252950282633e-08
11 O 0 2.5915914747542956e-08
- O 0 2.963572001135617e-07
15 O 0 2.8406151386661804e-07
. O 0 2.2788073295032518e-07

There O 0 1.5184042467808467e-07
is O 0 1.2259119275270791e-09
constitutive O 0 1.0858294530180501e-07
methylation O 0 2.953037494535238e-07
in O 0 8.754006586286778e-08
intron O 0 2.0795005184481852e-05
12 O 0 6.40674898022553e-07
at O 0 2.5174633933033874e-08
restriction O 0 2.5334363940032745e-08
sites O 0 3.2713438624654145e-09
of O 0 1.1894801810186095e-09
SacII O 0 2.899203366268921e-07
and O 0 1.7854646650050654e-09
HhaI O 0 9.78981688604108e-07
, O 0 4.3363623802861184e-10
localized O 0 6.10243766629992e-09
1 O 0 7.786105093998685e-09
, O 0 2.2878673955339934e-10
159 O 0 2.4072472903924336e-09
- O 0 5.890786880513588e-08
1 O 0 1.466022894192065e-07
, O 0 5.85645754114239e-09
232 O 0 1.2054847786657774e-08
bp O 0 5.910087352845039e-08
upstream O 0 9.572177717132035e-09
of O 0 4.545338327943682e-09
the O 0 1.3103845120099322e-08
CTG O 0 1.5231106772262137e-05
repeat O 0 3.7334120861487463e-07
, O 0 3.7011318454460707e-09
whereas O 0 2.632482010156423e-09
most O 0 7.091404546910596e-11
, O 0 1.4320133620571163e-11
if O 0 5.812225700729812e-12
not O 0 3.0753975754915786e-11
all O 0 3.3147352918039275e-11
, O 0 9.726876942783846e-11
of O 0 5.013965354017103e-10
the O 0 4.905558181889091e-10
other O 0 7.813812791246377e-11
sites O 0 1.3423827605052452e-09
of O 0 1.44674372482001e-09
SacII O 0 1.985350309041678e-06
, O 0 3.1426079516450045e-09
HhaI O 0 1.2401770618453156e-05
, O 0 2.890107708708456e-09
and O 0 2.228493833911216e-09
HpaII O 0 5.6272779147548135e-06
in O 0 2.307625202035979e-09
this O 0 3.904493117712349e-10
region O 0 1.3225928796600783e-08
are O 0 2.702840729007505e-10
unmethylated O 0 2.497949083135609e-07
, O 0 6.33996299903572e-10
in O 0 3.6099845335257896e-10
normal O 0 8.072367663203295e-09
individuals O 0 1.9623578803584785e-11
and O 0 8.036043358528033e-11
most O 0 3.2931030125027405e-10
of O 0 6.572405397697878e-10
the O 0 2.964632539459444e-09
patients O 0 7.13967285292938e-09
. O 0 7.226220333222955e-08

In O 0 6.189537060663497e-08
a O 0 3.3459526260770645e-09
number O 0 3.922856206539649e-10
of O 0 2.0638629694147426e-10
young O 0 4.640106354703022e-10
and O 0 2.245358621255633e-10
severely O 0 4.390027754652692e-07
affected O 0 2.596651782482695e-09
patients O 0 4.6280876908610935e-09
, O 0 1.9773652160104405e-10
however O 0 4.097183980977803e-10
, O 0 3.3823069345295664e-10
complete O 0 9.471057715870757e-09
methylation O 0 6.160328069881871e-08
of O 0 1.5492286564722235e-08
these O 0 4.3080122802408027e-10
restriction O 0 4.734939551553907e-09
sites O 0 5.268389613455327e-10
was O 0 1.3125550646364559e-09
found O 0 2.3735940990476934e-10
in O 0 4.000456632624605e-10
the O 0 2.961541012425073e-09
mutated O 0 6.707027466745785e-08
allele O 0 3.3488151984784054e-07
. O 0 5.030096872360446e-07

In O 0 5.094609889511048e-08
most O 0 4.999860525600752e-10
of O 0 2.439290158751106e-10
these O 0 9.316263038794403e-12
patients O 0 3.326705924622253e-11
, O 0 3.373348041874058e-12
the O 0 2.5773265466266793e-11
onset O 0 3.5416039168012503e-07
of O 0 4.218322757765236e-08
the O 0 6.040692568376471e-08
disease O 0 0.00021517886489164084
was O 0 5.0705850298982114e-05
congenital O 1 1.0
. O 0 0.0008214234258048236

Preliminary O 0 3.4533102279965533e-06
in O 0 4.4066467808079324e-07
vivo O 0 0.00016335312102455646
footprinting O 0 0.0008380056824535131
data O 0 4.4413692990019626e-07
gave O 0 1.387546699760378e-08
evidence O 0 5.7470734837750115e-09
for O 0 1.659300197243141e-10
protein O 0 3.090841471653505e-10
- O 0 1.1780111996984033e-08
DNA O 0 3.7777695638396835e-08
contact O 0 1.6740177954943647e-07
in O 0 3.3792133535825997e-09
normal O 0 2.76560996326225e-08
genes O 0 1.128279913942265e-09
at O 0 8.484200897385108e-09
an O 0 7.336231067078813e-10
Sp1 O 0 2.1153935847451066e-07
consensus O 0 2.657896480684485e-08
binding O 0 2.674871213415031e-09
site O 0 5.416658233059479e-09
upstream O 0 1.093631074589041e-09
of O 0 1.3131785658870854e-09
the O 0 1.9829029529461195e-09
CTG O 0 1.8177090623794356e-06
repeat O 0 3.3815361177857994e-08
and O 0 1.8162262804821694e-09
for O 0 6.935504393013048e-10
a O 0 1.6822829240759063e-10
significant O 0 5.3168115743407185e-11
reduction O 0 7.831232551325229e-09
of O 0 2.824644962373668e-09
this O 0 7.852613698178246e-11
interaction O 0 3.3324995540873203e-10
in O 0 1.5261485131201624e-10
cells O 0 4.881998694195033e-10
with O 0 7.432890414271753e-11
a O 0 1.6359715360181326e-08
hypermethylated O 0 1.5847964505155687e-06
DMPK O 0 1.0578175533737522e-05
gene O 0 2.7610560948687635e-08
. O 0 3.188739583492861e-08
. O 0 4.3599789023573976e-07

The O 0 8.8150380179286e-05
hemochromatosis B-Disease 1 1.0
gene O 0 3.203614937774546e-07
product O 0 6.226263948860833e-09
complexes O 0 4.095123351532948e-09
with O 0 2.155591399821688e-10
the O 0 2.200549076292191e-09
transferrin O 0 8.980953936088554e-08
receptor O 0 8.793713313082208e-09
and O 0 4.49235759703015e-09
lowers O 0 3.3635834029155376e-07
its O 0 4.631195871240834e-09
affinity O 0 7.776338684095663e-09
for O 0 6.822316600541001e-10
ligand O 0 2.35288464267569e-08
binding O 0 5.741017972127338e-08
. O 0 5.589872102973459e-07

We O 0 4.553106407456653e-07
recently O 0 4.542376430549666e-08
reported O 0 3.8745535668738285e-09
the O 0 5.700182548196153e-10
positional O 0 5.349197067516798e-07
cloning O 0 7.260427281607917e-08
of O 0 4.747835458118743e-09
a O 0 2.1257258175921834e-09
candidate O 0 7.507185983968157e-09
gene O 0 5.3847792003125505e-08
for O 0 1.6754340776969912e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.999994158744812
HFE O 1 0.9783123731613159
. O 0 1.5243775806084159e-06

The O 0 7.182276107187135e-08
gene O 0 1.8409577196010218e-09
product O 0 3.644659851698151e-10
, O 0 1.0627666802154323e-10
a O 0 3.1790683974186607e-10
member O 0 6.195909896256069e-10
of O 0 6.763536397613734e-09
the O 0 1.4076082521796707e-08
major O 0 1.0668931338386756e-07
histocompatibility O 0 5.70800011701067e-06
complex O 0 5.927766721924854e-08
class O 0 6.7318377539038465e-09
I O 0 7.597014928251156e-08
- O 0 4.4777571872600674e-08
like O 0 6.058295531907731e-10
family O 0 1.4281271998317635e-10
, O 0 2.0381836843275103e-11
was O 0 2.28695562487502e-10
found O 0 2.567151179133642e-11
to O 0 1.7934265184038622e-10
have O 0 3.485781108203412e-10
a O 0 3.2206817213165095e-09
mutation O 0 2.4959281308412073e-09
, O 0 1.8806611823407593e-09
Cys O 0 1.2712233001366258e-05
- O 0 1.1328819709888194e-05
282 O 0 2.863409918063553e-06
- O 0 0.0007173574413172901
- O 0 5.6406039220746607e-05
> O 0 6.7245391619508155e-06
Tyr O 0 2.1084995751152746e-05
( O 0 2.5275359583076806e-10
C282Y O 0 4.710926049256159e-08
) O 0 1.6354386594974457e-11
, O 0 9.622283005106258e-12
in O 0 4.76377756686297e-11
85 O 0 6.3852323428648106e-09
% O 0 4.5861694997206826e-10
of O 0 3.1104478992460827e-09
patient O 0 2.6019083776418483e-08
chromosomes O 0 1.8898212772455736e-07
. O 0 1.4086739383856184e-06

This O 0 2.057462467064397e-08
mutation O 0 1.048132602932128e-08
eliminates O 0 2.907558815934408e-08
the O 0 5.840472550033837e-09
ability O 0 5.923695312048949e-09
of O 0 2.2230185692251325e-08
HFE O 0 0.0004857369640376419
to O 0 3.838277962131542e-08
associate O 0 1.9472980739010382e-07
with O 0 1.2582336283983864e-09
beta2 O 0 0.001090268837288022
- O 0 0.0016969733405858278
microglobulin O 0 0.014250076375901699
( O 0 4.993239599571098e-09
beta2m O 0 2.0999275420763297e-06
) O 0 7.997483786326143e-10
and O 0 4.164524280980686e-10
prevents O 0 2.705090818011513e-09
cell O 0 1.5741996151064086e-07
- O 0 8.637572364023072e-07
surface O 0 2.308175197640594e-07
expression O 0 1.8055324062515865e-06
. O 0 8.03414479833009e-07

A O 0 5.975790827505989e-06
second O 0 1.9332428280449676e-07
mutation O 0 2.0973059733364607e-08
that O 0 2.65910543584269e-10
has O 0 7.948088021070276e-11
no O 0 1.3649968655382594e-10
effect O 0 1.1120362408689743e-09
on O 0 1.9263408645997515e-08
beta2m O 0 1.8462475281921797e-06
association O 0 5.533193014883864e-09
, O 0 9.804368428234511e-10
H63D O 0 1.006636466627242e-06
, O 0 3.101305601216353e-10
was O 0 1.0609504386138724e-09
found O 0 4.729230895783587e-11
in O 0 6.35359057032936e-11
eight O 0 2.310760055523886e-10
out O 0 7.603091767283132e-11
of O 0 5.117247181551932e-10
nine O 0 2.4006310272994824e-09
patients O 0 6.284257558775153e-10
heterozygous O 0 7.435290161339481e-10
for O 0 2.69482214321215e-09
the O 0 4.2157004997989134e-08
C282Y O 0 1.618643909750972e-05
mutant O 0 8.88819670308294e-07
. O 0 9.71319650489022e-07

In O 0 2.9495408782054255e-08
this O 0 3.053492181326334e-10
report O 0 9.419385271769443e-10
, O 0 1.6341360209448652e-10
we O 0 2.647571883951372e-10
demonstrate O 0 4.656803831437628e-09
in O 0 5.757704979458822e-09
cultured O 0 9.012946975417435e-07
293 O 0 2.0611946638382506e-07
cells O 0 1.7729610135575058e-07
overexpressing O 0 2.4834059786371654e-06
wild O 0 1.291376747758477e-07
- O 0 3.5222058158979053e-07
type O 0 2.591374936855573e-07
or O 0 4.4485418015938194e-08
mutant O 0 1.5037400658002298e-07
HFE O 0 1.236627099387988e-06
proteins O 0 2.993221781544264e-10
that O 0 7.514628502791609e-11
both O 0 2.031265156077211e-10
the O 0 3.784669466710966e-09
wild O 0 1.1469738581126876e-07
- O 0 4.857556632487103e-07
type O 0 3.6887800547447114e-07
and O 0 2.3783465508131485e-07
H63D O 0 0.003180114086717367
HFE O 0 6.889848009450361e-05
proteins O 0 3.550779892336209e-09
form O 0 4.4361242457213734e-10
stable O 0 2.808642385332405e-08
complexes O 0 1.7224637272050813e-09
with O 0 9.912368148512485e-11
the O 0 3.4383713654051462e-09
transferrin O 0 5.3885500506112294e-08
receptor O 0 8.461027434236712e-09
( O 0 1.1592473647681345e-09
TfR O 0 1.6206344071179046e-06
) O 0 5.490384591411157e-09
. O 0 7.434744730971943e-08

The O 0 9.423641245120962e-07
C282Y O 0 1.6388519725296646e-05
mutation O 0 8.0246437050846e-08
nearly O 0 2.5609574461071816e-09
completely O 0 5.845253614467083e-09
prevents O 0 5.269967240373319e-10
the O 0 5.226782340272962e-10
association O 0 8.164527387499732e-10
of O 0 4.890202465190896e-09
the O 0 4.453276414295715e-09
mutant O 0 3.833785555684699e-08
HFE O 0 2.1201690287853125e-06
protein O 0 4.945185594351642e-09
with O 0 3.7825748089304057e-10
the O 0 6.019094200837571e-08
TfR O 0 9.132663399213925e-05
. O 0 1.6792891983641312e-06

Studies O 0 2.905652536355774e-07
on O 0 3.0015719687526143e-08
cell O 0 2.5553573479442093e-08
- O 0 2.5759053556839717e-08
associated O 0 3.690304950509926e-09
transferrin O 0 2.1275077699556277e-08
at O 0 5.7730455971238825e-09
37 O 0 7.03405245161548e-09
degrees O 0 1.749326656863559e-07
C O 0 3.9721996358821343e-07
suggest O 0 1.0149180384999568e-09
that O 0 7.2092082303854e-11
the O 0 3.036581208704092e-09
overexpressed O 0 1.1993244015684468e-06
wild O 0 5.096650852465245e-07
- O 0 1.1774719723689486e-06
type O 0 5.245183842816914e-07
HFE O 0 2.638648948050104e-05
protein O 0 6.2151941371269e-09
decreases O 0 2.328502946014055e-09
the O 0 2.5839727579857197e-10
affinity O 0 1.1466971816531668e-09
of O 0 1.1224829066236452e-08
the O 0 1.6914802003498153e-08
TfR O 0 3.759737637665239e-06
for O 0 7.473127894286336e-09
transferrin O 0 1.1521213991727564e-06
. O 0 6.473181883848156e-07

The O 0 7.636160262336489e-06
overexpressed O 0 0.00042886551818810403
H63D O 0 0.0008569876663386822
protein O 0 1.0041284781436843e-07
does O 0 8.315131916347696e-10
not O 0 3.5474881365793465e-10
have O 0 6.183251827218683e-11
this O 0 1.3891599676130184e-11
effect O 0 5.718270301713346e-10
, O 0 1.8041376725896896e-10
providing O 0 5.011118631159661e-09
the O 0 2.9839419823929347e-10
first O 0 3.526702263556558e-10
direct O 0 1.1636180907714788e-09
evidence O 0 4.432089972805642e-10
for O 0 1.6226782417749774e-10
a O 0 7.521916423058883e-10
functional O 0 6.382042005981248e-09
consequence O 0 1.1242097919250682e-08
of O 0 3.741425835812606e-09
the O 0 1.2386633052585694e-08
H63D O 0 2.6726635041995905e-05
mutation O 0 6.729208479328008e-08
. O 0 2.076356508950994e-07

Addition O 0 7.718165875303384e-07
of O 0 1.1314683234786571e-07
soluble O 0 2.8466084245337697e-07
wild O 0 4.4440806590273496e-08
- O 0 2.012529307648947e-07
type O 0 1.223842332365166e-06
HFE O 1 1.0
/ O 1 1.0
beta2m O 1 0.979828417301178
heterodimers O 0 5.518239049706608e-05
to O 0 6.8992413559954e-08
cultured O 0 1.2527179933385924e-06
cells O 0 1.8209938446034357e-07
also O 0 1.6158413496114576e-09
decreased O 0 1.5762411376130103e-09
the O 0 2.388626796356874e-10
apparent O 0 1.0630347713203037e-09
affinity O 0 1.303473884384232e-09
of O 0 7.471588681084995e-09
the O 0 4.008233744912104e-09
TfR O 0 2.1172624542487029e-07
for O 0 2.4400859111040063e-10
its O 0 1.2286775763481472e-11
ligand O 0 4.296474565013142e-10
under O 0 1.6500161237331668e-09
steady O 0 1.970417251584422e-08
- O 0 7.68852714827517e-09
state O 0 1.8338915108717657e-10
conditions O 0 1.8154201697484496e-08
, O 0 5.002369074524893e-10
both O 0 1.0913633885500928e-10
in O 0 3.7697112098555863e-10
293 O 0 2.901640705488262e-09
cells O 0 2.3051793807127297e-09
and O 0 5.997340846164434e-09
in O 0 5.064807595545062e-08
HeLa O 0 1.400061410095077e-05
cells O 0 4.297814939491218e-07
. O 0 7.766512908347067e-07

Furthermore O 0 1.8651127220437047e-07
, O 0 1.3193621750673401e-09
at O 0 8.770426052073788e-10
4 O 0 9.048315874338186e-09
degrees O 0 1.6503731785633136e-06
C O 0 3.1334695904661203e-06
, O 0 1.6311164641180653e-09
the O 0 5.898957766703461e-09
added O 0 4.672785536286028e-08
soluble O 0 4.43039560593661e-08
complex O 0 2.704065593661653e-08
of O 0 5.617009080083335e-08
HFE O 0 0.0008480180404148996
/ O 0 3.7906491343164816e-05
beta2m O 0 2.695559032872552e-06
inhibited O 0 3.5282802457459184e-08
binding O 0 6.989263834356052e-09
of O 0 1.759102552512104e-08
transferrin O 0 9.478322908762493e-07
to O 0 6.805557006828167e-08
HeLa O 0 3.374552761670202e-05
cell O 0 3.3632350096013397e-06
TfR O 0 2.4536377623007866e-06
in O 0 2.3325257281214817e-09
a O 0 2.3130233284263113e-09
concentration O 0 5.550679205157394e-08
- O 0 5.910324318847415e-08
dependent O 0 2.4873937576330718e-08
manner O 0 1.466006125383501e-07
. O 0 8.645302500553953e-07

Scatchard O 0 0.001411684788763523
plots O 0 1.5844217386984383e-06
of O 0 2.1449001508244692e-07
these O 0 4.109983020583741e-09
data O 0 1.5222457960817337e-08
indicate O 0 1.0933855598693754e-08
that O 0 6.880205849491006e-10
the O 0 8.78399131210017e-09
added O 0 5.847631356914462e-08
heterodimer O 0 3.692461447712958e-08
substantially O 0 2.1364497726494847e-08
reduced O 0 6.18513329442294e-09
the O 0 1.7797424645138449e-09
affinity O 0 1.1247931475111272e-08
of O 0 2.9554763969485975e-08
TfR O 0 2.457736172800651e-06
for O 0 1.7381376338221344e-08
transferrin O 0 3.096946102232323e-06
. O 0 9.593179584044265e-07

These O 0 4.194462377427044e-08
results O 0 1.2532907156526107e-08
establish O 0 4.8047937184492184e-08
a O 0 5.067230191002636e-09
molecular O 0 4.001040565526637e-08
link O 0 4.70957850495779e-08
between O 0 1.6743736397373254e-09
HFE O 0 0.4834754467010498
and O 0 1.4790282421017764e-07
a O 0 1.3132749643318675e-07
key O 0 3.761369669064152e-07
protein O 0 2.04644790002817e-09
involved O 0 8.853521804574882e-10
in O 0 1.4514535129350747e-09
iron O 0 8.071198749348696e-07
transport O 0 7.317956942642923e-07
, O 0 4.370491968330725e-09
the O 0 4.9240278521267555e-09
TfR O 0 1.4878434058118728e-06
, O 0 4.759130312059767e-10
and O 0 2.109978997077988e-10
raise O 0 3.2312588160721134e-09
the O 0 8.965986841857898e-10
possibility O 0 8.183660860083819e-09
that O 0 1.2430073637048622e-10
alterations O 0 1.8795862644083172e-08
in O 0 1.9433896714105003e-09
this O 0 4.745105697256946e-11
regulatory O 0 8.822083619186571e-10
mechanism O 0 9.630340080946098e-09
may O 0 3.2628363899611657e-10
play O 0 1.5795879049207429e-09
a O 0 2.863297376975993e-10
role O 0 5.501304967125975e-10
in O 0 1.0984120279999843e-09
the O 0 4.148994481312229e-09
pathogenesis O 0 0.4989769160747528
of O 0 1.0907092473644298e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.00020059788948856294
. O 0 4.30158763720101e-07

Genomic O 0 5.134704679221613e-07
organization O 0 3.315840402251524e-08
of O 0 9.99099825094163e-09
the O 0 2.0686139023951e-08
UBE3A O 1 0.9951098561286926
/ O 0 0.012865382246673107
E6 O 0 2.251570731459651e-05
- O 0 6.0985988966422155e-05
AP O 0 0.0002675361174624413
gene O 0 2.5298581007859866e-08
and O 0 4.430571021174501e-09
related O 0 1.3028100909195928e-07
pseudogenes O 0 2.648711642905255e-06
. O 0 6.596486059606832e-07

The O 0 1.2829671049985336e-06
UBE3A O 0 4.5217006118036807e-05
gene O 0 5.532499258720236e-08
encodes O 0 8.43659719862444e-09
the O 0 8.327499578797415e-09
E6 O 0 1.2931379842484603e-06
- O 0 3.926213139493484e-06
AP O 0 4.292549783713184e-05
ubiquitin O 0 7.562289283669088e-08
- O 0 3.9679964203287454e-08
protein O 0 2.4159996225847635e-10
ligase O 0 1.6144641179494101e-09
and O 0 6.477794967096884e-10
has O 0 1.0639165937131878e-10
recently O 0 4.839167955239532e-10
been O 0 5.954705478705691e-11
shown O 0 4.923581334304039e-11
to O 0 8.510610272072228e-11
be O 0 2.99789554292218e-10
mutated O 0 3.941595494438843e-08
in O 0 2.0753700482600834e-06
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.003984008450061083
who O 0 2.873338011966098e-09
lack O 0 1.5729412439213775e-08
15q11 O 0 4.524833002506057e-06
- O 0 1.5674479527660878e-06
q13 O 0 1.0923913578153588e-05
deletions O 0 7.619150323989743e-07
or O 0 3.391172853639546e-08
chromosome O 0 6.942497634554456e-07
15 O 0 2.3362927095149644e-06
paternal O 0 0.0004715814720839262
uniparental B-Disease 1 0.9987637996673584
disomy I-Disease 0 0.002368824789300561
. O 0 4.787856141774682e-06

Previous O 0 1.2452319424482994e-06
UBE3A O 0 1.1033828741346952e-05
cDNA O 0 2.0548334589420847e-07
analysis O 0 1.4600367137518333e-08
has O 0 1.8608818652676717e-10
shown O 0 1.3354510552954224e-10
a O 0 3.4083599831369327e-10
coding O 0 2.8123038120497768e-08
region O 0 4.886463678133168e-09
of O 0 3.2372302616323623e-09
approximately O 0 6.204199931580945e-10
2 O 0 3.509286727876315e-08
. O 0 1.0296439256762824e-07

6 O 0 5.9768904066004325e-06
kb O 0 5.037392384110717e-06
and O 0 1.7117093520369053e-08
a O 0 8.473009849296886e-09
3 O 0 1.3748940830282663e-07
- O 0 2.4947548808995634e-06
untranslated O 0 0.4813153147697449
region O 0 8.482730322612042e-07
( O 0 1.0122906957121813e-09
UTR O 0 5.218487785896286e-06
) O 0 1.758196033208037e-09
of O 0 4.775609241391976e-09
< O 0 6.190329031596775e-07
50 O 0 8.145931218450642e-08
bp O 0 4.076889226212188e-08
, O 0 1.8913874633152972e-10
whereas O 0 1.3622041272753904e-09
Northern O 0 3.2767579760673016e-09
analysis O 0 1.232575153053972e-09
has O 0 2.9081145477838355e-11
indicated O 0 1.4803784934014352e-11
mRNA O 0 6.942780378382807e-11
sizes O 0 9.655145571940693e-10
of O 0 1.8731614037648114e-09
5 O 0 3.754201571837257e-08
- O 0 1.2110915577068226e-06
8 O 0 1.5807994486749521e-06
kb O 0 0.00010292197111994028
. O 0 4.068393991474295e-06

We O 0 2.1919686332694255e-06
have O 0 3.316321084412266e-08
analyzed O 0 2.5472358444744714e-08
additional O 0 2.297306167520219e-08
cDNA O 0 2.0470704953368113e-07
clones O 0 8.682685148642122e-08
and O 0 1.5828782728988244e-09
provide O 0 2.569171986266383e-09
evidence O 0 6.728624324381371e-10
for O 0 6.16056719526803e-11
an O 0 6.920740369675826e-11
additional O 0 4.3584131859120134e-09
0 O 0 1.880160596101632e-07
. O 0 2.7358782972441986e-07

5 O 0 8.365070698346244e-07
kb O 0 2.6173293008469045e-06
of O 0 9.795311228799619e-08
5 O 0 2.3173261354259012e-07
- O 0 8.460205549454258e-07
UTR O 0 9.003167360788211e-05
and O 0 5.284083925971572e-08
> O 0 4.643298154860531e-07
2 O 0 8.283811325782153e-08
kb O 0 9.872134114630171e-07
of O 0 5.1749367457887274e-08
3 O 0 6.492037982752663e-07
- O 0 1.1171280675625894e-05
UTR O 0 0.002285339403897524
. O 0 1.0039892913482618e-05

We O 0 2.2808077915215108e-07
have O 0 7.142093583212272e-10
established O 0 8.670860696113891e-10
the O 0 5.642279976569853e-10
genomic O 0 8.679502450092969e-09
organization O 0 5.593549179394586e-09
of O 0 5.447117867873885e-09
UBE3A O 0 5.3637318160326686e-06
and O 0 3.827748340512471e-09
the O 0 5.551481052634699e-09
sequence O 0 1.1359737595029173e-09
of O 0 2.1270411210139173e-08
intron O 0 1.6076055544544943e-06
- O 0 2.1735959307989106e-06
exon O 0 1.212166239383805e-06
borders O 0 2.11188009302532e-07
. O 0 5.004798140362254e-07

We O 0 2.733851715674973e-06
have O 0 3.3271867039275094e-08
also O 0 6.446221778588779e-09
mapped O 0 2.7396739099572187e-08
two O 0 1.86265114443529e-09
highly O 0 1.1266697796941116e-08
homologous O 0 8.394862582861151e-09
processed O 0 4.0204024998047316e-08
pseudogenes O 0 8.327884160053145e-08
, O 0 2.918502994830874e-09
UBE3AP1 O 0 2.2375684238795657e-06
and O 0 3.101218393197769e-09
UBE3AP2 O 0 7.976466804393567e-06
, O 0 1.035691865602928e-09
to O 0 2.233079554603279e-10
chromosomes O 0 3.5058642100516124e-10
2 O 0 2.34858354986045e-09
and O 0 4.583598778307163e-10
21 O 0 2.1014464834934188e-08
, O 0 9.229449426939595e-10
respectively O 0 2.920368391556849e-09
, O 0 4.2315181913998856e-10
and O 0 2.75174771857678e-10
determined O 0 2.048603731097387e-09
their O 0 1.6153389736928148e-09
genomic O 0 2.6663207108867937e-07
organization O 0 3.7568634070339613e-07
. O 0 4.490411242841219e-07

These O 0 2.6150429377480577e-08
results O 0 3.750306731831188e-09
will O 0 2.5144808457611134e-10
form O 0 2.693945934384434e-11
the O 0 1.10251287266383e-10
basis O 0 2.88393892100558e-10
for O 0 1.9879981341675013e-11
studies O 0 5.783236667333824e-10
of O 0 8.870593704024543e-10
mutation O 0 5.623703169810312e-10
and O 0 1.9549366570004167e-09
imprinting O 0 2.337828391318908e-06
of O 0 8.203657671401743e-06
UBE3A O 0 0.27431878447532654
. O 0 8.477153642161284e-06

Mutation O 0 4.282711415726226e-06
spectrum O 0 6.003134558341117e-07
and O 0 9.950681167936182e-09
genotype O 0 1.1380864179955097e-06
- O 0 8.314555998367723e-06
phenotype O 0 1.3470570081608457e-07
analyses O 0 4.6849137902427174e-08
in O 0 1.152945916516046e-08
Cowden B-Disease 1 0.9347134232521057
disease I-Disease 0 1.0096342748511233e-06
and O 0 6.765588533852451e-09
Bannayan B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.3965554934713964e-08
two O 0 6.333355173637756e-09
hamartoma B-Disease 0 0.012117303907871246
syndromes I-Disease 0 6.476000180555275e-06
with O 0 3.397543579808371e-08
germline O 1 0.9346743822097778
PTEN O 0 0.38470178842544556
mutation O 0 1.6490940879521077e-06
. O 0 1.4927850315871183e-06

The O 0 9.018457603815477e-06
tumour B-Disease 1 1.0
suppressor O 0 0.4370935559272766
gene O 0 2.631590632518055e-06
PTEN O 0 1.8691294826567173e-05
, O 0 9.902476172385377e-09
which O 0 1.6447364303839862e-10
maps O 0 1.218452894136135e-08
to O 0 1.1297513147212612e-08
10q23 O 0 1.5093336514837574e-05
. O 0 7.379574071819661e-07

3 O 0 6.225518518476747e-07
and O 0 1.6989265105848972e-08
encodes O 0 5.367774669196024e-09
a O 0 2.6087942917030205e-09
403 O 0 3.478125565337109e-09
amino O 0 1.4247868440619982e-09
acid O 0 4.247077356467344e-09
dual O 0 2.4603997417216306e-07
specificity O 0 1.4635492107117898e-06
phosphatase O 0 0.0014292254345491529
( O 0 3.3899507201340384e-08
protein O 0 9.909787657136349e-09
tyrosine O 0 2.342683558254066e-08
phosphatase O 0 1.6596443686012208e-07
; O 0 3.33204824842781e-10
PTPase O 0 3.062729376779316e-07
) O 0 1.1302674768343124e-10
, O 0 4.920136173480749e-11
was O 0 7.827002934668315e-10
shown O 0 2.096608026080915e-10
recently O 0 1.3944599919213374e-09
to O 0 6.187666490298227e-10
play O 0 9.444288906479414e-09
a O 0 5.099691779975046e-09
broad O 0 3.079815069639835e-09
role O 0 6.55444409858319e-09
in O 0 1.4381578594679922e-08
human O 0 6.188085421854339e-08
malignancy B-Disease 0 2.5382752937730402e-05
. O 0 5.100901034893468e-07

Somatic O 0 0.0024655621964484453
PTEN O 0 0.001295296591706574
deletions O 0 4.143076239415677e-06
and O 0 1.1292945245600094e-08
mutations O 0 2.28965846282847e-09
were O 0 1.4402514736389094e-09
observed O 0 3.762075651003727e-10
in O 0 2.5096702493954126e-10
sporadic B-Disease 0 3.968503961004899e-07
breast I-Disease 0 0.25378018617630005
, I-Disease 0 2.931767255631712e-07
brain I-Disease 1 1.0
, I-Disease 0 1.5672816516598687e-05
prostate I-Disease 1 1.0
and I-Disease 1 1.0
kidney I-Disease 1 1.0
cancer I-Disease 1 0.9997920393943787
cell O 0 1.0499700692889746e-05
lines O 0 2.3390535730527517e-08
and O 0 7.265466450689928e-09
in O 0 1.0607284828267893e-08
several O 0 4.317943336218377e-09
primary O 0 1.9379906746053166e-07
tumours B-Disease 1 1.0
such O 0 9.825680535868742e-08
as O 0 1.241490554093616e-05
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 1.0
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9999982118606567
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 0.0008733244612812996

In O 0 1.3722610958666337e-07
addition O 0 3.566902861962262e-08
, O 0 9.579812498827778e-09
PTEN O 0 6.935020792298019e-06
was O 0 1.3485403371760185e-07
identified O 0 1.0947356798851615e-08
as O 0 1.2929849413367833e-09
the O 0 4.926731245191718e-10
susceptibility O 0 1.1349299278151648e-09
gene O 0 3.391007752373554e-10
for O 0 1.931818482958647e-09
two O 0 1.5066827074861067e-07
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 0.9999773502349854
( O 0 2.350599159761657e-10
CD B-Disease 0 1.4035514368515578e-06
; O 0 3.064579701117509e-09
MIM O 0 6.158946234791074e-06
158350 O 0 1.0450922900417936e-06
) O 0 1.0412160023065553e-09
and O 0 1.8454717753968453e-09
Bannayan B-Disease 0 4.152064866502769e-05
- I-Disease 0 3.3650729164946824e-05
Zonana I-Disease 0 0.4677424728870392
( I-Disease 0 2.0799053146447477e-08
BZS I-Disease 0 5.5878525017760694e-05
) I-Disease 0 6.619586656597676e-09
or I-Disease 0 2.951784816573877e-09
Ruvalcaba I-Disease 0 9.388644684804603e-06
- I-Disease 0 1.469452035962604e-05
Riley I-Disease 0 0.00016847737424541265
- I-Disease 1 1.0
Smith I-Disease 1 0.9999550580978394
syndrome I-Disease 1 1.0
( O 0 5.994804297415612e-08
MIM O 0 0.0003631700237747282
153480 O 0 2.2449241441790946e-05
) O 0 2.302447299484811e-08
. O 0 1.2580596830957802e-07

Constitutive O 0 3.2336638469132595e-06
DNA O 0 4.71238649879524e-07
from O 0 1.552470862975497e-08
37 O 0 3.97302493126972e-08
CD B-Disease 0 3.7871950553380884e-06
families O 0 1.1800526111827025e-09
and O 0 2.282882105575368e-09
seven O 0 1.1618201511964799e-08
BZS B-Disease 0 7.803808330208994e-06
families O 0 9.950961166182992e-10
was O 0 1.5204003389612808e-08
screened O 0 7.456230122215857e-08
for O 0 9.31516055402426e-08
germline O 0 0.00015824928414076567
PTEN O 0 0.00029683278989978135
mutations O 0 1.0164857258132542e-06
. O 0 1.5915303492874955e-06

PTEN O 0 0.00027344623231329024
mutations O 0 7.997354600774997e-08
were O 0 6.939887331469663e-09
identified O 0 3.1241946807369914e-09
in O 0 2.4087434824515697e-10
30 O 0 1.983902642166413e-08
of O 0 4.493188932030989e-09
37 O 0 3.867193854034667e-08
( O 0 1.237460689473835e-09
81 O 0 3.437789430904559e-08
% O 0 7.249350564286772e-10
) O 0 8.521622990587119e-11
CD B-Disease 0 3.256635068282776e-07
families O 0 4.720356328036246e-10
, O 0 2.86963980355992e-10
including O 0 8.256199612866055e-10
missense O 0 2.7997430152026936e-07
and O 0 1.4708565032606202e-08
nonsense O 0 1.5807512454557582e-06
point O 0 2.032973327459331e-07
mutations O 0 6.43614672668491e-09
, O 0 2.077834349023533e-09
deletions O 0 2.2755969553145405e-08
, O 0 2.6914062090099833e-09
insertions O 0 6.04802465886678e-08
, O 0 3.651425162232158e-09
a O 0 7.180533945216894e-09
deletion O 0 4.957536816618813e-07
/ O 0 6.039338586560916e-06
insertion O 0 3.5343359172657074e-07
and O 0 2.0749245877027533e-08
splice O 0 5.895074082218343e-06
site O 0 4.293841016078659e-07
mutations O 0 5.6294290118330537e-08
. O 0 2.2011930411736103e-07

These O 0 3.309200025114478e-08
mutations O 0 2.1543604233897895e-08
were O 0 9.054255123430721e-09
scattered O 0 1.5157465282911176e-09
over O 0 2.4023980027543246e-10
the O 0 5.097802180387134e-10
entire O 0 1.5150325438639811e-09
length O 0 1.241290292774977e-09
of O 0 2.0112038701114443e-09
PTEN O 0 1.3424684652818542e-07
, O 0 1.3860165792856094e-10
with O 0 9.203125241052934e-12
the O 0 9.726246891217372e-11
exception O 0 1.9745009793847856e-10
of O 0 6.84885828605708e-11
the O 0 3.922397823208357e-11
first O 0 2.2237288399562516e-10
, O 0 1.9466828149461435e-10
fourth O 0 1.1561940738147314e-08
and O 0 2.765476736499295e-09
last O 0 4.767784744785786e-08
exons O 0 6.322000558611762e-07
. O 0 2.4947544829956314e-07

A O 0 1.5403034922201186e-05
hot O 0 8.345273090526462e-05
spot O 0 2.680593524928554e-06
for O 0 2.0189069971365825e-08
PTEN O 0 6.675505574094132e-06
mutation O 0 9.874204565107902e-09
in O 0 3.448255458948779e-09
CD B-Disease 0 3.53236282535363e-05
was O 0 2.784071284622769e-07
identified O 0 1.9990812560877202e-08
in O 0 2.952015742962999e-09
exon O 0 1.8647730826160114e-07
5 O 0 6.543591979379926e-08
that O 0 2.947755095572546e-10
contains O 0 3.4890870748149894e-10
the O 0 3.99418914609484e-10
PTPase O 0 3.514706747864693e-07
core O 0 3.926415814703432e-08
motif O 0 3.775109558290524e-09
, O 0 7.248945194104905e-11
with O 0 7.253728000200521e-12
13 O 0 3.3511386998696935e-09
of O 0 3.0360947089747015e-09
30 O 0 3.36183809679369e-08
( O 0 7.852617445180954e-10
43 O 0 1.5564110000809706e-08
% O 0 3.1339153494513994e-10
) O 0 2.1589037502156572e-10
CD B-Disease 0 9.478973765908449e-07
mutations O 0 7.3313803916619236e-09
identified O 0 2.2678928957020617e-08
in O 0 5.783416412441511e-09
this O 0 1.0069282296853999e-08
exon O 0 3.101633865298936e-06
. O 0 1.5704388260928681e-06

Seven O 0 6.681759145976685e-08
of O 0 8.70636185368312e-09
30 O 0 2.6785686557673216e-08
( O 0 5.952380255358491e-10
23 O 0 1.1301672486752068e-08
% O 0 3.2672517469301e-10
) O 0 6.487634041096868e-11
were O 0 2.3393278980599064e-10
within O 0 2.5274682347031785e-10
the O 0 1.8350111707921002e-10
core O 0 3.1700722047389718e-09
motif O 0 1.1712334435642902e-09
, O 0 7.656646150433488e-11
the O 0 2.2701410196113159e-10
majority O 0 2.548174518612889e-11
( O 0 6.3809769967893e-11
five O 0 1.3284773281441176e-10
of O 0 1.404528021664575e-10
seven O 0 7.571197141453823e-11
) O 0 3.7841889344303326e-11
of O 0 1.5243623030514186e-10
which O 0 2.8293870718565373e-11
were O 0 1.6828742843699729e-09
missense O 0 1.0788065196720709e-07
mutations O 0 1.3245746721679552e-08
, O 0 3.138953985626358e-09
possibly O 0 2.0913047649173677e-07
pointing O 0 1.2214690059408895e-07
to O 0 4.950867271702464e-09
the O 0 2.974975599201457e-09
functional O 0 8.233967285775634e-09
significance O 0 8.490514069592336e-09
of O 0 1.6664436497393353e-09
this O 0 2.4665472442286784e-10
region O 0 1.8972679427520234e-08
. O 0 1.2206631083699904e-07

Germline O 0 0.07611460983753204
PTEN O 0 0.00021283782552927732
mutations O 0 6.029538468510509e-08
were O 0 5.003220948651688e-09
identified O 0 1.144204397895976e-09
in O 0 3.7515854311998e-10
four O 0 3.678721494093651e-10
of O 0 6.298668808746299e-10
seven O 0 1.2687334516314763e-09
( O 0 5.598969066156201e-10
57 O 0 4.007823051210835e-08
% O 0 3.6281821991224206e-09
) O 0 2.4622286431963403e-09
BZS B-Disease 0 2.755202876869589e-05
families O 0 6.802699292762782e-09
studied O 0 7.780857913530781e-07
. O 0 8.275621325992688e-07

Interestingly O 0 3.8392558963096235e-06
, O 0 3.491354050311202e-08
none O 0 2.96972739732837e-08
of O 0 1.7291030829369447e-09
these O 0 9.139176221362177e-11
mutations O 0 1.0502213543261973e-09
was O 0 1.1021376700171004e-08
observed O 0 7.028982285106622e-09
in O 0 9.967130232269028e-09
the O 0 5.164642402633035e-08
PTPase O 0 2.2355538021656685e-05
core O 0 2.5820202154136496e-06
motif O 0 8.959949013842561e-07
. O 0 3.928064415958943e-07

It O 0 3.669439863074331e-08
is O 0 3.371556922537877e-10
also O 0 7.448160838086082e-11
worthy O 0 2.315671876473857e-09
of O 0 2.652678521286589e-09
note O 0 5.223047772062728e-09
that O 0 5.435166899880883e-11
a O 0 3.9639377891198535e-10
single O 0 4.986443702392762e-09
nonsense O 0 5.215872889152706e-08
point O 0 1.0283697449153806e-08
mutation O 0 6.22885076850821e-10
, O 0 1.2254064429839673e-10
R233X O 0 7.076686614482242e-08
, O 0 5.076185027874658e-10
was O 0 1.7786496719907063e-09
observed O 0 2.938066734348155e-10
in O 0 3.1709293524251336e-10
the O 0 2.5974096207193043e-09
germline O 0 2.2328266879867442e-07
DNA O 0 3.61272256554912e-08
from O 0 4.578995849158218e-09
two O 0 6.61856069950062e-10
unrelated O 0 4.17852197287516e-09
CD B-Disease 0 9.679853974375874e-06
families O 0 1.075522448878985e-09
and O 0 2.1391357574174208e-09
one O 0 1.280322603491868e-08
BZS B-Disease 0 0.0008248030208051205
family O 0 4.7462629026995273e-07
. O 0 4.5946936211294087e-07

Genotype O 0 1.184881057270104e-05
- O 0 3.8014886740711518e-06
phenotype O 0 2.4565773415474723e-08
studies O 0 1.012617545370631e-08
were O 0 9.542968637532567e-10
not O 0 6.488352216615922e-11
performed O 0 4.768107020325374e-10
on O 0 2.4955186805897256e-09
this O 0 2.1584836695787146e-10
small O 0 2.6446092538101595e-10
group O 0 2.0455338811675716e-10
of O 0 6.446762235157166e-09
BZS B-Disease 0 0.00010462015779921785
families O 0 1.686760242591845e-08
. O 0 2.8385923656060186e-07

However O 0 1.238545621617959e-07
, O 0 3.4331484322080996e-09
genotype O 0 8.097953951846648e-08
- O 0 4.139547513659636e-07
phenotype O 0 1.6126831425822274e-08
analysis O 0 8.667226936154293e-09
inthe O 0 9.874374882201664e-07
group O 0 1.539110949799749e-09
of O 0 1.285739958944987e-09
CD B-Disease 0 0.00017700131866149604
families O 0 1.0773415493048333e-09
revealed O 0 9.103776621444126e-10
two O 0 5.128716201729944e-11
possible O 0 8.513699745194003e-10
associations O 0 1.5114902385260365e-10
worthy O 0 1.2489689282801919e-08
of O 0 2.3526558479147752e-08
follow O 0 2.2662757004354717e-08
- O 0 2.391556677139306e-07
up O 0 4.357981087110829e-09
in O 0 1.446484265699155e-09
independent O 0 2.382212871410161e-09
analyses O 0 5.821401671823878e-08
. O 0 2.919981056948018e-07

The O 0 9.364488562368933e-08
first O 0 5.757001986239629e-09
was O 0 5.0006065954733e-09
an O 0 9.025933472850411e-11
association O 0 5.268115457757183e-11
noted O 0 6.017688569670554e-10
in O 0 3.812888893506283e-10
the O 0 1.0084422186196207e-09
group O 0 7.913175670282158e-11
of O 0 5.030499350411333e-10
CD B-Disease 0 0.019036199897527695
families O 0 5.8843041550460384e-09
with O 0 1.0786004089879953e-08
breast B-Disease 1 1.0
disease I-Disease 1 0.9994252920150757
. O 0 4.461311982595362e-05

A O 0 3.477696850495704e-07
correlation O 0 5.339092279399438e-09
was O 0 3.34651417688292e-09
observed O 0 2.5808205572630527e-10
between O 0 1.6029653299165503e-11
the O 0 1.721940506849151e-10
presence O 0 2.8081641456623174e-09
/ O 0 2.9666376576642506e-05
absence O 0 1.0730179837992182e-06
of O 0 6.434590460457912e-08
a O 0 2.3890894595979262e-08
PTEN O 0 3.7842494293727214e-06
mutation O 0 2.972842860771152e-09
and O 0 2.739503901505458e-10
the O 0 1.3503665963199296e-09
type O 0 8.5668105498371e-08
of O 0 2.9386478672677185e-07
breast O 0 0.29139867424964905
involvement O 0 6.51025538900285e-06
( O 0 1.914761504906437e-08
unaffected O 0 4.9898517318069935e-06
versus O 0 0.006752938963472843
benign O 0 0.19119562208652496
versus O 0 2.385345578659326e-05
malignant O 0 2.9502043616957963e-06
) O 0 1.7095787896437287e-08
. O 0 1.0410381889869313e-07

Specifically O 0 5.222637469159963e-07
and O 0 2.071119942215205e-09
more O 0 4.977611031686813e-11
directly O 0 1.0793690247146159e-10
, O 0 5.242165035390656e-11
an O 0 4.956644816811462e-11
association O 0 5.717801232485442e-10
was O 0 7.07374203656741e-09
also O 0 4.928328856124153e-10
observed O 0 2.3603796694970924e-10
between O 0 2.7835459631697645e-11
the O 0 3.7910974359789407e-10
presence O 0 7.412507274651148e-10
of O 0 2.7106428213130584e-09
a O 0 1.5505472461541103e-08
PTEN O 0 0.00033870709012262523
mutation O 0 2.5242970878025517e-06
and O 0 8.56996962284029e-07
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 0.9999988079071045
. O 0 5.256638360151555e-06

Secondly O 0 6.101228336774511e-06
, O 0 5.2685152240883326e-08
there O 0 1.6288468351888241e-09
appeared O 0 1.1383210818394218e-08
to O 0 7.734266005421375e-10
be O 0 1.1178034053926922e-09
an O 0 6.512383410317568e-10
interdependent O 0 2.480751959410554e-07
association O 0 3.777401857973928e-08
between O 0 3.5641538609354484e-09
mutations O 0 5.34489030812324e-09
upstream O 0 2.00812211303969e-09
and O 0 9.986725890698267e-10
within O 0 3.483729082986997e-09
the O 0 8.641806381604056e-09
PTPase O 0 8.633479637865094e-07
core O 0 3.917177693324447e-08
motif O 0 1.9030704123679243e-08
, O 0 6.947115105404578e-10
the O 0 9.416044610688346e-10
core O 0 1.5745442283332522e-08
motif O 0 5.970838490299002e-09
containing O 0 1.0751409762477238e-09
the O 0 1.045571754176855e-10
majority O 0 6.103700878057339e-11
of O 0 2.8922859662827705e-09
missense O 0 2.765020212791569e-07
mutations O 0 1.0488105495198852e-08
, O 0 1.5166313760417438e-09
and O 0 2.914853691748931e-09
the O 0 1.2662711412758654e-07
involvement O 0 0.06197790801525116
of O 0 0.00020341029448900372
all O 0 1.4319964769526905e-08
major O 0 7.13389027851008e-08
organ O 1 0.9996899366378784
systems O 1 0.9999991655349731
( O 0 1.6702159655324067e-07
central O 1 0.9999991655349731
nervous O 1 0.9982518553733826
system O 1 0.9999896287918091
, O 0 3.749354107185354e-07
thyroid O 1 0.9735629558563232
, O 0 3.051734722703259e-07
breast O 1 0.9999997615814209
, O 0 7.737214036751539e-05
skin O 1 1.0
and O 1 0.9977243542671204
gastrointestinal O 1 1.0
tract O 0 2.944250991276931e-05
) O 0 8.802405915275813e-09
. O 0 9.168801540226923e-08

However O 0 2.7170221983396914e-07
, O 0 5.357760901603115e-09
these O 0 1.3922110686515055e-10
observations O 0 3.030309114748775e-09
would O 0 5.586616169672709e-10
need O 0 1.823129758271591e-09
to O 0 8.270984452884989e-10
be O 0 1.0549412454707863e-09
confirmed O 0 1.7065675539384983e-09
by O 0 9.837405889889794e-11
studying O 0 8.78206485310784e-09
a O 0 7.836802318195168e-10
larger O 0 3.04352598679003e-10
number O 0 4.0468406403704194e-10
of O 0 1.0429014318802388e-09
CD B-Disease 0 3.876495156873716e-06
families O 0 7.321570461016336e-09
. O 0 1.8908812648987805e-07

Molecular O 0 0.0003316916699986905
defects O 1 0.9998006224632263
leading O 0 2.716550682180241e-07
to O 0 6.633157356716879e-10
human O 0 2.5749152809950715e-10
complement B-Disease 0 8.553912067554847e-08
component I-Disease 1 1.0
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 8.739904799881515e-09
an O 0 6.112615968945079e-10
African O 0 1.3210398996932327e-08
- O 0 5.948289327761813e-08
American O 0 2.7173687300319216e-08
family O 0 3.105385504298397e-09
. O 0 1.8409936686225592e-08

Complement B-Disease 0 4.5256915655045304e-06
component I-Disease 1 0.9999963045120239
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.1997358662085844e-09
C6D B-Disease 0 7.624784075233038e-07
) O 0 1.6027063010071174e-10
was O 0 2.8087854264668977e-09
diagnosed O 0 1.084731948708395e-08
in O 0 3.437340134748723e-10
a O 0 4.0101968967753976e-10
16 O 0 1.0378492509843795e-09
- O 0 2.0771686592979677e-09
year O 0 2.733845649860456e-10
- O 0 1.2493287293580124e-08
old O 0 3.23715170225114e-08
African O 0 2.9397511980278068e-08
- O 0 1.9933395378757268e-08
American O 0 4.055001667779834e-09
male O 0 9.22964260574588e-10
with O 0 1.6060325291888944e-10
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 9.830008593780803e-07

The O 0 1.399064899487712e-07
patients O 0 3.250280400379779e-08
father O 0 1.827503304241418e-08
and O 0 1.694046014577566e-09
two O 0 2.327703585436325e-09
brothers O 0 3.4853863439821e-07
also O 0 3.0378803472785876e-08
had O 0 2.840638835266418e-08
C6D B-Disease 0 3.7839170545339584e-05
, O 0 2.052812364539136e-09
but O 0 3.4350461364240914e-10
gave O 0 7.086584652427064e-09
no O 0 2.4851734004016635e-09
history O 0 3.2885665302018197e-09
of O 0 7.116044642430097e-09
meningitis B-Disease 1 0.9999994039535522
or O 0 3.212191179713386e-09
other O 0 1.6963709326134335e-09
neisserial B-Disease 0 7.531192295573419e-06
infection I-Disease 0 7.235991006382392e-07
. O 0 3.781908333166939e-07

By O 0 1.5439514555737333e-08
using O 0 7.87109577515821e-09
exon O 0 3.757103073098733e-08
- O 0 2.039952562427061e-08
specific O 0 1.5464970415379753e-09
polymerase O 0 1.0726917132330982e-08
chain O 0 5.851064965867181e-09
reaction O 0 5.679974268701926e-10
( O 0 1.1453588771859202e-10
PCR O 0 1.4016071858691248e-08
) O 0 2.677835730935385e-10
/ O 0 1.0821054274856579e-08
single O 0 2.9360907038977757e-09
- O 0 6.106419814244646e-09
strand O 0 3.3445042291191385e-09
conformation O 0 7.711610794380874e-10
polymorphism O 0 1.4658873004336215e-09
as O 0 3.1929967003740956e-10
a O 0 1.6896339882777056e-10
screening O 0 7.396646628521353e-10
step O 0 2.9238462762037898e-09
and O 0 2.4993854208510413e-10
nucleotide O 0 7.73791086761122e-10
sequencing O 0 3.4573175433649794e-09
of O 0 1.968755602987926e-09
target O 0 1.1433454183418235e-08
exons O 0 9.002559586690495e-09
, O 0 2.1867617439053078e-10
we O 0 7.893428272121028e-11
determined O 0 1.99370644993202e-10
that O 0 5.917477619021838e-11
the O 0 1.1926220011559963e-09
proband O 0 1.1030966788894148e-06
was O 0 4.8835218535714375e-08
a O 0 2.2722952408571473e-09
compound O 0 4.0319363847629575e-08
heterozygote O 0 1.2990447828542528e-07
for O 0 8.518036276328189e-10
two O 0 1.3855361302717029e-09
C6 O 0 6.0675640270346776e-05
gene O 0 1.0085700807849207e-07
mutations O 0 8.222796310519698e-08
. O 0 5.162436877981236e-07

The O 0 1.3949774313459784e-07
first O 0 2.362471995809301e-08
, O 0 7.463381024308546e-10
1195delC O 0 2.003788246440763e-08
located O 0 3.473549226029604e-10
in O 0 1.7781298655705768e-10
exon O 0 4.340024162274858e-08
7 O 0 9.161249892031265e-08
, O 0 1.4381323909518073e-09
is O 0 3.564068484784855e-11
a O 0 2.4889420385809657e-11
novel O 0 3.313129631754563e-11
mutation O 0 3.4913620605703244e-11
, O 0 1.102186484441825e-11
while O 0 3.779175930529455e-11
the O 0 1.5672678432832043e-10
second O 0 1.9348531665741575e-09
, O 0 7.836021415075223e-11
1936delG O 0 3.1036919700966337e-09
in O 0 1.8749619912217241e-10
exon O 0 4.33520916942598e-08
12 O 0 2.7910672883990628e-08
, O 0 7.896564513387716e-10
has O 0 3.553967883873632e-11
been O 0 2.0664104108392145e-11
described O 0 3.85985618467366e-11
before O 0 3.0855754062919516e-10
to O 0 8.270700790902197e-10
cause O 0 4.680329457329435e-09
C6D B-Disease 0 4.3361874304537196e-06
in O 0 3.1226992103228213e-09
an O 0 2.533496468171137e-10
unrelated O 0 2.4391530573097953e-08
African O 0 1.512002967274384e-07
- O 0 1.7415165132206312e-07
American O 0 7.139620805673985e-08
individual O 0 2.6344759707086496e-09
. O 0 4.3810352678974596e-08

Both O 0 1.193822640743747e-07
mutations O 0 8.447836208347326e-09
result O 0 3.104408285992122e-09
in O 0 1.0161445906931021e-08
premature O 0 3.5095385442218685e-07
termination O 0 1.5828345567570068e-07
codons O 0 4.483722761960962e-07
and O 0 1.6517432754881156e-07
C6 O 0 0.0002944370498880744
null O 0 1.6828452089612256e-06
alleles O 0 2.095271440794022e-07
. O 0 5.127531039761379e-07

Allele O 0 5.64002505143435e-07
- O 0 6.518403949939966e-08
specific O 0 2.5403736891860262e-09
PCR O 0 1.6702126970358222e-07
indicated O 0 7.803201640399493e-09
that O 0 2.9055032685354476e-11
the O 0 4.1041137155417573e-10
probands O 0 1.6544973391319218e-07
two O 0 8.13404676947016e-10
brothers O 0 4.6676014164859225e-08
also O 0 1.9654278204939146e-09
inherited O 0 1.730476384409485e-08
the O 0 4.91095342169956e-09
1195delC O 0 3.1981929993207814e-08
mutation O 0 1.947433048155034e-10
from O 0 9.495738223508354e-11
their O 0 3.6213290699471656e-10
heterozygous O 0 2.5905078082644195e-09
mother O 0 1.8909735999272925e-09
and O 0 5.044719642022244e-10
the O 0 1.4776212475808848e-09
1936delG O 0 1.216068490350608e-08
mutation O 0 1.8424531345040407e-10
from O 0 1.1338366356916652e-10
their O 0 3.889775168630649e-10
homozygous O 0 2.1121071114293954e-08
father O 0 7.727859241413171e-08
. O 0 9.33105752665142e-08
. O 0 4.6714535528735723e-07

PAX6 O 0 0.00470559298992157
mutations O 0 5.0387043302180246e-06
reviewed O 0 1.7566922906553373e-05
. O 0 6.931271855137311e-06

Mutations O 0 5.531926035473589e-06
in O 0 1.3192904191328125e-07
PAX6 O 0 0.0002667974040377885
are O 0 1.4566395867277038e-09
responsible O 0 6.035393518288856e-09
for O 0 1.0301184349970072e-09
human O 0 1.5605964520659654e-08
aniridia B-Disease 1 1.0
and O 0 3.899998262113513e-07
have O 0 1.275545091772301e-08
also O 0 1.5224801419577716e-09
been O 0 2.5087273924917497e-10
found O 0 8.67497532142103e-11
in O 0 1.3443217372621774e-10
patients O 0 1.0102075842510772e-09
with O 0 2.7984048411866524e-10
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 6.663673701723383e-08
with O 0 7.480146990701542e-08
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 9.661055173637578e-07
with O 0 6.56010001875984e-08
autosomal B-Disease 1 0.9999974966049194
dominant I-Disease 0 0.18776628375053406
keratitis I-Disease 1 0.9999997615814209
, O 0 3.858027231018468e-09
and O 0 1.4096197542556865e-09
with O 0 7.092980425227324e-09
isolated B-Disease 1 0.9999281167984009
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 1 0.999880313873291

No O 0 1.7749873677530559e-06
locus O 0 1.7200146373852476e-07
other O 0 7.434737270273217e-10
than O 0 3.072842535978282e-10
chromosome O 0 5.334005948043341e-08
11p13 O 0 3.091430926360772e-06
has O 0 1.0262471983324417e-09
been O 0 1.0082076284945174e-09
implicated O 0 2.810280452791858e-09
in O 0 6.360168836039293e-09
aniridia B-Disease 1 1.0
, O 0 2.248364872059483e-08
and O 0 4.179804946602417e-09
PAX6 O 0 0.45049968361854553
is O 0 3.1027271862882344e-09
clearly O 0 1.00564556682059e-09
the O 0 4.3775813529656205e-10
major O 0 5.173157457960542e-09
, O 0 2.9377361654425727e-10
if O 0 9.293780328656354e-11
not O 0 1.3642159624183137e-10
only O 0 1.696946055895765e-10
, O 0 5.711686124065807e-10
gene O 0 1.2733688548038913e-09
responsible O 0 1.6570348293498682e-07
. O 0 2.4056801066763e-06

Twenty O 0 1.3683056749869138e-06
- O 0 7.674025255255401e-07
eight O 0 9.513660081950093e-09
percent O 0 1.6922860890389302e-09
of O 0 7.419254099971795e-10
identified O 0 9.599200545551412e-09
PAX6 O 0 4.418674870976247e-05
mutations O 0 9.007630552559931e-08
are O 0 1.1552677703363656e-09
C O 0 0.001623943797312677
- O 0 0.1424184888601303
T O 0 0.00016523613885510713
changes O 0 1.4514216672978364e-07
at O 0 1.3791094488624367e-07
CpG O 0 3.1600771421835816e-07
dinucleotides O 0 4.449636321623984e-07
, O 0 1.3988795677377652e-09
20 O 0 7.895379461331231e-09
% O 0 2.5475344056502536e-10
are O 0 9.601932964009574e-12
splicing O 0 1.018253659168522e-08
errors O 0 4.0291226355293475e-08
, O 0 1.5485926985192577e-09
and O 0 4.46640807671983e-10
more O 0 1.318880248069032e-11
than O 0 2.3528361550728683e-11
30 O 0 1.1703245039740295e-09
% O 0 1.7645311600755775e-10
are O 0 6.602078606032791e-11
deletion O 0 8.837329978916841e-09
or O 0 2.5884134835507666e-09
insertion O 0 3.878991705619228e-08
events O 0 3.5445228974140264e-08
. O 0 3.474451375495846e-07

There O 0 1.4666271397345554e-07
is O 0 2.946334509701387e-09
a O 0 4.876482773141788e-09
noticeably O 0 2.6376557116236654e-07
elevated O 0 1.0305477360361692e-07
level O 0 1.5966483246643293e-08
of O 0 1.3178329538732214e-09
mutation O 0 4.754630023029449e-10
in O 0 7.112757050009577e-10
the O 0 4.8978661126852785e-09
paired O 0 3.022868177993132e-09
domain O 0 2.4533313158769943e-09
compared O 0 1.6121277923719646e-10
with O 0 4.050496917040736e-12
the O 0 3.4972622020568167e-10
rest O 0 2.5946120807418538e-09
of O 0 2.2760124895881972e-09
the O 0 1.945833938421515e-09
gene O 0 6.412522512988517e-09
. O 0 3.241934507514088e-07

Increased O 0 4.5059704234517994e-07
mutation O 0 1.175829300592568e-08
in O 0 2.1924551063534636e-09
the O 0 2.852196034908161e-09
homeodomain O 0 3.9564494613841816e-07
is O 0 3.0086533264750415e-10
accounted O 0 1.5013484899739638e-09
for O 0 1.460194049007768e-10
by O 0 4.930792441015797e-10
the O 0 3.0689680130535635e-08
hypermutable O 0 5.96591644352884e-06
CpG O 0 4.259599336364772e-06
dinucleotide O 0 1.0939072126348037e-05
in O 0 1.0076798417912869e-07
codon O 0 1.177361923510034e-06
240 O 0 6.284598157435539e-07
. O 0 3.896269333836244e-07

Very O 0 1.5336179615133005e-07
nearly O 0 3.5729272873652462e-09
all O 0 1.313155417737022e-10
mutations O 0 2.4764892914141967e-10
appear O 0 9.622660446240161e-10
to O 0 6.215274406251581e-10
cause O 0 1.892959211602374e-08
loss O 0 9.901645725562958e-09
of O 0 1.5472915393388575e-08
function O 0 1.958321727002499e-09
of O 0 5.8720388551591896e-09
the O 0 8.815457253064096e-10
mutant O 0 1.0517192450265611e-08
allele O 0 2.3731652198932807e-09
, O 0 1.200866212025531e-10
and O 0 2.079332123150479e-10
more O 0 2.7636547564324765e-11
than O 0 2.743926787174278e-11
80 O 0 9.87549930719922e-10
% O 0 2.0030792302616618e-10
of O 0 1.2391423442892346e-09
exonic O 0 1.392174482361952e-07
substitutions O 0 2.6225704274907002e-08
result O 0 1.8535677437370168e-09
in O 0 8.7508462698338e-09
nonsense O 0 8.788936156634009e-07
codons O 0 7.436998430421227e-07
. O 0 6.97894847689895e-07

In O 0 2.9354322350627626e-07
a O 0 3.975837259417858e-08
gene O 0 7.0795596052164456e-09
with O 0 2.480805560978183e-10
such O 0 4.433309719331646e-09
extraordinarily O 0 1.7614804903587356e-07
high O 0 4.665358588340496e-08
sequence O 0 1.6236503808109148e-10
conservation O 0 3.317034202865443e-09
throughout O 0 8.29825819170793e-10
evolution O 0 2.166102186507146e-09
, O 0 2.6566976396580344e-10
there O 0 1.6676574010610068e-10
are O 0 1.9931474526391213e-10
presumed O 0 2.822016824666207e-07
undiscovered O 0 3.030636980838608e-05
missense O 0 2.0756051526404917e-05
mutations O 0 2.2214720729607507e-07
, O 0 4.572136447222874e-09
these O 0 7.711493665851776e-10
are O 0 9.792383570683683e-11
hypothesized O 0 1.953896822115553e-09
to O 0 4.365641181891533e-10
exist O 0 1.856972020597425e-09
in O 0 1.522674653031686e-09
as O 0 4.079687254687769e-09
- O 0 1.2789305969818088e-07
yet O 0 9.108019227710429e-09
unidentified O 0 4.789148277950517e-08
phenotypes O 0 1.611185673766613e-08
. O 0 6.644151451240532e-09
. O 0 8.282390240310633e-08

Genetic O 0 3.281055114712217e-06
heterogeneity O 0 5.070921247352089e-07
and O 0 7.280364755501978e-09
penetrance O 0 2.2625403062193072e-07
analysis O 0 1.5859706437026944e-08
of O 0 1.2596413689891506e-08
the O 0 1.7055532097742798e-08
BRCA1 O 0 3.565903909930057e-07
and O 0 5.999860519523281e-08
BRCA2 O 0 8.628236400909373e-07
genes O 0 1.6974301075833864e-08
in O 0 1.6659080870340404e-07
breast B-Disease 1 0.9999186992645264
cancer I-Disease 0 0.0001190389011753723
families O 0 5.953488013688002e-08
. O 0 7.226481102406979e-07

The O 0 0.0023715123534202576
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 4.136177449254319e-05
Consortium O 0 3.7718371004302753e-07
. O 0 2.8886219638479815e-07

The O 0 5.2335810352133194e-08
contribution O 0 1.2861875120506738e-07
of O 0 5.7839596223629997e-08
BRCA1 O 0 5.763398576164036e-07
and O 0 3.678360371850431e-08
BRCA2 O 1 0.9617559909820557
to O 0 2.1297106286510825e-05
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 1 0.7874429225921631
assessed O 0 1.0070822753505126e-07
by O 0 1.906175439714275e-09
linkage O 0 4.521250929201415e-08
and O 0 1.5097075811709715e-09
mutation O 0 1.807651112128994e-10
analysis O 0 9.135883022315383e-11
in O 0 4.742979620164789e-11
237 O 0 1.3378705088218368e-10
families O 0 5.8354306629870845e-12
, O 0 1.0637050268380577e-11
each O 0 8.156545642894197e-13
with O 0 1.9077220272251116e-12
at O 0 1.9954915497777392e-09
least O 0 2.520333941546937e-10
four O 0 1.7703227772614127e-10
cases O 0 2.5929583480355234e-10
of O 0 3.6255137558782735e-08
breast B-Disease 1 0.9391127824783325
cancer I-Disease 0 2.6346140202804236e-06
, O 0 8.003744333962004e-09
collected O 0 1.2925418069187344e-08
by O 0 7.3521193577619215e-09
the O 0 1.6755438991822302e-05
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 1.857945608207956e-05
Consortium O 0 9.504265108262189e-07
. O 0 8.036711278691655e-07

Families O 0 9.643905229950178e-09
were O 0 2.110769115049038e-09
included O 0 6.158678012013752e-10
without O 0 1.200724741856618e-09
regard O 0 4.703597067390319e-09
to O 0 9.277526524797963e-10
the O 0 1.4312965257445853e-09
occurrence O 0 3.924110387742985e-07
of O 0 3.1857659905654145e-06
ovarian B-Disease 1 1.0
or I-Disease 0 0.0004449576954357326
other I-Disease 0 2.7716253043763572e-06
cancers I-Disease 1 0.9999065399169922
. O 0 1.2668049748754129e-05

Overall O 0 2.492048679414438e-06
, O 0 3.71256625442129e-08
disease O 0 7.652832323401526e-08
was O 0 1.0534377814508389e-08
linked O 0 2.040112079271239e-08
to O 0 1.727168186249628e-09
BRCA1 O 0 1.8058885942195957e-08
in O 0 3.031060735736446e-09
an O 0 1.6822507276081922e-10
estimated O 0 9.316232507661226e-11
52 O 0 6.349184511478256e-10
% O 0 2.4250334379471994e-11
of O 0 2.2368596558353104e-11
families O 0 7.340394785060322e-12
, O 0 3.3026876372632685e-11
to O 0 7.993701811592757e-10
BRCA2 O 0 1.9890668667699174e-08
in O 0 1.3487911898479865e-09
32 O 0 1.1975531677421714e-08
% O 0 3.1770255870533504e-10
of O 0 1.3771439544285613e-10
families O 0 9.78530277639944e-12
, O 0 1.1553106561701387e-11
and O 0 1.9254965677450997e-11
to O 0 1.6322047879935297e-10
neither O 0 1.528762560987218e-09
gene O 0 1.417321537910965e-10
in O 0 1.4997799668847733e-09
16 O 0 2.090779815944188e-08
% O 0 5.120772139655116e-10
( O 0 4.219974023000894e-11
95 O 0 6.427792520469211e-09
% O 0 2.264657350536936e-10
confidence O 0 2.909676499740499e-09
interval O 0 1.0393632621230608e-08
[ O 0 9.824556457260769e-08
CI O 0 1.0023113645729609e-05
] O 0 1.1679529166030989e-07
6 O 0 3.755462429921863e-08
% O 0 9.903907693953329e-10
- O 0 1.904181523570969e-08
28 O 0 7.75688846488265e-09
% O 0 4.997591229738418e-10
) O 0 1.5720878765446145e-10
, O 0 1.8623305675369295e-10
suggesting O 0 3.0575382226061265e-09
other O 0 5.554613435876377e-10
predisposition O 0 1.611782636246062e-07
genes O 0 4.925448848780434e-08
. O 0 9.262149660571595e-07

The O 0 1.2531070581189852e-07
majority O 0 4.837562017634411e-10
( O 0 2.0378000675780328e-10
81 O 0 9.088062746798187e-09
% O 0 1.1514042497218213e-10
) O 0 2.0000279210563576e-11
of O 0 2.849546432148742e-10
the O 0 4.5123602632202164e-08
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.1796413623699209e-08
were O 0 1.5158245769697487e-09
due O 0 2.7936544189088863e-09
to O 0 2.5361470701312783e-09
BRCA1 O 0 8.411418228604362e-09
, O 0 5.507141964677942e-10
with O 0 4.260273037126616e-11
most O 0 9.729368422028983e-10
others O 0 1.326624587960623e-09
( O 0 1.722531839387642e-10
14 O 0 2.6432189770275727e-09
% O 0 2.8232430282493226e-10
) O 0 1.7919904449215096e-10
due O 0 6.855608969402738e-09
to O 0 5.75527074886395e-08
BRCA2 O 0 5.334216439223383e-06
. O 0 2.790163080135244e-06

Conversely O 0 6.192926775838714e-07
, O 0 3.738636511485538e-09
the O 0 9.81383529996549e-10
majority O 0 8.978919691093878e-11
of O 0 4.5188586206279524e-10
families O 0 4.38814574954538e-11
with O 0 1.528093450386958e-11
male B-Disease 0 2.325901693467358e-09
and I-Disease 0 5.350418774696664e-09
female I-Disease 0 7.767090437482693e-07
breast I-Disease 1 0.997184693813324
cancer I-Disease 1 0.9952722191810608
were O 0 0.09851475805044174
due O 1 0.9591152667999268
to O 0 1.3665524420503061e-05
BRCA2 O 0 1.828839344852895e-06
( O 0 6.6141345733683465e-09
76 O 0 2.80857364032272e-07
% O 0 2.9116973276899216e-09
) O 0 2.4358091099685453e-09
. O 0 5.167933636585076e-08

The O 0 2.038412958427216e-07
largest O 0 1.1874610628126447e-08
proportion O 0 1.0183599519208997e-09
( O 0 1.995125453735369e-10
67 O 0 1.60169335572391e-08
% O 0 3.3564145907050147e-10
) O 0 5.648414028169846e-11
of O 0 1.6259064927748312e-10
families O 0 3.318644664629389e-11
due O 0 7.512467870007811e-10
to O 0 6.217930059726484e-10
other O 0 1.1929035537150412e-10
genes O 0 2.6994870228058687e-10
was O 0 3.5124994024471334e-09
found O 0 1.1693690460390371e-10
in O 0 1.2592461795524201e-10
families O 0 2.3068836771389378e-11
with O 0 1.4299144333873581e-11
four O 0 1.771907204295431e-10
or O 0 2.0554913326975566e-10
five O 0 1.540076399741963e-10
cases O 0 4.4206902027887907e-11
of O 0 1.1415907108514034e-09
female O 0 9.335526129916616e-08
breast B-Disease 0 0.00020580792624969035
cancer I-Disease 0 1.0209576430497691e-05
only O 0 3.8727162632312684e-07
. O 0 6.4782361732795835e-06

These O 0 4.6270926645775035e-08
estimates O 0 1.577580377443155e-08
were O 0 2.303939927728038e-09
not O 0 1.9653779992356846e-10
substantially O 0 3.853511731932713e-09
affected O 0 1.5334081227003082e-10
either O 0 1.4652352942068347e-10
by O 0 1.0252840243474282e-10
changing O 0 8.366153991801184e-09
the O 0 2.732200021782205e-09
assumed O 0 1.4899839584359142e-08
penetrance O 0 1.190561249586608e-08
model O 0 3.402210957403895e-09
for O 0 9.356035945984331e-10
BRCA1 O 0 1.2151434525264904e-08
or O 0 7.896640563664903e-10
by O 0 1.479171368723442e-10
including O 0 4.87686113714858e-10
or O 0 2.1520061288526904e-09
excluding O 0 1.5099422512321325e-07
BRCA1 O 0 1.7028982313149754e-07
mutation O 0 8.775032256380655e-09
data O 0 5.8220791743224254e-08
. O 0 1.7612150315926556e-07

Among O 0 4.543988296745738e-08
those O 0 6.186887668846452e-10
families O 0 5.910213984883228e-11
with O 0 1.4509869868117864e-11
disease O 0 3.035654394523135e-09
due O 0 4.6703352296617595e-08
to O 0 4.920706686561971e-08
BRCA1 O 0 2.3413798544424935e-07
that O 0 2.643496088694519e-09
were O 0 1.731315002473366e-08
tested O 0 1.4187611085958451e-09
by O 0 6.286579590231156e-11
one O 0 1.5506372574858318e-10
of O 0 2.925133191222784e-10
the O 0 1.1902875907132682e-10
standard O 0 1.66106162158286e-09
screening O 0 5.885985032705321e-10
methods O 0 9.181835736171706e-09
, O 0 1.4799340641857839e-09
mutations O 0 8.037457366327772e-10
were O 0 5.268874225805575e-09
detected O 0 1.921251424619186e-08
in O 0 2.087475303724773e-09
the O 0 4.880753579072916e-09
coding O 0 5.882522557953962e-08
sequence O 0 9.519554033943223e-10
or O 0 1.8029278070486043e-09
splice O 0 1.547796202316931e-08
sites O 0 7.543784485974925e-10
in O 0 7.161515130915674e-11
an O 0 2.3251274169910907e-11
estimated O 0 5.070918338012653e-11
63 O 0 2.326500547766841e-09
% O 0 4.596862890338116e-10
( O 0 1.6612984599095881e-10
95 O 0 4.794970465127335e-08
% O 0 2.144925126401631e-09
CI O 0 1.9141373286402086e-06
51 O 0 4.2221380169849e-08
% O 0 1.4087382371741342e-09
- O 0 7.2590559341279e-08
77 O 0 2.8592785028536127e-08
% O 0 2.4681390264902348e-09
) O 0 2.318734759754193e-09
. O 0 4.246706808430645e-08

The O 0 1.4178426965827384e-07
estimated O 0 5.496482824440818e-09
sensitivity O 0 2.018976452689003e-08
was O 0 1.3265188947286788e-08
identical O 0 5.608845610183266e-10
for O 0 1.195979149049009e-10
direct O 0 5.691676019381475e-10
sequencing O 0 2.8246611716298275e-09
and O 0 3.4176903529470337e-09
other O 0 2.7285649295549774e-09
techniques O 0 2.034118779192795e-06
. O 0 8.329360525749507e-07

The O 0 7.580397323181387e-07
penetrance O 0 1.541482015454676e-05
of O 0 1.2307397128097364e-06
BRCA2 O 0 3.6151259337202646e-06
was O 0 2.5329821795594398e-08
estimated O 0 1.3925456621155519e-10
by O 0 5.710482000459427e-12
maximizing O 0 3.842627105399288e-09
the O 0 2.16712714440348e-09
LOD O 0 6.170541018946096e-05
score O 0 3.1762539265400846e-07
in O 0 9.040832082973793e-08
BRCA2 O 0 1.5557512824670994e-06
- O 0 9.038450343723525e-07
mutation O 0 1.7642023397712592e-09
families O 0 6.563357496380817e-11
, O 0 6.850230105381883e-11
over O 0 3.1895618091137834e-11
all O 0 2.116553182718306e-10
possible O 0 3.969145012661102e-09
penetrance O 0 2.6912337602880143e-07
functions O 0 1.6920294854116946e-07
. O 0 6.43537646283221e-07

The O 0 3.792692382376117e-08
estimated O 0 5.445162098993706e-10
cumulative O 0 4.820818855222342e-09
risk O 0 1.8862664319385658e-08
of O 0 9.167909809093544e-08
breast B-Disease 1 0.9906802773475647
cancer I-Disease 0 2.6724950657808222e-05
reached O 0 9.192052630169201e-07
28 O 0 1.5904606698313728e-07
% O 0 7.652066202901153e-10
( O 0 5.335686406593432e-11
95 O 0 6.57790177882589e-09
% O 0 2.779107222128374e-10
CI O 0 1.8299874682270456e-07
9 O 0 1.1430052460070783e-08
% O 0 4.689459931483952e-10
- O 0 5.924496893072728e-09
44 O 0 6.437224087108007e-10
% O 0 2.6763381441585743e-11
) O 0 2.6359196943215313e-12
by O 0 3.5503613937670764e-12
age O 0 5.823025395201853e-11
50 O 0 2.1775341252361358e-10
years O 0 2.255762764080682e-11
and O 0 1.3404553855789203e-10
84 O 0 1.2050410447272952e-08
% O 0 3.5750591376171315e-10
( O 0 1.5455173252298948e-10
95 O 0 2.207431926137815e-08
% O 0 1.1436545044318791e-09
CI O 0 7.215105028990365e-07
43 O 0 1.8605962992523928e-08
% O 0 2.0631152342076575e-10
- O 0 6.433115817827684e-09
95 O 0 9.647473930840533e-09
% O 0 8.569331355623433e-11
) O 0 1.1938453697846185e-11
by O 0 1.0822524300346803e-11
age O 0 5.43344924608391e-10
70 O 0 6.819717679462656e-09
years O 0 2.2639241592514736e-09
. O 0 4.167802103438589e-08

The O 0 1.638973458284454e-06
corresponding O 1 0.9407142996788025
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 8.620780135970563e-06
were O 0 7.844391802791506e-08
0 O 0 3.346088988109841e-07
. O 0 1.4438394657645404e-07

4 O 0 1.86811382718588e-06
% O 0 1.6648845857503147e-08
( O 0 4.6176190648949955e-10
95 O 0 4.391175068008124e-08
% O 0 1.4638030787494927e-09
CI O 0 7.387417895188264e-07
0 O 0 9.102635090130207e-09
% O 0 1.1042596004262606e-10
- O 0 1.7217115511058978e-09
1 O 0 2.039869828607266e-09
% O 0 6.128828694551558e-11
) O 0 5.4126841897428335e-12
by O 0 2.5665819296250003e-12
age O 0 6.333832069937984e-11
50 O 0 2.0885217166810577e-10
years O 0 1.5817269369278186e-11
and O 0 5.437769678984239e-11
27 O 0 4.681079079915662e-09
% O 0 1.9139087537034527e-10
( O 0 6.367067983958918e-11
95 O 0 1.082842526756167e-08
% O 0 3.729276609742982e-10
CI O 0 2.766217619409872e-07
0 O 0 4.3659595938549955e-09
% O 0 2.3774726631842213e-10
- O 0 6.184365908268319e-09
47 O 0 2.61338617413287e-09
% O 0 5.918165957297106e-11
) O 0 8.163802099614426e-12
by O 0 6.7097915765201854e-12
age O 0 3.498736855789275e-10
70 O 0 7.015508174390561e-09
years O 0 3.3167875113093714e-09
. O 0 6.406497732314165e-08

The O 0 4.515287699291548e-08
lifetime O 0 1.2464171561532567e-07
risk O 0 1.5130066799429187e-07
of O 0 3.177014207267348e-07
breast B-Disease 1 0.9999935626983643
cancer I-Disease 0 0.04236007109284401
appears O 0 1.3891355621353796e-08
similar O 0 1.9685368612964993e-10
to O 0 1.3189973557814483e-09
the O 0 1.4207441445535096e-08
risk O 0 2.1935568383923965e-07
in O 0 1.958614070929343e-08
BRCA1 O 0 2.9594870554205954e-08
carriers O 0 2.009739041852754e-09
, O 0 5.388873236533698e-10
but O 0 1.6869966534827086e-10
there O 0 2.1333650124244485e-10
was O 0 3.86018417231071e-09
some O 0 6.529195240023711e-11
suggestion O 0 2.3934711990136748e-09
of O 0 1.1957288492681073e-09
a O 0 6.999198443047305e-10
lower O 0 3.2283080653172647e-09
risk O 0 1.1792387510922708e-08
in O 0 4.260651387255621e-09
BRCA2 O 0 1.3874969795324432e-07
carriers O 0 1.1814697664647156e-08
< O 0 4.799985049430688e-07
50 O 0 3.333786935399985e-08
years O 0 8.445302235315921e-10
of O 0 1.3786295438578122e-09
age O 0 1.630774981720151e-08
. O 0 7.984855443510241e-08

Eye B-Disease 1 0.9999992847442627
movement I-Disease 0 0.00011064303544117138
abnormalities I-Disease 0 4.6378943807212636e-05
correlate O 0 8.31399731282545e-08
with O 0 3.385224045526769e-10
genotype O 0 8.914955174077477e-07
in O 0 5.662726039190602e-07
autosomal O 1 0.9312925934791565
dominant O 0 0.0014629797078669071
cerebellar B-Disease 1 0.9999970197677612
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 1.0
. O 0 7.335221744142473e-05

We O 0 1.315791450906545e-06
compared O 0 1.310952484345762e-07
horizontal O 0 2.3214679458760656e-06
eye O 0 0.2828620970249176
movements O 0 4.788933892996283e-06
( O 0 1.1189984938653197e-08
visually O 0 4.5190954978124864e-08
guided O 0 1.4411778010980925e-06
saccades O 0 2.29885245062178e-05
, O 0 1.0992342147631007e-08
antisaccades O 0 2.064720092675998e-07
, O 0 4.387369634262228e-10
and O 0 2.1805141026121078e-10
smooth O 0 5.179387585485529e-09
pursuit O 0 5.1756476437958554e-08
) O 0 1.5103460149212822e-10
in O 0 2.2642297758945773e-10
control O 0 4.107578988055138e-08
subjects O 0 1.071771293936763e-06
( O 0 3.4952549188282944e-10
n O 0 3.3263984899889465e-09
= O 0 2.2919317999026134e-08
14 O 0 6.229685212133518e-09
) O 0 2.6546712050823373e-10
and O 0 1.430951884762166e-10
patients O 0 7.980737182222697e-10
with O 0 1.3057493454537994e-11
three O 0 1.1438480718162225e-10
forms O 0 1.3855043778931986e-09
of O 0 5.492806920415205e-08
autosomal O 0 4.74155740448623e-06
dominant O 0 1.3635224149766145e-06
cerebellar B-Disease 0 4.687753607868217e-05
ataxias I-Disease 0 7.157446816563606e-05
type I-Disease 0 1.2725369742838666e-05
I I-Disease 0 1.6388361473218538e-05
spinocerebellar B-Disease 0 0.00046989493421278894
ataxias I-Disease 0 7.867458407417871e-06
1 I-Disease 0 9.380737964193031e-08
and I-Disease 0 3.8364316168326695e-09
2 I-Disease 0 4.051671709248694e-08
( O 0 5.671108582738782e-10
SCA1 B-Disease 0 1.97060285245243e-06
, O 0 6.073486158442165e-10
n O 0 8.475123380868865e-10
= O 0 4.1675853879041824e-09
11 O 0 1.8555451619661767e-09
; O 0 1.3199101533967195e-10
SCA2 B-Disease 0 5.952902597528009e-07
, O 0 6.297528054588497e-10
n O 0 1.2583344366490223e-09
= O 0 9.651560439749574e-09
10 O 0 2.6946935793858984e-09
) O 0 3.1193403415841203e-10
and O 0 1.894525869516883e-09
SCA3 B-Disease 1 1.0
/ O 0 0.0003873177047353238
Machado B-Disease 0 1.5289492694137152e-06
- I-Disease 0 9.001478247228079e-06
Joseph I-Disease 0 8.217109098040964e-06
disease I-Disease 0 0.012998202815651894
( O 0 1.4155498995194193e-09
MJD B-Disease 1 1.0
) O 0 1.7840418031767058e-09
( O 0 2.3398322168688424e-10
n O 0 4.491603977641034e-09
= O 0 2.5951232274223912e-08
16 O 0 2.723907144286386e-08
) O 0 5.86575854555349e-09
. O 0 7.735808082998119e-08

In O 0 6.806439500905981e-07
SCA1 B-Disease 0 6.26568726147525e-05
, O 0 1.2713818442477987e-08
saccade O 0 8.08555171261105e-07
amplitude O 0 3.213687804759502e-08
was O 0 1.5665072794490698e-08
significantly O 0 5.123519830618761e-09
increased O 0 9.60164947549913e-10
, O 0 1.163417834293412e-10
resulting O 0 2.845939872653247e-10
in O 0 1.3718202129808788e-09
hypermetria B-Disease 0 2.2972792521613883e-06
. O 0 3.020495853434113e-07

The O 0 1.3030391983193113e-06
smooth O 0 3.029079607586027e-06
pursuit O 0 9.671005500422325e-06
gain O 0 2.662184442669968e-06
was O 0 1.4128781344879826e-07
decreased O 0 1.2232888479957182e-07
. O 0 1.0280328410772199e-07

In O 0 1.641772087168647e-06
SCA2 B-Disease 0 9.901119483401999e-05
, O 0 2.993590442201821e-08
saccade O 0 4.578955667966511e-06
velocity O 0 3.070678644689906e-07
was O 0 1.6312486650349456e-07
markedly O 0 4.770349733007606e-07
decreased O 0 6.052099479347817e-07
. O 0 1.7106265204347437e-07

The O 0 8.338167845067801e-08
percentage O 0 1.0862707000569571e-07
of O 0 7.97576493738461e-09
errors O 0 3.873196305903548e-07
in O 0 1.4504523804248493e-08
antisaccades O 0 1.6806394341983832e-05
was O 0 6.99561439887475e-08
greatly O 0 3.833654105278583e-08
increased O 0 4.453429180983903e-09
and O 0 4.659670982398723e-10
was O 0 3.5439662315894793e-09
significantly O 0 6.692785770034959e-10
correlated O 0 2.0752877194496477e-09
with O 0 5.2756368718043234e-11
age O 0 1.951126904486955e-08
at O 0 6.73162148245865e-08
disease O 0 4.718578949791663e-08
onset O 0 8.704056426722673e-07
. O 0 3.4210353305752506e-07

In O 0 2.026360412799022e-08
addition O 0 1.8745589525082096e-09
, O 0 1.5210978310253864e-10
a O 0 5.987699225329379e-11
correlation O 0 4.232557360150935e-11
between O 0 2.3886071939815956e-11
smooth O 0 1.975855390412562e-08
pursuit O 0 3.2293971230501484e-07
gain O 0 3.8818782854832534e-08
and O 0 2.0084045537771544e-10
the O 0 2.945366450735065e-10
number O 0 2.1060549137974505e-10
of O 0 1.5658730978529434e-09
trinucleotide O 0 8.829884450278769e-07
repeats O 0 2.4465336423418194e-08
was O 0 1.2183255648778868e-07
found O 0 1.9193834077668726e-08
. O 0 2.6467878910807485e-07

In O 0 2.222172270194278e-06
SCA3 B-Disease 1 1.0
, O 0 3.1412500334226934e-07
gaze B-Disease 0 2.7428892281022854e-05
- I-Disease 0 1.1279004866082687e-05
evoked I-Disease 0 4.4322129610918637e-07
nystagmus I-Disease 0 1.0321847184968647e-05
was O 0 1.3482183369717404e-08
often O 0 7.833914072996606e-11
present O 0 5.129645666568372e-11
as O 0 5.051083995510908e-10
was O 0 7.3210677520307854e-09
saccade O 0 7.651182158951997e-07
hypometria O 0 1.1406431212890311e-06
and O 0 1.1123359122677812e-08
smooth O 0 8.78905382251105e-07
pursuit O 0 1.385879295412451e-05
gain O 0 4.584863290801877e-06
was O 0 2.4937673970271135e-07
markedly O 0 1.7374058813857118e-07
decreased O 0 1.7005872621211893e-07
. O 0 1.0154417395824566e-07

Three O 0 7.278785574271751e-08
major O 0 1.4353433996916465e-08
criteria O 0 2.4305149892711597e-08
, O 0 1.3746698224181841e-09
saccade O 0 7.211005481622124e-07
amplitude O 0 1.611769739895408e-08
, O 0 7.256792944332346e-10
saccade O 0 2.2229089324810047e-07
velocity O 0 2.8688544873034516e-08
, O 0 1.0313530030003903e-09
and O 0 6.808861807705568e-10
presence O 0 4.904774808522916e-09
of O 0 4.26950421683614e-08
gaze B-Disease 0 4.918018476018915e-06
- I-Disease 0 4.331202944740653e-06
evoked I-Disease 0 1.844303341158593e-07
nystagmus I-Disease 0 8.845393040246563e-07
, O 0 2.901356932483168e-10
permitted O 0 1.602575627757119e-09
the O 0 1.3049558655886528e-10
correct O 0 1.8386907552070397e-09
assignment O 0 4.175366719039175e-09
of O 0 8.450636301837733e-10
90 O 0 3.036430440417348e-09
% O 0 7.465284640462144e-11
of O 0 6.067624874761535e-11
the O 0 6.318110618019901e-11
SCA1 B-Disease 0 2.956091691430629e-07
, O 0 2.0862087057871292e-10
90 O 0 2.0859509675119625e-09
% O 0 9.295872405168382e-11
of O 0 2.23660479026222e-10
the O 0 2.03290079214824e-10
SCA2 B-Disease 0 4.311781651722413e-07
, O 0 2.6153046395194224e-10
and O 0 2.3222035405723318e-10
93 O 0 1.8814837687841646e-08
% O 0 1.886894251956761e-10
of O 0 2.0640794629045445e-10
the O 0 8.06155836530209e-11
patients O 0 5.585443774158705e-10
with O 0 2.567769608052828e-10
SCA3 B-Disease 1 1.0
to O 0 2.2674133504096972e-07
their O 0 2.490298989243911e-08
genetically O 0 1.0268021810588834e-07
confirmed O 0 2.5583565488318527e-08
patient O 0 1.6711592820684018e-07
group O 0 6.225489013189645e-10
and O 0 5.312333906104527e-10
, O 0 5.19787157760021e-10
therefore O 0 1.4112635504659465e-09
, O 0 5.538353109457717e-10
may O 0 6.742888913890965e-09
help O 0 4.319988633483263e-08
orient O 0 5.225200766290072e-06
diagnoses O 0 0.00020931591279804707
of O 0 2.406558508027956e-07
SCA1 B-Disease 0 0.0006347455200739205
, O 0 6.673082975083844e-09
SCA2 B-Disease 0 1.9456349036772735e-05
, O 0 1.7233050542131423e-09
and O 0 2.8518858385950807e-09
SCA3 B-Disease 1 1.0
at O 0 6.748899750164128e-08
early O 0 5.617180320882653e-08
clinical O 0 1.1857093973333122e-08
stages O 0 3.538535686686828e-09
of O 0 6.057189416708297e-09
the O 0 3.368042733598031e-09
diseases O 0 7.932015932965442e-08
. O 0 7.484939779089927e-09
. O 0 1.4640417589362187e-07

Genetic O 0 7.679106488467369e-07
basis O 0 4.473617210010161e-08
and O 0 4.598090241891839e-10
molecular O 0 3.604619713826196e-09
mechanism O 0 1.862617153847168e-07
for O 0 2.2424937640153075e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 1 0.9999967813491821

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 1.0
causes O 0 3.036593852812075e-06
more O 0 1.2892950596032904e-10
than O 0 2.6957087603807217e-11
300 O 0 3.5156477729003655e-10
, O 0 5.1008253176831886e-11
000 O 0 2.7176175976251216e-08
sudden O 0 3.348678667691729e-09
deaths O 0 2.5396848513103976e-10
each O 0 1.0714059847649615e-11
year O 0 1.2063068599577065e-10
in O 0 8.525138928128229e-10
the O 0 2.389285391757312e-08
USA O 0 1.9301455722597893e-06
alone O 0 1.0485829449180528e-07
. O 0 2.0434990233297867e-07

In O 0 5.895698862445897e-08
approximately O 0 7.632824372549862e-10
5 O 0 4.991582258639937e-09
- O 0 1.0348219348088605e-07
12 O 0 1.7590892298358085e-08
% O 0 8.147229002553047e-10
of O 0 3.026974504383162e-10
these O 0 9.041711823698506e-12
cases O 0 8.653025344862453e-12
, O 0 2.2986439141003956e-11
there O 0 2.5145418733329983e-11
are O 0 8.142346519246502e-11
no O 0 5.0637614101844974e-09
demonstrable O 0 0.0002405960694886744
cardiac O 1 1.0
or O 0 6.660001190539333e-07
non O 1 1.0
- O 1 0.9999998807907104
cardiac O 1 1.0
causes O 0 1.7940070051736257e-07
to O 0 2.4750537730433564e-10
account O 0 2.3872512300293636e-10
for O 0 9.128183625639608e-11
the O 0 1.985499098466903e-09
episode O 0 3.16353840901229e-08
, O 0 5.692153415282064e-10
which O 0 3.235411938362631e-11
is O 0 1.495849559669804e-12
therefore O 0 2.795464033866768e-11
classified O 0 1.0628786739630414e-09
as O 0 1.8976949789362152e-08
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 2.41277462009748e-07
IVF B-Disease 1 1.0
) O 0 1.637557467404349e-08
. O 0 7.608790042468172e-08

A O 0 1.6653885950290714e-06
distinct O 0 1.2624483680667709e-08
group O 0 5.4128572735123726e-09
of O 0 6.713527067603309e-09
IVF B-Disease 1 1.0
patients O 0 6.820007001806516e-06
has O 0 1.7048651379525381e-10
been O 0 9.232613978893411e-11
found O 0 6.062234048087589e-11
to O 0 1.4555724681120097e-10
present O 0 2.7036298200222575e-10
with O 0 2.425002421091449e-10
a O 0 2.1536621375162213e-08
characteristic O 0 4.7675843717343014e-08
electrocardiographic O 0 2.8790286705770995e-06
pattern O 0 6.737697333392134e-08
. O 0 5.53670020053687e-07

Because O 0 1.542318557312683e-07
of O 0 2.3476083299556194e-08
the O 0 2.2202968352758035e-09
small O 0 2.3097819490391913e-10
size O 0 5.359976351648754e-10
of O 0 1.392395088117837e-09
most O 0 1.5669419928254769e-10
pedigrees O 0 9.422516988877305e-09
and O 0 4.1408967921263695e-10
the O 0 1.911082847527723e-09
high O 0 1.8309469496102793e-08
incidence O 0 1.5663609076455032e-08
of O 0 1.4861344377337105e-09
sudden B-Disease 0 1.642148994562831e-08
death I-Disease 0 3.937387660357672e-08
, O 0 1.2712866315212068e-09
however O 0 1.444730779454062e-09
, O 0 4.635090922189278e-10
molecular O 0 2.1958532769872363e-09
genetic O 0 1.4112743196292854e-09
studies O 0 4.664572728074745e-09
of O 0 2.509553098661854e-08
IVF B-Disease 1 1.0
have O 0 1.103702729210454e-08
not O 0 1.0914680270701638e-09
yet O 0 2.7991480244793365e-09
been O 0 4.031157629924564e-09
done O 0 5.6126502556708147e-08
. O 0 6.051822083463776e-07

Because O 0 8.412881129515881e-07
IVF B-Disease 1 1.0
causes O 0 1.6120782674988732e-05
cardiac O 1 1.0
rhythm O 1 0.9999955892562866
disturbance O 0 0.0021563610062003136
, O 0 4.061317948611531e-09
we O 0 2.454655811945372e-09
investigated O 0 1.0671674210982474e-08
whether O 0 8.029432230216571e-09
malfunction O 0 2.096537355100736e-05
of O 0 2.3440691165887984e-08
ion O 0 1.6004787539714016e-07
channels O 0 7.75207027459146e-08
could O 0 2.868962400981445e-09
cause O 0 5.668418623372418e-09
the O 0 1.803275084810707e-09
disorder O 0 6.027868870717157e-09
by O 0 2.407194409081992e-11
studying O 0 1.1912125730262346e-09
mutations O 0 6.125708273962971e-11
in O 0 3.5130198750010777e-10
the O 0 4.421605304116838e-09
cardiac O 0 0.0024620182812213898
sodium O 0 4.2662750274757855e-06
channel O 0 4.214398074964265e-07
gene O 0 5.659325452711528e-08
SCN5A O 0 6.97000723448582e-05
. O 0 3.377209623067756e-06

We O 0 1.0150893103855196e-07
have O 0 7.299925663950546e-10
now O 0 2.967051881963556e-10
identified O 0 1.4013230575926627e-09
a O 0 1.4397570913260438e-09
missense O 0 2.339951095109427e-07
mutation O 0 6.538935615196806e-09
, O 0 9.983640580912834e-10
a O 0 1.6491382703875956e-09
splice O 0 5.1345285356774184e-08
- O 0 3.9052117983828794e-08
donor O 0 7.243397437406429e-09
mutation O 0 4.207679482615134e-10
, O 0 5.535826311242609e-11
and O 0 1.0013003620690242e-10
a O 0 6.227544036008226e-10
frameshift O 0 1.9947583140833558e-08
mutation O 0 2.470657844977353e-10
in O 0 4.1297440467324975e-10
the O 0 2.231632878491041e-09
coding O 0 3.0563393238480785e-07
region O 0 3.221445155077163e-08
of O 0 1.040589037160089e-08
SCN5A O 0 2.896543946917518e-06
in O 0 3.0280444818231445e-09
three O 0 4.766345540474504e-09
IVF B-Disease 1 1.0
families O 0 1.883304179273182e-08
. O 0 9.798748834555226e-08

We O 0 8.664603257102499e-08
show O 0 6.878464464676881e-09
that O 0 5.4176031716313133e-11
sodium O 0 1.6965456817175095e-09
channels O 0 7.064057117034395e-10
with O 0 4.013354926168944e-11
the O 0 2.7585806972041382e-09
missense O 0 3.0526049954460177e-07
mutation O 0 1.532649385183049e-08
recover O 0 6.300165011907666e-08
from O 0 1.704274388281135e-09
inactivation O 0 1.6200736752125522e-07
more O 0 1.598816495862465e-10
rapidly O 0 3.6186914575964124e-10
than O 0 7.0543692415325765e-12
normal O 0 8.270696627565854e-11
and O 0 5.304817696227815e-11
that O 0 3.396916428699548e-11
the O 0 5.890904430927435e-10
frameshift O 0 1.9811295715044253e-07
mutation O 0 3.580042262640859e-09
causes O 0 8.913708104962836e-10
the O 0 1.0487180013285524e-09
sodium O 0 4.0919552191098774e-08
channel O 0 1.0738258282572133e-08
to O 0 8.313768007361944e-10
be O 0 1.0812218897982007e-09
non O 0 5.011747816752177e-07
- O 0 5.757333951805776e-07
functional O 0 5.500732527252694e-07
. O 0 5.034084438193531e-07

Our O 0 6.328636459329573e-07
results O 0 4.502276240714309e-08
indicate O 0 2.011504207644066e-08
that O 0 1.2273385086025712e-10
mutations O 0 1.0896707980379006e-09
in O 0 9.51677625593561e-10
cardiac O 0 5.456372036860557e-06
ion O 0 1.1066391607528203e-06
- O 0 0.15150193870067596
channel O 0 9.002509386846214e-07
genes O 0 1.2012013606010896e-09
contribute O 0 2.7460131946099864e-09
to O 0 1.0263490057837998e-09
the O 0 1.5561548716291895e-09
risk O 0 5.998599394985149e-09
of O 0 2.3417441319395493e-09
developing O 0 4.4658506226369354e-08
IVF B-Disease 1 1.0
. O 0 1.7491716164386162e-07
. O 0 4.2430229996170965e-07

Molecular O 0 1.209585320793849e-06
heterogeneity O 0 6.732276460752473e-07
in O 0 2.919840902393389e-08
mucopolysaccharidosis B-Disease 0 2.780192698992323e-05
IVA I-Disease 0 0.017857307568192482
in O 0 3.1096490715754044e-07
Australia O 0 5.194993235591028e-08
and O 0 5.614582132551504e-10
Northern O 0 1.0519761062255384e-08
Ireland O 0 4.451195856347567e-09
: O 0 7.176915173268128e-10
nine O 0 6.499824567463008e-10
novel O 0 8.355720004793454e-10
mutations O 0 7.128211909623872e-10
including O 0 9.518736909797099e-10
T312S O 0 2.0140589640504913e-06
, O 0 3.208113108499333e-09
a O 0 5.1262469824564505e-09
common O 0 4.974664236101489e-09
allele O 0 5.8212319409278734e-09
that O 0 7.431968929161314e-11
confers O 0 5.380282530609293e-08
a O 0 5.519577328527703e-08
mild O 0 4.793297421201714e-07
phenotype O 0 3.070590821607766e-07
. O 0 4.314693740070652e-07

Mucopolysaccharidosis B-Disease 0 0.05247887969017029
IVA I-Disease 1 0.9999990463256836
( O 0 1.3506924915418494e-05
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 8.18736509700102e-08
is O 0 2.9478970375862446e-09
an O 0 2.0100918707299797e-09
autosomal B-Disease 1 0.9964522123336792
recessive I-Disease 1 0.9999727010726929
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 5.31426458394435e-08
by O 0 1.5093296057422378e-10
a O 0 1.0499118019424714e-07
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 8.60202760577522e-07
N O 0 1.4912367873876065e-07
- O 0 1.308358292817502e-07
acetylgalactosamine O 0 4.453661404113518e-07
- O 0 1.415220822309493e-06
6 O 0 3.566186478565214e-06
- O 0 2.77677972917445e-05
sulfate O 0 1.4633147884524078e-06
sulfatase O 0 2.1603393179248087e-05
( O 0 4.076226023386198e-09
GALNS O 0 8.014004379219841e-06
) O 0 8.067164714020691e-09
. O 0 5.9217210690576394e-08

Previous O 0 5.969485528112273e-08
studies O 0 8.367494253036512e-09
of O 0 7.353560538270187e-10
patients O 0 7.185622930006019e-11
from O 0 5.893160265335595e-11
a O 0 2.0914317500064783e-10
British O 0 3.198119813418998e-08
- O 0 2.7090996468359663e-07
Irish O 0 1.5386010687734597e-08
population O 0 4.642706358248816e-11
showed O 0 8.901453185661268e-11
that O 0 3.582140443644799e-12
the O 0 2.4734822523519995e-10
I113F O 0 4.59743745295782e-07
mutation O 0 3.6940512870842213e-09
is O 0 1.2950475414275076e-10
the O 0 5.253227852719533e-10
most O 0 1.8361735742988827e-10
common O 0 3.088684308316658e-10
single O 0 7.434329596378575e-09
mutation O 0 8.345084623329058e-09
among O 0 2.953502553637577e-09
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 4.237218490743544e-06
and O 0 2.413172994764068e-09
produces O 0 4.2338513250861354e-10
a O 0 1.3740328874689567e-09
severe O 0 2.524994080488341e-08
clinical O 0 1.7257488593713788e-07
phenotype O 0 7.324381101625477e-08
. O 0 4.550423682303517e-07

We O 0 3.328510729261325e-07
studied O 0 3.157236676543107e-07
mutations O 0 2.7280199432766494e-08
in O 0 5.6267848158597644e-09
the O 0 5.075509790231081e-09
GALNS O 0 5.014046109863557e-06
gene O 0 2.5814865800555253e-09
from O 0 7.144382307977537e-10
23 O 0 2.7313049599797523e-08
additional O 0 2.3357996781214752e-07
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 1.11488143375027e-05
( O 0 3.203965426301636e-10
15 O 0 1.6165595528860877e-09
from O 0 2.680385358111437e-10
Australia O 0 1.0104407310862484e-09
, O 0 6.811157193808981e-11
8 O 0 1.1362164542561004e-09
from O 0 2.496474416080474e-10
Northern O 0 3.0188176403100897e-09
Ireland O 0 3.8574015093217895e-09
) O 0 2.816289146334583e-10
, O 0 1.6483700515657063e-10
with O 0 1.3705842884237374e-11
various O 0 9.99598737116969e-10
clinical O 0 2.1896693169765058e-07
phenotypes O 0 9.055464715856942e-07
( O 0 3.3709026681094656e-09
severe O 0 4.414967236243683e-07
, O 0 2.6469271219298207e-09
16 O 0 8.361144665514075e-09
cases O 0 1.4308727813716615e-10
; O 0 4.276221737820052e-11
intermediate O 0 3.935193060300435e-09
, O 0 1.39516703745457e-10
4 O 0 2.248479624711308e-09
cases O 0 9.572533044011067e-11
; O 0 3.143350024714664e-10
mild O 0 1.3278200761135395e-08
, O 0 4.969749056726869e-10
3 O 0 5.956994897360346e-09
cases O 0 9.956845348213506e-10
) O 0 2.525580411472106e-09
. O 0 7.104830501702963e-08

We O 0 1.0396505558674107e-06
found O 0 3.34951728575561e-08
two O 0 8.981289045806307e-10
common O 0 7.568602411467396e-10
mutations O 0 8.12398426308647e-10
that O 0 1.4465794014040245e-11
together O 0 1.602219572294228e-11
accounted O 0 1.0115881465821985e-09
for O 0 6.595033408274276e-10
32 O 0 2.93374107229738e-08
% O 0 6.191704371438789e-10
of O 0 2.4743420645734204e-09
the O 0 1.3137222421022443e-09
44 O 0 1.14215321644906e-08
unrelated O 0 6.416804421149891e-09
alleles O 0 9.555026769803021e-10
in O 0 1.8066937945704353e-09
these O 0 1.8579887628433767e-09
patients O 0 3.016574368075453e-08
. O 0 1.1293015234059567e-07

One O 0 9.979955706285182e-08
is O 0 1.2217242773004955e-09
the O 0 2.3860462494695867e-09
T312S O 0 2.0434144971659407e-06
mutation O 0 1.9381081628466745e-08
, O 0 8.57628468242666e-10
a O 0 9.590593874619913e-10
novel O 0 5.252468682215294e-09
mutation O 0 7.180602334955211e-09
found O 0 2.931489495594519e-10
exclusively O 0 1.7333561252996788e-09
in O 0 1.0657207338837793e-09
milder O 0 3.819262133220036e-07
patients O 0 9.357524533015749e-08
. O 0 4.170172758222179e-07

The O 0 1.9456942368378805e-07
other O 0 1.3392805753298376e-09
is O 0 7.148604624918065e-11
the O 0 1.532302895679294e-10
previously O 0 2.8461204504282023e-09
described O 0 2.5207100851076802e-09
I113F O 0 2.1914136993927968e-07
that O 0 8.942857565585882e-11
produces O 0 1.8211059049644263e-10
a O 0 2.9938627132963802e-09
severe O 0 1.5212479809179058e-07
phenotype O 0 5.516050691767305e-07
. O 0 2.198596803282271e-06

The O 0 1.1593330100367893e-06
I113F O 0 2.8734806619468145e-05
and O 0 4.3677690797494506e-08
T312S O 0 2.910433067881968e-06
mutations O 0 3.2455826914912222e-09
accounted O 0 3.1991307380963008e-09
for O 0 4.35164126955101e-10
8 O 0 5.031377270370285e-08
( O 0 5.652059931193776e-10
18 O 0 2.514227936956104e-09
% O 0 4.8618692405355546e-11
) O 0 8.422757283299553e-12
and O 0 3.725378686092462e-11
6 O 0 4.106480488985653e-09
( O 0 2.250860053898407e-10
14 O 0 2.3048454256269224e-09
% O 0 1.2114557967901618e-10
) O 0 5.295517496728408e-11
of O 0 3.7029870836313705e-10
44 O 0 1.951956152268508e-09
unrelated O 0 1.5125580787866966e-09
alleles O 0 7.434595716837578e-10
, O 0 1.834525642507856e-09
respectively O 0 1.167523038247964e-07
. O 0 3.6329902286524884e-07

The O 0 5.183304097045038e-07
relatively O 0 1.0438019160119438e-07
high O 0 7.26056583744139e-08
residual O 0 6.861837960059347e-07
GALNS O 0 6.172388111735927e-06
activity O 0 3.3063169979641316e-08
seen O 0 2.230211570974916e-09
when O 0 3.6744157716483983e-10
the O 0 1.6835677296711538e-09
T312S O 0 1.3847105151398864e-07
mutant O 0 1.0392641414114223e-08
cDNA O 0 1.0314857235016461e-07
is O 0 1.7395461737734763e-09
overexpressed O 0 1.3052228098331398e-07
in O 0 2.057430004143157e-09
mutant O 0 6.565467280950088e-09
cells O 0 1.7303435351223584e-09
provides O 0 2.4655405495010996e-10
an O 0 4.815352977471932e-12
explanation O 0 3.4052605180079354e-10
for O 0 9.348360974215097e-11
the O 0 1.8685439862053954e-09
mild O 0 4.544005705042764e-08
phenotype O 0 6.160161269974651e-09
in O 0 1.4526111424828514e-09
patients O 0 8.746571245055179e-10
with O 0 2.2333128402163283e-11
this O 0 1.0992651233721062e-09
mutation O 0 1.1166148006225285e-08
. O 0 1.1314014614072221e-07

The O 0 3.417209626377371e-08
distribution O 0 1.1053328252685901e-09
and O 0 1.262415727509847e-10
relative O 0 3.2778832981250616e-09
frequencies O 0 8.149610764007775e-09
of O 0 3.0641937875941494e-09
the O 0 2.3946218341563963e-09
I113F O 0 6.458826078414859e-07
and O 0 1.2401265792050253e-08
T312S O 0 1.549038870507502e-06
mutations O 0 1.0879497303051266e-08
in O 0 5.136102654290653e-09
Australia O 0 6.223996873444548e-09
corresponded O 0 1.8125476675123764e-09
to O 0 2.2717437653252404e-10
those O 0 1.0314409742973041e-10
observed O 0 4.037273015899956e-10
in O 0 5.828562077425659e-10
Northern O 0 1.638144553339771e-08
Ireland O 0 1.925951309544871e-08
and O 0 1.1717026238144967e-09
are O 0 1.326416337876779e-10
unique O 0 5.045364681599551e-10
to O 0 3.09761660766128e-10
these O 0 4.019590910120385e-11
two O 0 4.29508754951069e-11
populations O 0 1.0993064791797735e-10
, O 0 1.7441134647633305e-10
suggesting O 0 3.2913778369447755e-09
that O 0 4.760834435013628e-11
both O 0 1.1500698310351609e-10
mutations O 0 3.4341030019646723e-10
were O 0 1.0861308519238833e-09
probably O 0 9.203450224148924e-10
introduced O 0 2.583845803982854e-09
to O 0 1.1178566960978742e-09
Australia O 0 2.662248199669648e-09
by O 0 7.067166990504248e-11
Irish O 0 4.288395860641003e-09
migrants O 0 1.934709281670166e-09
during O 0 1.0843446140995638e-09
the O 0 5.786083279168963e-10
19th O 0 7.620845110523078e-08
century O 0 6.997923378548876e-07
. O 0 2.822589806328324e-07

Haplotype O 0 9.280910489906091e-06
analysis O 0 8.579286969734312e-08
using O 0 5.7597294045308445e-08
6 O 0 2.862337566966744e-07
RFLPs O 0 7.151960744522512e-06
provides O 0 6.912739269893109e-09
additional O 0 1.4454308860933907e-09
data O 0 2.628192552478481e-09
that O 0 9.750578816580813e-11
the O 0 1.6779384548470944e-09
I113F O 0 7.594811677336111e-07
mutation O 0 2.6945961018043363e-09
originated O 0 1.7847121558389745e-09
from O 0 8.359849479333548e-10
a O 0 2.6312119150162516e-09
common O 0 4.082629345703026e-09
ancestor O 0 1.121255053249115e-07
. O 0 1.1245255393532716e-07

The O 0 1.7781289329832362e-07
other O 0 2.0710291259717906e-09
9 O 0 1.3343474769555996e-08
novel O 0 2.328689241437587e-09
mutations O 0 1.7014194497733115e-09
identified O 0 1.508478453260409e-09
in O 0 2.494127959717929e-10
these O 0 1.1352973422473767e-10
23 O 0 2.5773060130518388e-08
patients O 0 1.0762549740306326e-09
were O 0 3.222019318016578e-10
each O 0 1.7605666924325192e-11
limited O 0 1.0047942478053074e-09
to O 0 1.2739469479328136e-09
a O 0 7.1327037609592026e-09
single O 0 7.380067046369732e-08
family O 0 6.296548349382647e-08
. O 0 3.472636080914526e-07

These O 0 7.715959071674661e-08
data O 0 4.934485176022463e-08
provide O 0 1.7998116330630864e-09
further O 0 2.0842995385184082e-10
evidence O 0 2.460570081019853e-10
for O 0 1.2198422827403022e-10
extensive O 0 1.0435823760701624e-08
allelic O 0 9.117929522517443e-08
heterogeneity O 0 9.41705877721688e-08
in O 0 1.0394924743195588e-07
MPS B-Disease 1 0.9999990463256836
IVA I-Disease 1 1.0
in O 0 1.1507449926284607e-07
British O 0 2.7208438950765412e-06
- O 0 3.5211451177019626e-06
Irish O 0 1.3753157723783715e-08
patients O 0 7.204482566081083e-10
and O 0 5.884093125935186e-12
provide O 0 3.4890854094804524e-11
evidence O 0 6.268237318085568e-11
for O 0 4.508344739195813e-11
their O 0 3.36121908084408e-10
transmission O 0 1.407623699378746e-06
to O 0 1.004593652709218e-08
Australia O 0 1.0688439466832733e-08
by O 0 7.839178750579379e-10
British O 0 6.266296850299113e-07
- O 0 8.996879614642239e-07
Irish O 0 5.354187848638503e-08
migrants O 0 1.3603199455758386e-08
. O 0 1.0385442505977949e-09
. O 0 1.589671505541901e-08

Identification O 0 4.657676981878467e-06
of O 0 8.098277248791419e-07
constitutional O 0 1.7970780390896834e-05
WT1 O 1 0.9817905426025391
mutations O 0 2.467270121542242e-07
, O 0 1.4244553314668451e-09
in O 0 6.143332509367383e-10
patients O 0 9.132506972875376e-10
with O 0 1.4320057639682915e-10
isolated O 0 8.4306788039612e-07
diffuse B-Disease 1 0.9999901056289673
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 4.35195318004844e-07
and O 0 8.126064265923105e-09
analysis O 0 2.6089152171948626e-08
of O 0 4.004476039654037e-08
genotype O 0 2.4255513153548236e-07
/ O 0 2.8010301775793778e-06
phenotype O 0 8.353048031040089e-09
correlations O 0 6.844512734360819e-10
by O 0 9.723872401723455e-11
use O 0 5.569192218501939e-09
of O 0 9.283833257711649e-09
a O 0 6.555732401380965e-09
computerized O 0 4.1094605762737046e-07
mutation O 0 9.693032154700632e-09
database O 0 6.369020866259234e-08
. O 0 2.0299432890169555e-07

Constitutional O 0 8.812203304842114e-06
mutations O 0 1.2318547248924006e-07
of O 0 4.898569372357997e-08
the O 0 1.1461643190102677e-08
WT1 O 0 5.270226665743394e-06
gene O 0 1.727953247154801e-08
, O 0 1.4668830594644078e-09
encoding O 0 2.1736275002126604e-08
a O 0 4.98004020244025e-08
zinc O 0 4.980564335710369e-05
- O 0 0.34469491243362427
finger O 0 3.0921513825887814e-05
transcription O 0 1.5220710338326171e-05
factor O 0 4.5843555085411936e-07
involved O 0 6.026662280333994e-09
in O 0 1.226965107292699e-08
renal O 1 1.0
and O 0 3.973820639657788e-05
gonadal O 1 1.0
development O 1 0.9999914169311523
, O 0 1.3894695172211868e-08
are O 0 1.3187878566967015e-10
found O 0 1.7070679592112725e-10
in O 0 1.9011274499103337e-10
most O 0 8.088572867048782e-11
patients O 0 1.9725809874415745e-10
with O 0 1.318113951320754e-10
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 4.2647595677181016e-08
DDS B-Disease 1 1.0
) O 0 5.013021553423869e-09
, O 0 9.037583459381437e-10
or O 0 7.612662500378065e-09
diffuse B-Disease 1 0.9983769655227661
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 5.725893288399675e-07
DMS B-Disease 1 0.8609040975570679
) O 0 8.561477082835722e-10
associated O 0 1.6783168632628076e-08
with O 0 1.1536382960031233e-09
pseudohermaphroditism B-Disease 1 1.0
and O 0 2.5110957722063176e-06
/ O 1 0.9999784231185913
or O 0 1.9892318050551694e-06
Wilms B-Disease 1 1.0
tumor I-Disease 0 0.06345415860414505
( O 0 4.190543734239327e-08
WT B-Disease 1 0.9999295473098755
) O 0 2.273072396974385e-08
. O 0 9.424156388604388e-08

Most O 0 1.753947316274207e-07
mutations O 0 1.4884307120155427e-07
in O 0 7.05387179777972e-08
DDS B-Disease 1 1.0
patients O 0 0.0018093667458742857
lie O 0 3.4187483066716595e-08
in O 0 1.0046850018596842e-09
exon O 0 6.021424781010865e-08
8 O 0 1.7278453867675125e-07
or O 0 6.481011727288433e-09
exon O 0 1.497711821230041e-07
9 O 0 1.3268660836729396e-07
, O 0 4.0547392110568126e-09
encoding O 0 1.3552859456922306e-07
zinc O 0 0.0008010643068701029
finger O 0 0.00010368559014750645
2 O 0 6.929877145012142e-06
or O 0 3.398043304514431e-07
zinc O 0 0.00027706564287655056
finger O 0 2.2010935936123133e-06
3 O 0 5.68757982932766e-08
, O 0 6.272234398529974e-10
respectively O 0 1.1136196409466947e-09
, O 0 5.7498745348327773e-11
with O 0 1.0963220782589378e-11
a O 0 3.175924634390981e-09
hot O 0 1.1594203215281595e-06
spot O 0 1.992218869872886e-07
( O 0 1.901919066682467e-09
R394W O 0 4.596666087763879e-07
) O 0 9.843510451190696e-10
in O 0 4.043124057773184e-09
exon O 0 9.409945391780639e-07
9 O 0 2.4165658487618202e-06
. O 0 1.315914346378122e-06

We O 0 4.853546897720662e-08
analyzed O 0 2.2711049041390652e-08
a O 0 1.7579278033252876e-09
series O 0 6.920664596954396e-10
of O 0 5.182507756273935e-10
24 O 0 9.188422467332202e-09
patients O 0 5.767396560329985e-10
, O 0 1.603424892859806e-10
10 O 0 4.2061807370430415e-09
with O 0 1.1778039654686268e-09
isolated B-Disease 0 1.093257378670387e-05
DMS I-Disease 1 0.9999970197677612
( O 0 2.2880908545630518e-07
IDMS B-Disease 1 0.99643874168396
) O 0 3.2876572575446517e-09
, O 0 6.748881453688682e-10
10 O 0 4.073513526492434e-09
with O 0 4.270387932159281e-10
DDS B-Disease 1 1.0
, O 0 1.4073774146083906e-08
and O 0 9.429361735868724e-10
4 O 0 1.4979559637140483e-07
with O 0 4.341727866119527e-09
urogenital B-Disease 1 0.8377383947372437
abnormalities I-Disease 1 0.9999991655349731
and O 0 3.4358538414380746e-06
/ O 1 0.9999997615814209
or O 0 3.1746068998472765e-05
WT B-Disease 1 1.0
. O 0 6.7008277255808935e-06

We O 0 2.66729739450966e-06
report O 0 4.1959026475524297e-07
WT1 O 0 0.0002924125292338431
heterozygous O 0 6.183183813845972e-07
mutations O 0 7.54754392318091e-09
in O 0 9.769759445887871e-10
16 O 0 1.1797943955116352e-08
patients O 0 1.4289753824670015e-09
, O 0 1.1540074451588112e-10
4 O 0 7.5570518731638e-09
of O 0 5.786273682417686e-09
whom O 0 6.213854764069993e-09
presented O 0 6.065480562256198e-08
with O 0 5.04802599721188e-08
IDMS B-Disease 1 0.9999996423721313
. O 0 8.461772813461721e-05

One O 0 3.079664168126328e-07
male O 0 2.0493160945989075e-08
and O 0 2.3044717245568336e-09
two O 0 2.2850428216258933e-09
female O 0 8.175657484343901e-09
IDMS B-Disease 0 0.000931473565287888
patients O 0 1.6358410448447103e-07
with O 0 3.812258064783691e-09
WT1 O 1 0.9995405673980713
mutations O 0 2.5212366381310858e-06
underwent O 0 0.3162826597690582
normal O 0 2.2839667508378625e-05
puberty O 0 1.1534314580785576e-05
. O 0 6.740614821865165e-07

Two O 0 7.851753593968169e-07
mutations O 0 1.2518457026544638e-07
associated O 0 4.1230433112104947e-07
with O 0 1.0466922439889004e-08
IDMS B-Disease 1 0.9999963045120239
are O 0 1.3228874662374324e-09
different O 0 1.1965678448078165e-10
from O 0 1.1466622096278911e-09
those O 0 5.020233118102624e-10
described O 0 2.5933453162707565e-09
in O 0 3.033068907143388e-08
DDS B-Disease 1 1.0
patients O 0 9.778670937521383e-05
. O 0 1.0353467132517835e-06

No O 0 7.5856423791265115e-06
WT1 O 0 0.0002473870408721268
mutations O 0 2.148849489458371e-07
were O 0 2.0980023052175056e-08
detected O 0 3.1190698024374797e-08
in O 0 2.0461863314835682e-09
the O 0 8.893808356447153e-09
six O 0 1.3591761494069488e-08
other O 0 2.846440638748504e-09
IDMS B-Disease 1 0.9999604225158691
patients O 0 1.444088724156245e-07
, O 0 2.2158506141067846e-09
suggesting O 0 1.781278236023809e-08
genetic O 0 1.7385586303930722e-08
heterogeneity O 0 3.518690050441364e-08
of O 0 4.448074975016425e-08
this O 0 6.144390329865246e-09
disease O 0 2.3198292353754368e-07
. O 0 2.675873531643447e-07

We O 0 1.111301003220433e-06
analyzed O 0 1.027844177770021e-06
genotype O 0 5.139945187693229e-06
/ O 0 9.622403013054281e-06
phenotype O 0 5.646052869678897e-08
correlations O 0 3.5260852015994715e-09
, O 0 1.2556580775147097e-10
on O 0 4.313553958468219e-10
the O 0 3.563823888774742e-11
basis O 0 1.3326648118372475e-10
of O 0 1.0913030895620679e-10
the O 0 1.6057845331207687e-10
constitution O 0 3.770762813104511e-09
of O 0 5.2044217824231964e-09
a O 0 6.583737999221739e-09
WT1 O 0 6.736926479788963e-06
mutation O 0 9.977096482316483e-09
database O 0 7.081476738335368e-09
of O 0 5.655276247296115e-09
84 O 0 8.178312782547437e-08
germ O 1 0.5221942663192749
- O 0 0.00011531518975971267
line O 0 4.458548517050076e-07
mutations O 0 1.0670635930409844e-08
, O 0 4.855032487149913e-10
to O 0 2.986276226302209e-10
compare O 0 3.0290669972288242e-09
the O 0 8.102118420616478e-10
distribution O 0 5.263428026758277e-10
and O 0 3.631136225035192e-10
type O 0 7.333061802228258e-08
of O 0 5.0627598113806016e-08
mutations O 0 1.4673056103475801e-09
, O 0 2.223164707881864e-10
according O 0 2.1900757596338138e-10
to O 0 2.281078936849923e-10
the O 0 5.775432354582222e-10
different O 0 1.4260101988128326e-09
symptoms O 0 2.373588046111763e-07
. O 0 2.574076631844946e-07

This O 0 2.655302111520541e-08
demonstrated O 0 7.944492352862653e-08
( O 0 4.500022299236406e-10
1 O 0 1.140690120138288e-08
) O 0 4.926420937856335e-10
the O 0 1.3168429680021632e-09
association O 0 6.063381463583539e-10
between O 0 9.540889606141079e-11
mutations O 0 1.0971683561677992e-09
in O 0 1.2848867525505625e-09
exons O 0 7.422215730912285e-09
8 O 0 1.2061793341899829e-08
and O 0 1.97376381905201e-09
9 O 0 5.7870494174494524e-08
and O 0 1.0244562531624979e-08
DMS B-Disease 0 7.612282388436142e-06
; O 0 4.949715304292113e-09
( O 0 5.145630588287986e-10
2 O 0 8.036204590666784e-09
) O 0 1.8709681026685132e-10
among O 0 2.5419610860666353e-11
patients O 0 1.344019062710089e-10
with O 0 3.236566223363546e-11
DMS B-Disease 0 1.2103757853765273e-06
, O 0 1.995309029112491e-09
a O 0 1.0705368813646032e-09
higher O 0 2.7815107994655364e-09
frequency O 0 5.945790970685039e-09
of O 0 1.5209390413772894e-09
exon O 0 4.697413658050209e-08
8 O 0 1.058408756193785e-07
mutations O 0 8.043365973264827e-09
among O 0 1.06211262007605e-09
46 O 0 2.8666393703247195e-08
, O 0 8.417662122894853e-09
XY O 0 3.456829290371388e-05
patients O 0 1.2275269689610013e-08
with O 0 3.081870036947265e-10
female O 0 4.5621275646112736e-09
phenotype O 0 2.22543139472009e-09
than O 0 1.0659457344575074e-10
among O 0 1.0051618565265485e-10
46 O 0 2.099443463521311e-08
, O 0 1.348210609819489e-08
XY O 0 0.0008023749105632305
patients O 0 4.146124510384652e-08
with O 0 1.9661428041217732e-10
sexual O 0 2.0621995222569467e-09
ambiguity O 0 1.5919775719908102e-08
or O 0 4.855831292616131e-09
male O 0 2.6032322963942534e-09
phenotype O 0 8.939758378012641e-10
; O 0 6.834594695748208e-11
and O 0 6.86738388377961e-10
( O 0 1.980599989570564e-10
3 O 0 1.6438036709587323e-08
) O 0 6.148830333785327e-10
statistically O 0 1.1732994575908151e-09
significant O 0 3.42673556197326e-10
evidence O 0 1.172757890799403e-09
that O 0 9.353211954943319e-11
mutations O 0 6.577685063291483e-10
in O 0 4.2648546916268515e-09
exons O 0 4.1657514771031856e-08
8 O 0 3.842262685793685e-08
and O 0 4.363196026702099e-09
9 O 0 5.0713321542161793e-08
preferentially O 0 4.247093343678898e-09
affect O 0 4.908724537955322e-09
amino O 0 7.835173065906531e-10
acids O 0 2.1692310447907204e-10
with O 0 4.078233844378998e-12
different O 0 2.3990356576297778e-11
functions O 0 1.8515925459539062e-09
. O 0 4.153681842922197e-09
. O 0 7.39335348498571e-08

The O 0 1.9408569187362446e-06
185delAG O 0 1.7970814951695502e-05
BRCA1 O 0 1.1029030702047748e-06
mutation O 0 4.895437832885818e-09
originated O 0 4.819541210565603e-09
before O 0 1.2245937597299417e-09
the O 0 1.431175733479506e-10
dispersion O 0 7.574036509083726e-09
of O 0 1.885549494318184e-09
Jews O 0 1.1579067482614391e-08
in O 0 5.476429865147736e-10
the O 0 4.4898973428075806e-10
diaspora O 0 6.121580131690507e-09
and O 0 3.5506222961778633e-10
is O 0 3.5594492631130237e-11
not O 0 7.612640379184299e-11
limited O 0 7.95835042310955e-09
to O 0 6.865530366439998e-08
Ashkenazim O 0 8.170392538886517e-05
. O 0 2.468478214723291e-06

The O 0 1.269482652332954e-07
185delAG O 0 5.662024022967671e-07
mutation O 0 1.1219520423821905e-08
in O 0 4.789145524597416e-09
BRCA1 O 0 1.440417776166214e-07
is O 0 2.9709990023718547e-10
detected O 0 3.1874851647017977e-09
in O 0 6.613349312623029e-10
Ashkenazi O 0 4.738185737096501e-07
Jews O 0 3.6489208099510506e-08
both O 0 1.7720558354028526e-10
in O 0 4.751203319663944e-10
familial B-Disease 0 0.001128839561715722
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 0.004087652545422316
in O 0 1.1253859355520035e-07
the O 0 6.529127460908057e-09
general O 0 1.0368406577754286e-08
population O 0 2.2175025704562756e-10
. O 0 1.0303507380626797e-08

All O 0 1.8599807845021132e-06
tested O 0 1.317124770139344e-06
Ashkenazi O 0 2.0085999494767748e-06
mutation O 0 8.203587142929791e-09
carriers O 0 2.090348116823293e-09
share O 0 6.114889705699511e-10
the O 0 1.3178072522102013e-10
same O 0 2.1679363859661294e-10
allelic O 0 2.2241806618694682e-08
pattern O 0 3.058775011055559e-09
at O 0 2.8153520403861876e-08
the O 0 5.9400015572919074e-08
BRCA1 O 0 4.893330469712964e-07
locus O 0 8.92295020094025e-07
. O 0 9.440515782443981e-07

Our O 0 1.0856633707589936e-06
previous O 0 4.992175206552929e-08
study O 0 1.2395023674116601e-08
showed O 0 3.4165301698863004e-09
that O 0 1.7610269145706958e-11
this O 0 1.2951612005096536e-10
Ashkenazi O 0 4.638155530756194e-07
mutation O 0 3.8746716946036486e-09
also O 0 2.900029105745716e-10
occurs O 0 2.2859774836958557e-11
in O 0 1.2503764690308117e-10
Iraqi O 0 2.0927547694782334e-08
Jews O 0 9.279442103604651e-09
with O 0 3.243784754691781e-11
a O 0 3.553711769299639e-10
similar O 0 2.3763982448521404e-10
allelic O 0 5.162180727324994e-08
pattern O 0 3.128555192688509e-08
. O 0 2.1386314585924993e-07

We O 0 3.090512166181725e-07
extended O 0 7.998162487865557e-08
our O 0 3.8494931686727796e-09
analysis O 0 1.4409907711510073e-09
to O 0 6.598355195563954e-10
other O 0 5.592650786923059e-10
non O 0 2.9351019747991813e-07
- O 0 3.326140358694829e-07
Ashkenazi O 0 7.201795710898296e-07
subsets O 0 3.4135357651621234e-08
354 O 0 1.3442281066033956e-08
of O 0 1.1866363447410322e-09
Moroccan O 0 2.257200776512036e-06
origin O 0 7.632405818469579e-09
, O 0 8.889156632996276e-10
200 O 0 1.5817352760905123e-08
Yemenites O 0 1.2746983202305273e-06
and O 0 5.661190183303688e-09
150 O 0 6.261338825197527e-08
Iranian O 0 2.377316974389032e-07
Jews O 0 5.740469646298152e-07
. O 0 2.434243526749924e-07

Heteroduplex O 0 5.299000986269675e-05
analysis O 0 1.1064263816251696e-07
complemented O 0 3.136753079502341e-08
by O 0 4.714579837639121e-10
direct O 0 3.025735217931924e-09
DNA O 0 3.792068437036278e-09
sequencing O 0 3.8515665323757275e-08
of O 0 5.3181381076683465e-08
abnormally O 0 2.356995167929199e-07
migrating O 0 1.6032368321816648e-08
bands O 0 8.246136218303945e-08
were O 0 4.033105582834651e-08
employed O 0 4.6218269744713325e-07
. O 0 4.5491566424971097e-07

Four O 0 1.5103282180461974e-07
of O 0 1.9583973553949363e-08
Moroccan O 0 0.0001924206007970497
origin O 0 7.262903611859883e-09
( O 0 5.866233887541483e-11
1 O 0 2.8233940185806716e-10
. O 0 2.730103122738914e-11
1 O 0 1.1014814615961654e-09
% O 0 1.2168609175855494e-10
) O 0 2.4019659525253978e-11
and O 0 4.7040950995613784e-11
none O 0 1.6562908822237432e-09
of O 0 1.7657811879345786e-09
the O 0 3.5401830356107666e-09
Yemenites O 0 1.627396272851911e-06
or O 0 4.904961770080263e-09
Iranians O 0 1.532348932187233e-07
was O 0 1.2619667977276094e-08
a O 0 8.858032085612422e-10
carrier O 0 1.6144888759228593e-09
of O 0 2.4381843211074283e-09
the O 0 3.962503658527794e-09
185delAG O 0 1.0861853070309735e-06
mutation O 0 9.691778757314751e-08
. O 0 2.795906084429589e-07

BRCA1 O 0 9.992193372454494e-05
allelic O 0 1.9796045762632275e-06
patterns O 0 1.1647022901684068e-08
were O 0 1.264534588152344e-09
determined O 0 1.0259516569632865e-09
for O 0 5.484332432637018e-10
four O 0 3.326263708913757e-10
of O 0 3.042829599397834e-10
these O 0 1.0853263600341112e-11
individuals O 0 1.977412374468135e-12
and O 0 2.9193744643940533e-11
for O 0 5.658650770179463e-10
12 O 0 1.8249814104365214e-08
additional O 0 2.229515416729555e-08
non O 0 1.1950087355216965e-06
- O 0 1.1389550991225406e-06
Ashkenazi O 0 5.443245640890382e-07
185delAG O 0 8.036499110630757e-08
mutation O 0 1.541037963903591e-09
carriers O 0 1.9237915704906072e-09
who O 0 6.331253743496745e-09
had O 0 9.183813745039515e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9998621940612793

Six O 0 6.764873887732392e-07
non O 0 7.519651717302622e-06
- O 0 2.9864841053495184e-06
Ashkenazi O 0 9.040002737492614e-07
individuals O 0 2.333525594977459e-10
shared O 0 5.860946727942462e-10
the O 0 3.6829478355926426e-10
common O 0 1.7469843349715575e-09
Ashkenazi O 0 9.542910675008898e-07
haplotype O 0 1.9203011447643803e-07
, O 0 8.467092582620239e-10
four O 0 1.8859955819294782e-09
had O 0 1.3510061513954952e-08
a O 0 2.497185125349688e-09
closely O 0 3.824185412781844e-10
related O 0 1.6243606459909188e-09
pattern O 0 1.1319356563177507e-09
, O 0 1.456927911647199e-10
and O 0 2.1998095012243368e-10
the O 0 5.827897719967723e-09
rest O 0 2.0172903347770443e-08
( O 0 3.4156033557053433e-10
n O 0 2.7830708848597396e-09
= O 0 1.185049214313949e-08
6 O 0 1.3204000559596807e-08
) O 0 4.315356127992942e-10
displayed O 0 9.371542653013876e-09
a O 0 6.762517656966338e-09
distinct O 0 5.964725602325416e-09
BRCA1 O 0 5.219181957727415e-07
allelic O 0 5.921195906921639e-07
pattern O 0 9.227873221107075e-08
. O 0 4.946745093548088e-07

We O 0 5.947359227320703e-08
conclude O 0 4.382564711136183e-08
that O 0 4.2200082317478405e-10
the O 0 2.748413052700016e-09
185delAG O 0 1.9057348481510417e-06
BRCA1 O 0 1.3213532383815618e-06
mutation O 0 4.707196410436154e-09
occurs O 0 1.7777330996171514e-10
in O 0 2.2730178850238758e-10
some O 0 1.5700113431549312e-10
non O 0 8.705384288987261e-07
- O 0 2.7068758754467126e-06
Ashkenazi O 0 1.238601612385537e-06
populations O 0 1.6901925414813945e-09
at O 0 5.134728753297679e-10
rates O 0 1.128118598536787e-09
comparable O 0 5.792388235725809e-10
with O 0 2.721612692158093e-11
that O 0 3.7219713422409484e-10
of O 0 5.034766203948493e-08
Ashkenazim O 0 2.649016460054554e-05
. O 0 1.2426860394043615e-06

The O 0 3.018865584181185e-07
majority O 0 1.9604555756558284e-09
of O 0 8.44930259091825e-09
Jewish O 0 1.7059021217846748e-07
185delAG O 0 4.0700135173210583e-07
mutation O 0 4.3631458446213855e-09
carriers O 0 2.080126293435569e-09
have O 0 5.573269623582178e-10
a O 0 1.6073082864664912e-09
common O 0 4.737613856775624e-09
allelic O 0 1.7068687441224029e-07
pattern O 0 2.6947915010566703e-09
, O 0 4.5293599426621256e-10
supporting O 0 2.5947157755723538e-09
the O 0 2.294239909161888e-09
founder O 0 2.5609343978771903e-08
effect O 0 2.657742914635719e-09
notion O 0 4.053749336208057e-09
, O 0 1.2604957355666357e-10
but O 0 3.8310677547004346e-11
dating O 0 2.672759791266799e-09
the O 0 1.4147827354094034e-10
mutations O 0 1.0838952652081346e-10
origin O 0 1.8623447228804935e-10
to O 0 1.7524365292231892e-10
an O 0 4.5441546359104024e-11
earlier O 0 4.6010031895526993e-10
date O 0 4.335664272048234e-08
than O 0 1.838950325350197e-09
currently O 0 1.3343187665881828e-09
estimated O 0 1.0894380952919391e-09
. O 0 3.0937641781747516e-08

However O 0 3.920264646239957e-08
, O 0 8.736534273801055e-10
the O 0 1.1945702760307597e-10
different O 0 9.085102462003114e-12
allelic O 0 1.0671633354775167e-08
pattern O 0 2.343616412048277e-09
at O 0 1.3161506551284674e-08
the O 0 2.7063927987569514e-08
BRCA1 O 0 2.0443820858417894e-07
locus O 0 7.558207926194882e-08
even O 0 4.043062329373015e-09
in O 0 1.1216583217787957e-09
some O 0 1.9771201342777545e-10
Jewish O 0 1.0405930339629776e-08
mutation O 0 7.96449683981848e-10
carriers O 0 4.393206354258439e-10
, O 0 2.3223896417068346e-10
might O 0 1.5666619113119395e-09
suggest O 0 1.7528319906645606e-09
that O 0 1.0302592806654687e-10
the O 0 1.1868265259451505e-09
mutation O 0 6.256200557608338e-10
arose O 0 1.938462279582609e-09
independently O 0 5.567949212803569e-09
. O 0 1.293831708437665e-08
. O 0 2.736643125444971e-07

Crystal O 0 2.49126469498151e-06
structure O 0 4.5946936211294087e-07
of O 0 2.9201084998931037e-06
the O 0 1.563763021295017e-06
hemochromatosis B-Disease 1 1.0
protein O 0 9.419624689144257e-07
HFE O 0 6.665541150141507e-05
and O 0 1.6297736493697812e-08
characterization O 0 3.4873210097430274e-08
of O 0 2.1321712395661052e-08
its O 0 8.655163252768716e-10
interaction O 0 9.645243492784061e-10
with O 0 1.403901300767174e-10
transferrin O 0 1.0602857969388424e-07
receptor O 0 2.999396997438453e-08
. O 0 1.9423460173584317e-07

HFE O 1 0.8599981665611267
is O 0 1.7282242481542198e-07
an O 0 4.484113969027703e-09
MHC O 0 6.504692464659456e-07
- O 0 6.868523087177891e-06
related O 0 2.4968156253635243e-07
protein O 0 1.4766717848502253e-09
that O 0 6.016098209882248e-12
is O 0 1.882075658515836e-12
mutated O 0 1.0210025186419003e-10
in O 0 6.083213377472418e-10
the O 0 4.362789951528612e-08
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.0014864440308883786

HFE O 0 0.0003113154962193221
binds O 0 7.609486374349217e-08
to O 0 1.2912579450130579e-08
transferrin O 0 3.1462690230910084e-07
receptor O 0 2.514612873483202e-08
( O 0 1.8276766766689434e-09
TfR O 0 1.231118858413538e-06
) O 0 9.384882870833167e-10
and O 0 3.271897475176644e-10
reduces O 0 3.6123417590516738e-09
its O 0 3.2607583300148235e-10
affinity O 0 8.279417151868529e-09
for O 0 8.168082210602279e-09
iron O 0 1.2091874168618233e-06
- O 0 1.5306533214243245e-06
loaded O 0 2.7825078063870023e-07
transferrin O 0 1.1135329032185837e-06
, O 0 3.29631753004378e-08
implicating O 0 3.823657152679516e-06
HFE O 0 0.0003444375761318952
in O 0 7.865979227972275e-07
iron O 0 0.001046714256517589
metabolism O 0 0.0021130836103111506
. O 0 2.3568293272546725e-06

The O 0 1.1736802889572573e-06
2 O 0 3.19866785503109e-06
. O 0 8.769696364652191e-07

6 O 0 1.6575309928157367e-05
A O 0 1.1359178415659699e-06
crystal O 0 9.646998933021678e-08
structure O 0 8.823691644010978e-08
of O 0 1.4302338513516588e-06
HFE O 1 0.9999791383743286
reveals O 0 8.764665437865915e-08
the O 0 1.3066725479404795e-09
locations O 0 9.003692902354032e-09
of O 0 7.063376727955983e-08
hemochromatosis B-Disease 1 1.0
mutations O 0 2.4444537416457024e-07
and O 0 2.4154216404781437e-08
a O 0 1.727499125081522e-06
patch O 1 0.9986780285835266
of O 0 1.9057068129768595e-05
histidines O 0 2.624282024044078e-05
that O 0 2.884456007379299e-10
could O 0 4.1075359780151643e-10
be O 0 3.289129524297607e-10
involved O 0 1.3193822701040858e-09
in O 0 6.954489872867953e-09
pH O 0 1.1334137752783136e-06
- O 0 5.197619543650944e-07
dependent O 0 1.0308976072792575e-07
interactions O 0 2.286430245135307e-08
. O 0 1.381071825790059e-07

We O 0 9.888623253573314e-07
also O 0 4.4120373132727764e-08
demonstrate O 0 5.79190810867658e-08
that O 0 1.587507347799999e-09
soluble O 0 1.9867205480750272e-07
TfR O 0 3.2566895242780447e-06
and O 0 4.324091751328751e-09
HFE O 0 8.025690476642922e-06
bind O 0 4.982710066769869e-08
tightly O 0 1.4887402244312398e-07
at O 0 7.166744353526155e-08
the O 0 4.830704725122814e-09
basic O 0 2.61459462080893e-07
pH O 0 1.4687097404930682e-07
of O 0 1.789545733821285e-09
the O 0 1.2276246685871683e-09
cell O 0 5.040646300358276e-08
surface O 0 5.394706903416591e-09
, O 0 6.023108123365262e-10
but O 0 4.657262908658311e-10
not O 0 3.0375544302074786e-09
at O 0 4.6052043956024136e-08
the O 0 2.827654377313138e-08
acidic O 0 4.257773866811476e-07
pH O 0 1.683406935626408e-06
of O 0 1.265357383317678e-07
intracellular O 0 1.548567638565146e-06
vesicles O 0 2.9336539228097536e-05
. O 0 2.6865563995670527e-06

TfR O 0 0.0005561418365687132
HFE O 0 0.0002652715193107724
stoichiometry O 0 1.5226485174935078e-06
( O 0 6.2366050102014015e-09
2 O 0 2.7055154561139716e-08
1 O 0 6.208526315276686e-08
) O 0 1.2865936094286212e-09
differs O 0 2.2071486860397727e-09
from O 0 1.0090348556701656e-09
TfR O 0 1.4533274850236921e-07
transferrin O 0 6.4535412569455275e-09
stoichiometry O 0 1.5535095432284152e-09
( O 0 3.8148002118321145e-11
2 O 0 5.894107424353479e-10
2 O 0 3.0676090556625013e-09
) O 0 2.6539323516594493e-10
, O 0 2.0092090491363734e-10
implying O 0 3.802214987302932e-09
a O 0 2.1100474145718806e-10
different O 0 9.123079895700936e-12
mode O 0 1.7977091815168933e-08
of O 0 1.1455756343536905e-09
binding O 0 2.519431552272522e-09
for O 0 5.309540362929965e-09
HFE O 0 5.386500197346322e-05
and O 0 8.47648919943822e-08
transferrin O 0 1.967960542970104e-06
to O 0 4.134461306648518e-08
TfR O 0 3.7417887597257504e-06
, O 0 1.7802448404324878e-09
consistent O 0 1.2372301405605413e-08
with O 0 7.699071241651367e-11
our O 0 9.339940376662526e-09
demonstration O 0 3.420639771434253e-08
that O 0 4.70486039017004e-10
HFE O 0 4.309086762077641e-06
, O 0 9.21858145375154e-09
transferrin O 0 1.5860922530919197e-07
, O 0 7.859844330937449e-09
and O 0 3.748962473792972e-09
TfR O 0 3.075577524214168e-06
form O 0 1.742990418662771e-09
a O 0 4.285689580996177e-09
ternary O 0 5.201923869435632e-08
complex O 0 6.665763976343442e-07
. O 0 1.1127347079309402e-06

Identification O 0 3.0816140679235104e-06
of O 0 1.3954084465694905e-07
three O 0 6.316944745066166e-10
novel O 0 1.2859803222298183e-09
mutations O 0 1.7884939362833308e-10
and O 0 1.0425230123622953e-10
a O 0 3.786198299327026e-10
high O 0 1.3229429773886636e-09
frequency O 0 1.0575507580767862e-08
of O 0 3.753627186853237e-09
the O 0 5.6054685337869614e-09
Arg778Leu O 0 1.7525957218822441e-06
mutation O 0 1.2256897718998516e-09
in O 0 7.837595017434751e-10
Korean O 0 4.100546675545047e-07
patients O 0 3.4403131454752156e-09
with O 0 1.87439688770219e-10
Wilson B-Disease 0 1.1749290251827915e-06
disease I-Disease 0 1.343564832723132e-07
. O 0 1.423299664793376e-07

Four O 0 1.5598681102346745e-07
mutations O 0 6.611573954984351e-09
- O 0 6.096426119484022e-08
- O 0 1.9581850096983544e-07
R778L O 0 1.2847718835473643e-06
, O 0 5.312445483518502e-10
A874V O 0 1.4072436727019522e-07
, O 0 2.850356339845206e-10
L1083F O 0 5.0239069793178714e-08
, O 0 8.960101410826482e-11
and O 0 1.2391553061430471e-11
2304delC O 0 8.945710838759169e-10
- O 0 1.826234163893048e-09
- O 0 9.952085378017728e-09
in O 0 2.9040212456976633e-09
the O 0 1.7483310355004278e-09
copper O 0 9.932211497698518e-09
- O 0 1.63394755503532e-08
transporting O 0 1.3366984852325459e-08
enzyme O 0 5.124516810894875e-09
, O 0 1.3339396254252733e-09
P O 0 6.615398433496011e-07
- O 0 1.1649788120848825e-06
type O 0 1.2720266795440693e-06
ATPase O 0 0.00010494881280465052
( O 0 2.285147404634813e-09
ATP7B O 0 2.606304860819364e-06
) O 0 8.264593870377368e-11
, O 0 2.739168267207326e-11
were O 0 1.4238379919540023e-10
identified O 0 4.132060249517622e-10
in O 0 2.814957156260789e-10
Korean O 0 4.890400759904878e-07
Patients O 0 1.2357159739906365e-08
with O 0 3.1921318366379126e-10
Wilson B-Disease 0 1.7240577108168509e-06
disease I-Disease 0 6.395448508556001e-07
. O 0 3.935833774448838e-07

Arg778Leu O 0 6.200317875482142e-05
, O 0 1.7038102484434603e-08
the O 0 1.9023471686807625e-09
most O 0 1.7625870207815808e-10
frequently O 0 1.82178008789613e-10
reported O 0 3.851136631816132e-10
mutation O 0 3.0281352425554076e-10
of O 0 6.327097734626363e-10
this O 0 6.266408225652498e-11
enzyme O 0 2.3943924620795087e-10
, O 0 1.4738571474381956e-10
was O 0 4.101587958160735e-09
found O 0 1.590643589066687e-10
in O 0 2.2759245876802225e-10
six O 0 5.657366242139972e-10
of O 0 1.6554435600113493e-10
eight O 0 3.14471726436949e-10
unrelated O 0 9.291322156101955e-10
patients O 0 4.1030179254164523e-10
studied O 0 2.8048665612345758e-09
, O 0 1.7843641841874813e-10
an O 0 8.228887710126642e-11
allele O 0 1.793482140577396e-09
frequency O 0 2.9355881281389884e-08
of O 0 4.439997169924936e-08
37 O 0 2.004076577577507e-06
. O 0 2.5966537577915005e-06

5 O 0 2.2613762666878756e-06
% O 0 1.6082966070030125e-08
, O 0 6.698073207189736e-10
which O 0 3.0808990775232914e-11
is O 0 6.851924843481738e-12
considerably O 0 2.702212065219811e-10
higher O 0 7.807038349127993e-10
than O 0 4.589256405451714e-11
those O 0 6.826750970079232e-11
in O 0 9.985925419897512e-10
other O 0 3.3423805945176355e-09
Asian O 0 2.3301574003653514e-07
populations O 0 6.312623757054325e-09
. O 0 6.28250091949667e-08

The O 0 1.5065619152210274e-07
novel O 0 1.1945851419170594e-08
single O 0 6.220210568841367e-09
nucleotide O 0 5.058464225271564e-08
deletion O 0 9.987972759972763e-08
, O 0 1.6104138023109726e-09
2304delC O 0 8.1223490155935e-08
, O 0 7.646375754788437e-10
was O 0 4.709028278426786e-09
found O 0 3.130342929313912e-10
in O 0 5.78205705537016e-10
one O 0 1.897328516520247e-09
patient O 0 1.1695601642713882e-07
. O 0 3.0857350452606624e-07

Since O 0 1.2539989313609112e-07
a O 0 3.66037866683655e-09
mutation O 0 5.337928987714236e-10
at O 0 1.5997690949731691e-09
cDNA O 0 2.3047585173685547e-08
nucleotide O 0 1.0601624467199144e-07
2302 O 0 5.716463419958018e-05
( O 0 3.0742042245179846e-09
2302insC O 0 1.1687284029449074e-07
) O 0 4.828610844498371e-10
had O 0 1.2264849136300882e-09
been O 0 4.007528475735711e-10
previously O 0 5.97371707655725e-10
described O 0 3.671921655623578e-10
, O 0 3.588543004418021e-11
this O 0 2.702726063785743e-11
region O 0 2.141217647633198e-09
of O 0 5.928984858627473e-09
the O 0 3.867420605985217e-09
ATP7B O 0 1.5469600839423947e-05
gene O 0 4.609393755572455e-09
may O 0 4.159294686445492e-09
be O 0 5.271608483070622e-09
susceptible O 0 3.51747573290595e-08
to O 0 1.897405432771393e-08
gene O 0 1.1637678909437454e-07
rearrangements O 0 1.406066439813003e-05
causing O 0 5.3876838137512095e-06
Wilson B-Disease 0 4.829942190553993e-05
disease I-Disease 0 2.8097786071157316e-06
. O 0 6.244272299227305e-07

Disruption O 0 2.7248397600487806e-05
of O 0 2.605047484394163e-07
splicing O 0 2.8842865162914677e-07
regulated O 0 1.0703601560635434e-07
by O 0 4.044419910087527e-09
a O 0 1.1686254630660642e-08
CUG O 0 1.3267917893244885e-06
- O 0 4.107516815565759e-08
binding O 0 1.3641705542966065e-08
protein O 0 6.358812498774569e-08
in O 0 1.1585278514303354e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 7.929509592941031e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 2.6645921025192365e-06
DM B-Disease 1 1.0
) O 0 1.3206341797911136e-08
is O 0 2.788632935679658e-10
caused O 0 1.1577360181647123e-09
by O 0 1.617619649341151e-10
a O 0 1.7681369701705307e-09
CTG O 0 1.0810970252350671e-07
expansion O 0 6.80519107731925e-09
in O 0 8.442854193546623e-10
the O 0 1.3240966101335516e-09
3 O 0 1.041101338472572e-08
untranslated O 0 1.5755618960611173e-06
region O 0 2.725029624173203e-08
of O 0 1.4205598475314218e-08
the O 0 4.847024470677752e-08
DM B-Disease 1 1.0
gene O 0 1.1808117506006965e-06
. O 0 1.2930702268931782e-06

One O 0 1.9592677702462424e-08
model O 0 1.9174732912574655e-08
of O 0 6.484452086397141e-08
DM B-Disease 1 1.0
pathogenesis O 1 0.9999500513076782
suggests O 0 4.7854502582822533e-08
that O 0 1.9394772246550396e-11
RNAs O 0 2.3254358438862255e-09
from O 0 1.9804915485366337e-09
the O 0 1.2340666266652534e-09
expanded O 0 4.541490739029541e-09
allele O 0 1.7318458889192812e-09
create O 0 1.0689774065930635e-10
a O 0 5.099455857582313e-10
gain O 0 2.213269789663741e-09
- O 0 1.38386244685762e-08
of O 0 3.109421831126724e-09
- O 0 5.348836928931178e-09
function O 0 1.98207769641634e-10
mutation O 0 1.8496291998015835e-10
by O 0 3.4203931353893324e-11
the O 0 6.393588991571164e-10
inappropriate O 0 4.808954123802778e-09
binding O 0 9.590960248218039e-10
of O 0 4.556639954245156e-09
proteins O 0 1.7270652963308208e-10
to O 0 2.4210473625885243e-09
the O 0 2.685648858857803e-08
CUG O 0 0.0001470943243475631
repeats O 0 1.0087064765684772e-06
. O 0 5.908836442358734e-07

Data O 0 1.231916371580155e-06
presented O 0 8.541488227820082e-08
here O 0 2.0788780474845225e-08
indicate O 0 7.598822904242297e-09
that O 0 1.1461499804799047e-10
the O 0 3.2936997573784765e-10
conserved O 0 6.3683263107350285e-09
heterogeneous O 0 3.891114630505399e-08
nuclear O 0 2.224165200459538e-06
ribonucleoprotein O 0 1.92648053598532e-06
, O 0 5.151800763769643e-09
CUG O 0 6.582333753613057e-07
- O 0 1.624795231691678e-08
binding O 0 1.7031661636579543e-09
protein O 0 1.948218031344595e-09
( O 0 7.528098977527264e-11
CUG O 0 3.164401789490512e-07
- O 0 1.1910329789088792e-07
BP O 0 1.7331959156763332e-07
) O 0 2.018373801426776e-10
, O 0 1.2374648528101773e-10
may O 0 6.175298605803903e-10
mediate O 0 1.0986158649473055e-08
the O 0 2.4265995879346747e-09
trans O 0 2.000430185944424e-07
- O 0 3.3977323710132623e-07
dominant O 0 1.759105927590099e-08
effect O 0 7.129983714548871e-09
of O 0 3.4607150478649373e-09
the O 0 1.8759538367163486e-09
RNA O 0 1.1009026934516442e-07
. O 0 2.1056678178865695e-07

CUG O 0 0.001602838863618672
- O 0 4.7614306822652e-05
BP O 0 5.695086656487547e-06
was O 0 4.578596701776405e-08
found O 0 5.435449867974285e-10
to O 0 4.936426614698952e-11
bind O 0 2.2053885107009563e-10
to O 0 8.542392349042416e-10
the O 0 3.921825530994738e-09
human O 0 3.6073519282808775e-08
cardiac O 1 0.9999998807907104
troponin O 0 0.009241239167749882
T O 0 6.595834747713525e-06
( O 0 2.3042563412900563e-09
cTNT O 0 1.308082602236027e-07
) O 0 2.4559754230324415e-10
pre O 0 1.3175778690310835e-07
- O 0 2.491753114952644e-08
messenger O 0 9.40093869417069e-09
RNA O 0 4.023875455061443e-09
and O 0 6.46462550157878e-10
regulate O 0 1.9248302951524465e-09
its O 0 3.0684735308206257e-10
alternative O 0 3.0493399805209265e-08
splicing O 0 3.6851548657068633e-07
. O 0 4.0992094341163465e-07

Splicing O 0 3.838852990156738e-06
of O 0 5.622046046482865e-07
cTNT O 0 1.565427919558715e-05
was O 0 2.492383543994947e-07
disrupted O 0 1.3305069614943932e-06
in O 0 1.520612613603589e-07
DM B-Disease 1 1.0
striated O 0 0.001362896990031004
muscle O 0 1.9196088487660745e-06
and O 0 5.73771963274794e-09
in O 0 1.940112070997202e-09
normal O 0 4.007861065247198e-08
cells O 0 1.4286463567714236e-08
expressing O 0 2.4365665041159446e-09
transcripts O 0 2.269589316483689e-08
that O 0 1.2962591000587054e-09
contain O 0 1.4184588614796212e-08
CUG O 0 4.209050530334935e-06
repeats O 0 1.7152332532077708e-07
. O 0 4.401917408358713e-07

Altered O 0 5.028906343795825e-06
expression O 0 2.1152058593543188e-07
of O 0 1.8147659375244984e-08
genes O 0 1.6443860717529901e-09
regulated O 0 1.4365211242761688e-08
posttranscriptionally O 0 1.9076681212482072e-07
by O 0 2.510107233177905e-09
CUG O 0 9.981088805943727e-05
- O 0 1.7413552996004e-05
BP O 0 1.762624378898181e-06
therefore O 0 6.384829998040686e-09
may O 0 1.0440079911688827e-09
contribute O 0 7.573573768127062e-09
to O 0 3.4671057136392847e-08
DM B-Disease 1 1.0
pathogenesis O 1 0.9993780851364136
. O 0 2.831962433447188e-07
. O 0 8.37038555800973e-07

Identification O 0 1.3300983709996217e-06
of O 0 1.3037063695264806e-07
a O 0 5.849926321133125e-09
novel O 0 6.384063055975275e-09
nonsense O 0 5.7901296202089725e-08
mutation O 0 8.727073508296712e-10
and O 0 5.782343492910513e-10
a O 0 1.950523298432927e-09
missense O 0 1.5600607028432023e-08
substitution O 0 1.3683035149369971e-08
in O 0 6.700772381407205e-09
the O 0 1.427774609652488e-08
vasopressin O 0 8.47491889999219e-07
- O 0 1.5665287378396897e-07
neurophysin O 0 7.701151503169967e-07
II O 0 8.447333675576374e-05
gene O 0 3.5866309922027995e-09
in O 0 1.6072223552043852e-09
two O 0 7.184365879986387e-10
Spanish O 0 1.5791435714618274e-07
kindreds O 0 1.4013498912390787e-06
with O 0 4.0537799783635364e-09
familial B-Disease 0 0.21444760262966156
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
. O 0 1.8480550352251157e-05

Familial B-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 4.506425810291148e-08
FNDI B-Disease 1 1.0
) O 0 2.288977452025165e-09
is O 0 9.916414217547853e-11
an O 0 2.1448462450557315e-10
autosomal B-Disease 1 0.8036899566650391
dominant I-Disease 1 0.9999924898147583
disease I-Disease 1 1.0
caused O 0 3.32010614556566e-07
by O 0 6.889726567038679e-10
deficiency O 0 7.560717563137587e-08
in O 0 3.611571841588557e-08
the O 0 4.3858514686689887e-07
antidiuretic O 0 1.5051638001750689e-05
hormone O 0 7.025741410870978e-08
arginine O 0 4.7697131577706386e-08
vasopressin O 0 3.0135328188407584e-07
( O 0 5.853361129126711e-10
AVP O 0 3.5592037761489337e-07
) O 0 5.091891838726603e-11
encoded O 0 1.18340365284908e-10
by O 0 1.5030524047610072e-10
the O 0 9.085116658980041e-09
AVP O 0 9.994290303438902e-05
- O 0 4.977826392860152e-06
neurophysin O 0 5.403179602581076e-05
II O 1 1.0
( O 0 6.609320024608678e-08
AVP O 0 5.8358007663628086e-05
- O 0 5.921766046412813e-07
NPII O 0 8.943038665165659e-06
) O 0 1.3003772503239475e-09
gene O 0 2.123849540680567e-09
on O 0 2.570800816670271e-08
chromosome O 0 2.1196625255015533e-07
20p13 O 0 4.816286309505813e-05
. O 0 1.1655243952191086e-06

In O 0 5.705420136337125e-08
this O 0 6.52418175040026e-10
study O 0 1.4641660106562426e-09
, O 0 1.734936361241779e-10
we O 0 2.8702087928600406e-10
analyzed O 0 2.8773141647064904e-09
two O 0 2.7247668010765835e-10
families O 0 2.8761770742846693e-10
with O 0 1.524920606454927e-10
FNDI B-Disease 1 1.0
using O 0 1.481748057585719e-08
direct O 0 6.017140563585599e-09
automated O 0 8.514146543348033e-08
fluorescent O 0 2.301463908338519e-08
, O 0 2.4952282462464836e-09
solid O 0 6.463445334503604e-09
phase O 0 5.728622021194951e-09
, O 0 4.2539338718228237e-10
single O 0 1.3103089724353367e-09
- O 0 1.0339179290497214e-08
stranded O 0 1.852335351770762e-08
DNA O 0 1.2810350558112304e-09
sequencing O 0 7.83436959750361e-09
of O 0 1.9840010523353158e-08
PCR O 0 3.6182373150950298e-06
- O 0 3.3164727938128635e-05
amplified O 0 6.163532088976353e-05
AVP O 0 0.0003196707693859935
- O 0 6.640950232394971e-06
NPII O 0 4.362123945611529e-05
DNA O 0 8.488046887578093e-07
. O 0 6.48110699330573e-07

In O 0 5.1071605611241466e-08
one O 0 1.1952865364150966e-09
of O 0 4.2098946551050176e-10
the O 0 1.0789243803932536e-10
families O 0 2.6696492239075553e-11
, O 0 2.5983534768236893e-11
affected O 0 8.968526442332259e-12
individuals O 0 2.15656789301355e-12
presented O 0 9.089272112738911e-10
a O 0 2.5831856653724117e-09
novel O 0 5.371266986742285e-09
nonsense O 0 1.423103679343285e-08
mutation O 0 3.298836481757661e-10
in O 0 2.9894045572298467e-10
exon O 0 3.937926429387062e-09
3 O 0 3.745959986645175e-09
of O 0 1.4056329433742576e-09
the O 0 4.162808708851884e-10
gene O 0 1.0777109066273383e-10
, O 0 5.813104858587437e-11
consisting O 0 7.503514476425721e-11
in O 0 1.2226210321930608e-10
a O 0 1.4455768804211289e-09
G O 0 1.4412792381790496e-07
to O 0 1.8273919266675875e-08
T O 0 4.5140217252992443e-07
transition O 0 1.5930899621707795e-07
at O 0 2.2604476512810834e-08
nucleotide O 0 9.765012798368389e-09
2101 O 0 5.503287638930487e-07
, O 0 7.753053754555594e-10
which O 0 6.695434571352132e-12
produces O 0 2.993487185562471e-12
a O 0 4.0840584386581114e-11
stop O 0 4.425281530107128e-10
signal O 0 8.75612293782524e-09
in O 0 5.950419712519306e-09
codon O 0 1.7719163736273913e-07
82 O 0 1.0288837302141474e-06
( O 0 1.70044689440374e-08
Glu O 0 3.514044510666281e-05
) O 0 1.3971523493694349e-08
of O 0 8.305327270363705e-08
NPII O 0 0.00022129248827695847
. O 0 1.2997985550100566e-06

The O 0 3.1167033398560307e-07
premature O 0 4.869012855124311e-07
termination O 0 1.0096151470406767e-07
eliminates O 0 1.178189137363006e-07
part O 0 9.382792320877797e-09
of O 0 3.890031408104733e-08
the O 0 1.1992469239885395e-08
C O 0 4.6893390504010313e-07
- O 0 1.4586699847995988e-08
terminal O 0 1.782542646822094e-08
domain O 0 6.891899051453265e-09
of O 0 2.1784491988086074e-09
NPII O 0 1.8439232007949613e-06
, O 0 5.652566748004517e-10
including O 0 1.902592944302839e-10
a O 0 5.330440533413139e-10
cysteine O 0 2.712400026805284e-10
residue O 0 3.4714336294427994e-08
in O 0 4.446571555405399e-09
position O 0 1.4669963377400563e-07
85 O 0 4.2415021539454756e-07
, O 0 5.64662872015731e-10
which O 0 9.426925386135654e-12
could O 0 2.1416321840939112e-11
be O 0 2.358627876342112e-11
involved O 0 5.8057912644127185e-11
in O 0 2.90990287421522e-10
the O 0 4.900884587044629e-09
correct O 0 2.1231262792298367e-07
folding O 0 3.955521492571279e-07
of O 0 6.691119835977588e-08
the O 0 1.2364591839286732e-07
prohormone O 0 0.000592569587752223
. O 0 1.571393227095541e-06

In O 0 2.6170788203216944e-08
the O 0 3.2142686290370648e-09
second O 0 1.147362826969811e-08
family O 0 5.191391760916986e-10
, O 0 8.889728536631836e-11
a O 0 8.803807682866704e-11
G279A O 0 5.0536881346374685e-09
substitution O 0 1.4077874421758452e-09
at O 0 1.2295040541232538e-09
position O 0 1.1274818856321644e-09
- O 0 1.0529837446426882e-08
1 O 0 1.995439369295582e-08
of O 0 5.752106790879452e-09
the O 0 1.192756338141976e-09
signal O 0 1.5094000715976108e-08
peptide O 0 1.0980748532674056e-09
was O 0 5.446048056967356e-09
observed O 0 2.2460493465104037e-09
in O 0 1.015688866345954e-09
all O 0 1.3125051046003477e-09
affected O 0 1.2497141099743203e-09
individuals O 0 4.310962697928744e-10
. O 0 7.101037624579476e-08

This O 0 1.0602413880178574e-07
missense O 0 3.2394730169471586e-06
mutation O 0 9.13011177772205e-08
, O 0 3.897872247193845e-09
which O 0 7.565268411724446e-10
replaces O 0 9.336574180451862e-07
Ala O 0 0.38279345631599426
with O 0 2.7449777562083e-08
Thr O 1 0.9999998807907104
, O 0 1.3630444328782687e-08
is O 0 2.362519069265545e-10
frequent O 0 8.659175598779711e-10
among O 0 2.2871519955725006e-10
FNDI B-Disease 1 1.0
patients O 0 3.9868947965260304e-07
and O 0 2.1128554461569138e-09
is O 0 3.9476708013630457e-10
thought O 0 2.094950213304969e-09
to O 0 9.921755639297203e-10
reduce O 0 9.22403309289166e-09
the O 0 2.346282057530402e-09
efficiency O 0 2.293816692144901e-08
of O 0 1.4846393447953687e-08
cleavage O 0 3.737345988241714e-09
by O 0 3.0832827402349494e-09
signal O 0 4.897382837043551e-07
peptidases O 0 4.493920641834848e-06
. O 0 1.0442538211918873e-07
. O 0 3.819575340457959e-07

Genetic O 0 5.473920737131266e-06
heterogeneity O 0 1.3453883411784773e-06
of O 0 4.723428048691858e-07
Saethre B-Disease 1 0.9999997615814209
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 5.915294920555425e-09
due O 0 1.3421714584183064e-07
to O 0 1.162711260604965e-08
TWIST O 0 1.7724720464684651e-06
and O 0 3.142370701425534e-07
FGFR O 1 0.9984681010246277
mutations O 0 1.3133029597156565e-06
. O 0 2.95648533210624e-06

Thirty O 0 1.0790840860863682e-05
- O 0 5.210590643400792e-06
two O 0 5.699432592543019e-10
unrelated O 0 1.2134195870316944e-09
patients O 0 3.1646335552082405e-10
with O 0 1.9788157657602e-12
features O 0 1.4545545878874577e-09
of O 0 3.1823354618154553e-08
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 5.321990848017322e-09
a O 0 4.501209183160881e-09
common O 0 2.78632910521992e-07
autosomal B-Disease 0 0.3885374665260315
dominant I-Disease 0 0.00026987947057932615
condition I-Disease 1 1.0
of O 0 0.4618919789791107
craniosynostosis B-Disease 1 1.0
and O 0 1.018455714074662e-05
limb B-Disease 1 1.0
anomalies I-Disease 1 0.9999934434890747
, O 0 1.0886369139484486e-08
were O 0 1.3766910278434352e-08
screened O 0 2.7893271692391863e-08
for O 0 7.428192283498447e-09
mutations O 0 7.832722803691183e-10
in O 0 1.5508872408531715e-08
TWIST O 0 6.137925993243698e-06
, O 0 4.030122013887194e-08
FGFR2 O 0 2.8422535251593217e-05
, O 0 1.1826511325807587e-08
and O 0 1.4271591908254777e-08
FGFR3 O 0 0.0003152204735670239
. O 0 1.5932554333630833e-06

Nine O 0 2.855339005236601e-07
novel O 0 8.923782601755192e-09
and O 0 1.0469991540418278e-09
three O 0 4.1885339641112296e-10
recurrent O 0 2.4422767808118806e-08
TWIST O 0 6.229628297660383e-07
mutations O 0 7.566859139274129e-09
were O 0 6.494883741936519e-09
found O 0 1.0181832044153794e-09
in O 0 2.843239199634695e-09
12 O 0 2.2363474272424355e-07
families O 0 6.084191372934811e-09
. O 0 7.012233993464179e-08

Seven O 0 8.011475927105494e-08
families O 0 4.5450412877734436e-10
were O 0 3.6533948089001456e-10
found O 0 1.2341366817381072e-10
to O 0 4.2607550820861206e-10
have O 0 3.4330552289851823e-10
the O 0 3.81288334239116e-09
FGFR3 O 0 0.00012153133866377175
P250R O 0 5.725402843381744e-06
mutation O 0 6.748691827596076e-09
, O 0 2.857176439885478e-10
and O 0 2.1651881676465479e-10
one O 0 1.0225733454438668e-10
individual O 0 4.76945982708088e-11
was O 0 1.893770695815533e-09
found O 0 9.857766686272029e-11
to O 0 4.4947298660780177e-10
have O 0 5.087118504221166e-10
an O 0 3.0450822419147983e-10
FGFR2 O 0 2.4785720142972423e-06
VV269 O 0 2.2139267912280047e-06
- O 0 1.1164422630827175e-06
270 O 0 4.98427880302188e-07
deletion O 0 2.2270644421951147e-06
. O 0 6.885114771648659e-07

To O 0 7.18308470482043e-08
date O 0 1.459021206073885e-07
, O 0 2.1304222830309527e-09
our O 0 1.0324020527363587e-09
detection O 0 1.0725688781576537e-08
rate O 0 1.091459700397479e-09
for O 0 1.0261683863754811e-10
TWIST O 0 1.6898879096061137e-07
or O 0 2.5950489757065043e-08
FGFR O 0 2.8126740289735608e-05
mutations O 0 4.273535303411791e-09
is O 0 1.1620960443936568e-10
68 O 0 6.220139514567791e-09
% O 0 3.042115725993e-10
in O 0 1.477011846162668e-10
our O 0 1.577092234583688e-09
Saethre B-Disease 0 7.186410221038386e-05
- I-Disease 1 0.9998883008956909
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 8.057157430130246e-08
, O 0 9.34468891156115e-11
including O 0 7.926665573920744e-11
our O 0 1.8195897011352713e-09
five O 0 2.0277628465237285e-09
patients O 0 4.778576978559101e-10
elsewhere O 0 1.5260619434798173e-09
reported O 0 1.501451518670649e-09
with O 0 7.497981124870989e-10
TWIST O 0 0.000109074630017858
mutations O 0 2.9086211270623608e-06
. O 0 5.4695005928806495e-06

More O 0 1.6799246438381488e-08
than O 0 1.4111478652267806e-09
35 O 0 7.091168097161926e-09
different O 0 1.4099714451543122e-10
TWIST O 0 1.5567205480238044e-07
mutations O 0 2.7422657478126666e-09
are O 0 4.68790110896844e-11
now O 0 1.0430600133615187e-10
known O 0 2.76013711886236e-10
in O 0 2.403938159645236e-10
the O 0 1.0250401638600692e-09
literature O 0 3.944001747413495e-08
. O 0 1.0869317890183083e-07

The O 0 4.2284727896912955e-07
most O 0 1.3653725927653682e-09
common O 0 1.25790669547321e-10
phenotypic O 0 5.859080443038067e-10
features O 0 2.703856583075037e-10
, O 0 2.6474393857722767e-11
present O 0 2.0406461243016594e-11
in O 0 7.523606043724484e-11
more O 0 4.330952697167989e-12
than O 0 1.8101410995119416e-11
a O 0 1.681128153352418e-10
third O 0 2.6201891767385632e-09
of O 0 1.7168942934020492e-09
our O 0 6.114694972580992e-09
patients O 0 3.499886602753577e-09
with O 0 1.5037349143653955e-10
TWIST O 0 8.14139355043153e-07
mutations O 0 1.6536471036943112e-07
, O 0 1.2299737228715912e-08
are O 0 2.2192681026211858e-09
coronal B-Disease 0 1.587849396855745e-06
synostosis I-Disease 0 2.101944846799597e-05
, O 0 3.8949313108105343e-08
brachycephaly B-Disease 0 5.814037285745144e-05
, O 0 1.207916824341737e-07
low B-Disease 0 8.135313692037016e-05
frontal I-Disease 1 0.9999980926513672
hairline I-Disease 1 1.0
, O 0 1.1375567737559322e-05
facial B-Disease 1 1.0
asymmetry I-Disease 1 0.9999994039535522
, O 0 5.300992711454455e-07
ptosis B-Disease 1 0.9999765157699585
, O 0 9.255794708451504e-08
hypertelorism B-Disease 0 0.010784943588078022
, O 0 2.7615037367922923e-08
broad B-Disease 0 4.432568232459744e-07
great I-Disease 0 4.5451241021510214e-05
toes I-Disease 0 0.0001411741104675457
, O 0 3.660275638139865e-08
and O 0 3.9785458483265757e-08
clinodactyly B-Disease 0 0.00024377078807447106
. O 0 2.593896624603076e-06

Significant O 0 3.4653321563382633e-06
intra O 0 7.888780965004116e-05
- O 0 8.456111572741065e-06
and O 0 4.106717454988029e-08
interfamilial O 0 8.065249858191237e-06
phenotypic O 0 1.3502931039965915e-07
variability O 0 9.205087359021036e-09
is O 0 2.6903307706604984e-11
present O 0 9.366382669462325e-12
for O 0 2.485902039772725e-10
either O 0 4.085340066239951e-09
TWIST O 0 7.204606049526774e-07
mutations O 0 6.029596022472106e-08
or O 0 5.385056667250865e-08
FGFR O 0 5.095835149404593e-05
mutations O 0 2.8173349164717365e-07
. O 0 7.25076688468107e-07

The O 0 2.5201785547324107e-07
overlap O 0 1.0995696797522214e-08
in O 0 1.5519043827794121e-09
clinical O 0 7.648684352545843e-09
features O 0 7.269829738199007e-10
and O 0 1.332568222434105e-10
the O 0 1.608558841681429e-10
presence O 0 1.2431994322881224e-10
, O 0 3.483719215879866e-11
in O 0 8.21938211936768e-11
the O 0 2.7008414948959114e-10
same O 0 9.329337302688145e-11
genes O 0 1.9247999027971474e-10
, O 0 1.9959056629659244e-10
of O 0 1.1760641349667367e-09
mutations O 0 3.655283575820789e-10
for O 0 2.8300092824729006e-10
more O 0 3.759326877572633e-11
than O 0 1.0526373522834476e-10
one O 0 1.9197914091773072e-10
craniosynostotic B-Disease 0 1.258186728136934e-07
condition I-Disease 0 2.0439590286969178e-07
- O 0 1.879378999092296e-07
such O 0 3.6534384406650133e-09
as O 0 4.581328649777561e-09
Saethre B-Disease 0 2.5719784844113747e-06
- I-Disease 0 3.5160408629053563e-07
Chotzen I-Disease 0 1.5057165001053363e-05
, I-Disease 0 5.0251891536845505e-09
Crouzon I-Disease 0 5.154759492143057e-05
, I-Disease 0 9.761734531821276e-09
and I-Disease 0 2.3760152956242564e-08
Pfeiffer I-Disease 0 0.0006195840542204678
syndromes I-Disease 1 0.9995934367179871
- O 1 0.8756064772605896
support O 0 1.0923100489890203e-05
the O 0 5.0262649153864913e-08
hypothesis O 0 1.5315272605676e-08
that O 0 4.147028206946679e-11
TWIST O 0 1.1077017347815854e-07
and O 0 1.6456136009423972e-08
FGFRs O 0 1.2332951882854104e-05
are O 0 4.2640882491618015e-10
components O 0 1.5129426600424267e-08
of O 0 1.0789377391517974e-08
the O 0 1.6952840242723255e-09
same O 0 4.0307562843011624e-10
molecular O 0 1.1325770321590767e-09
pathway O 0 5.479919851225645e-10
involved O 0 8.237163034996442e-11
in O 0 1.9837227693830783e-10
the O 0 6.235332250525971e-09
modulation O 0 0.0004385233041830361
of O 0 1.0903098882408813e-05
craniofacial O 1 1.0
and O 0 8.31485704111401e-06
limb O 0 0.016475258395075798
development O 0 2.0676365863891988e-07
in O 0 5.611855424803025e-09
humans O 0 1.7849913769296677e-09
. O 0 1.0227299007681268e-09
. O 0 3.6135979541995766e-08

Mutation O 0 1.4513440760310914e-07
analysis O 0 2.9014316282882646e-08
of O 0 6.800353702374196e-08
UBE3A O 1 0.9999974966049194
in O 0 0.1681721806526184
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.0008233888074755669
. O 0 6.544727852997312e-07

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.7316733053339703e-07
AS B-Disease 1 1.0
) O 0 1.0781719961272529e-09
is O 0 5.639522529521379e-11
caused O 0 2.0284388058122715e-10
by O 0 9.399459682812861e-11
chromosome O 0 5.316626783269385e-08
15q11 O 0 1.3121926713210996e-05
- O 0 1.2725927263090853e-05
q13 O 0 1.2773347407346591e-05
deletions O 0 2.5253319790863316e-07
of O 0 1.0066210087700256e-08
maternal O 0 6.241593553113489e-08
origin O 0 2.24416507599301e-09
, O 0 2.0909132758539783e-10
by O 0 4.5010178917337385e-10
paternal O 0 0.0003474565746728331
uniparental B-Disease 1 1.0
disomy I-Disease 1 0.9999955892562866
( O 0 2.947247423890076e-07
UPD B-Disease 1 1.0
) O 0 8.911774429520847e-09
15 O 0 2.575060520371153e-08
, O 0 5.108908851525484e-10
by O 0 3.248243896081249e-10
imprinting O 0 1.4053814084036276e-05
defects O 0 0.0002657684381119907
, O 0 6.871842206379597e-09
and O 0 1.5446487422465793e-09
by O 0 2.676196486639526e-10
mutations O 0 2.439895230299527e-10
in O 0 2.898222328795441e-09
the O 0 4.889216498327187e-08
UBE3A O 0 9.021954610943794e-05
gene O 0 2.0570274728015647e-07
. O 0 1.3544502053264296e-06

UBE3A O 0 0.0017233513062819839
encodes O 0 2.026953779932228e-06
a O 0 1.0037014419594925e-07
ubiquitin O 0 9.721567550968757e-08
- O 0 1.4332483999623946e-07
protein O 0 2.0842130243892143e-09
ligase O 0 2.033717372285082e-08
and O 0 8.94914542470815e-09
shows O 0 3.2949472483778663e-08
brain O 0 1.5040310472613783e-06
- O 0 4.971527118868835e-07
specific O 0 1.2938198779011145e-07
imprinting O 0 5.9106772823724896e-05
. O 0 2.0995730665163137e-06

Here O 0 6.764208819731721e-07
we O 0 6.735217539244331e-08
describe O 0 1.5935275143874605e-07
UBE3A O 0 0.00019479068578220904
coding O 0 8.545480523025617e-05
- O 0 3.980814290116541e-05
region O 0 4.832033937418601e-07
mutations O 0 6.923087170207509e-08
detected O 0 3.9153551512072227e-08
by O 0 2.7232860411174897e-10
SSCP O 0 1.4656052371719852e-06
analysis O 0 2.9971938264594655e-09
in O 0 5.812752501554996e-10
13 O 0 3.884678179133516e-08
AS B-Disease 1 0.9999995231628418
individuals O 0 8.188946049036971e-11
or O 0 3.776310375513958e-10
families O 0 4.468734549067932e-10
. O 0 1.6005786918071863e-08

Two O 0 7.58874563189238e-08
identical O 0 1.8841735283103844e-08
de O 0 3.767393650377926e-07
novo O 0 2.5359560140714166e-07
5 O 0 4.084147349203704e-07
- O 0 1.4201420981407864e-06
bp O 0 3.485506283595896e-07
duplications O 0 6.55117275982775e-07
in O 0 1.8607629215239285e-08
exon O 0 7.696129387113615e-07
16 O 0 1.3711178326047957e-07
were O 0 3.5261475517245344e-08
found O 0 1.094073986962485e-08
. O 0 8.648982685599549e-08

Among O 0 1.3917484409375902e-07
the O 0 3.509506019128139e-09
other O 0 2.158306727784165e-10
11 O 0 1.4679326643118884e-09
unique O 0 3.3753208561471126e-10
mutations O 0 1.0596117316907794e-09
, O 0 2.531800880056778e-10
8 O 0 3.3035306046258484e-08
were O 0 5.956452753252961e-08
small O 0 1.022909845715958e-08
deletions O 0 2.7149553716299124e-07
or O 0 1.8532753998101725e-08
insertions O 0 1.7158058085442462e-07
predicted O 0 1.7696629939223385e-08
to O 0 5.848919681916698e-10
cause O 0 1.7530995544134953e-09
frameshifts O 0 5.8869900954050536e-08
, O 0 3.9424938313992186e-10
1 O 0 8.622772718069882e-09
was O 0 7.2656605176746325e-09
a O 0 3.0109265081179615e-10
mutation O 0 7.230455817408554e-11
to O 0 9.286214852632924e-11
a O 0 3.30717758734167e-10
stop O 0 9.024836988835716e-10
codon O 0 1.4344067045257702e-09
, O 0 1.98888280844578e-10
1 O 0 1.2488522216358433e-08
was O 0 2.7572408356490996e-08
a O 0 2.232245943645239e-09
missense O 0 2.0304112169355903e-08
mutation O 0 5.502773792187554e-10
, O 0 1.1413767153634069e-10
and O 0 1.9909550397212428e-10
1 O 0 3.5232297079801356e-08
was O 0 3.886211885628654e-08
predicted O 0 5.289223725668535e-09
to O 0 3.5187805447201015e-10
cause O 0 7.743728436260255e-10
insertion O 0 2.492730910574892e-09
of O 0 9.81005943145874e-09
an O 0 1.6577700323594513e-09
isoleucine O 0 1.3722089988732478e-06
in O 0 1.1664273991129903e-08
the O 0 2.897041007088319e-08
hect O 0 9.254820270143682e-07
domain O 0 1.591276266310615e-08
of O 0 2.9888420627344203e-09
the O 0 1.7190963097490908e-09
UBE3A O 0 3.4946367577504134e-06
protein O 0 5.54197043811655e-09
, O 0 2.336750237752483e-10
which O 0 1.3514679826631681e-11
functions O 0 2.3170139418215996e-10
in O 0 4.5284964667047234e-10
E2 O 0 6.470071411968092e-08
binding O 0 3.809256465814315e-09
and O 0 4.176736734251563e-09
ubiquitin O 0 4.7077197251610414e-08
transfer O 0 6.742756113453652e-07
. O 0 9.679379218141548e-07

Eight O 0 7.621353006470599e-07
of O 0 1.9274985163519887e-08
the O 0 1.3044463287315011e-09
cases O 0 1.223953438600489e-10
were O 0 3.415485949620489e-10
familial O 0 1.104022739895072e-08
, O 0 2.0557668900522685e-09
and O 0 1.9403709750065445e-09
five O 0 7.343472496756931e-09
were O 0 3.006694271334709e-08
sporadic O 0 1.152150957750564e-06
. O 0 2.270170625706669e-06

In O 0 2.326351591364073e-07
two O 0 7.0145178554525955e-09
familial O 0 4.5940890203155504e-08
cases O 0 4.387746277423332e-10
and O 0 1.631208779162563e-10
one O 0 1.330749538341891e-10
sporadic O 0 1.1731075666432389e-08
case O 0 4.925793994914329e-09
, O 0 4.344925308430447e-09
mosaicism O 0 4.96561115141958e-05
for O 0 7.054571682374444e-08
UBE3A O 0 5.802626765216701e-05
mutations O 0 5.452023721375099e-09
was O 0 5.160848637331128e-09
detected O 0 1.7175133537605802e-09
in O 0 1.2767266410751432e-10
the O 0 3.747130106201979e-10
mother O 0 4.1318004573298595e-10
of O 0 6.081995462814405e-10
three O 0 1.023898466012696e-10
AS B-Disease 1 0.9999648332595825
sons O 0 1.0821760554335924e-07
, O 0 3.3506705743313603e-10
in O 0 2.1158669261112095e-10
the O 0 3.0929880878716176e-10
maternal O 0 9.126105169343646e-07
grandfather O 0 6.480485353677068e-06
of O 0 4.831785190617666e-06
two O 0 1.0605548084186012e-07
AS B-Disease 1 1.0
first O 0 4.4163147094877786e-07
cousins O 0 1.700107361557457e-07
, O 0 5.048001461283036e-10
and O 0 1.4788524571596184e-10
in O 0 4.866742564502147e-10
the O 0 2.5143096493707162e-09
mother O 0 2.130865262017778e-09
of O 0 2.563402290434169e-08
an O 0 5.20589127361859e-09
AS B-Disease 1 1.0
daughter O 0 0.0029193090740591288
. O 0 7.125282718334347e-05

The O 0 1.7458567924677482e-07
frequencies O 0 4.89216382959512e-08
with O 0 1.1015018758220307e-10
which O 0 9.416273316631418e-11
we O 0 5.391875279592284e-10
detected O 0 2.9597566619798954e-09
mutations O 0 4.6536136055763677e-10
were O 0 2.329515691457118e-09
5 O 0 1.0821653795289876e-08
( O 0 4.197411029860376e-10
14 O 0 4.091672778372413e-09
% O 0 9.97476545805398e-11
) O 0 1.9550690927294667e-11
of O 0 1.0892817203789207e-10
35 O 0 3.65929481160876e-10
in O 0 4.874655193387589e-11
sporadic O 0 2.9549618307811443e-09
cases O 0 5.182663326275261e-11
and O 0 1.8260415401982755e-10
8 O 0 6.07784969020031e-08
( O 0 7.96393506696802e-10
80 O 0 5.325118568322296e-09
% O 0 1.2601832077852038e-10
) O 0 7.930461148886181e-11
of O 0 2.3925025849358406e-10
10 O 0 1.234033653041422e-09
in O 0 4.1106709702809496e-10
familial O 0 6.5375016511382e-09
cases O 0 1.6098579136425428e-09
. O 0 6.8377441486688895e-09
. O 0 1.735534453928267e-07

The O 0 3.827119144261815e-06
hemochromatosis B-Disease 1 1.0
845 O 0 1.2050855957568274e-06
G O 0 1.1658162435423947e-07
- O 0 6.207874747587994e-08
- O 0 6.655213979911423e-08
> O 0 1.485622931340913e-07
A O 0 1.4060733022347449e-08
and O 0 9.254404881309242e-11
187 O 0 9.991431015876628e-10
C O 0 7.976772309348235e-08
- O 0 1.973708947389241e-07
- O 0 3.21134643854748e-06
> O 0 2.6371621061116457e-05
G O 0 1.871451604529284e-05
mutations O 0 5.2599503419514804e-08
: O 0 6.521084228161556e-10
prevalence O 0 2.1368858682535574e-08
in O 0 2.8733199153307964e-10
non O 0 3.1645043918615556e-07
- O 0 9.867841299637803e-07
Caucasian O 0 5.751857088398538e-07
populations O 0 5.661614110863411e-08
. O 0 8.625573144627197e-08

Hemochromatosis B-Disease 1 0.9999526739120483
, O 0 1.7661601248164516e-07
the O 0 5.950569175183773e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 1.0
, O 0 3.404425896746943e-08
leads O 0 5.715255468885516e-08
, O 0 2.440305957307487e-09
if O 0 4.144691700957992e-09
untreated O 0 3.0026797048776643e-06
, O 0 3.2496463298059552e-09
to O 0 5.517451029390941e-08
progressive O 1 0.9999974966049194
iron B-Disease 1 1.0
overload I-Disease 1 0.9999980926513672
and O 0 1.1340700893924804e-06
premature B-Disease 0 3.76168500224594e-05
death I-Disease 0 1.7525273506180383e-05
. O 0 1.563390242154128e-06

The O 0 1.7862486856756732e-05
hemochromatosis B-Disease 1 1.0
gene O 0 4.701483703684062e-06
, O 0 2.7263345359074265e-08
HFE O 1 0.9976465106010437
, O 0 7.014092773260927e-08
recently O 0 2.7110477418545997e-08
has O 0 5.42997591335137e-11
been O 0 2.1610942202432426e-11
identified O 0 1.8850955518789902e-10
, O 0 7.528716539084712e-11
and O 0 1.883208866626518e-10
characterization O 0 5.0329966860829245e-09
of O 0 1.5076651038725686e-08
this O 0 3.999190145709264e-10
gene O 0 1.2423087003554656e-09
has O 0 1.2786226244454468e-10
shown O 0 2.1889690060561406e-10
that O 0 2.408880213355946e-11
it O 0 1.0312595395689517e-11
contains O 0 3.0637582748571646e-11
two O 0 3.638101625513812e-11
mutations O 0 6.476025271595631e-11
that O 0 1.9026355144169393e-11
result O 0 1.704712343508774e-10
in O 0 6.939937513550376e-10
amino O 0 3.543308979558901e-10
acid O 0 1.4072953913313313e-10
substitutions O 0 1.2157687079294988e-09
- O 0 1.6196705088233898e-09
cDNA O 0 1.16028546770508e-08
nucleotides O 0 9.1640900423684e-10
845 O 0 8.204119161803192e-09
G O 0 7.913304678197619e-09
- O 0 1.654088066516124e-08
- O 0 4.404453335382641e-08
> O 0 1.133729057301025e-07
A O 0 9.70776312669841e-08
( O 0 1.1456778581386828e-10
C282Y O 0 5.523684265540396e-08
) O 0 4.074270781861955e-11
and O 0 4.806161371662121e-11
187 O 0 1.0910454761869914e-09
C O 0 1.2549774908166e-07
- O 0 5.461455430122442e-07
- O 0 9.442439477425069e-06
> O 0 1.5276655176421627e-05
G O 0 4.561752575682476e-06
( O 0 5.395087931958642e-09
H63D O 0 8.605624316260219e-06
) O 0 9.606417883389895e-09
. O 0 6.514203221286152e-08

Although O 0 6.847509212093428e-05
hemochromatosis B-Disease 1 1.0
is O 0 1.9723197297594197e-08
common O 0 2.0284089963240604e-09
in O 0 6.078272329901324e-10
Caucasians O 0 1.1064432214880071e-07
, O 0 5.648740364350147e-10
affecting O 0 3.927132841141656e-09
> O 0 8.473384838225684e-08
= O 0 8.747563384758905e-08
1 O 0 8.270455964520806e-08
/ O 0 8.563360438529344e-07
300 O 0 1.3684182675888223e-08
individuals O 0 5.186025220371704e-11
of O 0 7.721988048992046e-10
northern O 0 3.280672844496735e-09
European O 0 6.544388142515345e-09
origin O 0 4.21421120222476e-09
, O 0 2.512731134274304e-10
it O 0 2.690777288483215e-11
has O 0 1.2344467462122033e-11
not O 0 3.0012124729861256e-11
been O 0 8.308548293811668e-11
recognized O 0 3.5961641997594995e-10
in O 0 3.711642382331348e-10
other O 0 5.445359163580576e-10
populations O 0 1.8603222295965338e-09
. O 0 3.0870385359094143e-08

The O 0 1.5123922025850334e-07
present O 0 5.841185313215647e-09
study O 0 1.894525869516883e-09
used O 0 6.23926632581373e-10
PCR O 0 4.2938655298030426e-08
and O 0 1.0509707548678193e-09
restriction O 0 1.3533687059918975e-08
- O 0 2.2804926835817696e-09
enzyme O 0 5.267090583127576e-11
digestion O 0 1.5403472941599716e-09
to O 0 8.851137184295865e-11
analyze O 0 3.005567461578096e-10
the O 0 1.715227404552877e-10
frequency O 0 5.401811442595772e-09
of O 0 5.098794719771149e-10
the O 0 4.76225392453955e-10
845 O 0 4.439418610502344e-09
G O 0 4.563267541612959e-09
- O 0 9.172873127738512e-09
- O 0 1.8604577434189196e-08
> O 0 9.900138309149042e-08
A O 0 1.188775566873801e-08
and O 0 9.738720940788426e-11
187 O 0 4.148343890619799e-10
C O 0 1.206943345266609e-08
- O 0 3.44718564804225e-08
- O 0 5.756143082180643e-07
> O 0 6.738738647982245e-06
G O 0 2.7766891435021535e-06
mutations O 0 4.0355910613243395e-08
in O 0 6.16208906123461e-09
HLA O 0 2.5289568839070853e-06
- O 0 4.213006377540296e-06
typed O 0 6.992372618697118e-07
samples O 0 3.378183777158483e-08
from O 0 5.472232111891628e-10
non O 0 1.3832281808845437e-07
- O 0 1.9428722453085356e-07
Caucasian O 0 6.95237076797639e-08
populations O 0 1.1888519058089742e-09
, O 0 1.4704538975340853e-10
comprising O 0 8.914421423256158e-10
Australian O 0 3.54468490115778e-08
Aboriginal O 0 4.3235164781663116e-08
, O 0 1.922334375015211e-10
Chinese O 0 2.7276283454114036e-09
, O 0 1.855664649719202e-10
and O 0 5.7731636138314e-10
Pacific O 0 2.2924437814708654e-07
Islanders O 0 1.566924765938893e-06
. O 0 3.6898356370329566e-07

Results O 0 4.045710966238403e-07
showed O 0 3.439521023551606e-08
that O 0 7.295495457748657e-11
the O 0 5.807078706787649e-10
845 O 0 1.523817338977551e-08
G O 0 5.2992742638480195e-08
- O 0 8.05915618684594e-08
- O 0 1.3574771173807676e-07
> O 0 2.112929706754585e-07
A O 0 1.9730872935497246e-08
mutation O 0 5.382175816137647e-10
was O 0 3.03969738268961e-10
present O 0 9.483063639903477e-12
in O 0 5.881134468310734e-11
these O 0 2.1271959887991798e-11
populations O 0 3.6783055767930506e-11
( O 0 1.236006436089454e-11
allele O 0 7.104675736613331e-10
frequency O 0 3.8321901207893916e-09
0 O 0 1.4002008441593716e-09
. O 0 5.418442361460052e-10
32 O 0 7.508017318968996e-09
% O 0 1.8278152602579922e-10
) O 0 4.9729893814021153e-11
, O 0 1.720872749855218e-11
and O 0 1.3893931144481897e-11
, O 0 1.7956469644531126e-11
furthermore O 0 1.3584880442785163e-10
, O 0 3.140076740293374e-11
it O 0 1.4604439185772478e-11
was O 0 1.7974959298783233e-09
always O 0 1.7628232207300698e-09
seen O 0 1.7532968410449712e-09
in O 0 3.839914497483221e-10
conjunction O 0 1.4810530579723036e-08
with O 0 1.1941084787636669e-09
HLA O 0 3.951961480197497e-05
haplotypes O 0 2.076822056551464e-07
common O 0 3.3011040567743066e-09
in O 0 4.980129642007114e-10
Caucasians O 0 2.1962858198776303e-08
, O 0 2.8291297082816413e-10
suggesting O 0 9.853448057484115e-10
that O 0 1.3839658585812487e-11
845 O 0 6.2513252352403015e-09
G O 0 2.059394716980023e-07
- O 0 1.493881654823781e-06
- O 0 1.6335558029823005e-05
> O 0 9.316137584391981e-05
A O 0 2.093275270453887e-06
may O 0 1.3097048778831777e-08
have O 0 3.558133787606721e-10
been O 0 1.371929375659775e-10
introduced O 0 4.081615601059241e-10
into O 0 4.3653722997527566e-11
these O 0 8.885283134252298e-12
populations O 0 1.924938507202878e-11
by O 0 9.625426844461771e-11
Caucasian O 0 8.168740350811277e-08
admixture O 0 3.7673865449505684e-07
. O 0 6.344020562210062e-07

187 O 0 2.781584669264703e-07
C O 0 2.849884310762718e-07
- O 0 8.58712851936616e-08
- O 0 7.705531857027381e-08
> O 0 2.1846756226295838e-07
G O 0 1.215389602293726e-07
was O 0 4.911599571499892e-09
present O 0 5.4018990669479905e-11
at O 0 8.196451295461316e-10
an O 0 3.1752732387868576e-11
allele O 0 4.388072682992572e-10
frequency O 0 5.266533431580456e-09
of O 0 1.5492316762788505e-08
2 O 0 1.3636797575600212e-06
. O 0 2.951760734504205e-06

68 O 0 5.593227797362488e-06
% O 0 8.126451511714095e-09
in O 0 9.054837435407137e-10
the O 0 2.7512650491168245e-10
two O 0 8.564249309728211e-11
populations O 0 9.06413000212325e-11
analyzed O 0 4.10308276244109e-09
( O 0 2.926206166264933e-09
Australian O 0 8.323484053107677e-07
Aboriginal O 0 2.2729255988451769e-07
and O 0 1.7502062021890197e-09
Chinese O 0 2.337782412098477e-08
) O 0 8.06364219840816e-09
. O 0 5.361433252915049e-08

In O 0 5.428907101645564e-08
the O 0 1.5503490047308333e-08
Australian O 0 1.2573015339967242e-07
Aboriginal O 0 4.086371063749539e-08
samples O 0 1.0581595599745697e-09
, O 0 2.930805945156045e-11
187 O 0 2.3230675716412463e-10
C O 0 1.7292160592319306e-08
- O 0 4.70498164872879e-08
- O 0 4.821833385904029e-07
> O 0 2.268045818709652e-06
G O 0 9.771590612217551e-07
was O 0 1.9655825411746264e-08
found O 0 2.984283375973007e-10
to O 0 1.0207707595855098e-10
be O 0 3.0209357237964696e-10
associated O 0 1.73382641577291e-08
with O 0 3.6199634401157255e-09
HLA O 1 0.9999998807907104
haplotypes O 0 1.203196825372288e-05
common O 0 4.825090016424838e-08
in O 0 2.1583117515433514e-09
Caucasians O 0 1.0774822811754348e-07
, O 0 5.610685804846582e-10
suggesting O 0 2.6839475086859466e-09
that O 0 1.539115362936272e-11
it O 0 7.321908704338576e-12
was O 0 9.997913608117415e-10
introduced O 0 1.2794405535032638e-09
by O 0 2.421369493799119e-10
recent O 0 3.154673189342816e-09
admixture O 0 9.835430603288842e-08
. O 0 1.927127755152469e-07

In O 0 8.823842989613695e-08
the O 0 8.703771925411274e-09
Chinese O 0 9.558111635499245e-09
samples O 0 7.916229893822901e-10
analyzed O 0 2.3096365098229654e-10
, O 0 8.965777426039878e-11
187 O 0 1.3559879885605142e-09
C O 0 4.243338835863142e-08
- O 0 3.7565008881301765e-08
- O 0 1.4583702068193816e-07
> O 0 3.7083313486618863e-07
G O 0 1.4740307108240813e-07
was O 0 3.037739615407986e-09
present O 0 9.04830724235417e-11
in O 0 1.6402816604976778e-10
association O 0 2.0843751724619608e-10
with O 0 1.9998447342572945e-11
a O 0 2.395896592233271e-09
wide O 0 7.96193333485462e-09
variety O 0 2.9836872972310857e-09
of O 0 1.4560015415554517e-08
HLA O 0 2.948179371742299e-06
haplotypes O 0 2.225025639290834e-07
, O 0 2.9976225945915758e-09
showing O 0 3.5198763903565577e-09
this O 0 4.5707541918016403e-11
mutation O 0 4.027495351111021e-11
to O 0 4.668644984495707e-11
be O 0 2.9157251613121105e-10
widespread O 0 4.708603507097564e-10
and O 0 7.371137727973931e-11
likely O 0 6.788929973744473e-10
to O 0 3.7929637208833356e-10
predate O 0 3.102870849147621e-08
the O 0 2.2849684366832435e-09
more O 0 8.12811762340715e-11
genetically O 0 8.573962095859144e-10
restricted O 0 1.8545686097937164e-09
845 O 0 1.6904641242376783e-08
G O 0 8.566336617832349e-08
- O 0 6.698518859593605e-07
- O 0 1.5102128827493289e-06
> O 0 3.113588945780066e-06
A O 0 4.411675718074548e-07
mutation O 0 6.617494108240862e-08
. O 0 6.713158029469923e-08

Genotype O 0 3.1654530175728723e-05
- O 0 8.005051313375589e-06
phenotype O 0 1.1116151910073313e-07
correlations O 0 7.320889494621952e-08
in O 0 2.5814640025600966e-07
attenuated B-Disease 1 0.999966025352478
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
. O 0 0.0001003535435302183

Germ O 1 0.8683115839958191
- O 0 0.00017934148490894586
line O 0 4.783780127581849e-07
mutations O 0 1.1301090729887164e-08
of O 0 1.0873128175603597e-08
the O 0 8.509531745914956e-09
tumor B-Disease 0 1.2373501476758975e-06
suppressor O 0 2.451157160976436e-05
APC O 0 4.467222254334047e-07
are O 0 5.753333365277058e-10
implicated O 0 2.1903204583395564e-08
in O 0 5.315683893059031e-08
attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 6.899213644828706e-07
AAPC B-Disease 1 1.0
) O 0 1.0265603922476885e-09
, O 0 1.3472324644769884e-10
a O 0 1.4714611473731765e-10
variant O 0 1.0048009357888077e-07
of O 0 4.257495675119571e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 5.238919698058453e-07
FAP B-Disease 0 7.5552338785200845e-06
) O 0 1.2051031283988323e-08
. O 0 1.1094081031615133e-07

AAPC B-Disease 1 1.0
is O 0 2.377683649967821e-08
recognized O 0 5.5444546731564515e-09
by O 0 1.3528304865229046e-10
the O 0 4.859507241050665e-10
occurrence O 0 4.562797695228937e-09
of O 0 3.586329899718521e-09
< O 0 3.223724434064934e-06
100 O 0 7.487575999221008e-07
colonic B-Disease 0 3.579338454073877e-06
adenomas I-Disease 0 1.8492659137336886e-06
and O 0 1.3449326097259018e-09
a O 0 5.557199145300729e-10
later O 0 1.3552019506590796e-09
onset O 0 5.303480429574847e-05
of O 0 1.8939141227747314e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.6035005262770028e-09
age O 0 2.3062260989803463e-09
> O 0 2.7331967800137136e-08
40 O 0 6.702651322854081e-09
years O 0 7.525418066478551e-10
) O 0 1.4892614919048697e-09
. O 0 6.347204362100456e-08

The O 0 1.0389335614036099e-07
aim O 0 2.222404305030068e-07
of O 0 2.435590618077299e-09
this O 0 7.544615626686735e-11
study O 0 4.047257529116166e-10
was O 0 1.996428355965918e-09
to O 0 9.35107657973333e-10
assess O 0 1.0132227146186779e-07
genotype O 0 1.0787350674945628e-06
- O 0 3.323257260490209e-05
phenotype O 0 1.7515034755888337e-07
correlations O 0 4.41414158558473e-08
in O 0 2.3264270510026108e-07
AAPC B-Disease 1 1.0
families O 0 4.4529727460940194e-08
. O 0 1.114130512291922e-07

By O 0 6.472389291189984e-09
protein O 0 1.1557284018692826e-09
- O 0 1.7404266472453855e-08
truncation O 0 1.3021258382650558e-07
test O 0 5.2209191636620744e-08
( O 0 2.206976157381746e-09
PTT O 0 3.6001833336740674e-07
) O 0 1.126883586444194e-10
assay O 0 2.562164258534949e-09
, O 0 2.0168576531087723e-10
the O 0 2.1136525862885946e-10
entire O 0 1.2329514076370174e-09
coding O 0 1.3694202039005177e-07
region O 0 2.0431377478757895e-08
of O 0 1.0580894382883343e-08
the O 0 2.6523447882453866e-09
APC B-Disease 0 2.3537687354746595e-08
gene O 0 1.1708491953754674e-09
was O 0 3.930152647768637e-09
screened O 0 5.853274753775395e-09
in O 0 1.9706267728736293e-09
affected O 0 6.774546479348942e-10
individuals O 0 2.298096088426682e-11
from O 0 1.3327214887226546e-09
11 O 0 2.4192581804527435e-07
AAPC B-Disease 1 1.0
kindreds O 0 1.32917284645373e-06
, O 0 3.017637473234913e-09
and O 0 5.531797797608817e-10
their O 0 1.1160820045930109e-09
phenotypic O 0 1.9432979669886663e-08
differences O 0 4.872587222592983e-09
were O 0 4.533634268000242e-08
examined O 0 1.2784577165803057e-06
. O 0 1.6435469660791568e-06

Five O 0 1.0735190159039121e-07
novel O 0 1.4562903771775382e-08
germ O 0 3.3629999961704016e-05
- O 0 6.7909509198216256e-06
line O 0 2.6449433221387153e-07
APC B-Disease 0 2.8642926963584614e-07
mutations O 0 2.752604810751791e-09
were O 0 1.8137442658883174e-09
identified O 0 4.60375293442894e-09
in O 0 5.104313860471166e-09
seven O 0 4.768021000245426e-08
kindreds O 0 4.862085006607231e-06
. O 0 7.18856654202682e-07

Mutations O 0 3.2818029467307497e-06
were O 0 1.1106742192623642e-07
located O 0 5.230335275996367e-09
in O 0 7.538117352545726e-10
three O 0 5.334506100740377e-11
different O 0 7.087763102125999e-12
regions O 0 8.888779989835172e-11
of O 0 1.4263339398468133e-09
the O 0 2.8614974834084705e-09
APC B-Disease 0 4.144851928344906e-08
gene O 0 2.593355308277978e-09
( O 0 1.7481432967869637e-10
1 O 0 9.854637106343489e-09
) O 0 2.6919746987097426e-10
at O 0 2.7946989167304537e-09
the O 0 7.568977666849719e-10
5 O 0 3.247229596325951e-09
end O 0 3.689073269086407e-09
spanning O 0 1.6840623340286243e-09
exons O 0 2.2695967327734934e-09
4 O 0 1.1354041040689822e-09
and O 0 2.4702148659905276e-10
5 O 0 2.83975976067552e-09
, O 0 5.844960626610884e-10
( O 0 3.0692386132624705e-11
2 O 0 7.201790275246367e-10
) O 0 4.4324002801410245e-11
within O 0 1.0118655219271133e-10
exon O 0 3.3189075931971956e-09
9 O 0 7.661737910780175e-09
, O 0 4.54297849339369e-10
and O 0 1.9661954009375648e-10
( O 0 2.99942709558465e-11
3 O 0 8.040063614878079e-10
) O 0 6.220370746268244e-11
at O 0 5.224868315778508e-10
the O 0 2.0816418033753337e-10
3 O 0 3.49929929477355e-09
distal O 0 1.4413790161427187e-08
end O 0 3.7164632260555663e-08
of O 0 2.0255953359082923e-08
the O 0 1.3380504704230134e-08
gene O 0 2.8679245644980256e-08
. O 0 3.3143010114145e-07

Variability O 0 2.6906845960184e-06
in O 0 9.012867785429535e-09
the O 0 4.4601193849302945e-09
number O 0 7.594881168415668e-09
of O 0 5.623096512863412e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 9.011356269184034e-06
most O 0 4.129208364123116e-10
apparent O 0 5.268872005359526e-10
in O 0 3.993090580411973e-11
individuals O 0 2.6358494380207542e-12
with O 0 2.596172625837778e-12
mutations O 0 1.6028836591353013e-10
in O 0 5.4328408438664155e-09
region O 0 5.766396043327404e-06
1 O 0 0.4353140592575073
, O 0 2.2634806029486754e-08
and O 0 7.611228625137301e-08
upper O 1 0.9999998807907104
- O 1 1.0
gastrointestinal O 1 0.9996089339256287
manifestations O 0 2.996749344674754e-06
were O 0 8.179291910437314e-09
more O 0 1.0935095884345714e-10
severe O 0 2.05408934306206e-09
in O 0 5.449900530862806e-10
them O 0 1.0884037004998959e-09
. O 0 1.0954190798884156e-07

In O 0 5.772399092052183e-08
individuals O 0 1.722226389277992e-10
with O 0 1.265088294538641e-11
mutations O 0 2.2433722934867006e-10
in O 0 2.2933636933952783e-10
either O 0 6.962888043915427e-10
region O 0 1.3715800939451128e-08
2 O 0 4.17748005077101e-08
or O 0 1.3409471311121024e-09
region O 0 4.032188360980626e-09
3 O 0 1.0627029034537827e-08
, O 0 2.6378838002827365e-10
the O 0 3.3816746625170424e-10
average O 0 1.3557862610369398e-09
number O 0 3.291658612347703e-10
of O 0 4.077850945805039e-09
adenomas B-Disease 0 1.9517394775903085e-06
tended O 0 7.104275567826335e-08
to O 0 3.2486173751067327e-09
be O 0 1.0623537605169986e-09
lower O 0 1.5934896735458892e-09
than O 0 5.825424864713824e-11
those O 0 3.108161644727048e-11
in O 0 1.0465214805854828e-10
individuals O 0 1.2931833555385186e-11
with O 0 6.292815227237902e-12
mutations O 0 1.1811125688598878e-10
in O 0 2.656596054251281e-10
region O 0 4.2136565348016575e-09
1 O 0 2.7115699907653834e-08
, O 0 7.796978618301864e-10
although O 0 3.5227759598299713e-10
age O 0 1.5284389309755397e-09
at O 0 2.4315525148921324e-09
diagnosis O 0 6.488707526841608e-08
was O 0 1.368872570850499e-08
similar O 0 4.9111497091303136e-09
. O 0 1.5481379023185582e-07

In O 0 2.7498781491885893e-06
all O 0 1.1481048431960517e-06
AAPC B-Disease 1 1.0
kindreds O 0 1.4533495232171845e-05
, O 0 1.1057212923049065e-08
a O 0 5.85364334781957e-09
predominance O 0 9.087899570658919e-07
of O 0 3.2674734029569663e-07
right O 1 0.5804681181907654
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9999154806137085
rectal B-Disease 1 1.0
polyp I-Disease 0 0.0014527423772960901
sparing O 0 1.574594534758944e-06
was O 0 1.0730644817158463e-07
observed O 0 6.651546158309429e-08
. O 0 9.457757244035747e-08

No O 0 0.00014694209676235914
desmoid B-Disease 1 0.9996911287307739
tumors I-Disease 1 1.0
were O 0 1.0982292906192015e-06
found O 0 1.3148559574460705e-08
in O 0 3.525991276731588e-09
these O 0 4.3110475189678255e-09
kindreds O 0 3.296027216492803e-06
. O 0 9.639694553698064e-07

Our O 0 3.3992012049566256e-06
data O 0 2.0233989062035107e-07
suggest O 0 1.2551422123863176e-08
that O 0 1.829381229834226e-10
, O 0 5.897615729111294e-10
in O 0 1.3613270510859365e-08
AAPC B-Disease 1 1.0
families O 0 3.4254892256058156e-09
, O 0 2.86132117999216e-10
the O 0 1.8902406029308594e-10
location O 0 5.4629745172007915e-09
of O 0 1.0000130501452986e-08
the O 0 2.6904839245389667e-08
APC B-Disease 0 2.5919430299836677e-06
mutation O 0 2.6488729432116997e-08
may O 0 8.96578633557965e-09
partially O 0 3.103332701925865e-08
predict O 0 8.800056683355706e-09
specific O 0 3.861436059793277e-09
phenotypic O 0 6.430786925193388e-08
expression O 0 1.383203169780245e-07
. O 0 4.153395707362506e-07

This O 0 4.019489807660648e-08
should O 0 1.3195691650480512e-08
help O 0 8.743639590136354e-09
in O 0 7.137858082373327e-10
the O 0 6.016609432890618e-10
design O 0 3.223006217467628e-08
of O 0 1.4383086721636573e-08
tailored O 0 1.9058025202411955e-07
clinical O 0 3.445217373609921e-07
- O 0 4.012213707937917e-07
management O 0 2.989698799638063e-08
protocols O 0 9.838870482781203e-07
in O 0 4.6382037099945705e-10
this O 0 6.776300354172093e-11
subset O 0 2.9764515296903937e-09
of O 0 1.4162711003962158e-09
FAP B-Disease 0 3.071633329909673e-07
patients O 0 1.273104732746333e-08
. O 0 1.111385827812228e-08
. O 0 1.7483409919805126e-07

Wilms B-Disease 1 0.9999972581863403
' I-Disease 0 0.0001406516821589321
tumor I-Disease 0 1.2239835086802486e-05
1 O 0 2.780263912427472e-07
and O 0 1.3707405877028123e-08
Dax O 1 0.9524552822113037
- O 0 5.632994088955456e-07
1 O 0 2.1098527724916494e-07
modulate O 0 3.940506019262102e-07
the O 0 1.2206580635165665e-08
orphan O 0 4.459296576442284e-08
nuclear O 0 3.7256327800605504e-08
receptor O 0 2.22948859374128e-09
SF O 0 4.1875705392158125e-06
- O 0 6.15273165749386e-07
1 O 0 5.8650790890624194e-08
in O 0 1.6583423523286456e-09
sex O 0 4.0460379491236154e-10
- O 0 9.47864342570881e-10
specific O 0 1.005077479576677e-10
gene O 0 7.617654840252897e-10
expression O 0 2.3881828070670963e-08
. O 0 1.6167274452527636e-07

Products O 0 1.2904254163004225e-06
of O 0 4.9230443721626216e-08
steroidogenic O 0 5.754322046414018e-06
factor O 0 7.535724222407225e-08
1 O 0 9.109707832521963e-08
( O 0 1.9094903436212007e-09
SF O 0 1.7283677152590826e-05
- O 0 3.5449561437417287e-06
1 O 0 3.789117499763961e-07
) O 0 7.031825344228082e-09
and O 0 7.855557981883976e-09
Wilms B-Disease 1 0.999983549118042
tumor I-Disease 0 0.019358867779374123
1 O 0 1.9571411939978134e-06
( O 0 1.6303706829035036e-08
WT1 O 0 1.1116867426608223e-05
) O 0 2.3754611611082055e-09
genes O 0 7.958650405370804e-10
are O 0 3.7130919866568135e-11
essential O 0 1.1976056590867756e-08
for O 0 4.6344367232720174e-10
mammalian O 0 2.447192173349322e-07
gonadogenesis O 0 1.2200387118355138e-06
prior O 0 1.1729032678431395e-07
to O 0 8.598351364241807e-09
sexual O 0 3.4034506324331915e-09
differentiation O 0 1.1889947870713513e-07
. O 0 1.2164332474640105e-07

In O 0 7.522325518038997e-08
males O 0 6.394604845638696e-09
, O 0 9.535146006101058e-10
SF O 0 2.124217826349195e-05
- O 0 2.584271896921564e-06
1 O 0 2.8096235382690793e-07
participates O 0 5.368768096758458e-09
in O 0 5.705447225778926e-10
sexual O 0 7.020480724539979e-11
development O 0 1.9776820459060929e-10
by O 0 3.794698236192495e-11
regulating O 0 4.86202234029065e-09
expression O 0 7.203222462948133e-09
of O 0 8.663127992747377e-09
the O 0 1.2662707327137923e-08
polypeptide O 0 4.1700852193571336e-07
hormone O 0 1.5476463488539594e-07
Mullerian O 0 2.566886678323499e-06
inhibiting O 0 2.984116065363196e-07
substance O 0 2.3562849094105331e-07
( O 0 8.909326609796153e-09
MIS O 0 7.283072045538574e-05
) O 0 4.8759549287069603e-08
. O 0 1.6204599262437114e-07

Here O 0 1.608166968480873e-07
, O 0 3.618223720636138e-09
we O 0 1.3421855848960718e-09
show O 0 4.987889656860034e-09
that O 0 4.1639444670060755e-10
WT1 O 0 8.47306364448741e-06
- O 0 6.1238292801135685e-06
KTS O 0 4.215464650769718e-05
isoforms O 0 6.889930403986e-08
associate O 0 7.426042714087089e-08
and O 0 1.3307072110890772e-09
synergize O 0 3.0567355224775383e-07
with O 0 1.3331943327088425e-09
SF O 0 0.011841163039207458
- O 0 1.1462403563200496e-05
1 O 0 7.666212695767172e-07
to O 0 1.8699424231272133e-08
promote O 0 7.357803042395972e-07
MIS O 0 0.0007355823181569576
expression O 0 1.530657641524158e-06
. O 0 5.491151000569516e-07

In O 0 1.2826670570120768e-07
contrast O 0 7.979298288773862e-08
, O 0 2.161357315344503e-08
WT1 O 0 3.3255968446610495e-05
missense O 0 2.1488917809620034e-06
mutations O 0 5.004130088082093e-08
, O 0 1.203588673170941e-09
associated O 0 7.883657282548029e-09
with O 0 2.5150420635000614e-10
male B-Disease 0 1.385129877462532e-08
pseudohermaphroditism I-Disease 1 1.0
in O 0 6.259535467734167e-08
Denys B-Disease 1 0.9999985694885254
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.0681062256878704e-08
fail O 0 9.504793752057594e-08
to O 0 2.4300410572664077e-09
synergize O 0 5.84295378303068e-07
with O 0 9.359395924946057e-09
SF O 1 1.0
- O 1 0.9995232820510864
1 O 0 0.004043003544211388
. O 0 7.166797331592534e-06

Additionally O 0 5.826466917824291e-07
, O 0 4.750408066911405e-09
the O 0 9.245623711073847e-10
X O 0 5.414707402451313e-07
- O 0 3.049506176466821e-07
linked O 0 1.644591520744143e-07
, O 0 1.6401033309243473e-10
candidate O 0 1.878007610534027e-10
dosage O 0 8.443603149999035e-08
- O 0 9.968522363124066e-08
sensitive O 0 9.057004746182429e-08
sex O 0 3.4214731048365365e-09
- O 0 2.8965423393145784e-09
reversal O 0 5.299884975329405e-10
gene O 0 8.364203774036127e-10
, O 0 8.696632303184515e-10
Dax O 0 0.00019791434169746935
- O 0 2.2110984332357475e-07
1 O 0 1.0106614212190834e-07
, O 0 2.1299997321477804e-09
antagonizes O 0 7.2044867849285765e-09
synergy O 0 3.0550435514697938e-09
between O 0 5.961413029886842e-10
SF O 0 8.02589493105188e-05
- O 0 3.1670090265834006e-06
1 O 0 3.7673865449505684e-07
and O 0 1.2217202360886859e-08
WT1 O 0 1.7709206076688133e-05
, O 0 1.7917828332159047e-09
most O 0 1.1382592091102595e-10
likely O 0 7.43249350954045e-11
through O 0 1.7810718178079554e-11
a O 0 5.6746544963015566e-11
direct O 0 1.87599200063282e-10
interaction O 0 2.9889088426493515e-10
with O 0 1.4426537742195933e-10
SF O 0 0.00023292146215680987
- O 0 6.85272752889432e-05
1 O 0 1.4022391951584723e-05
. O 0 3.871116859954782e-06

We O 0 6.278691557781713e-07
propose O 0 4.9289309345113e-07
that O 0 8.010097474198119e-09
WT1 O 0 2.9342694688239135e-05
and O 0 3.3141276389869745e-07
Dax O 1 0.995864748954773
- O 0 9.526116286906472e-07
1 O 0 9.279021639940765e-08
functionally O 0 1.652133185814364e-08
oppose O 0 6.678812614069329e-09
each O 0 5.422886098505053e-11
other O 0 9.88985837668821e-11
in O 0 1.2829594053798132e-09
testis O 0 1.9345708324181032e-07
development O 0 1.835554708229381e-09
by O 0 3.8981828875961355e-10
modulating O 0 1.4007977711116837e-07
SF O 0 6.949750968487933e-05
- O 0 3.926344106730539e-06
1 O 0 8.388685728277778e-07
- O 0 6.384954645000107e-07
mediated O 0 1.1930873711207823e-07
transactivation O 0 1.7545908121974207e-06
. O 0 2.429708523266072e-08
. O 0 6.018818510256096e-08

A O 0 2.1884929992666002e-06
mouse O 0 7.399165724564227e-08
model O 0 1.5119905327765082e-08
for O 0 7.360526410593593e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 1.0
- O 1 0.9999513626098633
centre O 0 1.5104668818821665e-05
mutations O 0 9.008282830791359e-08
. O 0 6.670120455964934e-08

Imprinting O 0 2.9050341254333034e-05
in O 0 1.1197590765732457e-07
the O 0 4.068484216190882e-08
15q11 O 0 4.4078669816371985e-06
- O 0 3.7257328244777455e-07
q13 O 0 9.289182685279229e-07
region O 0 7.639076038401527e-09
involves O 0 1.1605416627702425e-09
an O 0 1.658502918333582e-10
imprinting O 0 1.8769839016385959e-06
centre O 0 2.6181530756730353e-06
( O 0 8.814783902799661e-10
IC O 0 2.523208593174786e-07
) O 0 6.70528244040014e-10
, O 0 5.5911650309603544e-11
mapping O 0 4.309055612328194e-10
in O 0 1.0900340352559823e-10
part O 0 4.305761303058375e-10
to O 0 8.432892162346661e-10
the O 0 1.9336801049263386e-09
promoter O 0 2.9078472962851265e-08
and O 0 6.754215853277401e-09
first O 0 9.919228460830709e-08
exon O 0 4.4066214854865393e-07
of O 0 1.600438963578199e-07
SNRPN O 0 0.00013748437049798667
. O 0 1.3376342167248367e-06

Deletion O 0 1.1917120900761802e-05
of O 0 2.9116779387550196e-07
this O 0 4.158644539842271e-09
IC O 0 3.6850776723440504e-06
abolishes O 0 3.2662258035998093e-06
local O 0 7.478264052451777e-08
paternally O 0 1.0484729529025572e-07
derived O 0 9.598719596937144e-10
gene O 0 1.3510254026627422e-10
expression O 0 2.558529776930385e-10
and O 0 4.103336767591337e-11
results O 0 5.026720151235509e-10
in O 0 4.2338150763043814e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.7094871509470977e-05
PWS B-Disease 1 1.0
) O 0 1.295887130936535e-07
. O 0 2.4302795509356656e-07

We O 0 4.703882439116569e-07
have O 0 1.6334513741611545e-09
created O 0 1.198592225470918e-09
two O 0 5.098512168011382e-10
deletion O 0 1.575610752979628e-08
mutations O 0 1.6845707051516e-08
in O 0 2.7738934704757412e-08
mice O 0 1.0541995152379968e-06
to O 0 3.710032103754202e-08
understand O 0 7.012888545432361e-07
PWS B-Disease 1 1.0
and O 0 1.4367628864420112e-07
the O 0 2.5162632866226886e-08
mechanism O 0 1.159137923423259e-07
of O 0 9.548745794063507e-09
this O 0 2.294432421834358e-09
IC O 0 6.50552556180628e-06
. O 0 1.8469733049641945e-06

Mice O 0 0.0008671419345773757
harbouring O 0 0.00010234142246190459
an O 0 4.096937900044395e-08
intragenic O 0 2.0419578504515812e-05
deletion O 0 2.3805073396943044e-06
in O 0 8.18585021988838e-08
Snrpn O 0 9.423948358744383e-05
are O 0 5.931063418174176e-10
phenotypically O 0 3.8074355757089506e-07
normal O 0 9.492836028357488e-08
, O 0 1.718443942699821e-09
suggesting O 0 1.563352292066611e-08
that O 0 2.4989563196520237e-10
mutations O 0 3.5366938266889747e-09
of O 0 2.494368445127293e-08
SNRPN O 0 6.568538083229214e-05
are O 0 1.2727301434978244e-09
not O 0 1.7756701664595198e-09
sufficient O 0 1.3492478956322884e-07
to O 0 7.04686513586239e-08
induce O 0 2.317403777851723e-05
PWS B-Disease 1 1.0
. O 0 7.560316589660943e-05

Mice O 0 1.8910461221821606e-05
with O 0 1.6342054376394799e-09
a O 0 6.986478062742663e-09
larger O 0 2.477199112504991e-09
deletion O 0 6.865058566063453e-08
involving O 0 9.169287551458183e-09
both O 0 2.8179614197654246e-09
Snrpn O 0 5.827145059811301e-07
and O 0 2.5568431816225257e-09
the O 0 1.23945502750189e-08
putative O 0 1.916124347189907e-06
PWS O 1 1.0
- O 0 5.3286556067178026e-05
IC O 0 1.3143029718776233e-05
lack O 0 1.265792093363416e-06
expression O 0 3.840934681420549e-09
of O 0 1.3413871124967613e-09
the O 0 6.732758794925076e-10
imprinted O 0 2.002787091726077e-08
genes O 0 1.4005808957051613e-08
Zfp127 O 0 9.211664291797206e-06
( O 0 1.4111216195544785e-08
mouse O 0 1.4783485369207483e-07
homologue O 0 7.179474437180033e-07
of O 0 6.344517800016547e-08
ZNF127 O 0 0.0001509423163952306
) O 0 9.422588931329301e-09
, O 0 1.2620944289665204e-08
Ndn O 0 1.96756845980417e-05
and O 0 4.318538415759576e-08
Ipw O 0 3.902764728991315e-05
, O 0 1.882812128428668e-08
and O 0 3.315598684494603e-09
manifest O 0 3.753872235279232e-08
several O 0 1.8552903657820252e-09
phenotypes O 0 5.0870649914713795e-08
common O 0 8.82202133567489e-09
to O 0 6.614465064558317e-08
PWS B-Disease 1 1.0
infants O 0 0.05611802265048027
. O 0 2.4664357169967843e-06

These O 0 2.0119799160056573e-08
data O 0 1.8192608308709168e-08
demonstrate O 0 3.056168207393739e-09
that O 0 2.932477871642192e-11
both O 0 7.852793415530357e-11
the O 0 4.75328831850419e-10
position O 0 1.2875541521850664e-08
of O 0 4.687092047817032e-09
the O 0 1.5079694160036183e-09
IC O 0 9.951708790367775e-08
and O 0 1.397975291084208e-09
its O 0 1.8934123713343354e-10
role O 0 7.94791010783058e-10
in O 0 5.953845194639484e-10
the O 0 1.3354696237755093e-09
coordinate O 0 1.3525531805669289e-08
expression O 0 3.189426678318341e-08
of O 0 2.099319118542553e-08
genes O 0 1.9734400780180295e-09
is O 0 9.018190361143041e-11
conserved O 0 2.064488996422753e-10
between O 0 5.272711711690192e-10
mouse O 0 1.3395090547874133e-07
and O 0 1.1295784307918666e-09
human O 0 1.6480722342393506e-09
, O 0 1.5533251074284493e-10
and O 0 4.487422933241447e-10
indicate O 0 3.146992888503064e-09
that O 0 1.0011399348419658e-10
the O 0 1.8491855824365189e-09
mouse O 0 6.94734652029183e-08
is O 0 1.3757603389841222e-10
a O 0 7.794179884834662e-11
suitable O 0 1.8852797101232e-09
model O 0 8.027851161607202e-10
system O 0 1.0366285607688042e-09
in O 0 4.436961908993453e-10
which O 0 7.075380559218303e-11
to O 0 4.084068361276394e-10
investigate O 0 1.017600781416661e-09
the O 0 7.821495673354661e-10
molecular O 0 4.558291522016589e-09
mechanisms O 0 1.1000777533354267e-07
of O 0 9.957515700875774e-09
imprinting O 0 1.5231874783694366e-07
in O 0 1.58586088705448e-09
this O 0 2.2234107610596965e-10
region O 0 2.8835223098155893e-09
of O 0 1.0677939643599643e-09
the O 0 4.1311146170563973e-10
genome O 0 1.8343847274504554e-10
. O 0 9.006505541364618e-10
. O 0 3.167100359746655e-08

Mutations O 0 1.8447427692080964e-06
of O 0 1.600768797516139e-07
the O 0 2.2995727988472936e-08
ATM O 0 1.2434479685907718e-05
gene O 0 1.837212160182844e-08
detected O 0 4.324465052718551e-08
in O 0 4.8360142557157815e-09
Japanese O 1 0.999998927116394
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9999972581863403
: O 0 4.683113341563683e-10
possible O 0 3.67914254617574e-10
preponderance O 0 3.196241493697016e-08
of O 0 2.4618671545795223e-09
the O 0 1.269982785601087e-09
two O 0 1.601863641731427e-09
founder O 0 3.098642480381386e-07
mutations O 0 1.0095051017344758e-08
4612del165 O 0 4.232122137182159e-06
and O 0 1.0027313379623592e-07
7883del5 O 0 0.0010043780785053968
. O 0 3.0738885925529758e-06

The O 0 5.212188511904969e-07
ATM O 0 0.0012587455566972494
( O 0 5.751812750531826e-07
A O 1 1.0
- O 1 1.0
T O 1 1.0
, O 0 2.789630393351672e-08
mutated O 0 5.71541614036164e-09
) O 0 2.5670743308836563e-10
gene O 0 8.483014846127901e-10
on O 0 9.271622580797612e-09
human O 0 6.042534472783245e-09
chromosome O 0 1.7762306470103795e-07
11q22 O 0 1.4327662938740104e-05
. O 0 6.5243750668742e-07

3 O 0 5.482441338244826e-06
has O 0 5.020916127307373e-09
recently O 0 2.139845856063971e-09
been O 0 1.1878927008712736e-10
identified O 0 1.590664683304155e-10
as O 0 4.66725616488084e-11
the O 0 3.14530936018631e-11
gene O 0 2.8084612760381766e-11
responsible O 0 8.958034314332508e-11
for O 0 7.564456006026177e-11
the O 0 1.440883412584526e-09
human O 0 6.124396634277218e-08
recessive B-Disease 1 0.9999022483825684
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9359440207481384
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 7.012835112618632e-08
. O 0 1.791821802044069e-07

In O 0 4.4371862628622694e-08
order O 0 6.293628729281409e-09
to O 0 7.185627093342362e-10
define O 0 4.5964703154766084e-09
the O 0 6.012364495155964e-10
types O 0 3.0530626915492576e-09
of O 0 6.141789299363154e-09
disease O 0 2.1244908054995904e-08
- O 0 5.461320995436836e-08
causing O 0 3.7784952944264205e-09
ATM O 0 8.643125966045773e-07
mutations O 0 7.15698500464157e-10
in O 0 1.5001404563008691e-09
Japanese O 0 0.33153554797172546
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.418075186165879e-07
as O 0 3.989362451495282e-10
well O 0 1.7544700414706682e-10
as O 0 1.2424290762869106e-10
to O 0 1.7138343522127286e-10
look O 0 9.874915329888267e-10
for O 0 1.966454998836298e-09
possible O 0 2.7517504719298813e-08
mutational O 0 6.163446869322797e-06
hotspots O 0 2.828034666890744e-06
, O 0 3.5181983992771393e-09
reverse O 0 8.267155848784569e-09
- O 0 1.180757891461326e-08
transcribed O 0 5.852203166512027e-09
RNA O 0 1.4206485987600104e-09
derived O 0 2.717905067672888e-10
from O 0 6.349302333896745e-11
ten O 0 3.759536570946409e-10
patients O 0 3.54460523432909e-11
belonging O 0 1.9781649929218048e-10
to O 0 8.982602855978072e-11
eight O 0 2.196966497614028e-10
unrelated O 0 1.7660607420921792e-09
Japanese O 0 4.0413611714029685e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 4.37589697810381e-09
was O 0 4.503123651744545e-09
analyzed O 0 1.1591368975771843e-09
for O 0 4.574567946669106e-10
mutations O 0 6.366440707950005e-10
by O 0 6.235673644106043e-10
the O 0 1.0251364201963042e-08
restriction O 0 1.2862635401234002e-07
endonuclease O 0 1.6287333437503548e-07
fingerprinting O 0 1.1621398243732983e-07
method O 0 1.732045831204232e-07
. O 0 2.659154745288106e-07

As O 0 2.3058453280100366e-07
has O 0 7.913557587002629e-10
been O 0 1.25043364551658e-10
reported O 0 1.944258816444222e-11
by O 0 7.272429620314158e-12
others O 0 4.149008636655793e-10
, O 0 1.4467789466454661e-10
mutations O 0 1.3322581926544785e-10
that O 0 7.641458299456616e-11
lead O 0 5.110694978327501e-09
to O 0 1.7003950247840294e-08
exon O 0 8.037631005208823e-07
skipping O 0 6.391808824446343e-07
or O 0 2.3005773286399744e-08
premature O 0 7.94231098666387e-08
protein O 0 3.57485663293744e-09
truncation O 0 9.801421896327156e-08
were O 0 1.9898790171168912e-08
also O 0 2.1670691907615947e-09
predominant O 0 2.3482085609316528e-08
in O 0 4.108015705384105e-09
our O 0 1.0008186990262402e-07
mutants O 0 1.2171171874797437e-06
. O 0 5.39770383056748e-07

Six O 0 2.0101124675875326e-07
different O 0 7.775474708537899e-10
mutations O 0 7.581735794737199e-10
were O 0 3.5733546677185757e-10
identified O 0 5.213102727275043e-10
on O 0 3.934187642329334e-09
12 O 0 1.2388901460269608e-08
of O 0 3.466766873572169e-09
the O 0 3.6704599359893564e-09
16 O 0 6.472021141235018e-08
alleles O 0 4.522956675856449e-09
examined O 0 3.035630413705803e-07
. O 0 1.3873344641979202e-06

Four O 0 9.804915634958888e-07
were O 0 6.142377628748363e-08
deletions O 0 9.596659111821282e-08
involving O 0 4.584448820565967e-09
a O 0 3.970651807350123e-09
loss O 0 7.3401951183882375e-09
of O 0 2.5524688140876606e-08
a O 0 6.6991749925193744e-09
single O 0 1.0902784453037384e-08
exon O 0 2.063287212195064e-07
exon O 0 4.183480371011683e-07
7 O 0 1.4069929648030666e-06
, O 0 1.3230092577032337e-08
exon O 0 3.27606016981008e-07
16 O 0 2.0165524006188207e-07
, O 0 1.3787301966772247e-08
exon O 0 8.510507996106753e-07
33 O 0 8.532392143933976e-07
or O 0 3.192409181451694e-08
exon O 0 2.043303311438649e-06
35 O 0 2.48443166128709e-06
. O 0 6.594335104637139e-07

The O 0 1.7123061013535334e-07
others O 0 1.5786790541483242e-08
were O 0 7.722948502930649e-09
minute O 0 3.668592896133305e-08
deletions O 0 1.6403646441176534e-08
, O 0 8.166599063663682e-10
4649delA O 0 2.142538235716529e-08
in O 0 1.3012406707701984e-09
exon O 0 1.0686670748327742e-07
33 O 0 6.989786527356046e-08
and O 0 3.2285665252373974e-09
7883del5 O 0 7.921581186565163e-07
in O 0 2.0830894342793727e-08
exon O 0 2.2044757770345313e-06
55 O 0 1.596568381501129e-06
. O 0 4.566143161355285e-07

The O 0 1.3629685327032348e-06
mutations O 0 1.8926890277271013e-07
4612del165 O 0 2.6007878659584094e-06
and O 0 9.926832689188814e-09
7883del5 O 0 1.2559728475025622e-06
were O 0 9.575647830217804e-09
found O 0 3.907681678239072e-10
in O 0 1.2489080603028668e-10
more O 0 9.422862663754916e-12
than O 0 3.1015155721458854e-12
two O 0 2.0465855572748826e-12
unrelated O 0 4.6595800134996423e-11
families O 0 2.5007277065086653e-12
; O 0 7.558121663253647e-12
44 O 0 5.434060978970479e-10
% O 0 4.706697878664734e-11
( O 0 8.063937538549393e-12
7 O 0 6.396077001369349e-10
of O 0 8.394218098395356e-10
16 O 0 2.2822375100872705e-09
) O 0 2.056047970766528e-10
of O 0 8.796511297148868e-10
the O 0 3.364528933236244e-10
mutant O 0 3.781523538748388e-09
alleles O 0 6.153864084978977e-10
had O 0 2.087702455355611e-09
one O 0 1.8127645218246613e-10
of O 0 1.1471412708630169e-09
the O 0 2.846473279305428e-09
two O 0 2.6518185425317142e-09
mutations O 0 2.4421416000564022e-08
. O 0 4.019448169856332e-07

The O 0 4.1694886476761894e-07
4612del165 O 0 3.1142155876295874e-06
mutations O 0 9.125947109112076e-09
in O 0 6.299798460673856e-10
three O 0 3.105423904137261e-11
different O 0 2.849152120829035e-12
families O 0 4.240368906699432e-12
were O 0 3.8021027298773546e-11
all O 0 1.1434003049926034e-11
ascribed O 0 4.311409007584643e-09
to O 0 1.6446433104277958e-09
the O 0 4.197621361612391e-09
same O 0 2.42864173216617e-09
T O 0 3.467065923246082e-08
- O 0 6.99167941320411e-08
- O 0 1.5006511944193335e-07
> O 0 2.2018146239588532e-07
A O 0 1.2881904432049396e-08
substitution O 0 8.008936625003571e-09
at O 0 4.329984371054252e-09
the O 0 9.62820490002514e-10
splice O 0 3.8773350752308033e-08
donor O 0 1.976337671294459e-08
site O 0 6.008357900100236e-08
in O 0 1.4351929422673493e-08
intron O 0 1.632686507946346e-05
33 O 0 7.933882443467155e-06
. O 0 1.8891557829192607e-06

Microsatellite O 0 7.23427947377786e-05
genotyping O 0 1.0525466677790973e-05
around O 0 2.1871100486237083e-08
the O 0 5.994287732846715e-09
ATM O 0 8.823352800391149e-06
locus O 0 3.7802419683430344e-07
also O 0 5.090459609391473e-09
indicated O 0 1.6125469848304874e-09
that O 0 2.2415276232368164e-11
a O 0 3.7343445002946396e-10
common O 0 1.0975932385193232e-09
haplotype O 0 2.3985359476341728e-08
was O 0 8.610742341375044e-09
shared O 0 8.626272474110408e-10
by O 0 1.2463523269001797e-10
the O 0 3.702542439310008e-10
mutant O 0 1.7832286758334703e-09
alleles O 0 1.5225840033217253e-10
in O 0 4.40164404924559e-10
both O 0 4.7988018003763955e-09
mutations O 0 5.407814285263157e-08
. O 0 8.77843206126272e-07

This O 0 4.027178945875676e-08
suggests O 0 2.121935338550429e-08
that O 0 2.767832664452019e-11
these O 0 2.9171977333763977e-11
two O 0 2.7530183688284637e-10
founder O 0 1.5046350654301932e-07
mutations O 0 7.228698084560392e-09
may O 0 6.347879999424322e-09
be O 0 2.33716623831981e-09
predominant O 0 1.2312557373661548e-07
among O 0 4.805377873395855e-09
Japanese O 0 8.59815600051661e-07
ATM O 0 1.541787787573412e-05
mutant O 0 8.795627763902303e-07
alleles O 0 6.07978520861252e-08
. O 0 2.5595531383260095e-07

W474C O 0 2.093628245347645e-05
amino O 0 7.953983782726937e-08
acid O 0 5.436240346767818e-09
substitution O 0 7.970427873260633e-09
affects O 0 7.386594669256397e-10
early O 0 9.05073260781819e-09
processing O 0 1.336135202478772e-08
of O 0 5.981690254230898e-09
the O 0 3.2495575674751365e-10
alpha O 0 5.314076401141676e-10
- O 0 1.3857998082400513e-10
subunit O 0 5.771049749192514e-10
of O 0 3.868665943151939e-10
beta O 0 2.2342916849993344e-08
- O 0 8.54817017170717e-08
hexosaminidase O 0 8.238823738793144e-07
A O 0 2.387176323281892e-08
and O 0 3.431268047471292e-10
is O 0 1.912736462272857e-11
associated O 0 4.325681479677712e-10
with O 0 1.2510634195272985e-10
subacute O 0 0.00019539857748895884
G B-Disease 0 0.0007402123883366585
( I-Disease 0 2.6489686888453434e-08
M2 I-Disease 0 9.536415745969862e-05
) I-Disease 0 1.2503589630341594e-07
gangliosidosis I-Disease 0 4.507063204073347e-05
. O 0 1.7676779862085823e-06

Mutations O 0 5.312638222676469e-07
in O 0 4.176197165861595e-08
the O 0 3.5822296240439755e-08
HEXA O 0 1.3253160432213917e-05
gene O 0 1.177739417101975e-08
, O 0 8.840005949473095e-10
encoding O 0 2.35555952521338e-09
the O 0 1.5101654371463269e-09
alpha O 0 1.459749099375074e-09
- O 0 4.904426309515486e-10
subunit O 0 5.288111060153255e-10
of O 0 5.003265579617278e-10
beta O 0 1.818081507565239e-08
- O 0 1.1332328142543702e-07
hexosaminidase O 0 1.0548360478424001e-06
A O 0 9.336184803032666e-08
( O 0 3.17725595833096e-10
Hex O 0 2.8861538936553188e-08
A O 0 2.2566739588114615e-08
) O 0 1.851768183236402e-10
, O 0 9.383534921303394e-11
that O 0 2.8901709150930266e-11
abolish O 0 1.1957538958995428e-07
Hex O 0 3.688920742206392e-07
A O 0 3.596071707079318e-08
enzyme O 0 1.0044378662144027e-09
activity O 0 1.4725688224359601e-08
cause O 0 1.283241726923734e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.9170993681427717e-09
TSD B-Disease 0 2.4942291929619387e-06
) O 0 2.2284248057946598e-10
, O 0 1.3711209945199698e-10
the O 0 8.49588788209843e-10
fatal O 0 1.3241786689377477e-07
infantile B-Disease 0 1.0658715154931997e-06
form I-Disease 0 4.798518027371301e-09
of I-Disease 0 4.802842795470497e-06
G I-Disease 0 7.580161309306277e-06
( I-Disease 0 3.2995051135742415e-09
M2 I-Disease 0 2.094573119393317e-06
) I-Disease 0 3.141409576912224e-09
gangliosidosis I-Disease 0 2.457649088682956e-07
, I-Disease 0 1.3387340125348146e-09
Type I-Disease 0 4.796928365635722e-08
1 I-Disease 0 1.1194146054549492e-06
. O 0 8.82602876117744e-07

Less O 0 9.63787442742614e-07
severe O 0 1.3605643289338332e-05
, O 0 1.8597411610699055e-08
subacute O 0 1.3056329407845624e-05
( O 0 6.283310538535147e-10
juvenile O 0 3.800799959208234e-07
- O 0 1.8153494920625235e-06
onset O 1 1.0
) O 0 8.497221593017912e-09
and O 0 6.819135478508542e-08
chronic O 1 1.0
( O 0 9.755122265531213e-10
adult O 0 1.4696541938974406e-07
- O 0 3.661575078695023e-07
onset O 0 0.002985958708450198
) O 0 5.352712717510144e-10
variants O 0 5.456060492292636e-09
are O 0 7.425493553370188e-11
characterized O 0 2.6787705387221195e-10
by O 0 1.0076726258967383e-10
a O 0 2.700636603236717e-09
broad O 0 5.9524971618429845e-09
spectrum O 0 2.2150150158495308e-08
of O 0 8.257364791930399e-10
clinical O 0 7.520485567624746e-09
manifestations O 0 1.876497845998415e-09
and O 0 3.8980338401550796e-10
are O 0 4.516469490067898e-11
associated O 0 1.1688701118117706e-09
with O 0 1.7937480667473693e-10
residual O 0 1.8001527450905996e-06
levels O 0 3.0799981232121354e-06
of O 0 4.6643708628835157e-07
Hex O 0 1.6955474393398617e-06
A O 0 2.697606191759405e-07
enzyme O 0 1.085804157696657e-08
activity O 0 1.2539702254343865e-07
. O 0 2.046420490842138e-07

We O 0 5.267661151719949e-08
identified O 0 1.3302486223665255e-08
a O 0 2.667982279547232e-09
1422 O 0 4.551631718641147e-06
G O 0 1.2839010423704167e-06
- O 0 4.9305572247249074e-06
- O 0 3.994104645244079e-06
> O 0 2.033979171756073e-06
C O 0 1.3204803508415353e-06
( O 0 8.615234914355341e-11
amino O 0 2.650694663763886e-10
acid O 0 4.517833052108955e-10
W474C O 0 1.2500152024585987e-08
) O 0 2.687877915033554e-12
substitution O 0 1.491768097938717e-10
in O 0 1.4890165489500617e-10
the O 0 3.812161697425154e-10
first O 0 1.7150582065639242e-09
position O 0 5.438023809034576e-09
of O 0 2.233868867662636e-09
exon O 0 6.586177647704972e-08
13 O 0 5.028010008345518e-08
of O 0 3.722216490587016e-08
HEXA O 0 0.0002665187930688262
of O 0 9.255901289861868e-08
a O 0 1.7590153333912895e-08
non O 0 9.961487421605852e-07
- O 0 3.712510761033627e-07
Jewish O 0 6.082883032831887e-07
proband O 0 2.1108455257490277e-05
who O 0 7.852381855855128e-09
manifested O 0 1.2958000006335624e-08
a O 0 5.346898923619392e-09
subacute O 0 7.153209935495397e-07
variant O 0 3.935258973797318e-06
of O 0 2.261887857457623e-05
G B-Disease 0 0.0002432602341286838
( I-Disease 0 2.5779794299296555e-08
M2 I-Disease 0 3.5566972655942664e-05
) I-Disease 0 4.785268004070531e-08
gangliosidosis I-Disease 0 1.6791462257970124e-05
. O 0 5.170330155124248e-07

On O 0 2.1977414235152537e-06
the O 0 4.0192215777778983e-08
second O 0 1.60200571031055e-07
maternally O 0 3.7191089177213144e-06
inherited O 0 1.1016679763997672e-06
allele O 0 6.994227419454546e-08
, O 0 2.5938834413707923e-10
we O 0 1.6516084333506598e-10
identified O 0 1.4000246517653636e-09
the O 0 7.230059329010885e-10
common O 0 5.4369486690575286e-08
infantile O 1 0.8993118405342102
disease O 0 2.045044493570458e-05
- O 0 2.5118863504758338e-06
causing O 0 1.0919662827291177e-06
4 O 0 1.7883572581922635e-05
- O 0 3.504075721139088e-05
bp O 0 1.0343321719119558e-06
insertion O 0 9.001430356647688e-08
, O 0 9.39471878069753e-09
+ O 0 3.4644557445062674e-07
TATC O 0 9.2106356532895e-06
1278 O 0 1.1770041965064593e-05
, O 0 9.275443524359162e-09
in O 0 8.235820914137548e-09
exon O 0 1.4865825050947024e-06
11 O 0 9.15574389637186e-07
. O 0 6.791888154111803e-07

Pulse O 0 3.588254185160622e-05
- O 0 2.3757447706884705e-06
chase O 0 7.739187424249394e-08
analysis O 0 3.408680226968386e-09
using O 0 1.2761096179758624e-08
proband O 0 3.527046828821767e-06
fibroblasts O 0 6.004181614116533e-06
revealed O 0 1.5659784580179803e-08
that O 0 5.577095729680792e-11
the O 0 3.72468417220162e-10
W474C O 0 2.067292648177954e-08
- O 0 4.368816863831171e-09
containing O 0 3.7371375438688403e-10
alpha O 0 1.545317651618916e-09
- O 0 6.133029639698862e-10
subunit O 0 2.1205626143938616e-09
precursor O 0 1.3545157173666666e-07
was O 0 2.1391125315517456e-08
normally O 0 5.581056727876899e-10
synthesized O 0 1.8242088728470662e-08
, O 0 4.873857983866969e-10
but O 0 1.010648439936368e-10
not O 0 2.872059812197847e-10
phosphorylated O 0 8.59721982493511e-09
or O 0 1.4664802705510738e-09
secreted O 0 4.90911755690604e-09
, O 0 6.962954102185392e-10
and O 0 8.21020418317886e-10
the O 0 4.7141686110308e-09
mature O 0 1.5514286744178207e-08
lysosomal O 0 3.5007101928385964e-07
alpha O 0 2.6330509328431617e-08
- O 0 9.187336225124909e-09
subunit O 0 2.288088118973519e-08
was O 0 5.973711125761838e-08
not O 0 9.558549507460157e-09
detected O 0 1.925485264564486e-07
. O 0 1.9398174799789558e-07

When O 0 1.245498566504466e-07
the O 0 1.1201088945256288e-08
W474C O 0 2.811639490118978e-07
- O 0 1.3681208166360648e-08
containing O 0 7.936639123684586e-10
alpha O 0 6.511749472970507e-10
- O 0 3.292500161400369e-10
subunit O 0 1.5598903280178433e-09
was O 0 1.0574114917005772e-08
transiently O 0 3.121331459965404e-08
co O 0 8.119495298331003e-09
- O 0 9.666744205105715e-08
expressed O 0 3.413442639654818e-09
with O 0 3.286468666652276e-11
the O 0 1.903685542536948e-10
beta O 0 1.932989601716173e-10
- O 0 1.434430629831951e-10
subunit O 0 2.978204627357428e-10
to O 0 1.0999755967189273e-10
produce O 0 8.184515842835083e-10
Hex O 0 2.7373636157790315e-07
A O 0 1.028909196065797e-06
( O 0 2.4785269392424425e-09
alphabeta O 0 6.614465064558317e-07
) O 0 3.3029287638264293e-10
in O 0 8.228280279354294e-10
COS O 0 5.57327496153448e-07
- O 0 2.3773080215505615e-07
7 O 0 5.1458716399110926e-08
cells O 0 2.6270962294461242e-08
, O 0 6.883841829896653e-10
the O 0 3.2738201038995385e-10
mature O 0 4.6415135623867343e-10
alpha O 0 9.46895784004198e-10
- O 0 8.257318162563365e-10
subunit O 0 8.893329406234329e-10
was O 0 1.9124974937057004e-09
present O 0 7.396544488003087e-11
, O 0 6.303822047692975e-11
but O 0 1.4149816734976284e-11
its O 0 2.117638356335938e-11
level O 0 8.879040835907404e-10
was O 0 9.165733172444845e-10
much O 0 2.755597416914668e-10
lower O 0 4.29042273930591e-10
than O 0 1.7637362056954764e-11
that O 0 8.555852207270398e-12
from O 0 1.2209433464249742e-10
normal O 0 1.455689790930137e-09
alpha O 0 4.385531049422298e-09
- O 0 5.239681133417662e-09
subunit O 0 1.0124166394120948e-08
transfections O 0 2.932393670107558e-07
, O 0 5.722045059997072e-10
although O 0 3.052490760158122e-10
higher O 0 1.491151646604294e-09
than O 0 2.2245719155655763e-11
in O 0 6.038299721344842e-11
those O 0 9.391108723999508e-11
cells O 0 6.463553026136992e-10
transfected O 0 1.5474951098326528e-08
with O 0 6.506805511063973e-11
an O 0 1.0677894679567146e-10
alpha O 0 3.49285755874007e-09
- O 0 3.728666708724404e-09
subunit O 0 8.635281822932939e-09
associated O 0 1.3336723725387856e-07
with O 0 2.1546810557993012e-08
infantile O 0 0.20632661879062653
TSD B-Disease 0 0.013415657915174961
. O 0 3.175477104377933e-06

Furthermore O 0 2.632926054957352e-07
, O 0 1.6236636479760591e-09
the O 0 3.1989705329138474e-10
precursor O 0 1.8816848523783847e-08
level O 0 2.530944165357596e-08
of O 0 1.7753145620247324e-09
the O 0 1.3845085078401098e-09
W474C O 0 5.4050918407710924e-08
alpha O 0 3.63404817349533e-09
- O 0 1.1433710644936923e-09
subunit O 0 2.1757833312818775e-09
was O 0 7.000710677829147e-09
found O 0 2.7521884771175564e-10
to O 0 1.766828072735649e-10
accumulate O 0 2.000773768884301e-09
in O 0 8.095275005892688e-10
comparison O 0 1.2770732249478556e-09
to O 0 7.50437600949283e-10
the O 0 2.2410597821931333e-09
normal O 0 1.82435151430127e-08
alpha O 0 3.148849714307289e-08
- O 0 3.017598615429051e-08
subunit O 0 4.923175822568737e-08
precursor O 0 5.410929020399635e-07
levels O 0 3.5608948678600427e-07
. O 0 1.717918109989114e-07

We O 0 1.8753500086177155e-08
conclude O 0 2.3540021487633567e-08
that O 0 2.0040345771743517e-10
the O 0 9.961328428786942e-10
1422 O 0 7.899448974058032e-06
G O 0 1.0178864613408223e-06
- O 0 1.7325558019365417e-06
- O 0 1.130199621002248e-06
> O 0 1.5401329847009038e-06
C O 0 1.2076603752575465e-06
mutation O 0 3.235111345478714e-10
is O 0 8.946248256092026e-12
the O 0 9.559870950415217e-11
cause O 0 1.0196879784984958e-08
of O 0 8.722738442656919e-08
Hex B-Disease 0 5.057261296315119e-05
A I-Disease 0 0.1177973821759224
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.8288636144679913e-07
the O 0 1.4357382838170452e-07
proband O 0 9.926371603796724e-06
. O 0 1.7443723265841982e-07

The O 0 1.2915269564928167e-07
resulting O 0 1.2518619030288392e-08
W474C O 0 7.728713171673007e-07
substitution O 0 1.6266346847260138e-07
clearly O 0 7.050922956608474e-09
interferes O 0 3.377145008087723e-09
with O 0 6.652818573815722e-11
alpha O 0 5.944282843728388e-09
- O 0 1.7491414983084042e-09
subunit O 0 2.7156159543295644e-09
processing O 0 1.03668247319888e-08
, O 0 3.322662145421873e-10
but O 0 3.3735108456722784e-11
because O 0 7.519843255032743e-12
the O 0 1.7755092535098882e-11
base O 0 3.093802158904424e-10
substitution O 0 2.0354316010440243e-09
falls O 0 8.75469918781846e-10
at O 0 2.288216699453116e-10
the O 0 3.2332853061589617e-10
first O 0 4.193108082972685e-09
position O 0 1.924192538638181e-08
of O 0 9.72514335728647e-09
exon O 0 1.3096578754812072e-07
13 O 0 8.54039754472069e-08
, O 0 3.2205096367476926e-09
aberrant O 0 1.2033115837084551e-08
splicing O 0 5.4877176580703235e-08
may O 0 1.648365532957996e-08
also O 0 2.812087451786738e-09
contribute O 0 8.72830963061233e-09
to O 0 1.9588830113548283e-08
Hex B-Disease 0 3.791173003264703e-05
A I-Disease 0 0.0010491907596588135
deficiency I-Disease 0 1.1379539500921965e-05
in O 0 3.4093709189164656e-08
this O 0 6.256382523162074e-09
proband O 0 1.2779494227288524e-06
. O 0 1.3869884796235965e-08
. O 0 1.0740739497805407e-07

Two O 0 9.475470363895511e-08
frequent O 0 4.561276867320885e-08
missense O 0 3.801590310104075e-06
mutations O 0 9.109122629524791e-07
in O 0 7.521696261392208e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00012179120676591992

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.1625273188542451e-08
an O 0 1.8786980149343435e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 2.3344920919043943e-05
by O 0 2.024504175413e-10
early O 0 4.998730673833052e-07
childhood O 1 0.9996246099472046
deafness B-Disease 1 1.0
and O 1 0.9999966621398926
goiter B-Disease 1 1.0
. O 1 0.9997285008430481

A O 0 2.4899674144762685e-07
century O 0 5.712007578040357e-08
after O 0 1.5735016622997477e-09
its O 0 2.1732178556721493e-11
recognition O 0 4.122409080764555e-10
as O 0 5.66572400106935e-10
a O 0 6.721419421040764e-09
syndrome O 0 2.796402327476244e-07
by O 0 6.337919633558897e-10
Vaughan O 0 2.2721546883985866e-06
Pendred O 0 1.058035468304297e-05
, O 0 2.6721633794579702e-09
the O 0 4.552174637240114e-09
disease O 0 8.743343471451226e-08
gene O 0 4.0317114091692474e-09
( O 0 4.905261086207702e-09
PDS O 0 0.00014265884237829596
) O 0 6.840835897747866e-09
was O 0 1.1434025282142102e-07
mapped O 0 7.113482070053578e-08
to O 0 2.8503048810080145e-08
chromosome O 0 4.113656473236915e-07
7q22 O 0 5.0967773859156296e-05
- O 0 1.6621119357296266e-05
q31 O 0 5.576046169153415e-05
. O 0 9.836816161623574e-07

1 O 0 1.2845489436585922e-06
and O 0 1.7697844967301535e-08
, O 0 3.9952658958952725e-09
recently O 0 6.837522548153174e-09
, O 0 3.4765584855378506e-10
found O 0 2.673196941582745e-10
to O 0 4.3181061504249385e-10
encode O 0 1.5181138124376048e-08
a O 0 5.103128941641444e-08
putative O 0 1.7093233282139408e-06
sulfate O 0 2.3311804397962987e-06
transporter O 0 8.566198630433064e-06
. O 0 1.9103385966445785e-06

We O 0 2.5369476475134434e-07
performed O 0 3.015159322217187e-08
mutation O 0 2.6972903910404966e-09
analysis O 0 4.454567825717959e-09
of O 0 4.816242515914837e-09
the O 0 1.1132845756378629e-08
PDS B-Disease 0 3.852580903185299e-06
gene O 0 8.720554944829928e-09
in O 0 2.592573711268642e-09
patients O 0 5.6408619997228016e-09
from O 0 9.440753734324403e-10
14 O 0 1.3290008205046888e-08
Pendred B-Disease 0 1.9200393808205263e-07
families O 0 4.431445488339847e-11
originating O 0 8.808767049117705e-10
from O 0 1.5662786345682633e-10
seven O 0 2.5294888406079963e-10
countries O 0 4.2399018324035254e-11
and O 0 2.8343793978535814e-10
identified O 0 1.5275013254267833e-08
all O 0 1.0156602670008397e-08
mutations O 0 6.617707981604326e-08
. O 0 5.842636596753437e-07

The O 0 1.4824089475951041e-06
mutations O 0 9.533953715390453e-08
include O 0 1.3636944906636472e-08
three O 0 1.0087558566240773e-09
single O 0 1.4763119615679443e-08
base O 0 2.5685224613880564e-07
deletions O 0 4.92656226924737e-07
, O 0 1.1980763048313747e-08
one O 0 1.256804105231879e-09
splice O 0 1.0173901188181844e-07
site O 0 1.7147515407600622e-08
mutation O 0 1.2908952795598339e-09
and O 0 2.055508208087531e-09
10 O 0 1.8218206321307662e-07
missense O 0 3.6686321891465923e-06
mutations O 0 1.2425675777194556e-06
. O 0 3.110858415311668e-06

One O 0 5.787308623439458e-07
missense O 0 7.34240711608436e-06
mutation O 0 7.689381220643554e-08
( O 0 1.3330520021170855e-09
L236P O 0 1.4809293702455761e-07
) O 0 2.8431346166257754e-10
was O 0 1.7412425945551036e-09
found O 0 1.4757840782753107e-10
in O 0 8.048407079686015e-11
a O 0 2.338734483853244e-10
homozygous O 0 6.621376780202581e-10
state O 0 6.391927265259056e-11
in O 0 8.155764952277877e-10
two O 0 2.9316124527944964e-10
consanguineous O 0 3.042368490469016e-08
families O 0 4.9071368496411694e-11
and O 0 3.6059155661405384e-11
in O 0 2.5157328997771344e-10
a O 0 7.132781587593229e-10
heterozygous O 0 5.48628920071792e-10
state O 0 3.60538612853567e-11
in O 0 8.64826543711672e-10
five O 0 9.727810779125434e-10
additional O 0 2.552097422281463e-09
non O 0 4.81359961668204e-07
- O 0 1.0949393072223756e-06
consanguineous O 0 4.374291165731847e-06
families O 0 2.739261262263426e-08
. O 0 1.243473803924644e-07

Another O 0 1.6641914726278628e-06
missense O 0 8.48235322337132e-06
mutation O 0 1.0390643723212634e-07
( O 0 9.319525151596508e-10
T416P O 0 2.2981571135005652e-07
) O 0 2.635867080158505e-10
was O 0 2.634465978701428e-09
found O 0 1.0631944630246082e-10
in O 0 1.1792576637414953e-10
a O 0 1.9110198146155e-10
homozygous O 0 3.684500482492581e-10
state O 0 3.2473749383976624e-11
in O 0 6.751533221382999e-10
one O 0 4.209637916030573e-10
family O 0 4.4580481667333416e-11
and O 0 5.984365780697942e-11
in O 0 2.039300950329448e-10
a O 0 2.812225730064455e-10
heterozygous O 0 1.402803706529454e-10
state O 0 4.9076239599932237e-11
in O 0 8.531026995939328e-10
four O 0 2.8816582453572437e-09
families O 0 1.194652932134943e-09
. O 0 4.383701934784767e-08

Pendred B-Disease 0 0.000981076154857874
patients O 0 1.0782464414660353e-06
in O 0 2.823158373743695e-09
three O 0 5.916859779908634e-10
non O 0 1.3275014509872562e-07
- O 0 1.3595784764675045e-07
consanguineous O 0 5.884228357899701e-07
families O 0 3.464596665114783e-10
were O 0 5.440625727715087e-10
shown O 0 2.894442185930046e-10
to O 0 7.595819528916081e-10
be O 0 2.5859463459454446e-09
compound O 0 1.2787586456397548e-07
heterozygotes O 0 2.16707078948275e-07
for O 0 1.3942214494022664e-08
L236P O 0 3.241308604629012e-06
and O 0 9.803161304944297e-08
T416P O 0 6.851917714811862e-05
. O 0 1.1270168442933937e-06

In O 0 4.263897324108257e-08
total O 0 5.649411161101625e-09
, O 0 6.654091166957699e-10
one O 0 1.3009919530571068e-10
or O 0 1.821675726931815e-10
both O 0 1.217002471021189e-10
of O 0 4.128286879012677e-10
these O 0 1.7373328470293714e-11
mutations O 0 5.894756210933494e-11
were O 0 1.297421059476278e-10
found O 0 9.134105277697202e-11
in O 0 3.1859215265939156e-10
nine O 0 2.617047467623479e-09
of O 0 1.8564373371887655e-09
the O 0 1.3286352018582193e-09
14 O 0 2.0234212527725504e-08
families O 0 9.463776429186055e-10
analyzed O 0 3.799223335931856e-08
. O 0 2.7868921392837365e-07

The O 0 9.259608901857064e-08
identification O 0 3.136735529096768e-07
of O 0 1.0814064665964906e-07
two O 0 6.9885839337757716e-09
frequent O 0 3.505152434968295e-08
PDS B-Disease 0 2.3420459456247045e-06
mutations O 0 2.313168989687142e-09
will O 0 5.016969617521738e-10
facilitate O 0 4.1628524627412844e-08
the O 0 5.493684174240343e-09
molecular O 0 1.282199804109041e-07
diagnosis O 0 0.07761221379041672
of O 0 1.1761333553295117e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 4.611076292349026e-06

Insertional O 0 0.00011483127309475094
mutation O 0 7.656029765712447e-08
by O 0 8.979764154481984e-10
transposable O 0 4.1123385585706274e-07
element O 0 3.42873960335055e-08
, O 0 2.8514888228414748e-09
L1 O 0 6.191615966599784e-07
, O 0 1.2947591887524368e-09
in O 0 1.7188832579506652e-09
the O 0 3.1855602600217026e-08
DMD B-Disease 1 1.0
gene O 0 1.91839205854194e-07
results O 0 3.088781852511602e-08
in O 0 1.0503605096801039e-07
X B-Disease 1 1.0
- I-Disease 1 0.999962568283081
linked I-Disease 0 0.0002111367357429117
dilated I-Disease 0 0.0002558251144364476
cardiomyopathy I-Disease 1 1.0
. O 0 2.428944208077155e-05

X B-Disease 1 0.9999985694885254
- I-Disease 1 0.9999997615814209
linked I-Disease 1 0.9997530579566956
dilated I-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
( O 0 1.4064829656490474e-07
XLDCM B-Disease 1 0.7076930403709412
) O 0 1.4663571468176428e-09
is O 0 1.2387188497164914e-10
a O 0 5.523995150191752e-10
clinical O 0 3.436707629589364e-08
phenotype O 0 1.1266101296314446e-07
of O 0 1.1555567880350281e-06
dystrophinopathy B-Disease 0 0.00010290489444741979
which O 0 1.5877373860107014e-09
is O 0 1.0307565911915617e-10
characterized O 0 1.0062283645195791e-10
by O 0 1.1432940705269345e-10
preferential O 0 4.5907034973424743e-07
myocardial B-Disease 0 0.31914710998535156
involvement I-Disease 0 8.943619889123511e-08
without O 0 4.044581558559912e-09
any O 0 7.560839732079216e-10
overt O 0 6.417563369609525e-09
clinical O 0 2.0252831234301993e-07
signs O 0 3.542401145750773e-07
of O 0 5.176031208975473e-06
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.0029836995527148247

To O 0 2.858842051978172e-08
date O 0 4.3519442272099695e-08
, O 0 1.3629917194890595e-09
several O 0 1.2427631146394447e-10
mutations O 0 3.037205209555083e-10
in O 0 1.7581760491935938e-09
the O 0 3.3726800552358327e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 0 0.00015174799773376435
, O 0 3.512954890538822e-06
DMD O 1 1.0
, O 0 7.416869607368426e-08
have O 0 7.520338796140891e-10
been O 0 3.096458922602352e-10
identified O 0 2.1240469105787696e-10
in O 0 1.894850248929103e-10
patients O 0 4.791866348163865e-10
with O 0 5.350004467219449e-11
XLDCM B-Disease 0 2.9058461223030463e-05
, O 0 7.0907080207405215e-09
but O 0 8.331944023609594e-10
a O 0 7.833051429706472e-10
pathogenic O 0 1.287133621907799e-09
correlation O 0 1.3644144702951166e-09
of O 0 2.6431936639426112e-09
these O 0 5.577576733806211e-10
cardiospecific O 0 1.0837660511242575e-06
mutations O 0 6.5274714522445265e-09
in O 0 2.8747813018981105e-08
DMD O 1 1.0
with O 0 2.134197529812809e-08
the O 0 9.5972245617304e-07
XLDCM B-Disease 1 0.9999419450759888
phenotype O 0 5.351503205019981e-07
has O 0 1.8688932623689425e-09
remained O 0 1.1235881558491201e-08
to O 0 8.354063552040714e-10
be O 0 3.3381630792916894e-09
elucidated O 0 5.075937224319205e-06
. O 0 1.5344093071689713e-06

We O 0 2.0965266855910158e-07
report O 0 4.5924832825505746e-09
here O 0 2.0600285366434434e-10
the O 0 1.3873892312776803e-10
identification O 0 5.572220462823907e-09
of O 0 2.4490161010248812e-09
a O 0 1.0208063283556612e-09
unique O 0 9.419385271769443e-10
de O 0 1.4811185167218355e-07
novo O 0 1.6202992014768824e-07
L1 O 0 3.666498571419652e-07
insertion O 0 2.14601882930765e-08
in O 0 8.410151686177869e-09
the O 0 1.0365203806372847e-08
muscle O 0 2.2930597864956326e-08
exon O 0 1.0615587342499566e-07
1 O 0 1.44146483194163e-07
in O 0 3.530784553618105e-08
DMD O 1 1.0
in O 0 1.679720469383028e-07
three O 0 4.376573325970412e-09
XLDCM B-Disease 0 1.024375160341151e-05
patients O 0 2.9410116564321243e-09
from O 0 3.1260469213201247e-10
two O 0 1.080015590848582e-10
unrelated O 0 5.512546419339515e-09
Japanese O 0 9.966951211026753e-07
families O 0 4.1880809931171825e-09
. O 0 5.5224628425776245e-08

The O 0 6.338554214835312e-08
insertion O 0 6.202785129971744e-08
was O 0 3.359530609259309e-08
a O 0 1.5212290316313215e-09
5 O 0 3.991693198202029e-09
- O 0 7.221601094897778e-09
truncated O 0 2.65455635251044e-09
form O 0 1.4429647754443664e-10
of O 0 4.761091521032768e-10
human O 0 9.064285433346697e-11
L1 O 0 6.556470033558526e-09
inversely O 0 9.350701324351007e-10
integrated O 0 1.1894013773883216e-08
in O 0 1.4015422156177237e-09
the O 0 2.0702155545393452e-09
5 O 0 2.362048512338788e-08
- O 0 2.276431132486323e-07
untranslated O 0 1.9009621610166505e-05
region O 0 3.9537027873848274e-08
in O 0 2.310942104344349e-09
the O 0 1.923395442915421e-09
muscle O 0 1.7516355033109221e-09
exon O 0 2.1632544644489826e-08
1 O 0 1.7111673855652043e-08
, O 0 1.948603500778745e-10
which O 0 1.3489030205315888e-11
affected O 0 2.8642302071779646e-11
the O 0 2.950931859979633e-11
transcription O 0 1.2344385513785028e-09
or O 0 3.0468658152038586e-10
the O 0 8.30964574927151e-10
stability O 0 2.7002161004929803e-06
of O 0 1.609032906912944e-08
the O 0 2.0539403511321552e-09
muscle O 0 4.7477812792351415e-09
form O 0 2.4051166613858754e-10
of O 0 7.0220678161092565e-09
dystrophin O 0 1.614758247114878e-07
transcripts O 0 5.6527984071408355e-08
but O 0 2.783165087283379e-10
not O 0 1.0666006272641582e-10
that O 0 1.74990404111508e-11
of O 0 6.754831138877648e-10
the O 0 7.481699704214861e-09
brain O 0 2.8164424293208867e-05
or O 0 2.537155019410875e-08
Purkinje O 0 7.835984433768317e-05
cell O 0 4.155172518949257e-06
form O 0 1.8374567423151689e-09
, O 0 1.7241927885436326e-09
probably O 0 1.560900209085503e-08
due O 0 1.7788472916890896e-08
to O 0 2.1032779962126824e-09
its O 0 3.9486947045475063e-10
unique O 0 1.2016435624317978e-09
site O 0 3.2637030855653393e-09
of O 0 7.166847670880827e-10
integration O 0 2.2075539618526818e-08
. O 0 9.273448142721463e-08

We O 0 6.507298735414224e-07
speculate O 0 1.8676900026548537e-07
that O 0 9.411479234833209e-11
this O 0 3.3476089955630783e-11
insertion O 0 2.0512234133462925e-09
of O 0 3.7433030009026425e-09
an O 0 2.3615998046011555e-10
L1 O 0 1.1963412305249221e-07
sequence O 0 1.735950050374413e-09
in O 0 3.161174078059048e-08
DMD O 1 1.0
is O 0 3.4016205407993994e-09
responsible O 0 2.0327390881647034e-09
for O 0 3.192119901740398e-10
some O 0 7.813828056812966e-11
of O 0 2.3270808890973882e-10
the O 0 6.413286568474064e-11
population O 0 2.131866081236944e-12
of O 0 2.01658342802169e-11
Japanese O 0 1.2920043701569739e-08
patients O 0 3.755959709916823e-10
with O 0 5.53220559640355e-11
XLDCM B-Disease 0 1.3973669410916045e-05
. O 0 1.8645542354533973e-07
. O 0 1.5483210518141277e-06

Severe O 0 0.00025833796826191247
early O 1 0.9995176792144775
- O 1 0.9999971389770508
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 3.26594609134645e-08
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 3.503771949908696e-05
red O 1 0.9999990463256836
hair O 1 0.9999991655349731
pigmentation O 1 0.9999992847442627
caused O 0 8.193774192477576e-06
by O 0 1.2400225735120785e-08
POMC O 0 2.2728378098690882e-05
mutations O 0 1.093644197425192e-08
in O 0 8.242043492145967e-09
humans O 0 1.6822395920712552e-08
. O 0 7.086735820394097e-08

Sequential O 0 2.83700103409501e-07
cleavage O 0 7.909022770036245e-08
of O 0 3.9324042688804184e-08
the O 0 1.3005037047264523e-09
precursor O 0 2.660902831408407e-09
protein O 0 1.2136087967906661e-10
pre O 0 1.0054585430907537e-07
- O 0 2.51464939537982e-07
pro O 0 1.0633739293552935e-06
- O 0 1.953832679646439e-06
opiomelanocortin O 0 3.853554517263547e-06
( O 0 2.693948619736375e-09
POMC O 0 3.809552936218097e-06
) O 0 6.87754242445493e-10
generates O 0 3.265563097709645e-10
the O 0 8.25257862047124e-10
melanocortin O 0 2.0780037175427424e-06
peptides O 0 4.290590993605292e-08
adrenocorticotrophin O 0 1.3328462955541909e-06
( O 0 1.8378704114141442e-09
ACTH O 0 1.0785180393213523e-06
) O 0 1.0931889837806352e-09
, O 0 1.918339265216673e-09
melanocyte O 0 1.9669643734232523e-05
- O 0 1.350923139398219e-05
stimulating O 0 6.370664323185338e-06
hormones O 0 1.2731590004477766e-06
( O 0 1.1490398632574284e-09
MSH O 0 5.77811078983359e-06
) O 0 2.749156180481549e-10
alpha O 0 3.4790479386259676e-09
, O 0 8.240085697108768e-11
beta O 0 8.305700571753505e-10
and O 0 1.5131951247582265e-10
gamma O 0 1.3478660854104874e-08
as O 0 1.1200144145462332e-09
well O 0 8.627589198617613e-10
as O 0 7.125955381326321e-10
the O 0 2.943355836837469e-10
opioid O 0 9.454796057184467e-09
- O 0 3.959141903209229e-09
receptor O 0 5.718073792237988e-10
ligand O 0 1.712035846423987e-08
beta O 0 1.7614565877011046e-06
- O 0 6.143980954220751e-06
endorphin O 0 0.000440281699411571
. O 0 2.644814458108158e-06

While O 0 2.500485436485178e-07
a O 0 4.92158669374021e-09
few O 0 7.648038868879325e-10
cases O 0 8.094545173031875e-11
of O 0 2.616827865509208e-09
isolated O 0 1.64620587383979e-06
ACTH B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.5057429671287537
have O 0 1.3108099494729686e-07
been O 0 1.589725258099861e-07
reported O 0 3.37244117076807e-08
( O 0 1.4279645244030803e-09
OMIM O 0 1.1887721484526992e-05
201400 O 0 9.425186817679787e-07
) O 0 1.6927316215387123e-09
, O 0 7.679173408270401e-10
an O 0 8.776618320993634e-10
inherited O 0 0.017500821501016617
POMC O 1 1.0
defect O 1 1.0
has O 0 9.305496817546555e-09
not O 0 4.763144323405299e-10
been O 0 6.734428570354112e-10
described O 0 5.498409505477753e-10
so O 0 3.8294406534689074e-10
far O 0 4.808981213244579e-09
. O 0 5.099548516795949e-08

Recent O 0 4.759838816426054e-07
studies O 0 3.428203143585051e-08
in O 0 7.292716985851655e-10
animal O 0 2.373376772890623e-10
models O 0 1.6955710446797667e-10
elucidated O 0 7.3891066598719135e-09
a O 0 1.0659260141210325e-09
central O 0 5.330464070141261e-09
role O 0 4.050387136800282e-09
of O 0 1.8237496846040813e-08
alpha O 0 3.972756417169876e-07
- O 0 1.2742242461172282e-06
MSH O 0 0.00015302478277590126
in O 0 8.155176978164036e-09
the O 0 2.311629776485802e-09
regulation O 0 2.5177852691626867e-08
of O 0 7.525618461734496e-10
food O 0 2.7602320429309657e-10
intake O 0 3.16985153403504e-11
by O 0 6.939979732382973e-13
activation O 0 9.540476186842284e-10
of O 0 3.241777735141227e-09
the O 0 5.7437858913544915e-09
brain O 0 1.1231193752792024e-07
melanocortin O 0 4.0814100543684617e-07
- O 0 1.411687549079943e-07
4 O 0 6.17518622902935e-08
- O 0 1.26605385730727e-07
receptor O 0 5.054787255431847e-09
( O 0 6.75209999023707e-10
MC4 O 0 8.74170109455008e-06
- O 0 3.4653345437618555e-07
R O 0 3.4948584470839705e-08
; O 0 2.8314831035380905e-10
refs O 0 3.391897251958653e-08
3 O 0 2.9674609436369792e-09
- O 0 8.317229571730422e-09
5 O 0 2.952477595741243e-09
) O 0 5.118123286296239e-11
and O 0 5.228544333601981e-11
the O 0 2.909142371443352e-10
linkage O 0 1.0527170957175258e-07
of O 0 1.756125733720637e-08
human O 0 6.384260586855817e-08
obesity B-Disease 1 1.0
to O 0 1.5291737875955391e-09
chromosome O 0 4.477183068729573e-09
2 O 0 3.221899902428049e-08
in O 0 1.3449539260079746e-08
close O 0 1.6114931611355132e-08
proximity O 0 2.2269015076403775e-08
to O 0 3.980030971462156e-09
the O 0 1.9503232806528104e-08
POMC O 0 8.739708391658496e-06
locus O 0 6.82883225522346e-08
, O 0 1.2369392177191685e-09
led O 0 1.8207875207565394e-09
to O 0 2.04522565550036e-10
the O 0 2.0299638359144723e-10
proposal O 0 3.1412999978996936e-10
of O 0 9.502791886717432e-10
an O 0 2.435357471242128e-10
association O 0 7.199345564146142e-10
of O 0 1.8853203442859012e-08
POMC O 0 0.37779220938682556
with O 0 7.917517308442257e-09
human O 0 2.363457952014869e-06
obesity B-Disease 1 1.0
. O 0 6.944106871742406e-07

The O 0 5.825011584192907e-08
dual O 0 3.6443827866605716e-07
role O 0 7.733624585171128e-08
of O 0 1.2915836578031303e-07
alpha O 0 3.9180275052785873e-05
- O 0 0.0005454955389723182
MSH O 1 0.9993537068367004
in O 0 4.5406959969795935e-08
regulating O 0 6.710405386911589e-07
food O 0 5.596839613986049e-08
intake O 0 3.719973662441589e-08
and O 0 1.2427898710143381e-09
influencing O 0 1.2510198757809121e-05
hair O 0 0.002992096124216914
pigmentation O 0 0.0036466794554144144
predicts O 0 9.202386763718096e-08
that O 0 2.63808502820595e-10
the O 0 3.216358290814014e-10
phenotype O 0 1.1768809260459534e-09
associated O 0 1.6761023680089693e-09
with O 0 1.2443451824495355e-10
a O 0 1.086245404735564e-08
defect O 0 6.485058179350744e-07
in O 0 2.3749368693870565e-08
POMC O 0 4.76072273158934e-05
function O 0 9.051164262530165e-09
would O 0 1.3964749356887296e-09
include O 0 2.70793147905124e-08
obesity B-Disease 1 1.0
, O 0 3.386000591021343e-09
alteration O 0 6.864227088954067e-07
in O 0 3.896648479440046e-07
pigmentation O 1 0.9993484616279602
and O 0 1.2742358194373082e-05
ACTH B-Disease 1 0.9999998807907104
deficiency I-Disease 0 0.00012102931214030832
. O 0 1.538805690870504e-06

The O 0 2.831244216849882e-07
observation O 0 2.242280970676802e-06
of O 0 8.428330033893872e-09
these O 0 4.915392537441221e-10
symptoms O 0 2.7199044794201654e-08
in O 0 1.2216916367435715e-09
two O 0 1.1329055471520633e-09
probands O 0 1.313428128923988e-06
prompted O 0 1.8628865561254315e-08
us O 0 7.787886779908604e-09
to O 0 1.9824415442570853e-09
search O 0 1.1082592621391996e-08
for O 0 1.3542071908290154e-09
mutations O 0 2.4442468049556965e-09
within O 0 1.1621237305803334e-08
their O 0 6.227715942941359e-08
POMC O 0 0.00010607292642816901
genes O 0 4.707037248863344e-07
. O 0 1.4817644569120603e-06

Patient O 0 1.0174042472499423e-05
1 O 0 4.672072861922061e-07
was O 0 7.842536575708436e-08
found O 0 9.378942067428397e-10
to O 0 3.577773910468096e-10
be O 0 3.604913589860814e-10
a O 0 9.099228037712237e-10
compound O 0 2.5331464925670844e-08
heterozygote O 0 7.568941384761274e-08
for O 0 5.639718692052043e-10
two O 0 1.4807237380676241e-10
mutations O 0 2.3277202387816942e-10
in O 0 9.405490830616259e-10
exon O 0 1.1272441469145633e-07
3 O 0 1.4896576772116532e-07
( O 0 2.587771996687138e-09
G7013T O 0 8.133027904477785e-07
, O 0 2.102832574735203e-09
C7133delta O 0 2.505139775621501e-07
) O 0 1.1021176332670635e-10
which O 0 8.968201181680513e-12
interfere O 0 5.177034356762533e-10
with O 0 6.6525738910694354e-12
appropriate O 0 6.086605441879556e-09
synthesis O 0 1.806626244160725e-07
of O 0 1.079353992849974e-07
ACTH O 0 2.913054458986153e-06
and O 0 2.318032876758025e-08
alpha O 0 7.321996690734522e-06
- O 0 3.887953789671883e-05
MSH O 0 0.00640364782884717
. O 0 4.557904048851924e-06

Patient O 0 6.922426564415218e-06
2 O 0 2.421529359253327e-07
was O 0 5.2887422441472154e-08
homozygous O 0 9.475267681580135e-09
for O 0 3.628609357431145e-10
a O 0 8.46366976503532e-10
mutation O 0 6.799556473424673e-10
in O 0 2.3592960918250583e-09
exon O 0 2.751137344603194e-07
2 O 0 3.145704852158815e-07
( O 0 8.994115674454406e-09
C3804A O 0 1.141871962317964e-06
) O 0 1.0368441660801864e-09
which O 0 2.5258056757238023e-10
abolishes O 0 3.469170337666583e-07
POMC O 0 2.745838719420135e-05
translation O 0 8.761790013522841e-06
. O 0 2.0994928036088822e-06

These O 0 2.702214452199314e-08
findings O 0 1.0692314589277885e-08
represent O 0 1.6949017189737958e-10
the O 0 5.957423443447851e-10
first O 0 5.650938605938904e-10
examples O 0 7.54510842693179e-10
of O 0 9.304675918642147e-10
a O 0 7.0459758028107444e-09
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
within O 0 1.5278802223406274e-08
the O 0 4.683883503275865e-09
POMC O 0 3.4986182981811e-06
gene O 0 1.971190544125534e-09
and O 0 9.722208593743176e-10
define O 0 2.5229432765172533e-08
a O 0 1.0157203078620114e-08
new O 0 5.7593556590518347e-08
monogenic B-Disease 1 0.9999995231628418
endocrine I-Disease 1 0.9999995231628418
disorder I-Disease 0 0.03402078524231911
resulting O 0 2.023960776753597e-09
in O 0 3.46443151943987e-10
early O 0 4.373156116344035e-06
- O 0 0.00020078176748938859
onset O 1 0.9999995231628418
obesity B-Disease 1 1.0
, O 0 4.5132811266057615e-08
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.0002610732917673886
red O 1 0.9999728202819824
hair O 1 0.9995985627174377
pigmentation O 1 0.9325352907180786
. O 0 2.0459397092054132e-06
. O 0 1.19280207400152e-06

A O 0 1.4168548432280659e-06
European O 0 1.3026200917920505e-07
multicenter O 0 9.02824194781715e-06
study O 0 9.251029808865496e-08
of O 0 3.633028313743125e-07
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 4.077449133887967e-08
classification O 0 2.3500097867668046e-08
of O 0 7.892503539608242e-09
105 O 0 3.773570611542709e-08
mutations O 0 1.672097460492239e-10
and O 0 7.761868231481728e-11
a O 0 1.7615023883976733e-09
general O 0 4.414981713551924e-09
system O 0 5.785733225849299e-09
for O 0 6.655068163219369e-10
genotype O 0 4.394130392881834e-09
- O 0 6.467196556059207e-08
based O 0 3.353485489299146e-09
prediction O 0 2.642769629801478e-07
of O 0 2.351803374267547e-08
metabolic O 0 2.4960304472188e-06
phenotype O 0 4.932951469527325e-07
. O 0 3.133891937068256e-07

Phenylketonuria B-Disease 1 0.9989062547683716
( O 0 2.016121669612403e-07
PKU B-Disease 0 0.0003040350566152483
) O 0 2.715042590750727e-08
and O 0 1.1618179307504306e-08
mild B-Disease 0 0.00022417814761865884
hyperphenylalaninemia I-Disease 1 1.0
( O 0 2.3080718847268145e-07
MHP B-Disease 1 1.0
) O 0 1.5183282187081204e-08
are O 0 2.0448638338166347e-09
allelic B-Disease 0 4.988171895092819e-06
disorders I-Disease 0 1.50906307680998e-05
caused O 0 1.6281022752195895e-08
by O 0 1.3206706561685877e-10
mutations O 0 4.848866794193718e-11
in O 0 2.9758254194156564e-10
the O 0 1.096902568775704e-09
gene O 0 2.2630393115008474e-09
encoding O 0 3.487174637939461e-08
phenylalanine O 0 9.229032116309099e-07
hydroxylase O 0 1.6640831745462492e-05
( O 0 3.184904073805228e-08
PAH O 0 0.00930481031537056
) O 0 5.784125178820432e-08
. O 0 2.897721742556314e-07

Previous O 0 5.864956165169133e-07
studies O 0 5.962146332194607e-08
have O 0 3.24487520186878e-10
suggested O 0 1.1069742900104984e-09
that O 0 1.3629149024640963e-11
the O 0 1.5977281997425763e-10
highly O 0 6.569826460633976e-09
variable O 0 1.1037700460292399e-06
metabolic O 0 0.07162494957447052
phenotypes O 0 0.0002820440276991576
of O 0 0.36571380496025085
PAH B-Disease 1 1.0
deficiency I-Disease 1 0.9999970197677612
correlate O 0 3.131279663648456e-05
with O 0 1.820879163005884e-07
PAH O 1 1.0
genotypes O 0 0.00048809018335305154
. O 0 3.200919991286355e-06

We O 0 6.775520660085022e-07
identified O 0 2.080278989069484e-07
both O 0 4.65756766487857e-09
causative O 0 1.940050537996285e-07
mutations O 0 4.655615981619121e-08
in O 0 6.757591819450681e-09
686 O 0 4.993175366507785e-07
patients O 0 8.24953403366635e-08
from O 0 5.766486399494397e-09
seven O 0 6.496915894160793e-09
European O 0 2.0496013775073152e-08
centers O 0 8.092427350447906e-08
. O 0 1.1859190607310666e-07

On O 0 4.3453343323562876e-07
the O 0 3.2224882762221796e-09
basis O 0 4.002839837369265e-09
of O 0 1.3112789742919517e-09
the O 0 7.413807900924496e-10
phenotypic O 0 4.680383192123827e-09
characteristics O 0 3.982673746349974e-09
of O 0 1.7121175588385995e-08
297 O 0 1.966827412047678e-08
functionally O 0 4.57333371173263e-08
hemizygous O 0 8.146737400238635e-07
patients O 0 6.4988987524827735e-09
, O 0 9.842191645015319e-11
105 O 0 3.225785860649921e-08
of O 0 8.86031781277552e-09
the O 0 4.191309077583583e-09
mutations O 0 6.109247552288366e-10
were O 0 1.5759766824885446e-09
assigned O 0 3.4853393060529925e-08
to O 0 1.9841788656549397e-08
one O 0 4.293290167822761e-09
of O 0 1.019094941767662e-08
four O 0 9.86732806573798e-10
arbitrary O 0 3.416614768880777e-09
phenotype O 0 9.508181797457382e-09
categories O 0 1.4738951392700983e-08
. O 0 1.8416932334730518e-07

We O 0 4.2002585587397334e-07
proposed O 0 4.2189341797893576e-08
and O 0 4.48124959362417e-09
tested O 0 2.062538939640035e-08
a O 0 7.335517193673979e-10
simple O 0 9.355214380946109e-10
model O 0 7.161928272658713e-10
for O 0 1.5898882210763077e-10
correlation O 0 3.2826052986933973e-10
between O 0 1.3380185848177462e-10
genotype O 0 2.5687226568038568e-08
and O 0 1.005310501511758e-08
phenotypic O 0 1.512876934839369e-07
outcome O 0 4.929809733766888e-07
. O 0 3.964187271776609e-06

The O 0 9.200035577805465e-08
observed O 0 2.971489543313055e-08
phenotype O 0 2.500413032180404e-08
matched O 0 1.97824210346198e-08
the O 0 2.0916162135620198e-09
predicted O 0 5.557445614812195e-09
phenotype O 0 1.0599613409212338e-09
in O 0 5.539906866580679e-10
79 O 0 1.8865362605424707e-08
% O 0 2.616806493715984e-10
of O 0 1.5783732654206517e-10
the O 0 3.118256000633757e-11
cases O 0 6.97110685149438e-12
, O 0 7.904197261987544e-12
and O 0 2.0092349659051045e-11
in O 0 3.33569200039463e-10
only O 0 1.3754586358771803e-10
5 O 0 2.2198058946543142e-09
of O 0 5.445213724364351e-10
184 O 0 4.4788142083973526e-09
patients O 0 3.266885428843125e-09
was O 0 1.3575362167728144e-08
the O 0 1.9258070693695117e-09
observed O 0 7.501089527295335e-09
phenotype O 0 3.0941935680317556e-09
more O 0 5.880348985520811e-11
than O 0 3.5606847331726144e-11
one O 0 2.1668975641597754e-11
category O 0 5.765735666685146e-10
away O 0 5.289573778988199e-10
from O 0 5.082036458325945e-10
that O 0 7.056606687871891e-11
expected O 0 9.703094328017414e-09
. O 0 2.8995518164265377e-07

Among O 0 1.936926423695695e-07
the O 0 9.31039689788804e-09
seven O 0 9.84281545157728e-10
contributing O 0 1.3270092802386557e-09
centers O 0 5.434164229711769e-10
, O 0 5.5021102257635235e-11
the O 0 6.145989966954701e-11
proportion O 0 2.795428055701876e-10
of O 0 9.130469713625189e-10
patients O 0 9.62706470097885e-10
for O 0 6.779380945509672e-10
whom O 0 8.414900776188006e-09
the O 0 8.195048195602794e-09
observed O 0 8.681522167819367e-09
phenotype O 0 4.267654230005746e-09
did O 0 3.16532333677344e-09
not O 0 6.563786181246201e-10
match O 0 2.968785883794567e-09
the O 0 6.337738667205883e-10
predicted O 0 1.7062095070130567e-09
phenotype O 0 4.294729294418431e-10
was O 0 9.599598893572647e-10
4 O 0 2.145837729727873e-09
% O 0 2.553040556740882e-10
- O 0 1.0888154378108084e-08
23 O 0 8.25355872535738e-09
% O 0 9.201379103096485e-10
( O 0 2.7049137929502365e-10
P O 0 2.997052561681812e-08
< O 0 2.9693762115812206e-08
. O 0 5.15805120837598e-10
0001 O 0 5.482211690832628e-06
) O 0 4.730135172437144e-10
, O 0 2.58674415221094e-10
suggesting O 0 3.2195146548730236e-09
that O 0 2.8520460298997463e-11
differences O 0 5.254537777110713e-11
in O 0 8.557310415824304e-11
methods O 0 2.6297670707720044e-09
used O 0 5.951790171820903e-10
for O 0 3.102003653943086e-10
mutation O 0 2.24416507599301e-09
detection O 0 8.768985253482242e-07
or O 0 2.1430942354072613e-08
phenotype O 0 4.83067026380013e-08
classification O 0 5.00143659820651e-09
may O 0 8.6188556291944e-10
account O 0 3.0505173387318507e-10
for O 0 1.0757741919498187e-10
a O 0 2.2405073629716554e-10
considerable O 0 6.788049566885945e-10
proportion O 0 1.0453550247646604e-09
of O 0 3.767262057863263e-09
genotype O 0 2.493477211373829e-07
- O 0 1.3003791536903009e-05
phenotype O 0 8.754421401135914e-07
inconsistencies O 0 1.1909211252714158e-06
. O 0 2.679655381143675e-06

Our O 0 1.361191607429646e-06
data O 0 2.545436927903211e-07
indicate O 0 3.3173208180414804e-08
that O 0 4.0551467739291525e-10
the O 0 6.105953964663513e-09
PAH O 0 0.40646892786026
- O 0 9.876759577309713e-06
mutation O 0 6.59220722454279e-09
genotype O 0 8.141578078380007e-09
is O 0 8.776428889190058e-11
the O 0 2.3139268279237513e-10
main O 0 7.594765705221107e-09
determinant O 0 5.114949530593549e-08
of O 0 1.3498707573944557e-07
metabolic O 1 0.9997552037239075
phenotype O 0 1.3228448096924694e-06
in O 0 8.199163659128317e-08
most O 0 1.3772714524407093e-08
patients O 0 8.39818170561557e-08
with O 0 2.5124553104660663e-08
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 7.201632979558781e-05

In O 0 9.866187866691689e-08
the O 0 2.9775415466559707e-09
present O 0 4.683881615896723e-10
study O 0 4.3098283275533333e-10
, O 0 8.458484607176686e-11
the O 0 1.2671923232954185e-10
classification O 0 9.981907522771394e-10
of O 0 8.383022276348129e-09
105 O 0 9.866354275800404e-07
PAH O 1 0.9780846834182739
mutations O 0 3.1548434975547934e-08
may O 0 1.020500683956982e-09
allow O 0 1.6865535634735807e-09
the O 0 3.151888749997056e-09
prediction O 0 3.2877906619432906e-08
of O 0 2.136416155096299e-09
the O 0 1.3562776457476389e-09
biochemical O 0 5.985127415897296e-08
phenotype O 0 6.864021795394137e-09
in O 0 1.8252869216084378e-09
> O 0 2.757962249688717e-07
10 O 0 2.2944947275505e-08
, O 0 8.268570828029453e-10
000 O 0 7.416516467628753e-08
genotypes O 0 1.722284004301855e-08
, O 0 6.186250400830318e-10
which O 0 3.2673433403296315e-11
may O 0 4.986286730734868e-11
be O 0 2.4250287541938143e-11
useful O 0 4.720140389657956e-10
for O 0 7.950680391832776e-11
the O 0 8.70843397393628e-10
management O 0 1.527964599290499e-08
of O 0 5.210423736912162e-08
hyperphenylalaninemia B-Disease 1 1.0
in O 0 8.450370359014414e-08
newborns O 0 8.903484740585554e-07
. O 0 3.077632584336243e-07

Somatic O 0 3.3094838727265596e-05
instability O 0 2.1965681753499666e-06
of O 0 8.045809352097422e-08
the O 0 2.6073035286344748e-08
CTG O 0 9.291325113736093e-06
repeat O 0 7.08219545231259e-08
in O 0 1.437074725885168e-08
mice O 0 1.6574800199009587e-08
transgenic O 0 1.3408608445786285e-08
for O 0 2.7709308181300685e-09
the O 0 1.490154915018138e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 5.550791684072465e-06
is O 0 5.429512395238589e-10
age O 0 4.186209989764933e-10
dependent O 0 5.009997972038605e-10
but O 0 2.0173335224527023e-11
not O 0 7.858337591759579e-11
correlated O 0 1.872439758798805e-09
to O 0 8.956278496619063e-10
the O 0 4.41605951806423e-09
relative O 0 3.529613650243846e-07
intertissue O 0 2.365467253184761e-06
transcription O 0 5.531327360586147e-07
levels O 0 2.757736012881651e-07
and O 0 2.101771201523661e-08
proliferative O 0 0.0004330060910433531
capacities O 0 0.00021997035946696997
. O 0 1.1012026334356051e-05

A O 0 2.4345657948288135e-05
( O 0 1.7798111429101482e-08
CTG O 0 2.7886280804523267e-06
) O 0 1.0922468485219383e-09
nexpansion O 0 1.011340202694555e-07
in O 0 6.481304937189236e-10
the O 0 8.209625201871518e-10
3 O 0 2.5613838161575586e-08
- O 0 4.49346146069729e-07
untranslated O 0 0.000101400502899196
region O 0 4.166046494447073e-07
( O 0 1.001635219211039e-09
UTR O 0 4.566214101942023e-06
) O 0 1.9133949979988074e-09
of O 0 7.684304748067916e-09
the O 0 1.9328956213371384e-08
DM O 1 1.0
protein O 0 1.2157350681718526e-07
kinase O 0 3.985107923654141e-07
gene O 0 3.8463543461375593e-08
( O 0 8.800354334148608e-10
DMPK O 0 3.5961827506980626e-06
) O 0 3.484817157062281e-10
is O 0 1.4596364047991806e-11
responsible O 0 1.386722542351393e-10
for O 0 6.577471900470755e-10
causing O 0 6.799303719162708e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 4.501620423980057e-06
DM B-Disease 1 1.0
) O 0 1.2368082025204785e-07
. O 0 5.558566726904246e-07

Major O 0 1.6185358617804013e-05
instability O 0 7.05066995578818e-05
, O 0 9.407611578637898e-09
with O 0 1.4876254395002064e-10
very O 0 2.99789554292218e-10
large O 0 3.989590324771086e-10
expansions O 0 1.0492567703579425e-08
between O 0 1.024559326268104e-09
generations O 0 4.073187120923194e-09
and O 0 1.2345469091457062e-09
high O 0 5.6627236233453004e-09
levels O 0 3.816405413914481e-09
of O 0 1.5999034319591487e-09
somatic O 0 3.06912113501312e-07
mosaicism O 0 1.9004389741894556e-06
, O 0 8.829608710847481e-10
is O 0 2.853852744399976e-11
observed O 0 5.071568720538266e-10
in O 0 9.406208034690167e-10
patients O 0 1.0089814317382206e-08
. O 0 1.2040983676797623e-07

There O 0 8.911234061770301e-08
is O 0 9.20371334700576e-10
a O 0 4.314253121417977e-10
good O 0 6.201845148545715e-10
correlation O 0 1.0779904746627267e-10
between O 0 9.359672065167857e-11
repeat O 0 6.3226135438299025e-09
size O 0 1.330753551798125e-08
( O 0 1.0550620377358655e-09
at O 0 4.465635417005842e-09
least O 0 4.133873521272591e-10
in O 0 1.734307697454085e-10
leucocytes O 0 3.650410107525204e-08
) O 0 2.905105878081571e-10
, O 0 1.308255587195717e-10
clinical O 0 1.9236925385968107e-09
severity O 0 2.3349171485165243e-08
and O 0 2.2518131803650476e-10
age O 0 4.483232896035361e-09
of O 0 2.4572289092361643e-08
onset O 0 7.822912266419735e-06
. O 0 1.8293452797024656e-07

The O 0 2.5468311832810286e-06
trinucleotide O 0 0.00017565309826750308
repeat O 0 4.59006002984097e-07
instability O 0 2.9063122042316536e-07
mechanisms O 0 6.581957450180198e-07
involved O 0 2.1241017833517617e-08
in O 0 7.914878352721644e-08
DM B-Disease 1 1.0
and O 0 8.706530252311495e-07
other O 0 1.9271345408355955e-08
human O 0 1.1906548280649076e-07
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 1.0040773074093678e-10
unknown O 0 1.97131164725306e-08
. O 0 6.114557038472412e-08

We O 0 3.9529720652353717e-07
studied O 0 9.585753559804289e-07
somatic O 0 3.2803104659251403e-06
instability O 0 3.363772691500344e-07
by O 0 7.176860772339921e-10
measuring O 0 2.3576870233910086e-08
the O 0 2.6988600243527117e-09
CTG O 0 7.538525892414327e-07
repeat O 0 2.05920152041017e-08
length O 0 4.415301457783016e-09
at O 0 5.069888509012799e-09
several O 0 8.252417499354792e-11
ages O 0 1.2028290585774926e-09
in O 0 2.5384980228970733e-10
various O 0 5.756570775616865e-10
tissues O 0 1.4266067438484242e-08
of O 0 4.479344006824704e-09
transgenic O 0 3.6566333960763586e-08
mice O 0 1.1103305830317822e-08
carrying O 0 7.570035265302977e-09
a O 0 1.1037784908296544e-08
( O 0 6.882177938649647e-09
CTG O 0 2.6606360279401997e-06
) O 0 3.771064793767209e-09
55expansion O 0 4.154794339683576e-07
surrounded O 0 2.703488100053164e-08
by O 0 5.858298290917219e-10
45 O 0 9.080006080353087e-09
kb O 0 2.1668807903552079e-07
of O 0 1.2731436349611158e-08
the O 0 9.203401596380445e-09
human O 0 3.2979588837633855e-08
DM B-Disease 1 1.0
region O 0 7.77399748130847e-07
, O 0 2.367211315856821e-09
using O 0 5.87724935385836e-09
small O 0 6.716293299291465e-09
- O 0 3.3383372510797926e-07
pool O 0 5.798711413262936e-07
PCR O 0 1.8412522422295297e-06
. O 0 4.428794682098669e-07

These O 0 3.816014668700518e-07
mice O 0 2.9531781819969183e-07
have O 0 3.6434158467990585e-10
been O 0 3.2097027813371426e-10
shown O 0 2.616092897866906e-10
to O 0 5.71777902802495e-10
reproduce O 0 5.83359227590563e-09
the O 0 1.5107589623752915e-09
intergenerational O 0 1.2261931026102957e-08
and O 0 3.872167031460094e-09
somatic O 0 7.250311000461807e-07
instability O 0 2.852633542715921e-07
of O 0 1.046616393551858e-08
the O 0 4.7174877337852195e-09
55 O 0 1.3042709667843155e-07
CTG O 0 3.1285844670492224e-06
repeat O 0 1.432731835393497e-07
suggesting O 0 3.855697272570069e-08
that O 0 2.7850341477453355e-10
surrounding O 0 4.517083374011577e-10
sequences O 0 2.9975752435795755e-10
and O 0 4.232293127071074e-10
the O 0 1.4599941255966087e-09
chromatin O 0 1.2169920182714122e-08
environment O 0 6.089278770105011e-08
are O 0 2.1965392005274254e-10
involved O 0 3.199019382726931e-10
in O 0 1.5729254565499673e-09
instability O 0 2.508965053493739e-07
mechanisms O 0 2.8378392471495317e-06
. O 0 1.1197029152754112e-06

As O 0 5.3534730426463284e-08
observed O 0 7.74237385314791e-09
in O 0 5.832209715173065e-10
some O 0 1.8082718655776375e-10
of O 0 1.076914224462655e-09
the O 0 5.474737885258207e-10
tissues O 0 1.925139692104949e-08
of O 0 6.05596639502437e-08
DM B-Disease 1 1.0
patients O 0 4.0141276258509606e-07
, O 0 2.970970969240483e-10
there O 0 8.534408596494458e-11
is O 0 3.2649015435648465e-11
a O 0 1.2650575031969424e-10
tendency O 0 3.4785616054300306e-10
for O 0 2.5980770312905577e-10
repeat O 0 2.7471711572246704e-09
length O 0 3.1921214560526323e-09
and O 0 6.151907427920378e-09
somatic O 0 1.6022700037865434e-06
mosaicism O 0 1.258317865904246e-06
to O 0 8.157927111618335e-10
increase O 0 3.1463490146599327e-10
with O 0 2.4255375485893182e-11
the O 0 5.057813057263161e-10
age O 0 1.6970278515771042e-09
of O 0 2.15476214648902e-09
the O 0 4.950669207914871e-09
mouse O 0 2.6036019562525325e-07
. O 0 4.030484035411064e-07

Furthermore O 0 1.6730900824768469e-06
, O 0 1.037224350852739e-08
we O 0 1.981485198143673e-09
observed O 0 1.341213251571105e-09
no O 0 1.1441586567073614e-09
correlation O 0 3.685491634097815e-10
between O 0 1.9630252978686258e-10
the O 0 7.558276671204567e-09
somatic O 0 1.1081028787884861e-05
mutation O 0 1.1082131834427855e-07
rate O 0 5.797367634841066e-07
and O 0 1.98262029016405e-08
tissue O 0 4.066640485689277e-06
proliferation O 0 0.014966573566198349
capacity O 0 1.580106072651688e-06
. O 0 5.348523473003297e-07

The O 0 3.1477813422498e-07
somatic O 0 7.908924089861102e-06
mutation O 0 2.6894422688883424e-08
rates O 0 5.6016236982259215e-08
in O 0 5.47429934716348e-10
different O 0 1.0796449151362353e-10
tissues O 0 2.8477941782512062e-08
were O 0 7.400474899554865e-09
also O 0 2.476404359352813e-10
not O 0 5.5982510294150245e-11
correlated O 0 1.3583202340683442e-09
to O 0 6.533733554192622e-10
the O 0 2.1777346592699587e-09
relative O 0 1.2709556074241846e-07
inter O 0 2.975049255837803e-07
- O 0 7.496452781197149e-06
tissue O 0 7.263826660164341e-07
difference O 0 4.778442530550819e-09
in O 0 2.0098377129240674e-10
transcriptional O 0 8.390792505252875e-10
levels O 0 3.17788173553879e-09
of O 0 7.523093259464986e-10
the O 0 1.018150230791548e-09
three O 0 6.755179193795868e-10
genes O 0 1.0553760088072295e-09
( O 0 7.942696500506941e-10
DMAHP O 0 8.873596925695892e-06
, O 0 5.993716190033638e-09
DMPK O 0 7.014017683104612e-06
and O 0 3.928473990555403e-09
59 O 0 4.742561543480406e-08
) O 0 4.3487285994459057e-10
surrounding O 0 1.4404768489129083e-09
the O 0 9.210948670457242e-10
repeat O 0 4.4589198999744895e-09
. O 0 9.607590278903899e-09
. O 0 1.2582275132899667e-07

A O 0 1.2492880614445312e-06
novel O 0 2.025366114821736e-07
missense O 0 3.0251303542172536e-06
mutation O 0 2.1042701803253294e-08
in O 0 2.624365613712598e-09
patients O 0 3.29385230202206e-09
from O 0 8.178445698447945e-10
a O 0 5.138170333651715e-09
retinoblastoma B-Disease 0 3.4286626942048315e-06
pedigree O 0 5.716688633583544e-07
showing O 0 6.1671002526964e-08
only O 0 1.8597153816912737e-09
mild O 0 2.345169392015123e-08
expression O 0 3.802795411900206e-09
of O 0 2.3291202300157465e-09
the O 0 2.5893913679908565e-09
tumor B-Disease 0 2.81364577858767e-07
phenotype O 0 7.064966922598614e-08
. O 0 2.339241547133497e-07

We O 0 4.254721659435745e-07
have O 0 2.366669527020804e-09
used O 0 5.581514694874556e-10
single O 0 6.325058254930127e-10
strand O 0 2.4109554352946816e-09
conformation O 0 3.1362473729146245e-10
polymorphism O 0 2.12731987581094e-09
analysis O 0 2.54058080129127e-10
to O 0 1.218314615858418e-10
study O 0 4.014735210944309e-10
the O 0 5.713058914835756e-10
27 O 0 3.022460148827122e-08
exons O 0 1.6478342246273314e-08
of O 0 1.5678097708970995e-09
the O 0 2.3407038529654756e-09
RB1 O 0 6.494087756436784e-07
gene O 0 1.2453454933947228e-09
in O 0 2.1328767918493696e-10
individuals O 0 1.8916425717496743e-11
from O 0 2.1595172872146406e-10
a O 0 1.2067931098869167e-09
family O 0 8.65022886653577e-10
showing O 0 1.5115782403540834e-08
mild O 0 4.5240803103752114e-08
expression O 0 9.002491196952178e-09
of O 0 1.9079806179433945e-08
the O 0 2.154586553615445e-08
retinoblastoma B-Disease 0 3.859115167870186e-06
phenotype O 0 3.5234924666838197e-07
. O 0 7.213969297481526e-07

In O 0 1.7213849901054346e-07
this O 0 6.1518017346884335e-09
family O 0 2.8023801057486253e-09
affected O 0 1.4940725323597803e-09
individuals O 0 2.987847122493115e-11
developed O 0 9.456345928526844e-09
unilateral B-Disease 0 8.62032720760908e-06
tumors I-Disease 1 1.0
and O 0 2.6608313419274054e-07
, O 0 4.006384113353079e-09
as O 0 9.589826710509897e-10
a O 0 4.792661267849496e-10
result O 0 1.6468144903303283e-10
of O 0 1.0123120119942541e-09
linkage O 0 2.165054269198663e-08
analysis O 0 8.625339553702815e-09
, O 0 2.097513052135014e-09
unaffected O 0 2.763716899778501e-08
mutation O 0 5.133191094408573e-10
carriers O 0 1.4705051620822474e-09
were O 0 3.75989728240711e-09
also O 0 2.187492853522599e-09
identified O 0 3.668829018366182e-09
within O 0 1.9007948548477316e-09
the O 0 8.733572087749053e-09
pedigree O 0 1.4441164921663585e-06
. O 0 5.922115633438807e-07

A O 0 5.277788659441285e-07
single O 0 1.7234999205584245e-08
band O 0 4.352509108684899e-08
shift O 0 1.9464584610773272e-08
using O 0 4.480053217292834e-09
SSCP O 0 2.1190046481933678e-06
was O 0 2.0200740635800685e-08
identified O 0 4.591012014998341e-09
in O 0 8.326924150203752e-10
exon O 0 2.2991999415467035e-08
21 O 0 6.235700400480937e-09
which O 0 6.43929267546417e-12
resulted O 0 7.390212747315772e-11
in O 0 1.1463555105173384e-10
a O 0 6.128118568149432e-10
missense O 0 2.1272724026744072e-08
mutation O 0 5.42216493926162e-10
converting O 0 5.9409162034285146e-09
a O 0 9.373259501899156e-09
cys O 0 5.141592737345491e-06
- O 0 5.413414783106418e-06
- O 0 2.9531854579545325e-06
> O 0 1.0103411796080763e-06
arg O 0 5.562400247072219e-07
at O 0 7.99093147207941e-09
nucleotide O 0 1.7321275080917076e-08
position O 0 1.7940509522418324e-08
28 O 0 7.272859647855512e-08
in O 0 1.0184653120859366e-08
the O 0 2.5221494226457253e-08
exon O 0 4.5194592530606315e-06
. O 0 1.1662538099699304e-06

The O 0 2.3608290575793944e-06
mutation O 0 2.865478450075898e-07
destroyed O 0 2.332274789296207e-06
an O 0 1.4740357379139368e-08
NdeI O 0 3.28787700709654e-06
restriction O 0 2.0979388182240655e-07
enzyme O 0 1.2915707614524763e-08
site O 0 1.2245482139405794e-07
. O 0 1.1794078602633817e-07

Analysis O 0 1.5199950098576664e-07
of O 0 2.5480325405169424e-08
all O 0 1.298699259244529e-09
family O 0 2.553283973139031e-10
members O 0 6.221984039100903e-11
demonstrated O 0 7.799269563513178e-10
that O 0 4.9718510558571793e-11
the O 0 1.9965804565202916e-09
missense O 0 7.04061790202104e-07
mutation O 0 2.6660913476916903e-08
co O 0 1.6715368644781847e-07
- O 0 7.248470501508564e-05
segregated O 0 7.292402983694046e-07
with O 0 1.034173857661358e-09
patients O 0 3.009069615700355e-08
with O 0 4.527312968960473e-10
tumors B-Disease 1 1.0
or O 0 1.0860117072297726e-07
who O 0 5.530048863278125e-09
, O 0 5.50216538997006e-10
as O 0 5.378953393808672e-10
a O 0 3.29008320587576e-10
result O 0 3.040306062462861e-10
of O 0 2.485533556750852e-09
linkage O 0 1.4739625520121535e-08
analysis O 0 5.221224785856293e-09
had O 0 1.1429245994065695e-08
been O 0 2.301357326928155e-09
predicted O 0 3.602605769259526e-09
to O 0 1.6053688378647735e-09
carry O 0 2.722452840941969e-08
the O 0 3.515121704822377e-08
predisposing O 0 8.4515640992322e-06
mutation O 0 2.1460991206367908e-07
. O 0 4.434132279129699e-07

These O 0 2.3227288536986634e-08
observations O 0 4.834569367062613e-08
point O 0 7.4372659142341035e-09
to O 0 3.73808567433187e-10
another O 0 3.364804823657863e-10
region O 0 3.0575850740177657e-09
of O 0 9.444576676287397e-09
the O 0 8.543179497166875e-09
RB1 O 0 3.85325347451726e-06
gene O 0 3.113243440822089e-09
where O 0 1.0426149943398855e-09
mutations O 0 2.2300318536228048e-10
only O 0 2.4260388142849365e-10
modify O 0 4.237634243509092e-09
the O 0 9.709644199773493e-10
function O 0 2.041068425384651e-09
of O 0 2.532845488900648e-09
the O 0 1.255155979151823e-09
gene O 0 1.7014842867979496e-09
and O 0 1.6737063956995257e-09
raise O 0 2.093469397834724e-08
important O 0 2.657703923603094e-08
questions O 0 5.233069533261414e-09
for O 0 1.9168213682974056e-09
genetic O 0 1.7114711425847418e-08
counseling O 0 2.3960213368923178e-08
in O 0 1.5626351601571997e-10
families O 0 4.9722118783401825e-11
with O 0 9.920780343064539e-12
these O 0 2.4635568585118506e-10
distinctive O 0 7.050492634164129e-09
phenotypes O 0 4.105111983676579e-08
. O 0 3.276009863384388e-08
. O 0 3.861795789816824e-07

Maternal B-Disease 0 0.0007066918187774718
disomy I-Disease 0 0.0025008327793329954
and O 0 2.2592534151044674e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 1 0.9999831914901733
with O 0 2.4901933848298086e-09
gamete O 0 3.4151253203162923e-07
complementation O 0 8.048531299209571e-07
in O 0 1.572745600419978e-09
a O 0 7.166505722189243e-10
case O 0 6.172272137838775e-10
of O 0 2.0229922181869142e-09
familial O 0 1.435108032410426e-08
translocation O 0 5.850576556554188e-08
( O 0 1.039881722397773e-10
3 O 0 1.2497570756053733e-09
; O 0 1.4500579903486965e-10
15 O 0 1.245213088196806e-08
) O 0 3.0074370771515646e-10
( O 0 1.6501977562199954e-10
p25 O 0 1.3120556729973032e-07
; O 0 4.2515735376724706e-10
q11 O 0 1.4509150503272394e-07
. O 0 5.547244330550427e-10
2 O 0 1.3362117634585502e-08
) O 0 8.089106273700963e-09
. O 0 9.133334089028722e-08

Maternal B-Disease 1 0.9999994039535522
uniparental I-Disease 1 1.0
disomy I-Disease 1 1.0
( I-Disease 0 1.8207973653261433e-06
UPD I-Disease 1 1.0
) I-Disease 0 9.688152502462799e-09
for I-Disease 0 9.146348123323378e-10
chromosome I-Disease 0 1.4473571674500363e-08
15 I-Disease 0 1.1048443937511365e-08
is O 0 4.0987293420391424e-11
responsible O 0 8.057530337390872e-11
for O 0 5.92082008421535e-11
an O 0 2.5451630386585933e-11
estimated O 0 7.688109177061975e-11
30 O 0 6.986901057715045e-10
% O 0 1.9435545187129755e-11
of O 0 1.6113615650126256e-11
cases O 0 5.393351130283941e-12
of O 0 3.8458827233966986e-09
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 9.999130270443857e-06
PWS B-Disease 1 1.0
) O 0 7.54799387436833e-08
. O 0 1.228862771540662e-07

We O 0 1.4529574343669083e-07
report O 0 6.432661958655217e-09
on O 0 2.6583868439900016e-09
an O 0 5.579499709473801e-11
unusual O 0 1.3448525626458263e-10
case O 0 7.7467421366606e-10
of O 0 4.14007761406765e-09
maternal B-Disease 0 0.0002605714835226536
disomy I-Disease 0 0.00040244360570795834
15 I-Disease 0 1.6076116935437312e-06
in O 0 1.9364830450285808e-07
PWS B-Disease 1 1.0
that O 0 7.932905887741981e-09
is O 0 7.98863752926593e-11
most O 0 2.940498539105718e-11
consistent O 0 2.661749154420079e-10
with O 0 1.8939233861758886e-12
adjacent O 0 2.428103273999227e-10
- O 0 1.5294254751552216e-08
1 O 0 3.997806174993457e-08
segregation O 0 6.065030078161726e-08
of O 0 6.601783120174787e-09
a O 0 3.1032243441586616e-09
paternal O 0 6.212707717168087e-07
t O 0 3.427523509458297e-08
( O 0 8.857131694739451e-11
3 O 0 6.130199681209092e-10
; O 0 1.0564146779579175e-10
15 O 0 5.7352469440274945e-09
) O 0 1.9951480745294958e-10
( O 0 4.638467041018224e-11
p25 O 0 3.287878413971157e-08
; O 0 4.444548895587985e-11
q11 O 0 2.0279458112781867e-08
. O 0 7.915500893629357e-11
2 O 0 5.491785359801327e-10
) O 0 6.41381253663198e-11
with O 0 1.8776808233256226e-11
simultaneous O 0 2.0973780934241404e-08
maternal O 0 1.0674136774468934e-06
meiotic O 0 1.0069984455185477e-05
nondisjunction O 0 1.0571468010311946e-05
for O 0 3.356667477305564e-08
chromosome O 0 1.547398369439179e-07
15 O 0 7.009625164755562e-07
. O 0 3.567162139006541e-07

The O 0 1.2668524504988454e-06
patient O 0 7.251303941302467e-06
( O 0 1.6635443023105267e-09
J O 0 2.410203308045311e-07
. O 0 7.514603383995677e-10
B O 0 5.4146468642102263e-08
. O 0 3.6378448864393675e-11
) O 0 3.278880639223658e-11
, O 0 2.105688193254629e-11
a O 0 8.699050507710027e-11
17 O 0 4.891076987867393e-10
- O 0 1.3703530532538366e-09
year O 0 5.81091230689168e-10
- O 0 6.724319945305979e-08
old O 0 4.2073303063716594e-08
white O 0 2.580329505619261e-09
male O 0 7.741277063821883e-10
with O 0 2.6562401583829498e-11
PWS B-Disease 1 1.0
, O 0 3.436168460879685e-09
was O 0 1.076764810648001e-08
found O 0 5.151168935846329e-10
to O 0 5.965473670599408e-10
have O 0 1.225904933122024e-09
47 O 0 6.21007743006885e-08
chromosomes O 0 9.545231272056753e-09
with O 0 9.72265379317605e-10
a O 0 4.6345299153927044e-08
supernumerary O 0 0.00015017710393294692
, O 0 3.5654743157920166e-08
paternal O 0 2.694654540391639e-06
der O 0 0.04805599898099899
( O 0 2.951908717463425e-09
15 O 0 8.791165129196088e-09
) O 0 6.611743791351543e-11
consisting O 0 1.5925620544532393e-10
of O 0 5.822672899391534e-10
the O 0 5.628692512082978e-10
short O 0 7.789788369905182e-09
arm O 0 6.401941732292471e-08
and O 0 9.732788797123249e-09
the O 0 2.9757831754295694e-08
proximal O 0 4.319603249314241e-06
long O 0 1.7277152153383213e-07
arm O 0 4.7667390390415676e-07
of O 0 9.195158412467208e-08
chromosome O 0 1.7974418398125636e-08
15 O 0 5.3755947249101155e-08
, O 0 3.880307186676646e-09
and O 0 1.3542724275339424e-08
distal O 0 1.7883680811792146e-06
chromosome O 0 2.5754154194146395e-05
arm O 0 0.0001464667438995093
3p O 1 0.9938979744911194
. O 0 4.81968618259998e-06

The O 0 4.707625976152485e-06
t O 0 1.8085674469148216e-07
( O 0 2.1489657275886032e-10
3 O 0 5.967397131989571e-10
; O 0 5.361394661562713e-11
15 O 0 1.772803903676845e-09
) O 0 5.730102156653594e-11
was O 0 1.0104851400072334e-09
present O 0 4.2737511446455656e-11
in O 0 7.082456149332117e-11
the O 0 8.653045641127122e-11
balanced O 0 5.136531200378158e-10
state O 0 3.00452301926768e-11
in O 0 1.9753634838970413e-10
the O 0 3.8502259713801834e-10
patients O 0 3.080594668247727e-10
father O 0 1.2395986459523556e-09
and O 0 1.3976820811834045e-09
a O 0 3.239523138631739e-08
sister O 0 2.7402757041272707e-06
. O 0 2.695099283300806e-06

Fluorescent O 0 6.264962394197937e-06
in O 0 6.37861248264926e-08
situ O 0 6.303716872935183e-07
hybridization O 0 7.251082845272094e-09
analysis O 0 2.1966994889766056e-09
demonstrated O 0 3.768519274416349e-09
that O 0 7.368607807256566e-11
the O 0 2.926602515884724e-09
PWS B-Disease 1 1.0
critical O 0 3.587102582969237e-06
region O 0 1.626640155905079e-08
resided O 0 5.014726056629115e-08
on O 0 1.9601088752096985e-08
the O 0 3.4664210390999983e-10
derivative O 0 3.545000737403825e-09
chromosome O 0 9.02022900817201e-09
3 O 0 8.289909203540446e-09
and O 0 1.7320497813777536e-10
that O 0 2.645208357909823e-11
there O 0 8.217548169708877e-11
was O 0 4.3356869205979365e-09
no O 0 1.0324119337212778e-09
deletion O 0 1.6304693151170113e-09
of O 0 2.927166287136629e-09
the O 0 9.371542653013876e-09
PWS B-Disease 1 1.0
region O 0 9.356882202382621e-08
on O 0 1.2732043863650233e-08
the O 0 4.8962756071802e-10
normal O 0 8.009120477936449e-09
pair O 0 5.246671541669912e-09
of O 0 7.131996326847911e-09
15s O 0 1.6278712564599118e-06
present O 0 6.4201346461345565e-09
in O 0 9.258867805783666e-08
J O 0 0.0003665192925836891
. O 0 4.688346962211654e-06

B O 0 0.0028908641543239355
. O 0 3.114491846645251e-06

Methylation O 0 8.275203526864061e-07
analysis O 0 4.496483541061025e-08
at O 0 1.9974461196170523e-08
exon O 0 5.7920189533433586e-08
alpha O 0 4.615897708504235e-08
of O 0 4.483515336772825e-09
the O 0 2.3116428771174924e-09
small O 0 7.226613196742449e-10
nuclear O 0 1.2802094317976298e-07
ribonucleoprotein O 0 1.0077766319227521e-06
- O 0 5.311700874699454e-07
associated O 0 9.974341708129941e-08
polypeptide O 0 4.774664574824783e-08
N O 0 2.5072949938476086e-08
( O 0 1.0610714390457687e-10
SNRPN O 0 1.6297558147471136e-07
) O 0 2.3266813475864012e-10
gene O 0 9.509845133592876e-10
showed O 0 2.31145791396159e-09
a O 0 5.989461704380972e-10
pattern O 0 2.533926679593179e-10
characteristic O 0 1.0955978346771644e-09
of O 0 5.512903467064234e-09
only O 0 3.6401928693585717e-10
the O 0 2.8422075804002134e-10
maternal O 0 5.988324858208216e-08
chromosome O 0 4.891016303076867e-08
15 O 0 1.5431395183895802e-07
in O 0 9.768779563046337e-08
J O 0 0.00028270710026845336
. O 0 5.113206498208456e-06

B O 0 0.00230963877402246
. O 0 5.270413112157257e-06

Maternal B-Disease 0 0.00023548761964775622
disomy I-Disease 0 6.214121822267771e-05
was O 0 4.282366319330322e-07
confirmed O 0 8.149967811732495e-09
by O 0 2.498832529784778e-10
polymerase O 0 9.021038138712356e-09
chain O 0 1.2256640147256803e-09
reaction O 0 9.727489647115561e-11
analysis O 0 1.7184759171229302e-10
of O 0 4.1177725118579644e-10
microsatellite O 0 2.4670061549159072e-08
repeats O 0 2.698319789828929e-09
at O 0 3.595795661226475e-09
the O 0 1.6540619984795057e-09
gamma O 0 4.594237879018692e-08
- O 0 1.2240998614743148e-07
aminobutyric O 0 5.44014255865477e-07
acid O 0 9.853659221903399e-09
receptor O 0 2.1414789941331946e-09
beta3 O 0 1.9669143114242615e-07
subunit O 0 7.498016429963172e-08
( O 0 8.023889996877642e-09
GABRB3 O 0 2.897237936849706e-05
) O 0 3.150712046817716e-08
locus O 0 1.137461481448554e-06
. O 0 4.016570471776504e-07

A O 0 6.518587179016322e-05
niece O 0 0.020110804587602615
( O 0 3.372138834834004e-08
B O 0 7.739703278275556e-07
. O 0 1.5305036404900108e-10
B O 0 1.1990455739407935e-08
. O 0 3.8001594926395654e-11
) O 0 2.5759996566399046e-11
with O 0 8.913494942142108e-12
45 O 0 2.0818571311309597e-09
chromosomes O 0 3.476677834512998e-10
and O 0 2.1973102504180275e-10
the O 0 3.5945321719133005e-10
derivative O 0 2.0942672041002197e-09
3 O 0 2.5289159655272897e-09
but O 0 7.531503198876521e-11
without O 0 4.0371730958277396e-10
the O 0 4.4158718348619175e-10
der O 0 1.3953806501376675e-06
( O 0 9.399572231671982e-10
15 O 0 8.831668729669673e-09
) O 0 4.1946660034319905e-10
demonstrated O 0 3.2200981880947666e-09
a O 0 8.989274880022435e-10
phenotype O 0 5.2993422983149685e-09
consistent O 0 5.84067239017827e-09
with O 0 3.054638486599259e-11
that O 0 6.178170475212852e-11
reported O 0 1.967403323588357e-10
for O 0 1.5983468715230487e-10
haploinsufficiency O 0 2.24891451239273e-07
of O 0 2.7675518765590823e-08
distal O 0 1.4291853176473523e-06
3 O 0 4.059228740516119e-05
p O 0 7.081463263602927e-05
. O 0 1.3123400322001544e-06

Uniparental B-Disease 1 1.0
disomy I-Disease 1 1.0
associated O 0 6.811412731622113e-07
with O 0 7.731227880114488e-10
unbalanced O 0 3.235059580219968e-07
segregation O 0 5.196786787564633e-07
of O 0 4.974913281330373e-08
non O 0 4.921485469822073e-06
- O 0 2.4994651539600454e-06
Robertsonian O 0 1.2518792573246174e-05
translocations O 0 2.558484538894845e-06
has O 0 6.785680350951395e-10
been O 0 2.0885496110345514e-10
reported O 0 3.052514074841639e-10
previously O 0 4.133305642195495e-10
but O 0 7.958100151084224e-11
has O 0 3.6243813505976163e-11
not O 0 5.6153616478926693e-11
, O 0 7.240226473914646e-11
to O 0 2.532564158386208e-10
our O 0 3.2952849338130363e-09
knowledge O 0 2.4917389040979288e-08
, O 0 3.5775557516437573e-10
been O 0 1.5504124373233452e-10
observed O 0 2.354188233244514e-10
in O 0 1.8637057175308058e-10
a O 0 1.5247177964639036e-09
case O 0 5.0052060274197174e-09
of O 0 1.0994463650604303e-07
PWS B-Disease 1 1.0
. O 0 3.663150346255861e-05

Furthermore O 0 5.391425474954303e-06
, O 0 3.342535492834031e-08
our O 0 1.813046424103959e-08
findings O 0 5.864718044534811e-09
are O 0 8.831288478283739e-11
best O 0 1.3911977125857788e-09
interpreted O 0 2.4299762202417696e-09
as O 0 6.724955037284985e-10
true O 0 3.826055028355313e-09
gamete O 0 2.304836073108163e-07
complementation O 0 9.31583315377793e-07
resulting O 0 1.4631003963927469e-08
in O 0 1.753006806382018e-08
maternal B-Disease 0 0.16791675984859467
UPD I-Disease 1 1.0
15 I-Disease 0 0.0003436736005824059
and O 0 1.1195171282452065e-05
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9983566403388977
- I-Disease 1 1.0
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
type I-Disease 0 2.1133134850970237e-06
2 I-Disease 0 7.793364034114347e-07
and O 0 8.021931563462203e-09
Stuve B-Disease 1 1.0
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 4.485995575009838e-09
a O 0 1.2536246485339575e-09
case O 0 2.341399296668101e-10
for O 0 2.167994256341288e-10
" O 0 8.884144087062396e-09
lumping O 0 1.5966270083822565e-08
" O 0 3.374867674210691e-07
. O 0 4.2799084098987805e-07

Recent O 0 7.31244682583565e-08
studies O 0 1.2720852815562012e-08
demonstrated O 0 5.95991522800432e-09
the O 0 5.055835750056303e-10
existence O 0 2.0167738590259887e-09
of O 0 1.3278447230646861e-09
a O 0 9.983450732775623e-10
genetically O 0 1.4637527856464772e-09
distinct O 0 1.114345699049224e-10
, O 0 9.468447553784287e-11
usually O 0 6.756266986845949e-12
lethal O 0 9.861696875779202e-11
form O 0 2.310424074281059e-11
of O 0 1.9325481215304308e-09
the O 0 4.927936281262646e-09
Schwartz B-Disease 1 0.7641554474830627
- I-Disease 1 1.0
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 3.4997011510995435e-08
SJS B-Disease 1 0.9999135732650757
) O 0 3.130107018023409e-08
of O 0 5.454376719171705e-07
myotonia B-Disease 1 1.0
and O 0 2.0530349502223544e-05
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 9.047229809766577e-07
which O 0 5.969950311879302e-09
we O 0 1.0043158304995359e-08
called O 0 9.342954854218988e-08
SJS B-Disease 0 0.00029491379973478615
type I-Disease 0 1.678995613474399e-05
2 I-Disease 0 2.0458794097066857e-05
. O 0 2.650136821102933e-06

This O 0 1.3527187547879294e-07
disorder O 0 4.1523773688822985e-05
is O 0 1.5819960619278817e-10
reminiscent O 0 4.415503518373498e-09
of O 0 1.950954953144901e-09
another O 0 2.760358330800017e-10
rare O 0 2.24462315401297e-09
condition O 0 3.616032699937932e-06
, O 0 9.45435840726816e-10
the O 0 1.5926911345331973e-08
Stuve B-Disease 1 1.0
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 5.008760126656853e-06
SWS B-Disease 1 1.0
) O 0 1.1779207609308173e-09
, O 0 2.040888569254662e-10
which O 0 6.278874642440258e-11
comprises O 0 1.5218203086586612e-10
campomelia B-Disease 0 1.4782737878249463e-07
at O 0 9.50620471229513e-09
birth O 0 1.8670112922336557e-06
with O 0 3.703323159243155e-08
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 1.5241640483054653e-07
contractures B-Disease 0 6.262764145503752e-06
, O 0 8.741700696646149e-10
and O 0 2.7035212957216004e-10
early B-Disease 0 4.794686958575767e-08
death I-Disease 0 1.3439505153201026e-07
. O 0 1.6829561388931324e-07

To O 0 6.651266915014276e-08
test O 0 4.2650176723668665e-09
for O 0 2.3693785822231916e-10
possible O 0 2.0946264722709884e-09
nosologic O 0 2.0223699266352924e-06
identity O 0 3.1881192796845426e-08
between O 0 5.681513037814057e-10
these O 0 5.489418919424338e-10
disorders O 0 5.994644425300066e-08
, O 0 3.747750026983354e-11
we O 0 5.139605407933345e-11
reviewed O 0 2.0702946024186986e-09
the O 0 8.970451603751428e-10
literature O 0 3.7176737244237756e-09
and O 0 2.946967947448087e-10
obtained O 0 2.898089768166301e-09
a O 0 3.3603156368577913e-10
follow O 0 3.3344832450765693e-10
- O 0 7.468297091861587e-09
up O 0 8.058072542560524e-10
of O 0 4.6455259083977296e-10
the O 0 3.1761410168584803e-10
only O 0 6.474666636169246e-11
two O 0 2.9018037972505795e-11
surviving O 0 9.264233824524126e-09
patients O 0 1.560405138434362e-09
, O 0 1.5651796525517625e-10
one O 0 2.2629302598442536e-10
with O 0 2.2946676503377006e-10
SJS B-Disease 1 0.979617178440094
type I-Disease 1 0.8415728807449341
2 I-Disease 0 1.1677690963551868e-05
at O 0 3.716165153377915e-08
age O 0 1.0556980845066732e-09
10 O 0 4.1622927327011894e-10
years O 0 3.595942987821843e-11
and O 0 5.842427236446568e-11
another O 0 2.9241292720527667e-10
with O 0 2.879431970637114e-10
SWS B-Disease 0 5.4062355047790334e-05
at O 0 1.566101026639899e-08
age O 0 6.337258273703128e-09
7 O 0 7.156827308563152e-08
years O 0 1.083354916886492e-08
. O 0 2.198725752577957e-07

Patients O 0 9.027596206578892e-06
reported O 0 1.8495462938972196e-08
as O 0 8.086448177735406e-10
having O 0 1.3122621878025598e-09
either O 0 1.7004534669240456e-08
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 1 0.994716465473175
SWS B-Disease 1 0.9991990923881531
presented O 0 1.3991177105765473e-08
a O 0 6.473373503901314e-10
combination O 0 6.233485394524507e-10
of O 0 5.090738941504469e-10
a O 0 3.8077288544435817e-10
severe O 0 5.496263000281942e-09
, O 0 3.9110070737535807e-10
prenatal O 0 2.2213387637748383e-05
- O 0 2.8289869078435004e-05
onset O 1 0.9999997615814209
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 3.551247296229576e-09
with O 0 3.940315629336055e-09
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 0.9999997615814209
respiratory O 1 1.0
and O 1 0.9443666934967041
feeding O 1 0.9999622106552124
difficulties O 1 0.7704522609710693
, O 0 3.215858512817249e-08
tendency O 0 1.4052663033226054e-08
to O 0 3.1991307380963008e-09
hyperthermia B-Disease 0 3.3012631320161745e-05
, O 0 1.0970364616724737e-09
and O 0 4.4626616291232324e-10
frequent O 0 8.150881636304064e-10
death O 0 1.9907131498797526e-09
in O 0 3.5289227096058084e-10
infancy O 0 2.93163786579953e-08
) O 0 2.055969700043292e-10
with O 0 6.098661853304321e-11
a O 0 6.310047595547985e-09
distinct O 0 1.6296276328375825e-08
campomelic B-Disease 1 0.9766185283660889
- I-Disease 1 0.9999164342880249
metaphyseal I-Disease 1 0.9999520778656006
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.0004283772432245314

The O 0 2.422774514343473e-07
similarity O 0 7.636006671418727e-08
of O 0 6.596172141826173e-08
the O 0 1.3932909048719466e-08
clinical O 0 1.7774507909962267e-07
and O 0 3.4284892702629577e-09
radiographic O 0 1.1818452549050562e-05
findings O 0 1.2521728365300078e-07
is O 0 9.878513562711078e-10
so O 0 4.875522208180882e-10
extensive O 0 2.8690298137235004e-08
that O 0 3.761709832517113e-10
these O 0 7.701381199431978e-10
disorders O 0 3.538396526892029e-07
appear O 0 1.908438074238461e-09
to O 0 6.932554530436619e-10
be O 0 1.059393461844138e-09
a O 0 2.5849749007988976e-09
single O 0 1.6630183452548408e-08
entity O 0 7.8279057902364e-08
. O 0 1.3954764881418669e-06

The O 0 2.81335587715148e-07
follow O 0 7.54117337464777e-08
- O 0 2.1262303562252782e-07
up O 0 3.2956934958860984e-09
observation O 0 2.2787857290040847e-07
of O 0 2.264166187870842e-09
an O 0 4.1590054317142133e-11
identical O 0 2.2882427896941948e-10
and O 0 1.5808469810973946e-10
unique O 0 3.37901995273171e-09
pattern O 0 4.034621170490027e-08
of O 0 5.188606451156375e-07
progressive O 1 1.0
bone B-Disease 1 1.0
dysplasia I-Disease 1 1.0
in O 0 1.8421269487589598e-06
the O 0 5.78798164951877e-07
two O 0 1.4180286278531185e-08
patients O 0 2.566014600802191e-08
( O 0 1.2057985165903062e-10
one O 0 1.310370700835506e-10
with O 0 1.3417267297199942e-10
SJS B-Disease 0 3.7916648579994217e-05
type I-Disease 0 8.930049261834938e-06
2 I-Disease 0 1.940410811585025e-06
, O 0 5.203905750761351e-09
one O 0 1.5608456749305333e-09
with O 0 6.338173874631536e-10
SWS B-Disease 0 0.0031006797216832638
) O 0 2.0475567907851655e-09
surviving O 0 1.1193917259788577e-07
beyond O 0 7.091374243373139e-08
infancy O 0 2.4661270003889513e-07
adds O 0 7.404851398717938e-09
to O 0 6.898182025594224e-10
the O 0 5.463690611051675e-10
evidence O 0 1.0046985465805847e-09
in O 0 2.7044394501629654e-10
favor O 0 6.6882339666562984e-09
of O 0 8.726312117346424e-09
identity O 0 8.68975931211935e-08
. O 0 1.9058134625993262e-07

The O 0 7.4162471719319e-07
hypothesis O 0 9.751212246555951e-07
that O 0 9.954400859157886e-09
SWS B-Disease 1 0.7113547325134277
and O 0 8.909245252652909e-08
SJS B-Disease 1 0.9283102750778198
type I-Disease 0 0.00039992350502870977
2 I-Disease 0 2.6394150154374074e-06
are O 0 8.077414848095543e-10
the O 0 2.5197488540129598e-09
same O 0 1.9180072641233892e-08
disorder O 0 2.627605681482237e-06
should O 0 8.649783111991383e-10
be O 0 2.0681069357042503e-10
testable O 0 1.6946632985792576e-09
by O 0 4.432172337476281e-11
molecular O 0 9.67739888224628e-10
methods O 0 2.5527999270025248e-08
. O 0 1.2794437509455747e-08
. O 0 2.2250976883242402e-07

A O 0 4.629318027582485e-06
mouse O 0 3.403164328119601e-07
model O 0 2.260120091079898e-08
of O 0 1.6057615681575044e-08
severe O 0 0.006356287747621536
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.009090606123209
defects O 0 0.04740400239825249
in O 0 2.0612574758160918e-07
hemostasis O 0 0.01742337830364704
and O 0 1.2679967653639324e-07
thrombosis B-Disease 0 0.0018942269962280989
. O 0 9.044434818861191e-07

von B-Disease 0 0.4556247293949127
Willebrand I-Disease 1 0.9967547059059143
factor I-Disease 0 4.8937050451058894e-05
( I-Disease 0 2.3170873930666858e-07
vWf I-Disease 0 0.005402180831879377
) I-Disease 0 1.5112992741705966e-06
deficiency I-Disease 1 0.9809990525245667
causes O 0 0.038762129843235016
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 1 0.9990192651748657
humans O 0 1.11201768504543e-06
. O 0 1.6036167949096125e-07

We O 0 3.221525730623398e-07
generated O 0 1.0529918270663075e-08
a O 0 7.800166734739378e-09
mouse O 0 2.896344852842958e-08
model O 0 4.880846837806985e-09
for O 0 7.880135433069313e-10
this O 0 3.457922281846493e-10
disease O 0 1.2282007633146463e-09
by O 0 7.790270512009201e-11
using O 0 2.534208176641073e-09
gene O 0 2.411084443210143e-09
targeting O 0 1.7170680166600505e-07
. O 0 4.802219564226107e-07

vWf B-Disease 0 0.002496046246960759
- I-Disease 1 0.9835826754570007
deficient I-Disease 0 0.0019841506145894527
mice O 0 9.824396329349838e-06
appeared O 0 8.795596784239024e-08
normal O 0 3.337941834047342e-08
at O 0 2.9691029634904e-09
birth O 0 4.920338358971321e-09
; O 0 2.9484464869611315e-10
they O 0 6.035735244935836e-10
were O 0 1.4670621384382798e-09
viable O 0 6.556772547128276e-08
and O 0 2.9225430964174848e-08
fertile O 0 2.338782678634743e-06
. O 0 1.1391798580007162e-06

Neither O 0 7.240167178679258e-05
vWf O 0 0.0006143477512523532
nor O 0 7.118403300410137e-05
vWf O 0 0.0003870024811476469
propolypeptide O 0 0.0004187745216768235
( O 0 1.9406279250233638e-07
von B-Disease 0 0.0019329690840095282
Willebrand I-Disease 0 0.15663869678974152
antigen O 0 7.327633738896111e-06
II O 1 1.0
) O 0 1.0058037958060595e-07
were O 0 4.9508322774727276e-08
detectable O 0 1.28125378751065e-07
in O 0 1.0617480228347631e-09
plasma O 0 4.293210409400672e-08
, O 0 9.614018470216479e-10
platelets O 0 4.305806200477491e-08
, O 0 2.951970667908199e-09
or O 0 2.2516597475430444e-09
endothelial O 0 3.29382885411178e-08
cells O 0 1.8950579772081255e-08
of O 0 8.195971012980863e-09
the O 0 9.990808180759814e-09
homozygous O 0 2.5117566337939934e-07
mutant O 0 3.946884703509568e-07
mice O 0 1.4573582802768215e-06
. O 0 9.532769240649941e-07

The O 0 2.0488957943598507e-06
mutant O 0 1.9459856048342772e-05
mice O 0 2.731347194639966e-06
exhibited O 0 4.7564310534653487e-07
defects O 0 1.195783079310786e-05
in O 0 2.8836559806677542e-08
hemostasis O 0 6.066642527002841e-06
with O 0 4.4461620496427656e-10
a O 0 4.342373571830649e-09
highly O 0 2.8136341256868036e-08
prolonged O 0 4.469814939511707e-06
bleeding O 0 2.118406655426952e-06
time O 0 2.587526459763012e-08
and O 0 1.356889001158379e-08
spontaneous O 0 1.6333001440216321e-07
bleeding O 0 4.4451664393818646e-07
events O 0 4.751656290657991e-10
in O 0 3.2519387183072013e-10
approximately O 0 9.208976636809751e-11
10 O 0 1.2389863579542748e-09
% O 0 3.7494893301293075e-10
of O 0 2.3071853316736224e-09
neonates O 0 2.458319272591325e-07
. O 0 1.8404870161248255e-07

As O 0 5.537292224744306e-08
in O 0 1.6980996608850774e-09
the O 0 5.692609716945185e-10
human O 0 6.848900335754138e-10
disease O 0 1.0743989031780643e-09
, O 0 2.94696628211355e-11
the O 0 6.15191564357076e-10
factor O 0 4.781973927947547e-08
VIII O 1 0.916510283946991
level O 0 7.587291474919766e-05
in O 0 2.368291873722228e-08
these O 0 8.6447569103143e-09
mice O 0 1.3292877554249571e-07
was O 0 9.078638285586749e-09
reduced O 0 2.2425303836115518e-09
strongly O 0 3.131107317866366e-10
as O 0 2.4216467719995194e-10
a O 0 3.8716257977355895e-10
result O 0 2.9093533138180305e-10
of O 0 1.0940879313636742e-09
the O 0 8.091354253281224e-10
lack O 0 4.604797876339717e-09
of O 0 8.924492811424045e-10
protection O 0 7.792999134892398e-09
provided O 0 2.7301370053578466e-09
by O 0 7.421801506701797e-10
vWf O 0 8.761172466620337e-06
. O 0 1.982830099223065e-06

Defective O 0 0.1602262407541275
thrombosis B-Disease 1 0.9986935257911682
in O 0 2.719941392115288e-07
mutant O 0 9.998415180234588e-07
mice O 0 1.2639715407658514e-07
was O 0 6.988277068131765e-09
also O 0 3.21315751783402e-10
evident O 0 2.8447906252893063e-09
in O 0 6.55707932395444e-10
an O 0 1.1906713115461542e-10
in O 0 3.771394030405162e-10
vivo O 0 1.2425195450305182e-07
model O 0 8.494777858913949e-08
of O 0 3.741841965165804e-07
vascular B-Disease 1 1.0
injury I-Disease 1 1.0
. O 0 4.607634764397517e-05

In O 0 6.54450289516717e-08
this O 0 2.894928186059076e-10
model O 0 7.665875045859138e-09
, O 0 8.787690575218221e-10
the O 0 2.249667785392262e-09
exteriorized O 0 1.931745828187559e-06
mesentery O 0 1.0039069820777513e-05
was O 0 3.9087370851120795e-07
superfused O 0 2.6214711397187784e-06
with O 0 3.0070770318246787e-09
ferric O 0 5.116123702464392e-06
chloride O 0 1.2671375770878512e-06
and O 0 6.971798427457543e-08
the O 0 9.647551735270099e-08
accumulation O 0 2.3349675757344812e-06
of O 0 4.805802404916903e-07
fluorescently O 0 6.3970801420509815e-06
labeled O 0 8.474371071542919e-08
platelets O 0 3.9012363117763016e-08
was O 0 1.0706415309869044e-08
observed O 0 2.647138952482919e-09
by O 0 1.4854711904987994e-09
intravital O 0 3.447315293669817e-06
microscopy O 0 5.497284746525111e-06
. O 0 1.157305973720213e-06

We O 0 3.846376728233736e-07
conclude O 0 6.547524549205264e-07
that O 0 1.7189815126883445e-09
these O 0 1.8819494851385343e-09
mice O 0 9.552374535815034e-08
very O 0 3.613920052103481e-09
closely O 0 8.136086648846685e-08
mimic O 0 0.0005205306224524975
severe O 1 0.9992073178291321
human O 0 0.00043732961057685316
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 1.2712353964161593e-05
will O 0 1.4497664402313148e-08
be O 0 1.1325014259710997e-09
very O 0 8.437183590670472e-11
useful O 0 9.35865940299152e-10
for O 0 2.959285247405852e-11
investigating O 0 1.2065531906912952e-10
the O 0 6.148490605539791e-10
role O 0 1.0918017601113661e-08
of O 0 1.801471150031375e-08
vWf O 0 6.651051194239699e-07
in O 0 5.434395156100891e-09
normal O 0 2.977419342187204e-07
physiology O 0 1.7488407593191369e-06
and O 0 2.402921639443889e-09
in O 0 3.5872878001441677e-09
disease O 0 2.877489579944381e-09
models O 0 5.048919060612889e-09
. O 0 3.0882914003882433e-09
. O 0 1.1650205067326169e-07

Oral O 0 0.00012136134319007397
contraceptives O 0 0.00017859676154330373
and O 0 2.2407007360669695e-09
the O 0 2.1436450392542383e-09
risk O 0 2.1246249559681019e-07
of O 0 5.296816198097076e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9994059801101685

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 0 0.00011534278019098565
Study O 0 3.0036397902222234e-07
Group O 0 1.49109826708127e-08
. O 0 5.994186835778237e-08

BACKGROUND O 0 1.980426168302074e-05
Women O 0 3.005008863965486e-08
with O 0 1.521094188106087e-11
mutations O 0 2.8761040424263307e-11
in O 0 1.223299933572619e-10
either O 0 6.968374766103125e-10
the O 0 1.3968272760678246e-08
BRCA1 O 0 2.1746315326254262e-07
or O 0 1.675058136640928e-08
the O 0 2.9979670301827355e-08
BRCA2 O 0 1.0976025777154064e-07
gene O 0 1.2857448439262953e-09
have O 0 2.884180949624948e-10
a O 0 4.4755157913023424e-10
high O 0 3.6532152858370637e-09
lifetime O 0 1.7109423211536523e-08
risk O 0 5.506379920916515e-07
of O 0 1.1039237506338395e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.006976614240556955

Oral O 0 0.0003815133241005242
contraceptives O 1 0.9999994039535522
protect O 0 4.171746695647016e-05
against O 1 0.6973211765289307
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 3.521546386764385e-05
general O 0 2.087859343191667e-07
, O 0 1.3938908915989145e-09
but O 0 7.364336224169321e-11
it O 0 1.8116333086459768e-11
is O 0 8.678578689025329e-12
not O 0 1.6935309057886094e-11
known O 0 1.6279637360394617e-10
whether O 0 1.999330839774771e-10
they O 0 1.1149501322194055e-09
also O 0 8.639103654672908e-09
protect O 0 6.824743081779161e-08
against O 0 2.9598089312798948e-08
hereditary B-Disease 0 0.02375956065952778
forms I-Disease 0 8.170653018169105e-06
of I-Disease 1 0.9999933242797852
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 9.728567238198593e-05

METHODS O 0 9.732316357258242e-07
We O 0 4.258205787976976e-09
enrolled O 0 6.7616663379510555e-09
207 O 0 3.563557271490936e-08
women O 0 2.0521626620251254e-09
with O 0 4.017686627832973e-09
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.701945772149884e-08
161 O 0 3.738907849992756e-09
of O 0 3.9034224741385515e-09
their O 0 2.1761983326484824e-09
sisters O 0 9.075836970851014e-08
as O 0 8.094599657226809e-09
controls O 0 6.061051749384205e-08
in O 0 1.672934013541294e-09
a O 0 4.02643207664255e-09
case O 0 3.9615515312618754e-09
- O 0 1.4468609776940866e-07
control O 0 2.3402994031584967e-07
study O 0 4.7559410631947685e-08
. O 0 1.4913122470261442e-07

All O 0 1.2029036611238553e-07
the O 0 9.186723382015316e-09
patients O 0 3.4397029669008816e-09
carried O 0 6.885352288321656e-10
a O 0 1.1647723063834547e-10
pathogenic O 0 2.87466855874996e-10
mutation O 0 2.0859540483808559e-10
in O 0 1.0843922426673203e-09
either O 0 1.949352679275762e-08
BRCA1 O 0 9.299184000610694e-08
( O 0 3.817291205354678e-10
179 O 0 1.5396343755469388e-08
women O 0 1.2595903209344783e-09
) O 0 6.024693521844426e-10
or O 0 4.337291414913125e-09
BRCA2 O 0 1.689997475295968e-07
( O 0 4.523851571125448e-10
28 O 0 5.80101797709176e-08
women O 0 5.26521759525167e-09
) O 0 5.039605621703913e-09
. O 0 6.828479826026523e-08

The O 0 4.869389158557169e-07
control O 0 3.384240301329555e-07
women O 0 1.8873484997072865e-09
were O 0 2.7579691308510235e-10
enrolled O 0 1.660992010599216e-09
regardless O 0 4.5448850238827276e-10
of O 0 6.379775041587266e-10
whether O 0 3.2064598198822125e-10
or O 0 9.648463139555474e-10
not O 0 1.1300373969902466e-09
they O 0 7.950093361408506e-10
had O 0 1.1156058299377491e-08
either O 0 1.039285901782705e-08
mutation O 0 5.502527500311771e-08
. O 0 2.8350970637802675e-07

Lifetime O 0 1.698669393590535e-06
histories O 0 8.57936640841217e-07
of O 0 1.4804223269493377e-07
oral O 0 1.3463908317135065e-06
- O 0 3.7709381217609916e-07
contraceptive O 0 8.26700784273271e-07
use O 0 2.10187844906784e-09
were O 0 7.345541952474832e-10
obtained O 0 1.809680516551282e-09
by O 0 1.8969041615246596e-10
interview O 0 1.2430488638415227e-08
or O 0 2.3568211271474127e-10
by O 0 3.525920180824649e-11
written O 0 1.0231566982543683e-10
questionnaire O 0 1.5471238873354665e-11
and O 0 1.6219657561489242e-11
were O 0 2.3679147531652234e-10
compared O 0 6.61298030224522e-11
between O 0 1.9505324438950922e-11
patients O 0 9.670678147166711e-11
and O 0 5.730255159264175e-11
control O 0 2.1934599914175124e-08
women O 0 8.787556238232241e-10
, O 0 2.2034460367414965e-10
after O 0 4.643603557230591e-10
adjustment O 0 4.062805647464529e-09
for O 0 1.4707540740843683e-10
year O 0 4.4651476960311243e-10
of O 0 9.250668564497744e-10
birth O 0 1.6666765745299017e-08
and O 0 7.603593310534507e-09
parity O 0 2.763601514743641e-06
. O 0 3.1617352647117514e-07

RESULTS O 0 8.708855716577091e-07
The O 0 3.1937915423441154e-08
adjusted O 0 9.787822108364708e-08
odds O 0 6.30092173992125e-08
ratio O 0 1.8276364244229626e-07
for O 0 3.033126631635241e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 5.916306690778583e-06
with O 0 5.31582000640185e-10
any O 0 2.9732567519147324e-09
past O 0 2.36602870629099e-09
use O 0 4.877422021820621e-09
of O 0 5.262045021936501e-09
oral O 0 1.2331241805441095e-07
contraceptives O 0 1.4885572454659268e-06
was O 0 4.2933741895012645e-08
0 O 0 1.7468393309627572e-07
. O 0 1.822993738187506e-07

5 O 0 8.250711402979505e-07
( O 0 1.0145933870830959e-08
95 O 0 4.98864437759039e-07
percent O 0 1.6926193779909227e-08
confidence O 0 4.143545950796579e-09
interval O 0 1.221053258504412e-09
, O 0 1.7598961177256456e-10
0 O 0 2.92185442507531e-10
. O 0 4.298037967198631e-11
3 O 0 7.078921337999589e-10
to O 0 4.894716854053627e-10
0 O 0 1.4588389385394862e-09
. O 0 4.3496162227540935e-10
8 O 0 2.7310289141269095e-08
) O 0 9.230651798475265e-09
. O 0 1.0281113560495214e-07

The O 0 1.6831167215514142e-07
risk O 0 5.27879535638931e-08
decreased O 0 5.6962186079090316e-09
with O 0 9.303938695859326e-12
increasing O 0 3.537575787859737e-10
duration O 0 1.1853339643153049e-08
of O 0 2.374351604217395e-09
use O 0 3.2769595037507315e-08
( O 0 2.7704658567273555e-09
P O 0 1.4532137981859705e-07
for O 0 9.713941873101817e-10
trend O 0 5.8109157485830565e-09
, O 0 1.557425022280512e-10
< O 0 1.4681181603748428e-08
0 O 0 2.2799100385384463e-09
. O 0 1.1204667749176167e-10
001 O 0 1.3228503625839494e-08
) O 0 1.8800820275610697e-11
; O 0 2.4811817097430966e-12
use O 0 7.003388841075875e-11
for O 0 2.8262480897267572e-11
six O 0 6.07839681365796e-11
or O 0 1.9748688795395708e-11
more O 0 8.833537200325647e-13
years O 0 3.4959582971560987e-12
was O 0 8.820430497102905e-11
associated O 0 1.0750583756546916e-10
with O 0 1.216113060947821e-11
a O 0 1.5091173866110807e-09
60 O 0 8.045621058272445e-09
percent O 0 3.2433902785733437e-10
reduction O 0 1.216664102798859e-09
in O 0 4.651903307006933e-09
risk O 0 2.682383524188481e-07
. O 0 7.968163799887407e-07

Oral O 0 0.0003993057762272656
- O 0 1.2066854651493486e-05
contraceptive O 0 7.287464086402906e-06
use O 0 5.919225287698282e-08
protected O 0 0.00010291235230397433
against O 0 0.00882518757134676
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 1.552319695008464e-08
for O 0 3.36224520447459e-10
carriers O 0 3.3639191432399684e-10
of O 0 8.690099195796108e-10
the O 0 5.6951972027263764e-09
BRCA1 O 0 1.7681183805962064e-07
mutation O 0 1.3854595248830037e-09
( O 0 1.232685203911288e-10
odds O 0 9.372007170327379e-09
ratio O 0 1.2784086012018747e-09
, O 0 5.838929340029608e-11
0 O 0 1.2220149891994936e-10
. O 0 1.5129951111414464e-11
5 O 0 2.026833978430176e-10
; O 0 5.1217950020054914e-11
95 O 0 2.3885199595952145e-08
percent O 0 1.1056996429559263e-09
confidence O 0 5.255595514341849e-09
interval O 0 1.1564493807014742e-09
, O 0 2.4265198184103554e-10
0 O 0 5.385420998038626e-10
. O 0 7.193824008711047e-11
3 O 0 1.1533720645218182e-09
to O 0 2.895894635202012e-10
0 O 0 6.925431894622136e-10
. O 0 9.605601730688917e-11
9 O 0 3.6833289751569964e-09
) O 0 9.799613898131554e-11
and O 0 2.9056696285167938e-11
for O 0 2.280112036678883e-11
carriers O 0 3.946172555391314e-10
of O 0 9.303877668287441e-10
the O 0 1.3038724766545329e-08
BRCA2 O 0 1.7265784890696523e-06
mutation O 0 4.7981059125845604e-09
( O 0 1.8690704539636727e-10
odds O 0 9.654100630029916e-09
ratio O 0 1.7820318554129244e-09
, O 0 8.736862622260588e-11
0 O 0 1.5468561154197147e-10
. O 0 8.515591010116452e-12
4 O 0 1.734525995056302e-10
; O 0 6.540263469689833e-11
95 O 0 3.2923967552278555e-08
percent O 0 8.224403935663815e-10
confidence O 0 1.4231706924050513e-09
interval O 0 5.373005929065755e-10
, O 0 1.4256341940299677e-10
0 O 0 4.755137950063215e-10
. O 0 5.151382445611752e-11
2 O 0 8.779464377717261e-10
to O 0 2.2471879912444592e-10
1 O 0 2.238137897236925e-09
. O 0 7.895902265353527e-10
1 O 0 3.842335871695468e-08
) O 0 1.502053947888271e-08
. O 0 1.6204444364120718e-07

CONCLUSIONS O 0 1.5888213965808973e-05
Oral O 0 5.8921228628605604e-05
- O 0 3.900942374457372e-06
contraceptive O 0 8.264130428869976e-07
use O 0 1.082424816445382e-09
may O 0 7.016986297569971e-11
reduce O 0 2.8271607277474686e-10
the O 0 3.8247396916268883e-10
risk O 0 1.602123376187592e-07
of O 0 5.187731221667491e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.6841070191730978e-06
women O 0 2.9427680292570813e-09
with O 0 3.0567305631112873e-11
pathogenic O 0 5.123556579000876e-10
mutations O 0 3.1931549071551046e-10
in O 0 1.2428491569238531e-09
the O 0 5.02478876285295e-08
BRCA1 O 0 2.5591655230527977e-06
or O 0 1.5160296698013553e-06
BRCA2 O 0 2.5396142518729903e-05
gene O 0 3.936369921575533e-06

A O 0 6.945252266632451e-07
Japanese O 0 1.521509034319024e-06
family O 0 1.6993185525393528e-08
with O 0 1.7250052497530532e-09
adrenoleukodystrophy B-Disease 1 1.0
with O 0 4.212836746120274e-09
a O 0 1.2348843725362713e-08
codon O 0 8.622661340496052e-08
291 O 0 4.838591749489751e-08
deletion O 0 2.79361671573497e-07
: O 0 5.506493483409258e-09
a O 0 3.6942908732129354e-09
clinical O 0 3.885715571527726e-08
, O 0 7.266945378781031e-10
biochemical O 0 3.940257542467407e-08
, O 0 2.969119838880374e-09
pathological O 0 4.166972473740316e-07
, O 0 2.4622992533807064e-09
and O 0 2.058697878837279e-09
genetic O 0 3.0172305542919275e-08
report O 0 2.425920797577419e-08
. O 0 1.9952611296503164e-07

We O 0 1.4317348018266784e-07
report O 0 6.602676627665005e-09
a O 0 8.952077412693882e-10
Japanese O 0 1.4732914621617965e-07
family O 0 4.543188492078798e-09
with O 0 2.1487946977316597e-09
adrenoleukodystrophy B-Disease 1 1.0
( O 0 4.969972451362992e-07
ALD B-Disease 1 1.0
) O 0 5.286900917056414e-10
with O 0 2.6257648833016844e-11
a O 0 6.359862636529101e-10
three O 0 1.8221275877028376e-10
base O 0 2.574343405115087e-08
pair O 0 1.659517145924383e-08
deletion O 0 8.488493818958887e-08
( O 0 9.357052910274888e-10
delGAG O 0 1.5928985419577657e-07
291 O 0 8.369920756479132e-09
) O 0 2.6076985015777154e-10
in O 0 1.8595629480699927e-09
the O 0 7.014347147560329e-08
ALD B-Disease 1 1.0
gene O 0 1.704292003523733e-06
. O 0 2.629147275001742e-06

A O 0 1.7636433540246799e-06
variety O 0 4.0865348438501314e-08
of O 0 9.98646410010906e-09
phenotypes O 0 8.348269631142102e-09
were O 0 1.91979987462787e-09
observed O 0 8.055675015938846e-10
within O 0 3.535633175122399e-10
this O 0 4.874257664155834e-10
family O 0 3.957171479385124e-09
. O 0 6.438359889671119e-08

While O 0 3.1905955211186665e-07
the O 0 2.8202537194488286e-08
proband O 0 1.349833473796025e-05
( O 0 2.2321948733861063e-09
patient O 0 2.8497341375555152e-08
1 O 0 4.3721950504505e-08
) O 0 1.0185697840725538e-09
was O 0 9.719228089011267e-09
classified O 0 6.70244704181755e-09
as O 0 1.9907662185403296e-09
having O 0 2.7238797883910593e-09
a O 0 1.117436809749961e-09
rare O 0 1.303327223922679e-09
intermediate O 0 3.968304795876065e-09
type O 0 1.2293217110936894e-08
of O 0 3.861347241951307e-09
adult O 0 1.156971052296285e-07
cerebral O 0 2.27822511078557e-07
and O 0 8.419573482854048e-09
cerebello O 1 0.8980574011802673
- O 1 0.9995409250259399
brain O 1 0.6279697418212891
stem O 0 1.1513004238850044e-07
forms O 0 4.3490605561302687e-10
, O 0 9.88834847337472e-11
his O 0 1.3888168393094702e-09
younger O 0 2.006518862174289e-08
brother O 0 1.504374012029075e-07
( O 0 5.540857772601271e-10
patient O 0 1.049791276130918e-08
2 O 0 1.0075313916502182e-08
) O 0 3.7949030029515995e-10
and O 0 1.2234872004412978e-09
nephew O 0 0.0065804291516542435
( O 0 4.316963231332238e-09
patient O 0 2.198846459577908e-06
3 O 0 4.935360493618646e-07
) O 0 6.000956620511033e-09
had O 0 7.114065425639637e-08
a O 0 5.504437794456862e-08
childhood O 0 2.8765405659214593e-05
ALD B-Disease 1 1.0
type O 0 0.0035029056016355753
. O 0 1.4483574886980932e-05

Another O 0 1.7040271131918416e-06
nephew O 0 0.00012238633644301444
( O 0 1.0502198222184234e-08
patient O 0 2.9489510211533343e-07
4 O 0 7.611373575855396e-08
) O 0 5.785145140713155e-10
of O 0 2.740069948714563e-09
patient O 0 2.1186238541304192e-07
1 O 0 4.271076932127471e-07
was O 0 1.6449193651624228e-07
classified O 0 2.318112635180114e-08
as O 0 4.456199409474948e-09
having O 0 4.687673360592726e-09
an O 0 3.0243718640576844e-10
adolescent O 0 1.465703647340888e-08
form O 0 5.685382720166388e-10
. O 0 4.4449453895367697e-08

The O 0 2.7053354756390036e-07
tau O 0 1.4737327092007035e-07
level O 0 5.835586947000593e-08
in O 0 2.3648556446431712e-09
the O 0 1.9160328434963958e-08
cerebrospinal O 0 3.1620314985048026e-05
fluid O 0 4.2614888116077054e-06
( O 0 8.658238570546928e-09
CSF O 0 0.0002145188336726278
) O 0 7.213365460501109e-10
in O 0 2.049213465582511e-09
patient O 0 7.287987955351127e-07
1 O 0 4.298971134630847e-07
was O 0 1.0683348250495328e-07
as O 0 2.963942424827337e-09
high O 0 3.310625107388887e-09
as O 0 1.7996973356027013e-10
that O 0 7.516745906266387e-12
of O 0 9.158528796460175e-11
patients O 0 1.0049839849202158e-09
with O 0 9.290594960020826e-10
Alzheimers B-Disease 1 1.0
disease I-Disease 0 0.21898216009140015
( O 0 5.658812307629546e-10
AD B-Disease 0 7.291026236089237e-07
) O 0 1.2037614460780333e-08
. O 0 1.560621001317486e-07

His O 0 1.0070599273603875e-05
brain O 0 1.9565102775231935e-05
magnetic O 0 1.918775978992926e-06
resonance O 0 2.0235775082255714e-06
image O 0 6.605513362956117e-07
( O 0 8.487162972414808e-09
MRI O 1 0.9845444560050964
) O 0 5.888573539891695e-08
showed O 0 1.5279405829460302e-07
abnormalities B-Disease 0 3.735125346793211e-06
in I-Disease 0 1.243409375462079e-08
the I-Disease 0 5.817006254460466e-08
bilateral I-Disease 1 0.9995635151863098
cerebellar I-Disease 1 1.0
hemispheres I-Disease 0 0.012477979063987732
and O 0 1.1521242981871183e-07
brain O 0 0.00017215280968230218
stem O 0 3.784194646527794e-08
, O 0 8.095224490745068e-11
but O 0 1.5918658752278603e-11
not O 0 5.2146113815876305e-11
in O 0 1.9494064695813051e-10
the O 0 1.5237758832498116e-09
cerebral O 0 2.9651550903508905e-07
white O 0 3.7369969341227716e-09
matter O 0 1.8958852265882342e-09
, O 0 7.725151074389203e-11
where O 0 5.5220536476774384e-11
marked O 0 1.1791653764525734e-10
reductions O 0 1.450850106721191e-09
of O 0 3.5608651582919038e-09
the O 0 5.126198132643367e-09
cerebral O 0 2.6688493903748167e-07
blood O 0 1.1420071999168613e-08
flow O 0 1.1178976855319434e-08
and O 0 1.0842804432087405e-09
oxygen O 0 2.5427890903984007e-08
metabolism O 0 4.775511541765809e-08
were O 0 1.5144987486337413e-08
clearly O 0 5.715917517079561e-09
demonstrated O 0 2.532492882068027e-09
by O 0 3.6570479977626746e-10
positron O 0 4.9337696594875524e-08
emission O 0 1.334487933490891e-07
tomography O 0 3.6150930100120604e-05
( O 0 3.6728078356418337e-08
PET O 0 1.2964328561793081e-05
) O 0 2.502593510200768e-08
. O 0 1.1195881910452954e-07

In O 0 5.9676978025891e-08
patients O 0 1.02273229884986e-08
2 O 0 3.5101150874794484e-09
and O 0 3.601525189189658e-10
3 O 0 1.097953905571103e-08
, O 0 4.076721737966693e-10
the O 0 1.013948591754854e-09
autopsy O 0 1.1710970682088373e-07
findings O 0 2.3257609171878357e-08
showed O 0 6.388304996107763e-08
massive O 0 6.484204106982361e-08
demyelination B-Disease 1 1.0
of I-Disease 0 6.270099106586713e-07
the I-Disease 0 8.642040683071173e-08
cerebral I-Disease 0 0.00015320231614168733
white I-Disease 0 7.868453444359602e-09
matter I-Disease 0 9.381374566075351e-10
with O 0 1.6325590185273242e-11
sparing O 0 3.359056321983189e-08
of O 0 1.2502374602263444e-07
the O 0 1.2660562731525715e-07
U O 0 0.0001888932310976088
- O 0 1.4455811651714612e-05
fibers O 0 1.2290128381664545e-07
, O 0 2.170602142470557e-09
compatible O 0 1.1337711924852556e-07
with O 0 1.3800469100822e-10
the O 0 5.446473494430393e-09
findings O 0 1.389623260905637e-08
of O 0 8.441622867394472e-08
childhood O 0 0.007364319171756506
ALD B-Disease 1 1.0
. O 0 3.687256685225293e-05

Oleic O 0 0.002824548864737153
and O 0 1.0248215858155163e-06
erucic O 0 0.03387458249926567
acids O 0 1.8974490103573771e-06
( O 0 6.88990109409815e-09
Lorenzos O 0 3.4252209388796473e-06
Oil O 0 2.802991900807683e-07
) O 0 4.954908150445192e-10
were O 0 5.608374320509313e-10
administered O 0 6.58752830062781e-10
to O 0 3.536030912520971e-10
patients O 0 7.537973578664037e-10
1 O 0 2.088443196157641e-09
and O 0 1.1203177274765608e-09
4 O 0 4.233588768443042e-08
, O 0 6.41332653650295e-10
but O 0 9.721332072665234e-11
sufficient O 0 3.922035141101787e-09
effectiveness O 0 1.1295272273059709e-08
was O 0 6.52370024667448e-09
not O 0 1.8004501223245484e-09
obtained O 0 1.1505431984915049e-07
. O 0 3.11192764002044e-07

The O 0 6.816520681240945e-07
findings O 0 4.050751911677253e-08
in O 0 2.4038291357442176e-09
this O 0 2.912934615739715e-10
family O 0 6.390273310508121e-10
suggest O 0 9.788821975220685e-10
that O 0 8.045010838064748e-12
delGAG291 O 0 1.7937729079875453e-09
is O 0 1.3789858144264144e-11
part O 0 3.943213464085993e-11
of O 0 8.667387918492864e-10
the O 0 8.142351237694356e-10
cause O 0 2.5396857949999685e-09
of O 0 1.7816113029311964e-08
Japanese O 0 5.2173294534441084e-05
ALD B-Disease 1 1.0
with O 0 1.0481666201656026e-08
phenotypic O 0 3.481871715393936e-07
variations O 0 4.1461140654064366e-07
. O 0 6.716500706716033e-07

Moreover O 0 1.1041533980460372e-06
, O 0 3.6057679064782633e-09
although O 0 5.990147267098678e-10
the O 0 2.110099733831916e-10
scale O 0 7.604507246128378e-09
of O 0 2.975395707593975e-09
the O 0 1.2622695111375037e-09
study O 0 1.272072558400339e-09
is O 0 1.705713174871004e-11
limited O 0 4.685579702012888e-10
, O 0 2.399622722748518e-10
there O 0 2.8479812952397765e-10
is O 0 1.9221363389831936e-10
a O 0 1.8114727495799343e-09
possibility O 0 1.3437231771717961e-08
that O 0 8.519027705489179e-10
PET O 0 4.071934199600946e-06
can O 0 1.5696866029202283e-08
detect O 0 1.2100388175895205e-06
an O 0 2.2676420741163383e-08
insidious B-Disease 0 2.9188049666117877e-05
lesion I-Disease 1 0.999638557434082
which O 0 6.9720216266944135e-09
is O 0 1.854210257556943e-10
undetectable O 0 3.924564673241093e-09
by O 0 3.438499138197493e-11
computed O 0 6.7522063496028295e-09
tomogram O 0 3.014863068528939e-06
( O 0 4.501209183160881e-09
CT O 1 0.9317357540130615
) O 0 7.567494186844215e-09
or O 0 5.6024114236663536e-09
MRI O 0 2.2112385522632394e-06
analysis O 0 6.212598879784537e-09
, O 0 1.511853559010845e-10
and O 0 3.673061507725173e-11
that O 0 1.0937510445951926e-11
the O 0 5.948813663891883e-11
higher O 0 1.2776968372207875e-09
level O 0 5.979750916651483e-09
of O 0 8.190168543364962e-10
tau O 0 2.1022150686889063e-09
reflects O 0 3.002794124462582e-10
the O 0 2.445383340266005e-10
process O 0 9.211404972120363e-10
of O 0 6.512461681040804e-09
neuronal B-Disease 0 8.417258868576027e-06
degeneration I-Disease 1 0.9999985694885254
in O 0 5.969764515612042e-06
ALD B-Disease 1 1.0
. O 0 2.5825280317803845e-05

Lorenzos O 0 0.00017927924636751413
Oil O 0 6.13757663359138e-07
should O 0 1.1238596719920224e-09
be O 0 7.70875446809427e-11
given O 0 5.820770948572473e-11
in O 0 1.1330734961401134e-10
the O 0 1.516023279135581e-10
early O 0 5.8418874182564196e-09
stage O 0 4.591966362710309e-09
. O 0 6.04539351911626e-09
. O 0 1.1520715759161249e-07

Nonsense O 0 3.267835563747212e-05
mutation O 0 3.2992932119668694e-07
in O 0 1.5327049851521224e-08
exon O 0 7.215077175715123e-07
4 O 0 5.998247161187464e-07
of O 0 6.91056669666068e-08
human O 0 2.9643438814730416e-09
complement O 0 2.387991493435493e-08
C9 O 0 2.726508682826534e-05
gene O 0 3.581040886047049e-08
is O 0 3.8321440465338696e-10
the O 0 5.958332716105019e-10
major O 0 5.295502703006605e-09
cause O 0 5.22961673965483e-09
of O 0 8.689275077244929e-09
Japanese O 0 4.646753950510174e-06
complement B-Disease 0 1.648798570386134e-05
C9 I-Disease 1 0.9999895095825195
deficiency I-Disease 0 9.535006392979994e-05
. O 0 2.627934009069577e-06

Deficiency B-Disease 0 0.012812545523047447
of I-Disease 0 1.1925791341127479e-06
the I-Disease 0 1.5602280711846106e-07
ninth I-Disease 0 1.346691192338767e-06
component I-Disease 0 9.178442894608452e-08
of I-Disease 0 6.479639935719206e-09
human I-Disease 0 3.577036999935501e-10
complement I-Disease 0 3.3625241258050664e-08
( O 0 7.816071345700948e-09
C9 O 1 0.9940299987792969
) O 0 9.908578846307137e-09
is O 0 4.861500646491379e-10
the O 0 5.624163912365532e-10
most O 0 3.7934411167839244e-10
common O 0 3.227533795779891e-08
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 8.922421024237792e-09
Japan O 0 1.2259830839411734e-07
but O 0 1.8515704247601406e-10
is O 0 3.3688617867566606e-11
rare O 0 1.9226718828146971e-10
in O 0 1.8968751569481412e-10
other O 0 1.671039001616137e-10
countries O 0 8.576218624156695e-10
. O 0 4.562678057595804e-08

We O 0 1.2823173278775357e-07
studied O 0 8.721291067104175e-08
the O 0 1.0935894412256175e-09
molecular O 0 2.451483682719413e-09
basis O 0 9.418203994471241e-09
of O 0 1.7788337913771102e-08
C9 B-Disease 1 1.0
deficiency I-Disease 0 0.00058737862855196
in O 0 1.679816534760903e-07
four O 0 2.1109874737135215e-08
Japanese O 0 1.611839365978085e-06
C9 B-Disease 0 0.002308861119672656
- I-Disease 0 1.3880617188988253e-05
deficient I-Disease 0 9.143379884335445e-07
patients O 0 2.6963436994265066e-07
who O 0 8.206090917894926e-09
had O 0 1.9499296399771993e-07
suffered O 0 0.005105608142912388
from O 0 6.209619641595054e-06
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 5.1172410167055205e-06

Direct O 0 3.488036668386485e-07
sequencing O 0 1.979979487032324e-07
of O 0 1.2244022684626543e-07
amplified O 0 6.977823545639694e-07
C9 O 0 5.684689313056879e-06
cDNA O 0 1.1421666812339026e-07
and O 0 5.89250293003829e-09
DNA O 0 1.4043927798468303e-08
revealed O 0 9.282274504585075e-09
a O 0 1.8724470862707676e-09
nonsense O 0 8.795626449398242e-09
substitution O 0 7.92221488410405e-09
( O 0 6.908030258934161e-10
CGA O 0 3.5765293660006137e-07
- O 0 4.458395324036246e-07
- O 0 5.198040753384703e-07
> O 0 5.603610588877928e-07
TGA O 0 8.979684935184196e-06
) O 0 2.4248172914020927e-10
at O 0 8.128602235757398e-10
codon O 0 5.444271700127956e-09
95 O 0 2.1277390516161176e-08
in O 0 1.1424183821162615e-09
exon O 0 7.328461748556947e-08
4 O 0 6.503278626723841e-08
in O 0 1.1791082776824169e-08
the O 0 4.129109854034141e-08
four O 0 2.667434095826593e-08
C9 B-Disease 0 0.00024965801276266575
- I-Disease 0 2.9069271477055736e-05
deficient I-Disease 0 2.1969744921079837e-06
individuals O 0 1.0005110517852245e-08
. O 0 1.879766102774738e-07

An O 0 2.4049592184383073e-07
allele O 0 1.1324442539262236e-07
- O 0 7.495142284597023e-08
specific O 0 6.446541078730661e-09
polymerase O 0 1.008006620395463e-07
chain O 0 2.322179426528237e-08
reaction O 0 8.163219544776723e-10
system O 0 1.1273850741844171e-09
designed O 0 1.0021038221452727e-08
to O 0 2.5466222464132215e-09
detect O 0 5.760737220583678e-09
exclusively O 0 9.361891262216204e-10
only O 0 1.6081691533997855e-10
one O 0 1.5321618973551665e-11
of O 0 1.435862262422205e-10
the O 0 1.655405673650634e-10
normal O 0 2.6832718269531597e-09
and O 0 4.243140006021662e-10
mutant O 0 6.430870946871892e-09
alleles O 0 2.642148722031834e-10
indicated O 0 5.702868732804234e-10
that O 0 1.772463946447811e-11
all O 0 1.0668855382478526e-10
the O 0 3.766749967493155e-10
four O 0 2.5394714109339134e-10
patients O 0 1.4776428691742893e-10
were O 0 1.280677786041906e-10
homozygous O 0 2.4913940355197894e-10
for O 0 3.1119121168821096e-10
the O 0 1.041708497240279e-09
mutation O 0 8.918554228465325e-10
in O 0 1.5282057841403685e-09
exon O 0 8.175255317155461e-08
4 O 0 9.103576559255089e-08
and O 0 1.4637583367616003e-09
that O 0 7.458097334156477e-11
the O 0 3.406520898696641e-10
parents O 0 1.9283717678231227e-10
of O 0 2.1578046294212783e-10
patient O 0 4.171673229080852e-09
2 O 0 6.694081378100236e-08
were O 0 1.962234108532357e-07
heterozygous O 0 2.581547562385822e-07
. O 0 1.4385811937245307e-06

The O 0 3.107488169007411e-07
common O 0 2.272716947970821e-08
mutation O 0 2.7783504386036384e-09
at O 0 3.606497323005442e-09
codon O 0 4.6958369637195574e-08
95 O 0 1.479949531812963e-07
in O 0 6.138135333344508e-09
exon O 0 1.5448917167759646e-07
4 O 0 1.1854022119450747e-07
might O 0 7.485267516926797e-09
be O 0 2.696759482390121e-10
responsible O 0 9.576318626969282e-10
for O 0 7.610916341604934e-10
most O 0 4.059521163668478e-09
Japanese O 0 1.7935615687747486e-05
C9 B-Disease 1 0.999854326248169
deficiency I-Disease 0 4.130097295274027e-06
. O 0 4.23578612185338e-08
. O 0 1.6691713256022922e-07

BRCA1 O 0 3.372484798092046e-06
required O 0 9.454943494802137e-08
for O 0 4.050425772561539e-09
transcription O 0 9.218828722623584e-07
- O 0 4.627261205314426e-06
coupled O 0 1.464166189180105e-06
repair O 0 2.1100968297105283e-05
of O 0 1.4466429831827554e-07
oxidative O 0 1.1638149999271263e-06
DNA O 0 2.7677586444951885e-07
damage O 0 1.173643977381289e-05
. O 0 4.083117801201297e-06

The O 0 1.7970969565794803e-05
breast B-Disease 1 1.0
and I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 0.0029595796950161457
gene O 0 3.2277250738843577e-07
BRCA1 O 0 4.6567615186177136e-07
encodes O 0 1.9842055110075307e-08
a O 0 1.1568828028885036e-07
zinc O 0 1.741740561556071e-05
finger O 0 9.160513059214281e-07
protein O 0 3.5859879510269366e-09
of O 0 1.8037051852104469e-09
unknown O 0 2.0463669869741352e-08
function O 0 6.374061722880242e-09
. O 0 6.639264427121816e-08

Association O 0 6.666342642347445e-07
of O 0 5.511371625743777e-08
the O 0 9.840681158834741e-09
BRCA1 O 0 6.2945648693357725e-09
protein O 0 1.0348600448795153e-10
with O 0 8.806389645288348e-12
the O 0 5.261329705241735e-10
DNA O 0 6.8059309299428605e-09
repair O 0 1.1291027703919099e-06
protein O 0 1.7329536916577126e-08
Rad51 O 0 1.3953258815035952e-07
and O 0 5.914264633588573e-10
changes O 0 9.124776489954911e-10
in O 0 7.040034666339068e-10
the O 0 1.0039743481016217e-09
phosphorylation O 0 4.09920275501463e-09
and O 0 2.253541575569784e-09
cellular O 0 8.76581935926879e-08
localization O 0 9.501057434135873e-07
of O 0 1.794345116934437e-08
the O 0 2.8666486961981263e-09
protein O 0 2.322647629782182e-09
after O 0 2.6733002478351864e-09
exposure O 0 7.404855040249458e-08
to O 0 1.5343333270578796e-09
DNA O 0 8.585081445744436e-08
- O 0 4.259266006556572e-06
damaging O 0 2.7340450969859376e-07
agents O 0 1.3688464584049598e-08
are O 0 1.0035948461162292e-10
consistent O 0 1.024418661010884e-09
with O 0 3.1482308079922028e-12
a O 0 1.3291540090776266e-10
role O 0 1.6597599961087894e-09
for O 0 4.751540938485732e-09
BRCA1 O 0 7.208901564581538e-08
in O 0 4.98147478822375e-08
DNA O 0 8.792557650849631e-07
repair O 0 0.011300747282803059
. O 0 3.34026844939217e-05

Here O 0 2.828491290074453e-07
, O 0 3.5945477705467965e-09
it O 0 7.292768472444422e-11
is O 0 2.3239216107029392e-11
shown O 0 2.8955299269384227e-10
that O 0 2.650957509064966e-10
mouse O 0 9.880896101321923e-08
embryonic O 0 1.0012595339503605e-06
stem O 0 1.244821845602928e-07
cells O 0 7.910380617204282e-08
deficient B-Disease 0 2.2675519062431704e-07
in I-Disease 0 2.150952660429084e-08
BRCA1 I-Disease 0 4.295028688261482e-08
are O 0 1.6771632693757255e-10
defective O 0 2.3198950316327682e-08
in O 0 1.4763816835738908e-09
the O 0 1.5324088664669944e-09
ability O 0 1.4712373541669876e-09
to O 0 1.3694072542591584e-09
carry O 0 4.808816456147724e-09
out O 0 5.890162801946985e-10
transcription O 0 7.305852989247796e-08
- O 0 2.445389100103057e-06
coupled O 0 1.8025525605480652e-06
repair O 0 9.85600217973115e-06
of O 0 6.284406595113978e-08
oxidative O 0 1.3580313407146605e-07
DNA O 0 2.3954182637453414e-08
damage O 0 4.3967062879346486e-07
, O 0 7.0527255147112555e-09
and O 0 1.6318795204028902e-08
are O 0 1.2204159460793562e-08
hypersensitive O 0 1.0667344213288743e-05
to O 0 1.3500574880254135e-07
ionizing O 0 0.00017391984874848276
radiation O 0 0.000104184502561111
and O 0 1.5017157295460493e-08
hydrogen O 0 8.30133615181694e-08
peroxide O 0 3.069916147069307e-06
. O 0 7.2335006962021e-07

These O 0 1.3033904622261616e-07
results O 0 3.581655860784849e-08
suggest O 0 5.9418375997211115e-08
that O 0 1.8245490673862719e-09
BRCA1 O 0 8.858378208742579e-08
participates O 0 3.144658755616092e-09
, O 0 6.581938882810334e-10
directly O 0 8.519612237911645e-10
or O 0 9.94828441847062e-10
indirectly O 0 3.3380866959475952e-09
, O 0 1.6706692973489368e-10
in O 0 1.0929638305512412e-09
transcription O 0 1.2715852335531963e-06
- O 0 1.2496330782596488e-05
coupled O 0 7.900043783592992e-06
repair O 0 7.08225998096168e-05
of O 0 9.443931503483327e-08
oxidative O 0 1.1626431017930372e-07
DNA O 0 1.7212101965924376e-08
damage O 0 3.795898351199867e-08
. O 0 1.5970808675547232e-08
. O 0 1.2164007046067127e-07

Truncation O 0 1.682738911767956e-05
mutations O 0 9.2230692416706e-08
in O 0 4.735156267088314e-09
the O 0 4.037644441012844e-09
transactivation O 0 3.0819812764093513e-06
region O 0 6.020609788492948e-08
of O 0 3.92082561972984e-08
PAX6 O 0 0.00010696627577999607
result O 0 2.639607821208756e-08
in O 0 1.2184715458829487e-08
dominant O 0 9.536809386645473e-08
- O 0 5.091812340651813e-07
negative O 0 1.651632253185653e-08
mutants O 0 2.627512856179237e-07
. O 0 1.8761663511668303e-07

PAX6 O 0 0.0007544041727669537
is O 0 3.43780257594517e-08
a O 0 5.084646925723746e-09
transcription O 0 8.174959731377385e-08
factor O 0 1.9996113209685973e-08
with O 0 1.7457708889612178e-10
two O 0 3.330066222773098e-10
DNA O 0 3.3320561865224363e-09
- O 0 2.5742060927314014e-08
binding O 0 5.194821461884658e-09
domains O 0 1.359243562149004e-08
( O 0 3.096913558930936e-10
paired O 0 3.1850604376160163e-09
box O 0 1.5797363417391352e-08
and O 0 1.4000567372107753e-09
homeobox O 0 3.2468975064148253e-07
) O 0 3.2670396943323965e-10
and O 0 4.139933396096751e-10
a O 0 2.5142472548367323e-09
proline O 0 6.629343829445133e-08
- O 0 6.525955598135624e-08
serine O 0 1.3882275595733518e-07
- O 0 1.3144820059096674e-06
threonine O 0 7.089479936439602e-07
( O 0 1.2727812137569572e-09
PST O 0 1.4089901014813222e-05
) O 0 8.489591252214268e-09
- O 0 3.8124497336866625e-07
rich O 0 5.9592025536403526e-08
transactivation O 0 1.013772180158412e-05
domain O 0 3.898953195857757e-07
. O 0 5.8622497078886227e-08

PAX6 O 1 0.8175994753837585
regulates O 0 9.395962479175068e-06
eye O 0 0.017765456810593605
development O 0 3.509080102048756e-07
in O 0 1.0105492442846753e-08
animals O 0 1.3651616503906894e-09
ranging O 0 1.0169318720443243e-08
from O 0 1.2199312671157259e-09
jellyfish O 0 1.4120551394825043e-09
to O 0 2.7953814818459932e-09
Drosophila O 0 8.970236820005084e-08
to O 0 1.4688883887004067e-08
humans O 0 7.411382796362886e-08
. O 0 2.481201306636649e-07

Heterozygous O 0 3.2252435175905703e-06
mutations O 0 6.983083267186885e-08
in O 0 1.3904742246495516e-08
the O 0 1.407189476054782e-08
human O 0 9.950150037241201e-09
PAX6 O 0 1.6762151062721387e-05
gene O 0 3.1303102332458366e-08
result O 0 5.351531218167338e-09
in O 0 4.292487698620562e-09
various O 0 6.540070707217183e-09
phenotypes O 0 5.014142701043056e-08
, O 0 7.214576158709463e-10
including O 0 3.271425130790817e-09
aniridia B-Disease 1 1.0
, O 0 2.2089191986651713e-07
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 6.457237304857699e-07
autosomal B-Disease 0 0.008532180450856686
dominant I-Disease 0 9.688092177384533e-06
keratitis I-Disease 1 0.9999983310699463
, O 0 2.6465700742051013e-08
and O 0 2.4266288534136038e-08
familial B-Disease 1 0.9999585151672363
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 1 0.9999979734420776

It O 0 2.1249366710662798e-08
is O 0 7.536536394958659e-10
believed O 0 6.371703609175938e-09
that O 0 6.568918325955408e-11
the O 0 6.913382089024367e-10
mutated O 0 3.259735592564539e-08
allele O 0 1.2911500846257695e-07
of O 0 6.397681318048853e-08
PAX6 O 0 0.00023926078574731946
produces O 0 9.65358548654649e-09
an O 0 3.3965358303689186e-10
inactive O 0 2.11309423292505e-08
protein O 0 2.392161357889222e-09
and O 0 4.4757402228867704e-09
aniridia B-Disease 1 1.0
is O 0 1.7637783455981548e-09
caused O 0 2.4611817028841187e-09
due O 0 3.2807478955731995e-09
to O 0 3.9746073099422574e-09
genetic O 0 2.9647075905359088e-08
haploinsufficiency O 0 5.316294391377596e-06
. O 0 8.120487677842902e-07

However O 0 5.2150870288869555e-08
, O 0 1.990735798429455e-09
several O 0 6.057841728246416e-11
truncation O 0 8.521261918303935e-08
mutations O 0 2.0146055934588958e-09
have O 0 1.837168472906825e-10
been O 0 6.83140141677363e-11
found O 0 1.9698879680229986e-11
to O 0 1.8848715990782416e-11
occur O 0 2.1758764928714314e-11
in O 0 1.8563618697786666e-10
the O 0 8.526309658307696e-10
C O 0 1.0044234954875719e-07
- O 0 2.0331354377844946e-08
terminal O 0 2.4970056244910666e-08
half O 0 1.5067875835939049e-09
of O 0 9.546592405484944e-10
PAX6 O 0 7.170011713242275e-07
in O 0 1.9558281660891907e-09
patients O 0 3.296693140697471e-09
with O 0 2.025871553845704e-10
Aniridia B-Disease 1 1.0
resulting O 0 5.960327698062429e-08
in O 0 4.46256143149526e-09
mutant O 0 5.691776383542901e-09
proteins O 0 6.407954722398301e-11
that O 0 7.148031472281602e-11
retain O 0 4.856016477816638e-09
the O 0 1.9156308539436395e-08
DNA O 0 6.408049557649065e-08
- O 0 2.478443832387711e-07
binding O 0 1.1708765512707942e-08
domains O 0 6.491626347582269e-09
but O 0 3.4301358975419305e-10
have O 0 4.210039539209731e-10
lost O 0 9.267838940729689e-09
most O 0 4.609523596155185e-10
of O 0 1.7918341255196424e-09
the O 0 3.830136652283045e-09
transactivation O 0 4.191142124909675e-06
domain O 0 1.4671561530121835e-06
. O 0 3.725420185674011e-07

It O 0 6.975625854721557e-09
is O 0 1.4906731404806806e-10
not O 0 8.942857565585882e-11
clear O 0 2.1609347644613308e-10
whether O 0 2.3011104133274785e-10
such O 0 5.850403494989109e-10
mutants O 0 2.1696929763947992e-07
really O 0 1.887669931477376e-08
behave O 0 7.589852635270233e-10
as O 0 1.48273682221145e-09
loss O 0 2.009907795752497e-09
- O 0 3.5625038918851715e-08
of O 0 1.2781046443421928e-08
- O 0 2.97568671925319e-08
function O 0 8.43311753762066e-10
mutants O 0 4.7587698226436714e-09
as O 0 3.565858719412063e-10
predicted O 0 4.781405493758939e-09
by O 0 1.8689501057878033e-09
haploinsufficiency O 0 2.703617610677611e-05
. O 0 2.3928714654175565e-06

Contrary O 0 1.5031522480057902e-06
to O 0 3.825121108746998e-09
this O 0 5.440799200062685e-11
theory O 0 1.56349155844282e-09
, O 0 1.7440603128360266e-10
our O 0 1.2273203564561186e-09
data O 0 9.159882630171978e-09
showed O 0 4.105666029374788e-09
that O 0 7.032917997973342e-11
these O 0 2.3889457079206977e-10
mutants O 0 1.6833823224260414e-08
are O 0 4.707508272083771e-10
dominant O 0 1.8078667451959518e-08
- O 0 1.2182628950085927e-07
negative O 0 6.320213685739873e-09
in O 0 1.7511010419468676e-09
transient O 0 2.3865116105525885e-08
transfection O 0 1.9754979518893379e-07
assays O 0 1.120916781616188e-08
when O 0 5.39574607216764e-09
they O 0 1.4986847318709806e-09
are O 0 2.354502703916239e-10
coexpressed O 0 2.6260073582307086e-07
with O 0 5.756549126267885e-10
wild O 0 1.976462726815953e-07
- O 0 1.8914814745585318e-06
type O 0 4.335277481004596e-06
PAX6 O 0 0.288015216588974
. O 0 1.3746197510045022e-05

We O 0 1.0827562135773405e-07
found O 0 3.934600201205285e-09
that O 0 5.936379166016081e-11
the O 0 8.781859128781377e-10
dominant O 0 1.4877008069902331e-08
- O 0 1.7359815274176071e-07
negative O 0 9.596412553491973e-10
effects O 0 1.506834301778781e-08
result O 0 2.8294009357665573e-09
from O 0 3.125917080737395e-09
the O 0 2.5503164025053593e-09
enhanced O 0 6.313348421826959e-08
DNA O 0 1.4168796802493944e-08
binding O 0 2.713576030544118e-09
ability O 0 4.520627872039995e-09
of O 0 1.1555923329353845e-08
these O 0 2.568490975463078e-09
mutants O 0 2.7602857244346524e-07
. O 0 4.4445812363846926e-07

Kinetic O 0 1.2966067970410222e-06
studies O 0 1.443608113049777e-07
of O 0 5.35318456229561e-09
binding O 0 2.1150368123556973e-09
and O 0 1.477105437963644e-09
dissociation O 0 1.5793476748626745e-08
revealed O 0 5.220368581859702e-09
that O 0 2.941524801514106e-11
various O 0 1.1158324958460142e-10
truncation O 0 2.2012555334072204e-08
mutants O 0 3.481703148011661e-09
have O 0 9.360225788901388e-11
3 O 0 1.7194078383298006e-09
- O 0 2.8372545202159927e-08
5 O 0 7.699243553815904e-08
- O 0 9.052744758264453e-07
fold O 0 6.061848978333728e-08
higher O 0 2.4880201010546443e-08
affinity O 0 3.362676581630808e-09
to O 0 4.810730702686783e-10
various O 0 5.223373955587363e-10
DNA O 0 1.9846511101206943e-09
- O 0 3.848135143869058e-09
binding O 0 5.048762519166416e-10
sites O 0 6.270763353022346e-10
when O 0 4.651667592781017e-11
compared O 0 7.41024117068001e-11
with O 0 5.510803618991034e-12
the O 0 6.69785560347691e-10
wild O 0 2.8809070684587823e-08
- O 0 3.5498715078574605e-07
type O 0 1.0544005135670886e-06
PAX6 O 0 0.0016934159211814404
. O 0 7.908381121524144e-06

These O 0 2.363490558821013e-08
results O 0 3.123914460445576e-09
provide O 0 2.792301501131078e-09
a O 0 4.796539276874512e-10
new O 0 5.603306152401899e-10
insight O 0 6.697066901040216e-09
into O 0 1.3279226329654392e-10
the O 0 1.729953402751505e-10
role O 0 1.0357688040585344e-09
of O 0 3.5599958536636223e-09
mutant O 0 1.1736484850644047e-07
PAX6 O 0 2.2490081391879357e-05
in O 0 3.374899293362432e-08
causing O 0 2.354802290938096e-07
aniridia B-Disease 1 1.0
. O 0 1.7135558039171883e-07
. O 0 5.197579753257742e-07

Reversal O 0 1.225124606207828e-06
of O 0 1.81162278067859e-07
severe O 0 0.0003209875721950084
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 5.5807281569286715e-06
excellent O 0 2.3268871700565796e-06
neuropsychologic O 0 2.622316287670401e-06
outcome O 0 2.6189862722958424e-08
in O 0 1.1782157471884602e-08
very B-Disease 0 6.902278304465881e-09
- I-Disease 0 5.137104608365917e-07
long I-Disease 0 8.438048837433598e-08
- I-Disease 0 4.567920086628874e-07
chain I-Disease 0 1.026533951176134e-07
acyl I-Disease 0 1.2799729347534594e-06
- I-Disease 0 6.713439688610379e-07
coenzyme I-Disease 0 2.4651303647260647e-06
A I-Disease 0 2.537030241001048e-06
dehydrogenase I-Disease 0 3.65149462595582e-05
deficiency I-Disease 0 0.00013885430234950036
. O 0 2.032532620432903e-06

Very B-Disease 0 1.5537422370925924e-07
- I-Disease 0 5.855320637238037e-07
long I-Disease 0 2.8310433108913458e-08
- I-Disease 0 6.626347470728433e-08
chain I-Disease 0 1.6545929071298815e-08
acyl I-Disease 0 8.70269687425207e-08
- I-Disease 0 3.198723774744394e-08
coenzyme I-Disease 0 6.124688667341616e-08
A I-Disease 0 3.110520907512182e-08
dehydrogenase I-Disease 0 6.150853693043246e-08
( I-Disease 0 1.2934091575544926e-09
VLCAD I-Disease 0 0.0010325487237423658
) I-Disease 0 1.7751395020582095e-08
deficiency I-Disease 0 1.823402158152021e-06
is O 0 2.0621877538928857e-09
a O 0 6.265734953103674e-08
disorder O 1 0.9999874830245972
of O 0 1.987108362300205e-06
fatty O 0 6.585222536159563e-07
acid O 0 5.569290806306526e-08
beta O 0 2.3852697950133006e-07
oxidation O 0 1.6541896741273376e-07
that O 0 1.498822754797402e-08
reportedly O 0 1.8848750471534004e-07
has O 0 2.6366817063028236e-10
high O 0 2.571245438787173e-09
rates O 0 9.499788511391216e-09
of O 0 7.887442921017396e-10
morbidity O 0 9.145132935373113e-07
and O 0 5.467811536874478e-09
mortality O 0 9.502013199380599e-06
. O 0 3.4981405860889936e-07

We O 0 2.7000302438295876e-08
describe O 0 4.391415675542021e-09
the O 0 2.1635081226545338e-10
outcome O 0 9.537947098792188e-10
of O 0 3.4482752209186174e-09
a O 0 5.389551582801744e-10
5 O 0 6.727187695787507e-10
- O 0 8.487303637672028e-10
year O 0 1.48484724515896e-10
- O 0 4.006552423163612e-09
old O 0 9.94739846049697e-09
girl O 0 1.8218512920498142e-08
with O 0 5.180333384480207e-10
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 2.2517296471846748e-08
was O 0 2.9361705955466277e-08
first O 0 3.4503739865243688e-09
seen O 0 1.5686232313072423e-09
at O 0 1.2644043589915555e-09
5 O 0 8.683045393809152e-09
months O 0 9.231702624568072e-10
of O 0 2.964393452931091e-10
age O 0 7.627861675629788e-10
with O 0 6.627235565881406e-11
severe O 0 1.3247940842120443e-06
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999651908874512
hepatomegaly B-Disease 1 1.0
, O 1 0.5679014325141907
encephalopathy B-Disease 0 0.005660477094352245
, O 0 1.681008043874499e-08
and O 0 3.287383165684332e-08
hypotonia B-Disease 1 0.9514583945274353
. O 0 9.359232535643969e-06

Biochemical O 0 3.274414484621957e-05
studies O 0 2.347252484469209e-05
indicated O 0 0.0022145460825413465
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 2.0463301098061493e-06
by O 0 1.8236027132800814e-09
a O 0 6.981256017724036e-09
stable O 0 3.5627391525849816e-07
yet O 0 1.1702470104069107e-08
inactive O 0 1.20979933626586e-07
enzyme O 0 2.1446604492325605e-08
. O 0 2.5322438546027115e-07

Molecular O 0 1.7857435068435734e-06
genetic O 0 2.031925916412547e-08
analysis O 0 4.155813915218687e-09
of O 0 7.009649749534219e-09
her O 0 6.5999445908460075e-09
VLCAD O 0 0.0001817175798350945
gene O 0 2.9763679521011e-08
revealed O 0 3.539941673125213e-08
a O 0 2.420213007781058e-08
T1372C O 0 2.779542228381615e-06
( O 0 4.713197387928858e-09
F458L O 0 1.0774447218864225e-06
) O 0 4.658571306492831e-09
missense O 0 6.059780162104289e-07
mutation O 0 2.519605857287388e-08
and O 0 7.76784503386807e-09
a O 0 1.7135917573796178e-07
1668 O 1 0.7909870743751526
ACAG O 1 0.6182147860527039
1669 O 0 0.00050033611478284
splice O 0 2.2113474187790416e-05
site O 0 1.0662639624570147e-06
mutation O 0 1.4672929182779626e-07
. O 0 1.664166262571598e-07

After O 0 2.9355638275774254e-07
initial O 0 3.0149177376870284e-08
treatment O 0 1.5686383392221614e-07
with O 0 7.109758892731577e-10
intravenous O 0 2.208480331944429e-08
glucose O 0 2.2869885540899304e-08
and O 0 8.942452334181894e-10
carnitine O 0 1.5776713269133325e-07
, O 0 2.448128588738996e-09
the O 0 1.0045322795804168e-08
patient O 0 1.4974646944665437e-07
has O 0 2.872131144027179e-10
thrived O 0 3.877850929256965e-09
on O 0 1.8990482519853913e-09
a O 0 1.358947399054955e-09
low O 0 9.328157091204048e-08
- O 0 1.8012106295373087e-07
fat O 0 2.790509370242944e-07
diet O 0 9.358113572943694e-08
supplemented O 0 1.9913862558951223e-08
with O 0 2.305362845067549e-10
medium O 0 2.8138117613707436e-06
- O 0 4.411858299135929e-06
chain O 0 4.0536744450037077e-07
triglyceride O 0 8.406937581639795e-07
oil O 0 2.680624220374739e-07
and O 0 5.01014429943325e-09
carnitine O 0 3.446272387463978e-07
and O 0 2.3151021100176195e-09
avoidance O 0 1.962381702469429e-06
of O 0 1.9150213859120413e-07
fasting O 0 8.895659107110987e-07
. O 0 7.158369896842487e-08

Her O 0 9.326480721938424e-06
ventricular O 1 1.0
hypertrophy O 1 0.999998927116394
resolved O 0 2.274834741911036e-06
significantly O 0 1.5652086915451946e-07
over O 0 8.461006339999244e-10
1 O 0 5.774686062665069e-09
year O 0 8.28393020846363e-10
, O 0 1.994105713887251e-10
and O 0 1.3179957125686315e-10
cognitively O 0 7.317022721053945e-08
, O 0 6.892303394678834e-10
she O 0 6.084223125313315e-10
is O 0 2.5686498067445385e-11
in O 0 3.004809248641216e-11
the O 0 1.0252116516840104e-10
superior O 0 2.2038380009803404e-09
range O 0 1.1931437171597281e-08
for O 0 1.9152719410442387e-09
age O 0 9.723198957090062e-08
. O 0 5.501645432559599e-07

Clinical O 0 2.1821488189743832e-05
recognition O 0 2.0377559849293903e-05
of O 1 0.9999072551727295
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.4656728275497244e-08
important O 0 1.2145264793872457e-09
because O 0 3.7382832940302535e-11
it O 0 5.622678538041992e-12
is O 0 4.285413170157515e-12
one O 0 8.065475370910846e-12
of O 0 4.1640318970692647e-10
the O 0 2.2720785253227405e-09
few O 0 1.0434789032842673e-08
directly O 0 6.599655488770395e-09
treatable O 0 5.816717703055474e-07
causes O 0 9.576925918963752e-09
of O 0 3.688568739335096e-08
cardiomyopathy B-Disease 1 1.0
in O 0 2.0561328710755333e-05
children O 0 4.354966876007893e-08
. O 0 6.916814676571903e-09
. O 0 5.23651699779748e-08

Cloning O 0 2.237743501609657e-06
of O 0 2.0085673568814855e-08
a O 0 8.120544237044669e-10
novel O 0 2.2195094651067393e-09
member O 0 2.2931374576984354e-09
of O 0 4.257141750230176e-09
the O 0 8.891874792027465e-09
low O 0 2.2817171441147366e-07
- O 0 3.785436319958535e-08
density O 0 2.0439905323854646e-09
lipoprotein O 0 3.2411982431312936e-08
receptor O 0 9.25411782759511e-08
family O 0 7.000940627222008e-08
. O 0 1.8436876416672021e-06

A O 0 1.4452297136813286e-06
gene O 0 3.327961195509488e-08
encoding O 0 7.10641643308918e-08
a O 0 2.3930070369715395e-08
novel O 0 2.2805764388067473e-08
transmembrane O 0 6.532515861579213e-09
protein O 0 4.274820775140853e-10
was O 0 1.251708514615757e-09
identified O 0 1.2599861431983328e-10
by O 0 1.072207340274689e-11
DNA O 0 1.8599059792290262e-10
sequence O 0 2.30902311160186e-11
analysis O 0 1.1698887691924398e-10
within O 0 9.36379723759373e-11
the O 0 4.4380280006528494e-10
insulin B-Disease 0 0.0002423404948785901
- I-Disease 1 0.9999698400497437
dependent I-Disease 1 0.9999986886978149
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 2.4516625174442197e-08
IDDM B-Disease 0 1.8136111975763924e-05
) O 0 1.9048524979581316e-09
locus O 0 4.144037646369725e-08
IDDM4 O 0 4.152601832174696e-06
on O 0 1.0274428063894447e-07
chromosome O 0 3.001623838372325e-07
11q13 O 0 2.2274671209743246e-05
. O 0 6.641252525696473e-07

Based O 0 2.562469489930663e-07
on O 0 9.527754940563682e-08
its O 0 2.0749513218731863e-09
chromosomal O 0 3.149294798276969e-07
position O 0 3.4272105153831944e-07
, O 0 2.452606118197309e-09
this O 0 1.512084346622089e-10
gene O 0 4.2033398983676307e-10
is O 0 4.045958706955233e-11
a O 0 1.3838874490801345e-10
candidate O 0 3.705099560491476e-10
for O 0 2.071430943439978e-10
conferring O 0 8.328107270472174e-08
susceptibility O 0 7.861398444219958e-06
to O 0 5.808380478811159e-07
diabetes B-Disease 1 0.9999983310699463
. O 0 1.2596730812219903e-05

The O 0 7.112036541911948e-07
gene O 0 6.125845430915433e-08
, O 0 6.4367240426577155e-09
termed O 0 5.602927544146041e-08
low O 0 1.9031834597171837e-07
- O 0 1.1670794997087341e-08
density O 0 1.4898487998848964e-10
lipoprotein O 0 1.4044966301085537e-09
receptor O 0 5.524701252035413e-10
related O 0 2.3092192602547357e-09
protein O 0 1.8333817797255847e-09
5 O 0 1.7426188492208894e-08
( O 0 5.129570102013759e-10
LRP5 O 0 5.529397526515822e-07
) O 0 2.532395126930709e-10
, O 0 1.9152052166404587e-10
encodes O 0 3.593914887911609e-10
a O 0 4.0636408127348034e-10
protein O 0 9.002486534015475e-10
of O 0 2.4860788983005477e-09
1615 O 0 3.194680402884842e-06
amino O 0 3.0049630339590294e-08
acids O 0 9.540171319599722e-09
that O 0 2.625105133269301e-10
contains O 0 3.455166708299373e-10
conserved O 0 5.061480123913498e-10
modules O 0 4.635986261547487e-09
which O 0 7.20562012834769e-11
are O 0 1.5360594740609912e-11
characteristic O 0 4.358768346257591e-10
of O 0 6.908640326486193e-09
the O 0 1.0531524985424312e-08
low O 0 9.703993555376655e-07
- O 0 7.832625925630055e-08
density O 0 1.9608670243087545e-09
lipoprotein O 0 6.682051889583818e-08
( O 0 1.2951419936513275e-09
LDL O 0 5.936648221904761e-07
) O 0 7.104082655473576e-09
receptor O 0 1.5619491477991687e-07
family O 0 8.12643961012327e-08
. O 0 7.481730222025362e-07

These O 0 3.467952325308943e-08
modules O 0 1.2452065334400686e-07
include O 0 1.966392382257709e-08
a O 0 9.943888379382315e-09
putative O 0 2.017067828319341e-07
signal O 0 2.0939171463396633e-07
peptide O 0 5.136974401409589e-09
for O 0 1.2697138895845228e-09
protein O 0 1.3817411659289291e-09
export O 0 6.916949502056013e-08
, O 0 7.003662538807021e-09
four O 0 3.745845855718244e-09
epidermal O 0 5.987468654211625e-08
growth O 0 5.303993688698938e-09
factor O 0 4.1214991419735725e-09
( O 0 4.5104459056588553e-10
EGF O 0 4.6399162556554074e-07
) O 0 4.666279584952804e-10
repeats O 0 3.6677234582782603e-09
with O 0 3.403507198296296e-10
associated O 0 8.861098876877804e-08
spacer O 0 1.2746229458571179e-06
domains O 0 4.406217612995533e-08
, O 0 1.1583434211814847e-09
three O 0 1.7268214635990375e-10
LDL O 0 1.0581944209775429e-08
- O 0 6.109287653544015e-08
receptor O 0 1.1399507116038876e-08
( O 0 1.727520793082249e-09
LDLR O 0 2.35021816479275e-05
) O 0 1.0356997481864028e-09
repeats O 0 5.435182970359165e-09
, O 0 5.889129184311059e-10
a O 0 2.564853440745196e-09
single O 0 2.3929201731220928e-08
transmembrane O 0 3.166822537536973e-08
spanning O 0 1.6255112811336403e-08
domain O 0 8.843805687774875e-09
, O 0 4.670419606611631e-10
and O 0 7.703393478664111e-10
a O 0 4.4912868979452014e-09
cytoplasmic O 0 1.3557577460687753e-07
domain O 0 5.757366920988716e-07
. O 0 3.11935593799717e-07

The O 0 6.887853487569373e-07
encoded O 0 7.262061529900166e-08
protein O 0 1.532854021490948e-08
has O 0 4.99435104384105e-10
a O 0 2.875985005701409e-10
unique O 0 1.032474883366774e-09
organization O 0 5.229916499871479e-09
of O 0 1.2047744135657013e-08
EGF O 0 2.0338031390565448e-05
and O 0 3.429524397802197e-08
LDLR O 0 0.0008119239937514067
repeats O 0 7.250169797856643e-09
; O 0 3.7661967988711353e-10
therefore O 0 3.527020009386206e-09
, O 0 8.35012836652993e-10
LRP5 O 0 1.4759593796043191e-06
likely O 0 7.825006420603131e-09
represents O 0 6.913140893072267e-11
a O 0 7.994856859872002e-11
new O 0 9.353247343302229e-11
category O 0 2.8010707087133824e-09
of O 0 5.114829892960415e-09
the O 0 1.6450707462922765e-08
LDLR O 0 0.000275990751106292
family O 0 1.4558425220911886e-07
. O 0 3.2358249768549285e-07

Both O 0 3.139315367661766e-07
human O 0 7.76182034201156e-08
and O 0 2.5614912857463423e-08
mouse O 0 4.152649125899188e-06
LRP5 O 0 0.012648675590753555
cDNAs O 0 2.0568582840496674e-05
have O 0 8.310648169640444e-09
been O 0 8.027977393965102e-09
isolated O 0 7.3928565491598874e-09
and O 0 1.096967405800342e-09
the O 0 2.252780850753311e-09
encoded O 0 2.621543870873211e-09
mature O 0 1.9756170033247145e-09
proteins O 0 8.547115099011293e-11
are O 0 1.6419147291779623e-11
95 O 0 4.636755424058947e-09
% O 0 1.254442105746989e-10
identical O 0 1.9661804129267324e-10
, O 0 1.8361806519706647e-10
indicating O 0 2.3212836097741274e-09
a O 0 4.1288067409439577e-10
high O 0 1.0113508919218361e-09
degree O 0 2.657227327063083e-08
of O 0 3.6971670169805293e-09
evolutionary O 0 6.746568192994573e-09
conservation O 0 2.883126404285008e-09
. O 0 1.1999098381565432e-09
. O 0 3.216545607642729e-08

The O 0 3.141716206300771e-06
APC B-Disease 0 4.891883691016119e-06
variants O 0 6.845784810138866e-07
I1307K O 0 2.8140584618085995e-05
and O 0 1.2226270662551997e-08
E1317Q O 0 1.901938389892166e-06
are O 0 3.830455952424927e-10
associated O 0 7.800987589234865e-08
with O 0 3.5293038536110544e-07
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 5.335079436008527e-07
but O 0 2.4742796700394365e-10
not O 0 1.54550539033238e-10
always O 0 1.094674004220586e-10
with O 0 8.748797693247656e-12
a O 0 1.9891910341129915e-09
family O 0 1.0359150204308776e-09
history O 0 3.30532685666185e-08
. O 0 1.2212885280860064e-07

Classical O 0 0.16126294434070587
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 2.659454025888408e-07
FAP B-Disease 0 2.9287316465342883e-06
) O 0 7.991598494072605e-10
is O 0 4.676113316004482e-11
a O 0 3.837644646509375e-10
high O 0 3.6238209304428892e-06
- O 1 1.0
penetrance O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999998807907104
disease I-Disease 1 0.999990701675415
that O 0 7.819210556814227e-11
predisposes O 0 4.4686343514399596e-09
to O 0 2.626938389038713e-10
hundreds O 0 1.0271401507111477e-09
or O 0 1.0723576471249885e-09
thousands O 0 7.117727296446219e-09
of O 0 6.305767215053493e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
and O 0 1.5642149264749605e-07
that O 0 1.4488361899100966e-10
results O 0 1.653032988269132e-10
from O 0 2.93120999694807e-10
truncating O 0 2.2411931865917722e-08
mutations O 0 5.750425691175565e-10
in O 0 3.616064336853242e-09
the O 0 4.317056223612781e-08
APC B-Disease 0 1.2061790357620339e-06
gene O 0 2.0520781163213542e-07
. O 0 1.7430962770959013e-06

A O 0 6.233639737729391e-07
variant O 0 1.9764439684877289e-07
of O 0 4.145452692227991e-08
FAP B-Disease 0 7.184652872638253e-07
is O 0 7.172157090451492e-09
attenuated B-Disease 1 0.5193517804145813
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
, O 0 3.312515417519535e-08
which O 0 2.472614335502499e-10
results O 0 2.482126171265975e-10
from O 0 2.8789923223193625e-10
germ O 0 1.2338340411588433e-06
- O 0 1.180984625648307e-07
line O 0 6.5813026139949216e-09
mutations O 0 1.8715390348589267e-10
in O 0 1.0069445277594014e-10
the O 0 2.744022231659926e-10
5 O 0 2.5688240423704656e-09
and O 0 2.813094479581224e-10
3 O 0 1.257051618352989e-08
regions O 0 1.5687668941666288e-09
of O 0 1.0933646876765124e-08
the O 0 2.7664963653251107e-08
APC B-Disease 0 6.175811222419725e-07
gene O 0 1.827361018058582e-07
. O 0 3.521124881444848e-06

Attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 0 0.41909387707710266
have O 0 3.1244866693924678e-09
" O 0 7.921399536314766e-09
multiple O 0 5.1465590900079405e-08
" O 1 0.9999979734420776
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 7.96771004729635e-08
typically O 0 2.3018182915279795e-09
fewer O 0 6.793123008552726e-11
than O 0 1.3336914038430958e-11
100 O 0 1.2855683184653799e-09
) O 0 8.041532023606024e-11
without O 0 1.9713257692899333e-09
the O 0 5.4148920902719055e-09
florid O 0 3.0591735367124784e-07
phenotype O 0 2.0293736469056967e-08
of O 0 9.325752614586236e-09
classical O 0 8.94179265742423e-07
FAP B-Disease 0 6.048722298146458e-06
. O 0 6.990665610828728e-07

Another O 0 5.427141331892926e-07
group O 0 4.087834515331679e-09
of O 0 6.661815543651528e-09
patients O 0 8.292502684525971e-09
with O 0 1.2981339614359655e-10
multiple O 0 3.6509993606159696e-07
adenomas B-Disease 1 0.9999997615814209
has O 0 2.888131689360307e-07
no O 0 2.6199357350265018e-08
mutations O 0 1.7070200808433356e-09
in O 0 3.3218143791202692e-09
the O 0 1.180316555604577e-08
APC B-Disease 0 4.3514464920235696e-08
gene O 0 1.2173745345123166e-09
, O 0 7.41451455787967e-10
and O 0 5.171211792109887e-10
their O 0 1.1958201096007315e-09
phenotype O 0 3.446638086046505e-09
probably O 0 1.6274307457209147e-09
results O 0 2.1205212585861943e-10
from O 0 4.374893780578759e-10
variation O 0 3.0681355234207786e-09
at O 0 5.2544528728049045e-09
a O 0 1.8989974037708635e-09
locus O 0 8.056217026819468e-09
, O 0 9.33030319671957e-10
or O 0 5.186225893183405e-10
loci O 0 1.9974641940478932e-09
, O 0 2.3402518811721507e-10
elsewhere O 0 1.8445779348397195e-09
in O 0 9.480740637002327e-10
the O 0 2.3464790110949707e-09
genome O 0 1.2972244611830774e-08
. O 0 1.294284004416113e-07

Recently O 0 1.4428169379243627e-06
, O 0 1.2641246938116524e-09
however O 0 1.8310812588406833e-10
, O 0 1.387987363932197e-10
a O 0 4.6065529168970443e-10
missense O 0 3.014078231444728e-08
variant O 0 5.591172680396994e-07
of O 0 3.0169712772476487e-06
APC B-Disease 0 1.8419319530948997e-05
( O 0 5.69095170988021e-09
I1307K O 0 1.0746149200713262e-05
) O 0 1.8117112254856238e-09
was O 0 1.0043464726550155e-08
described O 0 1.8096873999340346e-09
that O 0 1.492496057298176e-11
confers O 0 1.959674422735702e-09
an O 0 3.3634879603727796e-11
increased O 0 1.1187802906320599e-09
risk O 0 2.1069855904443102e-07
of O 0 0.00011797260958701372
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.9260489807493286e-06
including O 0 1.0395356575543246e-08
multiple O 0 1.1977701497301041e-08
adenomas B-Disease 0 1.355091171717504e-06
, O 0 6.04716987595566e-09
in O 0 3.276191051782007e-08
Ashkenazim O 0 4.235544474795461e-05
. O 0 3.625742408530641e-07

We O 0 3.1264411859410757e-07
have O 0 5.276910020057812e-09
studied O 0 5.5845337243454196e-08
a O 0 4.6655519447824645e-09
set O 0 5.685971249391741e-09
of O 0 1.0948938422572496e-09
164 O 0 6.549758069240852e-09
patients O 0 1.4162251371629964e-09
with O 0 3.4347316657523663e-10
multiple O 1 0.8554261326789856
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
/ I-Disease 1 1.0
or I-Disease 0 0.3253294825553894
carcinoma I-Disease 1 1.0
and O 0 5.4973558150095414e-08
analyzed O 0 1.2161195606097408e-08
codons O 0 9.163517944443811e-09
1263 O 0 9.727443739393493e-07
- O 0 5.118316721564042e-07
1377 O 0 3.6431181342777563e-06
( O 0 3.0139732931644403e-09
exon O 0 1.380072518486486e-07
15G O 0 2.977824124172912e-06
) O 0 9.220616492555678e-10
of O 0 2.936936471797935e-09
the O 0 5.5733471171492965e-09
APC B-Disease 0 1.1954311673889606e-07
gene O 0 1.0226406388369469e-08
for O 0 1.015096628975698e-08
germ O 1 0.9882833957672119
- O 0 0.00010412511619506404
line O 0 1.2857475439886912e-06
variants O 0 6.644293080171337e-07
. O 0 2.5733376673997554e-07

Three O 0 1.09472352960438e-07
patients O 0 8.435775633586218e-09
with O 0 4.385685911656445e-11
the O 0 4.454125956954158e-09
I1307K O 0 1.39079190830671e-06
allele O 0 6.090623561050279e-09
were O 0 2.419122457908429e-09
detected O 0 6.397129936885904e-09
, O 0 2.177376334788761e-10
each O 0 8.680486190959513e-11
of O 0 7.283670555580102e-09
Ashkenazi O 0 2.375334588577971e-06
descent O 0 1.4580797369490028e-06
. O 0 4.3847893493875745e-07

Four O 0 3.037811211470398e-07
patients O 0 3.22557660581424e-08
had O 0 7.826872483462921e-09
a O 0 2.0702115577364566e-09
germ O 0 0.00010425804794067517
- O 0 1.7239066437468864e-05
line O 0 1.1230481504753698e-06
E1317Q O 0 1.442793472961057e-05
missense O 0 2.821631710503425e-07
variant O 0 1.583217965617223e-07
of O 0 3.833756423432533e-08
APC O 0 1.0736991384874273e-07
that O 0 1.6656834245232233e-10
was O 0 4.3069543487206374e-09
not O 0 2.1251857218462789e-10
present O 0 5.095992031134422e-11
in O 0 3.4699734752230427e-10
controls O 0 2.0985385873473206e-08
; O 0 1.5566883893036731e-10
one O 0 1.909901126140312e-10
of O 0 4.274021969674635e-10
these O 0 3.8733891094544504e-11
individuals O 0 1.619446417244763e-11
had O 0 1.9776453807907046e-09
an O 0 2.197746151733071e-10
unusually O 0 3.0834061970352877e-09
large O 0 7.95297494526892e-10
number O 0 6.288121134900848e-09
of O 0 3.6968021532857165e-08
metaplastic B-Disease 0 2.843082620529458e-05
polyps I-Disease 0 1.3395440419117222e-06
of I-Disease 0 5.684326254140615e-08
the I-Disease 0 3.972555262521382e-08
colorectum I-Disease 0 1.1338699550833553e-05
. O 0 6.360631914503756e-07

There O 0 2.0448420912089205e-07
is O 0 5.277944192805251e-10
increasing O 0 1.8488389985638065e-10
evidence O 0 6.784295902839688e-10
that O 0 3.592015226927536e-11
there O 0 1.1384806292147331e-10
exist O 0 6.423536147437403e-10
germ O 0 1.2032287486363202e-06
- O 0 1.7657019668604335e-07
line O 0 1.1220119056076783e-08
variants O 0 7.54342810438402e-09
of O 0 5.096064903398201e-09
the O 0 5.591949570060706e-09
APC B-Disease 0 1.2849149300109275e-07
gene O 0 4.633228023465108e-09
that O 0 2.2618168449284326e-10
predispose O 0 6.272814090380052e-08
to O 0 2.286394185091467e-09
the O 0 2.269189725012666e-09
development O 0 3.240376145186019e-08
of O 0 4.452047264180692e-08
multiple O 1 0.911266565322876
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
, O 0 3.269629900159998e-08
but O 0 3.8667774537870514e-10
without O 0 1.6330401475528333e-09
the O 0 4.926167251895208e-10
florid O 0 1.1773771291245794e-07
phenotype O 0 1.1078365780292643e-08
of O 0 7.286157899244472e-09
classical O 0 2.6945517106469197e-07
FAP B-Disease 0 1.8113584587808873e-07
, O 0 4.567331512994599e-10
and O 0 9.182772597871036e-11
possibly O 0 2.1263382166125666e-09
with O 0 1.4581337873242894e-11
importance O 0 6.50187701012328e-07
for O 1 0.9987549781799316
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 1 0.7608122229576111
in O 0 9.223153796256156e-09
the O 0 1.4492071986893507e-09
general O 0 3.157087258287561e-09
population O 0 2.2726915835380446e-11
. O 0 3.297848660821501e-10
. O 0 1.719156195179039e-08

Genomic O 0 5.782938501397439e-07
structure O 0 1.447997810544166e-08
of O 0 9.784663745904254e-09
the O 0 5.7295395095025015e-09
human O 0 2.3309353025524615e-07
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 2.277565499753109e-06
CLD B-Disease 1 0.9999836683273315
) O 0 3.197082776296156e-08
gene O 0 6.449815259657043e-08
. O 0 5.531607030206942e-07

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 2.8654866923716327e-07
CLD B-Disease 1 0.9999996423721313
) O 0 3.73667630171326e-09
is O 0 2.0634575992328763e-10
caused O 0 7.708111371407256e-10
by O 0 9.849027149400058e-11
mutations O 0 2.7783492173583113e-10
in O 0 3.4213363253599027e-09
a O 0 1.270770866312887e-08
gene O 0 2.595710757447023e-09
which O 0 9.079845764148331e-10
encodes O 0 5.0880037960610025e-09
an O 0 4.595453795275262e-09
intestinal O 0 8.799755732979975e-07
anion O 0 2.3711942276349873e-07
transporter O 0 1.077403680938005e-06
. O 0 4.834735136682866e-07

We O 0 5.433806791188545e-07
report O 0 3.480781884945827e-08
here O 0 1.959850060018198e-09
the O 0 8.409442031620529e-10
complete O 0 4.058491320790836e-09
genomic O 0 3.1690099433490104e-08
organization O 0 1.8961889836077717e-09
of O 0 1.6604788655172342e-09
the O 0 6.6177689994617594e-09
human O 0 4.294823696682215e-08
CLD B-Disease 0 0.0005247118533588946
gene O 0 5.1538279421947664e-08
which O 0 2.468096615970694e-09
spans O 0 4.669477693397539e-09
approximately O 0 2.698585799265629e-10
39kb O 0 7.426368142660067e-08
, O 0 7.631456022672012e-10
and O 0 1.530130799842766e-09
comprises O 0 7.76751907238804e-09
21 O 0 2.837239208020037e-07
exons O 0 1.0092587672261288e-06
. O 0 3.187204526966525e-07

All O 0 6.871280788800505e-07
exon O 0 5.94610446569277e-06
/ O 0 1.1076971532020252e-05
intron O 0 3.060264134546742e-06
boundaries O 0 6.655656026310908e-09
conform O 0 7.794547940420671e-08
to O 0 2.7879176300871222e-08
the O 0 9.48794891542093e-08
GT O 0 0.00024843536084517837
/ O 0 0.00020175724057480693
AG O 0 0.00014920324611011893
rule O 0 7.079149327182677e-06
. O 0 1.2454813713702606e-06

An O 0 7.181232497543988e-09
analysis O 0 3.064801745722434e-09
of O 0 2.5124065050619038e-09
the O 0 9.956238056219036e-10
putative O 0 1.7379319317001318e-08
promoter O 0 7.134148916065897e-08
region O 0 5.377078782231592e-09
sequence O 0 5.372750022658579e-10
shows O 0 7.312638494738621e-09
a O 0 2.4788025854149964e-08
putative O 0 3.1860756735113682e-06
TATA O 0 2.0186191250104457e-05
box O 0 8.872190733200114e-07
and O 0 2.619985650653689e-08
predicts O 0 6.163783439205872e-08
multiple O 0 2.6368691674605316e-09
transcription O 0 4.5375447399464974e-08
factor O 0 3.943430115782576e-08
binding O 0 2.7793484846938554e-08
sites O 0 3.413836111576529e-07
. O 0 3.542941442447045e-07

The O 0 2.1099050684370013e-07
genomic O 0 9.029165681795348e-08
structure O 0 4.326335734106124e-09
was O 0 1.0689133134178519e-08
determined O 0 1.1744121231060944e-09
using O 0 1.1025197421687949e-09
DNA O 0 6.488111381486306e-09
from O 0 7.701321802500161e-10
several O 0 1.4646736601342525e-10
sources O 0 1.5526860908110507e-09
including O 0 1.305787422634097e-10
multiple O 0 7.456294470742364e-10
large O 0 2.4195838665974634e-09
- O 0 5.887034149054671e-07
insert O 0 3.292386054454255e-06
libaries O 0 2.6945517674903385e-06
and O 0 2.5612065801539075e-09
genomic O 0 4.461389124799098e-08
DNA O 0 3.814966120785357e-08
from O 0 1.3072914306633265e-08
Finnish O 0 4.2438608943484724e-05
CLD B-Disease 1 0.9999154806137085
patients O 0 1.132981537921296e-06
and O 0 3.085119359980126e-08
controls O 0 2.1282730813254602e-05
. O 0 3.2048969842435326e-06

Exon O 0 4.317757338867523e-05
- O 0 2.5148272015940165e-06
specific O 0 1.797236137690561e-08
primers O 0 1.035647372304993e-07
developed O 0 4.200208181259768e-09
in O 0 2.7464988616721087e-10
this O 0 6.773508837154552e-11
study O 0 1.3371970197795235e-10
will O 0 3.786181784759535e-11
facilitate O 0 3.0553637397900957e-09
mutation O 0 7.030708792932217e-10
screening O 0 9.829083102985692e-10
studies O 0 8.158226982857286e-09
of O 0 2.9348086183489386e-09
patients O 0 1.7555957798620625e-09
with O 0 5.928617319295171e-11
the O 0 1.1238496355758798e-08
disease O 0 9.267595402207007e-08
. O 0 1.1118675757870733e-07

Genomic O 0 2.5437867634536815e-07
sequencing O 0 1.5074847681262327e-07
of O 0 9.56478984903697e-08
a O 0 1.34661519268775e-07
BAC O 1 0.8324239253997803
clone O 0 0.00010833740088855848
H O 1 1.0
_ O 0 8.047896216112349e-08
RG364P16 O 0 9.28208066852676e-07
revealed O 0 3.1793430110838017e-09
the O 0 2.8107349780981394e-10
presence O 0 3.600247600044071e-10
of O 0 8.94685381336302e-10
another O 0 3.017595617826885e-10
, O 0 7.604832735763623e-11
highly O 0 4.744628578912113e-10
homologous O 0 5.453643647790329e-10
gene O 0 1.0628259383693717e-09
3 O 0 3.5713892287958515e-08
of O 0 8.965772479996303e-08
the O 0 7.902418275307355e-08
CLD B-Disease 0 0.00012771642650477588
gene O 0 1.6702344396435365e-08
, O 0 1.7157452125715622e-09
with O 0 1.4208456633468813e-10
a O 0 1.821951145508649e-09
similar O 0 2.536828247468037e-10
genomic O 0 2.376807417547866e-09
structure O 0 1.5366177219533483e-09
, O 0 5.163839356114863e-10
recently O 0 1.0398861771676593e-09
identified O 0 5.467600261432892e-10
as O 0 3.0774352510754e-10
the O 0 2.1170317054952648e-08
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 5.749510023633775e-07
( O 0 3.930220149328534e-09
PDS B-Disease 0 2.459832330714562e-06
) O 0 1.2825607242916703e-09
. O 0 4.661317998255754e-09
. O 0 7.011484370877952e-08

The O 0 1.975246505026007e-06
APCI1307K O 1 0.9395749568939209
allele O 0 6.353233402478509e-06
and O 0 1.8247657607162182e-08
cancer B-Disease 0 7.323221211663622e-07
risk O 0 7.04110192373264e-08
in O 0 4.7847539264012084e-09
a O 0 2.4512216700856015e-09
community O 0 2.453905689758784e-10
- O 0 1.7531629481482014e-09
based O 0 1.438342916992852e-10
study O 0 3.574063822675555e-10
of O 0 7.301039217644245e-10
Ashkenazi O 0 1.1426853063767339e-07
Jews O 0 2.7793015533461585e-07
. O 0 1.3868341852685262e-07

Mutations O 0 9.502221473667305e-06
in O 0 2.2638828056642524e-07
APC O 0 1.371867483612732e-06
are O 0 1.9451065202957807e-09
classically O 0 3.139083673886489e-06
associated O 0 4.736581615816249e-07
with O 0 4.7099735667188725e-08
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 5.696732330306986e-08
FAP B-Disease 0 3.9829686215853144e-07
) O 0 1.3858209024775192e-10
, O 0 5.4690162121229235e-11
a O 0 3.780367685557451e-10
highly O 0 1.0929998097708449e-06
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 1.4878532965667546e-06
by O 0 6.414708764168608e-10
multiple O 0 5.2998906596712914e-08
intestinal O 1 0.66306471824646
polyps B-Disease 0 8.51914947475052e-08
and O 0 4.907467210379934e-10
, O 0 1.2235799873305808e-10
without O 0 1.2479325350867043e-09
surgical O 0 7.109769740054617e-06
intervention O 0 0.0001019877745420672
, O 0 8.868732970235271e-10
the O 0 7.004994917458873e-10
development O 0 7.650453426322201e-08
of O 1 0.9984762072563171
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 3.5956404076387116e-07
CRC B-Disease 0 3.011173612321727e-05
) O 0 1.6515219414259263e-08
. O 0 1.6394395174756937e-07

APC B-Disease 0 3.402708898647688e-05
is O 0 2.5285991966939037e-08
a O 0 2.4200700110554862e-08
tumour O 1 1.0
- O 0 4.58800423075445e-06
suppressor O 0 6.094488981034374e-06
gene O 0 1.1808592326190137e-08
, O 0 4.707328415953782e-10
and O 0 9.92404491917398e-10
somatic O 0 6.9011616687930655e-06
loss O 0 1.529076172346322e-07
occurs O 0 1.1560044477221254e-08
in O 0 1.3608317317448382e-07
tumours B-Disease 1 1.0
. O 0 1.5172609892033506e-05

The O 0 1.7118633195423172e-06
germline O 0 1.4353086044138763e-05
T O 0 4.479282154079556e-07
- O 0 7.734450946372817e-08
to O 0 3.6622083143811324e-09
- O 0 3.536844062068667e-08
A O 0 1.1792004706023818e-08
transversion O 0 4.230634687019119e-08
responsible O 0 1.7616635927808488e-09
for O 0 6.512582140238976e-10
the O 0 1.1226134688513412e-08
APC O 0 1.7246545667148894e-06
I1307K O 0 7.874582479416858e-06
allele O 0 3.3423312117975e-08
converts O 0 1.124947690556155e-08
the O 0 9.623504215738876e-10
wild O 0 1.797057058716689e-09
- O 0 2.2771764474072143e-09
type O 0 1.444749986312388e-09
sequence O 0 2.1723156606867633e-10
to O 0 2.2050026249331722e-09
a O 0 5.33792423595969e-08
homopolymer O 1 0.7009251117706299
tract O 0 0.00011882444232469425
( O 0 7.790471379109931e-09
A8 O 0 2.227733602921944e-06
) O 0 4.4066336690740116e-10
that O 0 4.906940825888384e-11
is O 0 5.863168978104127e-11
genetically O 0 5.127489099976401e-09
unstable O 0 5.9529202900421296e-08
and O 0 2.343193017395606e-08
prone O 0 7.723253361291427e-07
to O 0 6.093496551784483e-08
somatic O 0 1.1469358469184954e-05
mutation O 0 3.172206390900101e-07
. O 0 3.9194500800476817e-07

The O 0 6.422550313800457e-07
I1307K O 0 7.63253410696052e-06
allele O 0 9.835318337536592e-08
was O 0 1.7845430022589426e-08
found O 0 8.03030142382255e-10
in O 0 1.417108652645993e-09
6 O 0 4.395930943701387e-07
. O 0 4.085826219579758e-07

1 O 0 4.611102667695377e-06
% O 0 7.395426848688658e-08
of O 0 4.332423486630432e-08
unselected O 0 0.000128155603306368
Ashkenazi O 0 4.015755985165015e-05
Jews O 0 3.248768507546629e-07
and O 0 1.1056912052609391e-09
higher O 0 1.3797027964557174e-09
proportions O 0 9.501777142872925e-10
of O 0 3.4547531502227002e-09
Ashkenazim O 0 1.4099910004006233e-06
with O 0 3.7676625708193967e-10
family O 0 6.78585232449791e-09
or O 0 6.471796432094834e-09
personal O 0 1.5625032290245144e-07
histories O 0 3.1056126204020984e-07
of O 0 9.042485658028454e-07
CRC B-Disease 0 0.010748691856861115
( O 0 1.2636673041299673e-08
ref O 0 3.619520839492907e-06
. O 0 4.534064679262428e-09
2 O 0 1.1021906942687565e-07
) O 0 1.4347249610580093e-08
. O 0 1.5250392948473745e-07

To O 0 4.664646624519264e-08
evaluate O 0 5.0697266829047294e-08
the O 0 3.697413708536601e-09
role O 0 2.7053914664065815e-08
of O 0 8.327614153813556e-08
I1307K O 0 1.581501419423148e-05
in O 0 7.60047491610294e-09
cancer B-Disease 0 4.636616424136264e-08
, O 0 6.313077838271397e-10
we O 0 8.439907661639268e-10
genotyped O 0 4.1204489775736874e-07
5 O 0 1.422109789928072e-07
, O 0 2.3028823292747802e-08
081 O 0 1.8081263988278806e-05
Ashkenazi O 0 1.5982381000867463e-06
volunteers O 0 1.266954967604761e-07
in O 0 4.924121554950034e-09
a O 0 5.4086881640103e-09
community O 0 3.770230794231111e-09
survey O 0 1.2649573832845817e-08
. O 0 3.786692914786727e-08

Risk O 0 1.476664147048723e-05
of O 0 9.073846030105415e-08
developing O 0 3.6287714465288445e-05
colorectal B-Disease 1 1.0
, I-Disease 0 0.006669136229902506
breast I-Disease 1 0.9999998807907104
and I-Disease 0 6.857246148683771e-07
other I-Disease 0 7.353903441753573e-08
cancers I-Disease 0 0.029681619256734848
were O 0 2.117213995234124e-07
compared O 0 9.335754391770479e-09
between O 0 7.29753091288643e-10
genotyped O 0 2.0375151166263095e-07
I1307K O 0 1.875568784726056e-07
carriers O 0 3.867037356997116e-09
and O 0 4.89817186810626e-10
non O 0 3.374339385686653e-08
- O 0 1.384812886584541e-08
carriers O 0 7.673082169645795e-10
and O 0 5.899041671808547e-11
their O 0 3.410107612955571e-11
first O 0 1.0472588352072876e-09
- O 0 7.888019126767176e-09
degree O 0 4.8020361020917335e-08
relatives O 0 4.7913410128330725e-08
. O 0 5.386299761767077e-08

Sperm O 0 1.5925340335343208e-07
DNA O 0 7.93163490442339e-09
analysis O 0 3.2031055585690638e-09
in O 0 6.016864784186282e-09
a O 0 9.97428486471108e-08
Friedreich B-Disease 0 0.0010959409410133958
ataxia I-Disease 1 0.995599627494812
premutation O 1 0.8114541172981262
carrier O 0 3.669632860692218e-06
suggests O 0 2.8160562237644626e-07
both O 0 5.595811813918772e-09
meiotic O 0 2.592091504993732e-06
and O 0 1.5024722799239498e-08
mitotic O 0 3.494985776342219e-07
expansion O 0 3.4454308206477435e-07
in O 0 1.8093224696258403e-08
the O 0 2.9602267304085217e-08
FRDA B-Disease 0 2.4162285626516677e-05
gene O 0 1.2500227342115977e-07
. O 0 3.8502523125316657e-07

Friedreich B-Disease 1 0.9999994039535522
ataxia I-Disease 1 1.0
is O 0 1.4239770962376497e-07
usually O 0 8.582326849193578e-09
caused O 0 1.5212087145499709e-09
by O 0 2.0465787051171525e-11
an O 0 1.4553941385386793e-11
expansion O 0 2.3587742870034845e-09
of O 0 7.800403878377438e-09
a O 0 9.135822764960722e-09
GAA O 0 8.076266766465778e-08
trinucleotide O 0 8.666963822179241e-07
repeat O 0 1.647758907097341e-08
in O 0 9.293116498554355e-09
intron O 0 3.656529088402749e-07
1 O 0 1.596218197619237e-07
of O 0 3.824429839482946e-08
the O 0 2.5783583268434995e-08
FRDA B-Disease 0 2.4759949155850336e-05
gene O 0 1.5406118336613872e-07
. O 0 8.312409818245214e-07

Occasionally O 0 2.0135826162004378e-06
, O 0 1.1824052847941857e-08
a O 0 7.033179816318125e-09
fully O 0 7.253492384506899e-08
expanded O 0 3.0565018960260204e-08
allele O 0 4.987074220252907e-08
has O 0 1.3652284858167718e-10
been O 0 9.036855291855161e-11
found O 0 3.735795700565703e-11
to O 0 5.510406367315035e-11
arise O 0 2.7796634438637113e-10
from O 0 2.1625798374280691e-10
a O 0 6.23270102195761e-10
premutation O 0 8.606969714719526e-08
of O 0 2.2014305933737432e-09
100 O 0 3.2383436376903774e-08
or O 0 8.79317285651382e-10
less O 0 4.615103410543497e-09
triplet O 0 5.133412628310907e-07
repeats O 0 2.4919154384406283e-07
. O 0 1.0147965667783865e-06

We O 0 5.539034759749484e-07
have O 0 6.935044982725458e-09
examined O 0 2.8290569886735284e-08
the O 0 2.6968789423875705e-09
sperm O 0 1.3508619112201359e-08
DNA O 0 1.5143717391197242e-08
of O 0 2.048026459533503e-08
a O 0 2.6378916828662113e-08
premutation O 0 3.2975676731439307e-06
carrier O 0 6.142313395685051e-07
. O 0 6.908628620294621e-07

This O 0 3.789749314364599e-08
mans O 0 1.3657817135026562e-06
leucocyte O 0 1.861906412159442e-06
DNA O 0 1.3031345247327408e-07
showed O 0 1.3001275611657093e-08
one O 0 2.250224589994687e-10
normal O 0 6.453294787434061e-09
allele O 0 3.5880132198684578e-09
and O 0 4.67489380540087e-10
one O 0 1.0702061459255674e-09
allele O 0 2.180061908774178e-09
of O 0 1.6604059238645164e-09
approximately O 0 4.6217604743326035e-10
100 O 0 4.95155916269141e-08
repeats O 0 1.8516146838010172e-08
. O 0 1.2251007319719065e-07

His O 0 8.517911851413373e-07
sperm O 0 5.276611432236678e-07
showed O 0 2.275796617823289e-08
an O 0 2.452754666038004e-10
expanded O 0 3.821540417447977e-09
allele O 0 3.0872608913767863e-09
in O 0 7.180913086379803e-10
a O 0 7.041354610493045e-09
tight O 0 9.826749192143325e-08
range O 0 2.0287698632159845e-08
centering O 0 3.842905549333864e-09
on O 0 1.3070664550696165e-09
a O 0 5.714606565732083e-10
size O 0 3.038908569230614e-10
of O 0 7.623963127478817e-10
approximately O 0 2.381089492242694e-10
320 O 0 1.9413009866298125e-08
trinucleotide O 0 1.3901051261200337e-06
repeats O 0 9.172142512170467e-08
. O 0 4.127654165131389e-07

His O 0 1.8826164023266756e-06
affected O 0 2.54855308412516e-07
son O 0 5.4111951612867415e-06
has O 0 4.3147081463246195e-09
repeat O 0 6.662349338881768e-09
sizes O 0 7.835954107804355e-09
of O 0 8.781244176248038e-09
1040 O 0 1.6883575426618336e-07
and O 0 2.6171088407522802e-08
540 O 0 1.9980727756774286e-06
. O 0 6.427108587558905e-07

These O 0 1.2889847766928142e-07
data O 0 7.52831113004504e-08
suggest O 0 2.1555597307099106e-09
that O 0 9.132115202925561e-12
expansion O 0 3.11782322182097e-10
occurs O 0 1.6827827326038047e-11
in O 0 1.9233493270265356e-11
two O 0 5.29299000462391e-12
stages O 0 6.590993723021299e-11
, O 0 5.8008986503210735e-11
the O 0 1.6169070249372197e-10
first O 0 1.1143123090917584e-09
during O 0 2.677249755222988e-09
meiosis O 0 2.681455724129478e-09
followed O 0 9.702294523350474e-10
by O 0 8.038894550033149e-11
a O 0 1.6015031523153311e-09
second O 0 6.632502991266165e-09
mitotic O 0 4.587298860769806e-07
expansion O 0 1.763655177455803e-06
. O 0 7.113318361007259e-07

We O 0 5.992941396470997e-07
also O 0 1.7100679983172995e-08
show O 0 5.435099925676923e-09
that O 0 7.793258399724223e-11
in O 0 2.4472590620661094e-10
all O 0 2.2035637203821068e-10
informative O 0 1.357629386689041e-08
carrier O 0 1.2302036722644516e-08
father O 0 2.3303433849264366e-08
to O 0 3.65757979459147e-09
affected O 0 4.393392760704273e-09
child O 0 1.3785644625841087e-08
transmissions O 0 1.8912888322120125e-07
, O 0 3.6254754753883844e-10
with O 0 1.141630887047107e-11
the O 0 8.800941642128635e-10
notable O 0 2.1771697777950294e-09
exception O 0 4.882056980903826e-09
of O 0 2.1572872377362273e-09
the O 0 2.3341322208381143e-09
premutation O 0 2.823088038894639e-07
carrier O 0 1.2439786978291067e-08
, O 0 1.138902638864181e-09
the O 0 1.6481697118209127e-09
expansion O 0 2.858253189685911e-08
size O 0 4.023238631134518e-09
decreases O 0 9.067303352594536e-09
. O 0 5.0237320969870325e-09
. O 0 1.7172757793559867e-07

The O 0 6.991092504904373e-07
R496H O 0 2.515222513466142e-05
mutation O 0 7.083452402412149e-08
of O 0 2.6932152508152285e-08
arylsulfatase O 0 1.8835049559129402e-05
A O 0 1.0648545867297798e-06
does O 0 6.97585189612937e-09
not O 0 6.050977052751705e-09
cause O 0 1.152297159023874e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 1.778224941517692e-05

Deficiency B-Disease 0 0.001978227635845542
of I-Disease 0 6.708410637656925e-06
arylsulfatase I-Disease 1 0.8579309582710266
A I-Disease 0 0.0003136460727546364
( O 0 8.147469543473562e-08
ARSA O 0 0.00010343752364860848
) O 0 2.0855213112014326e-09
enzyme O 0 2.4502775364254603e-09
activity O 0 6.703817234665621e-08
causes O 0 8.399156286031939e-07
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 1.7953625786049088e-07
MLD B-Disease 1 1.0
) O 0 4.3329112742185316e-08
. O 0 9.859528660172145e-08

A O 0 9.063343782145239e-07
number O 0 2.054944658880231e-08
of O 0 5.523136792362493e-08
ARSA O 0 0.0003778190293814987
gene O 0 1.890996799147615e-07
mutations O 0 4.650264173733376e-08
responsible O 0 5.4382347514092544e-08
for O 0 6.598839519256217e-08
MLD B-Disease 1 1.0
have O 0 1.8083983377437107e-07
been O 0 9.262607569837655e-09
identified O 0 1.2632986212679498e-08
. O 0 6.339050173664873e-08

Recently O 0 1.3802347211822052e-06
, O 0 4.1649075299687865e-09
the O 0 2.0070423101259394e-09
R496H O 0 6.172620032884879e-07
mutation O 0 3.183926011729454e-08
of O 0 3.421996908059555e-08
ARSA O 0 0.00022405867639463395
was O 0 2.2850619529890537e-07
proposed O 0 3.2164704233395014e-09
to O 0 2.388909070560885e-10
be O 0 1.3380593855139011e-10
a O 0 3.0553562457846795e-10
cause O 0 3.2237976732574225e-09
of O 0 3.5253744812280274e-08
MLD B-Disease 1 1.0
( O 0 2.21703118086225e-08
Draghia O 0 1.9768822312471457e-06
et O 0 5.628440362670517e-07
al O 0 7.192879820649978e-07
. O 0 1.5768004679728165e-09
, O 0 6.553353415483798e-10
1997 O 0 1.0050938747951932e-08
) O 0 4.412287424315764e-09
. O 0 6.397522867018779e-08

We O 0 6.586691938537115e-07
have O 0 8.905962189942329e-09
investigated O 0 1.9116997762580468e-08
the O 0 4.043478885051854e-09
R496H O 0 1.3984022189106327e-06
mutation O 0 3.326734887565408e-09
and O 0 3.4670230575351013e-10
found O 0 1.8093930520546309e-10
this O 0 4.613725720914452e-11
mutation O 0 4.522885399538268e-10
at O 0 7.196077622673158e-10
a O 0 1.692365830807674e-10
relatively O 0 1.3654759267733851e-10
high O 0 1.4838281992002322e-10
frequency O 0 3.66173841248596e-10
in O 0 6.611680647417018e-11
an O 0 1.356659923290593e-10
African O 0 3.391746883352198e-09
American O 0 2.2491186690842824e-09
population O 0 1.6625402443626314e-11
( O 0 6.7196660562263144e-12
f O 0 2.92654100952916e-09
= O 0 4.95303975611705e-09
0 O 0 5.900642752187935e-10
. O 0 1.5322824953312164e-10
09 O 0 5.072580222531542e-08
, O 0 1.130662563575413e-09
n O 0 7.85447884510404e-09
= O 0 8.593223554953511e-08
61 O 0 3.2157359441953304e-08
subjects O 0 9.791780541945627e-08
) O 0 1.5777398942873333e-08
. O 0 7.9326966329063e-08

The O 0 1.4594914318877272e-05
ARSA O 0 0.00016731784853618592
enzyme O 0 2.6808740116734953e-08
activity O 0 1.7789490769359873e-08
in O 0 4.70002592400931e-10
subjects O 0 9.95696414207714e-09
with O 0 2.2468096827488182e-11
and O 0 7.805456281317902e-11
without O 0 7.385298483875147e-10
the O 0 7.062467277663131e-10
R496H O 0 1.4242554868815205e-07
mutation O 0 6.305280186857942e-10
was O 0 6.293937593326859e-10
determined O 0 4.762962246829261e-10
and O 0 5.781516376757168e-10
found O 0 7.387412348514033e-10
to O 0 5.682174175625221e-10
be O 0 1.3910942397998838e-09
normal O 0 8.640920157176879e-08
. O 0 4.7308259354394977e-07

It O 0 1.9173050702647743e-08
is O 0 1.4487754051994983e-10
therefore O 0 2.625635819875072e-10
concluded O 0 1.7728917223180929e-09
that O 0 7.46509937199491e-11
the O 0 1.4578792617570002e-09
R496H O 0 1.6896506167540792e-06
mutation O 0 2.785993480358684e-08
of O 0 5.292476146223635e-08
ARSA O 0 0.00031336062238551676
does O 0 8.877098167658914e-09
not O 0 2.231215878722992e-09
negatively O 0 1.148018902163983e-09
influence O 0 9.712241677561906e-09
the O 0 3.3047831138333095e-09
activity O 0 1.4013505023058315e-08
of O 0 4.6263579633887275e-09
ARSA O 0 8.421007805736735e-06
and O 0 3.387434777124554e-09
is O 0 2.3636548274197366e-10
not O 0 3.726219055533164e-10
a O 0 1.970265950390626e-09
cause O 0 4.5269462844999e-08
of O 0 1.6274196923404816e-06
MLD B-Disease 1 1.0

Down O 0 4.28752537118271e-06
- O 0 8.57428631206858e-07
regulation O 0 5.676708951796172e-07
of O 0 1.1972201718890574e-07
transmembrane O 0 7.654655860278581e-07
carbonic O 0 0.00012920914741698653
anhydrases O 0 0.0013606544816866517
in O 0 2.847544692485826e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 7.347286157255439e-08
by O 0 3.025054207128619e-09
wild O 0 7.212435804149209e-08
- O 0 7.142862159525976e-07
type O 0 4.280514531274093e-06
von B-Disease 1 0.9999992847442627
Hippel I-Disease 1 0.9999916553497314
- I-Disease 0 0.13980969786643982
Lindau I-Disease 0 0.005179521162062883
transgenes O 0 0.0002381572121521458
. O 0 6.4627352003299166e-06

To O 0 2.727104799760127e-07
discover O 0 7.208653585166758e-08
genes O 0 3.761884137531979e-09
involved O 0 5.2786717219532875e-09
in O 0 8.060797362929861e-09
von B-Disease 1 0.9999997615814209
Hippel I-Disease 1 1.0
- I-Disease 1 1.0
Lindau I-Disease 1 0.9999998807907104
( O 0 1.0163969932364125e-07
VHL B-Disease 0 3.6395493225427344e-05
) O 0 7.518592859412365e-09
- O 0 1.5152997434597637e-07
mediated O 0 2.1390515314578806e-07
carcinogenesis O 0 0.0006010978831909597
, O 0 7.14994818906689e-09
we O 0 4.213351001425281e-09
used O 0 2.2584056580399192e-07
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 6.972329060772608e-07
stably O 0 1.1148761132062646e-06
transfected O 0 2.162912693393082e-07
with O 0 3.7185937662442825e-10
wild O 0 4.9206693830683434e-08
- O 0 3.6277415915719757e-07
type O 0 1.4458611303780344e-06
VHL O 0 0.004101851489394903
- O 0 0.00022526271641254425
expressing O 0 8.990137985165347e-07
transgenes O 0 4.126285421079956e-05
. O 0 1.4211921097739832e-06

Large O 0 7.3360411079193e-08
- O 0 5.7325163282939684e-08
scale O 0 3.162567097092506e-08
RNA O 0 4.521992735817548e-08
differential O 0 7.309072458383525e-08
display O 0 4.47352110910515e-09
technology O 0 1.0752074786068988e-07
applied O 0 2.128843732407404e-07
to O 0 2.252742214992054e-09
these O 0 3.2244235059764037e-10
cell O 0 4.856528690311279e-08
lines O 0 3.1886526752344935e-09
identified O 0 7.120633416235478e-09
several O 0 1.0003043948714208e-09
differentially O 0 1.7999467161189386e-07
expressed O 0 9.324965244417172e-10
genes O 0 4.617125848316306e-10
, O 0 3.9643233140651546e-10
including O 0 7.897423270897264e-10
an O 0 3.34873462293217e-10
alpha O 0 1.8532823276018462e-08
carbonic O 0 7.982995953170757e-07
anhydrase O 0 3.3351914225931978e-06
gene O 0 8.6024726897449e-08
, O 0 4.169161726963466e-08
termed O 0 3.242452748963842e-06
CA12 O 0 0.0013448544777929783
. O 0 4.130656634515617e-06

The O 0 5.392106459112256e-07
deduced O 0 1.288554472012038e-07
protein O 0 7.480853159158585e-10
sequence O 0 3.7463440683005444e-10
was O 0 5.501874067448398e-09
classified O 0 3.781177149164705e-09
as O 0 9.653597921044366e-10
a O 0 1.6092562837854985e-09
one O 0 1.0927887483802579e-09
- O 0 3.6655231383520004e-07
pass O 0 3.1185140869638417e-07
transmembrane O 0 6.185566689964617e-07
CA O 0 4.339041879575234e-06
possessing O 0 7.082843467287603e-07
an O 0 1.0035728692514567e-08
apparently O 0 1.628994397151473e-07
intact O 0 1.252547860985942e-07
catalytic O 0 5.1302013304166394e-08
domain O 0 9.999104122471181e-08
in O 0 9.299197856194041e-09
the O 0 1.8785899058570976e-08
extracellular O 0 2.6630908678271226e-07
CA O 0 4.379178790259175e-06
module O 0 6.299086635408457e-06
. O 0 1.014863300952129e-06

Reintroduced O 0 1.1459310371719766e-05
wild O 0 2.586693199191359e-06
- O 0 3.770402145164553e-06
type O 0 9.219003800353676e-07
VHL B-Disease 0 0.000537215149961412
strongly O 0 8.173135057631953e-08
inhibited O 0 9.149147928155799e-08
the O 0 7.855168959736147e-09
overexpression O 0 1.125798121393018e-07
of O 0 1.5590018165312358e-08
the O 0 6.621392767414136e-09
CA12 O 0 3.1044392017065547e-06
gene O 0 2.9413596003280418e-09
in O 0 1.3570591317346725e-09
the O 0 1.7096439819397347e-08
parental O 0 0.3218664228916168
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 9.177160791296046e-06
. O 0 3.1015570129966363e-06

Similar O 0 5.131953173531656e-08
results O 0 8.349973157351087e-09
were O 0 4.214853799311413e-09
obtained O 0 1.5853657941988786e-08
with O 0 4.5220055477912524e-10
CA9 O 0 2.3097738448996097e-05
, O 0 5.082077869644763e-09
encoding O 0 6.540721386727455e-08
another O 0 2.872336857251412e-08
transmembrane O 0 2.2770824159579206e-07
CA O 0 2.6633420020516496e-06
with O 0 1.895711587707183e-09
an O 0 2.02070893351447e-09
intact O 0 9.347427720740598e-08
catalytic O 0 3.18582209501983e-07
domain O 0 1.3581366147263907e-06
. O 0 3.543820241702633e-07

Although O 0 9.047437288245419e-07
both O 0 1.275450145499235e-08
domains O 0 8.611629631616324e-09
of O 0 1.153894046979076e-08
the O 0 5.9505897986866785e-09
VHL B-Disease 0 3.704323262354592e-06
protein O 0 3.4150577921110425e-09
contribute O 0 3.736070564031024e-09
to O 0 2.5804378633864644e-09
regulation O 0 1.81426787548844e-06
of O 0 1.853832259257615e-06
CA12 O 0 0.07199762016534805
expression O 0 1.4001646775341214e-07
, O 0 2.3314448149847067e-09
the O 0 2.1565549346291846e-09
elongin O 0 1.1072371108866719e-07
binding O 0 4.197397096561417e-09
domain O 0 2.2245963293698878e-08
alone O 0 3.2910514313755357e-09
could O 0 8.252263872243759e-10
effectively O 0 9.816348622848636e-09
regulate O 0 1.8986983718605188e-07
CA9 O 0 0.0011179328430444002
expression O 0 1.2675566722464282e-05
. O 0 3.953891337005189e-06

We O 0 3.591757831600262e-06
mapped O 0 6.9289785642467905e-06
CA12 O 0 0.0002995563263539225
and O 0 6.603756332879129e-07
CA9 O 0 0.0009488518116995692
loci O 0 1.2320762152739917e-06
to O 0 6.865923296572873e-08
chromosome O 0 1.5717094470346638e-07
bands O 0 7.147809242269432e-07
15q22 O 0 6.302631845755968e-06
and O 0 4.99274648291248e-08
17q21 O 0 3.7026722566224635e-05
. O 0 4.888731268692936e-07

2 O 0 1.920255044751684e-06
respectively O 0 1.7728494583479915e-07
, O 0 3.5819955890303845e-09
regions O 0 8.890483904622215e-09
prone O 0 5.954169424171596e-08
to O 0 4.4228536388857265e-09
amplification O 0 1.8320808976568514e-06
in O 0 2.236526484011847e-07
some O 0 2.5162778527487717e-08
human O 0 3.579456731017672e-08
cancers B-Disease 0 1.6963480220510974e-06
. O 0 2.1412334660908527e-07

Additional O 0 1.3348697791570885e-07
experiments O 0 4.923560581460151e-08
are O 0 1.6118879841986455e-10
needed O 0 6.614639058710736e-09
to O 0 3.967886297306933e-10
define O 0 1.8616497232670781e-09
the O 0 1.238107616430284e-09
role O 0 1.4312564466933964e-08
of O 0 1.6690185589141038e-07
CA O 0 4.620646450348431e-06
IX O 1 0.758206844329834
and O 0 1.5556860262222472e-06
CA O 0 1.7632750314078294e-05
XII O 0 4.618501043296419e-05
enzymes O 0 3.3983973413143076e-09
in O 0 4.29222568598675e-09
the O 0 3.887989930007052e-09
regulation O 0 9.888060503726592e-08
of O 0 9.645063414609467e-09
pH O 0 7.867361517810423e-08
in O 0 2.4331019421452993e-09
the O 0 2.768310691791953e-09
extracellular O 0 3.0365594483328096e-08
microenvironment O 0 7.020918815214827e-07
and O 0 1.505179092475828e-09
its O 0 2.6311705592085843e-10
potential O 0 1.3770736773111025e-09
impact O 0 2.890450900849828e-08
on O 0 1.6711592820684018e-07
cancer B-Disease 0 6.651051194239699e-07
cell O 0 1.7291520180151565e-06
growth O 0 1.0375018888453269e-07
. O 0 2.798205684939603e-07

A O 0 1.2683005934377434e-06
gene O 0 2.1151508988737078e-08
encoding O 0 7.067702512131291e-08
a O 0 6.245522854442243e-08
transmembrane O 0 3.9161616172123104e-08
protein O 0 6.409929476092202e-09
is O 0 7.756628672694887e-11
mutated O 0 1.2904127766333318e-09
in O 0 7.464291962300251e-10
patients O 0 5.472811892559548e-08
with O 0 2.1230487590173652e-08
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9999998807907104
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 0 6.572964593942743e-06
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 1.4705228146283389e-08
. O 0 1.2578917107930465e-07

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 9.263774813916825e-07
WFS B-Disease 0 0.007216733880341053
; O 0 3.121914815551463e-08
OMIM O 0 2.442216282361187e-05
222300 O 0 7.785274647176266e-07
) O 0 4.222568406042626e-10
is O 0 1.0390688309769303e-10
an O 0 1.1076881634153324e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 2.7128114865604402e-08
by O 0 6.708502503505187e-11
young O 0 1.3835026457797994e-09
- O 0 8.245758209568521e-08
onset O 1 0.9999946355819702
non O 1 0.9999991655349731
- O 0 0.004810252692550421
immune O 0 0.00011422287207096815
insulin B-Disease 1 1.0
- I-Disease 1 1.0
dependent I-Disease 1 1.0
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.20056012272834778
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9983298182487488
. O 0 1.4788571206736378e-05

Linkage O 0 2.5014800485223532e-05
to O 0 4.931718677880781e-08
markers O 0 7.36690353164704e-08
on O 0 2.2367099461462203e-07
chromosome O 0 1.5434103488587425e-06
4p O 0 0.0001413760328432545
was O 0 1.1817767386901323e-07
confirmed O 0 6.25707485824023e-09
in O 0 8.693978870155661e-10
five O 0 1.7332436597072842e-09
families O 0 5.486633924967066e-10
. O 0 1.9767750103483195e-08

On O 0 5.305433319335862e-07
the O 0 3.838759088381494e-09
basis O 0 1.4848941631839807e-08
of O 0 1.065989518878041e-08
meiotic O 0 0.00014425834524445236
recombinants O 1 0.8244368433952332
and O 0 8.622530600632672e-08
disease O 0 3.818187451543054e-06
- O 0 5.483971108333208e-07
associated O 0 1.2166628948762082e-07
haplotypes O 0 1.467263501808702e-07
, O 0 1.4386180025027784e-09
the O 0 4.735526637489329e-09
WFS B-Disease 0 2.512640639906749e-05
gene O 0 4.463498015638834e-09
was O 0 8.236009207962525e-09
localized O 0 3.400830550503997e-08
to O 0 9.524572242014528e-09
a O 0 2.751069132500561e-07
BAC O 1 0.9980192184448242
/ O 0 0.0011253844713792205
P1 O 0 1.967913703992963e-05
contig O 0 1.533218710392248e-05
of O 0 7.066570617553225e-08
less O 0 1.2797316983892415e-08
than O 0 1.5912845485743787e-09
250 O 0 1.0768083313905663e-07
kb O 0 5.8364157666801475e-06
. O 0 9.27353312363266e-07

Mutations O 0 1.1645651198932683e-07
in O 0 2.798838716344676e-09
a O 0 1.1922672848996285e-09
novel O 0 3.746460475184676e-09
gene O 0 2.738366644550183e-09
( O 0 1.170532226701937e-09
WFS1 O 0 3.0526562113664113e-06
) O 0 1.4183634267084244e-09
encoding O 0 2.93403186191199e-08
a O 0 1.6570373517765802e-08
putative O 0 2.4254492814179685e-07
transmembrane O 0 7.85978393480491e-09
protein O 0 6.350734382820633e-10
were O 0 5.006416392561164e-10
found O 0 1.4113893387346366e-10
in O 0 1.986634606820914e-10
all O 0 1.8279720792602205e-10
affected O 0 3.0844810039454273e-10
individuals O 0 7.875875299157009e-12
in O 0 8.86102247132925e-10
six O 0 3.075361121318565e-08
WFS B-Disease 0 0.011800576001405716
families O 0 5.364384492168028e-10
, O 0 4.014321652867636e-10
and O 0 3.0939911743743664e-10
these O 0 1.6316568929308772e-10
mutations O 0 1.2786769421069266e-09
were O 0 3.40930439435283e-09
associated O 0 2.4179751534347815e-08
with O 0 8.968757958527362e-10
the O 0 1.286474571315921e-07
disease O 0 2.974989570247999e-07
phenotype O 0 6.349286962858969e-08
. O 0 1.7380008898726373e-07

WFS1 O 0 0.0007366632926277816
appears O 0 2.606968507734564e-07
to O 0 1.309029884488666e-09
function O 0 7.359593490186e-10
in O 0 1.275821781554498e-09
survival O 0 9.4211456598714e-05
of O 0 7.717607530821624e-08
islet O 0 3.9131307971729257e-07
beta O 0 6.442438120757288e-07
- O 0 9.568582299834816e-07
cells O 0 5.087220245059143e-08
and O 0 4.4633448048614355e-09
neurons O 0 6.663673701723383e-08
. O 0 9.637012965413305e-08
. O 0 7.765823966110474e-07

Stable O 0 1.3437070265354123e-05
interaction O 0 1.680931127623353e-08
between O 0 3.94414084725625e-10
the O 0 3.8584008210662546e-10
products O 0 2.2434161195405977e-09
of O 0 2.4091810768567257e-09
the O 0 9.945368084629536e-09
BRCA1 O 0 1.3569594159434928e-07
and O 0 1.1186681803110332e-07
BRCA2 O 0 1.2164603049313882e-06
tumor B-Disease 0 9.068670010492497e-07
suppressor O 0 8.706048220119555e-07
genes O 0 7.1249806055107e-09
in O 0 4.4099399687524965e-09
mitotic O 0 3.6328864894130675e-07
and O 0 1.0436187380946649e-07
meiotic O 0 4.9814243539003655e-05
cells O 0 4.914698820357444e-06
. O 0 2.2269391592999455e-06

BRCA1 O 0 0.0005030041793361306
and O 0 3.773996013478609e-07
BRCA2 O 0 2.2287090359895956e-06
account O 0 6.306750677254058e-09
for O 0 3.8875277996730517e-10
most O 0 3.1766669156274574e-11
cases O 0 1.5322378782434143e-11
of O 0 1.5702869560207944e-10
familial O 0 5.010946768635449e-09
, O 0 4.2040373959828514e-10
early O 0 3.1439293479706976e-07
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 1.0
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.9191839985287515e-06
encode O 0 5.2686228713128e-09
products O 0 5.691374926897197e-09
that O 0 6.034788641029465e-11
each O 0 1.743952898758394e-11
interact O 0 1.3466339154888374e-10
with O 0 1.6681504788618184e-10
hRAD51 O 0 1.2546393008960877e-06
. O 0 3.938330621622299e-07

Results O 0 3.399722459107579e-07
presented O 0 5.914034062470819e-08
here O 0 2.326027015442378e-08
show O 0 1.0630171409786726e-08
that O 0 1.1085355966500288e-09
BRCA1 O 0 8.128702688736666e-08
and O 0 1.6048492312847884e-08
BRCA2 O 0 1.7429088927656267e-07
coexist O 0 5.583444373513657e-09
in O 0 3.333626485968466e-09
a O 0 2.578224078675362e-09
biochemical O 0 1.6515471656930458e-08
complex O 0 2.6420407195359985e-08
and O 0 1.2497124224353229e-08
colocalize O 0 1.679379965935368e-05
in O 0 6.476194869264873e-08
subnuclear O 0 1.350385991827352e-05
foci O 0 2.5952599571610335e-06
in O 0 9.019884394945166e-09
somatic O 0 1.4325023300898465e-07
cells O 0 1.1297922597464094e-08
and O 0 2.0374240072840166e-09
on O 0 4.4089333073316084e-08
the O 0 2.6494624272288547e-09
axial O 0 6.0034524018703905e-09
elements O 0 1.661471316083407e-08
of O 0 4.350724580604037e-08
developing O 0 1.78091553948434e-07
synaptonemal O 0 1.535589262857684e-06
complexes O 0 1.7536194718559273e-07
. O 0 4.906910930913e-07

Like O 0 7.388048743450781e-06
BRCA1 O 0 7.1787540036893915e-06
and O 0 1.4790859381719201e-07
RAD51 O 0 0.0001691849174676463
, O 0 1.844614700985403e-07
BRCA2 O 0 4.6698636424480355e-07
relocates O 0 1.1611294326030475e-07
to O 0 1.2318896125407264e-08
PCNA O 0 1.0531975931371562e-06
+ O 0 2.0434418601666948e-08
replication O 0 1.2258417614319228e-09
sites O 0 1.5449286294710873e-09
following O 0 1.1715082237628849e-09
exposure O 0 5.500114141909762e-08
of O 0 4.219784965897588e-09
S O 0 4.496328998015997e-08
phase O 0 2.542459398569008e-08
cells O 0 4.170673051362428e-08
to O 0 2.9250024624616344e-08
hydroxyurea O 0 6.819057489337865e-06
or O 0 1.117578420917198e-07
UV O 0 0.00018181224004365504
irradiation O 0 2.7727462565962924e-06
. O 0 7.440332865371602e-07

Thus O 0 1.0869686093428754e-06
, O 0 5.5269410381697526e-08
BRCA1 O 0 2.135138714720597e-07
and O 0 1.2719397091132123e-08
BRCA2 O 0 8.064061063350891e-08
participate O 0 2.150360778330196e-09
, O 0 3.8785144540476324e-10
together O 0 3.424251160399905e-11
, O 0 6.740876606903257e-11
in O 0 1.2235053248321748e-10
a O 0 3.160796901990892e-10
pathway O 0 1.2840464247432237e-09
( O 0 1.8383952693490357e-10
s O 0 4.682276344425418e-09
) O 0 4.172258025181286e-11
associated O 0 3.6930630775700024e-10
with O 0 1.1108225450584541e-11
the O 0 1.7617902969835342e-10
activation O 0 4.861771873976295e-09
of O 0 1.1603601413057163e-09
double O 0 1.518446146597796e-09
- O 0 1.1958253054444867e-08
strand O 0 1.1090183882345173e-08
break O 0 8.228413150845881e-08
repair O 0 2.1749810912297107e-06
and O 0 4.8568804089654805e-08
/ O 0 3.7115371469553793e-06
or O 0 7.856007400164344e-09
homologous O 0 4.915601259369851e-09
recombination O 0 2.4285037980575908e-08
. O 0 2.706811699226819e-07

Dysfunction O 1 0.9998440742492676
of O 0 8.801283684078953e-07
this O 0 6.128983431885615e-10
pathway O 0 2.1430193175575596e-09
may O 0 1.7454013234718957e-10
be O 0 9.954238822107442e-11
a O 0 2.380558250525411e-10
general O 0 1.33563016202487e-09
phenomenon O 0 2.8189721668070433e-09
in O 0 9.049584692721879e-11
the O 0 1.9499345194073925e-10
majority O 0 7.142222143569077e-12
of O 0 1.1075142886118883e-10
cases O 0 3.03549546609716e-11
of O 0 3.3338234395330346e-09
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.121327972621657e-05
. O 0 2.6413135856273584e-06

A O 0 4.2828727941923717e-07
novel O 0 2.10922053156537e-08
Arg362Ser O 0 7.094606644386658e-07
mutation O 0 8.4685786161387e-10
in O 0 5.2140070039286e-10
the O 0 4.436132572394058e-10
sterol O 0 5.1087486241385704e-08
27 O 0 4.1557572671990783e-07
- O 0 1.6567979344017658e-07
hydroxylase O 0 7.727209663244139e-07
gene O 0 8.09809019841623e-09
( O 0 2.0854210025511577e-10
CYP27 O 0 9.984103144233814e-07
) O 0 2.1227875013352104e-10
: O 0 5.16797507565947e-11
its O 0 2.682000108111815e-11
effects O 0 2.7171651595381263e-09
on O 0 1.170557251128912e-08
pre O 0 2.0529904531940701e-07
- O 0 1.4557294036876556e-08
mRNA O 0 6.942985741886787e-09
splicing O 0 3.422623606752495e-08
and O 0 1.767631041538209e-09
enzyme O 0 1.3422726263812024e-09
activity O 0 3.059506070712814e-08
. O 0 6.411620034896259e-08

A O 0 2.579795079782343e-07
novel O 0 3.516086977128907e-08
C O 0 3.6307113759903586e-07
to O 0 7.526795853252111e-10
A O 0 6.377138372926083e-09
mutation O 0 9.90326487482207e-10
in O 0 7.552797276488832e-10
the O 0 2.0368529085601494e-09
sterol O 0 4.750175364165443e-08
27 O 0 6.237552838683769e-07
- O 0 4.435350433595886e-07
hydroxylase O 0 2.1966332042211434e-06
gene O 0 3.591616248854734e-08
( O 0 1.1145291356484677e-09
CYP27 O 0 2.7501141630636994e-06
) O 0 6.553840803391608e-10
was O 0 6.064483581980085e-09
identified O 0 1.6868398899916315e-09
by O 0 1.735856458573437e-10
sequencing O 0 2.9649168453715902e-08
amplified O 0 6.407695991583751e-07
CYP27 O 0 2.60352244367823e-05
gene O 0 8.388716388196826e-09
products O 0 5.6987721208656694e-09
from O 0 7.483165198607367e-10
a O 0 2.2132276011888052e-09
patient O 0 2.1858296506138686e-08
with O 0 9.458416272423165e-10
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 1.2667663895626902e-07
CTX B-Disease 0 0.0001419066684320569
) O 0 3.2995821186432295e-08
. O 0 1.6479354769671772e-07

The O 0 6.484637538051174e-07
mutation O 0 3.087350819441781e-08
changed O 0 6.487952930456231e-08
the O 0 1.266280325040725e-08
adrenodoxin O 0 4.436661811269005e-07
cofactor O 0 6.779321637395697e-08
binding O 0 5.6754831945227124e-09
residue O 0 2.9787246447199323e-08
362Arg O 0 9.141665202605509e-08
to O 0 4.2644074937925325e-09
362Ser O 0 2.536681620313175e-07
( O 0 2.8385576111844557e-09
CGT O 0 5.097273287901771e-07
362Arg O 0 2.746591576396895e-07
to O 0 1.133009863707457e-08
AGT O 0 1.865165904746391e-05
362Ser O 0 1.6523009094271401e-07
) O 0 1.398225285553778e-10
, O 0 1.3107249660637699e-11
and O 0 5.574497894539343e-12
was O 0 1.5184338508777984e-10
responsible O 0 3.150805172325022e-10
for O 0 2.7506785738040662e-09
deficiency O 0 0.00014168655616231263
in O 0 4.692086349677993e-06
the O 0 2.4787091206235345e-06
sterol O 0 9.775337730388856e-07
27 O 0 9.960233455785783e-07
- O 0 8.051858202406947e-08
hydroxylase O 0 1.1964874602199416e-07
activity O 0 2.103113461160433e-09
, O 0 3.75193418000741e-11
as O 0 2.1264415575594775e-11
confirmed O 0 3.714678911692637e-11
by O 0 6.810815800228909e-12
expression O 0 3.759177968909455e-10
of O 0 7.656007494638573e-10
mutant O 0 1.2223512202425013e-09
cDNA O 0 2.650909713963756e-08
into O 0 6.046616096710977e-09
COS O 0 3.03384422295494e-06
- O 0 1.6986759874271229e-06
1 O 0 3.4664188319766254e-07
cells O 0 1.976911505607859e-07
. O 0 4.078841584487236e-07

Quantitative O 0 5.594305548584089e-06
analysis O 0 5.434833383333171e-08
showed O 0 1.2391335957318006e-08
that O 0 4.530066252672604e-11
the O 0 4.07521349998774e-10
expression O 0 1.209959799020055e-09
of O 0 1.310633823692342e-09
CYP27 O 0 5.217126286538587e-08
gene O 0 4.7599264807463015e-11
mRNA O 0 5.156103877190787e-10
in O 0 1.2492995526969253e-09
the O 0 2.8880855484914036e-09
patient O 0 2.0217855833948306e-08
represented O 0 8.567264231373883e-09
52 O 0 8.106715085887117e-07
. O 0 6.391138072103786e-07

5 O 0 7.331802862609038e-07
% O 0 6.685899389680117e-09
of O 0 3.179682295240127e-09
the O 0 1.4433948480885306e-09
normal O 0 3.788940006188568e-08
level O 0 4.1183903931596433e-07
. O 0 3.045893492981122e-07

As O 0 2.333176318813912e-08
the O 0 6.591587831117351e-10
mutation O 0 1.037654753788253e-10
occurred O 0 2.63112032161672e-10
at O 0 2.885281458198108e-10
the O 0 1.1950579414943263e-10
penultimate O 0 1.8014360003704155e-09
nucleotide O 0 2.2539283772715635e-09
of O 0 3.3469291782495247e-09
exon O 0 1.4850187746162646e-08
6 O 0 2.5325475050408386e-08
( O 0 2.2190173309954986e-10
- O 0 8.060982104041159e-09
2 O 0 1.5237707984283588e-08
position O 0 2.7100085731035506e-08
of O 0 4.9828501325066554e-09
exon O 0 1.1470525862478098e-07
6 O 0 3.5052534030910465e-07
- O 0 1.3183109786041314e-06
intron O 0 3.997877229267033e-06
6 O 0 1.9952230445596797e-07
splice O 0 2.4408848275925266e-07
site O 0 2.316022040815824e-08
) O 0 2.0088526675454688e-10
of O 0 4.658027297210765e-10
the O 0 4.19042800459124e-10
gene O 0 1.741913613351187e-09
, O 0 1.0748826273498935e-09
we O 0 2.1012289685984342e-09
hypothesized O 0 5.2642237236000256e-09
that O 0 1.03396430306546e-10
the O 0 8.660133721249963e-10
mutation O 0 1.627862400432889e-09
may O 0 1.277380090591862e-09
partially O 0 1.1083776563225456e-08
affect O 0 7.005222513178921e-10
the O 0 4.009760856682476e-10
normal O 0 4.788430763014162e-10
splicing O 0 2.2975765734400966e-09
efficiency O 0 1.633829249669816e-08
in O 0 7.689553882528344e-09
exon O 0 2.5932956759788794e-07
6 O 0 1.288249791286944e-07
and O 0 1.5693892851942337e-09
cause O 0 1.0391565385958756e-09
alternative O 0 2.1899015933968258e-09
splicing O 0 7.345013042225901e-09
elsewhere O 0 6.413708675268026e-09
, O 0 1.9594641187392625e-10
which O 0 4.283460305204434e-12
resulted O 0 8.141957941187883e-11
in O 0 3.6044719292638305e-11
decreased O 0 9.262232647522239e-10
transcript O 0 5.8644835654320104e-09
in O 0 1.1549857736881108e-09
the O 0 6.682329800611342e-09
patient O 0 1.4304764306416473e-07
. O 0 2.937468366326357e-07

Transfection O 0 4.276333129382692e-05
of O 0 3.1767203267918376e-07
constructed O 0 3.7748666414927357e-08
minigenes O 0 5.78662991301826e-07
, O 0 2.298903845066036e-10
with O 0 4.1133411780858165e-12
or O 0 6.087144677202616e-11
without O 0 7.922875688848308e-10
the O 0 5.853584839066173e-10
mutation O 0 6.974065769327353e-10
, O 0 3.3004413091397566e-10
into O 0 1.5237439088267024e-09
COS O 0 1.9020019408344524e-06
- O 0 2.3830923510104185e-06
1 O 0 1.8001905743858515e-07
cells O 0 1.485693079672501e-08
confirmed O 0 1.7000505447839487e-09
that O 0 3.3950897648793443e-11
the O 0 2.8978117128097836e-10
mutant O 0 1.407361249761152e-08
minigene O 0 1.245177969622091e-07
was O 0 9.797568090164077e-09
responsible O 0 1.3296999057388348e-09
for O 0 2.429131618075786e-10
a O 0 2.1114081316664368e-10
mRNA O 0 1.4085582700218424e-09
species O 0 2.163020110246272e-11
alternatively O 0 2.2275918609704348e-10
spliced O 0 6.97913948854989e-09
at O 0 1.3284989996975582e-08
an O 0 2.324074710458035e-09
activated O 0 4.069527221872704e-06
cryptic O 0 9.886737188935513e-07
5 O 0 7.682183422730304e-08
splice O 0 2.7387918066779093e-07
site O 0 7.152924297315622e-08
88 O 0 6.814713771063907e-08
bp O 0 1.542423788691849e-08
upstream O 0 8.772601534090541e-10
from O 0 2.695967338262051e-10
the O 0 6.934538498981624e-10
3 O 0 6.352227632788754e-09
end O 0 2.1268665051366042e-08
of O 0 1.1902002938768419e-08
exon O 0 2.7169653549208306e-07
6 O 0 8.717563559912378e-07
. O 0 8.793841175247508e-07

Our O 0 3.0459108302238747e-07
data O 0 2.8449115063722274e-08
suggest O 0 8.657441430415247e-10
that O 0 1.6157686300033447e-11
the O 0 1.112415368154096e-10
C O 0 2.938557130960362e-08
to O 0 2.1802189220654355e-10
A O 0 2.5065571840343637e-09
mutation O 0 1.6775152100745316e-10
at O 0 1.304001018276324e-09
the O 0 1.3476854077154599e-09
penultimate O 0 2.8782048744346866e-08
nucleotide O 0 9.71933911131373e-09
of O 0 7.85972442685079e-09
exon O 0 4.395741726170854e-08
6 O 0 7.419402692221411e-08
of O 0 6.464024870922458e-09
the O 0 1.872368482480624e-09
CYP27 O 0 8.737497410038486e-07
gene O 0 1.6232395427806523e-09
not O 0 2.3681404059949784e-10
only O 0 1.9804451134586287e-10
causes O 0 9.852751947647675e-10
the O 0 3.5422633715143093e-09
deficiency B-Disease 0 4.2734967564683757e-07
in I-Disease 0 5.784654533158573e-08
the I-Disease 0 7.564597126474837e-08
sterol I-Disease 0 4.630049943443737e-07
27 I-Disease 0 2.3827424229239114e-06
- I-Disease 0 2.573021049556701e-07
hydroxylase I-Disease 0 3.853881764825928e-07
activity I-Disease 0 5.643982614600418e-09
, O 0 6.471679442343614e-11
but O 0 3.435876583246511e-11
also O 0 1.5804911546180023e-10
partially O 0 4.170949363668797e-09
leads O 0 1.0265638339390648e-10
to O 0 4.0703329595714877e-11
alternative O 0 2.238406793253489e-09
pre O 0 3.5501855677466665e-08
- O 0 2.632748241637728e-09
mRNA O 0 2.42498487956766e-09
splicing O 0 2.3101145885107144e-08
of O 0 5.581357598316572e-09
the O 0 4.037206124962722e-09
gene O 0 1.8290656100816705e-08
. O 0 2.8584503297679476e-07

To O 0 8.876882162667243e-08
our O 0 6.546423403364088e-09
knowledge O 0 4.4668277965342895e-09
, O 0 4.2650296488977446e-11
this O 0 3.1485311319939813e-12
is O 0 2.335936999386945e-12
the O 0 1.5067402187041168e-11
first O 0 3.5888597649247345e-10
report O 0 6.610054170685942e-11
regarding O 0 6.354611836734136e-10
effects O 0 3.7966572108416585e-09
on O 0 4.517499263556601e-09
pre O 0 1.1070866889895115e-08
- O 0 8.264108841693485e-10
mRNA O 0 2.586369174384373e-10
splicing O 0 2.7604545316251006e-09
of O 0 8.949960217385922e-10
a O 0 2.4318852487326126e-10
mutation O 0 7.332379842184267e-11
at O 0 2.2372234620426923e-10
the O 0 1.1013170236884307e-10
- O 0 7.272205060360193e-09
2 O 0 1.687239681302799e-08
position O 0 1.801299376325005e-08
of O 0 5.761341181909074e-09
a O 0 4.329125502522402e-09
5 O 0 6.605753100075162e-08
splice O 0 9.737524351294269e-07
site O 0 5.497376491803152e-07
. O 0 3.1911190490063746e-07

ATM O 0 0.00034749851329252124
germline O 0 6.95871640346013e-05
mutations O 0 1.7351077019611694e-07
in O 0 3.518871238838983e-08
classical O 1 0.999996542930603
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 1.0
in O 0 1.1624895712714078e-08
the O 0 2.5994761898573415e-09
Dutch O 0 1.0211241487922962e-06
population O 0 2.724673542342515e-10
. O 0 4.617480620083825e-09

Germline O 0 0.0003210812574252486
mutations O 0 5.981042363600864e-07
in O 0 1.7852340050694693e-08
the O 0 3.87789489408874e-09
ATM O 0 3.4639006685210916e-07
gene O 0 6.131977148271517e-10
are O 0 3.2550008695342303e-12
responsible O 0 3.490968972230668e-11
for O 0 1.5374465589523822e-10
the O 0 1.1020788406312931e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 7.315819402720081e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.3585339786459372e-07
. O 0 4.08807551366408e-07

In O 0 4.3743472843971176e-08
our O 0 7.62671614751298e-09
study O 0 2.1056019150478278e-09
, O 0 9.650132776206632e-11
we O 0 8.499351916713138e-11
have O 0 1.1359161875001966e-11
determined O 0 1.6883937303813212e-10
the O 0 8.693000763670966e-10
ATM O 0 9.463526112085674e-06
mutation O 0 9.687062707541827e-09
spectrum O 0 6.968697618958686e-09
in O 0 4.865629010808448e-10
19 O 0 1.3662640796496817e-08
classical O 0 7.0549335760006215e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 8.829951525513025e-07
, O 0 4.925594376814502e-10
including O 0 1.3224428496716456e-10
some O 0 7.374044083685583e-12
immigrant O 0 1.0261017729940036e-10
populations O 0 1.7129870438781225e-11
, O 0 1.1217107104277702e-11
as O 0 3.1130324013028954e-11
well O 0 8.009035101785855e-11
as O 0 2.156685385834578e-10
12 O 0 1.7949673969397395e-09
of O 0 1.2310433783468966e-09
Dutch O 0 1.3332298465229542e-07
ethnic O 0 4.4650880215435507e-10
origin O 0 8.60266613500471e-09
. O 0 6.560900800423042e-08

Both O 0 2.3115383385174937e-08
the O 0 2.767286622074039e-09
protein O 0 2.0859977634124505e-10
truncation O 0 5.8074505204785964e-08
test O 0 2.153920775072038e-08
( O 0 3.1197227023938012e-09
PTT O 0 1.272179588340805e-06
) O 0 8.712819909995062e-10
and O 0 3.2789698733992623e-10
the O 0 4.514482399020636e-10
restriction O 0 1.5303532663324404e-08
endonuclease O 0 2.2519706988077814e-07
fingerprinting O 0 9.469288784202945e-07
( O 0 3.386427138707404e-09
REF O 0 3.4387508662803157e-07
) O 0 1.2239066704555768e-10
method O 0 1.1566655411243687e-09
were O 0 6.267630303646854e-10
used O 0 7.032358029235297e-10
and O 0 1.2540760097046189e-10
compared O 0 1.990245190874873e-10
for O 0 5.368505986980132e-11
their O 0 4.423541047349211e-11
detection O 0 8.634721382350108e-09
efficiency O 0 7.623822462221597e-09
, O 0 6.104623473390802e-10
identifying O 0 1.1739581751157857e-08
76 O 0 5.323283502889353e-08
% O 0 3.236666767936214e-10
and O 0 6.993510631714273e-11
60 O 0 2.9308313553855214e-09
% O 0 1.5014965659698731e-10
of O 0 5.838364236510074e-10
the O 0 7.733499396422872e-10
mutations O 0 1.7076029479312638e-09
, O 0 3.703165551982579e-09
respectively O 0 1.1208360461978373e-07
. O 0 6.459577548412199e-07

Most O 0 2.8585540690073685e-07
patients O 0 4.1044152965241665e-08
were O 0 6.465997515192612e-09
found O 0 9.820800839221988e-10
to O 0 1.3526556541521018e-09
be O 0 7.0540435714860905e-09
compound O 0 9.630790600567707e-07
heterozygote O 0 7.517859557992779e-06
. O 0 9.557310249874718e-07

Seventeen O 0 6.635246336372802e-06
mutations O 0 6.629053217466208e-08
were O 0 4.194044223027049e-09
distinct O 0 5.672319836058648e-10
, O 0 2.784115438192458e-10
of O 0 1.8643279975361082e-10
which O 0 8.673928762747973e-12
10 O 0 2.3949087157859594e-10
were O 0 3.64723279355772e-10
not O 0 4.330097669313915e-10
reported O 0 6.952566966589302e-09
previously O 0 4.802750908083908e-08
. O 0 2.4121024466694507e-07

Mutations O 0 3.695050963870017e-06
are O 0 9.551841984034581e-09
small O 0 2.1339614519888528e-08
deletions O 0 5.312882876751246e-06
or O 0 1.338175252385554e-06
point O 0 2.513501385692507e-06
mutations O 0 3.144732474424927e-08
frequently O 0 1.2599969956283985e-08
affecting O 0 1.1911631681016388e-08
splice O 0 5.612413929156901e-07
sites O 0 2.0698973912658403e-07
. O 0 2.2740313454505667e-07

Moreover O 0 5.987560030007444e-07
, O 0 1.519191528132069e-08
a O 0 2.0632393571418106e-08
16 O 0 4.5456960151568637e-07
. O 0 2.847884559287195e-07

7 O 0 5.529489044420188e-06
- O 0 1.681998014646524e-06
kb O 0 3.623375050665345e-06
genomic O 0 3.1179371262624045e-07
deletion O 0 1.6825966042688378e-07
of O 0 1.2447239683410771e-08
the O 0 1.7505966676267803e-09
3 O 0 1.4499433653725191e-08
end O 0 8.266604289985935e-09
of O 0 1.270455185498065e-09
the O 0 2.4792540243012695e-10
gene O 0 2.0266871514351692e-10
, O 0 7.605311519442992e-11
most O 0 1.4307220339015991e-11
likely O 0 1.811558264508406e-10
a O 0 1.75759157228228e-10
result O 0 2.455015357671897e-10
of O 0 8.42372949172443e-10
recombination O 0 2.692585876484799e-10
between O 0 1.695528994982709e-10
two O 0 2.788776432005591e-10
LINE O 0 7.419809655573317e-09
elements O 0 1.45922007810384e-09
, O 0 6.975249822183116e-10
was O 0 8.64022364766015e-09
identified O 0 3.622789890300737e-08
. O 0 2.1788166293390532e-07

The O 0 2.3215422118028073e-07
most O 0 1.3356225014860001e-09
frequently O 0 3.801945147596797e-10
found O 0 6.745686648157445e-11
mutation O 0 4.6281801308056814e-11
, O 0 1.2702213413040564e-11
identified O 0 1.752837736068713e-10
in O 0 2.445537106154916e-10
three O 0 8.155744829485556e-11
unrelated O 0 8.581487742631566e-10
Turkish O 0 8.27364274869069e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
individuals O 0 1.0379892778633604e-10
, O 0 2.963521442134187e-11
was O 0 5.786756629433398e-10
previously O 0 5.621880183603878e-10
described O 0 1.0512288262098934e-10
to O 0 2.2146019393320948e-11
be O 0 5.156051974264386e-11
a O 0 3.2130717531053676e-10
Turkish O 0 1.671659646262924e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
founder O 0 1.1611594345595222e-05
mutation O 0 1.7294476606366516e-07
. O 0 1.1314597259115544e-07

The O 0 1.714768842475678e-07
presence O 0 1.718972519881845e-08
of O 0 1.670677107767915e-08
a O 0 1.632253088246216e-08
founder O 0 6.545589030793053e-07
mutation O 0 1.9352675906247896e-08
among O 0 1.2028100737637715e-10
relatively O 0 2.9653943189877907e-10
small O 0 6.258071144626953e-11
ethnic O 0 7.266509009090649e-12
population O 0 1.2176281033796088e-12
groups O 0 1.2139733662763774e-12
in O 0 1.765594268010595e-11
Western O 0 1.2524446368900044e-08
Europe O 0 2.4670674392268666e-08
could O 0 2.759517281347712e-09
indicate O 0 3.4380629454489053e-09
a O 0 7.660594381064811e-10
high O 0 2.457433811997589e-09
carrier O 0 9.364570230374625e-10
frequency O 0 2.2936285759556085e-08
in O 0 9.96391302798827e-10
such O 0 1.648462144565599e-09
communities O 0 2.2290083112608272e-09
. O 0 1.1258271825909105e-07

In O 0 5.68456499649983e-08
patients O 0 1.5175841028280956e-08
of O 0 1.6291263893464247e-09
Dutch O 0 3.250069937621447e-07
ethnic O 0 2.622187744716342e-10
origin O 0 1.3502841067492e-09
, O 0 1.0504231512387108e-10
however O 0 1.6788659351618662e-10
, O 0 2.2553980905115623e-10
no O 0 1.2160980000786026e-09
significant O 0 2.0596209182599523e-09
founder O 0 3.1275469325464655e-08
effect O 0 7.774426435958048e-09
could O 0 3.090961042673257e-09
be O 0 2.825485623247914e-09
identified O 0 6.756976489441513e-08
. O 0 4.671422288993199e-07

The O 0 2.8158521558907523e-07
observed O 0 4.995585101141842e-08
genetic O 0 7.992425388181346e-09
heterogeneity O 0 1.2330908738533708e-08
including O 0 5.427845395367115e-10
the O 0 1.0838979713767571e-09
relative O 0 1.3002347998281039e-07
high O 0 2.2041758995783312e-07
percentage O 0 4.789477259237174e-08
of O 0 7.933889101252589e-09
splice O 0 9.323992458121211e-07
- O 0 3.734177880687639e-06
site O 0 1.4691538297029183e-07
mutations O 0 1.2865795540051295e-08
had O 0 1.2740010824074943e-08
no O 0 5.8881659548148946e-09
reflection O 0 1.322451570473504e-08
on O 0 3.456448993688355e-08
the O 0 7.065947826845331e-09
phenotype O 0 8.576488852440889e-08
. O 0 2.8665036211350525e-07

All O 0 4.1962145758134284e-08
patients O 0 2.481057359560168e-09
manifested O 0 1.8036466764570491e-09
classical O 0 6.049895091564395e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
and O 0 2.696150716019474e-07
increased O 0 1.048923536473012e-06
cellular O 0 4.4074283778172685e-07
radioresistant O 0 5.499148869603232e-07
DNA O 0 3.146460159086928e-08
synthesis O 0 7.275467623912846e-07
. O 0 4.688077979153604e-07

Determination O 0 2.3523607524111867e-06
of O 0 1.8698929693528044e-07
the O 0 3.3714362412951004e-09
genomic O 0 7.601852480831894e-09
structure O 0 1.8721149075417998e-09
of O 0 3.6921281587609656e-09
the O 0 1.4198033859713632e-09
COL4A4 O 0 1.2050799114149413e-06
gene O 0 9.039307080627168e-10
and O 0 5.557241333775664e-10
of O 0 3.1138551737086573e-09
novel O 0 2.851310831886167e-08
mutations O 0 3.1653164000999823e-07
causing O 0 1.3990825209475588e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 9.516894351691008e-05

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.8926090916693283e-08
a O 0 1.2301473617526426e-08
progressive O 0 0.00018478298443369567
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.09076894819736481
by O 0 1.0273821260398108e-07
glomerular B-Disease 1 0.9999349117279053
basement I-Disease 1 1.0
membrane I-Disease 1 0.9999995231628418
abnormalities I-Disease 1 0.9994342923164368
and O 0 5.368727240551152e-09
associated O 0 4.858177931055252e-07
with O 0 1.0696143970534422e-09
mutations O 0 2.1850738995965457e-09
in O 0 8.377379678847774e-09
either O 0 1.0857441168354853e-08
the O 0 2.7901201349322946e-08
COL4A3 O 0 2.3143074940890074e-05
or O 0 8.029248377283693e-09
the O 0 6.975759081484512e-09
COL4A4 O 0 2.3586371753481217e-06
gene O 0 3.910762824688163e-09
, O 0 4.3665654425595335e-10
which O 0 6.195363666527953e-11
encode O 0 3.3244131891763118e-09
the O 0 8.441199739195326e-09
alpha3 O 0 9.589790352038108e-06
and O 0 6.538240171494181e-08
alpha4 O 0 0.0002489736652933061
type O 0 9.80244149104692e-05
IV O 1 1.0
collagen O 0 5.29145218024496e-05
chains O 0 2.4975877295219107e-06
, O 0 1.7889732362164068e-08
respectively O 0 1.225971431040307e-07
. O 0 1.263436359977277e-07

To O 0 5.461685148588913e-08
date O 0 8.455609901147909e-08
, O 0 1.2427637807732594e-09
mutation O 0 1.1428274993008358e-10
screening O 0 1.3404561904906132e-09
in O 0 1.4419859750702813e-09
the O 0 8.304611220921743e-09
two O 0 1.2442200603146603e-09
genes O 0 1.6404388958335403e-09
has O 0 1.4575783635617512e-10
been O 0 8.075485419256623e-11
hampered O 0 5.990710150172163e-09
by O 0 2.1930018911930915e-10
the O 0 5.5574984614281675e-09
lack O 0 4.253589480640585e-08
of O 0 5.181116424779475e-09
genomic O 0 4.3369277058502576e-09
structure O 0 2.8635174231794736e-09
information O 0 4.28280699793504e-08
. O 0 1.580623063546227e-07

We O 0 1.227590615826557e-07
report O 0 2.7307098804385532e-09
here O 0 1.1136196409466947e-09
the O 0 3.351456889788551e-10
complete O 0 1.4667319581107563e-09
characterization O 0 2.1384667370227817e-09
of O 0 1.4641688972361067e-09
the O 0 7.305580584926474e-10
48 O 0 3.066914189275849e-08
exons O 0 2.2392663723280748e-08
of O 0 5.619588794303354e-09
the O 0 6.012115250086936e-09
COL4A4 O 0 1.3379531083046459e-05
gene O 0 1.3745080629234963e-08
, O 0 2.8399331775119663e-09
a O 0 2.1137542827176503e-09
comprehensive O 0 3.346643495660828e-08
gene O 0 1.6462690100027544e-09
screen O 0 5.0844821686268915e-09
, O 0 9.715905857632379e-10
and O 0 4.208883241929584e-10
the O 0 3.4591954300999816e-10
subsequent O 0 6.128341167865869e-10
detection O 0 8.188594691205253e-09
of O 0 5.236860944890509e-10
10 O 0 6.476930103360701e-10
novel O 0 5.133122815692559e-10
mutations O 0 3.7099934235840237e-10
in O 0 2.101921414698893e-10
eight O 0 6.357209425544852e-09
patients O 0 1.6954659898260616e-08
diagnosed O 0 7.44476835734531e-07
with O 0 5.5810623678098636e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 4.357201396487653e-05

Furthermore O 0 8.521861332155822e-07
, O 0 1.3765387052444567e-08
we O 0 2.436970847341513e-09
identified O 0 5.6641926704514844e-09
a O 0 2.37817232573434e-09
glycine O 0 3.8763218412896094e-08
to O 0 1.0875597311610363e-08
alanine O 0 1.2629341483716416e-07
substitution O 0 4.5418221361614997e-07
in O 0 1.2810021132736438e-07
the O 0 8.850356181255847e-08
collagenous O 0 1.478447302361019e-06
domain O 0 3.712486762452727e-09
that O 0 7.993053267874028e-12
is O 0 3.5325286532744693e-12
apparently O 0 4.792899410688278e-10
silent O 0 2.28289076531496e-09
in O 0 6.095989824039805e-10
the O 0 8.109679039414175e-10
heterozygous O 0 6.152432452388723e-10
carriers O 0 5.742446518297584e-10
, O 0 2.8065669233079404e-10
in O 0 2.1322026366732416e-09
11 O 0 1.6305268957239605e-07
. O 0 3.1027056479615567e-07

5 O 0 1.3830227771904902e-06
% O 0 1.0752891910215112e-08
of O 0 4.663327946019535e-09
all O 0 4.030725198056473e-10
control O 0 3.96449939543686e-09
individuals O 0 2.6555563303887197e-11
, O 0 7.906900134635464e-11
and O 0 2.0443792492219615e-10
in O 0 2.172358071206304e-09
one O 0 5.844492112494493e-10
control O 0 7.877163810121601e-09
individual O 0 6.639803151742285e-10
homozygous O 0 7.329045370596532e-09
for O 0 1.3218508509993399e-09
this O 0 2.0607133777161835e-09
glycine O 0 7.686170278020654e-08
substitution O 0 6.452694378822343e-07
. O 0 1.5799056427567848e-06

There O 0 1.824731441502081e-07
has O 0 1.2314120834133746e-09
been O 0 2.988726488517557e-10
no O 0 2.39653991096489e-10
previous O 0 5.439391159711704e-10
finding O 0 4.516439666701899e-09
of O 0 2.269449517200428e-09
a O 0 7.243200483841861e-10
glycine O 0 8.348062685570312e-09
substitution O 0 1.0611092449153148e-07
that O 0 5.066512209772611e-10
is O 0 9.1288629433528e-11
not O 0 9.703732956056754e-11
associated O 0 8.027345455019486e-10
with O 0 9.184243643378665e-11
any O 0 3.0116862337337125e-09
obvious O 0 2.1414148676512923e-08
phenotype O 0 1.1407750299952113e-08
in O 0 3.3316431835572757e-09
homozygous O 0 3.6793423419112514e-08
individuals O 0 2.1444710451845594e-09
. O 0 1.7622534187466954e-07

Founder O 0 0.0001414511352777481
BRCA1 O 0 4.814546173292911e-06
and O 0 7.704326776547532e-08
BRCA2 O 0 2.0867088323939242e-07
mutations O 0 1.6105704547797473e-09
in O 0 2.9761562103658434e-09
French O 0 9.648279956309125e-06
Canadian O 0 0.08001140505075455
breast B-Disease 1 1.0
and I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.221689894417068e-06
. O 0 1.358517465632758e-06

We O 0 5.848802686614363e-08
have O 0 7.778011013037656e-10
identified O 0 1.2461509601990883e-09
four O 0 9.73114505642414e-11
mutations O 0 3.453649519147284e-11
in O 0 7.971923815519588e-11
each O 0 3.021089628463258e-11
of O 0 2.1080370782300406e-09
the O 0 3.610952603594342e-07
breast B-Disease 1 1.0
cancer I-Disease 1 0.9998973608016968
- O 0 0.4157729744911194
susceptibility O 0 4.721406185126398e-06
genes O 0 3.9538385010473576e-08
, O 0 4.433294975569879e-08
BRCA1 O 0 2.0674038125889638e-07
and O 0 4.334018655072214e-08
BRCA2 O 0 1.233340611861422e-07
, O 0 6.732784330054642e-10
in O 0 4.85935014449268e-10
French O 0 3.036785756194149e-07
Canadian O 0 9.95073946796765e-07
breast B-Disease 0 1.5002167856437154e-05
cancer I-Disease 0 8.887874400897999e-07
and O 0 0.032019585371017456
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.3068086818511802e-07
from O 0 2.6973536293439793e-08
Quebec O 0 1.0691966281228815e-06
. O 0 5.768270625594596e-07

To O 0 4.548909373625065e-07
identify O 0 1.2649616110138595e-07
founder O 0 8.964419180301775e-07
effects O 0 2.988837422890356e-06
, O 0 1.0477169354317084e-08
we O 0 8.64167404301952e-09
examined O 0 2.2318978665225586e-08
independently O 0 1.0541814532416538e-08
ascertained O 0 5.283474706629931e-07
French O 0 1.5158561836869922e-06
Canadian O 0 5.008112111681839e-07
cancer B-Disease 0 2.442151014747651e-08
families O 0 4.848034126925249e-11
for O 0 2.5096353814535455e-11
the O 0 3.9127291684426524e-11
distribution O 0 3.1895028285156e-10
of O 0 8.774777016107294e-10
these O 0 4.328041813828065e-10
eight O 0 9.987759952423403e-09
mutations O 0 3.6595984909126855e-08
. O 0 6.456756977968325e-07

Mutations O 0 3.1428260172106093e-07
were O 0 2.510836161206953e-08
found O 0 1.7661079265707258e-09
in O 0 8.353234215441319e-10
41 O 0 2.409467292352474e-08
of O 0 1.1996472260022983e-08
97 O 0 1.7752175835994422e-06
families O 0 5.9826485987457545e-09
. O 0 1.8188261208251788e-07

Six O 0 4.659746934976283e-07
of O 0 1.8901200604659607e-08
eight O 0 3.5801925868383933e-09
mutations O 0 5.204776609701867e-10
were O 0 1.7362083992722432e-09
observed O 0 1.425855211678595e-09
at O 0 6.374937466802066e-09
least O 0 2.4689017497081522e-09
twice O 0 1.5220917859437577e-08
. O 0 1.0542824213644053e-07

The O 0 3.6107983305555535e-06
BRCA1 O 0 7.633648237970192e-06
C4446T O 0 5.059843260823982e-06
mutation O 0 2.2446927872010747e-08
was O 0 2.2736273308510135e-08
the O 0 1.7702764809612859e-09
most O 0 1.314521130835189e-10
common O 0 2.947108390660702e-10
mutation O 0 2.0769062858416731e-10
found O 0 2.5737993333829756e-11
, O 0 3.589884986499037e-11
followed O 0 4.713617829388284e-10
by O 0 3.329018172237852e-10
the O 0 2.7756190235095346e-08
BRCA2 O 0 6.723216756654438e-07
8765delAG O 0 8.621031497568765e-07
mutation O 0 5.0896272085765304e-08
. O 0 1.203955974915516e-07

Together O 0 2.5763968736214338e-08
, O 0 2.000281718039787e-09
these O 0 2.546556715499193e-11
mutations O 0 9.643711523787957e-11
were O 0 9.734672096195496e-11
found O 0 4.782577806006216e-11
in O 0 2.0209431350615148e-10
28 O 0 3.4534373583028355e-08
of O 0 3.9119938399778675e-09
41 O 0 8.305562460009241e-09
families O 0 4.844336737308552e-11
identified O 0 3.743729493077552e-10
to O 0 9.47372735815577e-10
have O 0 2.9332190010222803e-09
a O 0 4.236173722915737e-08
mutation O 0 1.0796134830570736e-07
. O 0 7.269003958754183e-07

The O 0 2.1994620169607515e-07
odds O 0 2.158852936418043e-07
of O 0 2.9337898777015425e-09
detection O 0 2.75905136959409e-07
of O 0 4.63505767100969e-09
any O 0 4.6835063605144e-10
of O 0 4.843621059791303e-09
the O 0 5.4908455560109815e-09
four O 0 1.1568648261572889e-08
BRCA1 O 0 3.5276340071277446e-08
mutations O 0 3.668213288676725e-09
was O 0 1.4779580226331746e-07
18 O 0 5.438700441118272e-07
. O 0 9.970782457457972e-07

7x O 0 0.0005172877572476864
greater O 0 2.603115376587084e-07
if O 0 3.5874860859763658e-09
one O 0 3.004742010759287e-10
or O 0 8.307977916732767e-11
more O 0 2.737934228294603e-12
cases O 0 3.117839666999522e-11
of O 0 4.498233252547834e-08
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 8.073615390458144e-06
also O 0 3.6929099778149066e-09
present O 0 1.2632490886677061e-10
in O 0 9.62603774468107e-10
the O 0 9.103694686984909e-09
family O 0 2.5660291669282742e-08
. O 0 1.2429534024249733e-07

The O 0 2.4608715420981753e-07
odds O 0 3.1062998573361256e-07
of O 0 4.539290721083944e-09
detection O 0 2.2709366476192372e-07
of O 0 5.190691432233052e-09
any O 0 5.803225677780688e-10
of O 0 4.291341504369939e-09
the O 0 5.830877558565817e-09
four O 0 1.1042543768269297e-08
BRCA2 O 0 7.745197194708453e-08
mutations O 0 2.4875539406110647e-09
was O 0 7.537549606695393e-08
5 O 0 1.1409368880777038e-06
. O 0 1.4470778069153312e-06

3x O 0 0.0005640496383421123
greater O 0 1.5551920284906373e-07
if O 0 1.1211812589451142e-09
there O 0 1.0441308928577087e-10
were O 0 5.895378074605162e-10
at O 0 1.2013067207661265e-09
least O 0 1.1800992127941612e-10
five O 0 2.40224090619634e-11
cases O 0 2.4882821497707042e-11
of O 0 1.2342360466988112e-09
breast B-Disease 0 4.267118129064329e-05
cancer I-Disease 0 8.399460966757033e-07
in O 0 2.7541562985788914e-07
the O 0 2.1892610675422475e-06
family O 0 3.6193236496728787e-07
. O 0 1.5447606074303621e-06

Interestingly O 0 6.974836423978559e-07
, O 0 1.9408299412049246e-09
the O 0 3.333046338926948e-10
presence O 0 7.129463130972624e-10
of O 0 3.2821372286662154e-09
a O 0 3.9324191902778693e-08
breast B-Disease 1 0.9803445339202881
cancer I-Disease 0 1.5848185284994543e-05
case O 0 1.733317311902738e-08
< O 0 2.9715745313296793e-06
36 O 0 5.146764792129943e-08
years O 0 2.077858329840865e-09
of O 0 1.3842945678632645e-09
age O 0 1.80377746072935e-09
was O 0 2.227584339209443e-09
strongly O 0 9.069300865860441e-11
predictive O 0 1.5301920841537253e-09
of O 0 1.0403742312092845e-09
the O 0 5.443230310930858e-10
presence O 0 8.52234283144071e-10
of O 0 6.849018019394748e-10
any O 0 3.628553846279914e-10
of O 0 1.2589705944421326e-09
the O 0 1.8142631841300272e-09
eight O 0 2.837215129503079e-09
mutations O 0 1.1549151635037447e-09
screened O 0 1.2852751751779579e-07
. O 0 1.3542912711272947e-06

Carriers O 0 5.360544150789792e-07
of O 0 1.994099996238674e-08
the O 0 1.4913678070271885e-09
same O 0 3.377536306192752e-10
mutation O 0 3.8429037729770243e-10
, O 0 5.59196543237217e-11
from O 0 6.071641800442507e-11
different O 0 1.042721464727947e-11
families O 0 4.0703093673322144e-11
, O 0 8.004270857231433e-11
shared O 0 3.092569256235578e-10
similar O 0 1.7189151491070476e-10
haplotypes O 0 1.898364665464669e-08
, O 0 1.20584287000014e-09
indicating O 0 1.801429938552701e-08
that O 0 1.4159001748836886e-10
the O 0 5.136521208370937e-10
mutant O 0 7.000404256274351e-09
alleles O 0 3.0958918761925247e-10
were O 0 4.994217817078095e-10
likely O 0 5.275095915635575e-10
to O 0 8.718351041103745e-11
be O 0 3.8872662033728744e-11
identical O 0 4.712060602818369e-11
by O 0 1.5019827395712504e-11
descent O 0 1.4397955050426958e-09
for O 0 1.4171593065714916e-10
a O 0 2.224356532298799e-10
mutation O 0 9.622507651796397e-11
in O 0 4.3465975263501377e-10
the O 0 3.706628337596385e-09
founder O 0 2.708895578962256e-07
population O 0 3.055764252746229e-10
. O 0 1.592263032534902e-08

The O 0 6.952118525305195e-08
identification O 0 1.6545463665806892e-07
of O 0 7.481788344421147e-08
common O 0 3.973745492658054e-07
BRCA1 O 0 3.5101013509120094e-06
and O 0 1.856070639405516e-07
BRCA2 O 0 6.098065910009609e-07
mutations O 0 8.457666789141172e-10
will O 0 2.064307891291861e-10
facilitate O 0 3.3216498440680198e-09
carrier O 0 4.749699522577089e-10
detection O 0 1.5489893812059563e-08
in O 0 1.8346550945125273e-09
French O 0 4.048481059726328e-06
Canadian O 0 1.4406541595235467e-05
breast B-Disease 0 0.0007119261426851153
cancer I-Disease 0 2.1583887246379163e-06
and O 0 0.0006791551131755114
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.9128106032439973e-06
. O 0 2.3892503122624476e-06

Are O 0 6.797299647587352e-07
Dp71 O 0 0.00011862836254294962
and O 0 2.7437903327154345e-07
Dp140 O 0 0.00024338897492270917
brain O 0 6.242404197109863e-05
dystrophin O 0 1.7363370261591626e-06
isoforms O 0 1.054688709700713e-07
related O 0 6.026847643170186e-08
to O 0 3.967631112544723e-09
cognitive B-Disease 0 3.519047140798648e-06
impairment I-Disease 0 0.013808046467602253
in O 0 0.00014354661107063293
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.9999943971633911

Molecular O 0 3.1222148209053557e-06
study O 0 8.144144914012941e-08
and O 0 2.968593371122097e-09
neuropsychological O 0 9.25434733289876e-08
analysis O 0 4.229002481537236e-09
were O 0 1.8928210110402688e-09
performed O 0 1.2253204006995588e-09
concurrently O 0 2.725797365599192e-09
on O 0 8.486110480987463e-09
49 O 0 8.598171064022608e-09
patients O 0 2.6972852840145833e-09
with O 0 8.462414768928284e-09
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.5985786376404576e-05
DMD B-Disease 1 1.0
) O 0 3.45648665245335e-09
in O 0 8.80619743792721e-10
order O 0 1.0366898450797635e-09
to O 0 3.5129665842958957e-10
find O 0 6.471126967610985e-10
a O 0 1.7214184244718211e-10
molecular O 0 1.3639460672010273e-09
explanation O 0 3.071812804122942e-09
for O 0 6.332143698273285e-10
the O 0 4.769492356615501e-09
cognitive B-Disease 0 1.368337052554125e-06
impairment I-Disease 0 2.5799624836508883e-07
observed O 0 3.361112055344506e-09
in O 0 4.4526138331946186e-09
most O 0 3.298443473909174e-08
DMD B-Disease 1 1.0
patients O 0 6.500216841232032e-06
. O 0 4.078452775502228e-07

Complete O 0 1.0515771720065459e-07
analysis O 0 1.6733592289597254e-08
of O 0 4.420483534772757e-09
the O 0 1.617358247330003e-09
dystrophin O 0 5.2569617992048734e-08
gene O 0 4.6723731550457615e-09
was O 0 1.7450203060320746e-08
performed O 0 9.746090157136678e-09
to O 0 2.4980475465952168e-09
define O 0 1.0924933846467866e-08
the O 0 1.252860393208266e-08
localization O 0 2.0409494027262554e-05
of O 0 3.617639663389127e-07
deletions O 0 4.1441174403189507e-07
and O 0 1.44927705392206e-08
duplications O 0 7.110239863550305e-08
in O 0 3.3756186734734683e-09
relation O 0 4.433132083647706e-09
to O 0 8.058856360015909e-10
the O 0 2.3971766793806637e-09
different O 0 1.6536716884729685e-08
DMD B-Disease 1 1.0
promoters O 0 6.289831071626395e-05
. O 0 5.8247442211722955e-06

Qualitative O 0 5.0859189286711626e-06
analysis O 0 1.1288029355682738e-07
of O 0 2.522298636620235e-08
the O 0 7.018185144147537e-09
Dp71 O 0 3.234422820241889e-06
transcript O 0 1.7594490486771974e-07
and O 0 9.481772034192204e-10
testing O 0 1.415630945800217e-09
for O 0 7.451627509480474e-11
the O 0 6.442133632100777e-11
specific O 0 3.4060401721269784e-10
first O 0 2.7165691918185075e-09
exon O 0 3.735174658459073e-08
of O 0 1.1816839062817053e-08
Dp140 O 0 1.7975365835809498e-06
were O 0 1.9008284724009172e-08
also O 0 1.6538412861422103e-09
carried O 0 5.752073928277923e-09
out O 0 4.703597067390319e-09
. O 0 1.1725196458201026e-07

Neuropsychological O 0 5.125857933307998e-05
analysis O 0 1.8684917790778854e-07
assessed O 0 5.75231752009131e-07
verbal O 0 4.270213196377881e-07
and O 0 2.696643797150955e-08
visuospatial O 0 7.49925384297967e-05
intelligence O 0 1.3790295270155184e-06
, O 0 7.89467158313073e-09
verbal O 0 3.043279406256261e-08
memory O 0 6.169653943288722e-07
, O 0 5.0671911111521695e-09
and O 0 3.2919051928814724e-09
reading O 0 8.275250706901716e-07
skills O 0 1.351386890746653e-05
. O 0 1.4666119341200101e-06

Comparison O 0 1.5922620377750718e-06
of O 0 1.0374800751833391e-07
molecular O 0 1.632326984690735e-07
and O 0 1.2773831770118704e-08
psychometric O 0 1.3737679182668217e-05
findings O 0 1.7569372801062855e-07
demonstrated O 0 1.238351927668191e-07
that O 0 1.9362635939046413e-09
deletions O 0 8.694136255371632e-08
and O 0 6.388229056852879e-09
duplications O 0 3.949165616745631e-08
that O 0 1.7944974672889913e-10
were O 0 1.36592992472373e-09
localized O 0 4.4566075274588e-09
in O 0 7.548188740713613e-10
the O 0 1.3326705294858243e-09
distal O 0 3.189463271269233e-08
part O 0 7.920371913883173e-09
of O 0 1.819615391696061e-07
the O 0 5.0659860306723203e-08
gene O 0 1.8592233530512203e-08
seemed O 0 9.588060123633113e-08
to O 0 2.6280821963098333e-09
be O 0 1.4694706562679016e-09
preferentially O 0 6.097155669237964e-09
associated O 0 4.869393421813584e-08
with O 0 4.6129913222614505e-09
cognitive B-Disease 0 0.001064301817677915
impairment I-Disease 0 0.0069595626555383205
. O 0 4.6650925469293725e-06

Two O 0 1.448830033723425e-07
altered O 0 4.1867892264235707e-07
Dp71 O 0 1.1543602340680081e-05
transcripts O 0 6.13149154560233e-07
and O 0 6.188295653686282e-09
two O 0 1.1224137175247506e-09
deleted O 0 2.625278128220998e-08
Dp140 O 0 1.190121352578899e-07
DNA O 0 8.30193080947339e-10
sequences O 0 6.856896300755366e-11
were O 0 3.1599289851413914e-10
found O 0 1.1068385791235258e-10
in O 0 2.2513665931533922e-10
four O 0 5.821673698669372e-10
patients O 0 7.659250456093503e-10
with O 0 1.8583670713390177e-10
severe O 0 3.104555435129441e-05
cerebral B-Disease 1 0.9999983310699463
dysfunction I-Disease 1 0.9997633099555969
. O 0 8.946604793891311e-05

These O 0 2.1228913738013944e-07
findings O 0 8.952204666456964e-08
suggest O 0 1.3393425923879931e-08
that O 0 1.8951176739001596e-10
some O 0 5.8189508767014786e-11
sequences O 0 6.077550962491074e-11
located O 0 5.548366210916811e-10
in O 0 3.180038732342183e-10
the O 0 1.8911754384731694e-09
distal O 0 5.043877848720513e-08
part O 0 1.614532862959095e-08
of O 0 5.516840673180923e-08
the O 0 3.1432796365749027e-09
gene O 0 3.995850317295435e-10
and O 0 5.943894265669769e-10
, O 0 3.680714621978609e-10
in O 0 5.274632952634306e-10
particular O 0 2.8538882368422946e-09
, O 0 6.779018457692132e-10
some O 0 9.87772197369452e-10
DMD B-Disease 1 1.0
isoforms O 0 1.0187532240024666e-07
expressed O 0 3.907303369743431e-09
in O 0 2.4514461571811808e-09
the O 0 1.7110924233065816e-08
brain O 0 5.9269800658512395e-06
may O 0 2.693927969588117e-09
be O 0 3.0517685600806033e-10
related O 0 1.4272837356443802e-09
to O 0 1.199760957248941e-09
the O 0 5.804889458005391e-09
cognitive B-Disease 0 7.959110916999634e-06
impairment I-Disease 0 1.2712785064650234e-06
associated O 0 1.0785699799953363e-07
with O 0 1.2870434495937388e-08
DMD B-Disease 1 1.0
. O 0 3.537327529556933e-06
. O 0 8.624920724287222e-07

I1307K O 0 0.00013341568410396576
APC O 0 6.418719749490265e-06
and O 0 1.2471241817024747e-08
hMLH1 O 0 1.9473168322292622e-07
mutations O 0 2.752982952713978e-09
in O 0 7.260987922030893e-10
a O 0 9.304818027189299e-10
non O 0 4.915997564580721e-08
- O 0 4.99119465757758e-08
Jewish O 0 2.438632051848799e-08
family O 0 3.535093606732431e-10
with O 0 3.588796620990209e-11
hereditary B-Disease 1 0.9999997615814209
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9999990463256836

We O 0 1.0180675502624581e-07
describe O 0 7.6135513893405e-08
a O 0 1.0361447699835935e-08
French O 0 4.1385055737919174e-07
Canadian O 0 7.147004907892551e-07
hereditary B-Disease 1 0.9999990463256836
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.8685038867261028e-06
HNPCC B-Disease 1 0.999363124370575
) O 0 1.900363644224967e-09
kindred O 0 9.947116552666557e-08
which O 0 1.1881962080906305e-10
carries O 0 1.3330589410109894e-10
a O 0 1.069148658494612e-10
novel O 0 1.1131736643577028e-09
truncating O 0 4.2111921061405155e-08
mutation O 0 3.131048975646422e-09
in O 0 7.497455989380342e-09
hMLH1 O 0 2.3180830339697422e-06
. O 0 6.922379611751239e-07

Interestingly O 0 2.0516372387646697e-06
, O 0 4.094008687616224e-08
the O 0 1.973290508772152e-08
I1307K O 0 3.593464043660788e-06
APC O 0 4.1452878463132947e-07
polymorphism O 0 1.0358093760487463e-07
, O 0 8.566262699183369e-10
associated O 0 2.78640133188901e-09
with O 0 2.920153702179462e-11
an O 0 4.6076399640160304e-11
increased O 0 1.4734052866671732e-09
risk O 0 1.4084170629757864e-07
of O 0 3.7686295399907976e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 6.717859264426806e-07
is O 0 3.4276900762186813e-10
also O 0 6.853771022941046e-11
present O 0 1.0818231727105498e-11
in O 0 1.6946689884722588e-10
this O 0 3.4771552304135867e-10
family O 0 9.242172360757195e-09
. O 0 1.0176326270538993e-07

The O 0 8.425566875303048e-07
I1307K O 0 1.1083247045462485e-05
polymorphism O 0 2.6763966616272228e-06
has O 0 2.2449870851204423e-09
previously O 0 8.836348319718468e-10
only O 0 3.162954620439251e-11
been O 0 4.803301853484321e-11
identified O 0 6.159391746640708e-11
in O 0 3.276548476982555e-11
individuals O 0 9.042540154158285e-12
of O 0 6.760708104458502e-10
self O 0 2.1518599169212393e-07
- O 0 1.181626316792972e-06
reported O 0 2.739036375487558e-08
Ashkenazi O 0 5.396607889451843e-07
Jewish O 0 1.863924836698061e-07
origins O 0 2.1530219385113014e-07
. O 0 7.613928687533189e-08

In O 0 3.911100421305491e-08
addition O 0 5.828186822043335e-09
, O 0 1.4678086524000378e-10
in O 0 8.198854789531751e-11
this O 0 3.467748657670633e-11
family O 0 1.0014913204292597e-10
, O 0 6.387393391982243e-11
there O 0 3.816764959641006e-11
appears O 0 3.272384307972942e-10
to O 0 2.386827679945469e-10
be O 0 3.3785172437461597e-09
no O 0 1.458592180370033e-08
relationship O 0 6.025820398214421e-10
between O 0 4.0165121228952216e-10
the O 0 7.299674753546981e-10
I1307K O 0 2.575880841959588e-08
polymorphism O 0 1.9244923432637506e-09
and O 0 1.2554138284492922e-10
the O 0 5.60677004823873e-10
presence O 0 2.5284048188467523e-09
or O 0 2.5655628732579316e-09
absence O 0 5.575561701220977e-08
of O 0 8.114819927129702e-09
cancer B-Disease 0 9.442451265329055e-09
. O 0 4.593972757760412e-09
. O 0 8.730744838203464e-08

Identification O 0 1.105565274883702e-06
of O 0 4.3829661677818876e-08
a O 0 1.5500053462957908e-09
novel O 0 7.107413546592056e-10
mutation O 0 9.143697465852085e-10
of O 0 3.2497826651933792e-09
the O 0 8.271935136860975e-09
CPO O 0 9.304787340624898e-07
gene O 0 2.2643216190942894e-09
in O 0 5.3973314706468045e-09
a O 0 3.765345724104918e-08
Japanese O 0 1.301567772316048e-05
hereditary B-Disease 1 0.7556788921356201
coproporphyria I-Disease 0 0.00047794703277759254
family O 0 8.465260492585003e-08
. O 0 9.318944904634918e-08

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.99994957447052
( O 0 5.808680114682829e-08
HCP B-Disease 0 0.00022943846124690026
) O 0 5.982990991526549e-09
is O 0 9.121157162894633e-10
an O 0 1.1551619660821189e-09
autosomal B-Disease 1 0.9999946355819702
dominant I-Disease 1 0.9999991655349731
disease I-Disease 1 0.9999990463256836
characterized O 0 8.135214280002856e-09
by O 0 3.6333325237336567e-10
a O 0 6.294324617073244e-09
deficiency B-Disease 0 1.4248587376641808e-07
of I-Disease 0 7.660352139282622e-07
coproporphyrinogen I-Disease 0 3.0021471957297763e-06
oxidase I-Disease 0 2.440865820574345e-08
( O 0 5.666675462201454e-10
CPO O 0 1.518033485581327e-07
) O 0 2.5471844078417405e-10
caused O 0 6.009200359535782e-10
by O 0 2.4767665349201273e-11
a O 0 1.8601083173752642e-10
mutation O 0 1.0086034091250085e-10
in O 0 9.440050963149815e-10
the O 0 3.4054263409188934e-08
CPO O 0 7.732230187684763e-06
gene O 0 9.359220598526008e-08
. O 0 1.3538058283302234e-06

Only O 0 2.544352071254252e-07
11 O 0 7.407652447000146e-08
mutations O 0 7.263651458089271e-09
of O 0 1.1583705550322065e-08
the O 0 5.165595506895215e-09
gene O 0 2.3591972819758666e-09
have O 0 1.0811415096512178e-09
been O 0 1.7867830548468078e-09
reported O 0 1.7019159415099239e-09
in O 0 4.803013986531823e-09
HCP B-Disease 1 0.999562680721283
patients O 0 1.0412271876703016e-05
. O 0 4.755827831104398e-06

We O 0 1.9881191803960974e-07
report O 0 5.648700174276655e-09
another O 0 3.7215666659484725e-10
mutation O 0 2.8241911587123525e-10
in O 0 7.404932778065643e-10
a O 0 5.237223543730352e-09
Japanese O 0 4.102586899534799e-06
family O 0 6.257423024180753e-08
. O 0 1.287247641812428e-07

Polymerase O 0 3.5633681818580953e-06
chain O 0 2.8068893698218744e-07
reaction O 0 9.26508203491494e-09
- O 0 3.5620214333675904e-08
single O 0 2.9555538016978744e-09
strand O 0 3.27107541053806e-09
conformational O 0 7.207314189905389e-10
polymorphism O 0 1.176077679687637e-09
and O 0 4.197329289690188e-11
direct O 0 1.932749793542854e-10
sequence O 0 8.65185353915443e-12
analyses O 0 4.590887114908071e-10
demonstrated O 0 1.4264672776320708e-09
a O 0 1.491683554455392e-09
C O 0 7.710809057925871e-08
to O 0 5.240458067490295e-10
T O 0 4.482232807134778e-09
substitution O 0 2.0575479098283722e-09
in O 0 7.108281185885801e-10
exon O 0 1.3774343443628823e-08
1 O 0 1.576668928748859e-08
of O 0 9.011183799145783e-09
the O 0 8.225726766397656e-09
CPO O 0 6.436027319978166e-07
gene O 0 2.1581636477918664e-09
at O 0 4.393183150597224e-09
nucleotide O 0 2.7717517170344763e-08
position O 0 1.1768550933766164e-07
85 O 0 2.447257543281012e-07
, O 0 1.2198195786794486e-09
which O 0 1.0389994420378912e-10
lies O 0 4.405389941730675e-10
in O 0 1.6948693837282036e-10
the O 0 7.079029029632977e-10
putative O 0 2.8985997602148927e-08
presequence O 0 2.0784388254924124e-07
for O 0 4.353768456866192e-09
targeting O 0 1.357541918878269e-07
to O 0 4.024245825462458e-08
mitochondria O 0 1.9026296058655134e-06
. O 0 1.5306912928281236e-06

This O 0 8.546030549894112e-09
mutation O 0 2.3693931261448142e-09
changes O 0 6.322923296053773e-10
the O 0 5.189570440045088e-10
codon O 0 6.515493033987241e-09
for O 0 4.5714276808439536e-10
glutamine O 0 3.454234587252358e-08
to O 0 1.6374878120117842e-09
a O 0 1.315409670077372e-09
termination O 0 1.2291341278114487e-08
codon O 0 2.671364640605134e-08
at O 0 1.0404739292368959e-08
amino O 0 1.2227103773909676e-09
acid O 0 4.752619631176458e-09
position O 0 5.988507467691306e-08
29 O 0 2.034599901890033e-06
. O 0 1.3810088148602517e-06

MaeI O 0 0.00012285989942029119
restriction O 0 2.164771103707608e-06
analysis O 0 9.920022847609289e-08
showed O 0 1.945140937209544e-08
two O 0 2.442129831692341e-10
other O 0 4.329550606918531e-11
carriers O 0 5.808928893458187e-10
in O 0 6.082714332222849e-10
the O 0 7.208967645055964e-09
family O 0 3.004836912623432e-08
. O 0 2.727536525526375e-07

The O 0 1.5196513913906529e-06
C O 0 0.0006623823428526521
- O 0 3.786475645028986e-05
T O 0 2.360860662520281e-06
mutation O 0 4.362763039722495e-09
is O 0 1.0409136746991621e-10
located O 0 8.876428758686217e-11
within O 0 1.8924736777670148e-10
a O 0 4.466033376449019e-10
recently O 0 4.5571244000619515e-10
proposed O 0 1.5725229451923894e-10
putative O 0 5.821185200538537e-10
alternative O 0 3.287419003683567e-09
translation O 0 3.148535654418083e-09
initiation O 0 1.3688744582296408e-09
codon O 0 1.969969964932261e-08
( O 0 3.027488260087807e-10
TIC O 0 3.901437395370522e-08
- O 0 2.952112865273193e-08
1 O 0 2.0372967313164736e-08
) O 0 2.3033060181365528e-10
, O 0 4.3355666279332183e-11
supporting O 0 1.8729173767439988e-10
that O 0 1.887803975642033e-11
TIC O 0 4.010369281104431e-08
- O 0 9.605849982108339e-07
1 O 0 4.523771622189088e-06
is O 0 2.6515150075567817e-09
the O 0 2.5147026683214335e-09
real O 0 9.591279592768842e-08
TIC O 0 1.369971755593724e-06
rather O 0 1.1446982917107107e-08
than O 0 1.2579745023444389e-09
TIC O 0 1.2603135246536112e-07
- O 0 2.707023156744981e-07
2 O 0 1.2081022759957705e-07
. O 0 3.01447506956265e-08
. O 0 1.3051119651663612e-07

Human B-Disease 0 1.3873606974357244e-07
complement I-Disease 0 3.2346986245102016e-07
factor I-Disease 0 1.047327805281384e-05
H I-Disease 1 1.0
deficiency I-Disease 0 0.000512595463078469
associated O 0 6.2519156927010044e-06
with O 0 4.973414888809202e-07
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999984502792358

This O 0 1.3313120383884325e-08
study O 0 4.744956871860495e-09
reports O 0 7.349003627865613e-10
on O 0 1.0148754059358112e-09
six O 0 4.891739235901582e-10
cases O 0 7.274167379556218e-11
of O 0 1.661467297076058e-09
deficiency B-Disease 0 2.0813102352690294e-08
in I-Disease 0 7.26341609080805e-09
the I-Disease 0 1.3569278145553199e-08
human I-Disease 0 2.4290203182175674e-10
complement I-Disease 0 4.3433490137800845e-10
regulatory I-Disease 0 2.9401929779737657e-09
protein I-Disease 0 4.991239421769933e-09
Factor I-Disease 0 3.585962105034923e-08
H I-Disease 1 0.9996833801269531
( O 0 2.3082682432118418e-09
FH O 0 1.4043976079847198e-06
) O 0 2.0962642732769154e-10
in O 0 7.730516227155704e-11
the O 0 6.550525399884322e-11
context O 0 1.1074514638664823e-09
of O 0 2.1614994516472308e-10
an O 0 1.6090283272429673e-10
acute B-Disease 0 4.0648268623044714e-05
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.36876553297042847

Five O 0 1.9560759767500713e-07
of O 0 6.089299287026506e-09
the O 0 3.812016258208928e-10
cases O 0 2.061690054788734e-11
were O 0 1.609292282767072e-10
observed O 0 5.1599970823934527e-11
in O 0 9.423388458440485e-11
children O 0 2.466622739394353e-10
presenting O 0 1.980227093412168e-09
with O 0 6.325158175002343e-09
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 8.86151974555105e-06
HUS B-Disease 1 1.0
) O 0 1.7225048054569925e-07
. O 0 4.425632482707442e-07

Two O 0 1.1588744186497024e-08
of O 0 2.1161263852320644e-09
the O 0 4.595714364619141e-10
children O 0 1.1509475317250661e-10
exhibited O 0 2.2592956394618113e-09
a O 0 2.4518168828535636e-08
homozygous O 0 3.0930998491385253e-06
deficiency O 0 1.1123999144047048e-07
characterized O 0 2.977365465284265e-09
by O 0 3.8841924121513216e-10
the O 0 1.1330508975504472e-08
absence O 0 8.81766837323994e-08
of O 0 5.1181965332602886e-09
the O 0 6.028509913491575e-10
150 O 0 1.8769845677724106e-09
- O 0 3.322815578243876e-09
kD O 0 2.8413114705472253e-07
form O 0 7.707552374114357e-10
of O 0 3.0669653483528236e-09
Factor O 0 7.206070051779534e-08
H O 1 1.0
and O 0 4.648787466088322e-10
the O 0 2.9972610504636066e-10
presence O 0 2.347292638038567e-10
, O 0 2.2669035051881004e-11
upon O 0 2.44717524022775e-10
immunoblotting O 0 1.6381820344690823e-08
, O 0 1.0977057457450812e-10
of O 0 4.0311096127787494e-10
the O 0 3.80375814179601e-10
42 O 0 4.52011050811052e-09
- O 0 1.1516579689896389e-08
kD O 0 5.655774657498114e-07
Factor O 0 5.123727930822497e-08
H O 0 0.4170040488243103
- O 0 9.817325974381674e-08
like O 0 5.053078511174647e-10
protein O 0 1.0411836670609631e-10
1 O 0 4.615384963102542e-09
( O 0 1.9893722780217615e-10
FHL O 0 4.872701424574188e-07
- O 0 3.240481589728006e-07
1 O 0 9.469778916582072e-08
) O 0 1.5879827452991435e-09
and O 0 8.999654355079656e-10
other O 0 3.891303945735558e-10
FH O 0 2.089533381877118e-06
- O 0 2.234543785561982e-07
related O 0 3.2239100278275146e-08
protein O 0 1.4929929514906348e-09
( O 0 1.3612866389678402e-10
FHR O 0 6.738500815117732e-07
) O 0 6.708096300656052e-10
bands O 0 1.9651294280720322e-07
. O 0 2.444957374336809e-07

Southern O 0 1.3213041711424012e-05
blot O 0 5.482112101162784e-06
and O 0 5.335611064083423e-09
PCR O 0 2.22729656940146e-08
analysis O 0 6.011883213474789e-10
of O 0 1.770552454649632e-10
DNA O 0 6.545445851990905e-10
of O 0 8.129114048571751e-10
one O 0 1.189690707059654e-10
patient O 0 2.3934803028424767e-09
with O 0 4.891879124002685e-10
homozygous O 0 2.1664935047738254e-05
deficiency O 0 5.775994850409916e-06
ruled O 0 1.2194462328807276e-07
out O 0 1.6453962636830965e-09
the O 0 1.6836929628283315e-09
presence O 0 1.502815205611796e-09
of O 0 1.5054202329167765e-09
a O 0 3.3723349113223833e-10
large O 0 2.0267681977159668e-10
deletion O 0 6.436024602152202e-09
of O 0 4.333076475404596e-08
the O 0 4.982159040878287e-08
FH O 0 0.0002161397278541699
gene O 0 1.7295459286970072e-08
as O 0 9.644052667567848e-09
the O 0 8.784359906144346e-09
underlying O 0 5.103800617689558e-07
defect O 0 3.7769953564747993e-07
for O 0 6.365617810644153e-09
the O 0 2.10556351021296e-07
deficiency O 0 0.00021891019423492253
. O 0 5.2217433221812826e-06

The O 0 1.464888157443056e-07
other O 0 1.4286292149279234e-09
four O 0 3.0633390268874905e-10
children O 0 9.304333692394806e-11
presented O 0 1.5469101555254383e-09
with O 0 9.88586434935712e-10
heterozygous O 0 4.035991878481582e-07
deficiency O 0 2.772471248135844e-07
and O 0 9.329346184472342e-09
exhibited O 0 1.3737864890117635e-07
a O 0 2.312870073239992e-08
normal O 0 1.0293749141965236e-07
immunoblotting O 0 3.260799701365613e-07
pattern O 0 1.9091737080145776e-09
of O 0 1.1442393699212516e-09
proteins O 0 3.8087658027485816e-11
of O 0 3.240992807462817e-09
the O 0 1.4472743004034783e-08
FH O 0 0.000591442221775651
family O 0 3.6013369708598475e-07
. O 0 1.0810841786224046e-06

Factor B-Disease 1 0.9995726943016052
H I-Disease 1 1.0
deficiency I-Disease 1 0.9689328670501709
is O 0 3.267165871179145e-09
the O 0 2.655726083489185e-09
only O 0 1.2081825317977746e-08
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 5.53671816305723e-06
with O 0 2.5506828649213276e-08
HUS B-Disease 1 1.0
. O 0 8.138603152474388e-05

These O 0 4.482029680730193e-08
observations O 0 6.20954452301703e-08
suggest O 0 7.0872872015570465e-09
a O 0 4.592822511195749e-10
role O 0 2.0831876224036705e-09
for O 0 4.957292798479784e-09
FH O 1 0.9764328598976135
and O 0 6.125417712610215e-06
/ O 1 0.9999996423721313
or O 0 4.874857495451579e-07
FH O 0 4.6401597501244396e-05
receptors O 0 6.694487186820197e-09
in O 0 4.40220038200323e-09
the O 0 6.639312655210006e-09
pathogenesis O 0 1.0402048246760387e-05
of O 0 2.525008646614424e-08
idiopathic O 0 0.00011196900595678017
HUS B-Disease 1 1.0
. O 0 2.544818187288911e-07
. O 0 3.1356645990854304e-07

Further O 0 3.1169827252597315e-07
evidence O 0 2.0148485546656048e-08
for O 0 6.716802669615163e-10
a O 0 1.1710881153703667e-09
major O 0 5.470763841941562e-09
ancient O 0 4.0711782389735163e-07
mutation O 0 3.371500952198403e-06
underlying O 0 0.036012064665555954
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 2.509874548195512e-07
linkage O 0 1.6105258282550494e-07
disequilibrium O 0 5.736255843658e-07
studies O 0 1.040420372078188e-08
in O 0 8.155562891687396e-10
the O 0 6.756222803439016e-10
Japanese O 0 9.019526459042027e-08
population O 0 1.7835474763749914e-10
. O 0 5.11608844178113e-09

The O 0 2.1272750018397346e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 6.093409297136532e-07
DM B-Disease 1 1.0
) O 0 4.741337988889427e-09
mutation O 0 1.9367436543404892e-09
is O 0 9.421519120422772e-11
an O 0 1.1707460001453285e-10
unstable O 0 5.469065911256621e-08
( O 0 2.1608945743878394e-09
CTG O 0 4.790450134350976e-07
) O 0 2.706921631290271e-10
n O 0 3.94509619416894e-10
repeat O 0 1.9474441503852802e-10
, O 0 5.217018830827591e-11
present O 0 1.3447517405174025e-11
at O 0 1.1355832246762176e-10
a O 0 4.3585916126298585e-11
copy O 0 1.6396567437126919e-09
number O 0 4.3760096241074464e-11
of O 0 6.086901122026589e-11
5 O 0 5.577662220979107e-10
- O 0 6.665374030490057e-09
37 O 0 8.91697649052503e-09
repeats O 0 5.54415569009592e-10
on O 0 2.663269160763093e-09
normal O 0 2.293977230394262e-09
chromosomes O 0 4.2093170615764564e-10
but O 0 1.1741181638047493e-10
amplified O 0 2.2998928983497535e-08
to O 0 4.005421327946124e-09
50 O 0 4.5161744566257767e-08
- O 0 1.1493872165146968e-07
3000 O 0 6.643038830134174e-08
copies O 0 1.1126652310622376e-07
on O 0 3.8625654497081996e-07
DM B-Disease 1 0.9999998807907104
chromosomes O 0 1.323728270108404e-06
. O 0 7.916672757346532e-07

Previous O 0 3.313669196813862e-07
findings O 0 2.1155422302854276e-08
in O 0 2.3628177192591693e-09
Caucasian O 0 3.018980265778737e-08
populations O 0 5.941117597885182e-10
of O 0 1.8556726155694037e-09
a O 0 1.903912583145484e-08
DM B-Disease 1 1.0
founder O 0 1.7009559087455273e-05
chromosome O 0 3.374845221060241e-07
raise O 0 2.8840188903700437e-08
a O 0 5.9592335510672e-09
question O 0 4.656075081044264e-09
about O 0 4.288980628985861e-11
the O 0 6.150129711057772e-11
molecular O 0 2.468867610350145e-10
events O 0 8.331606238254352e-11
involved O 0 1.7210638469933315e-10
in O 0 3.9202383006475827e-10
the O 0 4.6010404375351754e-09
expansion O 0 2.2483720840682508e-07
mutation O 0 7.721582306885466e-08
. O 0 1.7748828895491897e-07

To O 0 2.1829637830705906e-07
investigate O 0 8.259704031843285e-08
whether O 0 7.90350007662255e-09
a O 0 1.081562750471221e-08
founder O 0 3.0566627629013965e-07
chromosome O 0 3.6309462103645274e-08
for O 0 3.0520146410140114e-09
the O 0 3.463246045498636e-08
DM B-Disease 1 1.0
mutation O 0 1.4041544815768248e-08
exists O 0 2.1060267418882006e-10
in O 0 6.255349710437841e-11
the O 0 4.8796317680954715e-11
Japanese O 0 6.6067205040099e-09
population O 0 7.408556407240141e-12
, O 0 1.4857021862768605e-11
we O 0 6.287143722305544e-11
genotyped O 0 7.722683825761578e-09
families O 0 5.84994344632328e-11
using O 0 1.0955137491608369e-10
polymorphic O 0 1.1342460304319957e-09
markers O 0 3.496817280179698e-09
near O 0 8.557077535442659e-08
the O 0 2.468112114684118e-08
( O 0 3.518077829056665e-09
CTG O 0 1.6015214896469843e-06
) O 0 2.169716184496906e-09
n O 0 1.146759043280099e-08
repeat O 0 1.323970977296085e-08
region O 0 2.8004047081253702e-08
and O 0 5.958437743203149e-09
constructed O 0 4.2726207993837306e-07
haplotypes O 0 1.730176450109866e-06
. O 0 3.787943398947391e-07

Six O 0 2.2646213437838014e-07
different O 0 1.0748067991173116e-09
haplotypes O 0 9.040488180289685e-08
were O 0 8.690915542786115e-09
found O 0 1.6314648521031927e-09
and O 0 8.436098042352569e-09
DM B-Disease 1 1.0
alleles O 0 5.070142705676517e-08
were O 0 9.519217059050789e-08
always O 0 5.8903371069618515e-08
haplotype O 0 6.610472951251722e-07
A O 0 1.106128365790937e-06
. O 0 6.51671371088014e-07

To O 0 3.370447743122895e-08
find O 0 2.314179514684156e-09
an O 0 3.089466876771141e-11
origin O 0 2.4912466534132705e-10
of O 0 8.485459002116613e-10
the O 0 2.423551359598264e-09
( O 0 1.7162328225239776e-09
CTG O 0 6.5840231400216e-07
) O 0 8.487142100221945e-10
n O 0 6.984586242708701e-09
repeat O 0 7.62120500041874e-09
mutation O 0 1.4275750581660418e-09
and O 0 6.830975229910052e-10
to O 0 2.5327246966355688e-09
investigate O 0 1.5072935122262265e-09
the O 0 1.1640555186431811e-09
mechanism O 0 9.207109741282693e-08
of O 0 3.75613407044284e-09
the O 0 2.4294560807547327e-10
expansion O 0 8.023074982155265e-10
mutation O 0 2.5530881228585933e-11
in O 0 3.301144774203735e-11
the O 0 1.5594760205406288e-10
Japanese O 0 2.7066146657261925e-08
population O 0 2.2545453351452416e-11
we O 0 2.690731144838754e-11
have O 0 1.5630547203770995e-11
studied O 0 1.6839917238442581e-09
90 O 0 1.1848208636422441e-08
Japanese O 0 5.642797532345867e-06
DM B-Disease 1 1.0
families O 0 6.362109949975547e-09
comprising O 0 1.5838356182129587e-09
190 O 0 9.844360882027559e-09
affected O 0 9.272201895171861e-10
and O 0 8.254751326930432e-10
130 O 0 7.183550110312353e-08
unaffected O 0 1.2127289039653988e-07
members O 0 1.2565937623776335e-08
. O 0 2.9253550337671186e-07

The O 0 6.7249351332066e-07
results O 0 5.0582908528440385e-08
suggest O 0 2.4442060819751532e-08
that O 0 3.009341942306065e-10
a O 0 1.7344938818553146e-09
few O 0 2.0691337532241505e-09
common O 0 9.685080515353661e-10
ancestral O 0 7.698946369316673e-09
mutations O 0 1.3400368592542122e-09
in O 0 8.099105830439157e-10
both O 0 1.592286524854103e-09
Caucasian O 0 7.194574180857671e-08
and O 0 3.0634166314769118e-09
Japanese O 0 6.554359401889087e-07
populations O 0 1.4912275581036027e-10
have O 0 1.4627459399979559e-12
originated O 0 7.658380873909465e-12
by O 0 7.521388568389187e-13
expansion O 0 1.1075967226714667e-10
of O 0 2.2041773961589683e-10
an O 0 2.8455364800561433e-11
ancestral O 0 6.412518849252535e-10
n O 0 5.504705580250402e-10
= O 0 2.7917048672776446e-09
5 O 0 1.492269752212394e-09
repeat O 0 2.8869728829761243e-09
to O 0 2.1146777662295335e-09
n O 0 8.367543102849595e-09
= O 0 5.577124895239649e-08
19 O 0 6.939837504660318e-08
- O 0 3.141040281207097e-07
37 O 0 1.397376649947546e-07
copies O 0 2.9863480222047656e-07
. O 0 2.549746795921237e-07

These O 0 4.1309771603437184e-08
data O 0 2.9082467989383076e-08
support O 0 2.288876865819134e-09
multistep O 0 3.22236068939219e-08
models O 0 1.3339713689219934e-07
of O 0 8.589110933598931e-08
triplet O 0 2.9007460398133844e-06
repeat O 0 2.010839210697668e-07
expansion O 0 2.0988072435557115e-07
that O 0 6.214586623087826e-10
have O 0 8.444783067274031e-11
been O 0 8.36774191603773e-11
proposed O 0 1.2507365976244245e-10
for O 0 3.578688456684631e-10
both O 0 1.2461967457966239e-08
DM B-Disease 1 1.0
and O 0 1.0159468502024538e-06
Friedreichs B-Disease 1 0.8652920126914978
ataxia I-Disease 0 0.07451535761356354
. O 0 7.200985692179529e-07
. O 0 1.2331470315984916e-06

The O 0 3.9545021479625575e-08
molecular O 0 1.5724973323472113e-08
basis O 0 3.8386733791639926e-08
of O 0 8.460907565677189e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.363050282700897e-08
the O 0 2.974249513343352e-09
western O 0 9.034864412171828e-09
Cape O 0 4.6878632531388575e-08
, O 0 3.152139382844865e-10
South O 0 6.271687169601137e-09
Africa O 0 1.2994160414336875e-08
. O 0 8.361847214644058e-09

Deficiency B-Disease 0 0.00025944330263882875
of I-Disease 0 5.371525162445323e-07
the I-Disease 0 4.533357866876031e-08
sixth I-Disease 0 3.01579262895757e-07
component I-Disease 0 5.5590707148667207e-08
of I-Disease 0 3.044398511065083e-09
human I-Disease 0 1.9370899329018698e-10
complement I-Disease 0 9.995611449653552e-09
( O 0 5.412465142740075e-09
C6 O 1 0.9999293088912964
) O 0 1.7728140067063691e-09
has O 0 1.0260450822308087e-10
been O 0 5.341531730818083e-11
reported O 0 2.291045478330922e-11
in O 0 1.728547339985287e-11
a O 0 1.0398083782892087e-10
number O 0 4.888780005818383e-11
of O 0 4.503359837815246e-11
families O 0 5.5930932628400765e-12
from O 0 1.0471738927375629e-11
the O 0 4.126576511054303e-11
western O 0 3.572007356567042e-09
Cape O 0 5.3676956213166704e-08
, O 0 1.2186568421057586e-09
South O 0 4.4315701330788215e-08
Africa O 0 6.01891017026901e-08
. O 0 7.434999105271345e-08

Meningococcal B-Disease 1 0.9999772310256958
disease I-Disease 0 0.0033703166991472244
is O 0 3.705410700494127e-10
endemic O 0 1.0157193142124044e-10
in O 0 4.472586884185503e-11
the O 0 4.547842380464573e-10
Cape O 0 1.0485310042440688e-07
and O 0 7.335292928623005e-10
almost O 0 3.0082802915387674e-10
all O 0 2.6206113667992526e-11
pedigrees O 0 1.7870455115698292e-09
of O 0 2.6363058402978368e-09
total O 0 2.5950496365112485e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.7285170628156266e-08
C6Q0 O 0 4.829670433537103e-05
) O 0 3.6694150495897304e-10
have O 0 6.301189431345833e-11
been O 0 3.9079628422200585e-11
ascertained O 0 6.9531904678399314e-09
because O 0 1.995871384830039e-10
of O 0 3.0959583785516998e-09
recurrent O 0 3.0369069463631604e-06
disease O 0 4.393798462842824e-06
. O 0 4.0776126297714654e-07

We O 0 2.1339985778467963e-07
have O 0 1.7310961553107518e-09
sequenced O 0 1.5753853332967083e-08
the O 0 5.396240343458203e-09
expressed O 0 3.376101842533785e-09
exons O 0 2.8458503109618505e-08
of O 0 4.064805381176484e-09
the O 0 7.4142643136099196e-09
C6 O 0 1.8214352166978642e-05
gene O 0 9.423505531458432e-09
from O 0 1.0339746836507402e-09
selected O 0 3.937115522489876e-09
cases O 0 2.867276138740493e-10
and O 0 2.3928811709872377e-10
have O 0 3.3045735592374115e-10
found O 0 2.9473556928394373e-10
three O 0 2.3820478922687016e-10
molecular O 0 2.611380125472351e-07
defects O 0 0.09373343735933304
leading O 0 1.1398482229196816e-06
to O 0 7.544309710283414e-08
total O 0 3.2492193895450328e-06
deficiency O 0 0.0001272381196031347
879delG O 0 1.1130955499538686e-06
, O 0 1.3891534589305365e-09
which O 0 1.4653497859562492e-10
is O 0 3.41983871776641e-11
the O 0 1.7866595702908938e-10
common O 0 2.3929234149733247e-09
defect O 0 2.1424365570510417e-07
in O 0 5.224811250315042e-09
the O 0 2.9340544216438502e-08
Cape O 0 1.351371679447766e-06
and O 0 3.315687058247363e-09
hitherto O 0 1.2171921071058023e-07
unreported O 0 1.50144661148488e-08
, O 0 5.408600303735689e-11
and O 0 7.236153343193052e-11
1195delC O 0 1.79361983043691e-08
and O 0 2.4194765635421334e-10
1936delG O 0 3.918298574490109e-08
, O 0 1.5248972917714099e-10
which O 0 1.1715494893649314e-11
have O 0 1.0679864111129422e-11
been O 0 7.491758602373721e-11
previously O 0 1.8404161528096097e-10
reported O 0 1.5339259029634178e-10
in O 0 3.341888155095063e-10
African O 0 1.0551192985985836e-07
- O 0 7.76130093527172e-07
Americans O 0 2.7075137154497497e-07
. O 0 2.711979334435455e-07

We O 0 5.199399311095476e-07
also O 0 8.583555199948023e-09
show O 0 1.998028187344403e-09
that O 0 3.979412285803896e-11
the O 0 3.1546176781915847e-10
879delG O 0 9.107014875553432e-08
and O 0 5.0542565688260765e-09
1195delC O 0 2.7116739147459157e-06
defects O 0 1.941432628882467e-06
are O 0 1.4802381542722287e-10
associated O 0 5.4976574404008716e-09
with O 0 4.5249215485654304e-10
characteristic O 0 4.6056626160861924e-05
C6 O 1 1.0
/ O 1 1.0
C7 O 1 0.7479903101921082
region O 0 3.353590045662713e-07
DNA O 0 2.3310019514610758e-07
marker O 0 1.7436238408663485e-07
haplotypes O 0 7.046113381647956e-08
, O 0 6.797481466591648e-10
although O 0 4.1999018152161227e-10
small O 0 1.5557802268695298e-10
variations O 0 1.4506895684718302e-09
were O 0 7.94839927209523e-09
observed O 0 4.804720177276067e-08
. O 0 3.7229162330731924e-07

The O 0 3.368520538060693e-07
1936delG O 0 4.193089353066171e-06
defect O 0 1.63439551670308e-06
was O 0 1.833382690108465e-08
observed O 0 1.3640606422171686e-09
only O 0 5.2205323397558345e-11
once O 0 1.5034395950408452e-10
in O 0 8.14261089110424e-11
the O 0 3.495568279276995e-10
Cape O 0 4.655970897715633e-08
, O 0 1.816928690834274e-10
but O 0 4.906229242318538e-11
its O 0 7.928298295656333e-11
associated O 0 1.7211140290740445e-09
haplotype O 0 3.796448666548713e-08
could O 0 8.609921664515241e-09
be O 0 9.95273108372885e-09
deduced O 0 7.052794899209403e-07
. O 0 5.374578790906526e-07

The O 0 4.867054030910367e-07
data O 0 1.6068959496351454e-07
from O 0 3.1242719522595053e-09
the O 0 3.648549906642984e-09
haplotypes O 0 2.259189813003104e-07
indicate O 0 2.5016342775074918e-08
that O 0 9.746600748705703e-11
these O 0 5.849151024639454e-11
three O 0 9.407207651745964e-11
molecular O 0 1.1882744566094061e-08
defects O 0 1.334334687186356e-08
account O 0 2.823932476747615e-10
for O 0 5.528147939415362e-10
the O 0 2.097190154870532e-08
defects O 0 0.003658250905573368
in O 0 5.172686812215943e-08
all O 0 1.4623721789064348e-08
the O 0 2.026182599479398e-08
38 O 0 1.5368273409421818e-07
unrelated O 0 1.5253380780677617e-08
C6Q0 O 0 5.1944953156635165e-06
individuals O 0 8.343883917127926e-11
we O 0 5.710270034597897e-10
have O 0 1.5069594183625412e-10
studied O 0 9.544612211698222e-09
from O 0 5.4560707063444625e-09
the O 0 1.6916994027837973e-08
Cape O 0 1.8061007267533569e-06
. O 0 4.689034938110126e-07

We O 0 2.485047332356771e-07
have O 0 2.4630366635136625e-09
also O 0 5.409263037492451e-10
observed O 0 9.009460399944658e-10
the O 0 5.500706556915702e-10
879delG O 0 1.9057334554872796e-07
defect O 0 1.1264403809718715e-07
in O 0 3.2579001718602285e-09
two O 0 1.3734178239133144e-08
Dutch O 1 1.0
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 1.2532648725027684e-05
, O 0 1.476167632574743e-09
but O 0 6.082189613065836e-11
the O 0 1.2499781765207274e-10
879delG O 0 2.0171212256059334e-08
defect O 0 1.4985511498366577e-08
in O 0 8.297514342281431e-10
the O 0 8.668202156059124e-09
Cape O 0 8.259985975200834e-07
probably O 0 2.3667656279258154e-08
did O 0 9.878513562711078e-10
not O 0 1.6447677941844319e-10
come O 0 3.74494352195498e-10
from O 0 2.941526466848643e-10
The O 0 3.1265015021375575e-09
Netherlands O 0 2.8046656552760396e-07
. O 0 4.4813116772957073e-08
. O 0 4.5762132572235714e-07

Complement B-Disease 1 0.9999998807907104
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 9.65834061616988e-08
seven O 0 7.5101365126784e-09
further O 0 1.5032625144684175e-09
molecular O 0 4.1183266574762456e-08
defects O 0 6.175104658723285e-07
and O 0 2.787980069030027e-09
their O 0 3.407719972869927e-08
associated O 0 0.0004018315812572837
marker O 0 1.0696192475734279e-05
haplotypes O 0 3.996810391981853e-06
. O 0 1.5422964452227461e-06

Seven O 0 2.8570548238349147e-07
further O 0 1.0675786477065685e-08
molecular O 0 1.7726017986774423e-08
bases O 0 3.3878086469485424e-07
of O 0 3.3983260436798446e-06
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.788481445747948e-08
described O 0 1.0975146125247193e-07
. O 0 1.844048114207908e-07

All O 0 1.666445257342275e-07
these O 0 1.609974598082431e-09
new O 0 5.121077339964586e-09
molecular O 0 7.87377203437245e-08
defects O 0 1.204414132871534e-07
involve O 0 2.3896031819958807e-09
single O 0 4.6398165309824435e-09
- O 0 3.284681682202972e-08
nucleotide O 0 4.078024673503933e-08
events O 0 2.5912950007977997e-08
, O 0 2.9398563583526993e-09
deletions O 0 3.409397208997689e-08
and O 0 3.064737574831611e-09
substitutions O 0 4.6594003322297795e-08
, O 0 1.6846566364137061e-09
some O 0 2.955168887375237e-10
of O 0 2.532753562434209e-09
which O 0 4.456279789621931e-11
alter O 0 5.131147950976356e-09
splice O 0 1.0481010548346603e-07
sites O 0 2.5030040262663533e-08
, O 0 1.3865777415134062e-09
and O 0 1.5798982122561256e-09
others O 0 1.745492994587039e-08
codons O 0 8.544549814359925e-07
. O 0 8.099883075374237e-07

They O 0 8.941845663912318e-08
are O 0 2.977738888798598e-10
distributed O 0 8.733068157518176e-10
along O 0 8.821579577933392e-10
the O 0 3.361734002282901e-09
C7 O 0 1.1079041541961487e-05
gene O 0 8.727877087721936e-09
, O 0 7.850131655828818e-10
but O 0 4.60681388869677e-11
predominantly O 0 2.4373031370927833e-11
towards O 0 1.5717131762738035e-10
the O 0 1.2006601268765849e-10
3 O 0 6.50702336457698e-09
end O 0 8.299595322114328e-08
. O 0 2.4170950041479955e-07

All O 0 9.751094864896004e-08
were O 0 2.5749965715249346e-08
found O 0 9.235048836764292e-10
in O 0 7.853067085505927e-10
compound O 0 1.3643207807945146e-07
heterozygous O 0 1.566728258239891e-08
individuals O 0 2.9093533138180305e-10
. O 0 6.440472333224534e-08

The O 0 2.347838926652912e-05
C6 O 1 0.9999998807907104
/ O 1 0.9999852180480957
C7 O 1 0.7350183725357056
marker O 0 3.590662117858301e-06
haplotypes O 0 1.358209146928857e-06
associated O 0 7.859232908913327e-08
with O 0 1.696409679396993e-09
most O 0 4.192558478166575e-08
C7 B-Disease 1 1.0
defects I-Disease 0 0.02882268838584423
are O 0 4.438978518095382e-09
tabulated O 0 4.442072309984724e-08
. O 0 1.7656237361052263e-08
. O 0 2.1289207552399603e-07

A O 0 1.3970438885735348e-06
genome O 0 2.454348191349709e-08
- O 0 1.0759173107999231e-07
wide O 0 2.5070163722773486e-09
search O 0 4.468591718875814e-09
for O 0 2.405437793395748e-10
chromosomal O 0 1.1389252563276386e-07
loci O 0 1.1989580173121794e-07
linked O 0 6.110120011726394e-06
to O 0 1.055537524052852e-08
mental O 1 0.991407036781311
health O 0 8.342669843841577e-08
wellness O 0 1.5310838819004857e-07
in O 0 4.0911727339221216e-09
relatives O 0 1.3251938213443282e-08
at O 0 5.187840823595025e-09
high O 0 4.0560870218087075e-08
risk O 0 2.1998499732944765e-07
for O 0 3.665417978027108e-07
bipolar B-Disease 1 1.0
affective I-Disease 1 0.9999996423721313
disorder I-Disease 1 0.9886215329170227
among O 0 1.0460410315715762e-09
the O 0 2.5132691483520375e-09
Old O 0 1.0986288856429383e-07
Order O 0 8.247157978757969e-08
Amish O 0 8.898052328731865e-06
. O 0 4.7471183961533825e-07

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 1.4795854497151595e-07
BPAD B-Disease 1 1.0
; O 0 2.8774256861652248e-06
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 9.125651345698316e-09
is O 0 4.3844060326758694e-11
characterized O 0 3.121648078918682e-11
by O 0 2.576874304216492e-11
episodes O 0 6.679500952344597e-09
of O 0 2.4966482214949792e-08
mania B-Disease 0 3.0609245982304856e-07
and O 0 1.3333730564113466e-08
/ O 0 0.008034764789044857
or O 0 1.2071394905888155e-07
hypomania B-Disease 0 1.0950761861749925e-05
interspersed O 0 2.2027664137169722e-09
with O 0 2.3524366482563508e-11
periods O 0 4.240038009584168e-08
of O 0 2.3462833453891108e-08
depression B-Disease 0 1.1717812640199554e-06
. O 0 9.944935186467774e-08

Compelling O 0 4.1617363422119524e-06
evidence O 0 1.1028424751202692e-07
supports O 0 2.0331897943037802e-08
a O 0 1.3352505767727507e-09
significant O 0 1.2492208378844794e-09
genetic O 0 4.219205429478734e-09
component O 0 8.472540891091285e-09
in O 0 6.106976035979983e-10
the O 0 2.8707469734712276e-09
susceptibility O 0 9.154314994930246e-08
to O 0 2.9728500550163517e-08
develop O 0 6.6343673097435385e-06
BPAD B-Disease 1 1.0
. O 0 0.00013610692985821515

To O 0 2.4249031227441264e-08
date O 0 4.5863142617008634e-08
, O 0 2.0106785125761917e-09
however O 0 6.843220434760156e-10
, O 0 2.601716897476791e-10
linkage O 0 1.0788842708109314e-08
studies O 0 1.2469474341969544e-09
have O 0 2.385348585320912e-10
attempted O 0 1.280210248921776e-08
only O 0 3.722581964904492e-10
to O 0 1.517736825107363e-09
identify O 0 1.2514703939814353e-08
chromosomal O 0 1.4824046274952707e-06
loci O 0 2.7087483545074065e-07
that O 0 2.1046222542508985e-09
cause O 0 1.6651258150091053e-08
or O 0 3.836634343556966e-10
increase O 0 5.346488252122583e-10
the O 0 6.402045560349734e-10
risk O 0 1.1188491022551261e-08
of O 0 1.8455502015513048e-08
developing O 0 1.0080765378006618e-06
BPAD B-Disease 1 1.0
. O 0 1.63469958351925e-05

To O 0 8.783760563346732e-08
determine O 0 1.8792528422295618e-08
whether O 0 4.6630077576992335e-09
there O 0 1.8900143672340164e-09
could O 0 5.511620937426187e-09
be O 0 2.19086659924983e-09
protective O 0 5.2916686144044434e-08
alleles O 0 1.5789071161620427e-09
that O 0 6.167397148537646e-11
prevent O 0 1.0390455162934131e-09
or O 0 3.4561159489854276e-10
reduce O 0 2.2853914316556256e-09
the O 0 5.963027849276159e-10
risk O 0 5.965772764682242e-09
of O 0 1.7856724987552752e-09
developing O 0 2.4064085835107107e-08
BPAD B-Disease 1 1.0
, O 0 6.60198118396238e-10
similar O 0 6.916887201890987e-11
to O 0 2.1827820106956608e-10
what O 0 8.865160688875662e-11
is O 0 6.4932512491844285e-12
observed O 0 6.609524733081074e-11
in O 0 2.307170843263151e-10
other O 0 1.867020138490716e-08
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 2.2755914930172594e-09
we O 0 8.061500356149054e-10
used O 0 1.194867671472366e-08
mental O 0 2.7902640340471407e-06
health O 0 1.005212713067749e-08
wellness O 0 7.096583232168996e-08
( O 0 2.776600893650283e-10
absence O 0 8.983279897734064e-09
of O 0 5.958745052936365e-09
any O 0 4.194444347405124e-09
psychiatric B-Disease 1 0.8250090479850769
disorder I-Disease 0 2.901027983170934e-06
) O 0 1.115466399803644e-10
as O 0 2.2367584173732524e-10
the O 0 2.46713566243173e-10
phenotype O 0 1.1983225522982366e-09
in O 0 1.15597309502391e-09
our O 0 1.390635961939779e-08
genome O 0 1.1730560522948963e-08
- O 0 7.538180852861842e-07
wide O 0 1.8522440825563535e-07
linkage O 0 1.2014147614536341e-06
scan O 0 9.259162652597297e-06
of O 0 1.0103337189093509e-07
several O 0 4.375337869788609e-09
large O 0 1.9513530791215317e-09
multigeneration O 0 1.5097780305950437e-06
Old O 0 2.3393486969780497e-07
Order O 0 1.2091349788079242e-07
Amish O 0 1.4628877806899254e-06
pedigrees O 0 8.96440397468723e-08
exhibiting O 0 7.994529482857615e-09
an O 0 1.0837655217699194e-09
extremely O 0 2.326062542579166e-08
high O 0 7.697965997977008e-08
incidence O 0 1.4678698789793998e-06
of O 0 5.976542979624355e-06
BPAD B-Disease 1 1.0
. O 0 0.0001431072159903124

We O 0 7.912204864624073e-07
have O 0 6.853399181494524e-09
found O 0 1.1228248331107693e-09
strong O 0 5.846332307157809e-10
evidence O 0 3.7053257684327434e-10
for O 0 1.5671601516498157e-10
a O 0 5.049426987646655e-10
locus O 0 4.487964222477103e-09
on O 0 2.1592805765635603e-08
chromosome O 0 1.46043007021035e-07
4p O 0 1.8221267964690924e-05
at O 0 7.239739829856262e-08
D4S2949 O 0 8.033845801946882e-07
( O 0 3.930143155361776e-10
maximum O 0 1.944525074293324e-08
GENEHUNTER O 0 3.303241271623847e-07
- O 0 8.707645093863903e-08
PLUS O 0 7.881495633910163e-08
nonparametric O 0 2.868929129817843e-07
linkage O 0 1.9754370583768832e-08
score O 0 1.9295094411120317e-09
= O 0 2.305003521385629e-09
4 O 0 1.7806489616134513e-09
. O 0 2.0662656308179095e-10
05 O 0 1.5517873919179692e-07
, O 0 1.2871581578366431e-09
P O 0 3.29590861269935e-08
= O 0 6.160232324248227e-09
5 O 0 1.3605994109155972e-09
. O 0 1.3199932813456883e-10
22 O 0 2.1993153964672274e-09
x O 0 1.5654348928251238e-08
10 O 0 3.756305932967052e-09
( O 0 9.436572356857909e-11
- O 0 1.278397210313642e-08
4 O 0 7.740069918327208e-09
) O 0 3.08696485040727e-10
; O 0 3.399186487840211e-10
SIBPAL O 0 1.2370576314424397e-06
Pempirical O 0 1.7862106460597715e-07
value O 0 1.5981648227025858e-09
< O 0 1.6303021155295028e-08
3 O 0 3.440569162904694e-09
x O 0 3.448178631515475e-08
10 O 0 3.6820646531765533e-09
( O 0 1.0971196173770181e-10
- O 0 8.63903792946985e-09
5 O 0 6.649958361748531e-09
) O 0 3.3011085531775564e-10
) O 0 1.7301314547690794e-10
and O 0 1.4014987781418853e-10
suggestive O 0 4.450593227289801e-09
evidence O 0 4.20869866735174e-10
for O 0 5.230190239235988e-11
a O 0 5.29576216212746e-10
locus O 0 8.143691054840474e-09
on O 0 4.046906454391319e-08
chromosome O 0 2.1798889804358623e-07
4q O 0 1.781516516530246e-06
at O 0 4.250961538332376e-08
D4S397 O 0 6.311548759185825e-07
( O 0 3.990595076608372e-10
maximum O 0 1.9925792571484635e-08
GENEHUNTER O 0 5.933116540290939e-07
- O 0 9.363076713952978e-08
PLUS O 0 1.5816816301139625e-07
nonparametric O 0 2.5226913180631527e-07
linkage O 0 2.1521591619944047e-08
score O 0 1.9417185637138346e-09
= O 0 3.2267812866138e-09
3 O 0 1.1224480234162115e-09
. O 0 1.7320332668102623e-10
29 O 0 9.269271572520665e-09
, O 0 3.4295602469036623e-10
P O 0 9.345695772822182e-09
= O 0 4.178904333684841e-09
2 O 0 1.035555530215504e-09
. O 0 1.665686616414419e-10
57 O 0 2.0134069966815105e-09
x O 0 1.4617977051045727e-08
10 O 0 4.640984485604349e-09
( O 0 7.886656605560205e-11
- O 0 1.791780235294027e-08
3 O 0 9.212482332543459e-09
) O 0 3.2568547858602415e-10
; O 0 3.3552047251639294e-10
SIBPAL O 0 8.853798476593511e-07
Pempirical O 0 2.2127184706732805e-07
value O 0 1.3427718936753763e-09
< O 0 1.7423662512783267e-08
1 O 0 6.4850183001397e-09
x O 0 5.635810396142915e-08
10 O 0 7.162669568572255e-09
( O 0 1.2917049374561174e-10
- O 0 1.715942410385196e-08
3 O 0 6.208630054516107e-09
) O 0 2.1396487359659488e-10
) O 0 5.4979031743895845e-11
that O 0 4.5983841734376085e-12
are O 0 1.001529068012097e-11
linked O 0 9.231249542551723e-09
to O 0 9.716206506027447e-09
mental O 0 0.14368480443954468
health O 0 3.5302603009768063e-06
wellness O 0 2.907567613874562e-05
. O 0 7.243785944410774e-07

These O 0 3.5980036727778497e-07
findings O 0 8.246151850244132e-08
are O 0 1.0027265684442455e-09
consistent O 0 1.2884212807762196e-08
with O 0 1.4078699317465748e-10
the O 0 1.4501307932235363e-09
hypothesis O 0 7.292081161125452e-09
that O 0 2.2734590252038167e-11
certain O 0 2.0620254115311099e-10
alleles O 0 7.882179353657648e-10
could O 0 1.0579597198301371e-09
prevent O 0 7.935569534822662e-09
or O 0 6.282306674876281e-09
modify O 0 1.2002679738998268e-07
the O 0 6.451215117664333e-09
clinical O 0 6.269752361731662e-08
manifestations O 0 6.825394649467853e-08
of O 0 9.833892278265921e-08
BPAD B-Disease 1 1.0
and O 0 7.252908496013788e-09
perhaps O 0 2.8642166416403825e-09
other O 0 5.011144832423042e-10
related O 0 9.764141140067295e-08
affective B-Disease 0 7.077900590957142e-06
disorders I-Disease 0 0.023041896522045135
. O 0 1.0414755706733558e-06

Segregation O 0 3.477407881291583e-05
distortion O 0 0.00016372441314160824
in O 0 4.266417363396613e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00010546747216721997

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 3.7582178720185766e-06
DM B-Disease 1 1.0
) O 0 2.8653220240926203e-08
is O 0 1.1154733803309114e-09
an O 0 1.7106476235539958e-09
autosomal B-Disease 1 0.9469006657600403
dominant I-Disease 0 0.3679359555244446
disease I-Disease 1 0.5802498459815979
which O 0 7.877106085463215e-12
, O 0 3.5637744925237635e-12
in O 0 1.805989038872191e-11
the O 0 2.2810353605962064e-10
typical O 0 1.2055668685562182e-09
pedigree O 0 9.842477943777794e-10
, O 0 1.4547842097645258e-10
shows O 0 4.364334171835793e-10
a O 0 6.532063778763586e-10
three O 0 3.504821155519977e-10
generation O 0 8.8204771486744e-08
anticipation O 0 4.1476405954199436e-07
cascade O 0 6.742402547388338e-07
. O 0 9.800335192267084e-07

This O 0 1.784781211711106e-08
results O 0 5.078298670468939e-09
in O 0 1.1261499288650612e-08
infertility B-Disease 0 0.027934864163398743
and O 0 4.575001185003202e-06
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 5.0438369036953645e-09
CDM B-Disease 0 1.4262128900099924e-07
) O 0 5.6734856396234434e-11
with O 0 1.516120909372809e-11
the O 0 2.1102617431267845e-09
disappearance O 0 4.798483814738574e-07
of O 0 1.209079698583082e-07
DM B-Disease 1 1.0
in O 0 3.175669291977101e-07
that O 0 7.120402045757146e-09
pedigree O 0 3.333361462409812e-07
. O 0 1.9447631416369404e-07

The O 0 2.7944446756578145e-08
concept O 0 3.626779232490662e-08
of O 0 5.737478936396201e-09
segregation O 0 6.279518061091949e-08
distortion O 0 1.6779992506599228e-07
, O 0 2.90817703252344e-10
where O 0 1.843254576749942e-10
there O 0 2.2064730251236675e-11
is O 0 4.819745297313105e-12
preferential O 0 2.0883237361601914e-09
transmission O 0 1.1968886326485517e-08
of O 0 2.3359181255955264e-09
the O 0 1.0144844964088406e-09
larger O 0 5.705196870486873e-10
allele O 0 9.85562853550448e-10
at O 0 2.10494333074962e-09
the O 0 1.645560310237215e-08
DM B-Disease 1 1.0
locus O 0 3.9875260426924797e-07
, O 0 1.6614989384322598e-09
has O 0 5.244005230053972e-11
been O 0 3.419740879362365e-11
put O 0 1.9258244998709984e-10
forward O 0 2.1033461639063944e-09
to O 0 1.3026636436208605e-09
explain O 0 5.739920094782747e-09
partially O 0 1.995370801921581e-08
the O 0 4.600476666283271e-10
maintenance O 0 1.2193996212772618e-07
of O 0 1.4383969926257123e-07
DM B-Disease 1 1.0
in O 0 3.808117909898101e-08
the O 0 4.03620514788372e-09
population O 0 3.558540961901002e-10
. O 0 7.913426358641118e-09

In O 0 5.175637696197555e-08
a O 0 1.0325424071311318e-08
survey O 0 3.209043475393969e-09
of O 0 2.542477561817691e-09
DM B-Disease 1 1.0
in O 0 2.8400753748769603e-08
Northern O 0 1.0466646926943213e-07
Ireland O 0 1.3934165110640606e-07
, O 0 4.944940457107805e-09
59 O 0 1.0907531589054997e-07
pedigrees O 0 4.5493217726289004e-07
were O 0 7.117580480553443e-08
ascertained O 0 3.7201411942078266e-06
. O 0 1.061329385265708e-06

Sibships O 0 3.551087502273731e-05
where O 0 9.008915391461869e-09
the O 0 3.996002695405565e-10
status O 0 2.002828125569067e-09
of O 0 1.3859670078275599e-09
all O 0 1.2788251013695628e-10
the O 0 2.8356988979183484e-10
members O 0 4.391503133360786e-11
had O 0 2.9709310012115964e-10
been O 0 8.964921860421526e-11
identified O 0 1.5739240466494664e-10
were O 0 7.025734993781896e-10
examined O 0 2.602800419637674e-09
to O 0 6.364145876958105e-10
determine O 0 9.180990412360757e-10
the O 0 2.9562134962191067e-09
transmission O 0 2.579091926691035e-07
of O 0 8.077156721242318e-09
the O 0 3.358620759286168e-08
DM B-Disease 1 1.0
expansion O 0 1.4002517900735256e-06
from O 0 8.946415164245991e-09
affected O 0 9.998504246766515e-10
parents O 0 5.088204857450762e-10
to O 0 6.850964795468428e-10
their O 0 2.8710316346547415e-09
offspring O 0 2.014826208096565e-07
. O 0 4.4153375711175613e-07

Where O 0 1.09351525168222e-07
the O 0 1.1447812475751107e-08
transmitting O 0 5.980677428851777e-07
parent O 0 6.935904295346518e-09
was O 0 2.9613447694032402e-08
male O 0 1.1958229961805955e-08
, O 0 4.893197402822125e-09
58 O 0 2.3409823768361093e-07
. O 0 2.777944700937951e-07

3 O 0 1.2042044090776471e-06
% O 0 1.253070713858051e-08
of O 0 3.4327751752272206e-09
the O 0 3.70257047244138e-10
offspring O 0 1.012624761820291e-09
were O 0 1.329519938586543e-09
affected O 0 2.716733504826152e-10
, O 0 8.840220916406238e-11
and O 0 1.0187460597332887e-10
in O 0 3.092681388761065e-10
the O 0 2.3921967184925563e-10
case O 0 3.134644765978578e-10
of O 0 5.131057245755244e-10
a O 0 1.5675346576315974e-09
female O 0 1.9296308995109257e-09
transmitting O 0 6.289119625080275e-08
parent O 0 8.729442058097447e-09
, O 0 2.7503126887040708e-08
68 O 0 3.769499699046719e-06
. O 0 4.943226485920604e-06

7 O 0 4.98103690915741e-06
% O 0 5.5698642142942845e-08
were O 0 2.7107530442549432e-08
affected O 0 1.6886595233245316e-08
. O 0 1.5206532566480746e-07

Studies O 0 7.337566216847335e-07
on O 0 1.240037335037414e-07
meiotic O 0 2.077048748105881e-06
drive O 0 6.757297796866624e-07
in O 0 6.570392940830061e-08
DM B-Disease 1 1.0
have O 0 5.065587505015401e-09
shown O 0 3.1551891654935105e-10
increased O 0 2.581874158913422e-10
transmission O 0 1.1312882852720918e-09
of O 0 1.8586542027687614e-10
the O 0 1.8042960181485768e-10
larger O 0 2.5948235227168936e-10
allele O 0 1.210262223771963e-09
at O 0 3.0420534979924696e-09
the O 0 1.586315612200906e-08
DM B-Disease 1 1.0
locus O 0 8.056312594817427e-08
in O 0 6.672777441707467e-09
non O 0 7.909693522378802e-06
- O 0 6.839070556452498e-05
DM O 1 1.0
heterozygotes O 0 1.815206815081183e-05
for O 0 7.09792331576864e-08
CTGn O 0 4.449445259524509e-05
. O 0 4.552325094664411e-07

This O 0 6.43851905124393e-08
study O 0 1.3748331362251065e-08
provides O 0 5.886220399986541e-10
further O 0 1.0945863659905797e-10
evidence O 0 3.899565670373306e-10
that O 0 9.583530496959369e-11
the O 0 1.7464786949972222e-08
DM B-Disease 1 1.0
expansion O 0 1.0282215953338891e-05
tends O 0 1.2404535709720221e-07
to O 0 3.1551063983670247e-09
be O 0 1.9353958435885943e-09
transmitted O 0 2.5563080541246563e-08
preferentially O 0 1.984095554519172e-08
. O 0 2.0525675381577457e-07

Diagnosis O 1 1.0
of O 0 0.0005926229641772807
hemochromatosis B-Disease 1 1.0
. O 0 0.0013245188165456057

If O 0 8.684819476911798e-07
untreated O 0 4.103862011106685e-05
, O 0 3.629021350093353e-08
hemochromatosis B-Disease 1 1.0
can O 0 3.1741276274033225e-08
cause O 0 5.092880428492208e-07
serious O 0 7.966735324771435e-07
illness O 0 7.203444170045259e-07
and O 0 1.2464973497827714e-10
early B-Disease 0 1.4355679311961467e-08
death I-Disease 0 6.522953732712722e-09
, O 0 1.4535526948744604e-10
but O 0 4.594493882570383e-11
the O 0 7.446062100235906e-10
disease O 0 3.04425906705319e-09
is O 0 1.3560408872181906e-11
still O 0 3.739944812175544e-11
substantially O 0 1.513793423946197e-09
under O 0 3.740906890925544e-07
- O 1 0.99998939037323
diagnosed O 0 0.0028865078929811716
. O 0 3.530546337060514e-06

The O 0 6.343488507809525e-07
cornerstone O 0 2.1404412109404802e-05
of O 0 4.0989391436596634e-08
screening O 0 2.868832815750011e-08
and O 0 1.0739440448048754e-09
case O 0 5.319086282540297e-10
detection O 0 8.518451011241268e-08
is O 0 1.98871960566116e-10
the O 0 4.2829007007583186e-10
measurement O 0 5.704332295408676e-08
of O 0 1.8077839669672358e-08
serum O 0 5.773213729298732e-08
transferrin O 0 2.38909450445135e-07
saturation O 0 2.368839204791584e-07
and O 0 5.968412875034801e-09
the O 0 3.4145251959216694e-08
serum O 0 3.9769980730852694e-07
ferritin O 0 1.9557417090254603e-06
level O 0 9.92539526123437e-07
. O 0 5.247244985184807e-07

Once O 0 1.1637051784418873e-06
the O 0 1.988259157315042e-08
diagnosis O 0 9.06619789020624e-06
is O 0 4.4685724565063367e-10
suspected O 0 5.4443681563043356e-08
, O 0 2.211750560476844e-09
physicians O 0 1.630502026728209e-07
must O 0 2.9889804409322096e-08
use O 0 5.458664986690565e-07
serum O 0 4.756539965455886e-06
ferritin O 0 1.8278406059835106e-05
levels O 0 9.69108623394277e-06
and O 0 1.5571124833968497e-07
hepatic O 0 0.14021213352680206
iron O 1 0.9943524599075317
stores O 0 6.0502679843921214e-06
on O 0 1.1773483947763452e-06
liver O 0 2.6851475922740065e-06
biopsy O 0 2.594901161501184e-06
specimens O 0 2.886313765770865e-08
to O 0 2.3414448158121104e-09
assess O 0 1.3110199859056593e-07
patients O 0 1.855432785191624e-08
for O 0 1.9123880257154724e-09
the O 0 6.368921390276228e-09
presence O 0 1.596352916521937e-08
of O 0 1.3014008004574862e-07
iron B-Disease 0 0.0017464833799749613
overload I-Disease 0 0.00028543410007841885
. O 0 3.1207680422085105e-06

Liver O 1 1.0
biopsy O 1 1.0
is O 0 1.2649310043855166e-08
also O 0 5.721739193553788e-10
used O 0 2.8960656095478043e-10
to O 0 1.5102308292824773e-10
establish O 0 1.0321013377279087e-08
the O 0 4.970832634398903e-09
presence O 0 1.9375832494006318e-08
or O 0 6.176493627663149e-08
absence O 0 1.9852386685670353e-06
of O 0 7.891438258411654e-08
cirrhosis B-Disease 0 0.00831571500748396
, O 0 1.7090692194798862e-09
which O 0 4.598088229612607e-11
can O 0 3.783084956410221e-11
affect O 0 1.3039612722920424e-09
prognosis O 0 2.04479670173896e-06
and O 0 4.28584705502999e-08
management O 0 3.1796651001059217e-06
. O 0 1.711616732791299e-06

A O 0 9.794878224056447e-07
DNA O 0 6.371038097086057e-08
- O 0 8.897816172748207e-08
based O 0 2.079404426424958e-09
test O 0 2.3411010907636864e-09
for O 0 1.1284542189571312e-09
the O 0 7.286088621327735e-09
HFE O 0 0.00018471320800017565
gene O 0 7.347972541538184e-08
is O 0 1.7061371759830024e-10
commercially O 0 8.737838008698873e-09
available O 0 5.349612308691576e-09
, O 0 1.2221430811809597e-10
but O 0 1.0964120236711672e-11
its O 0 7.1539202513293265e-12
place O 0 1.1790912690656796e-10
in O 0 2.5897900490789993e-10
the O 0 8.184921629350583e-10
diagnosis O 0 8.254526619566604e-06
of O 0 1.1612490169454759e-07
hemochromatosis B-Disease 1 1.0
is O 0 1.2616130362630429e-08
still O 0 3.1916831400025103e-09
being O 0 1.5825010191150568e-09
evaluated O 0 3.878740173490769e-08
. O 0 3.379306008355343e-07

Currently O 0 3.6777925060960115e-07
, O 0 2.4093005368541753e-09
the O 0 6.625684445538127e-10
most O 0 6.029944599195147e-11
useful O 0 1.390035975212811e-09
role O 0 6.546108100025094e-10
for O 0 1.214530420678983e-10
this O 0 3.8537870811206076e-11
test O 0 3.5654304508803136e-10
is O 0 6.767874888985448e-12
in O 0 2.4577829355054703e-11
the O 0 8.006851431874296e-11
detection O 0 5.505933700078458e-07
of O 0 6.852735623397166e-08
hemochromatosis B-Disease 1 1.0
in O 0 5.334586035132816e-07
the O 0 1.3890752370571136e-07
family O 0 1.2361679457839614e-09
members O 0 1.1574131236757879e-10
of O 0 3.5742955817319455e-10
patients O 0 3.291351080569882e-10
with O 0 1.3526052673740185e-11
a O 0 2.285757583209147e-09
proven O 0 7.40872607707388e-08
case O 0 6.167732991002595e-09
of O 0 7.054961770336377e-08
the O 0 2.786004813515319e-07
disease O 0 1.439835614291951e-06
. O 0 3.855973602640006e-07

It O 0 6.580866340755165e-08
is O 0 1.7181358558104876e-09
crucial O 0 1.3652591235313594e-07
to O 0 1.1669442301354138e-07
diagnose O 1 0.9999995231628418
hemochromatosis B-Disease 1 1.0
before O 1 1.0
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 8.246765048625093e-08
because O 0 7.004032909208036e-10
phlebotomy O 0 5.250420599622885e-06
therapy O 0 7.672093715882511e-07
can O 0 5.34067845503472e-10
avert O 0 1.2142511423007818e-06
serious O 0 0.0011462877737358212
chronic O 1 1.0
disease O 0 6.716386451444123e-06
and O 0 7.259423617789196e-10
can O 0 4.89895679578467e-10
even O 0 1.078562794631921e-09
lead O 0 4.290588329070033e-09
to O 0 1.2478277300331797e-09
normal O 0 1.6477651243462788e-08
life O 0 1.1113031384013539e-08
expectancy O 0 1.3842662127672156e-08
. O 0 3.6878278208973825e-09
. O 0 1.4022066352481488e-07

Prevalence O 0 0.00015605347289238125
of O 0 1.5216890858482657e-07
the O 0 6.522793682961492e-08
I1307K O 0 1.1386941878299695e-05
APC B-Disease 0 7.595781994496065e-07
gene O 0 8.57367243867202e-09
variant O 0 4.4774669305525094e-08
in O 0 3.1188420734906686e-09
Israeli O 0 1.3243570720078424e-06
Jews O 0 1.8670984758273335e-08
of O 0 1.4650201884958136e-10
differing O 0 5.233301205581631e-12
ethnic O 0 2.0806631157582745e-12
origin O 0 3.1534309885561385e-11
and O 0 4.5178305541071495e-11
risk O 0 8.562755837715486e-09
for O 0 4.954384280608792e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 1.0

BACKGROUND O 0 9.32796101551503e-05
& O 0 1.75509321707068e-05
AIMS O 0 3.7467020774784032e-06
Israeli O 0 5.675528882420622e-07
Jews O 0 3.5976015055894095e-08
of O 0 1.6288810300579826e-09
European O 0 1.6871488650593847e-09
birth O 0 1.2987346309500936e-08
, O 0 5.249672363483171e-10
i O 0 2.583525615662552e-09
. O 0 5.372268740977404e-10
e O 0 8.113488547678571e-09
. O 0 3.3726180181936627e-10
, O 0 9.520716437450005e-10
Ashkenazim O 0 3.5204226378482417e-07
, O 0 4.946466569677455e-10
have O 0 2.0046500570636283e-10
the O 0 3.6191485364156506e-09
highest O 0 0.06780339032411575
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.07823395729064941
of O 0 5.823689264161658e-08
any O 0 6.252731665767897e-09
Israeli O 0 2.4042215045483317e-06
ethnic O 0 6.2275593570859655e-09
group O 0 1.582749220574442e-08
. O 0 1.3485994543316338e-07

The O 0 3.3109474770753877e-06
I1307K O 0 6.93121983204037e-05
APC B-Disease 0 1.865699459813186e-06
gene O 0 1.2764966861311677e-08
variant O 0 4.537700348805629e-08
was O 0 6.407169905742194e-08
found O 0 1.5325550828393375e-09
in O 0 2.2390473919386977e-09
6 O 0 1.103574390981521e-06
. O 0 4.5401245074572216e-07

1 O 0 6.460255690399208e-07
% O 0 5.1970614478591415e-09
of O 0 1.1617863338031498e-09
American O 0 2.0172510328819726e-09
Jews O 0 2.7881181807742905e-09
, O 0 6.480486286486453e-11
28 O 0 1.082373191074737e-09
% O 0 1.5357966287599112e-10
of O 0 3.871655218645742e-10
their O 0 1.1765179941392034e-08
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 2.0821871657972224e-05
, O 0 8.990235222938736e-10
but O 0 1.4510707913029108e-10
not O 0 3.230474221460611e-10
in O 0 5.143138692709215e-10
non O 0 9.565501102315466e-08
- O 0 2.5758765787031734e-07
Jews O 0 3.8495838339258626e-07
. O 0 1.8470313989382703e-07

We O 0 2.4356020844606974e-07
assessed O 0 5.276158390188357e-07
the O 0 3.504731438397357e-08
I1307K O 0 6.0446282077464275e-06
prevalence O 0 1.0717104004243083e-07
in O 0 1.8307740046186183e-10
Israeli O 0 4.292178701348348e-08
Jews O 0 5.8470264185928045e-09
of O 0 1.6428991500561096e-10
differing O 0 1.3841030752081984e-11
ethnic O 0 6.761075206640488e-12
origin O 0 5.858920987256155e-11
and O 0 6.87844434188456e-11
risk O 0 1.1705863833810781e-08
for O 0 5.141613996784145e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 1.0

METHODS O 0 5.8495052144280635e-06
DNA O 0 1.8658404599136702e-07
samples O 0 4.5837783346769356e-08
from O 0 1.5723435886627612e-09
500 O 0 1.051805487151114e-08
unrelated O 0 1.3439428458994485e-09
Jews O 0 5.362136512587767e-09
of O 0 1.2506536917200606e-09
European O 0 2.685048405837165e-09
or O 0 4.3995035392541126e-10
non O 0 9.548181800766997e-09
- O 0 6.849805611608417e-09
European O 0 7.575101101942039e-10
origin O 0 2.397664566888835e-10
, O 0 1.273047032374075e-11
with O 0 4.108164275342524e-13
or O 0 1.8228774392725633e-11
without O 0 1.3021264622103956e-10
a O 0 1.0442563480594913e-10
personal O 0 2.2330295390560195e-09
and O 0 7.871572282880379e-10
/ O 0 0.031099287793040276
or O 0 5.547154913188024e-08
family O 0 1.070426636218258e-09
history O 0 2.621143968539741e-09
of O 0 1.1734044846889446e-09
neoplasia B-Disease 0 2.8369441906761494e-07
, O 0 1.6893996201972072e-09
were O 0 1.6045239581430337e-09
examined O 0 9.857550331560105e-09
for O 0 2.0366779374114685e-09
the O 0 2.5026305472408694e-09
I1307K O 0 1.0380105663898576e-07
variant O 0 4.001824649435548e-09
by O 0 1.8530331435950842e-10
the O 0 1.7293075860180807e-09
allele O 0 5.491914034649881e-09
- O 0 2.0694308489055402e-08
specific O 0 1.1311118264245579e-08
oligonucleotide O 0 1.019932938106649e-06
( O 0 1.834579066439801e-08
ASO O 0 5.822156253998401e-06
) O 0 1.3563293821405864e-09
method O 0 5.966890626041277e-08
. O 0 5.769833677504721e-08

RESULTS O 0 3.088717619448289e-07
In O 0 9.588002392035833e-09
persons O 0 1.859477793964004e-09
at O 0 6.311657307911389e-10
average O 0 3.5624256322641656e-10
risk O 0 8.292846964685907e-10
for O 0 2.69004765129921e-08
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.1296626325929537e-05
I1307K O 0 5.104514457343612e-06
was O 0 1.1488059392661398e-08
found O 0 2.9901517373254194e-10
in O 0 7.962051018495231e-10
5 O 0 1.4286005978192406e-07
. O 0 2.2585845727007836e-07

0 O 0 1.2006815950371674e-06
% O 0 6.522108186857167e-09
of O 0 2.04969041739389e-09
120 O 0 9.227429487168592e-09
European O 0 6.123202833663299e-09
and O 0 6.167991895011937e-09
1 O 0 1.5828707091714023e-06
. O 0 1.5433543012477458e-06

6 O 0 1.7063199493350112e-06
% O 0 1.095696600117435e-08
of O 0 3.018644889607458e-09
188 O 0 9.920927190876228e-09
non O 0 2.715701157285366e-07
- O 0 4.0548420088271087e-07
European O 0 4.5886157096219904e-08
Jews O 0 1.5654893559258198e-07
( O 0 2.5159871408497736e-10
P O 0 1.904875190916755e-08
= O 0 6.651645456656752e-09
0 O 0 1.392841286751434e-09
. O 0 3.250853197744874e-10
08 O 0 9.843031278933267e-08
) O 0 6.7921197555165236e-09
. O 0 6.851637834870417e-08

It O 0 7.09346759109053e-09
occurred O 0 2.0916532506021213e-08
in O 0 3.0611095880317407e-09
15 O 0 1.3661956188570912e-07
. O 0 1.4391325464657712e-07

4 O 0 4.955268195772078e-07
% O 0 6.550907372115944e-09
of O 0 2.876183957667422e-09
52 O 0 1.227042378815213e-08
Ashkenazi O 0 1.2519913639152946e-07
Israelis O 0 4.3036803276663704e-07
with O 0 1.635786617271151e-09
familial O 1 0.9963799118995667
cancer B-Disease 1 1.0
( O 0 4.746178561276793e-09
P O 0 5.155981739335402e-07
= O 0 2.4749096994014508e-08
0 O 0 2.4018951272353206e-09
. O 0 3.841130469250942e-10
02 O 0 9.76186953494107e-08
) O 0 9.710823811737157e-11
and O 0 6.488599241238902e-11
was O 0 2.989486214133308e-09
not O 0 2.9336372220356566e-10
detected O 0 2.935177878526929e-09
in O 0 7.628021547745334e-10
51 O 0 2.622665462581608e-08
non O 0 1.2586982620632625e-06
- O 0 1.7476537550464855e-06
European O 0 1.335659334245065e-07
Jews O 0 1.1003275091070464e-07
at O 0 1.037093877442885e-08
increased O 0 4.5029264761353716e-09
cancer B-Disease 0 9.066801531787405e-09
risk O 0 1.593988940840063e-08
. O 0 5.624792365210851e-08

Colorectal B-Disease 1 0.9932106137275696
neoplasia I-Disease 0 0.0007269785273820162
occurred O 0 4.32655861004605e-06
personally O 0 2.5978618367616946e-08
or O 0 1.9659479599809515e-10
in O 0 7.172409194344809e-11
the O 0 3.7199823083033934e-11
families O 0 4.798583839310533e-12
of O 0 3.701573075831632e-11
13 O 0 1.2385042991169826e-09
of O 0 4.099742323404598e-09
20 O 0 6.311410771786541e-08
Ashkenazi O 0 4.692810477990861e-07
I1307K O 0 1.295284164370969e-07
carriers O 0 1.2034900853663544e-09
, O 0 2.4756438565809447e-10
8 O 0 7.311216076999472e-09
of O 0 3.457066855006019e-09
whom O 0 4.114760088214098e-09
also O 0 1.9973385168015056e-09
had O 0 3.4115421598812645e-09
a O 0 1.7683460251660676e-09
personal O 0 1.1563654567225967e-07
or O 0 3.74191833074633e-09
family O 0 1.0547722695264383e-09
history O 0 5.305542227773685e-09
of O 0 1.1976421632198253e-08
noncolonic O 0 6.453817150031682e-06
neoplasia B-Disease 0 0.0003496760327834636
. O 0 1.6318741472787224e-05

CONCLUSIONS O 0 1.7988149920711294e-05
The O 0 6.011212576595426e-07
I1307K O 0 3.8469235732918605e-05
APC O 0 3.4190334190498106e-06
variant O 0 1.046220063471992e-06
may O 0 2.0461524030679357e-08
represent O 0 8.982111165956042e-10
a O 0 5.422922555453624e-09
susceptibility O 0 1.1985498815647588e-07
gene O 0 4.5601375120440935e-08
for O 0 1.6969971738944878e-07
colorectal B-Disease 1 1.0
, I-Disease 0 0.1715131402015686
or I-Disease 0 1.6817862160678487e-06
other I-Disease 0 2.178151170539877e-08
, I-Disease 0 3.4760563316638127e-09
cancers I-Disease 0 1.920903827112852e-07
in O 0 4.25277590920814e-09
Ashkenazi O 0 3.6552322058014397e-07
Jews O 0 2.1097276814430188e-08
, O 0 3.04360758818234e-10
and O 0 1.3197842818613026e-10
partially O 0 1.2301614837895158e-08
explains O 0 1.0728610222443535e-09
the O 0 3.02125269247e-10
higher O 0 3.3223610529375946e-08
incidence O 0 8.641757744953793e-07
of O 0 0.00020743087225127965
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.748164140735753e-05
European O 0 4.954894734510162e-07
Israelis O 0 2.1772139007225633e-06
. O 0 2.4473973780914093e-07

Systematic O 0 1.3113642580719898e-06
analysis O 0 1.4668285075458698e-07
of O 0 7.242833532927762e-08
coproporphyrinogen O 0 4.778400125360349e-06
oxidase O 0 2.2105680272943573e-06
gene O 0 8.226527938859363e-07
defects O 0 1.4894496416673064e-05
in O 0 2.6514160822443955e-07
hereditary B-Disease 1 0.9999998807907104
coproporphyria I-Disease 1 0.9990854263305664
and O 0 9.860450234100426e-08
mutation O 0 3.8868570584327244e-08
update O 0 4.429670752870152e-06
. O 0 5.889629051125667e-07

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999977350234985
( O 0 1.0182850473938743e-07
HC B-Disease 1 0.7438483238220215
) O 0 1.4472687936972761e-08
is O 0 1.0802222449868282e-09
an O 0 5.058073404562435e-10
acute O 0 0.023302743211388588
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 1 0.9996410608291626
autosomal O 1 1.0
dominant O 1 0.5990898609161377
inheritance O 0 8.397234410040255e-07
caused O 0 4.6123332708702947e-08
by O 0 7.347976394012079e-11
deficient B-Disease 0 2.6983866252550115e-09
activity I-Disease 0 3.3270330934698222e-09
of I-Disease 0 5.672517566779334e-09
coproporphyrinogen I-Disease 0 4.3473943378558033e-07
III I-Disease 0 0.00021168059902265668
oxidase I-Disease 0 6.512253207802132e-07
( O 0 1.4362635525344558e-08
CPO O 0 3.979687789978925e-06
) O 0 1.609103605915152e-08
. O 0 1.8174164040374308e-07

Clinical O 0 5.3132196626393124e-05
manifestations O 0 8.157604497682769e-06
of O 0 2.616360745832935e-07
the O 0 4.6428290545463824e-08
disease O 0 1.0655895010813765e-07
are O 0 1.9807462961485278e-11
characterized O 0 8.819774771628985e-11
by O 0 4.8036869620959877e-11
acute O 0 3.0635763437203423e-07
attacks O 0 2.759614403657906e-07
of O 0 0.006280419882386923
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 3.2898668678171816e-08
precipitated O 0 5.4319078124365205e-09
by O 0 3.274224641414136e-11
drugs O 0 2.3184782982355046e-09
, O 0 2.0580491477684149e-10
fasting O 0 1.908861513300053e-08
, O 0 2.7487434550721446e-09
cyclical O 0 8.694150892551988e-07
hormonal O 0 9.10931430553319e-06
changes O 0 1.0488109580819582e-07
, O 0 2.7086960230349177e-08
or O 0 1.0611699963192223e-07
infectious B-Disease 0 1.9754461391130462e-05
diseases I-Disease 0 7.415188974846387e-06
. O 0 2.6078760129166767e-07

Skin O 1 1.0
photosensitivity O 1 0.9999998807907104
may O 0 2.096201797030517e-06
also O 0 5.702958549846926e-09
be O 0 3.465621123410756e-10
present O 0 1.7463247514726277e-09
. O 0 1.2170202978722955e-07

The O 0 7.924392662062019e-07
seven O 0 4.994146962644663e-08
exons O 0 1.0179549292388401e-07
, O 0 2.4145774268902187e-09
the O 0 2.433849344285477e-09
exon O 0 3.6238273537492205e-07
/ O 0 1.810864432627568e-06
intron O 0 8.380146141462319e-07
boundaries O 0 9.142825385666242e-10
and O 0 1.7145994346545734e-10
part O 0 3.316615038162496e-10
of O 0 1.7438482879938988e-09
3 O 0 2.3462194409518133e-09
noncoding O 0 1.8147824354386444e-09
sequence O 0 1.8404863744159172e-10
of O 0 3.5543239462754173e-09
the O 0 7.566960391613975e-09
CPO O 0 5.15714248194854e-07
gene O 0 2.6277415798858783e-09
were O 0 3.557891314898143e-09
systematically O 0 2.6990298884754793e-09
analyzed O 0 5.715042328269249e-10
by O 0 1.3875293969345392e-10
an O 0 1.6623286080985622e-10
exon O 0 1.3974268853189642e-08
- O 0 4.043758394800534e-08
by O 0 8.255589989403234e-09
- O 0 8.394127348765323e-07
exon O 0 1.898529603749921e-06
denaturing O 0 1.4165023458190262e-05
gradient O 0 4.532173250026972e-07
gel O 0 6.960596579119738e-07
electrophoresis O 0 5.087220245059143e-08
( O 0 5.212923426256566e-10
DGGE O 0 1.0622346735544852e-06
) O 0 1.7019118059291571e-10
strategy O 0 2.284297639931765e-09
followed O 0 6.005602681824485e-10
by O 0 7.141922903769471e-12
direct O 0 1.1150558254513498e-10
sequencing O 0 1.094390578160187e-09
in O 0 1.3233188989048017e-09
seven O 0 4.666851349810486e-09
unrelated O 0 5.4885973099771945e-08
heterozygous O 0 8.955380792485812e-08
HC B-Disease 0 2.852661782526411e-05
patients O 0 3.0183647936610214e-07
from O 0 7.538379698246445e-09
France O 0 7.006083535543439e-08
, O 0 1.5449167500847238e-09
Holland O 0 8.960832076354563e-08
, O 0 1.1750641570884568e-09
and O 0 9.605569672999081e-10
Czech O 0 5.544393388845492e-07
Republic O 0 3.2868485959625104e-06
. O 0 2.0679926819866523e-06

Seven O 0 1.3277345090045856e-07
novel O 0 1.6535832259023664e-08
mutations O 0 3.994130359785686e-09
and O 0 7.948031122140264e-10
two O 0 4.686223076255658e-10
new O 0 3.801751358167849e-09
polymorphisms O 0 7.180262286965444e-07
were O 0 8.382008331864199e-07
detected O 0 1.7089582797780167e-06
. O 0 1.1206793715246022e-06

Among O 0 1.63736444847018e-07
these O 0 3.583075391944135e-09
mutations O 0 4.562927813367423e-09
two O 0 7.156766290705718e-10
are O 0 3.723789054888016e-10
missense O 0 3.545321192177653e-07
( O 0 5.328847585417407e-09
G197W O 0 3.170490344928112e-06
, O 0 2.192592996053122e-09
W427R O 0 6.74290390634269e-07
) O 0 5.493398513856107e-10
, O 0 2.900211459877511e-10
two O 0 1.796661985853376e-10
are O 0 1.8243705157683365e-10
nonsense O 0 1.6735260999212187e-07
( O 0 3.376662061072011e-09
Q306X O 0 3.0073224479565397e-06
, O 0 4.551393484319988e-09
Q385X O 0 9.676047056927928e-07
) O 0 9.088440000581954e-10
, O 0 3.4714631169663335e-10
two O 0 1.4064822917436715e-10
are O 0 5.501364988558244e-11
small O 0 9.8356478517303e-10
deletions O 0 3.760315223644284e-07
( O 0 4.415874332863723e-09
662de14bp O 0 4.159694526606472e-07
; O 0 1.3052203762242698e-09
1168del3bp O 0 2.3093178924682434e-07
removing O 0 4.9630855869509105e-08
a O 0 2.5761495159315473e-09
glycine O 0 1.2416224492994843e-08
at O 0 2.655489339531414e-08
position O 0 8.546063412495641e-09
390 O 0 3.914285340300694e-09
) O 0 4.5977111007289295e-11
, O 0 1.608551833398586e-11
and O 0 7.615947802963596e-12
one O 0 4.371936406649679e-12
is O 0 1.1038184255518502e-12
a O 0 1.7804740320981338e-11
splicing O 0 7.270138269177551e-09
mutation O 0 7.801490120584731e-09
( O 0 5.184188633933218e-10
IVS1 O 0 1.1104100394732086e-06
- O 0 1.87274835639073e-07
15c O 0 3.4500055789976614e-06
- O 0 3.3295489743068174e-07
- O 0 2.1240374792341754e-07
> O 0 2.1793007931592e-07
g O 0 3.1393028621096164e-08
) O 0 8.856219924080477e-11
which O 0 1.15562143188086e-11
creates O 0 4.5674776461002153e-11
a O 0 1.5434845068718062e-10
new O 0 8.569792653290165e-10
acceptor O 0 5.747994080707031e-09
splice O 0 1.9406477349548368e-06
site O 0 1.5500289691772196e-06
. O 0 5.211174425312493e-07

The O 0 5.012761334910465e-07
pathological O 0 5.645772489515366e-07
significance O 0 1.029830514198693e-07
of O 0 3.672975878998841e-08
the O 0 6.78750966542907e-09
point O 0 1.953976003221669e-08
mutations O 0 1.7339513158631803e-09
G197W O 0 8.187208777599153e-08
, O 0 6.958041920412938e-10
W427R O 0 2.2174504010763485e-07
, O 0 6.961932141891225e-10
and O 0 4.65998239995713e-10
the O 0 4.596917957400137e-09
in O 0 8.270846230118423e-09
- O 0 2.4649560259604186e-07
frame O 0 4.172550802650221e-07
deletion O 0 1.0383887882881027e-07
390delGly O 0 1.924449399837158e-08
were O 0 3.4073915911037034e-10
assessed O 0 7.762537834743455e-10
by O 0 4.49748883968315e-11
their O 0 2.7960733728349396e-10
respective O 0 4.9449502270704215e-09
expression O 0 4.3484407186156204e-09
in O 0 7.589360806470324e-10
a O 0 4.539652265211913e-10
prokaryotic O 0 2.219110312173811e-10
system O 0 1.0674580108727127e-09
using O 0 2.507355878478279e-09
site O 0 4.841228751217841e-09
- O 0 2.9104536558577365e-09
directed O 0 1.970686724916959e-09
mutagenesis O 0 2.429813434901007e-07
. O 0 3.943107458326267e-07

These O 0 1.2502727742003117e-08
mutations O 0 1.6984753603566105e-09
resulted O 0 5.649095635718027e-10
in O 0 2.4417665112075326e-10
the O 0 6.749267811301252e-10
absence O 0 7.984273686645338e-09
or O 0 5.650960255287885e-10
a O 0 5.46895584374596e-10
dramatic O 0 1.9911041704290255e-09
decrease O 0 2.4400977238769883e-08
of O 0 3.6578998674485774e-07
CPO O 0 3.5971825127489865e-05
activity O 0 9.629054602555698e-07
. O 0 7.600564799759013e-07

The O 0 3.7484494441741845e-07
two O 0 6.122012230491691e-09
polymorphisms O 0 3.25209690288375e-08
were O 0 3.1242004538967194e-09
localized O 0 4.703363920555148e-09
in O 0 1.0931514582424029e-09
noncoding O 0 1.1621327011823723e-08
part O 0 3.011433324928703e-09
of O 0 4.873832448737403e-09
the O 0 3.210633703343291e-10
gene O 0 6.530391505332744e-11
1 O 0 2.4372681650675077e-09
) O 0 3.196957698570202e-10
a O 0 2.691750378147617e-09
C O 0 2.2609916072724445e-07
/ O 0 9.549258805918726e-08
G O 0 2.96230506791062e-08
polymorphism O 0 1.1061811910906272e-08
in O 0 1.3531975540104213e-09
the O 0 4.1268481965062165e-09
promotor O 0 3.786689603657578e-06
region O 0 6.71226203508013e-08
, O 0 4.29059676676502e-09
142 O 0 2.493426443095359e-08
bp O 0 1.8568275805819212e-08
upstream O 0 3.272536019949257e-09
from O 0 4.3492431878178195e-10
the O 0 1.6245735312558907e-10
transcriptional O 0 6.611886038676573e-10
initiation O 0 2.369962670556447e-09
site O 0 5.725923735155902e-09
( O 0 1.5385406837431503e-10
- O 0 1.9163801212584985e-08
142C O 0 4.672607474276447e-07
/ O 0 8.430279052618062e-08
G O 0 3.038512019770678e-08
) O 0 6.184289191857317e-11
, O 0 1.906675338447794e-11
and O 0 2.1496943114485134e-11
2 O 0 1.6025267779440355e-09
) O 0 2.7839242022764665e-10
a O 0 2.1784907211497284e-09
6 O 0 4.305412204530512e-08
bp O 0 3.749814680986674e-08
deletion O 0 6.614513381464349e-09
polymorphism O 0 5.764947186293057e-09
in O 0 1.0176589571031514e-09
the O 0 1.1503050734162912e-09
3 O 0 5.5158908551788954e-09
noncoding O 0 1.162782314878541e-08
part O 0 3.5249623220323656e-09
of O 0 8.488441949339176e-09
the O 0 5.944906344979017e-09
CPO O 0 9.061788546205207e-07
gene O 0 1.013701655949717e-08
, O 0 6.06195094121631e-09
574 O 0 9.704820058686892e-08
bp O 0 4.4508755792094234e-08
downstream O 0 3.0335824963145797e-09
of O 0 1.1955737511115672e-09
the O 0 3.46155826225214e-10
last O 0 4.757079730133285e-10
base O 0 2.436863821841939e-09
of O 0 1.295353962982304e-10
the O 0 6.211289121926811e-11
normal O 0 6.490781245815924e-10
termination O 0 1.1070508065813556e-08
codon O 0 9.413538748503925e-08
( O 0 4.300920508626405e-09
+ O 0 3.803755532771902e-07
574 O 0 4.363398034001875e-07
delATTCTT O 0 1.6883009266166482e-06
) O 0 2.6313337286865135e-08
. O 0 1.284963957459695e-07

Five O 0 6.9413067649293225e-06
intragenic O 0 3.387139440746978e-05
dimorphisms O 0 1.686953146418091e-05
are O 0 1.5933163677317452e-09
now O 0 9.909235654248505e-10
well O 0 7.044749228413139e-10
characterized O 0 3.447070129336538e-10
and O 0 3.316963093080716e-10
the O 0 6.15151707350492e-10
high O 0 3.78545639279082e-09
degree O 0 3.053763109051033e-08
of O 0 1.2989501918525548e-08
allelic O 0 6.872448210515358e-08
heterogeneity O 0 2.430413204024262e-08
in O 0 3.730843634031089e-09
HC B-Disease 0 1.191658611787716e-05
is O 0 2.164656676129084e-09
demonstrated O 0 5.433234306906343e-09
with O 0 4.123822811008537e-11
seven O 0 2.5546381676733176e-10
new O 0 1.191848286730135e-10
different O 0 1.7811873503914555e-11
mutations O 0 6.883904557497544e-11
making O 0 7.78918596289202e-11
a O 0 3.1783528586792897e-10
total O 0 8.106864068935238e-10
of O 0 3.1883122808551434e-09
nineteen O 0 1.0808801107486943e-06
CPO O 0 4.959790385328233e-05
gene B-Disease 0 1.0279383104716544e-06
defects I-Disease 0 1.9356355551281013e-05
reported O 0 6.089476300985552e-08
so O 0 3.672945947386097e-09
far O 0 4.565583466842327e-09
. O 0 4.5828576489270745e-09
. O 0 8.24824368805821e-08

Coincidence O 0 1.3526430393540068e-06
of O 0 1.1123723453465573e-07
two O 0 1.7500059179553773e-09
novel O 0 4.7560475557872905e-09
arylsulfatase O 0 3.160432697768556e-07
A O 0 2.4381902719028403e-08
alleles O 0 3.283139093923637e-09
and O 0 3.332672804390313e-09
mutation O 0 1.9144547280802726e-08
459 O 0 1.4015863314398302e-07
+ O 0 1.1394852208468365e-06
1G O 0 8.800059731584042e-06
> O 0 2.8037561605742667e-07
A O 0 2.2413130906784318e-08
within O 0 1.2014236272506196e-09
a O 0 3.6437652894960593e-09
family O 0 1.143009020765362e-09
with O 0 1.8855854655441817e-09
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 6.499642601909272e-09
molecular O 0 3.2747087264084485e-09
basis O 0 5.533931535239844e-09
of O 0 5.212180465008487e-09
phenotypic O 0 2.574429913693166e-07
heterogeneity O 0 2.713329422476818e-06
. O 0 3.4657948617677903e-06

In O 0 8.079117463921648e-08
a O 0 2.429347034649254e-08
family O 0 1.2573507790492044e-09
with O 0 7.100161431017327e-11
three O 0 5.054042184760021e-10
siblings O 0 1.0552436258137732e-08
, O 0 1.3916216790033076e-10
one O 0 9.704024042656023e-12
developed O 0 6.399527435752006e-11
classical O 0 2.5292317218372773e-07
late O 1 0.9975402355194092
infantile O 1 1.0
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 1.863408982671899e-08
MLD B-Disease 1 1.0
) O 0 5.72068115101132e-10
, O 0 1.6796571078447897e-10
fatal O 0 2.694863443508666e-09
at O 0 1.867008547762339e-09
age O 0 1.7240711081001336e-09
5 O 0 7.208389884993949e-09
years O 0 1.2522911596590802e-09
, O 0 1.3449347191496486e-10
with O 0 4.244173762435466e-11
deficient O 0 8.797223927103914e-08
arylsulfatase O 0 9.232226148014888e-06
A O 0 1.3400792340689804e-05
( O 0 1.949267058876103e-08
ARSA O 0 1.1616578376560938e-05
) O 0 6.703670951679896e-10
activity O 0 1.000235783088499e-09
and O 0 1.2038842145400963e-10
increased O 0 6.3559726370954195e-09
galactosylsulfatide O 0 9.834030834099394e-07
( O 0 7.874069396507366e-09
GS O 0 0.3330300450325012
) O 0 3.612791488194489e-08
excretion O 0 1.6962447091373178e-07
. O 0 6.864220836177992e-08

The O 0 2.3635946888589388e-07
two O 0 1.941726113230402e-09
other O 0 8.963212116963604e-11
siblings O 0 2.405847521202986e-09
, O 0 1.8395950041050213e-10
apparently O 0 5.625239829498696e-09
healthy O 0 3.4099809642640366e-09
at O 0 6.223153992124253e-09
12 O 0 7.42850758683744e-08
( O 0 7.673623958481812e-10
1 O 0 8.025685360735224e-08
/ O 0 7.466106239917281e-07
2 O 0 5.093531285638164e-08
) O 0 2.3583052177755803e-10
and O 0 1.2710799079940216e-10
15 O 0 1.2095306978210374e-09
years O 0 2.3170845797615414e-10
, O 0 6.303497307458272e-11
respectively O 0 4.049411916895451e-10
, O 0 4.2093706992263336e-11
and O 0 4.3490832463133344e-11
their O 0 1.4196915865127835e-10
father O 0 7.377347621684294e-09
, O 0 1.0614746859261004e-09
apparently O 0 1.2545247507489421e-08
healthy O 0 3.0421580810013893e-09
as O 0 2.912062535553872e-10
well O 0 6.396760343641006e-10
, O 0 9.840639414449015e-10
presented O 0 7.327804496526369e-08
ARSA O 0 0.000742145988624543
and O 0 1.8938735024676134e-07
GS O 1 0.9999815225601196
values O 0 4.977910528225493e-09
within O 0 3.243446067280331e-10
the O 0 1.4880000009931393e-10
range O 0 3.6515783730095563e-09
of O 0 8.465692147296977e-09
MLD B-Disease 1 1.0
patients O 0 2.799529283947777e-06
. O 0 5.911000471314765e-07

Mutation O 0 1.113892551529716e-07
screening O 0 3.4915469626639606e-08
and O 0 2.4282618138471435e-09
sequence O 0 5.107028688833282e-10
analysis O 0 2.006904420426281e-09
disclosed O 0 1.528521309523967e-08
the O 0 1.7219677905799813e-09
involvement O 0 1.5508872408531715e-08
of O 0 3.517198754465767e-09
three O 0 2.1814791639762632e-10
different O 0 1.4788975599699938e-10
ARSA O 0 1.0783024663396645e-05
mutations O 0 7.601504314891372e-09
being O 0 1.9858892308377563e-09
the O 0 2.731656567611651e-10
molecular O 0 4.169016687427529e-09
basis O 0 1.0763582025674623e-08
of O 0 2.2305616909079617e-08
intrafamilial O 0 5.294917173159774e-06
phenotypic O 0 1.2234082760187448e-06
heterogeneity O 0 5.922860509599559e-06
. O 0 6.684997970296536e-06

The O 0 7.328028317488133e-08
late O 0 3.612444743339438e-06
infantile O 0 8.405659173149616e-06
patient O 0 7.59511706860394e-08
inherited O 0 2.4765389738945487e-08
from O 0 1.5568859978998262e-08
his O 0 4.328392932961833e-08
mother O 0 1.215822642564035e-08
the O 0 5.547078352208246e-09
frequent O 0 2.8956363973264843e-09
0 O 0 9.184234706083316e-09
- O 0 5.934962032938529e-08
type O 0 2.8271372798371885e-07
mutation O 0 9.694200997500957e-08
459 O 0 1.3838101153851312e-07
+ O 0 2.8752151592925657e-07
1G O 0 1.1026801303160028e-06
> O 0 5.080568143966957e-08
A O 0 7.682018576815608e-09
, O 0 4.469107375837389e-11
and O 0 1.904116794793076e-11
from O 0 1.0471124661792786e-10
his O 0 1.0526739480098968e-09
father O 0 5.201464592374805e-09
a O 0 3.497936107432764e-10
novel O 0 2.971362045300907e-10
, O 0 7.564384535418966e-11
single O 0 1.3560500500275907e-09
basepair O 0 2.3427288908806077e-07
microdeletion O 0 2.815044126691646e-07
of O 0 1.7651455408440597e-08
guanine O 0 2.7235435240413608e-08
at O 0 7.74832731309516e-09
nucleotide O 0 8.434247966704334e-09
7 O 0 7.088871711857792e-08
in O 0 7.424878045725336e-09
exon O 0 1.394844275637297e-07
1 O 0 1.0123939375716873e-07
( O 0 4.63514604476245e-09
7delG O 0 3.2747857403592207e-07
) O 0 8.327658562734541e-09
. O 0 6.544291153431914e-08

The O 0 2.0203792416850774e-07
two O 0 7.50406581317975e-09
clinically O 0 4.052888471051119e-06
unaffected O 0 1.0777329606526109e-07
siblings O 0 1.2076019295648166e-08
carried O 0 4.878855097700807e-09
the O 0 1.9916130966635137e-09
maternal O 0 3.056274181290064e-06
mutation O 0 2.9009116886413722e-08
459 O 0 8.888046210131506e-08
+ O 0 2.727120715917408e-07
1G O 0 2.765547378658084e-06
> O 0 1.1674362099256541e-07
A O 0 1.9555010055682942e-08
and O 0 5.026049021417123e-10
, O 0 3.3755656603240425e-10
on O 0 2.1250448067888783e-09
their O 0 5.34126909368382e-10
paternal O 0 1.8486510100501619e-07
allele O 0 8.394350103912984e-09
, O 0 3.4199579279636794e-10
a O 0 6.003621488837041e-10
novel O 0 3.109913881971238e-09
cytosine O 0 1.8642159815840387e-08
to O 0 8.427843423142178e-10
thymidine O 0 3.125531691239303e-07
transition O 0 1.0916647141812064e-07
at O 0 5.875200770333322e-08
nucleotide O 0 1.0760015101141107e-07
2435 O 0 4.472223281482002e-06
in O 0 8.698560982622894e-09
exon O 0 1.0000992745062831e-07
8 O 0 5.198769414960225e-08
, O 0 6.238837779726225e-10
resulting O 0 1.7313463163137754e-10
in O 0 1.2245487956974443e-10
substitution O 0 5.772692990291262e-09
of O 0 1.0510494696802652e-08
alanine O 0 7.242142885388603e-08
464 O 0 6.254809647998627e-08
by O 0 8.7047018482167e-09
valine O 0 2.5126573746092618e-05
( O 0 1.3966701573053797e-08
A464V O 0 6.6033621806127485e-06
) O 0 1.2722964903844058e-08
. O 0 7.080925712443786e-08

The O 0 5.627678660857782e-07
fathers O 0 5.457758902593923e-07
genotype O 0 6.026560583904939e-08
thus O 0 2.5835417361008695e-08
was O 0 1.3023965550473804e-07
7delG O 0 7.259689937200164e-06
/ O 0 7.526263652835041e-05
A464V O 0 0.00014992414799053222
. O 0 1.2408268048602622e-06

Mutation O 0 1.7910837186718709e-06
A464V O 0 2.228572839158005e-06
was O 0 3.0107802473366974e-08
not O 0 2.6339622150040043e-10
found O 0 1.3022059819345344e-10
in O 0 2.4627488937056796e-10
18 O 0 3.2948843653457516e-08
unrelated O 0 6.752054559910903e-07
MLD B-Disease 1 1.0
patients O 0 2.8659587769652717e-06
and O 0 1.801151583435967e-08
50 O 0 7.610523198309238e-07
controls O 0 2.5607280349504435e-06
. O 0 2.097217475238722e-06

A464V O 0 0.00011354555317666382
, O 0 4.522959073938182e-08
although O 0 1.4736589726283e-08
clearly O 0 7.420350556230915e-08
modifying O 0 8.496165719407145e-06
ARSA O 1 0.9999492168426514
and O 0 3.2532066143176053e-06
GS O 1 1.0
levels O 0 6.641747859248426e-06
, O 0 2.963750578288682e-09
apparently O 0 4.718102175615968e-08
bears O 0 5.6126502556708147e-08
little O 0 1.9887207436397603e-09
significance O 0 3.772021806014436e-09
for O 0 5.137256176013238e-10
clinical O 0 1.469894606032085e-08
manifestation O 0 7.526372058919151e-08
of O 0 1.4350948163155408e-07
MLD B-Disease 1 1.0
, O 0 1.0921624493676063e-07
mimicking O 0 5.61707793167443e-07
the O 0 8.854442512529204e-08
frequent O 0 1.1480588000267744e-06
ARSA O 0 0.0015293442411348224
pseudodeficiency O 0 0.00010336278501199558
allele O 0 3.038326212845277e-06
. O 0 6.063543764867063e-07

Our O 0 3.4780384794430574e-07
results O 0 1.2786191661007251e-08
demonstrate O 0 8.574342125200474e-09
that O 0 2.673776651473947e-11
in O 0 7.426485121309057e-11
certain O 0 2.4750679283869204e-10
genetic O 0 3.959753858140402e-09
conditions O 0 3.2566785534982046e-07
MLD B-Disease 1 1.0
- O 1 0.9999926090240479
like O 0 4.8154001888178755e-06
ARSA O 1 0.9999986886978149
and O 0 2.0080597096239217e-06
GS O 1 1.0
values O 0 5.8908316447059406e-08
need O 0 6.569826460633976e-09
not O 0 1.4124934555326263e-10
be O 0 5.250650608745744e-11
paralleled O 0 7.45160322335181e-10
by O 0 1.5907497541434168e-10
clinical O 0 1.4945442217140226e-07
disease O 0 2.9264645817761448e-08
, O 0 2.985615366046801e-10
a O 0 6.888820069939072e-10
finding O 0 5.231253208393127e-09
with O 0 9.647648652189034e-11
serious O 0 9.207163031987875e-08
diagnostic O 0 2.0649891666835174e-05
and O 0 2.6868664804169384e-07
prognostic O 0 0.0024815150536596775
implications O 0 1.0467427273397334e-05
. O 0 1.3088803143546102e-06

Moreover O 0 9.139743269770406e-06
, O 0 9.604350026393149e-08
further O 0 1.2068953481048084e-07
ARSA O 0 0.00011467042349977419
alleles O 0 4.098751560377423e-08
functionally O 0 4.1080493673462115e-08
similar O 0 2.1392663196451167e-09
to O 0 2.2022748069616682e-09
A464V O 0 4.692783761583996e-07
might O 0 2.463360848636853e-09
exist O 0 7.067696428109116e-10
which O 0 3.1597585659071115e-11
, O 0 2.5208521034492115e-11
together O 0 1.8656751490930823e-11
with O 0 3.403135412360925e-11
0 O 0 1.9121484839956793e-08
- O 0 2.502656002434378e-07
type O 0 4.1640444692347955e-07
mutations O 0 1.1312783954053884e-07
, O 0 2.944474664090535e-09
may O 0 2.550522104627362e-08
cause O 0 1.0974806627928047e-06
pathological O 0 0.005483704153448343
ARSA O 1 0.9998264908790588
and O 0 6.892466331009928e-07
GS O 1 1.0
levels O 0 1.0182495771005051e-06
, O 0 2.913785046576578e-10
but O 0 2.0460126648469412e-11
not O 0 2.8316115077697823e-11
clinical O 0 1.0893840274306399e-09
outbreak O 0 7.567837467803429e-10
of O 0 2.809105448253746e-10
the O 0 1.3662582176721116e-09
disease O 0 1.1057424309512953e-08
. O 0 5.831299887404384e-09
. O 0 2.009522148682663e-07

Human O 0 0.000347178807714954
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 0 0.003704661037772894
to O 0 5.891595264984062e-07
hematological B-Disease 1 0.9999997615814209
malignancy I-Disease 1 0.9999988079071045
and O 0 9.818711532716407e-08
neurofibromatosis B-Disease 1 0.6012423038482666
type I-Disease 0 1.3563162610807922e-05
1 I-Disease 0 0.00014057995576877147
. O 0 2.7664018489304e-06

Heterozygous O 0 2.499002675904194e-06
germ O 0 5.7868783187586814e-05
- O 0 4.763912329508457e-06
line O 0 1.2746589561629662e-07
mutations O 0 3.729541564467809e-09
in O 0 6.367557592312778e-10
the O 0 6.410159070213695e-10
DNA O 0 7.865692985831174e-09
mismatch O 0 8.272015747934347e-07
repair O 0 1.602467818884179e-05
genes O 0 1.3349411176477588e-07
lead O 0 8.173476544470759e-07
to O 0 8.235461450567527e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.07349762320518494

The O 0 5.165864536138542e-07
disease O 0 8.982689791992016e-07
susceptibility O 0 1.0232498226514508e-07
of O 0 1.6081340703522073e-08
individuals O 0 4.827082622504975e-10
who O 0 1.4813467785756984e-08
constitutionally O 0 3.646545337687712e-06
lack O 0 2.8304332317929948e-06
both O 0 9.334899964130727e-09
wild O 0 2.4882954363647514e-08
- O 0 4.7469960406942846e-08
type O 0 8.43828651397871e-09
alleles O 0 7.40100758456208e-10
is O 0 8.025657222132665e-11
unknown O 0 3.424190708756214e-08
. O 0 6.69557564947354e-08

We O 0 1.3664418929693056e-07
have O 0 1.0241471004590608e-09
identified O 0 2.9723892236432903e-09
three O 0 1.3857415215312585e-10
offspring O 0 2.4385657937386895e-09
in O 0 7.78523967515099e-10
a O 0 2.0968540681565173e-08
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 1 0.9787503480911255
who O 0 3.40140822174817e-08
developed O 0 2.0333764894076012e-07
hematological B-Disease 1 0.9999499320983887
malignancy I-Disease 0 0.0005986125906929374
at O 0 1.16580025633084e-08
a O 0 2.4609550508536415e-10
very O 0 1.7295895618496537e-11
early O 0 1.444449670984227e-09
age O 0 5.568998595606445e-10
, O 0 5.879384479268168e-11
and O 0 4.623036328754715e-11
at O 0 9.739618000992323e-10
least O 0 8.951799718159847e-11
two O 0 2.1549900752759754e-11
of O 0 1.9991859556700575e-10
them O 0 1.850585379381542e-10
displayed O 0 3.331212639068326e-08
signs O 0 2.3927154302327835e-07
of O 0 1.3101750084842934e-07
neurofibromatosis B-Disease 0 0.1617652326822281
type I-Disease 0 4.316209924581926e-06
1 I-Disease 0 6.4427727011207025e-06
( O 0 1.8484424657572163e-08
NF1 B-Disease 0 2.536499232519418e-05
) O 0 8.484609281822486e-08
. O 0 4.5193803543952527e-07

DNA O 0 4.162352595926677e-08
sequence O 0 5.927195401156382e-10
analysis O 0 2.3745960753274176e-09
and O 0 3.449510121988908e-10
allele O 0 7.762138709566102e-10
- O 0 1.2617880074117238e-09
specific O 0 1.9266289952302174e-10
amplification O 0 1.0931687555171266e-08
in O 0 8.049408917187861e-10
two O 0 5.441528339034107e-10
siblings O 0 1.9496091852033715e-08
revealed O 0 1.0326013821781999e-08
a O 0 1.1892426599047212e-08
homozygous O 0 2.3036055551983736e-07
MLH1 O 0 0.00016287209291476756
mutation O 0 9.206846129927726e-08
( O 0 2.5306290396542863e-09
C676T O 0 1.6228707409027265e-06
- O 0 4.340614395914599e-06
- O 0 4.982861355529167e-06
> O 0 5.571645033342065e-06
Arg226Stop O 0 4.245447780704126e-05
) O 0 9.589941285526038e-09
. O 0 5.0436856469104896e-08

Thus O 0 4.447163348686445e-07
, O 0 1.3832000433922076e-08
a O 0 1.0281854478932928e-08
homozygous O 0 6.471058355828063e-08
germ O 0 0.0006161227356642485
- O 0 0.00010717567784013227
line O 0 3.244883828301681e-06
MLH1 O 0 0.00026654827524907887
mutation O 0 1.449274300568959e-08
and O 0 4.836012146292035e-10
consequent O 0 3.1725892313261284e-06
mismatch O 1 0.9849446415901184
repair O 1 1.0
deficiency O 1 0.6453875303268433
results O 0 5.307032324708416e-08
in O 0 2.1396674654283743e-08
a O 0 1.2295468643230834e-08
mutator O 0 9.129394129558932e-06
phenotype O 0 3.989305241702823e-08
characterized O 0 1.1526177789988878e-09
by O 0 1.0089227370224663e-10
leukemia B-Disease 1 0.9984109401702881
and O 0 3.311198088340461e-05
/ O 1 1.0
or O 1 0.9999998807907104
lymphoma B-Disease 1 1.0
associated O 1 1.0
with O 0 7.361285270235385e-08
neurofibromatosis B-Disease 1 1.0
type I-Disease 0 0.001357798813842237
1 I-Disease 0 4.51234845968429e-05
. O 0 1.1943099309519312e-07
. O 0 3.049566998925002e-07

Missense O 0 6.0114911320852116e-05
mutations O 0 2.202112767690778e-07
in O 0 1.7422699727376312e-08
the O 0 7.17784987003256e-09
most O 0 3.4033839635405627e-10
ancient O 0 1.48192258464519e-09
residues O 0 2.5673496661937634e-09
of O 0 2.852157843236114e-09
the O 0 7.773076404760104e-09
PAX6 O 0 4.2395524360472336e-05
paired O 0 2.1738809152793692e-07
domain O 0 1.0745760903319024e-07
underlie O 0 7.255899276970013e-07
a O 0 6.793415607830866e-09
spectrum O 0 6.034105837215975e-08
of O 0 7.31210825222206e-09
human O 0 4.941643396705331e-07
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 0.22874873876571655

Mutations O 0 8.152643431458273e-07
of O 0 6.151522313757596e-08
the O 0 5.925118617966518e-09
human O 0 4.543206255647192e-09
PAX6 O 0 0.0002821653033606708
gene O 0 2.433489726172411e-06
underlie O 1 0.9999998807907104
aniridia B-Disease 1 1.0
( O 0 0.01269762497395277
congenital B-Disease 1 1.0
absence I-Disease 0 0.02702607959508896
of I-Disease 0 5.069243798061507e-07
the I-Disease 0 2.539033161497173e-08
iris I-Disease 0 7.041242042760132e-07
) O 0 5.066657093877325e-10
, O 0 2.171814394991145e-10
a O 0 3.2582112563517285e-09
rare O 0 3.5984983242087765e-06
dominant O 1 0.9999960660934448
malformation B-Disease 1 1.0
of I-Disease 1 1.0
the I-Disease 1 1.0
eye I-Disease 1 1.0
. O 0 0.04634017497301102

The O 0 1.1610402452788549e-06
spectrum O 0 2.757162519628764e-06
of O 0 3.0242168236327416e-07
PAX6 O 0 0.09336668252944946
mutations O 0 1.5588047972414643e-06
in O 0 1.3065690041003108e-07
aniridia B-Disease 1 1.0
patients O 0 2.9242445975796727e-07
is O 0 3.301887582796148e-11
highly O 0 1.0342995904188967e-10
biased O 0 4.219726512655342e-10
, O 0 3.7287554988107985e-11
with O 0 9.625440201832536e-12
92 O 0 4.959527188930224e-08
% O 0 1.5898972416383828e-10
of O 0 1.5728077173982058e-10
all O 0 5.771244940278031e-11
reported O 0 3.317671692926183e-10
mutations O 0 3.8879802155555865e-10
leading O 0 3.2256368687200165e-09
to O 0 3.0873963385857905e-09
premature O 0 1.71440248664112e-07
truncation O 0 6.160705083857465e-07
of O 0 3.1695725510871853e-07
the O 0 1.600905363829952e-08
protein O 0 2.0284323110075775e-09
( O 0 2.767137630144134e-10
nonsense O 0 1.2895473133767155e-08
, O 0 3.4516228764047696e-10
splicing O 0 1.0125074112465882e-08
, O 0 1.186333142833007e-09
insertions O 0 1.170503782788046e-08
and O 0 1.6406351277531428e-10
deletions O 0 1.861528931001999e-09
) O 0 3.6905825617772336e-11
and O 0 4.4149853911656933e-11
just O 0 2.539040644400359e-10
2 O 0 4.329596237084843e-09
% O 0 4.917502516299521e-10
leading O 0 7.112824218502567e-10
to O 0 6.421083803553884e-11
substitution O 0 4.072573389635181e-09
of O 0 9.678843504445922e-09
one O 0 5.030518224202751e-10
amino O 0 2.7638460964318767e-10
acid O 0 1.8990617411951405e-10
by O 0 7.976030946821311e-11
another O 0 3.727564479305556e-09
( O 0 2.4865718373234813e-09
missense O 0 4.981056918040849e-07
) O 0 2.6896371352336246e-08
. O 0 2.3070769827882032e-07

The O 0 3.571941817881452e-07
extraordinary O 0 6.323942614017142e-08
conservation O 0 6.681274555830896e-08
of O 0 1.3169390911116352e-08
the O 0 9.294605973764192e-09
PAX6 O 0 7.87238241173327e-06
protein O 0 1.3852303304418001e-08
at O 0 1.4643510404255267e-08
the O 0 4.804488806797735e-09
amino O 0 2.0093875008342366e-08
acid O 0 5.343842701677204e-08
level O 0 6.636092280132289e-07
amongst O 0 1.1762502793999374e-07
vertebrates O 0 8.871446652847226e-07
predicts O 0 8.35878921634503e-08
that O 0 7.787437361628236e-10
pathological O 0 6.285701488195627e-07
missense O 0 6.671992196061183e-06
mutations O 0 8.67962199890826e-08
should O 0 5.124614066431832e-09
in O 0 1.946888206205699e-09
fact O 0 1.3446967983554714e-09
be O 0 3.2225849766476244e-10
common O 0 4.0748168728121925e-10
even O 0 6.540563229906482e-11
though O 0 5.409466624639592e-11
they O 0 7.485587844024977e-11
are O 0 8.574971288588529e-11
hardly O 0 2.2886815997935628e-08
ever O 0 6.132565122385358e-09
seen O 0 1.01623962578401e-08
in O 0 3.218264055249165e-08
aniridia B-Disease 1 1.0
patients O 0 4.834163064515451e-06
. O 0 5.330608701115125e-07

This O 0 4.695640143381752e-08
indicates O 0 1.854710873772092e-08
that O 0 3.534309997443863e-11
there O 0 1.4248913680903197e-11
is O 0 6.958937332629533e-12
a O 0 5.759621599099596e-11
heavy O 0 7.193202833377654e-08
ascertainment O 0 6.343310815282166e-06
bias O 0 5.862115415311564e-08
in O 0 3.791150060550308e-09
the O 0 2.0302746150946405e-09
selection O 0 5.269547909136918e-09
of O 0 3.159219552628656e-09
patients O 0 8.192777567472831e-10
for O 0 1.3645073959622778e-10
PAX6 O 0 5.225491577220964e-07
mutation O 0 1.1426318780038969e-09
analysis O 0 6.106976035979983e-10
and O 0 1.7730431012275005e-10
that O 0 1.0300470892898872e-10
the O 0 7.630266196656521e-09
missing O 0 1.8037701465800637e-06
PAX6 O 0 0.0019624577835202217
missense O 0 8.744760270928964e-05
mutations O 0 8.388445849050186e-07
frequently O 0 2.7912378186556452e-08
may O 0 1.3122728681480567e-08
underlie O 0 4.6549499188586196e-07
phenotypes O 0 1.3316402203145117e-07
distinct O 0 2.9275908364212455e-09
from O 0 1.0253437210394623e-08
textbook O 0 1.7578302504261956e-05
aniridia B-Disease 1 1.0
. O 0 1.5829009498702362e-06

Here O 0 6.987599476815376e-07
we O 0 1.553531170372935e-08
present O 0 8.900795656074934e-10
four O 0 1.7575589872365072e-09
novel O 0 2.6941195940821672e-08
PAX6 O 0 7.054718298604712e-05
missense O 0 4.719911885331385e-06
mutations O 0 8.825778508025905e-08
, O 0 5.115063927974006e-09
two O 0 1.39129063825294e-09
in O 0 3.4262208625790436e-09
association O 0 1.9581798404999518e-09
with O 0 2.3936619353293054e-10
atypical O 0 1.5911873560980894e-06
phenotypes O 0 1.5469924619537778e-05
ectopia B-Disease 0 0.0010648708557710052
pupillae I-Disease 0 0.0002553373051341623
( O 0 1.1641175801102577e-09
displaced B-Disease 0 5.086790988428902e-09
pupils I-Disease 0 7.224838949326795e-09
) O 0 1.55687940317506e-09
and O 0 4.5829999351099104e-08
congenital B-Disease 1 1.0
nystagmus I-Disease 1 1.0
( O 0 3.4691414185772373e-09
searching B-Disease 0 1.1136334165939843e-07
gaze I-Disease 0 2.464184944983572e-07
) O 0 4.5300857509644743e-10
, O 0 2.8747673685991515e-10
and O 0 4.42664904731771e-10
two O 0 3.7356268078880817e-10
in O 0 1.4970934492097854e-09
association O 0 1.2241828661885279e-09
with O 0 1.5405669795409693e-10
more O 0 1.271167837657572e-09
recognizable O 0 1.0210910659225192e-06
aniridia B-Disease 1 1.0
phenotypes O 0 2.810823843901744e-06
. O 0 1.3355310102269868e-06

Strikingly O 0 2.2858232114231214e-05
, O 0 9.839859416160834e-08
all O 0 1.0935232275244289e-08
four O 0 3.0868603229095015e-09
mutations O 0 1.5001976327866373e-09
are O 0 1.3731021875074134e-10
located O 0 1.2197125531798747e-09
within O 0 3.731797093564637e-09
the O 0 4.727885283273281e-08
PAX6 O 0 0.00019356758275534958
paired O 0 1.1478485930638271e-06
domain O 0 1.737564900849975e-07
and O 0 5.6348614663193075e-09
affect O 0 1.6915510769877073e-08
amino O 0 1.6245961242944418e-09
acids O 0 1.7431764920416981e-09
which O 0 3.3776505897753495e-11
are O 0 8.346378276014033e-12
highly O 0 4.068642922572252e-10
conserved O 0 8.189215416898321e-10
in O 0 1.8887493791197585e-09
all O 0 1.7906691684999032e-09
known O 0 1.0497572588974435e-08
paired O 0 5.8648863543453444e-09
domain O 0 3.1128415400871745e-08
proteins O 0 1.4464511810530212e-09
. O 0 3.6413005943813914e-08

Our O 0 1.515890971859335e-06
results O 0 5.419099480263867e-08
support O 0 1.1567367508291682e-08
the O 0 4.838355827097018e-10
hypothesis O 0 5.827361371224526e-10
that O 0 1.562964384652088e-12
the O 0 2.9712187571417914e-11
under O 0 7.135584900730407e-10
- O 0 1.357587908756841e-08
representation O 0 4.015855648020761e-09
of O 0 2.063916326733306e-08
missense O 0 8.747227866479079e-07
mutations O 0 2.678129362720938e-08
is O 0 3.4819272465291817e-10
caused O 0 1.5200456449093736e-09
by O 0 7.893853903873094e-10
ascertainment O 0 0.00016517785843461752
bias O 0 5.84992903895909e-07
and O 0 3.7028407007255737e-09
suggest O 0 1.6169428462831092e-08
that O 0 4.533359798664094e-11
a O 0 1.9661954009375648e-10
substantial O 0 6.944654629137403e-09
burden O 0 5.668388780577516e-07
of O 0 5.216768386162585e-07
PAX6 B-Disease 1 0.9999992847442627
- I-Disease 1 0.9997953772544861
related I-Disease 0 7.89421537774615e-05
disease I-Disease 0 0.0002900474355556071
remains O 0 7.88161180764746e-09
to O 0 2.1946129635797007e-10
be O 0 3.260615111244647e-10
uncovered O 0 2.935465026610018e-08
. O 0 1.5846765677451913e-08
. O 0 2.5431512540308177e-07

The O 0 1.9395122308196733e-07
chromosomal O 0 4.6431478040176444e-07
order O 0 4.887249360763235e-08
of O 0 5.7727731928025605e-08
genes O 0 1.4088491262498337e-08
controlling O 0 3.582571395099876e-08
the O 0 1.6490581344896782e-07
major O 0 2.997729779963265e-06
histocompatibility O 1 0.584787905216217
complex O 0 5.185823283682112e-06
, O 0 4.79920414520052e-09
properdin O 0 2.31137136097459e-07
factor O 0 1.4437838480318987e-08
B O 0 1.488809971306182e-06
, O 0 2.976801860565814e-10
and O 0 1.5547307885555028e-09
deficiency B-Disease 0 2.7779763058788376e-06
of I-Disease 0 3.522634142427705e-05
the I-Disease 0 4.305414222471882e-06
second I-Disease 0 2.558367441451992e-06
component I-Disease 0 6.670068728453771e-07
of I-Disease 0 6.069345914738733e-08
complement I-Disease 0 4.492582945658796e-07
. O 0 1.1632567975539132e-06

The O 0 9.887155272281234e-08
relationship O 0 1.8149312053239441e-09
of O 0 3.499933232120611e-09
the O 0 3.9757194758571757e-10
genes O 0 1.796034987400219e-10
coding O 0 3.102799794874045e-08
for O 0 2.736753046406193e-09
HLA O 0 8.103352229227312e-06
to O 0 1.920460057647233e-08
those O 0 2.614502836451038e-09
coding O 0 1.2439163299404754e-07
for O 0 2.3919606295663698e-09
properdin O 0 1.6951693737610185e-07
Factor O 0 1.7177304911797364e-08
B O 0 1.2018119832646335e-07
allotypes O 0 2.9454929162398003e-08
and O 0 3.017054661658136e-10
for O 0 1.9254764449527784e-09
deficiency B-Disease 0 9.81770043040342e-08
of I-Disease 0 3.747302059764479e-07
the I-Disease 0 4.974078393615855e-08
second I-Disease 0 2.238395069298349e-08
component I-Disease 0 2.2787155273817916e-08
of I-Disease 0 8.353254976611879e-09
complement I-Disease 0 2.487565495812305e-07
( O 0 9.935357425661095e-09
C2 O 0 3.655361433629878e-05
) O 0 3.7780031880707554e-10
was O 0 4.558100563656353e-09
studied O 0 1.8289471270804825e-08
in O 0 1.1401131150279298e-09
families O 0 2.718454628070077e-10
of O 0 1.4019673200138527e-09
patients O 0 5.997180974048888e-09
with O 0 1.7475841884717624e-09
connective O 1 0.9999759197235107
tissue O 1 1.0
disorders O 1 1.0
. O 0 5.9299123677192256e-05

Patients O 0 3.080324177062721e-06
were O 0 1.0643582015745778e-08
selected O 0 1.411618932856129e-09
because O 0 5.978512823689996e-11
they O 0 2.0983602355695297e-10
were O 0 3.670971082669894e-09
heterozygous O 0 2.2237776065026083e-08
or O 0 3.645268620289244e-08
homozygous O 0 5.437971594801638e-06
for O 0 3.12109877995681e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 1.1510424883454107e-05

12 O 0 2.228893890787731e-06
families O 0 6.215656433994354e-09
with O 0 3.262730363662314e-10
15 O 0 2.81559380255203e-08
matings O 0 6.243307666409237e-07
informative O 0 3.858548097923631e-06
for O 0 7.882598765718285e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 7.814798550498381e-07
found O 0 3.17558104256932e-08
. O 0 5.8679660241978127e-08

Of O 0 3.0259905088314554e-06
57 O 0 1.218548050019308e-06
informative O 0 3.6815120552091685e-07
meioses O 0 4.251758127793437e-06
, O 0 1.4801034842193417e-09
two O 0 5.4937207560890045e-11
crossovers O 0 1.3721812575084869e-09
were O 0 5.959298610136443e-10
noted O 0 2.4847324198162823e-09
between O 0 2.370830642917099e-09
the O 0 2.7348296498530544e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 2.5734646413866358e-08
and O 0 4.246818452458001e-09
the O 0 2.6402020125715353e-08
HLA O 0 6.395182936103083e-06
- O 0 1.0283187293680385e-05
B O 0 5.400297141022747e-06
gene O 0 5.395661695217768e-10
, O 0 7.727331968743201e-11
with O 0 7.023222715202282e-12
a O 0 1.981639019543735e-10
recombinant O 0 5.54548795772547e-10
fraction O 0 2.9445983429354783e-09
of O 0 1.5878898196319824e-08
0 O 0 3.651706208529504e-07
. O 0 3.38703983970845e-07

035 O 0 0.013708289712667465
. O 0 6.460748409153894e-05

A O 0 5.287683393362386e-07
lod O 0 1.4632039892603643e-05
score O 0 1.4161426520331588e-07
of O 0 3.264314685225145e-08
13 O 0 1.156026563364776e-08
was O 0 9.877081375009311e-10
calculated O 0 4.3777148572843316e-10
for O 0 4.023121280560815e-10
linkage O 0 6.564983777934685e-06
between O 0 0.13966254889965057
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 2.794082121226893e-08
HLA O 0 4.3686627577699255e-06
- O 0 6.602637768082786e-06
B O 0 5.461552063934505e-06
at O 0 4.224552263565329e-09
a O 0 8.213442426185935e-11
maximum O 0 4.390115215802126e-10
likelihood O 0 6.758668624762265e-11
value O 0 3.8996106344058035e-10
of O 0 1.1807302913169337e-09
the O 0 9.140750378833218e-10
recombinant O 0 2.1342045908312457e-09
fraction O 0 2.727888359643771e-09
of O 0 1.3145650790136187e-08
0 O 0 1.480248812413265e-07
. O 0 2.8268408414078294e-07

04 O 0 0.003486507572233677
. O 0 2.647837027325295e-05

18 O 0 5.13895713538659e-07
families O 0 2.5588042795732235e-09
with O 0 1.4806587900206836e-10
21 O 0 2.6184668655560017e-08
informative O 0 1.252019465880494e-08
matings O 0 4.178316714842367e-08
for O 0 4.120823238196181e-09
both O 0 3.309520435479385e-09
properdin O 0 3.778385689656716e-06
Factor O 0 9.476398190599866e-07
B O 0 3.7444517602125416e-06
allotype O 0 5.138525693837437e-07
and O 0 8.44880343464638e-09
HLA O 0 2.046864938165527e-05
- O 0 8.632075332570821e-05
B O 0 0.00014754328003618866
were O 0 3.6825792193440066e-08
found O 0 9.97915172717967e-09
. O 0 4.5763268730070195e-08

Of O 0 7.314396043511806e-06
72 O 0 5.308173058438115e-06
informative O 0 5.554586550715612e-07
meioses O 0 6.6962534219783265e-06
, O 0 4.708093914729261e-09
three O 0 4.3550038575368433e-10
recombinants O 0 9.362898367726302e-08
were O 0 1.7776933258772942e-09
found O 0 6.721005973986394e-10
, O 0 1.8643030175180542e-10
giving O 0 4.551738708169495e-10
a O 0 2.4180649149663225e-10
recombinant O 0 7.301373394774657e-10
fraction O 0 3.3243816588424124e-09
of O 0 2.061413972853643e-08
0 O 0 5.581487130257301e-07
. O 0 4.624825180599146e-07

042 O 0 0.00395654933527112
. O 0 2.9277452995302156e-05

A O 0 4.110581812710734e-07
lod O 0 1.130995042331051e-05
score O 0 2.7151571657668683e-07
of O 0 9.74750591353768e-08
16 O 0 1.7359550952278369e-07
between O 0 1.7588199785478764e-09
HLA O 0 1.3060202036285773e-05
- O 0 3.045096127607394e-05
B O 0 2.2194710254552774e-05
and O 0 5.035942218789558e-10
Factor O 0 3.243492585625063e-08
B O 0 4.104995525722188e-07
allotypes O 0 4.4940826171568915e-08
was O 0 3.41435435480264e-09
calculated O 0 3.6550695803327926e-09
at O 0 1.6414404280240547e-09
a O 0 2.615160032970465e-10
maximum O 0 2.288802702921089e-09
likelihood O 0 3.1811550615934436e-10
value O 0 6.815878417221199e-10
of O 0 1.3811615184877724e-09
the O 0 4.359890781735487e-10
recombinant O 0 8.456036981741022e-10
fraction O 0 1.8516738142793088e-09
of O 0 5.324133578454848e-09
0 O 0 1.0075664391706596e-07
. O 0 2.137436609928045e-07

04 O 0 0.0025760207790881395
. O 0 1.531144152977504e-05

A O 0 6.267062246934074e-08
crossover O 0 1.8502872123349334e-08
was O 0 8.009517493690055e-09
shown O 0 7.967550508247712e-10
to O 0 2.3068363885769827e-10
have O 0 4.1183442073267074e-11
occurred O 0 2.59992111173446e-10
between O 0 7.76177559724811e-12
genes O 0 5.320240081818639e-11
for O 0 1.283181477740314e-10
Factor O 0 6.182113487795959e-09
B O 0 1.3178819813219889e-07
and O 0 9.233921960394298e-10
HLA O 0 6.353660637614666e-07
- O 0 4.513962721830467e-06
D O 0 2.0754214347107336e-06
, O 0 2.1993658005925454e-09
in O 0 1.052208320473369e-09
which O 0 7.024458792415089e-11
HLA O 0 8.880353874474167e-08
- O 0 8.831468107928231e-07
D O 0 1.7249326447199564e-06
segregared O 0 3.678820576169528e-06
with O 0 1.5374443940174842e-09
HLA O 0 2.1020028725615703e-05
- O 0 7.400422327918932e-05
A O 0 1.0959099199681077e-05
and O 0 6.868686597272244e-08
B O 0 8.302212518174201e-05
. O 0 7.450586281265714e-08

These O 0 7.66983809796784e-09
studies O 0 6.174631028699196e-09
suggest O 0 8.982796173562235e-10
that O 0 1.2169599529487929e-11
the O 0 5.3266981103750055e-11
genes O 0 2.081312205914898e-10
for O 0 3.0084812419062246e-10
Factor O 0 1.5045188774820417e-06
B O 1 1.0
and O 0 0.222166508436203
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.6545163017411824e-09
located O 0 2.992102954291198e-10
outside O 0 8.269627760348897e-10
those O 0 4.873771872193622e-11
for O 0 1.2731253551390154e-10
HLA O 0 9.048112303844391e-08
, O 0 4.719276081033286e-10
that O 0 1.5360740457381894e-11
the O 0 6.765375065720391e-11
order O 0 3.9778963456527094e-10
of O 0 8.431605413861121e-10
genese O 0 1.0718780885099477e-07
is O 0 1.305259650363766e-10
HLA O 0 3.717767782518422e-08
- O 0 3.113284208211553e-07
A O 0 6.301907546912844e-07
, O 0 1.4531652547944418e-09
- O 0 3.732041164994371e-08
B O 0 2.8062174806109397e-07
, O 0 2.2262411358831002e-10
- O 0 1.666622573281984e-08
D O 0 1.1520934606323863e-07
, O 0 1.3469402260213315e-09
Factor O 0 8.717250210565908e-08
B O 0 2.6595083909342065e-05
allotype O 0 0.00031109267729334533
, O 0 1.2285573802728322e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 1.960874573825322e-09
that O 0 3.7784046724720355e-11
the O 0 2.4546312205053766e-10
genes O 0 1.6418097992243474e-09
coding O 0 5.703538136003772e-06
for O 0 5.7321772146678995e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.3872371695811125e-08
Factor O 0 7.596029405476656e-08
B O 0 2.5965795202864683e-07
allotypes O 0 3.111820490175887e-08
are O 0 6.690571274087231e-12
approximately O 0 3.781935702107386e-12
3 O 0 6.824994042142762e-11
- O 0 2.297883439084103e-09
- O 0 4.992099178480203e-08
5 O 0 3.3375027186366424e-08
centimorgans O 0 5.651585297528072e-07
from O 0 2.040936086800116e-09
the O 0 1.1033528535264736e-09
HLA O 0 2.840731667674845e-07
- O 0 8.555344948035781e-07
A O 0 3.4519629821261333e-07
and O 0 3.858895425423725e-09
HLA O 0 2.2637584606854944e-06
- O 0 1.4142696045382763e-06
B O 0 9.938656830854598e-07
loci O 0 9.660966471258803e-10
, O 0 1.7665204368744192e-11
and O 0 3.5009627575438573e-12
that O 0 1.2536323975437247e-12
the O 0 3.95375711337298e-11
apparent O 0 8.445033117254752e-09
lack O 0 5.691507567462395e-07
of O 0 4.2057740756717976e-07
recombinants O 0 2.5096260287682526e-06
between O 0 9.676550671855466e-10
the O 0 3.606159815205956e-09
Factor O 0 1.3149994515515573e-07
B O 0 8.788172999629751e-05
gene O 0 2.0876848338957643e-06
and O 0 0.014851379208266735
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.741916548780864e-06
suggests O 0 2.6724856994064794e-08
that O 0 2.6101355452001762e-11
these O 0 7.779591207346392e-12
two O 0 4.2569347352694464e-11
genes O 0 2.0405303835513422e-10
lie O 0 3.439847295894083e-09
in O 0 8.409714591373074e-10
close O 0 1.1685897582935922e-08
proximity O 0 4.643165496531765e-08
to O 0 8.515230298655752e-09
one O 0 8.631016790161539e-09
another O 0 2.3776699720201577e-08
. O 0 4.762535752433905e-07

Distribution O 0 1.6688436232925596e-07
of O 0 5.5865363890461595e-08
emerin O 0 4.984467977919849e-06
and O 0 1.888984613174216e-08
lamins O 0 5.823520041303709e-05
in O 0 3.3705891411273114e-08
the O 0 2.8064308210673516e-08
heart O 0 2.9020083047726075e-07
and O 0 2.032382262484589e-09
implications O 0 2.8822976005926648e-08
for O 0 1.3092852135798694e-08
Emery B-Disease 1 0.997248113155365
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00010866579395951703

Emerin O 0 0.005287364590913057
is O 0 7.616456798587024e-08
a O 0 1.0327748434235673e-08
nuclear O 0 1.7343796798741096e-07
membrane O 0 3.764383649240699e-08
protein O 0 1.4088429312053563e-09
which O 0 2.9117611100026863e-11
is O 0 3.233974546490437e-11
missing O 0 6.7725602903578874e-09
or O 0 6.971778154785113e-10
defective O 0 2.4495830075466074e-07
in O 0 2.0128230460159102e-07
Emery B-Disease 1 1.0
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.6448173312255676e-07
EDMD B-Disease 1 1.0
) O 0 5.284043780307002e-08
. O 0 1.8051106565053487e-07

It O 0 8.932978801112768e-09
is O 0 1.5944100206777279e-10
one O 0 6.425910498153442e-11
member O 0 4.107355844329419e-10
of O 0 7.455629891239823e-09
a O 0 3.468084486257794e-08
family O 0 9.109044185606763e-09
of O 0 4.438947343032851e-08
lamina O 1 0.9983476400375366
- O 1 0.9995409250259399
associated O 0 6.389452664734563e-06
proteins O 0 1.7291450216117e-10
which O 0 5.705107219977634e-11
includes O 0 2.491769568457869e-10
LAP1 O 0 3.4102572499250527e-06
, O 0 6.878766445339579e-09
LAP2 O 0 2.2584501493838616e-05
and O 0 7.43066124186953e-08
lamin O 0 0.00011486258881632239
B O 0 2.555685114202788e-06
receptor O 0 1.9538083151360297e-08
( O 0 4.036559086983971e-09
LBR O 0 9.92194236459909e-06
) O 0 2.5233619638243e-08
. O 0 2.641718879203836e-07

A O 0 7.045883194223279e-06
panel O 0 2.022924263656023e-07
of O 0 4.2035924963101934e-08
16 O 0 9.732435302112208e-09
monoclonal O 0 1.3750789396027585e-09
antibodies O 0 1.1043886916084489e-09
( O 0 7.165562587729823e-10
mAbs O 0 6.7107640688846e-07
) O 0 2.630464290831469e-09
has O 0 3.3839070434638074e-10
been O 0 6.61938170942733e-10
mapped O 0 5.341201259057016e-09
to O 0 1.862864529300623e-09
six O 0 1.2490302125911512e-09
specific O 0 3.924188196613443e-10
sites O 0 1.4496053246659812e-09
throughout O 0 1.346020739312337e-09
the O 0 2.008589294888452e-09
emerin O 0 5.840976413651333e-08
molecule O 0 5.599118946264525e-10
using O 0 8.01758748281145e-09
phage O 0 8.868589418398187e-08
- O 0 1.6165795102551783e-07
displayed O 0 2.9987848648715953e-08
peptide O 0 6.475389557891731e-09
libraries O 0 1.05279491791066e-08
and O 0 6.991286438662314e-10
has O 0 7.723942319071142e-11
been O 0 8.735496354050909e-11
used O 0 7.112050948165916e-10
to O 0 1.2099183877012365e-09
localize O 0 9.104580840357812e-07
emerin O 0 8.922167580749374e-06
in O 0 2.5868059694289514e-08
human O 0 2.7398046498205986e-08
and O 0 5.4082576639302715e-08
rabbit O 0 1.4101232409302611e-05
heart O 0 0.00010255409142700955
. O 0 4.762403932545567e-06

Several O 0 3.479256065475056e-07
mAbs O 0 9.680833500169683e-06
against O 0 3.060877418192831e-08
different O 0 2.602259296935472e-09
emerin O 0 5.9258663895889185e-06
epitopes O 0 1.041065502249694e-06
did O 0 8.717632482557747e-08
not O 0 1.0221687496425602e-08
recognize O 0 1.3442486235248907e-08
intercalated O 0 1.7039881186065031e-06
discs O 0 8.571877515350934e-06
in O 0 1.1765113328010557e-08
the O 0 1.0013434526001674e-08
heart O 0 5.622807179861411e-07
, O 0 1.4560340710900732e-09
though O 0 5.185385454353764e-10
they O 0 4.513870943689824e-10
recognized O 0 8.617083935291703e-09
cardiomyocyte O 0 7.352205670940748e-07
nuclei O 0 2.0388873167576094e-07
strongly O 0 4.270269826633921e-08
, O 0 3.0719533583578595e-09
both O 0 2.939155363534951e-09
at O 0 4.551552024167904e-08
the O 0 1.8488128361582312e-08
rim O 0 5.892348440283968e-07
and O 0 1.9463535227970397e-09
in O 0 6.06739902764275e-09
intranuclear O 0 4.503995114646386e-06
spots O 0 1.9414977714404813e-07
or O 0 2.1350809120690428e-08
channels O 0 2.388661641816725e-07
. O 0 2.452926253226906e-07

A O 0 1.525779862276977e-05
polyclonal O 0 9.576850425219163e-05
rabbit O 0 1.1168468518008012e-05
antiserum O 0 1.5437532056239434e-05
against O 0 5.521472701275343e-08
emerin O 0 2.2784543034504168e-05
did O 0 3.081506463331607e-07
recognize O 0 9.139398571278434e-08
both O 0 8.419958952288198e-09
nuclear O 0 6.59944362269016e-07
membrane O 0 1.0409745954120808e-07
and O 0 1.740103727776443e-09
intercalated O 0 1.7558903664394165e-07
discs O 0 1.160188531912354e-07
but O 0 2.6246996243095566e-10
, O 0 8.241327759117567e-11
after O 0 1.5619260052002204e-10
affinity O 0 1.2683093464360695e-10
purification O 0 5.744892561665438e-09
against O 0 3.3234731633413617e-10
a O 0 7.018502445887975e-10
pure O 0 4.058269098550227e-08
- O 0 1.2067964405559906e-07
emerin O 0 5.388178578868974e-07
band O 0 1.3243224827874656e-07
on O 0 1.2730221321533008e-08
a O 0 1.7990118283961465e-09
western O 0 2.6766281635559608e-08
blot O 0 1.071695692189678e-06
, O 0 4.9825743531073385e-09
it O 0 6.680109243539789e-10
stained O 0 2.5683533522169455e-07
only O 0 1.852768938270799e-09
the O 0 8.232989845424754e-10
nuclear O 0 1.9568540210457286e-07
membrane O 0 6.753741672582692e-07
. O 0 5.829812721458438e-07

These O 0 6.034876776084275e-08
results O 0 8.726162015193495e-09
would O 0 1.3620976568873289e-09
not O 0 4.758386462633268e-10
be O 0 2.722517489228693e-10
expected O 0 1.7643435601399915e-09
if O 0 1.3435584866883232e-09
immunostaining O 0 5.615776217382518e-07
at O 0 2.09181685306703e-08
intercalated O 0 3.557395018560783e-07
discs O 0 1.157328028966731e-06
were O 0 8.972851794908365e-09
due O 0 9.939792100510658e-09
to O 0 1.5524106444786412e-09
a O 0 9.699278047392568e-10
product O 0 6.34091834594841e-10
of O 0 1.5263356134553874e-09
the O 0 2.030708490252664e-09
emerin O 0 3.226604690098611e-07
gene O 0 3.5494187589080184e-09
and O 0 2.2209534211725668e-09
, O 0 9.412399748498501e-10
therefore O 0 2.015558830947839e-09
, O 0 1.2428058582258927e-10
cast O 0 6.797987173179365e-10
some O 0 1.4592195507479033e-10
doubt O 0 2.5388335878062662e-09
upon O 0 1.1795665555425217e-09
the O 0 8.496309766847787e-10
hypothesis O 0 3.2557883056227865e-09
that O 0 7.127026052655694e-11
cardiac B-Disease 1 0.9948311448097229
defects I-Disease 0 0.00027566440985538065
in O 0 1.04794264643715e-06
EDMD B-Disease 1 1.0
are O 0 4.449710377940619e-09
caused O 0 4.3820276296457905e-09
by O 0 2.0309474935142902e-10
absence O 0 1.2067215493516414e-07
of O 0 6.771413296746687e-08
emerin O 0 1.2829736988351215e-05
from O 0 6.344251346490637e-08
intercalated O 0 2.509960722818505e-05
discs O 0 0.0004753662506118417
. O 0 2.362684881518362e-06

Although O 0 4.946754756929295e-07
emerin O 0 6.5327444644935895e-06
was O 0 4.427591093758565e-08
abundant O 0 2.9333603990266965e-08
in O 0 2.2086983353375444e-09
the O 0 6.195948643039628e-09
membranes O 0 6.191201862293383e-08
of O 0 6.972420418804859e-09
cardiomyocyte O 0 3.6748961207422326e-08
nuclei O 0 2.7069075869690096e-09
, O 0 6.882726055756905e-10
it O 0 2.3551088856876845e-10
was O 0 6.830199339447063e-08
absent O 0 5.836143373016967e-07
from O 0 7.64637952954672e-09
many O 0 2.9340066487471006e-10
non O 0 8.750934910040087e-08
- O 0 8.829145770050673e-08
myocyte O 0 1.1256794323344366e-06
cells O 0 6.294913035276295e-09
in O 0 1.92708560220467e-09
the O 0 7.522207745580545e-09
heart O 0 4.79549214560393e-07
. O 0 6.360414204209519e-07

This O 0 2.815468747030536e-09
distribution O 0 1.0261336225170226e-09
of O 0 2.0826433910769993e-09
emerin O 0 1.952080452838345e-07
was O 0 1.2189084408475992e-08
similar O 0 3.0388741523168505e-10
to O 0 2.167655083207265e-10
that O 0 2.9958188707546185e-11
of O 0 1.1127490040507837e-09
lamin O 0 1.3085383443467435e-06
A O 0 3.001640536126615e-08
, O 0 6.058156754029653e-10
a O 0 5.812198500265708e-10
candidate O 0 7.623032760584181e-10
gene O 0 9.284359947514531e-10
for O 0 1.1623271234384447e-09
an O 0 1.197687282683546e-09
autosomal O 0 5.806509051353714e-08
form O 0 2.9642947652064322e-08
of O 0 0.0001793346309568733
EDMD B-Disease 1 1.0
. O 0 1.2564841199491639e-05

In O 0 1.8081534847169678e-07
contrast O 0 6.235048743974403e-08
, O 0 4.723468549627796e-08
lamin O 0 0.0010646816808730364
B1 O 1 0.866945743560791
was O 0 2.521539499866776e-06
absent O 0 3.114898618150619e-06
from O 0 1.705774366200785e-08
cardiomyocyte O 0 3.122379723663471e-07
nuclei O 0 5.864743357619773e-08
, O 0 7.727265938228811e-09
showing O 0 1.197429213561918e-07
that O 0 3.854982111306526e-09
lamin O 0 0.0005155791295692325
B1 O 0 0.00023552376660518348
is O 0 1.2265293225510732e-09
not O 0 1.3225613659795243e-10
essential O 0 5.652343038065055e-09
for O 0 3.857915098492981e-10
localization O 0 1.0721863645812846e-06
of O 0 5.3888374651478443e-08
emerin O 0 1.989611291719484e-06
to O 0 4.392973540490175e-09
the O 0 7.974776394803484e-09
nuclear O 0 1.5741140941827325e-06
lamina O 0 0.0005985244060866535
. O 0 4.774227818415966e-06

Lamin O 1 0.9999985694885254
B1 O 1 0.9985766410827637
is O 0 5.1353609364923614e-08
also O 0 8.337766921329148e-09
almost O 0 1.5588998980575752e-09
completely O 0 3.526679037690883e-08
absent O 0 1.1843875569184092e-07
from O 0 1.0423769403189453e-08
skeletal O 0 1.294095341108914e-06
muscle O 0 2.38441458577654e-07
nuclei O 0 9.87964881460357e-07
. O 0 1.1140364222228527e-06

In O 0 8.30272085750039e-07
EDMD B-Disease 1 1.0
, O 0 1.948144578989286e-08
the O 0 1.467728272253055e-09
additional O 0 4.392672003916687e-09
absence O 0 1.6541613945264544e-07
of O 0 4.774992135025968e-07
lamin O 1 0.9999998807907104
B1 O 1 1.0
from O 0 3.891756477969466e-06
heart O 1 0.9999995231628418
and O 0 2.89805575448554e-05
skeletal O 1 1.0
muscle O 0 4.70092345494777e-06
nuclei O 0 7.02846875810792e-07
which O 0 1.5088936322626978e-08
already O 0 1.3384640062952258e-08
lack O 0 3.2643401937093586e-07
emerin O 0 3.6148123854218284e-06
may O 0 4.65827820761433e-09
offer O 0 1.7161444487712174e-09
an O 0 3.364520814730376e-11
alternative O 0 6.291732024266139e-09
explanation O 0 2.264305365429209e-08
of O 0 1.0971668018555647e-08
why O 0 2.5528777314320905e-08
these O 0 2.0741837136739605e-09
tissues O 0 4.56332216458577e-08
are O 0 3.057875064271798e-10
particularly O 0 8.443450383310847e-10
affected O 0 6.757227555276302e-10
. O 0 3.1610396522552264e-09
. O 0 1.2352899148027063e-07

Genetic O 0 1.0524355502639082e-06
mapping O 0 8.95500562592133e-08
of O 0 4.275021225907949e-08
the O 0 4.5087467981375084e-08
copper B-Disease 0 4.75382330478169e-06
toxicosis I-Disease 0 0.04079562425613403
locus O 0 8.553566317459627e-07
in O 0 4.262669506260863e-08
Bedlington O 0 1.900287861644756e-05
terriers O 0 4.13179168390343e-06
to O 0 3.3766699658599464e-08
dog O 0 9.674509726664837e-08
chromosome O 0 5.676132452947513e-09
10 O 0 5.626152432824938e-09
, O 0 1.803181354231853e-10
in O 0 1.7867583801400855e-10
a O 0 9.39831656943113e-10
region O 0 1.1265623989231699e-08
syntenic O 0 5.244988301456033e-07
to O 0 2.4914426077771168e-09
human O 0 3.970477724379862e-09
chromosome O 0 7.115001920965369e-08
region O 0 1.4064173115002632e-07
2p13 O 0 8.964436710812151e-05
- O 0 2.227190816483926e-05
p16 O 0 1.8055039618047886e-05
. O 0 2.007833700190531e-06

Abnormal O 1 0.9999915361404419
hepatic B-Disease 1 0.9999998807907104
copper I-Disease 0 0.00031271003535948694
accumulation I-Disease 0 7.681511306145694e-06
is O 0 3.607953658057994e-10
recognized O 0 2.6577720579901154e-10
as O 0 2.1735961641677903e-10
an O 0 6.800723872935066e-10
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 3.683218778860464e-07
man O 0 5.6758324262773385e-08
, O 0 3.353171962316992e-09
mouse O 0 1.4443352824855538e-07
, O 0 1.6724403195667037e-08
rat O 0 1.699049425951671e-05
and O 0 1.87779653515463e-06
dog O 0 0.10600907355546951
. O 0 7.885773084126413e-05

The O 0 3.583419072583638e-07
major O 0 3.4886653565990855e-07
cause O 0 5.563535410146869e-07
of O 0 2.5052924002011423e-07
hepatic B-Disease 1 0.9999845027923584
copper I-Disease 1 0.9955039620399475
accumulation I-Disease 1 0.9999940395355225
in O 0 7.87071530794492e-06
man O 0 3.5045857202931074e-06
is O 0 2.40180808575019e-09
a O 0 4.3324464016336606e-09
dysfunctional O 0 2.8955053466006575e-08
ATP7B O 0 4.5664419303648174e-05
gene O 0 6.440767208459874e-08
, O 0 1.1674134547945414e-08
causing O 0 2.7808550839836244e-07
Wilson B-Disease 0 1.9828185031656176e-05
disease I-Disease 0 2.1787386685900856e-06
( O 0 2.809240839951599e-09
WD B-Disease 0 1.6632722690701485e-05
) O 0 1.0669948125041628e-07
. O 0 6.85138218159409e-07

Mutations O 0 1.4298615269581205e-06
in O 0 5.622969112550891e-08
the O 0 7.141596114479398e-08
ATP7B O 0 0.0005693986313417554
genes O 0 2.3143529759295234e-08
have O 0 1.5652907858765275e-09
also O 0 1.1020908630143822e-09
been O 0 7.986996064524021e-10
demonstrated O 0 5.634205990645569e-09
in O 0 8.344767543633225e-09
mouse O 0 5.364410640140704e-07
and O 0 2.2577746960905642e-07
rat O 0 0.00015309208538383245
. O 0 5.834635430801427e-06

The O 0 3.6360927424539113e-06
ATP7B O 0 0.003160415682941675
gene O 0 2.0184380389309808e-07
has O 0 7.44634631733021e-10
been O 0 2.441924995544298e-10
excluded O 0 2.4592905489839723e-09
in O 0 4.359350380678251e-10
the O 0 1.0129377336909329e-09
much O 0 2.2911263997116293e-09
rarer O 0 4.5207681864667393e-07
human O 0 5.6364552136756174e-08
copper B-Disease 0 0.014660162851214409
overload I-Disease 1 0.999968409538269
disease O 0 0.002618337282910943
non B-Disease 0 9.835907803790178e-06
- I-Disease 0 2.7903306545340456e-06
Indian I-Disease 0 5.2103246162005235e-08
childhood I-Disease 0 6.9619107989638e-07
cirrhosis I-Disease 0 3.111778141828836e-06
, O 0 4.539411957438233e-09
indicating O 0 4.439065648398355e-08
genetic O 0 7.711338412264013e-08
heterogeneity O 0 1.8947238231703523e-06
. O 0 9.278310244553722e-07

By O 0 4.5090371436629084e-09
investigating O 0 9.749268947700784e-09
the O 0 7.574223914730283e-09
common O 0 3.9630958781344816e-07
autosomal O 1 0.9994668364524841
recessive O 1 0.9611536860466003
copper B-Disease 1 0.9999803304672241
toxicosis I-Disease 1 1.0
( O 0 1.644358604835361e-08
CT B-Disease 0 0.0025804743636399508
) O 0 1.0371467018543967e-09
in O 0 5.215491594157129e-09
Bedlington O 0 6.392752402462065e-05
terriers O 0 1.6632406186545268e-05
, O 0 3.3734111060113037e-09
we O 0 1.6852512718656953e-09
have O 0 1.5321216517705238e-10
identified O 0 3.9165834464505167e-10
a O 0 1.444278169282498e-10
new O 0 1.9302152931555128e-10
locus O 0 5.084899168394941e-09
involved O 0 1.0002949579757114e-09
in O 0 9.85161108246757e-09
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 9.392942956765182e-06

We O 0 1.0205624221271137e-06
examined O 0 1.569341520735179e-06
whether O 0 3.5849158308565165e-08
the O 0 6.291782739253904e-08
WD B-Disease 0 0.0006027492345310748
gene O 0 3.3452320167270955e-06
ATP7B O 0 0.46454891562461853
was O 0 1.1492604699014919e-06
also O 0 3.056733755002483e-09
causative O 0 7.896824527620083e-09
for O 0 7.515061906104847e-10
CT B-Disease 0 8.111300303426106e-06
by O 0 2.285461153661572e-09
investigating O 0 3.470062992505518e-08
the O 0 1.856285791745904e-08
chromosomal O 0 1.3742441069553024e-06
co O 0 1.3929621900388156e-06
- O 0 2.0634635802707635e-05
localization O 0 0.36760926246643066
of O 0 1.4683066638099262e-06
ATP7B O 0 7.071125583024696e-05
and O 0 8.526802375286024e-09
C04107 O 0 5.217161174186913e-07
, O 0 5.546345049900481e-10
using O 0 4.615241799843517e-10
fluorescence O 0 1.200581145610613e-08
in O 0 7.2960872898875095e-09
situ O 0 1.2792578445441904e-06
hybridization O 0 7.467687623829988e-08
( O 0 8.665474560132225e-09
FISH O 0 1.3313573390405509e-06
) O 0 1.600209209584591e-08
. O 0 2.6819307663572545e-07

C04107 O 0 0.00010941839718725532
is O 0 1.3924037034485082e-08
an O 0 4.684033161339585e-10
anonymous O 0 2.4391995978589875e-08
microsatellite O 0 1.3846751016899361e-06
marker O 0 4.716545447536191e-07
closely O 0 6.635479365968422e-08
linked O 0 7.897037335169443e-07
to O 0 1.8202766227659595e-07
CT B-Disease 1 1.0
. O 0 6.753367779310793e-05

However O 0 2.132880581484642e-06
, O 0 2.3180069774753065e-07
BAC O 0 4.652725692722015e-05
clones O 0 1.3647583045894862e-06
containing O 0 1.8035518678516382e-07
ATP7B O 0 2.353263698751107e-05
and O 0 3.8572711247297775e-08
C04107 O 0 8.105625056487042e-06
mapped O 0 3.0973220077612496e-07
to O 0 1.648871794657225e-08
the O 0 2.218405903420262e-08
canine O 0 1.0191899946221383e-06
chromosome O 0 3.6827833582719904e-07
regions O 0 1.4260735703430782e-08
CFA22q11 O 0 1.6454524711662089e-06
and O 0 4.342390003131413e-09
CFA10q26 O 0 9.145194326265482e-07
, O 0 1.3301107992802486e-09
respectively O 0 2.957595279795555e-09
, O 0 3.2891231405152155e-10
demonstrating O 0 2.1089379131922215e-09
that O 0 9.203111883682169e-11
WD B-Disease 0 5.155479811946861e-07
cannot O 0 2.7572093941330422e-08
be O 0 4.051136759386509e-09
homologous O 0 1.1880342043468772e-08
to O 0 9.369723130703278e-08
CT B-Disease 1 0.8979406356811523
. O 0 2.1258027118165046e-05

The O 0 2.681769728951622e-06
copper O 0 1.2024440820823656e-06
transport O 0 1.5174951784047153e-07
genes O 0 7.176934957442427e-08
CTR1 O 0 4.998698568670079e-05
and O 0 4.000720110752809e-08
CTR2 O 0 0.023868093267083168
were O 0 9.442202042464487e-08
also O 0 5.844595474258085e-09
excluded O 0 7.977849492135647e-09
as O 0 9.064341499609441e-10
candidate O 0 8.001939111323964e-10
genes O 0 3.9223099768115333e-10
for O 0 1.264127025280004e-09
CT B-Disease 0 0.03582627326250076
since O 0 3.854852081985882e-07
they O 0 1.1727272486439233e-08
both O 0 8.06805733333249e-09
mapped O 0 7.131414037075956e-08
to O 0 3.827976513548492e-08
canine O 0 1.491464445280144e-06
chromosome O 0 7.760123139632924e-07
region O 0 1.850532612479583e-06
CFA11q22 O 0 0.0006999446195550263
. O 0 4.6256641326181125e-06

2 O 0 4.293875917937839e-06
- O 0 1.6123580280691385e-05
22 O 0 3.6990140870329924e-06
. O 0 1.2744637842843076e-06

5 O 0 5.577908086706884e-05
. O 0 6.718167696817545e-06

A O 0 4.895907181889925e-07
transcribed O 0 2.6331512970045878e-08
sequence O 0 4.124414976214297e-10
identified O 0 4.4537604715344514e-09
from O 0 8.314132715625533e-10
the O 0 8.530294803854588e-10
C04107 O 0 2.8758159942299244e-07
- O 0 5.827745397368744e-08
containing O 0 2.2641228891728815e-09
BAC O 0 1.136427044912125e-06
was O 0 7.311578453794709e-09
found O 0 1.1072755906615939e-10
to O 0 5.676733041970472e-11
be O 0 2.240920643492572e-11
homologous O 0 2.3409615912406423e-10
to O 0 1.7999042256633402e-09
a O 0 8.148911767591471e-09
gene O 0 3.582837848625786e-08
expressed O 0 7.601258289469115e-09
from O 0 4.138593467928331e-09
human O 0 2.380809105417825e-09
chromosome O 0 1.0157938490351626e-08
2p13 O 0 1.3862906200756697e-07
- O 0 9.065991690704323e-08
p16 O 0 9.311714421755823e-08
, O 0 7.949441105381538e-10
a O 0 5.52089818306456e-10
region O 0 2.1124766380609117e-09
devoid O 0 2.597703563367304e-08
of O 0 1.2470853238966129e-09
any O 0 7.64941054942625e-10
positional O 0 9.417882438356173e-07
candidate O 0 9.17147673362706e-08
genes O 0 9.87036727906343e-08
. O 0 8.575717629355495e-07

Molecular O 0 1.0483049805998235e-07
analysis O 0 8.181382682437288e-09
of O 0 8.307589283162997e-09
the O 0 4.946770548741597e-09
APC B-Disease 0 7.400012691505253e-08
gene O 0 1.4552732352512976e-09
in O 0 2.478957483731392e-09
205 O 0 2.8609314028926747e-08
families O 0 1.012447126136351e-09
: O 0 1.0143104134385794e-09
extended O 0 3.5551526167409975e-08
genotype O 0 1.2108266389532218e-07
- O 0 1.0371907137596281e-06
phenotype O 0 3.016436167513348e-08
correlations O 0 9.373205323015554e-09
in O 0 3.835846307254087e-09
FAP B-Disease 0 6.93869921519763e-08
and O 0 2.122058778697422e-10
evidence O 0 3.466784914696319e-10
for O 0 1.3056977721248586e-10
the O 0 5.639159139647631e-10
role O 0 9.708611692360591e-09
of O 0 6.139202923804987e-08
APC B-Disease 0 3.5888433558284305e-07
amino O 0 8.533228346152555e-09
acid O 0 1.1232709873354452e-08
changes O 0 4.0849915450280605e-08
in O 1 0.9679370522499084
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9999974966049194
. O 0 7.218240625661565e-06

BACKGROUND O 0 0.001071428181603551
/ O 0 6.231877341633663e-05
AIMS O 0 2.856163291653502e-06
The O 0 8.620355984589878e-09
development O 0 4.01567348262688e-08
of O 0 3.8855855564179365e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.405963925866672e-07
a O 0 3.0129041483917263e-09
variable O 0 2.638292695422706e-09
range O 0 2.8544873131863824e-09
of O 0 8.172208465495601e-10
extracolonic O 0 2.3323404718667007e-07
manifestations O 0 1.7596940438124875e-07
in O 0 6.612408469663933e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 2.8266835983004057e-08
FAP B-Disease 0 3.6660335922533704e-07
) O 0 1.9682815100008355e-10
is O 0 1.1962203796955784e-11
the O 0 1.874689119218953e-11
result O 0 1.0105674630445094e-10
of O 0 1.8796499912099307e-09
the O 0 3.59430085694612e-09
dominant O 0 1.8066085516466046e-08
inheritance O 0 7.978536018526938e-07
of O 0 0.0011699158931151032
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 1.971492302743627e-08
APC B-Disease 0 3.05558728541655e-07
) O 0 1.9349417623715226e-09
gene O 0 9.904270292793171e-09
mutations O 0 9.492311647818497e-08
. O 0 1.92361289919063e-06

In O 0 5.400454483606154e-08
this O 0 4.3713821451518697e-10
study O 0 3.306244167333716e-10
, O 0 1.2691823286781201e-11
direct O 0 1.3248437069623975e-10
mutation O 0 3.9543906343864066e-11
analysis O 0 4.155320254550787e-10
of O 0 2.087288342167426e-09
the O 0 4.207985959681082e-09
APC B-Disease 0 8.437421428197922e-08
gene O 0 5.779754896906297e-09
was O 0 4.323384672488828e-08
performed O 0 3.313930818649169e-08
to O 0 9.886396590275126e-09
determine O 0 7.98468402507524e-09
genotype O 0 1.3040519775131543e-07
- O 0 2.088607061523362e-06
phenotype O 0 8.913545457289729e-08
correlations O 0 1.5763051308681497e-08
for O 0 3.802875347957979e-09
nine O 0 1.0417607221313574e-08
extracolonic O 0 2.0948839107859385e-07
manifestations O 0 7.50068807064963e-09
and O 0 4.842879985922366e-10
to O 0 8.375362625656635e-10
investigate O 0 1.7482110203914658e-09
the O 0 2.634747531260473e-09
incidence O 0 8.200694310289691e-07
of O 0 2.873696587357699e-07
APC B-Disease 0 9.258775435228017e-07
mutations O 0 1.1044440029195357e-08
in O 0 1.950158434738114e-07
non O 1 1.0
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00011220489250263199

METHODS O 0 1.6297575712087564e-05
The O 0 6.77788591474382e-07
APC B-Disease 0 9.780727623365237e-07
gene O 0 2.8797535023272758e-08
was O 0 1.1067134408904167e-07
analysed O 0 9.618869967198407e-08
in O 0 3.523530356375204e-09
190 O 0 1.5874869419008064e-08
unrelated O 0 8.888584979160896e-09
FAP B-Disease 0 1.3841982138274034e-07
and O 0 3.3315608050088485e-09
15 O 0 2.377933725483672e-07
non O 1 0.9138918519020081
- O 1 0.9999998807907104
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 4.0669820009497926e-06
using O 0 1.689858031284075e-08
denaturing O 0 5.271340342005715e-07
gradient O 0 1.4510084689334235e-08
gel O 0 4.546944509797868e-08
electrophoresis O 0 9.568144498928177e-09
, O 0 6.565964993932027e-10
the O 0 6.94768464981621e-10
protein O 0 3.252310920576207e-10
truncation O 0 2.15175273154955e-08
test O 0 2.4124691133664555e-09
, O 0 3.0612420931497297e-10
and O 0 1.422475331969153e-10
direct O 0 4.623402993786385e-09
sequencing O 0 1.219739260704955e-07
. O 0 2.1335101507702348e-07

RESULTS O 0 4.112896931474097e-06
Chain O 0 2.595148771433742e-07
terminating O 0 7.993998707434002e-08
signals O 0 8.784481053680793e-08
were O 0 4.97543295452374e-09
only O 0 3.9402683893463575e-10
identified O 0 6.876217928386552e-10
in O 0 1.735101784472448e-10
patients O 0 2.1133704508624618e-10
belonging O 0 1.3299180645631736e-09
to O 0 3.187088648548553e-10
the O 0 4.61272708918159e-09
FAP B-Disease 0 3.82572920898383e-07
group O 0 2.5140889370334207e-09
( O 0 2.7708874084098056e-10
105 O 0 1.317798989930452e-07
patients O 0 2.182525982163952e-08
) O 0 4.9728239304158706e-09
. O 0 2.65368271357147e-07

Amino O 0 3.57616130486349e-07
acid O 0 1.924772519146245e-08
changes O 0 1.4448739982242387e-09
were O 0 1.1401501964769523e-09
identified O 0 1.8684369607058215e-09
in O 0 3.5704117440360505e-10
four O 0 1.7139585584136086e-10
patients O 0 9.48780914944436e-11
, O 0 1.4943360784891446e-11
three O 0 3.160518374789589e-11
of O 0 1.6331056507112862e-09
whom O 0 1.0738810729549186e-08
belonged O 0 9.365913911096868e-07
to O 0 5.919055823255803e-08
the O 0 1.639523929952702e-07
non O 1 0.9858917593955994
- O 0 0.0007657077512703836
FAP O 0 2.2503170839627273e-05
group O 0 7.129550994022793e-08
of O 0 2.058345671684947e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9996080994606018
. O 0 2.363047997278045e-06

Genotype O 0 0.00036965636536478996
- O 0 0.00013798789586871862
phenotype O 0 4.271793727639306e-07
correlations O 0 4.7041741169095985e-08
identified O 0 9.734793415816512e-09
significant O 0 2.843467017399348e-09
differences O 0 2.5825650507016462e-09
in O 0 4.279383514216306e-09
the O 0 2.7831132953792803e-09
nature O 0 7.141930380427652e-10
of O 0 2.385686537209608e-09
certain O 0 1.6600227858987182e-09
extracolonic O 0 4.6569616074521036e-07
manifestations O 0 4.678368270560895e-08
in O 0 9.336324602315926e-09
FAP B-Disease 0 5.960088742540393e-07
patients O 0 1.8299520121445312e-08
belonging O 0 7.46372563753539e-09
to O 0 3.085218081011476e-09
three O 0 2.669173104763445e-09
mutation O 0 9.069673012618296e-09
subgroups O 0 1.011245700510699e-07
. O 0 2.4120751618283975e-07

CONCLUSIONS O 0 1.1445254131103866e-05
Extended O 0 1.2150434258728637e-06
genotype O 0 1.2180995554444962e-06
- O 0 2.236143473055563e-06
phenotype O 0 7.110497790563386e-08
correlations O 0 1.5066792258267014e-08
made O 0 1.9982606680457593e-09
in O 0 6.379823336288837e-10
this O 0 4.9793863476921274e-11
study O 0 2.0462245786667665e-10
may O 0 1.0987782211868691e-10
have O 0 2.7658432835697688e-11
the O 0 4.065444508816185e-11
potential O 0 1.3215425975765527e-10
to O 0 2.4683075028342216e-10
determine O 0 1.928792014993519e-09
the O 0 1.2525067205615414e-08
most O 0 3.3460738624313535e-09
appropriate O 0 5.656098878148441e-08
surveillance O 0 7.19368108548224e-06
and O 0 3.640113277469936e-08
prophylactic O 0 0.00023576126841362566
treatment O 0 8.550858865419286e-07
regimens O 0 5.038243600097303e-08
for O 0 7.908201316020325e-10
those O 0 2.1902805957818572e-10
patients O 0 6.198203061913432e-10
with O 0 8.394817826995471e-12
mutations O 0 1.9418952557082036e-10
associated O 0 1.6302299510329021e-09
with O 0 1.166266111463088e-10
life O 0 3.536581161256436e-08
threatening O 0 1.1111674247388237e-08
conditions O 0 2.423400928819319e-07
. O 0 4.073527861692128e-07

This O 0 3.832739992049028e-08
study O 0 1.2335589438805528e-08
also O 0 4.0129438660940764e-10
provided O 0 7.211604091672541e-10
evidence O 0 3.46283279828441e-10
for O 0 1.0807368194809541e-10
the O 0 2.170361890208028e-09
pathological O 0 2.4257269615191035e-07
nature O 0 6.811553987517982e-09
of O 0 5.663814750533902e-09
amino O 0 4.913667805972466e-10
acid O 0 5.149970450091246e-10
changes O 0 1.2679230998458024e-09
in O 0 1.8164454829161514e-08
APC O 0 1.4656052371719852e-06
associated O 0 3.1453987503482495e-07
with O 0 8.006229013091115e-10
both O 0 3.459303066222219e-09
FAP B-Disease 0 8.031366149907626e-08
and O 0 3.0379307958128265e-09
non O 1 0.9994291663169861
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 8.802896445558872e-06
. O 0 1.3395162312690445e-08
. O 0 3.246401547585265e-08

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 0 9.990420949179679e-05
cancer B-Disease 1 0.9944989085197449
risk O 0 1.8262475123265176e-06
of O 0 8.025759257179743e-07
the O 0 1.1224207128179842e-06
APC O 0 9.758397027326282e-06
I1307K O 0 4.260633068042807e-05
polymorphism O 0 2.2269414330367e-06
. O 0 1.2261040183147998e-06

Germ O 0 0.0007160487584769726
- O 0 8.146417712850962e-06
line O 0 1.4407227411084023e-07
and O 0 5.018598869810376e-09
somatic O 0 3.4450764019311464e-07
truncating O 0 4.081293241142703e-07
mutations O 0 1.2360813705925011e-08
of O 0 2.132805754229139e-08
the O 0 5.7222582228178e-08
APC B-Disease 0 3.236182521959563e-07
gene O 0 1.0011715012581135e-08
are O 0 9.946691248430284e-10
thought O 0 1.4770893841387078e-08
to O 0 4.104945716676411e-09
initiate O 0 6.545526503032306e-07
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.0022247275337576866
formation O 0 4.912735676043667e-07
in O 0 9.045763249559968e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 2.266069714096375e-06
sporadic O 1 0.9999673366546631
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 1.9452394553809427e-05
respectively O 0 9.465005859965459e-06
. O 0 1.0663472949090647e-06

Recently O 0 8.036389544940903e-07
, O 0 3.4463225606629067e-09
an O 0 2.713719526870051e-10
isoleucine O 0 4.4586590774997603e-07
- O 0 3.048535006655584e-07
- O 0 3.6691605487249035e-07
> O 0 3.566543398392241e-07
lysine O 0 2.593198544786901e-08
polymorphism O 0 3.433999973267987e-09
at O 0 3.4700149420530124e-09
codon O 0 2.3967571038951974e-08
1307 O 0 8.224865268857684e-07
( O 0 2.8260083162479077e-09
I1307K O 0 4.572845568873163e-07
) O 0 7.707537941215037e-10
of O 0 3.1022773239186563e-09
the O 0 3.880233023778601e-09
APC B-Disease 0 1.5809095543772855e-07
gene O 0 3.5651193108776624e-09
has O 0 1.8678801561033964e-10
been O 0 1.3747845917233548e-10
identified O 0 1.4331015540935965e-10
in O 0 8.035016402230255e-11
6 O 0 8.086853853228604e-09
% O 0 2.1229169810954573e-10
- O 0 3.921055480304858e-09
7 O 0 9.85469306158393e-09
% O 0 3.4834879425460485e-10
of O 0 3.9818209840447594e-10
the O 0 4.5682199689700553e-10
Ashkenazi O 0 2.7896996712684086e-08
Jewish O 0 3.175799179189198e-08
population O 0 2.467507309589223e-10
. O 0 8.04853783620274e-09

To O 0 1.1929849108582857e-07
assess O 0 5.951937964709941e-07
the O 0 1.0984440024230935e-08
risk O 0 3.624704447702243e-08
of O 0 4.3354884127211335e-09
this O 0 2.933357723389207e-10
common O 0 3.971871276320371e-09
APC B-Disease 0 1.505955822267424e-07
allelic O 0 2.5890034294207e-07
variant O 0 1.4470004998656805e-06
in O 0 3.5116511298838304e-07
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 3.1773080877428583e-07
we O 0 1.521119763481238e-08
have O 0 7.998582352009009e-10
analyzed O 0 2.6733408819978877e-09
a O 0 1.1331821037074974e-09
large O 0 1.8749271024631753e-09
cohort O 0 3.1810949963073654e-07
of O 0 1.547731898199345e-07
unselected O 0 0.00018601934425532818
Ashkenazi O 0 2.1621099222102202e-05
Jewish O 0 5.768441724285367e-07
subjects O 0 6.419341502805764e-07
with O 0 2.9678572932567704e-09
adenomatous B-Disease 0 0.0002602695603854954
polyps I-Disease 0 4.319183062762022e-06
and O 0 5.122318125216907e-09
. O 0 3.3590886516776663e-08
or O 0 0.1187986433506012
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 8.397797301995524e-08
for O 0 5.093946597867216e-09
the O 0 5.97849876271539e-08
APC O 0 1.5936461750243325e-06
I1307K O 0 4.410167093737982e-06
polymorphism O 0 4.941200018038217e-07
. O 0 2.9479389240805176e-07

The O 0 2.333872316739871e-06
APC O 0 8.469347449135967e-06
I1307K O 0 9.394197149958927e-06
allele O 0 1.2150233885677153e-07
was O 0 1.60902686729969e-08
identified O 0 5.576196837608904e-09
in O 0 1.3886924943307122e-09
48 O 0 2.7571514849000778e-08
( O 0 1.0847349407594464e-10
10 O 0 4.4573533752867434e-10
. O 0 6.473888786162618e-11
1 O 0 3.0453624066950624e-09
% O 0 1.7224235926427411e-10
) O 0 9.90987292226464e-11
of O 0 8.558472819331087e-10
476 O 0 5.546615255980214e-08
patients O 0 1.0278681372710707e-07
. O 0 2.0834160352478648e-07

Compared O 0 3.3844528957160946e-08
with O 0 4.54953158479654e-11
the O 0 2.142895583201465e-10
frequency O 0 5.560488514078088e-09
in O 0 1.5556496368862582e-10
two O 0 4.4468720372670134e-11
separate O 0 5.0209874452589176e-11
population O 0 1.3195017127543007e-11
control O 0 5.745996456418823e-10
groups O 0 9.122144012385647e-11
, O 0 3.6639741241017987e-10
the O 0 8.779067250941353e-09
APC O 0 1.6912113096623216e-06
I1307K O 0 7.64655942475656e-06
allele O 0 3.475090082361021e-08
is O 0 8.624820302394198e-11
associated O 0 3.062848308310606e-10
with O 0 1.1586162584897863e-11
an O 0 2.3960449943571938e-11
estimated O 0 2.303238849643563e-11
relative O 0 7.017993963742697e-10
risk O 0 1.6835806082582394e-09
of O 0 6.775570771111461e-09
1 O 0 1.4631334579462418e-06
. O 0 1.997432718781056e-06

5 O 0 2.8803578970837407e-06
- O 0 5.834434887219686e-06
1 O 0 3.0382479963009246e-06
. O 0 1.9896720004908275e-06

7 O 0 3.80318579118466e-06
for O 0 2.0244411302883236e-07
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9999998807907104
( O 0 1.0062547062261729e-07
both O 0 9.0280778408669e-09
P O 0 6.034912303221063e-07
= O 0 6.096646387732108e-08
. O 0 2.048947678190416e-09
01 O 0 9.250567245544516e-07
) O 0 5.488290710786714e-09
. O 0 7.061127149654567e-08

Furthermore O 0 8.647231766190089e-07
, O 0 7.340083207907355e-09
compared O 0 3.106344959036278e-09
with O 0 2.2705134994360776e-10
noncarriers O 0 5.175335445528617e-06
, O 0 4.7370921407718924e-08
APC O 0 1.0025149776993203e-06
I1307K O 0 4.11624841945013e-06
carriers O 0 1.1905272323531335e-08
had O 0 6.312804501362734e-09
increased O 0 3.4506835167036343e-09
numbers O 0 1.1696037471864429e-09
of O 0 2.988511216273082e-09
adenomas B-Disease 0 0.0001975864579435438
and O 0 2.2654672648059204e-05
colorectal B-Disease 1 1.0
cancers I-Disease 1 1.0
per O 0 9.160774425254203e-06
patient O 0 4.075640390510671e-05
( O 0 2.093336393116374e-09
P O 0 5.21049344115454e-07
= O 0 3.9808835339272264e-08
. O 0 6.854232736941412e-10
03 O 0 2.1033235952927498e-07
) O 0 4.3151421325049455e-10
, O 0 5.3560184065659655e-11
as O 0 6.064929114479867e-11
well O 0 1.0787185728000637e-10
as O 0 1.3078138572097942e-10
a O 0 3.8538700009027593e-10
younger O 0 3.2360634172334812e-09
age O 0 4.556831356694602e-09
at O 0 2.6010251730212985e-08
diagnosis O 0 5.948430498392554e-06
. O 0 4.0010485236052773e-07

We O 0 2.1860803656181815e-07
conclude O 0 4.680805147927458e-07
that O 0 2.788054453972677e-09
the O 0 1.684686345981845e-08
APC O 0 3.4926245007227408e-06
I1307K O 0 2.0640658476622775e-05
variant O 0 6.947100700926967e-06
leads O 0 5.962703397699443e-08
to O 0 3.67102681586573e-09
increased O 0 7.248250426528102e-07
adenoma B-Disease 1 1.0
formation O 0 3.587337857879902e-07
and O 0 2.4844528656586817e-09
directly O 0 5.206742814678478e-10
contributes O 0 3.5763414452105735e-10
to O 0 5.0014790919927776e-11
3 O 0 7.583659256127362e-10
% O 0 1.6130659308277728e-10
- O 0 6.415311393226375e-09
4 O 0 7.089923759195926e-09
% O 0 4.959503918655628e-10
of O 0 3.558249250801282e-10
all O 0 2.1587513721055274e-10
Ashkenazi O 0 5.936654474680836e-07
Jewish O 0 6.291650061029941e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.6478097677463666e-05

The O 0 2.488685595380957e-07
estimated O 0 7.59659091187359e-09
relative O 0 9.132532596822784e-08
risk O 0 1.1717501635644112e-08
for O 0 5.104038858227966e-10
carriers O 0 4.609525650067781e-09
may O 0 7.7490955874282e-09
justify O 0 2.305083768305849e-08
specific O 0 7.882645092216478e-10
clinical O 0 9.148354851440388e-10
screening O 0 4.401795039576939e-10
for O 0 2.288635669867034e-10
the O 0 3.974658102645634e-10
360 O 0 4.477686665893543e-09
, O 0 1.925861276008689e-10
000 O 0 1.798498061589271e-08
Americans O 0 1.169122021416058e-09
expected O 0 3.994554964581454e-10
to O 0 3.180226915144857e-10
harbor O 0 2.8264034668268323e-08
this O 0 5.596288987774756e-10
allele O 0 5.9283968845136314e-09
, O 0 3.0940086603870043e-10
and O 0 1.667320448373033e-10
genetic O 0 3.722503694181256e-10
testing O 0 1.729211079881665e-10
in O 0 4.734267144979043e-11
the O 0 1.1843158398416875e-10
setting O 0 2.2777584263167228e-09
of O 0 3.4349348365658727e-10
long O 0 1.0870173511312586e-10
- O 0 1.8239784127516145e-09
term O 0 8.002737139634064e-09
- O 0 6.03253891284794e-09
outcome O 0 3.2567304408814834e-10
studies O 0 5.887893506084652e-10
may O 0 8.455453004430069e-11
impact O 0 1.1820620038349716e-09
significantly O 0 2.8727258793992405e-08
on O 0 0.36605119705200195
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 1 0.9571423530578613
in O 0 3.6033618311392956e-09
this O 0 8.272530438446779e-10
population O 0 3.0880012436007576e-10
. O 0 2.646888042079354e-08

Localization O 0 2.4739059881540015e-05
of O 0 1.2123703641009342e-07
human O 0 1.035536278948257e-08
BRCA1 O 0 2.9542478685584683e-08
and O 0 9.734417716344979e-10
its O 0 9.587831639734645e-10
loss O 0 1.1268245891926654e-08
in O 0 2.9891669139914256e-09
high O 0 5.249036405530205e-08
- O 0 5.598194974254511e-08
grade O 0 2.3585420194649487e-07
, O 0 9.237097309267028e-09
non B-Disease 1 0.6679319143295288
- I-Disease 1 0.999946117401123
inherited I-Disease 1 0.9999997615814209
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.2998635172843933

Although O 0 8.584934363398133e-08
the O 0 7.140136037975253e-09
link O 0 1.560745310769107e-08
between O 0 2.296769302523316e-10
the O 0 7.493881959419468e-09
BRCA1 O 0 8.545755463273963e-07
tumour B-Disease 1 1.0
- O 0 2.712022978812456e-05
suppressor O 0 9.798664541449398e-05
gene O 0 3.0968524811214593e-07
and O 0 1.239498175209519e-07
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 9.431111891444743e-09
established O 0 1.8642578591965275e-09
, O 0 1.0971112907043334e-10
the O 0 1.7620424563880022e-10
role O 0 7.514775468564494e-10
, O 0 2.003086863044956e-10
if O 0 7.166324478280472e-11
any O 0 3.9413358687845346e-10
, O 0 8.799044826091063e-10
of O 0 5.153658388934446e-09
BRCA1 O 0 5.448045570233262e-08
in O 0 1.6991954510103824e-08
non B-Disease 1 0.9999979734420776
- I-Disease 1 0.9997703433036804
familial I-Disease 0 9.145605145022273e-05
cancers I-Disease 1 0.9999853372573853
is O 0 1.9978756427008193e-09
unclear O 0 3.372518619926268e-08
. O 0 1.6291994597850135e-07

BRCA1 O 0 0.0001398496824549511
mutations O 0 1.0723258725420237e-07
are O 0 6.416825404365056e-10
rare O 0 3.959126804176094e-09
in O 0 2.6733206759388395e-09
sporadic B-Disease 0 2.8366412152536213e-07
cancers I-Disease 0 4.321383130445611e-06
, O 0 3.724416330896929e-09
but O 0 2.0096777575417946e-09
loss O 0 7.536787904882658e-08
of O 0 1.812761411201791e-06
BRCA1 O 0 4.281157117702605e-08
resulting O 0 1.24845622728742e-09
from O 0 4.027397582095915e-10
reduced O 0 8.123240413659971e-10
expression O 0 8.365703130230884e-10
or O 0 5.890454790602462e-10
incorrect O 0 1.0835367270090046e-08
subcellular O 0 3.457471677847934e-07
localization O 0 3.963560175179737e-06
is O 0 8.173875465367075e-10
postulated O 0 1.2345616084985522e-08
to O 0 2.492853146129903e-10
be O 0 8.007065149806536e-11
important O 0 2.3600868481743476e-10
in O 0 7.289740477922635e-10
non B-Disease 0 0.01947609893977642
- I-Disease 1 0.9985312223434448
familial I-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 1 1.0

Epigenetic O 0 0.0003911061503458768
loss O 0 4.33233526564436e-06
, O 0 8.266004769552637e-09
however O 0 8.746587898400549e-10
, O 0 3.488674349405585e-10
has O 0 9.400028498640634e-12
not O 0 6.89880617910088e-12
received O 0 2.9050156377663505e-11
general O 0 7.093950982195452e-10
acceptance O 0 7.175057437081023e-09
due O 0 8.330994560878935e-09
to O 0 3.9372203275434e-09
controversy O 0 6.662959517456102e-09
regarding O 0 9.767825659423579e-09
the O 0 2.3454140851697503e-09
subcellular O 0 7.021226906545053e-07
localization O 0 1.3286697139847092e-05
of O 0 1.6576386485667172e-07
BRCA1 O 0 2.6542437581156264e-08
proteins O 0 1.4038985252096126e-10
, O 0 4.1996933708432493e-10
reports O 0 4.384048679639818e-10
of O 0 4.66431282486468e-10
which O 0 3.3748621952600644e-11
have O 0 1.4920347943259138e-11
ranged O 0 3.077043508881161e-09
from O 0 8.31830021530422e-11
exclusively O 0 2.362703921399145e-10
nuclear O 0 8.900766346187083e-09
, O 0 4.5927700531578353e-10
to O 0 8.903954240579992e-10
conditionally O 0 6.653155359970242e-09
nuclear O 0 3.85865490670767e-08
, O 0 9.81821624002066e-10
to O 0 1.290080597904364e-09
the O 0 8.155783604024691e-09
ER O 0 2.4648090402479284e-05
/ O 0 2.429859341646079e-05
golgi O 0 2.201785537181422e-05
, O 0 4.9639563570735845e-08
to O 0 1.2954343375781718e-08
cytoplasmic O 0 1.1125400334321967e-07
invaginations O 0 1.2524920975920395e-06
into O 0 7.3693318114465e-09
the O 0 5.229387589622547e-09
nucleus O 0 1.8304622528830805e-07
. O 0 5.221566539148625e-07

In O 0 1.676263039485093e-08
an O 0 3.700212636292832e-10
attempt O 0 5.9972267152375025e-09
to O 0 1.0203528022501018e-09
resolve O 0 4.146162524421015e-09
this O 0 1.6428051974326507e-10
issue O 0 6.786201822706062e-09
, O 0 8.069114820763446e-10
we O 0 1.1231504615238919e-09
have O 0 1.2242085123403967e-09
comprehensively O 0 1.0220658452908538e-07
characterized O 0 9.063136019449303e-09
19 O 0 3.720882659763447e-07
anti O 0 6.463746558438288e-06
- O 0 1.7526142983115278e-05
BRCA1 O 0 4.209128405818774e-07
antibodies O 0 2.406206434102387e-08
. O 0 2.3335331889029476e-07

These O 0 6.290498788530385e-08
reagents O 0 5.9570595567493e-07
detect O 0 2.498378250948008e-07
a O 0 1.578191444195909e-08
220 O 0 4.986684132290975e-08
- O 0 2.0285382618112635e-07
kD O 0 3.1378833682538243e-06
protein O 0 7.828723447289576e-09
localized O 0 5.3843173475343065e-08
in O 0 1.904830737586849e-09
discrete O 0 7.1128418710486585e-09
nuclear O 0 5.111346013109141e-07
foci O 0 1.6194818499570829e-06
in O 0 3.499707901255533e-08
all O 0 5.5398667875294905e-09
epithelial O 0 4.933751256430696e-07
cell O 0 6.844218205515062e-07
lines O 0 4.1930361405206895e-09
, O 0 3.087618216657262e-10
including O 0 3.6512351475614935e-10
those O 0 2.4482907368117424e-10
derived O 0 8.73817107560626e-09
from O 0 3.724837327467867e-08
breast B-Disease 0 8.973426702141296e-06
malignancies I-Disease 0 4.0133745642378926e-05
. O 0 2.0573309029714437e-06

Immunohistochemical O 0 0.0013019420439377427
staining O 0 1.5746361896162853e-05
of O 0 5.852211302226351e-07
human O 0 1.330133585497606e-07
breast O 0 5.025027803640114e-06
specimens O 0 3.095922238571802e-07
also O 0 7.70511974224064e-08
revealed O 0 2.1038292175035167e-07
BRCA1 O 0 4.775675961354864e-07
nuclear O 0 4.424882718012668e-06
foci O 0 2.0537594537017867e-05
in O 0 4.907163315692742e-07
benign O 1 1.0
breast O 1 1.0
, O 0 2.5156716674246127e-06
invasive B-Disease 1 1.0
lobular I-Disease 1 1.0
cancers I-Disease 1 1.0
and O 0 5.683052677341038e-06
low B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
grade I-Disease 1 0.9999995231628418
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.00018185176304541528

Conversely O 0 3.8138712170621147e-06
, O 0 6.594221702016512e-08
BRCA1 O 0 3.0252553528953285e-07
expression O 0 7.3454611282386395e-09
was O 0 4.556770072383642e-09
reduced O 0 1.2053484876872744e-09
or O 0 1.6279763648263668e-10
undetectable O 0 6.444930367166535e-09
in O 0 7.939663509981543e-11
the O 0 1.677799982280348e-10
majority O 0 1.9825453778654634e-11
of O 0 5.102968048120715e-10
high O 0 1.6045492046146137e-08
- O 0 4.2755186768772546e-07
grade O 0 1.1494301361381076e-05
, O 0 2.848686051493132e-07
ductal B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 3.603026499376938e-08
suggesting O 0 1.3717789570932837e-08
that O 0 5.901540367503344e-11
absence O 0 7.874069396507366e-09
of O 0 2.1789281490214307e-08
BRCA1 O 0 4.748182647063004e-08
may O 0 1.1252195841748858e-09
contribute O 0 1.9574553089540814e-09
to O 0 1.6562150539911613e-09
the O 0 4.974654910228082e-09
pathogenesis O 0 5.052594860899262e-05
of O 0 3.7651016526751846e-08
a O 0 3.215648414212069e-09
significant O 0 5.9402589513979365e-09
percentage O 0 2.758092776389276e-08
of O 0 6.304176736193767e-09
sporadic B-Disease 0 3.921848110621795e-05
breast I-Disease 1 0.9874119758605957
cancers I-Disease 1 0.5795278549194336
. O 0 1.4534812180500012e-05
. O 0 2.948145083792042e-05

